{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "vscode": {
     "languageId": "plaintext"
    }
   },
   "source": [
    "### Open Targets lab meeting 1/10/25\n",
    "\n",
    "- Run through demoing our new cellate model, showing promise of adding insight into promise of therapeutic targets\n",
    "- We can consider times where cell specificity is crucial for the complete understanding of a target's function in a given disease\n",
    "    - Big examples seen in recent years include: \n",
    "        - the different roles of APOE in Alzheimer's disease, depending on their context - microglia, neurons\n",
    "        - PD-1 in CD8+ T cells vs. TREG cells in cancer - https://pmc.ncbi.nlm.nih.gov/articles/PMC10754338/\n",
    "    - Links to one of our therapeutic hypoethsis Qs:\n",
    "        - _\"What is the function of target [y] in cell type [d] in disease [x]?\"_\n",
    "\n",
    "- As an OTs user, we can search for the target PDCD1 (~ PD-1), seeing in these results high associations with many types of cancer, including NSCLC.\n",
    "    - https://partner-platform.opentargets.org/target/ENSG00000188389/associations\n",
    "- Supporting evidence here currently links cooccurences of the target _PD-1_ to the disease _NSCLC_, but:\n",
    "    - We can see that the literature already contains cell-type specific information\n",
    "    - Our data as it stands doesn't reflect this - potential therapeutic insights are buried here, but aren't specifically captured\n",
    "- OpenAI even gives us a nod, stating \"Specific information about PDCD1 would require additional _context_ / sources\"\n",
    "\n",
    "### Advice when running the notebook\n",
    "\n",
    "- This notebook will run in two parts, due to incompatability between ONNX and tensorflow\n",
    "- Vars that are needed will be saved, venvs will need to be switched part way through"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "/Users/withers/GitProjects/OTAR3088/Data_mining/otarlab/labenv/bin/python\n"
     ]
    }
   ],
   "source": [
    "# Helper - check which venv is in use\n",
    "import sys\n",
    "print(sys.executable)  # Shows the Python binary in use"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Query ran successfully\n"
     ]
    }
   ],
   "source": [
    "import requests\n",
    "import json\n",
    "\n",
    "variables = {\n",
    "  \"ensemblId\": \"ENSG00000188389\", # PDCD1\n",
    "  \"efoId\": \"EFO_0003060\", # NSCLC\n",
    "  \"size\": 100\n",
    "}\n",
    "\n",
    "# Build query string to get literature information linking PDCD1 and NSCLC\n",
    "# TODO - Alter Q to return annotations from ePMC as well?\n",
    "query_string = \"\"\"\n",
    "query EuropePMCQuery(\n",
    "  $ensemblId: String!\n",
    "  $efoId: String!\n",
    "  $size: Int!\n",
    "  $cursor: String\n",
    ") {\n",
    "  disease(efoId: $efoId) {\n",
    "    id\n",
    "    europePmc: evidences(\n",
    "      ensemblIds: [$ensemblId]\n",
    "      enableIndirect: true\n",
    "      size: $size\n",
    "      datasourceIds: [\"europepmc\"]\n",
    "      cursor: $cursor\n",
    "    ) {\n",
    "      count\n",
    "      cursor\n",
    "      rows {\n",
    "        disease {\n",
    "          name\n",
    "          id\n",
    "        }\n",
    "        target {\n",
    "          approvedSymbol\n",
    "          id\n",
    "        }\n",
    "        literature\n",
    "        textMiningSentences {\n",
    "          tStart\n",
    "          tEnd\n",
    "          dStart\n",
    "          dEnd\n",
    "          section\n",
    "          text\n",
    "        }\n",
    "        resourceScore\n",
    "      }\n",
    "    }\n",
    "  }\n",
    "}\n",
    "\"\"\"\n",
    "\n",
    "# GraphQL API request\n",
    "base_url = \"https://api.platform.opentargets.org/api/v4/graphql\"\n",
    "\n",
    "r = requests.post(base_url, json={\"query\": query_string, \"variables\": variables})\n",
    "if r.status_code == 200:\n",
    "    print(\"Query ran successfully\")\n",
    "resp = json.loads(r.text)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['32154170'],\n",
      " 'resourceScore': 106,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 289,\n",
      "                          'dStart': 285,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Given that Science-LUAD cohort was only '\n",
      "                                  'treated with PD-1 blockade and performed '\n",
      "                                  'better than Cancer Cell-LUAD cohort on '\n",
      "                                  'predicting ICB efficacy (Figure 2B; AUC = '\n",
      "                                  '0.82 and 0.80, respectively), we stratified '\n",
      "                                  'the Discovery-LUAD cohort into two groups '\n",
      "                                  'based on the TMB cutoff from Science-LUAD '\n",
      "                                  'cohort (Figure 2C; TMB = 166.5).'},\n",
      "                         {'dEnd': 304,\n",
      "                          'dStart': 300,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 435,\n",
      "                          'dStart': 431,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 261,\n",
      "                          'tStart': 257,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 174,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 477,\n",
      "                          'dStart': 473,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 435,\n",
      "                          'dStart': 431,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 347,\n",
      "                          'tStart': 343,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 28,\n",
      "                          'dStart': 24,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Of particular note, one LUAD patient who '\n",
      "                                  'derived durable clinical benefit from '\n",
      "                                  'anti-PD-1 therapy showed the strong '\n",
      "                                  'staining of both PD-L1 expression and CD8+ '\n",
      "                                  'T cell infiltration.'},\n",
      "                         {'dEnd': 315,\n",
      "                          'dStart': 311,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 416,\n",
      "                          'dStart': 412,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 16,\n",
      "                          'dStart': 12,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 143,\n",
      "                          'tStart': 139,\n",
      "                          'text': 'However, in LUAD, the positivity rate of '\n",
      "                                  'MMRd/MSI assessed by genomic variations is '\n",
      "                                  '<1% and much lower than the objective '\n",
      "                                  'response rate to PD-1 blockade in '\n",
      "                                  'unselected patients (13, 19, 30–33).'},\n",
      "                         {'dEnd': 477,\n",
      "                          'dStart': 473,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 261,\n",
      "                          'tStart': 257,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 174,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 220,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Given that Science-LUAD cohort was only '\n",
      "                                  'treated with PD-1 blockade and performed '\n",
      "                                  'better than Cancer Cell-LUAD cohort on '\n",
      "                                  'predicting ICB efficacy (Figure 2B; AUC = '\n",
      "                                  '0.82 and 0.80, respectively), we stratified '\n",
      "                                  'the Discovery-LUAD cohort into two groups '\n",
      "                                  'based on the TMB cutoff from Science-LUAD '\n",
      "                                  'cohort (Figure 2C; TMB = 166.5).'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Given that Science-LUAD cohort was only '\n",
      "                                  'treated with PD-1 blockade and performed '\n",
      "                                  'better than Cancer Cell-LUAD cohort on '\n",
      "                                  'predicting ICB efficacy (Figure 2B; AUC = '\n",
      "                                  '0.82 and 0.80, respectively), we stratified '\n",
      "                                  'the Discovery-LUAD cohort into two groups '\n",
      "                                  'based on the TMB cutoff from Science-LUAD '\n",
      "                                  'cohort (Figure 2C; TMB = 166.5).'},\n",
      "                         {'dEnd': 23,\n",
      "                          'dStart': 19,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Given that Science-LUAD cohort was only '\n",
      "                                  'treated with PD-1 blockade and performed '\n",
      "                                  'better than Cancer Cell-LUAD cohort on '\n",
      "                                  'predicting ICB efficacy (Figure 2B; AUC = '\n",
      "                                  '0.82 and 0.80, respectively), we stratified '\n",
      "                                  'the Discovery-LUAD cohort into two groups '\n",
      "                                  'based on the TMB cutoff from Science-LUAD '\n",
      "                                  'cohort (Figure 2C; TMB = 166.5).'},\n",
      "                         {'dEnd': 304,\n",
      "                          'dStart': 300,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 276,\n",
      "                          'tStart': 272,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 435,\n",
      "                          'dStart': 431,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 315,\n",
      "                          'dStart': 311,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 261,\n",
      "                          'tStart': 257,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 477,\n",
      "                          'dStart': 473,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 347,\n",
      "                          'tStart': 343,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 230,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 416,\n",
      "                          'dStart': 412,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 261,\n",
      "                          'tStart': 257,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 304,\n",
      "                          'dStart': 300,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapies '\n",
      "                                  'that target programmed cell death 1 (PD1) '\n",
      "                                  'and PD1 ligand 1 (PDL1) have demonstrated '\n",
      "                                  'promising benefits in lung adenocarcinoma '\n",
      "                                  '(LUAD), and tumor mutational burden (TMB) '\n",
      "                                  'is the most robust biomarker associated '\n",
      "                                  'with the efficacy of PD-1-PD-L1 axis '\n",
      "                                  'blockade in LUAD, but the assessment of TMB '\n",
      "                                  'by whole-exome sequencing (WES) is rather '\n",
      "                                  'expensive and time-consuming.'},\n",
      "                         {'dEnd': 416,\n",
      "                          'dStart': 412,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 347,\n",
      "                          'tStart': 343,\n",
      "                          'text': 'We retrieved many previous studies and '\n",
      "                                  'cancer databases, only collecting four '\n",
      "                                  'high-quality LUAD datasets that contained '\n",
      "                                  'both clinical and genomic information: 29 '\n",
      "                                  'LUAD patients treated with anti-PD-1 '\n",
      "                                  'therapy (Science-LUAD) (1), 59 LUAD '\n",
      "                                  'patients treated with PD-1 plus CTLA-4 '\n",
      "                                  'blockade (Cancer Cell-LUAD) (2), 186 LUAD '\n",
      "                                  'patients treated with anti-PD-1/PD-L1 '\n",
      "                                  'therapies or in combination with '\n",
      "                                  'anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 '\n",
      "                                  'LUAD patients without immunotherapy '\n",
      "                                  '(TCGA-LUAD) (Figure 1; Table S1).'},\n",
      "                         {'dEnd': 44,\n",
      "                          'dStart': 40,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Therefore, this study mainly focused on '\n",
      "                                  'LUAD for anti-PD-1 therapy.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38299030'],\n",
      " 'resourceScore': 152,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'In the current study, we tested the '\n",
      "                                  'feasibility of employing the TIME-EMS to '\n",
      "                                  'explore the tumoricidal function of PD-1 '\n",
      "                                  'antibody against NSCLC in the context of '\n",
      "                                  'NSCLC-TME.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'We found that VentX-TAMs promote the '\n",
      "                                  'cytocidal effect of PD-1 antibody against '\n",
      "                                  'NSCLC in TME for about 4-fold; however, '\n",
      "                                  'there was no significant increase in the '\n",
      "                                  'death of normal epithelial cells (Figures '\n",
      "                                  '4A–4D).'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'In the current study, we tested the '\n",
      "                                  'feasibility of employing the TIME-EMS to '\n",
      "                                  'explore the tumoricidal function of PD-1 '\n",
      "                                  'antibody against NSCLC in the context of '\n",
      "                                  'NSCLC-TME.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'We found that consistent with clinical '\n",
      "                                  'outcomes, the application of anti-PD-1 '\n",
      "                                  'antibodies to ex vivo en bloc NSCLC culture '\n",
      "                                  'led to a modest increase of PI-staining of '\n",
      "                                  'tumor cells but not the normal epithelial '\n",
      "                                  'cells of nLung tissues (Figures S4A and '\n",
      "                                  'S4B).'},\n",
      "                         {'dEnd': 43,\n",
      "                          'dStart': 38,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Whether the NSG-PDX models of primary NSCLC '\n",
      "                                  'can be used to evaluate the function of '\n",
      "                                  'PD-1 antibody against NSCLC in vivo remains '\n",
      "                                  'underexplored.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'Together with the findings of the TIME-EMS '\n",
      "                                  'studies, our data suggest that VentX-TAMs '\n",
      "                                  'promote the efficacy of PD-1 antibody '\n",
      "                                  'against NSCLC by reversing immune '\n",
      "                                  'suppression in the TME (Figure 7).'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Consistent with these ex vivo findings, we '\n",
      "                                  'showed that VentX-modulated-TAMs enhance '\n",
      "                                  'the efficacy of PD-1-antibody against NSCLC '\n",
      "                                  'tumorigenesis in vivo in pre-clinical '\n",
      "                                  'NSG-PDX models of primary human NSCLC.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'As shown in Figures 6B and 6C, VentX-TAMs '\n",
      "                                  'promote the efficacy of PD-1 antibody '\n",
      "                                  'against tumorigenesis of NSCLC for about '\n",
      "                                  '4-fold.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Consistent with the presence of functional '\n",
      "                                  'CD8 T cells in the implanted tumors, we '\n",
      "                                  'found that the infusion of PD-1 antibody '\n",
      "                                  'caused modest inhibition of tumorigenesis '\n",
      "                                  'in these individual NSG-PDX models of '\n",
      "                                  'primary NSCLC (Figure S6).'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'To test this possibility, PD-1 antibody was '\n",
      "                                  'applied to en bloc NSCLC and nLung tissue '\n",
      "                                  'cultures for 5 days and the viability of '\n",
      "                                  'the NSCLC cancer and normal lung epithelial '\n",
      "                                  'cells was determined by PI staining and '\n",
      "                                  'FACS analysis.'},\n",
      "                         {'dEnd': 230,\n",
      "                          'dStart': 225,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 207,\n",
      "                          'tStart': 203,\n",
      "                          'text': 'We showed that the restoration of VentX '\n",
      "                                  'expression in TAMs reignites the '\n",
      "                                  'phagocytotic function of TAMs, which in '\n",
      "                                  'turn, transforms TIME, activates CTLs in a '\n",
      "                                  'tumor-specific manner and promotes efficacy '\n",
      "                                  'of PD-1 antibody against NSCLC but not '\n",
      "                                  'toxicity on normal lung epithelial cells.'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Our findings that PD-1 antibody activates '\n",
      "                                  'CD8 T cells in the en bloc NSCLC culture '\n",
      "                                  'made us wonder whether en bloc NSCLC could '\n",
      "                                  'be employed to evaluate the tumoricidal '\n",
      "                                  'efficacy of PD-1 antibody against NSCLC ex '\n",
      "                                  'vivo.'},\n",
      "                         {'dEnd': 208,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 185,\n",
      "                          'tStart': 181,\n",
      "                          'text': ',34,50 Using the TIME-EMS models, we '\n",
      "                                  'demonstrated that reprogramming TME by '\n",
      "                                  'VentX-modulated-TAMs (VentX-TAMs) enhance '\n",
      "                                  'the reinvigoration of CD8 T cells and the '\n",
      "                                  'cytocidal effects of PD-1 antibody against '\n",
      "                                  'NSCLC approximately 4-fold, but not the '\n",
      "                                  'cytocidal effects on normal lung epithelial '\n",
      "                                  'cells (Figure 4).'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Our findings that PD-1 antibody activates '\n",
      "                                  'CD8 T cells in the en bloc NSCLC culture '\n",
      "                                  'made us wonder whether en bloc NSCLC could '\n",
      "                                  'be employed to evaluate the tumoricidal '\n",
      "                                  'efficacy of PD-1 antibody against NSCLC ex '\n",
      "                                  'vivo.'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 182,\n",
      "                          'tStart': 178,\n",
      "                          'text': 'Our findings that PD-1 antibody activates '\n",
      "                                  'CD8 T cells in the en bloc NSCLC culture '\n",
      "                                  'made us wonder whether en bloc NSCLC could '\n",
      "                                  'be employed to evaluate the tumoricidal '\n",
      "                                  'efficacy of PD-1 antibody against NSCLC ex '\n",
      "                                  'vivo.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'VentX-regulated-tumor associated '\n",
      "                                  'macrophages promote efficacy of PD-1 '\n",
      "                                  'antibodies against non-small cell lung '\n",
      "                                  'cancer through the tumor-specific '\n",
      "                                  'activation of cytotoxic T lymphocytes'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Our findings that PD-1 antibody activates '\n",
      "                                  'CD8 T cells in the en bloc NSCLC culture '\n",
      "                                  'made us wonder whether en bloc NSCLC could '\n",
      "                                  'be employed to evaluate the tumoricidal '\n",
      "                                  'efficacy of PD-1 antibody against NSCLC ex '\n",
      "                                  'vivo.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Whether the NSG-PDX models of primary NSCLC '\n",
      "                                  'can be used to evaluate the function of '\n",
      "                                  'PD-1 antibody against NSCLC in vivo remains '\n",
      "                                  'underexplored.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'We found that the application of PD-1 '\n",
      "                                  'antibody to the TIME-EMS of NSCLC led to '\n",
      "                                  'the modest activation of CD8 T cells but no '\n",
      "                                  'significant alteration in the immune '\n",
      "                                  'landscape of NSCLC-TME.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'The specificity of the assay platform was '\n",
      "                                  'further indicated by our findings that the '\n",
      "                                  'application of PD-1 antibody to the en bloc '\n",
      "                                  'NSCLC culture caused no significant '\n",
      "                                  'phenotypic changes in the Treg cells and '\n",
      "                                  'TAMs.'},\n",
      "                         {'dEnd': 203,\n",
      "                          'dStart': 198,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Consistent with these ex vivo findings, we '\n",
      "                                  'showed that VentX-modulated-TAMs enhance '\n",
      "                                  'the efficacy of PD-1-antibody against NSCLC '\n",
      "                                  'tumorigenesis in vivo in pre-clinical '\n",
      "                                  'NSG-PDX models of primary human NSCLC.'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 16,\n",
      "                          'tStart': 12,\n",
      "                          'text': 'Clinically, PD-1 antibody treatment elicits '\n",
      "                                  'an overall response in about 20% of '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 142,\n",
      "                          'text': 'As TME has been implicated in ICI '\n",
      "                                  'resistance, we asked whether reversal of '\n",
      "                                  'immune suppression in the NSCLC-TME would '\n",
      "                                  'increase the efficacy of PD-1 antibodies.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 antibodies activate cytotoxic CD8 T '\n",
      "                                  'cells in non-small cell lung cancer-tumor '\n",
      "                                  'microenvironments'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'VentX-regulated-tumor associated '\n",
      "                                  'macrophages promote efficacy of PD-1 '\n",
      "                                  'antibody against non-small cell lung cancer '\n",
      "                                  'in vivo'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'We showed that the restoration of VentX '\n",
      "                                  'expression in NSCLC-TAMs reverts immune '\n",
      "                                  'landscape of NSCLC-TME and promotes the '\n",
      "                                  'tumoricidal effects of PD-1 antibody on '\n",
      "                                  'NSCLC cells about 4-fold but does not alter '\n",
      "                                  'its cytocidal effects on normal lung '\n",
      "                                  'epithelial cells.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'As VentX has been shown to modulate '\n",
      "                                  'phagocytosis,22 to elucidate the mechanisms '\n",
      "                                  'of VentX-TAM in promoting efficacy of PD-1 '\n",
      "                                  'antibody against NSCLC, we hypothesized '\n",
      "                                  'that VentX promotes NSCLC-TAM phagocytosis '\n",
      "                                  'of NSCLC tumor cells, which in turn, '\n",
      "                                  'promotes CD8 T cell activation in a '\n",
      "                                  'cancer-specific manner.'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'We found that the application of PD-1 '\n",
      "                                  'antibody to the TIME-EMS of NSCLC led to '\n",
      "                                  'the modest activation of CD8 T cells but no '\n",
      "                                  'significant alteration in the immune '\n",
      "                                  'landscape of NSCLC-TME.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'As VentX has been shown to modulate '\n",
      "                                  'phagocytosis,22 to elucidate the mechanisms '\n",
      "                                  'of VentX-TAM in promoting efficacy of PD-1 '\n",
      "                                  'antibody against NSCLC, we hypothesized '\n",
      "                                  'that VentX promotes NSCLC-TAM phagocytosis '\n",
      "                                  'of NSCLC tumor cells, which in turn, '\n",
      "                                  'promotes CD8 T cell activation in a '\n",
      "                                  'cancer-specific manner.'},\n",
      "                         {'dEnd': 14,\n",
      "                          'dStart': 9,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'En block NSCLC or control nLung tissues '\n",
      "                                  'were treated with PD-1 or control '\n",
      "                                  'antibodies and co-cultured with autologous '\n",
      "                                  'TAMs transfected with VentX or control '\n",
      "                                  'GFP.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'As VentX has been shown to modulate '\n",
      "                                  'phagocytosis,22 to elucidate the mechanisms '\n",
      "                                  'of VentX-TAM in promoting efficacy of PD-1 '\n",
      "                                  'antibody against NSCLC, we hypothesized '\n",
      "                                  'that VentX promotes NSCLC-TAM phagocytosis '\n",
      "                                  'of NSCLC tumor cells, which in turn, '\n",
      "                                  'promotes CD8 T cell activation in a '\n",
      "                                  'cancer-specific manner.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'To test this possibility, PD-1 antibody was '\n",
      "                                  'applied to en bloc NSCLC and nLung tissue '\n",
      "                                  'cultures for 5 days and the viability of '\n",
      "                                  'the NSCLC cancer and normal lung epithelial '\n",
      "                                  'cells was determined by PI staining and '\n",
      "                                  'FACS analysis.'},\n",
      "                         {'dEnd': 219,\n",
      "                          'dStart': 214,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 143,\n",
      "                          'tStart': 139,\n",
      "                          'text': 'In this study, using a tumor immune '\n",
      "                                  'microenvironment enabling model system '\n",
      "                                  '(TIME-EMS) of non-small cell lung cancer '\n",
      "                                  '(NSCLC), we found that PD-1 antibody '\n",
      "                                  'modestly activates cytotoxic T lymphocytes '\n",
      "                                  '(CTLs) within the NSCLC-TME but not the '\n",
      "                                  'status of TIME.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 149,\n",
      "                          'tStart': 145,\n",
      "                          'text': 'As shown in Figures 3E and 3F, we found '\n",
      "                                  'that the application of VentX-TAMs to the '\n",
      "                                  'en bloc NSCLC culture led to about the '\n",
      "                                  '4-fold amplification of PD-1 '\n",
      "                                  'antibody-induced CD8 T cell activation.'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'Small pieces of freshly isolated NSCLC or '\n",
      "                                  'nLung tissues were incubated in RPMI-based '\n",
      "                                  'media and subjected to PD-1 antibody '\n",
      "                                  'treatment for indicated times (Figure 2).'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'To further evaluate the effects of '\n",
      "                                  'VentX-TAMs on the PD-1 treatment of NSCLC '\n",
      "                                  'in vivo, NSG-PDX models of primary human '\n",
      "                                  'NSCLC were treated by the tail-vein '\n",
      "                                  'injection of TAMs transfected with VentX or '\n",
      "                                  'control GFP combined with the weekly '\n",
      "                                  'injection of PD-1 or control antibody for 5 '\n",
      "                                  'weeks.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'To further evaluate the effects of '\n",
      "                                  'VentX-TAMs on the PD-1 treatment of NSCLC '\n",
      "                                  'in vivo, NSG-PDX models of primary human '\n",
      "                                  'NSCLC were treated by the tail-vein '\n",
      "                                  'injection of TAMs transfected with VentX or '\n",
      "                                  'control GFP combined with the weekly '\n",
      "                                  'injection of PD-1 or control antibody for 5 '\n",
      "                                  'weeks.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34194433'],\n",
      " 'resourceScore': 126,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'Thus, PD-1 was highly expressed on ILC2s '\n",
      "                                  'obtained from NSCLC patients both in terms '\n",
      "                                  'of mRNA level and protein level, indicating '\n",
      "                                  'that PD-1 may function as a regulatory '\n",
      "                                  'factor, to some degree, in ILC2s from NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Thus, PD-1 upregulation on ILC2s scarcely '\n",
      "                                  'effects p-STAT5 signaling and may activate '\n",
      "                                  'the AKT-S6 signaling pathway in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'We also found that high expression of PD-1 '\n",
      "                                  'on ILC2s enhanced IL-4 and IL-13 secretion '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 207,\n",
      "                          'tStart': 203,\n",
      "                          'text': 'While, we did not find a significant '\n",
      "                                  'difference in p-STAT5 levels between '\n",
      "                                  'PD-1high ILC2s and PD-1low ILC2s (Figures '\n",
      "                                  '5E, F), suggesting that p-STAT5 played a '\n",
      "                                  'marginal role in the functional regulation '\n",
      "                                  'of PD-1 on ILC2s in human NSCLC tumors.'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 on total ILCs obtained from PBMCs '\n",
      "                                  '(P<0.0001) and tumor tissues (P<0.0001) of '\n",
      "                                  'NSCLC patients were significantly '\n",
      "                                  'upregulated compared with those on ILCs '\n",
      "                                  'obtained from HD PBMCs (Figure 3C).'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Increased Expression of PD-1 on ILC2s in '\n",
      "                                  'NSCLC Patients'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'After screening for the main immune '\n",
      "                                  'checkpoint molecules, we found that PD-1 '\n",
      "                                  'was upregulated in ILC2s in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 acts as a positive regulator of the '\n",
      "                                  'immunosuppressive function of ILC2s in '\n",
      "                                  'human NSCLC.'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 112,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Moreover, PDCD1 expression was increased in '\n",
      "                                  'ILC2s obtained from tumor tissues compared '\n",
      "                                  'with ILC2s obtained from NSCLC PBMCs '\n",
      "                                  '(Figure 3B).'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'Upregulation of PD-1 Correlated With the '\n",
      "                                  'AKT-S6 Signaling Pathway Activation in '\n",
      "                                  'ILC2s Obtained From NSCLC Patients'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Thus, in the present study, we found that '\n",
      "                                  'PD-1 upregulation might be due to ILC2 '\n",
      "                                  'activation and represented a '\n",
      "                                  'high-functioning stage in NSCLC ILC2s.'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'In this study, we found that the '\n",
      "                                  'phosphorylation levels of AKT and S6 were '\n",
      "                                  'increased in PD-1high ILC2s, indicating '\n",
      "                                  'that the PD-1 downstream signaling pathway '\n",
      "                                  'could be activated in ILC2s obtained from '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Thus, PD-1 was highly expressed on ILC2s '\n",
      "                                  'obtained from NSCLC patients both in terms '\n",
      "                                  'of mRNA level and protein level, indicating '\n",
      "                                  'that PD-1 may function as a regulatory '\n",
      "                                  'factor, to some degree, in ILC2s from NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Thus, the present study assessed the '\n",
      "                                  'distribution and functional features of '\n",
      "                                  'ILC2s, as well as PD-1 expression and '\n",
      "                                  'function on ILC2s in NSCLC patients.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Thus, PD-1 was highly expressed on ILC2s '\n",
      "                                  'obtained from NSCLC patients both in terms '\n",
      "                                  'of mRNA level and protein level, indicating '\n",
      "                                  'that PD-1 may function as a regulatory '\n",
      "                                  'factor, to some degree, in ILC2s from NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'ILC2s are enriched in NSCLC patients and '\n",
      "                                  'upregulate PD-1 expression.'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 5,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PDCD1 was obviously upregulated in ILC2s '\n",
      "                                  'obtained from PBMCs (P<0.0001) and tumor '\n",
      "                                  'tissues (P<0.0001) of NSCLC patients '\n",
      "                                  'compared with ILC2s from HDs (Figure 3B).'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'To explore the role of PD-1 upregulation in '\n",
      "                                  'ILC2s, we sorted PD-1high ILC2s and PD-1low '\n",
      "                                  'ILC2s from NSCLC tumor tissues by FACS and '\n",
      "                                  'performed qPCR.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Next, we investigated the levels of PD-1 on '\n",
      "                                  'three subsets of ILCs from PBMCs and tumor '\n",
      "                                  'tissues of NSCLC patients.'},\n",
      "                         {'dEnd': 64,\n",
      "                          'dStart': 59,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'Based on the finding that PD-1 was '\n",
      "                                  'upregulated on ILC2s in NSCLC patients, we '\n",
      "                                  'hypothesized that PD-1 might play a role in '\n",
      "                                  'the regulation of ILC2 function.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'However, the present study showed that high '\n",
      "                                  'expression of PD-1 boosted the function of '\n",
      "                                  'ILC2, such as enhancing IL4 and IL13 '\n",
      "                                  'expression, in NSCLC patients.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Thus, we explored the gene expression '\n",
      "                                  'profile of PDCD1 (encoding PD-1) as well as '\n",
      "                                  'other cardinal immune checkpoint molecules '\n",
      "                                  'in ILC2s from NSCLC patients.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 was upregulated in ILC2s obtained from '\n",
      "                                  'NSCLC patients and corelated with high '\n",
      "                                  'expression of IL-4 and IL-13.'},\n",
      "                         {'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'However, phosphorylated STAT5, which was '\n",
      "                                  'reported to be involved in the regulation '\n",
      "                                  'of cytokine secretion in PD-1 expressing '\n",
      "                                  'ILC2s in the context of Nippostrongylus '\n",
      "                                  'brasiliensis infection (30), showed no '\n",
      "                                  'difference in PD-1high ILC2s and PD-1low '\n",
      "                                  'ILC2s among NSCLC patients.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'These findings suggested that PD-1 '\n",
      "                                  'upregulation activated its downstream '\n",
      "                                  'signaling molecules in ILC2s of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 Affects the Immunosuppressive Function '\n",
      "                                  'of Group 2 Innate Lymphoid Cells in Human '\n",
      "                                  'Non-Small Cell Lung Cancer'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Similarly, we found that PD-1 was highly '\n",
      "                                  'expressed in ILC2s compared with matched '\n",
      "                                  'ILC1s or ILC3s in NSCLC patients.'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Thus, further studies are needed to '\n",
      "                                  'elucidate the mechanism by which PD-1 '\n",
      "                                  'regulates the downstream signaling in ILC2s '\n",
      "                                  'obtained from NSCLC patients.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 17,\n",
      "                          'tStart': 13,\n",
      "                          'text': 'In addition, PD-1 expression on ILCs from '\n",
      "                                  'tumor tissues was higher than that on ILCs '\n",
      "                                  'from PBMCs of NSCLC patients (Figure 3C).'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Thus, we explored the gene expression '\n",
      "                                  'profile of PDCD1 (encoding PD-1) as well as '\n",
      "                                  'other cardinal immune checkpoint molecules '\n",
      "                                  'in ILC2s from NSCLC patients.'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'Our findings suggest that PD-1 plays an '\n",
      "                                  'important role in the immunosuppressive '\n",
      "                                  'function of ILC2s in human NSCLC.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'The proportions of PD-1 expression in ILC2s '\n",
      "                                  'were much higher than those in ILC1s or '\n",
      "                                  'ILC3s in both PBMCs (Figures 3D, E) and '\n",
      "                                  'tumor tissues (Figures 3F, G) from NSCLC '\n",
      "                                  'patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['30325558'],\n",
      " 'resourceScore': 116,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 168,\n",
      "                          'tStart': 164,\n",
      "                          'text': 'However, we further compared PD‐1 '\n",
      "                                  'expression of three Tfh subtypes in NSCLC '\n",
      "                                  'patients with those in HS and found that '\n",
      "                                  'the frequency and the number of PD‐1+‐Tfh2 '\n",
      "                                  'and PD‐1+‐Tfh17 in NSCLC patients were '\n",
      "                                  'higher than those in HS (Figure 1G).'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'We also observed a great skewing toward '\n",
      "                                  'PD‐1+‐Tfh2 and PD‐1+‐Tfh17 subtypes in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'These data suggest that circulating Tfh '\n",
      "                                  'cells, especially PD‐1+‐Tfh2 and '\n",
      "                                  'PD‐1+‐Tfh17 subtypes, expand in NSCLC and '\n",
      "                                  'indicate a potential involvement of Tfh '\n",
      "                                  'cells in NSCLC.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 142,\n",
      "                          'tStart': 138,\n",
      "                          'text': 'We also investigated PD‐1 expression of '\n",
      "                                  'three Tfh subtypes in HS and NSCLC patients '\n",
      "                                  'and found higher mean fluorescence '\n",
      "                                  'intensity (MFI) of PD‐1 in Tfh1 than in '\n",
      "                                  'Tfh2 and Tfh17, and higher MFI of PD‐1 in '\n",
      "                                  'Tfh1 in NSCLC patients than in HS (Figure '\n",
      "                                  '1E,F).'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'PD‐1/PD‐L1 checkpoint inhibitors show '\n",
      "                                  'impressive antitumor activity in NSCLC.4, '\n",
      "                                  '5, 6, 7, 8 The recently defined follicular '\n",
      "                                  'helper T (Tfh) cells express '\n",
      "                                  'characteristically high PD‐1, which is a '\n",
      "                                  'common mediator of immunosuppression in '\n",
      "                                  'multiple cancers,9, 10 but it is not clear '\n",
      "                                  'whether Tfh cells can also inhibit immune '\n",
      "                                  'responses in NSCLC.'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'In addition, we found increased circulating '\n",
      "                                  'CD4+PD‐1+ and Tfh cells in adenocarcinoma '\n",
      "                                  'than in squamous cell carcinoma or other '\n",
      "                                  'types, which suggested different '\n",
      "                                  'histological subtypes of NSCLC might have '\n",
      "                                  'different pathways of tumorigenesis.'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Increased PD‐1+‐Tfh2 and PD‐1+‐Tfh17 '\n",
      "                                  'subtypes in NSCLC could inhibit immune '\n",
      "                                  'response through interaction with PD‐L1.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Compared to HS, a significantly higher '\n",
      "                                  'frequency and number of circulating '\n",
      "                                  'CD4+PD‐1+, Tfh cells were observed in NSCLC '\n",
      "                                  'patients (Figure 1A,B), but there was no '\n",
      "                                  'significant difference in the frequency and '\n",
      "                                  'number of CD4+CXCR5+ cells between the two '\n",
      "                                  'groups (Figure 1A,B).'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'However, we further compared PD‐1 '\n",
      "                                  'expression of three Tfh subtypes in NSCLC '\n",
      "                                  'patients with those in HS and found that '\n",
      "                                  'the frequency and the number of PD‐1+‐Tfh2 '\n",
      "                                  'and PD‐1+‐Tfh17 in NSCLC patients were '\n",
      "                                  'higher than those in HS (Figure 1G).'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'However, we further compared PD‐1 '\n",
      "                                  'expression of three Tfh subtypes in NSCLC '\n",
      "                                  'patients with those in HS and found that '\n",
      "                                  'the frequency and the number of PD‐1+‐Tfh2 '\n",
      "                                  'and PD‐1+‐Tfh17 in NSCLC patients were '\n",
      "                                  'higher than those in HS (Figure 1G).'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'However, no significant association was '\n",
      "                                  'found between CD4+CXCR5+, CD4+PD‐1+, Tfh '\n",
      "                                  'cells, Tfh2, or Tf17 subtypes and '\n",
      "                                  'disease‐free survival of NSCLC patients '\n",
      "                                  '(Figure 5A,B,C,E,F).'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'These data suggest that circulating Tfh '\n",
      "                                  'cells, especially PD‐1+‐Tfh2 and '\n",
      "                                  'PD‐1+‐Tfh17 subtypes, expand in NSCLC and '\n",
      "                                  'indicate a potential involvement of Tfh '\n",
      "                                  'cells in NSCLC.'},\n",
      "                         {'dEnd': 361,\n",
      "                          'dStart': 356,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Our data showed lower numbers of CD4+PD‐1+ '\n",
      "                                  '(Figure 1I), Tfh cells (Figure 1J), Tfh2 '\n",
      "                                  '(Figure 1L) and Tfh17 subtypes (Figure 1M) '\n",
      "                                  'but a higher number of Tfh1 subtypes '\n",
      "                                  '(Figure 1K) in NSCLC patients with early '\n",
      "                                  'stage (I and II) relative to those with '\n",
      "                                  'advanced stage (III and IV); however, there '\n",
      "                                  'was no significant difference in the number '\n",
      "                                  'of CD4+CXCR5+ cells in NSCLC with different '\n",
      "                                  'stages (Figure 1H).'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'These data suggest that circulating Tfh '\n",
      "                                  'cells, especially PD‐1+‐Tfh2 and '\n",
      "                                  'PD‐1+‐Tfh17 subtypes, expand in NSCLC and '\n",
      "                                  'indicate a potential involvement of Tfh '\n",
      "                                  'cells in NSCLC.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 197,\n",
      "                          'tStart': 193,\n",
      "                          'text': 'We also investigated PD‐1 expression of '\n",
      "                                  'three Tfh subtypes in HS and NSCLC patients '\n",
      "                                  'and found higher mean fluorescence '\n",
      "                                  'intensity (MFI) of PD‐1 in Tfh1 than in '\n",
      "                                  'Tfh2 and Tfh17, and higher MFI of PD‐1 in '\n",
      "                                  'Tfh1 in NSCLC patients than in HS (Figure '\n",
      "                                  '1E,F).'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 checkpoint inhibitors show '\n",
      "                                  'impressive antitumor activity in NSCLC.4, '\n",
      "                                  '5, 6, 7, 8 The recently defined follicular '\n",
      "                                  'helper T (Tfh) cells express '\n",
      "                                  'characteristically high PD‐1, which is a '\n",
      "                                  'common mediator of immunosuppression in '\n",
      "                                  'multiple cancers,9, 10 but it is not clear '\n",
      "                                  'whether Tfh cells can also inhibit immune '\n",
      "                                  'responses in NSCLC.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'We also observed a great skewing toward '\n",
      "                                  'PD‐1+‐Tfh2 and PD‐1+‐Tfh17 subtypes in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'We investigated the levels of circulating '\n",
      "                                  'CD4+CXCR5+, CD4+PD‐1+ and Tfh cells in '\n",
      "                                  'these NSCLC histological subtypes.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Elevated numbers of Tfh cells and skewing '\n",
      "                                  'to PD‐1+‐Tfh2 and PD‐1+‐Tfh17 subtypes in '\n",
      "                                  'NSCLC patients'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'We also investigated PD‐1 expression of '\n",
      "                                  'three Tfh subtypes in HS and NSCLC patients '\n",
      "                                  'and found higher mean fluorescence '\n",
      "                                  'intensity (MFI) of PD‐1 in Tfh1 than in '\n",
      "                                  'Tfh2 and Tfh17, and higher MFI of PD‐1 in '\n",
      "                                  'Tfh1 in NSCLC patients than in HS (Figure '\n",
      "                                  '1E,F).'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'However, we further compared PD‐1 '\n",
      "                                  'expression of three Tfh subtypes in NSCLC '\n",
      "                                  'patients with those in HS and found that '\n",
      "                                  'the frequency and the number of PD‐1+‐Tfh2 '\n",
      "                                  'and PD‐1+‐Tfh17 in NSCLC patients were '\n",
      "                                  'higher than those in HS (Figure 1G).'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'Elevated numbers of Tfh cells and skewing '\n",
      "                                  'to PD‐1+‐Tfh2 and PD‐1+‐Tfh17 subtypes in '\n",
      "                                  'NSCLC patients'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'We also investigated PD‐1 expression of '\n",
      "                                  'three Tfh subtypes in HS and NSCLC patients '\n",
      "                                  'and found higher mean fluorescence '\n",
      "                                  'intensity (MFI) of PD‐1 in Tfh1 than in '\n",
      "                                  'Tfh2 and Tfh17, and higher MFI of PD‐1 in '\n",
      "                                  'Tfh1 in NSCLC patients than in HS (Figure '\n",
      "                                  '1E,F).'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 checkpoint inhibitors show '\n",
      "                                  'impressive antitumor activity in NSCLC.4, '\n",
      "                                  '5, 6, 7, 8 The recently defined follicular '\n",
      "                                  'helper T (Tfh) cells express '\n",
      "                                  'characteristically high PD‐1, which is a '\n",
      "                                  'common mediator of immunosuppression in '\n",
      "                                  'multiple cancers,9, 10 but it is not clear '\n",
      "                                  'whether Tfh cells can also inhibit immune '\n",
      "                                  'responses in NSCLC.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Thus, we determined whether Tfh cells with '\n",
      "                                  'high PD‐1 expression were also predictive '\n",
      "                                  'of survival time in NSCLC.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Our data showed lower numbers of CD4+PD‐1+ '\n",
      "                                  '(Figure 1I), Tfh cells (Figure 1J), Tfh2 '\n",
      "                                  '(Figure 1L) and Tfh17 subtypes (Figure 1M) '\n",
      "                                  'but a higher number of Tfh1 subtypes '\n",
      "                                  '(Figure 1K) in NSCLC patients with early '\n",
      "                                  'stage (I and II) relative to those with '\n",
      "                                  'advanced stage (III and IV); however, there '\n",
      "                                  'was no significant difference in the number '\n",
      "                                  'of CD4+CXCR5+ cells in NSCLC with different '\n",
      "                                  'stages (Figure 1H).'},\n",
      "                         {'dEnd': 235,\n",
      "                          'dStart': 230,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Follicular helper T (Tfh) cells have '\n",
      "                                  'characteristically high PD‐1 expression; '\n",
      "                                  'thus, in the present study, we investigated '\n",
      "                                  'the role of circulating Tfh cells and their '\n",
      "                                  'correlation with disease‐free survival '\n",
      "                                  'after tumor resection in NSCLC.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'These data suggest that circulating Tfh '\n",
      "                                  'cells, especially PD‐1+‐Tfh2 and '\n",
      "                                  'PD‐1+‐Tfh17 subtypes, expand in NSCLC and '\n",
      "                                  'indicate a potential involvement of Tfh '\n",
      "                                  'cells in NSCLC.'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Increased PD‐1+‐Tfh2 and PD‐1+‐Tfh17 '\n",
      "                                  'subtypes in NSCLC could inhibit immune '\n",
      "                                  'response through interaction with PD‐L1.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['27191652'],\n",
      " 'resourceScore': 137,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'We report that surface expression of PD-1 '\n",
      "                                  'on CD4+ T cells has a prognostic value in '\n",
      "                                  'NSCLC patients, as high expression of PD-1 '\n",
      "                                  'is associated with a shorter '\n",
      "                                  'progression-free survival and overall '\n",
      "                                  'survival.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': '2) High expression of PD-1 on CD4+ T cells '\n",
      "                                  'is strongly associated with poor clinical '\n",
      "                                  'outcome manifested by significant shorter '\n",
      "                                  'OS and PFS in patient with NSCLC and this '\n",
      "                                  'is prognostic.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Based on the level of PD-1 expression on '\n",
      "                                  'CD4+ T cells, we defined high-PD-1 '\n",
      "                                  '(PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) '\n",
      "                                  'subgroups in NSCLC patients.'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'In summary, our study demonstrates a '\n",
      "                                  'prognostic value of PD-1 expression on CD4+ '\n",
      "                                  'T cells from peripheral blood of patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'This has a significant impact on data '\n",
      "                                  'providing a potential predictive biomarker '\n",
      "                                  'for NSCLC patients receiving PD-1/PD-L1 '\n",
      "                                  'targeted treatment.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Based on the level of PD-1 expression on '\n",
      "                                  'CD4+ T cells, we defined high-PD-1 '\n",
      "                                  '(PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) '\n",
      "                                  'subgroups in NSCLC patients.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'Based on the level of PD-1 expression on '\n",
      "                                  'CD4+ T cells, we defined high-PD-1 '\n",
      "                                  '(PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) '\n",
      "                                  'subgroups in NSCLC patients.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'The data suggest that CD4+, and not CD8+, T '\n",
      "                                  'cells play a pivotal role in PD-1-dependent '\n",
      "                                  'immune tolerance in NSCLC patients.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 7,\n",
      "                          'tStart': 3,\n",
      "                          'text': '3) PD-1 expression on CD4+ T cells has '\n",
      "                                  'potential predictive value in NSCLC as high '\n",
      "                                  'PD-1 expression associates with worse '\n",
      "                                  'clinical outcome after anti-PD-L1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 is elevated on CD4+ T cells in '\n",
      "                                  'peripheral blood of patients with NSCLC'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'In our study, we used peripheral blood '\n",
      "                                  'samples from patients with NSCLC to '\n",
      "                                  'demonstrate a negative prognostic value of '\n",
      "                                  'PD-1 in this population, i.e. high '\n",
      "                                  'expression of PD-1 associates with poor PFS '\n",
      "                                  'and OS.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'This work highlights the potential of a '\n",
      "                                  'non-invasive and effective method to '\n",
      "                                  'determine prognostic and predictive '\n",
      "                                  'biomarkers for inhibiting the PD-1 pathway '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Two blocking antibodies for PD-1, nivolumab '\n",
      "                                  'and pembrolizumab have recently been '\n",
      "                                  'approved for treating advanced recurrent '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Expression of PD-1 on T cells from '\n",
      "                                  'peripheral blood does not correlate with '\n",
      "                                  'PD-L1 expression on tumor tissues in '\n",
      "                                  'patients with NSCLC'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'Based on the level of PD-1 expression on '\n",
      "                                  'CD4+ T cells, we defined high-PD-1 '\n",
      "                                  '(PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) '\n",
      "                                  'subgroups in NSCLC patients.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'Two blocking antibodies to PD-1, nivolumab '\n",
      "                                  'and pembrolizumab, have recently been '\n",
      "                                  'approved by FDA for treating advanced solid '\n",
      "                                  'tumors including NSCLC.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Expression of PD-1 on CD4+ T cells in '\n",
      "                                  'peripheral blood associates with poor '\n",
      "                                  'clinical outcome in non-small cell lung '\n",
      "                                  'cancer'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'As shown in Figure 1A–1B, the frequency of '\n",
      "                                  'PD-1+ cells among CD4+ T cells from NSCLC '\n",
      "                                  'patients was significantly higher than '\n",
      "                                  'those from HD (mean frequency 13.3%±1.1% '\n",
      "                                  'vs. 8.8%±0.7%, P=0.0045).'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'The mean value (12.27%) of PD-1 expression '\n",
      "                                  'on CD4+ T cells of the 42 NSCLC patients '\n",
      "                                  'was the cutoff.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Tumor burden is independent of PD-1+ T '\n",
      "                                  'cells from peripheral blood in patients '\n",
      "                                  'with NSCLC'},\n",
      "                         {'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'Our finding of high expression of PD-1 on '\n",
      "                                  'CD4+ T cells associates with poor clinical '\n",
      "                                  'outcome has significant clinical '\n",
      "                                  'implications as it provides a potential '\n",
      "                                  'prognostic biomarker for patients with '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'In contrast, expression of PD-1 on CD8+ T '\n",
      "                                  'cells was comparable between NSCLC patients '\n",
      "                                  'and HD.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'Based on the level of PD-1 expression on '\n",
      "                                  'CD4+ T cells, we defined high-PD-1 '\n",
      "                                  '(PD-1>12.27%) vs. low-PD-1 (PD-1<12.27%) '\n",
      "                                  'subgroups in NSCLC patients.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'We next assessed the correlation of PD-1 '\n",
      "                                  'expression with clinical characteristics of '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'The three most important findings are: 1) '\n",
      "                                  'PD-1 expression on CD4+ T cells is '\n",
      "                                  'significantly elevated in patients with '\n",
      "                                  'NSCLC at initial diagnosis, compared with '\n",
      "                                  'those of healthy donors.'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Thus, the expression of PD-1 on T cells '\n",
      "                                  'from peripheral blood does not associate '\n",
      "                                  'with PD-L1 expression on tumor tissues in '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'We assessed PBMCs from 42 NSCLC patients at '\n",
      "                                  'initial diagnosis for PD-1 expression on '\n",
      "                                  'both CD4+ and CD8+ T cells.'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 112,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Consistently, no correlation was found '\n",
      "                                  'between the PD-1 expression on peripheral '\n",
      "                                  'blood T cells and the stage of NSCLC '\n",
      "                                  'patients (data not shown).'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'We analyzed the correlation between PD-1 '\n",
      "                                  'expression on peripheral T cells and tumor '\n",
      "                                  'size in our patients with NSCLC.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'We utilized flow cytometry to evaluate '\n",
      "                                  'peripheral expression of PD-1 and further '\n",
      "                                  'dissect their prognostic and predictive '\n",
      "                                  'value in NSCLC.'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Agents blocking the PD-1 pathway, nivolumab '\n",
      "                                  'and pembrolizumab, have recently been '\n",
      "                                  'approved by the FDA for treating several '\n",
      "                                  'solid tumors including advanced NSCLC.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'High expression of PD-1 on CD4+ T cells at '\n",
      "                                  'initial diagnosis associates with poor '\n",
      "                                  'clinical outcome in NSCLC'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Two blocking antibodies for PD-1, nivolumab '\n",
      "                                  'and pembrolizumab have recently been '\n",
      "                                  'approved for treating advanced recurrent '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 143,\n",
      "                          'tStart': 139,\n",
      "                          'text': 'In this study, we evaluated the phenotype '\n",
      "                                  'of peripheral blood T cells collected from '\n",
      "                                  'NSCLC patients and determined the '\n",
      "                                  'correlation between PD-1 expression on T '\n",
      "                                  'cell of peripheral blood with clinical '\n",
      "                                  'outcome.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'These data demonstrate that PD-1 expression '\n",
      "                                  'on peripheral CD4+ T cells is associated '\n",
      "                                  'with worse clinical outcomes in NSCLC, '\n",
      "                                  'independent of age, stage, and histology '\n",
      "                                  'type.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35720783'],\n",
      " 'resourceScore': 105,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 168,\n",
      "                          'text': '(a) p-value, probability value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (c) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  'NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 335,\n",
      "                          'dStart': 330,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 10,\n",
      "                          'text': '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(e) NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 363,\n",
      "                          'dStart': 337,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 168,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': '(a) p-value, probability value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (c) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  'NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 327,\n",
      "                          'dStart': 301,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 155,\n",
      "                          'tStart': 132,\n",
      "                          'text': '(a) p-value, probability value; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 167,\n",
      "                          'tStart': 163,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type;  '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 310,\n",
      "                          'dStart': 305,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Given the above findings of the potential '\n",
      "                                  'role of inhibiting PGE-2 production along '\n",
      "                                  'with PD-1/PD-L1 blockade in enhancing '\n",
      "                                  'immunity against cancer cells, our study '\n",
      "                                  'aimed to determine whether there is a '\n",
      "                                  'synergetic effect when combining ASA with '\n",
      "                                  'immunotherapy in the treatment of non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients.'},\n",
      "                         {'dEnd': 359,\n",
      "                          'dStart': 333,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 168,\n",
      "                          'text': '(a) p-value, probability value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (c) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  'NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 299,\n",
      "                          'dStart': 294,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 155,\n",
      "                          'tStart': 132,\n",
      "                          'text': '(a) p-value, probability value; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 327,\n",
      "                          'dStart': 301,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 130,\n",
      "                          'tStart': 126,\n",
      "                          'text': '(a) p-value, probability value; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 169,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type;  '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'We performed a retrospective chart review '\n",
      "                                  'of 500 non-small cell lung cancer (NSCLC) '\n",
      "                                  'patients aged 21 years or older treated '\n",
      "                                  'with PD-1 and/or PD-L1 directed '\n",
      "                                  'immunotherapy at St.'},\n",
      "                         {'dEnd': 359,\n",
      "                          'dStart': 333,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': '(a) p-value, probability value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (c) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  'NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 363,\n",
      "                          'dStart': 337,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 335,\n",
      "                          'dStart': 330,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 168,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(e) NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 364,\n",
      "                          'dStart': 338,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 167,\n",
      "                          'tStart': 163,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type;  '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 364,\n",
      "                          'dStart': 338,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 169,\n",
      "                          'text': '(a) p-value, probability-value; based on '\n",
      "                                  'separate Chi-square tests; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type;  '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 299,\n",
      "                          'dStart': 294,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 130,\n",
      "                          'tStart': 126,\n",
      "                          'text': '(a) p-value, probability value; (b) '\n",
      "                                  'aspirin/aggregated immunotherapy, combined '\n",
      "                                  'aspirin use and immunotherapy of any type; '\n",
      "                                  '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'PD-L1, programmed death-ligand 1; (e) COPD, '\n",
      "                                  'chronic obstructive pulmonary disease; (f) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(g) NSCLC, non-small-cell lung cancer'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(e) NSCLC, non-small cell lung cancer'},\n",
      "                         {'dEnd': 303,\n",
      "                          'dStart': 277,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Given the above findings of the potential '\n",
      "                                  'role of inhibiting PGE-2 production along '\n",
      "                                  'with PD-1/PD-L1 blockade in enhancing '\n",
      "                                  'immunity against cancer cells, our study '\n",
      "                                  'aimed to determine whether there is a '\n",
      "                                  'synergetic effect when combining ASA with '\n",
      "                                  'immunotherapy in the treatment of non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 10,\n",
      "                          'text': '(c) PD-1, programmed cell death-1; (d) '\n",
      "                                  'ECOG, Eastern Cooperative Oncology Group; '\n",
      "                                  '(e) NSCLC, non-small cell lung cancer'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35909903'],\n",
      " 'resourceScore': 100.5,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Collectively, the current evidence-based '\n",
      "                                  'studies of PD-1 blockade monotherapy in '\n",
      "                                  'patients with advanced NSCLC was mainly '\n",
      "                                  'focused on relatively young patients, '\n",
      "                                  'suggesting that the efficacy and safety of '\n",
      "                                  'PD-1 inhibitors in elderly NSCLC patients '\n",
      "                                  'over 65 years was still scanty.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Furthermore, the safety profile of the 68 '\n",
      "                                  'elderly patients with advanced NSCLC who '\n",
      "                                  'received PD-1 inhibitor monotherapy was '\n",
      "                                  'also presented in this study.'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 195,\n",
      "                          'tStart': 191,\n",
      "                          'text': 'Unfortunately, several PD-1 '\n",
      "                                  'inhibitor-related studies excluded elderly '\n",
      "                                  'patients with NSCLC over 75 years of age, '\n",
      "                                  'resulting in relatively limited evidence '\n",
      "                                  'regarding the efficacy and safety of PD-1 '\n",
      "                                  'in elderly patients with NSCLC clinically.'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 206,\n",
      "                          'tStart': 202,\n",
      "                          'text': 'Collectively, the current evidence-based '\n",
      "                                  'studies of PD-1 blockade monotherapy in '\n",
      "                                  'patients with advanced NSCLC was mainly '\n",
      "                                  'focused on relatively young patients, '\n",
      "                                  'suggesting that the efficacy and safety of '\n",
      "                                  'PD-1 inhibitors in elderly NSCLC patients '\n",
      "                                  'over 65 years was still scanty.'},\n",
      "                         {'dEnd': 36,\n",
      "                          'dStart': 31,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Elderly patients with advanced NSCLC (≥65 '\n",
      "                                  'years) who received PD-1 blockade '\n",
      "                                  'monotherapy from September 2018 to December '\n",
      "                                  '2021 were screened retrospectively, and a '\n",
      "                                  'total of 68 elderly patients with NSCLC '\n",
      "                                  'were eligible for inclusion ultimately.'},\n",
      "                         {'dEnd': 170,\n",
      "                          'dStart': 165,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'And the safety profile in our study was '\n",
      "                                  'consistent with the adverse reactions of '\n",
      "                                  'the previous retrospective study regarding '\n",
      "                                  'PD-1 blockades in patients with advanced '\n",
      "                                  'NSCLC [8].'},\n",
      "                         {'dEnd': 66,\n",
      "                          'dStart': 61,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': '3.4. Safety Profile of the 68 Elderly '\n",
      "                                  'Patients with Advanced NSCLC Who Received '\n",
      "                                  'PD-1 Inhibitor Monotherapy'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'This study aimed to identify the '\n",
      "                                  'effectiveness and safety of PD-1 blockade '\n",
      "                                  'monotherapy among elderly patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Immunotherapy represented by PD-1 blockades '\n",
      "                                  'had become the standard of care for '\n",
      "                                  'advanced non-small cell lung cancer (NSCLC) '\n",
      "                                  'gradually.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Unfortunately, several PD-1 '\n",
      "                                  'inhibitor-related studies excluded elderly '\n",
      "                                  'patients with NSCLC over 75 years of age, '\n",
      "                                  'resulting in relatively limited evidence '\n",
      "                                  'regarding the efficacy and safety of PD-1 '\n",
      "                                  'in elderly patients with NSCLC clinically.'},\n",
      "                         {'dEnd': 72,\n",
      "                          'dStart': 67,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'All the adverse reactions of the 68 elderly '\n",
      "                                  'patients with advanced NSCLC during the '\n",
      "                                  'PD-1 inhibitor monotherapy administration '\n",
      "                                  'were collected as detailed as possible, and '\n",
      "                                  'the results are illustrated in Table 3.'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'Therefore, this study was to explore the '\n",
      "                                  'real-world evidence regarding the efficacy '\n",
      "                                  'and safety profile of PD-1 blockades among '\n",
      "                                  'elderly patients with advanced NSCLC '\n",
      "                                  'retrospectively.'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Additionally, PD-1 blockade monotherapy or '\n",
      "                                  'in combination with chemotherapy had become '\n",
      "                                  'the standard of care as second-line or '\n",
      "                                  'first-line treatment for patients with '\n",
      "                                  'advanced NSCLC, respectively [12].'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 177,\n",
      "                          'tStart': 173,\n",
      "                          'text': 'Noteworthily, the exploratory analysis '\n",
      "                                  'between PFS and baseline characteristic '\n",
      "                                  'subgroups in our study indicated that '\n",
      "                                  'elderly patients with advanced NSCLC might '\n",
      "                                  'benefit from PD-1 inhibitor monotherapy '\n",
      "                                  'uniformly regardless of the majority '\n",
      "                                  'baseline characteristic subgroups, which '\n",
      "                                  'highlighted that the effectiveness of PD-1 '\n",
      "                                  'blockades was stable and balanced across '\n",
      "                                  'different baseline characteristic subgroups '\n",
      "                                  '[34].'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Unfortunately, several PD-1 '\n",
      "                                  'inhibitor-related studies excluded elderly '\n",
      "                                  'patients with NSCLC over 75 years of age, '\n",
      "                                  'resulting in relatively limited evidence '\n",
      "                                  'regarding the efficacy and safety of PD-1 '\n",
      "                                  'in elderly patients with NSCLC clinically.'},\n",
      "                         {'dEnd': 307,\n",
      "                          'dStart': 302,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Furthermore, immunotherapy represented by '\n",
      "                                  'programmed cell death 1 (PD-1) blockades '\n",
      "                                  'also achieved convincing and durable '\n",
      "                                  'efficacy for advanced NSCLC with negative '\n",
      "                                  'driver gene mutation that was associated '\n",
      "                                  'with worse prognosis previously, which '\n",
      "                                  'improved the 5-year survival rate of '\n",
      "                                  'patients with advanced NSCLC from 5% to 20% '\n",
      "                                  '[6].'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'This study provided real-world evidence '\n",
      "                                  'regarding the feasibility and tolerability '\n",
      "                                  'regarding the administration of PD-1 '\n",
      "                                  'inhibitor monotherapy for previously '\n",
      "                                  'treated elderly patients with advanced '\n",
      "                                  'NSCLC retrospectively.'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 193,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'Collectively, whether number of metastatic '\n",
      "                                  'lesions and ECOG performance status might '\n",
      "                                  'be used as prognostic biomarkers for '\n",
      "                                  'elderly patients with advanced NSCLC who '\n",
      "                                  'received the treatment of PD-1 blockade '\n",
      "                                  'monotherapy should be validated in '\n",
      "                                  'prospective clinical trials subsequently.'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'The efficacy outcomes indicated that the '\n",
      "                                  'ORR and DCR of the 68 elderly patients with '\n",
      "                                  'advanced NSCLC who received PD-1 inhibitors '\n",
      "                                  'were 20.6% and 63.2%, respectively.'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Collectively, the current evidence-based '\n",
      "                                  'studies of PD-1 blockade monotherapy in '\n",
      "                                  'patients with advanced NSCLC was mainly '\n",
      "                                  'focused on relatively young patients, '\n",
      "                                  'suggesting that the efficacy and safety of '\n",
      "                                  'PD-1 inhibitors in elderly NSCLC patients '\n",
      "                                  'over 65 years was still scanty.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 blockade monotherapy exhibited '\n",
      "                                  'potential effectiveness and acceptable '\n",
      "                                  'toxicity for elderly patients with NSCLC.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 162,\n",
      "                          'tStart': 158,\n",
      "                          'text': 'As a result, it was necessary to identify '\n",
      "                                  'the association between baseline '\n",
      "                                  'characteristics and clinical outcomes of '\n",
      "                                  'patients with NSCLC who were treated with '\n",
      "                                  'PD-1 inhibitors, aiming to elucidate the '\n",
      "                                  'potential patients that might benefit from '\n",
      "                                  'PD-1 blockade administration.'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Elderly patients with advanced NSCLC (≥65 '\n",
      "                                  'years) who received PD-1 blockade '\n",
      "                                  'monotherapy from September 2018 to December '\n",
      "                                  '2021 were screened retrospectively, and a '\n",
      "                                  'total of 68 elderly patients with NSCLC '\n",
      "                                  'were eligible for inclusion ultimately.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Furthermore, immunotherapy represented by '\n",
      "                                  'programmed cell death 1 (PD-1) blockades '\n",
      "                                  'also achieved convincing and durable '\n",
      "                                  'efficacy for advanced NSCLC with negative '\n",
      "                                  'driver gene mutation that was associated '\n",
      "                                  'with worse prognosis previously, which '\n",
      "                                  'improved the 5-year survival rate of '\n",
      "                                  'patients with advanced NSCLC from 5% to 20% '\n",
      "                                  '[6].'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': 'The PFS survival curve is exhibited in '\n",
      "                                  'Figure 4, and the median PFS of the 68 '\n",
      "                                  'elderly patients with advanced NSCLC who '\n",
      "                                  'received PD-1 inhibitor monotherapy was 3.5 '\n",
      "                                  'months (95%CI: 2.38–4.62).'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Clinical outcomes and adverse reactions of '\n",
      "                                  'PD-1 blockade single agent were needed to '\n",
      "                                  'be confirmed in more elderly patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 116,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Effectiveness and Safety of PD-1 Inhibitor '\n",
      "                                  'Monotherapy for Elderly Patients with '\n",
      "                                  'Advanced Non-Small Cell Lung Cancer: A '\n",
      "                                  'Real-World Exploratory Study'},\n",
      "                         {'dEnd': 307,\n",
      "                          'dStart': 302,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'Furthermore, immunotherapy represented by '\n",
      "                                  'programmed cell death 1 (PD-1) blockades '\n",
      "                                  'also achieved convincing and durable '\n",
      "                                  'efficacy for advanced NSCLC with negative '\n",
      "                                  'driver gene mutation that was associated '\n",
      "                                  'with worse prognosis previously, which '\n",
      "                                  'improved the 5-year survival rate of '\n",
      "                                  'patients with advanced NSCLC from 5% to 20% '\n",
      "                                  '[6].'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': '3.2. Efficacy of the 68 Elderly Patients '\n",
      "                                  'with Advanced NSCLC Who Received PD-1 '\n",
      "                                  'Inhibitor Monotherapy'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'Furthermore, immunotherapy represented by '\n",
      "                                  'programmed cell death 1 (PD-1) blockades '\n",
      "                                  'also achieved convincing and durable '\n",
      "                                  'efficacy for advanced NSCLC with negative '\n",
      "                                  'driver gene mutation that was associated '\n",
      "                                  'with worse prognosis previously, which '\n",
      "                                  'improved the 5-year survival rate of '\n",
      "                                  'patients with advanced NSCLC from 5% to 20% '\n",
      "                                  '[6].'},\n",
      "                         {'dEnd': 267,\n",
      "                          'dStart': 262,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 blockade monotherapy yielded an '\n",
      "                                  'objective response rate (ORR) of '\n",
      "                                  'approximately 20%, a median '\n",
      "                                  'progression-free survival (PFS) of 3–6 '\n",
      "                                  'months, and a median overall survival (OS) '\n",
      "                                  'of 10–15 months as subsequent-line therapy '\n",
      "                                  'among patients with previously treated '\n",
      "                                  'NSCLC [13].'},\n",
      "                         {'dEnd': 375,\n",
      "                          'dStart': 370,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 310,\n",
      "                          'tStart': 306,\n",
      "                          'text': 'Nevertheless, ECOG performance status score '\n",
      "                                  '(HR = 0.69, P=0.03) and number of '\n",
      "                                  'metastatic lesions (HR = 0.61, P=0.02) were '\n",
      "                                  'also statistically significant after '\n",
      "                                  'multivariate analysis, suggesting that ECOG '\n",
      "                                  'performance status and number of metastatic '\n",
      "                                  'lesions were independent factors for '\n",
      "                                  'predicting the PFS of PD-1 inhibitor '\n",
      "                                  'monotherapy among elderly patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': '3.3. Prognostic Outcomes of the 68 Elderly '\n",
      "                                  'Patients with Advanced NSCLC Who Received '\n",
      "                                  'PD-1 Inhibitor Monotherapy'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Collectively, all the above studies '\n",
      "                                  'indicated that PD-1 inhibitor monotherapy '\n",
      "                                  'might be an efficacious therapeutic option '\n",
      "                                  'for elderly patients with advanced NSCLC in '\n",
      "                                  'real-world practice.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Immunotherapy represented by PD-1 blockades '\n",
      "                                  'had become the standard of care for '\n",
      "                                  'advanced non-small cell lung cancer (NSCLC) '\n",
      "                                  'gradually.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 171,\n",
      "                          'tStart': 167,\n",
      "                          'text': 'Another Italian, retrospective study '\n",
      "                                  'initiated by Andrea luciani et al. '\n",
      "                                  'recruited a total of 86 patients with '\n",
      "                                  'advanced NSCLC aged ≥75 years who were '\n",
      "                                  'administered with PD-1 inhibitors [32].'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'Given that some PD-1 blockades were '\n",
      "                                  'licensed as second-line monotherapy for '\n",
      "                                  'patients with advanced NSCLC in China, the '\n",
      "                                  'administration of PD-1 inhibitors in our '\n",
      "                                  'study was reasonable and ethical.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'Collectively, the findings of this study '\n",
      "                                  'were of clinical guiding significance to '\n",
      "                                  'provide the efficacy and safety data of '\n",
      "                                  'PD-1 inhibitor monotherapy in clinical '\n",
      "                                  'practice for elderly patients with advanced '\n",
      "                                  'NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37898752'],\n",
      " 'resourceScore': 101,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 187,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 115,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Concurrently, within the memory-enriched '\n",
      "                                  'compartment, we observed a higher frequency '\n",
      "                                  'of the less differentiated PD1+CD28+ '\n",
      "                                  'phenotype and fewer PD1−CD28− cells in '\n",
      "                                  'non-small cell lung cancer (NSCLC) patients '\n",
      "                                  'when compared to both HDs and other tumor '\n",
      "                                  'types (Fig. S3A).'},\n",
      "                         {'dEnd': 303,\n",
      "                          'dStart': 298,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 196,\n",
      "                          'text': 'To gain a baseline landscape of the '\n",
      "                                  'composition, functional states, and '\n",
      "                                  'transcriptomic signatures predictive of '\n",
      "                                  'prognosis, we analyzed CD8+ T-cell subsets '\n",
      "                                  'characterized by the presence/absence of '\n",
      "                                  'PD1 and CD28 from periphery, adjacent '\n",
      "                                  'non-tumor tissue and tumor site of a cohort '\n",
      "                                  'of treatment-naïve NSCLC patients, by '\n",
      "                                  'integrated multiparametric flow cytometry, '\n",
      "                                  'targeted multi-omic scRNA-seq analyses, and '\n",
      "                                  'computational pipelines.'},\n",
      "                         {'dEnd': 407,\n",
      "                          'dStart': 402,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'Considering the critical role of the '\n",
      "                                  'CXCL13/CXCR5 axis in modulating lymphocyte '\n",
      "                                  'infiltration [56, 57], our evidence that '\n",
      "                                  'intra-tumor PD1+CD28− TRM possess highest '\n",
      "                                  'CXCL13 chemokine, while memory stem-like '\n",
      "                                  'marker CXCR5 [58] is mostly expressed by '\n",
      "                                  'CD28+ (CD103 low) T cells (Fig. S9), '\n",
      "                                  'favours a scenario of CD28−CXCL13+ T cells '\n",
      "                                  'attracting memory reservoir CD28+CXCR5+ T '\n",
      "                                  'cells within the tumor site in our NSCLC '\n",
      "                                  'setting.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Interestingly, the CD8+PD1+CD28− T-cell '\n",
      "                                  'subset showed the highest polyfunctionality '\n",
      "                                  'in each melanoma, NSCLC, and PDAC cancer '\n",
      "                                  'patients (Fig. 2E,F).'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'In the present study, we in depth explored '\n",
      "                                  'the CD8+ T-cell subsets characterized by '\n",
      "                                  'the presence/absence of PD1 and CD28, by '\n",
      "                                  'integrated multiparametric flow cytometry '\n",
      "                                  'and multi-omic scRNA-Seq analyses in '\n",
      "                                  'treatment-naïve NSCLC patients.'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'CD28 impacts the periphery/tissue '\n",
      "                                  'compartmentalization, the transcriptional '\n",
      "                                  'profile and the (dys)functional states of '\n",
      "                                  'CD8+PD1+ T cells in NSCLC patients'},\n",
      "                         {'dEnd': 274,\n",
      "                          'dStart': 269,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Focusing on NSCLC, then we evaluated the '\n",
      "                                  'dynamic distribution and functionality of '\n",
      "                                  'PD1+CD28− and PD1+CD28+ T-cell subsets in '\n",
      "                                  '68 treatment-naïve NSCLC patients (Table '\n",
      "                                  'S1), by comparing peripheral blood, '\n",
      "                                  'adjacent non-tumor (NT) tissue and tumor '\n",
      "                                  'site (T) (n = 32 matched NSCLC patients).'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'The analysis of the T-cell differentiation '\n",
      "                                  'stage by CCR7 and CD45RA expression in '\n",
      "                                  'CD8+PD1+CD28− T cells isolated from '\n",
      "                                  'peripheral blood of NSCLC patients, showed '\n",
      "                                  'a predominant terminal-differentiated '\n",
      "                                  'effector-memory (EMRA, 65.4%) and '\n",
      "                                  'effector-memory (EM, 27.3%) phenotype (Fig. '\n",
      "                                  '2C,D).'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 126,\n",
      "                          'text': 'In conclusion our work highlights how the '\n",
      "                                  'co-stimulatory molecule CD28 is crucial in '\n",
      "                                  'dictating different functional states in '\n",
      "                                  'PD1+ CD8+ T cells in peripheral blood and '\n",
      "                                  'tumor site of NSCLC patients.'},\n",
      "                         {'dEnd': 17,\n",
      "                          'dStart': 12,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Focusing on NSCLC, then we evaluated the '\n",
      "                                  'dynamic distribution and functionality of '\n",
      "                                  'PD1+CD28− and PD1+CD28+ T-cell subsets in '\n",
      "                                  '68 treatment-naïve NSCLC patients (Table '\n",
      "                                  'S1), by comparing peripheral blood, '\n",
      "                                  'adjacent non-tumor (NT) tissue and tumor '\n",
      "                                  'site (T) (n = 32 matched NSCLC patients).'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'In the tumor, a considerable increase of '\n",
      "                                  'TRM phenotype was observed only in CD28− T '\n",
      "                                  'lymphocytes (percentage of TRM within '\n",
      "                                  'PD1+CD28− T cells, NT vs T, P = 0.01), '\n",
      "                                  'strongly indicating that most PD1+CD28− T '\n",
      "                                  'cells infiltrating the NSCLC tumor site '\n",
      "                                  'possess a TRM phenotype, as previously '\n",
      "                                  'reported [34, 36].'},\n",
      "                         {'dEnd': 247,\n",
      "                          'dStart': 242,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Herein, starting from the analysis of a '\n",
      "                                  'panel of Ag-specific melanoma CD8+PD1+ '\n",
      "                                  'T-cell clones, we have identified different '\n",
      "                                  'transcriptomic, phenotypic, and functional '\n",
      "                                  'patterns dictated by the presence/absence '\n",
      "                                  'of CD28 in peripheral and matched NSCLC '\n",
      "                                  'tissue.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'CD28/PD1 co-expression: dual impact on CD8+ '\n",
      "                                  'T cells in peripheral blood and tumor '\n",
      "                                  'tissue, and its significance in NSCLC '\n",
      "                                  \"patients' survival and ICB response\"},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'Focusing on NSCLC, then we evaluated the '\n",
      "                                  'dynamic distribution and functionality of '\n",
      "                                  'PD1+CD28− and PD1+CD28+ T-cell subsets in '\n",
      "                                  '68 treatment-naïve NSCLC patients (Table '\n",
      "                                  'S1), by comparing peripheral blood, '\n",
      "                                  'adjacent non-tumor (NT) tissue and tumor '\n",
      "                                  'site (T) (n = 32 matched NSCLC patients).'},\n",
      "                         {'dEnd': 274,\n",
      "                          'dStart': 269,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'Focusing on NSCLC, then we evaluated the '\n",
      "                                  'dynamic distribution and functionality of '\n",
      "                                  'PD1+CD28− and PD1+CD28+ T-cell subsets in '\n",
      "                                  '68 treatment-naïve NSCLC patients (Table '\n",
      "                                  'S1), by comparing peripheral blood, '\n",
      "                                  'adjacent non-tumor (NT) tissue and tumor '\n",
      "                                  'site (T) (n = 32 matched NSCLC patients).'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 115,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Concurrently, within the memory-enriched '\n",
      "                                  'compartment, we observed a higher frequency '\n",
      "                                  'of the less differentiated PD1+CD28+ '\n",
      "                                  'phenotype and fewer PD1−CD28− cells in '\n",
      "                                  'non-small cell lung cancer (NSCLC) patients '\n",
      "                                  'when compared to both HDs and other tumor '\n",
      "                                  'types (Fig. S3A).'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'Based on results obtained on Ag-specific '\n",
      "                                  'CD8+ T-cell clones, we then investigated '\n",
      "                                  'the frequency and fitness of CD8+ PD1+CD28− '\n",
      "                                  'and PD1+CD28+ T cells in the peripheral '\n",
      "                                  'blood of 68 patients with cancer of '\n",
      "                                  'different derivation (n = 48 NSCLC, Table '\n",
      "                                  'S1), n = 10 melanoma, n = 10 pancreas '\n",
      "                                  'ductal adenocarcinoma cancer (PDAC)) and in '\n",
      "                                  '25 healthy donors (HDs), by multi-color '\n",
      "                                  'flow-cytometry analysis (as outlined in the '\n",
      "                                  'gating strategy, Fig. S2) (Fig. 2A,B), '\n",
      "                                  'defined by the expression of CD28 and/or '\n",
      "                                  'PD1 within CD8+ T cells.'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Based on results obtained on Ag-specific '\n",
      "                                  'CD8+ T-cell clones, we then investigated '\n",
      "                                  'the frequency and fitness of CD8+ PD1+CD28− '\n",
      "                                  'and PD1+CD28+ T cells in the peripheral '\n",
      "                                  'blood of 68 patients with cancer of '\n",
      "                                  'different derivation (n = 48 NSCLC, Table '\n",
      "                                  'S1), n = 10 melanoma, n = 10 pancreas '\n",
      "                                  'ductal adenocarcinoma cancer (PDAC)) and in '\n",
      "                                  '25 healthy donors (HDs), by multi-color '\n",
      "                                  'flow-cytometry analysis (as outlined in the '\n",
      "                                  'gating strategy, Fig. S2) (Fig. 2A,B), '\n",
      "                                  'defined by the expression of CD28 and/or '\n",
      "                                  'PD1 within CD8+ T cells.'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 194,\n",
      "                          'tStart': 191,\n",
      "                          'text': 'In the tumor, a considerable increase of '\n",
      "                                  'TRM phenotype was observed only in CD28− T '\n",
      "                                  'lymphocytes (percentage of TRM within '\n",
      "                                  'PD1+CD28− T cells, NT vs T, P = 0.01), '\n",
      "                                  'strongly indicating that most PD1+CD28− T '\n",
      "                                  'cells infiltrating the NSCLC tumor site '\n",
      "                                  'possess a TRM phenotype, as previously '\n",
      "                                  'reported [34, 36].'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Focusing on NSCLC, then we evaluated the '\n",
      "                                  'dynamic distribution and functionality of '\n",
      "                                  'PD1+CD28− and PD1+CD28+ T-cell subsets in '\n",
      "                                  '68 treatment-naïve NSCLC patients (Table '\n",
      "                                  'S1), by comparing peripheral blood, '\n",
      "                                  'adjacent non-tumor (NT) tissue and tumor '\n",
      "                                  'site (T) (n = 32 matched NSCLC patients).'},\n",
      "                         {'dEnd': 247,\n",
      "                          'dStart': 242,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'However, CD28+ T-cell functional fitness '\n",
      "                                  'was not improved by the absence of the 4 '\n",
      "                                  'IRs evaluated, enforcing the role of PD1 '\n",
      "                                  'alone in impairing the functional '\n",
      "                                  'competence of CD8+ T cells through a '\n",
      "                                  'CD28-dependent mechanism in peripheral '\n",
      "                                  'blood of NSCLC patients.'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'CD28 expression dictates an opposite '\n",
      "                                  'functional behavior in CD8+PD1+ T cells '\n",
      "                                  'with the transition from the periphery to '\n",
      "                                  'the tumor site in NSCLC patients'},\n",
      "                         {'dEnd': 235,\n",
      "                          'dStart': 230,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'Next, we focused on the role of '\n",
      "                                  'co-stimulatory molecules other than CD28, '\n",
      "                                  'i.e. ICOS [30], CD137 (4-1BB) [31], and '\n",
      "                                  'integrin CD11a [32] (Fig. S2) as '\n",
      "                                  'contributors to the functional fitness of '\n",
      "                                  'PD1+CD28− T cells in peripheral blood of '\n",
      "                                  'NSCLC cancer patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35910005'],\n",
      " 'resourceScore': 117,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 246,\n",
      "                          'dStart': 241,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'Of interest, we found that the early‐like '\n",
      "                                  'differentiation status at baseline '\n",
      "                                  'represented by the ratio of PD‐1+CD8+ TEEM '\n",
      "                                  'to PD‐1+CD8 TE was associated with longer '\n",
      "                                  'progression‐free survival and durable '\n",
      "                                  'clinical benefit of anti‐PD‐1 therapy in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 233,\n",
      "                          'dStart': 228,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'In summary, our data demonstrates that '\n",
      "                                  'nivolumab therapy‐induced T‐cell expansion '\n",
      "                                  'is mostly observed with cells displaying a '\n",
      "                                  'PD‐1+CD8+ TEEM cell phenotype which is '\n",
      "                                  'associated with positive impact on '\n",
      "                                  'progression‐free survival in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Taken together, we have identified the '\n",
      "                                  'baseline PD‐1+ TEEM to PD‐1+ TE ratio as an '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'On the contrary, effector CD8+ T cells with '\n",
      "                                  'low PD‐1 incidence were found to be '\n",
      "                                  'associated with clinical benefit to '\n",
      "                                  'nivolumab therapy and prolonged PFS in a '\n",
      "                                  'cohort of NSCLC patients, suggesting that '\n",
      "                                  'presence of lower percentages of '\n",
      "                                  'intra‐tumoral PD‐1+ TE cells is in favor of '\n",
      "                                  'more proficient antitumor immunity.29'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 156,\n",
      "                          'tStart': 152,\n",
      "                          'text': 'However, such therapies are only beneficial '\n",
      "                                  'to a limited fraction of patients; the '\n",
      "                                  'majority of advanced NSCLC patients on '\n",
      "                                  'progression do not respond to PD‐1 '\n",
      "                                  'blockade.6'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Indeed, systemic PD‐1+CD8+ T cells were '\n",
      "                                  'shown to expand upon PD‐1 blockade in NSCLC '\n",
      "                                  'patients and that such activation '\n",
      "                                  'correlated well with clinical responses.13'},\n",
      "                         {'dEnd': 260,\n",
      "                          'dStart': 255,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'To explore the distinct peripheral CD8+ '\n",
      "                                  'T‐cell composition in NSCLC and its '\n",
      "                                  'potential association with responses to '\n",
      "                                  'PD‐1 blockade, we conducted a prospective '\n",
      "                                  'analysis on PBMC samples isolated from the '\n",
      "                                  'fresh blood of a discovery cohort of 47 '\n",
      "                                  'patients with NSCLC before the initiation '\n",
      "                                  'of PD‐1 blockade therapy (baseline) and '\n",
      "                                  'every 3 weeks upon nivolumab (anti‐PD‐1 '\n",
      "                                  'antibody therapy) allocation.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 148,\n",
      "                          'tStart': 144,\n",
      "                          'text': 'These findings also establish a clear '\n",
      "                                  'association between PD‐1 expression, the '\n",
      "                                  'differentiation status of systemic CD8+ T '\n",
      "                                  'cells and responses to PD‐1 blockade in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 456,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 352,\n",
      "                          'dStart': 347,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 283,\n",
      "                          'tStart': 279,\n",
      "                          'text': 'Furthermore, the divergence in the '\n",
      "                                  'differentiation status from early‐like '\n",
      "                                  'differentiated (ELD) for TEEM to highly '\n",
      "                                  'differentiated (HD) for TE infers more '\n",
      "                                  'significance in considering integrating '\n",
      "                                  'these two subsets into one novel parameter '\n",
      "                                  'which is the baseline ratio PD‐1+CD8+ '\n",
      "                                  'TEEM/PD‐1+CD8+ TE. By doing so, we were '\n",
      "                                  'more able to better identify the NSCLC '\n",
      "                                  'patients who were most likely to derive '\n",
      "                                  'clinical benefit form PD‐1 blockade (Figure '\n",
      "                                  '3).'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Hence, in this study, we analyzed the '\n",
      "                                  'distinct differentiation subsets within '\n",
      "                                  'circulating PD‐1+CD8+ T cells in advanced '\n",
      "                                  'NSCLC patients before and upon PD‐1 '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'In this model with more PD‐1+CD8+ TEEM and '\n",
      "                                  'less PD‐1+CD8+ TE in the peripheral blood '\n",
      "                                  'at baseline, NSCLC patients could mount '\n",
      "                                  'proficient anti‐tumor immunity upon '\n",
      "                                  'inhibition of PD‐1 pathway.'},\n",
      "                         {'dEnd': 456,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 424,\n",
      "                          'tStart': 420,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Indeed, systemic PD‐1+CD8+ T cells were '\n",
      "                                  'shown to expand upon PD‐1 blockade in NSCLC '\n",
      "                                  'patients and that such activation '\n",
      "                                  'correlated well with clinical responses.13'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'Taken together, we have identified the '\n",
      "                                  'baseline PD‐1+ TEEM to PD‐1+ TE ratio as an '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 456,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Interestingly, PD‐1+ TEEM to PD‐1+ TE ratio '\n",
      "                                  'exhibited a significant positive '\n",
      "                                  'association with PFS, NSCLC patients with a '\n",
      "                                  'ratio higher than 5.7 had a notable '\n",
      "                                  'prolonged PFS with a median of 173 days, '\n",
      "                                  'whereas those with values < 5.7 had a PFS '\n",
      "                                  'median of only 54 days (P = 0.006) (Figure '\n",
      "                                  '3f).'},\n",
      "                         {'dEnd': 216,\n",
      "                          'dStart': 211,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'These findings thus demonstrate the '\n",
      "                                  'relevance of the baseline T‐cell '\n",
      "                                  'differentiation status in determining '\n",
      "                                  'responses to PD‐1‐targeted immunotherapies '\n",
      "                                  'and provide a novel predictor of benefit to '\n",
      "                                  'PD‐1 blockade in NSCLC.'},\n",
      "                         {'dEnd': 57,\n",
      "                          'dStart': 52,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'We carried out a prospective study on a '\n",
      "                                  'total of 77 NSCLC patients receiving '\n",
      "                                  'anti‐PD‐1 blockers, among which 47 patients '\n",
      "                                  'were assigned as a discovery cohort and 30 '\n",
      "                                  'patients as a validation cohort.'},\n",
      "                         {'dEnd': 216,\n",
      "                          'dStart': 211,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 124,\n",
      "                          'tStart': 120,\n",
      "                          'text': 'These findings thus demonstrate the '\n",
      "                                  'relevance of the baseline T‐cell '\n",
      "                                  'differentiation status in determining '\n",
      "                                  'responses to PD‐1‐targeted immunotherapies '\n",
      "                                  'and provide a novel predictor of benefit to '\n",
      "                                  'PD‐1 blockade in NSCLC.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 246,\n",
      "                          'dStart': 241,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 229,\n",
      "                          'tStart': 225,\n",
      "                          'text': 'Of interest, we found that the early‐like '\n",
      "                                  'differentiation status at baseline '\n",
      "                                  'represented by the ratio of PD‐1+CD8+ TEEM '\n",
      "                                  'to PD‐1+CD8 TE was associated with longer '\n",
      "                                  'progression‐free survival and durable '\n",
      "                                  'clinical benefit of anti‐PD‐1 therapy in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 456,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 274,\n",
      "                          'tStart': 270,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 291,\n",
      "                          'dStart': 286,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'In our analysis of the peripheral '\n",
      "                                  'compartment of NSCLC patients, we also '\n",
      "                                  'noticed that PD‐1 expression was more '\n",
      "                                  'frequent on CD8+ T cells displaying memory '\n",
      "                                  'phenotypes including TCM, TTM, TEEM and TEM '\n",
      "                                  'subsets than on TN, TE, TpE2 and TpE3 '\n",
      "                                  'effector subsets in the peripheral '\n",
      "                                  'compartment of NSCLC patients (Figure 3b).'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'In this model with more PD‐1+CD8+ TEEM and '\n",
      "                                  'less PD‐1+CD8+ TE in the peripheral blood '\n",
      "                                  'at baseline, NSCLC patients could mount '\n",
      "                                  'proficient anti‐tumor immunity upon '\n",
      "                                  'inhibition of PD‐1 pathway.'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'The baseline ratio of PD‐1+ early effector '\n",
      "                                  'memory T cells to PD‐1+ fully '\n",
      "                                  'differentiated effector CD8+ T cell '\n",
      "                                  'predicts responses to PD‐1 blockade in '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 456,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Taken together, our study identified the '\n",
      "                                  'baseline PD‐1+CD8+ TEEM/PD‐1+CD8+ TE ratio '\n",
      "                                  'as a novel non‐invasive pre‐treatment '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC patients and describes a model in '\n",
      "                                  'which the differentiation state of '\n",
      "                                  'peripheral CD8+ T cells before PD‐1 therapy '\n",
      "                                  'in part orients the arm of antitumor '\n",
      "                                  'immunity through regulating the expansion '\n",
      "                                  'of TEEM fractions and therefore '\n",
      "                                  'conditioning responses to PD‐1‐targeted '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 70,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'To validate these findings, we included an '\n",
      "                                  'independent cohort of NSCLC patients '\n",
      "                                  'receiving different anti‐PD‐1 agents '\n",
      "                                  '(validation cohort) (Table 1 and '\n",
      "                                  'Supplementary table 1).'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'The baseline ratio of PD‐1+ early effector '\n",
      "                                  'memory T cells to PD‐1+ fully '\n",
      "                                  'differentiated effector CD8+ T cell '\n",
      "                                  'predicts responses to PD‐1 blockade in '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 218,\n",
      "                          'tStart': 214,\n",
      "                          'text': 'Considering the heterogeneity of the '\n",
      "                                  'peripheral CD8+ T‐cell pool in terms of '\n",
      "                                  'states of maturation and differentiation, '\n",
      "                                  'whether the differentiation status of CD8+ '\n",
      "                                  'T subsets with unique functionality '\n",
      "                                  'correlates with PD‐1 blockade in NSCLC has '\n",
      "                                  'not yet been addressed and is worthy of '\n",
      "                                  'investigation.'},\n",
      "                         {'dEnd': 246,\n",
      "                          'dStart': 241,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Of interest, we found that the early‐like '\n",
      "                                  'differentiation status at baseline '\n",
      "                                  'represented by the ratio of PD‐1+CD8+ TEEM '\n",
      "                                  'to PD‐1+CD8 TE was associated with longer '\n",
      "                                  'progression‐free survival and durable '\n",
      "                                  'clinical benefit of anti‐PD‐1 therapy in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Interestingly, PD‐1+ TEEM to PD‐1+ TE ratio '\n",
      "                                  'exhibited a significant positive '\n",
      "                                  'association with PFS, NSCLC patients with a '\n",
      "                                  'ratio higher than 5.7 had a notable '\n",
      "                                  'prolonged PFS with a median of 173 days, '\n",
      "                                  'whereas those with values < 5.7 had a PFS '\n",
      "                                  'median of only 54 days (P = 0.006) (Figure '\n",
      "                                  '3f).'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'In this study, we investigated whether the '\n",
      "                                  'differentiation status of systemic CD8+ T '\n",
      "                                  'cells predicts the outcome of PD‐1 blockade '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'The baseline ratio of PD‐1+ early effector '\n",
      "                                  'memory T cells to PD‐1+ fully '\n",
      "                                  'differentiated effector CD8+ T cell '\n",
      "                                  'predicts responses to PD‐1 blockade in '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Taken together, we have identified the '\n",
      "                                  'baseline PD‐1+ TEEM to PD‐1+ TE ratio as an '\n",
      "                                  'indicator of response to PD‐1 blockade in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 352,\n",
      "                          'dStart': 347,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 268,\n",
      "                          'tStart': 264,\n",
      "                          'text': 'Furthermore, the divergence in the '\n",
      "                                  'differentiation status from early‐like '\n",
      "                                  'differentiated (ELD) for TEEM to highly '\n",
      "                                  'differentiated (HD) for TE infers more '\n",
      "                                  'significance in considering integrating '\n",
      "                                  'these two subsets into one novel parameter '\n",
      "                                  'which is the baseline ratio PD‐1+CD8+ '\n",
      "                                  'TEEM/PD‐1+CD8+ TE. By doing so, we were '\n",
      "                                  'more able to better identify the NSCLC '\n",
      "                                  'patients who were most likely to derive '\n",
      "                                  'clinical benefit form PD‐1 blockade (Figure '\n",
      "                                  '3).'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'In our analysis of the peripheral '\n",
      "                                  'compartment of NSCLC patients, we also '\n",
      "                                  'noticed that PD‐1 expression was more '\n",
      "                                  'frequent on CD8+ T cells displaying memory '\n",
      "                                  'phenotypes including TCM, TTM, TEEM and TEM '\n",
      "                                  'subsets than on TN, TE, TpE2 and TpE3 '\n",
      "                                  'effector subsets in the peripheral '\n",
      "                                  'compartment of NSCLC patients (Figure 3b).'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'These findings also establish a clear '\n",
      "                                  'association between PD‐1 expression, the '\n",
      "                                  'differentiation status of systemic CD8+ T '\n",
      "                                  'cells and responses to PD‐1 blockade in '\n",
      "                                  'NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37430270'],\n",
      " 'resourceScore': 102,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'However, the overall objective response '\n",
      "                                  'rate for PD-1 and PD-L1 inhibitors in NSCLC '\n",
      "                                  'is unsatisfactory (less than 20%) [6], and '\n",
      "                                  'PD-1 resistance may appear in patients with '\n",
      "                                  'advanced NSCLC [7].'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 186,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'These results suggest that anti-PD-1 alone '\n",
      "                                  'does not provide an effective response '\n",
      "                                  'against NSCLC in the HuNCG mouse model, '\n",
      "                                  'however, PD-1 inhibitor combined with SMI '\n",
      "                                  'may increase the anti-NSCLC response.'},\n",
      "                         {'dEnd': 241,\n",
      "                          'dStart': 236,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Given that both SMI and PD-1/PD-L1 '\n",
      "                                  'inhibitors primarily induce '\n",
      "                                  'immunomodulatory effects and impact similar '\n",
      "                                  'immune cells, we investigated whether the '\n",
      "                                  'combination of SMI and ICIs exerts '\n",
      "                                  'synergistic antitumor effects with minimal '\n",
      "                                  'irAEs in NSCLC.'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 313,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 258,\n",
      "                          'tStart': 254,\n",
      "                          'text': 'Our findings revealed that the proportion '\n",
      "                                  'of tumor-infiltrating NK cells was '\n",
      "                                  'significantly increased following '\n",
      "                                  'combination therapy in both the LUAD and '\n",
      "                                  'LUSC humanized mouse models compared with '\n",
      "                                  'that in the monotherapy, suggesting that '\n",
      "                                  'the combination of PD-1 inhibitor with SMI '\n",
      "                                  'recruited NK cells into the TME of NSCLC.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 131,\n",
      "                          'tStart': 127,\n",
      "                          'text': 'However, the overall objective response '\n",
      "                                  'rate for PD-1 and PD-L1 inhibitors in NSCLC '\n",
      "                                  'is unsatisfactory (less than 20%) [6], and '\n",
      "                                  'PD-1 resistance may appear in patients with '\n",
      "                                  'advanced NSCLC [7].'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Therefore, the combined effects and '\n",
      "                                  'mechanisms of SMI and programmed death-1 '\n",
      "                                  '(PD-1) inhibitor against NSCLC was focused '\n",
      "                                  'on this study.'},\n",
      "                         {'dEnd': 303,\n",
      "                          'dStart': 298,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'In this study, we demonstrated that '\n",
      "                                  'combination therapy of a PD-1 inhibitor and '\n",
      "                                  'SMI significantly improved antitumor '\n",
      "                                  'efficacy and prolonged survival without '\n",
      "                                  'increasing irAEs in the LLC mouse and '\n",
      "                                  'NCI-H226 HuNCG mouse models, providing '\n",
      "                                  'preclinical evidence for a new combination '\n",
      "                                  'therapy strategy for NSCLC.'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Despite the promise of ICIs therapy, less '\n",
      "                                  'than 20% of patients with NSCLC respond to '\n",
      "                                  'immunotherapy alone, and a large proportion '\n",
      "                                  'do not respond to PD-1/PD-L1 monotherapy, '\n",
      "                                  'while some patients suffer severe irAEs.'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 163,\n",
      "                          'tStart': 159,\n",
      "                          'text': 'Besides, higher levels of GZMA and XCL1 '\n",
      "                                  'were observed in the NK cells from the '\n",
      "                                  'PD-1+SMI group compared with those in the '\n",
      "                                  'remaining groups, suggesting that the PD-1 '\n",
      "                                  'inhibitor combined with SMI induced '\n",
      "                                  'cytotoxic NK cells to infiltrate the NSCLC '\n",
      "                                  'tumor and may recruit DCs into the tumor '\n",
      "                                  'via NK cells, thus improving the antitumor '\n",
      "                                  'efficacy.'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Treatment with PD-1 inhibitor combined with '\n",
      "                                  'the immunomodulator SMI improved antitumor '\n",
      "                                  'efficacy and extended survival without '\n",
      "                                  'increasing irAEs in NSCLC.'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'The U.S. Food and Drug Administration has '\n",
      "                                  'approved pembrolizumab (a PD-1 inhibitor) '\n",
      "                                  'as a first-line therapy for tumors with a '\n",
      "                                  'PD-L1 tumor proportion score ≥ 1% in NSCLC, '\n",
      "                                  'cemiplimab (also a PD-1 inhibitor) for '\n",
      "                                  'patients with PD-L1 expression ≥ 50%, and '\n",
      "                                  'atezolizumab (a PD-L1 inhibitor) for '\n",
      "                                  'patients with high PD-L1-expressing '\n",
      "                                  'metastatic NSCLC [5].'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Programmed death-1/programmed death-ligand '\n",
      "                                  '1 (PD-1/PD-L1) inhibitors are ICIs that '\n",
      "                                  'have been shown to significantly prolong '\n",
      "                                  'the median progression-free survival (PFS) '\n",
      "                                  'and overall survival (OS) in patients with '\n",
      "                                  'NSCLC, including those with LUAD and LUSC '\n",
      "                                  '[3].'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'To determine whether PD-1 immune-checkpoint '\n",
      "                                  'blockade combined with the immunomodulator '\n",
      "                                  'SMI is more effective than PD-1 inhibitor '\n",
      "                                  'monotherapy in treating NSCLC, the LLC '\n",
      "                                  'subcutaneous C57BL/6 mouse model was first '\n",
      "                                  'adopted to detect the efficacy and safety '\n",
      "                                  'of this combined therapy.'},\n",
      "                         {'dEnd': 294,\n",
      "                          'dStart': 289,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Moreover, expression of CD163, ITGAM, CCL5, '\n",
      "                                  'and CD27 was lower in the macrophages of '\n",
      "                                  'the PD-1+SMI group compared with that in '\n",
      "                                  'the IgG, PD-1, and SMI groups (Fig. 6G), '\n",
      "                                  'and higher expression of these genes in '\n",
      "                                  'tumor-associated macrophages is associated '\n",
      "                                  'with lower PFS and OS in patients with '\n",
      "                                  'NSCLC and resistance to immunotherapy '\n",
      "                                  '[66].'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Besides, higher levels of GZMA and XCL1 '\n",
      "                                  'were observed in the NK cells from the '\n",
      "                                  'PD-1+SMI group compared with those in the '\n",
      "                                  'remaining groups, suggesting that the PD-1 '\n",
      "                                  'inhibitor combined with SMI induced '\n",
      "                                  'cytotoxic NK cells to infiltrate the NSCLC '\n",
      "                                  'tumor and may recruit DCs into the tumor '\n",
      "                                  'via NK cells, thus improving the antitumor '\n",
      "                                  'efficacy.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 93,\n",
      "                          'text': 'Single-cell RNA sequencing reveals enhanced '\n",
      "                                  'antitumor immunity after combined '\n",
      "                                  'application of PD-1 inhibitor and Shenmai '\n",
      "                                  'injection in non-small cell lung cancer'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 144,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'For the first time, our study reveals that '\n",
      "                                  'elevated GFPT2 expression is correlated '\n",
      "                                  'with poor clinical outcomes in LUSC, '\n",
      "                                  'suggesting that the PD-1 inhibitor combined '\n",
      "                                  'with SMI may prolong patient survival in '\n",
      "                                  'NSCLC by decreasing the proportion of '\n",
      "                                  'GFPT2+ CAFs.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'Importantly, numerous immune-related '\n",
      "                                  'adverse events (irAEs) have been reported '\n",
      "                                  'in patients with NSCLC treated with PD-1 or '\n",
      "                                  'PD-L1 inhibitors, including pneumonitis, '\n",
      "                                  'thyroiditis, and dermatitis [9].'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 139,\n",
      "                          'tStart': 135,\n",
      "                          'text': 'This study demonstrated that SMI reprograms '\n",
      "                                  'tumor immune microenvironment mainly by '\n",
      "                                  'inducing NK cells infiltration and '\n",
      "                                  'synergizes with PD-1 inhibitor against '\n",
      "                                  'NSCLC, suggested that targeting NK cells '\n",
      "                                  'may be an important strategy for combining '\n",
      "                                  'with ICIs.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'These results suggest that anti-PD-1 alone '\n",
      "                                  'does not provide an effective response '\n",
      "                                  'against NSCLC in the HuNCG mouse model, '\n",
      "                                  'however, PD-1 inhibitor combined with SMI '\n",
      "                                  'may increase the anti-NSCLC response.'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Using scRNA-seq, we determined that the '\n",
      "                                  'combination of PD-1 inhibitor and SMI '\n",
      "                                  'induced cytotoxic NK cells to infiltrate '\n",
      "                                  'the NSCLC tumor, recruited DCs to tumors '\n",
      "                                  'via NK cell activation, alleviated the '\n",
      "                                  'exhausted state of T and NK cells, reduced '\n",
      "                                  'angiogenic characteristics in the TME, and '\n",
      "                                  'diminished cancer metabolism '\n",
      "                                  'reprogramming-associated CAFs.'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 186,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'These results suggest that anti-PD-1 alone '\n",
      "                                  'does not provide an effective response '\n",
      "                                  'against NSCLC in the HuNCG mouse model, '\n",
      "                                  'however, PD-1 inhibitor combined with SMI '\n",
      "                                  'may increase the anti-NSCLC response.'},\n",
      "                         {'dEnd': 314,\n",
      "                          'dStart': 309,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 270,\n",
      "                          'tStart': 266,\n",
      "                          'text': 'Therefore, in this study, we evaluated the '\n",
      "                                  'combined effects of SMI and PD-1 inhibitors '\n",
      "                                  'in a Lewis lung carcinoma (LLC) C57BL/6 and '\n",
      "                                  'LUSC NCI-H226 humanized mouse model and '\n",
      "                                  'explored the synergistic mechanisms of '\n",
      "                                  'combined therapy using scRNA-seq to provide '\n",
      "                                  'insights on PD-1 inhibitor/SMI combination '\n",
      "                                  'therapy for NSCLC.'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'To determine whether PD-1 immune-checkpoint '\n",
      "                                  'blockade combined with the immunomodulator '\n",
      "                                  'SMI is more effective than PD-1 inhibitor '\n",
      "                                  'monotherapy in treating NSCLC, the LLC '\n",
      "                                  'subcutaneous C57BL/6 mouse model was first '\n",
      "                                  'adopted to detect the efficacy and safety '\n",
      "                                  'of this combined therapy.'},\n",
      "                         {'dEnd': 314,\n",
      "                          'dStart': 309,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'Therefore, in this study, we evaluated the '\n",
      "                                  'combined effects of SMI and PD-1 inhibitors '\n",
      "                                  'in a Lewis lung carcinoma (LLC) C57BL/6 and '\n",
      "                                  'LUSC NCI-H226 humanized mouse model and '\n",
      "                                  'explored the synergistic mechanisms of '\n",
      "                                  'combined therapy using scRNA-seq to provide '\n",
      "                                  'insights on PD-1 inhibitor/SMI combination '\n",
      "                                  'therapy for NSCLC.'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 193,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'The U.S. Food and Drug Administration has '\n",
      "                                  'approved pembrolizumab (a PD-1 inhibitor) '\n",
      "                                  'as a first-line therapy for tumors with a '\n",
      "                                  'PD-L1 tumor proportion score ≥ 1% in NSCLC, '\n",
      "                                  'cemiplimab (also a PD-1 inhibitor) for '\n",
      "                                  'patients with PD-L1 expression ≥ 50%, and '\n",
      "                                  'atezolizumab (a PD-L1 inhibitor) for '\n",
      "                                  'patients with high PD-L1-expressing '\n",
      "                                  'metastatic NSCLC [5].'},\n",
      "                         {'dEnd': 279,\n",
      "                          'dStart': 274,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 235,\n",
      "                          'tStart': 231,\n",
      "                          'text': 'Furthermore, high expression of TNXB is '\n",
      "                                  'correlated with a higher cancer survival '\n",
      "                                  'prognosis [70], which showed that the TNXB+ '\n",
      "                                  'fibroblasts may be associated with NSCLC '\n",
      "                                  'cancer survival prognosis, further '\n",
      "                                  'indicating that SMI assisting PD-1 '\n",
      "                                  'inhibitor may prolong the survival of NSCLC '\n",
      "                                  'patients by increasing the proportion of '\n",
      "                                  'TNXB+ fibroblasts.'},\n",
      "                         {'dEnd': 294,\n",
      "                          'dStart': 289,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 139,\n",
      "                          'tStart': 135,\n",
      "                          'text': 'Moreover, expression of CD163, ITGAM, CCL5, '\n",
      "                                  'and CD27 was lower in the macrophages of '\n",
      "                                  'the PD-1+SMI group compared with that in '\n",
      "                                  'the IgG, PD-1, and SMI groups (Fig. 6G), '\n",
      "                                  'and higher expression of these genes in '\n",
      "                                  'tumor-associated macrophages is associated '\n",
      "                                  'with lower PFS and OS in patients with '\n",
      "                                  'NSCLC and resistance to immunotherapy '\n",
      "                                  '[66].'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'This suggests that the PD-1 inhibitor '\n",
      "                                  'combined with SMI blocks inhibitory '\n",
      "                                  'receptors on NK and T cells and restores '\n",
      "                                  'their antitumoral activity in NSCLC more '\n",
      "                                  'effectively than PD-1 inhibitor '\n",
      "                                  'monotherapy.'},\n",
      "                         {'dEnd': 216,\n",
      "                          'dStart': 211,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'Since SMI had been reported to increase '\n",
      "                                  'activity of NK cells combined with '\n",
      "                                  'chemotherapy [79], combination of PD-1 '\n",
      "                                  'inhibitor and SMI may generate synergistic '\n",
      "                                  'therapeutic effect to recruit and activate '\n",
      "                                  'NK cell in NSCLC.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'Our data suggests that the PD-1 inhibitor '\n",
      "                                  'combined with SMI may reduce angiogenesis '\n",
      "                                  'and MDSCs in NSCLC, with SMI potentially '\n",
      "                                  'augmenting the PD-1 inhibitor.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'However, the overall objective response '\n",
      "                                  'rate for PD-1 and PD-L1 inhibitors in NSCLC '\n",
      "                                  'is unsatisfactory (less than 20%) [6], and '\n",
      "                                  'PD-1 resistance may appear in patients with '\n",
      "                                  'advanced NSCLC [7].'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'Similarly, Zhang et al. [20] performed '\n",
      "                                  'scRNA-seq on peripheral T cells from '\n",
      "                                  'patients with NSCLC before and after PD-1 '\n",
      "                                  'blockade and found that tumor-related CD4+ '\n",
      "                                  'T cell clones exhibited higher cytotoxicity '\n",
      "                                  'than controls.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'The U.S. Food and Drug Administration has '\n",
      "                                  'approved pembrolizumab (a PD-1 inhibitor) '\n",
      "                                  'as a first-line therapy for tumors with a '\n",
      "                                  'PD-L1 tumor proportion score ≥ 1% in NSCLC, '\n",
      "                                  'cemiplimab (also a PD-1 inhibitor) for '\n",
      "                                  'patients with PD-L1 expression ≥ 50%, and '\n",
      "                                  'atezolizumab (a PD-L1 inhibitor) for '\n",
      "                                  'patients with high PD-L1-expressing '\n",
      "                                  'metastatic NSCLC [5].'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Moreover, we discovered that PD-1 inhibitor '\n",
      "                                  'and SMI combination blocked inhibitory '\n",
      "                                  'receptors on NK and T cells and restores '\n",
      "                                  'their antitumoral activity in NSCLC better '\n",
      "                                  'than PD-1 inhibitor monotherapy, and immune '\n",
      "                                  'and stromal cells exhibited a decrease of '\n",
      "                                  'angiogenic features and attenuated cancer '\n",
      "                                  'metabolism reprogramming in '\n",
      "                                  'microenvironment of combination therapy.'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'As shown in Fig. 5F, immunofluorescence '\n",
      "                                  'staining showed that GZMAhigh NK cells '\n",
      "                                  'appeared in the PD-1+SMI group, showing '\n",
      "                                  'this kind of subcluster existed in the '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 299,\n",
      "                          'dStart': 294,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 254,\n",
      "                          'tStart': 250,\n",
      "                          'text': 'THBS1 inhibits tumor growth, cell '\n",
      "                                  'migration, and neovascularization, and low '\n",
      "                                  'expression of this gene is related to poor '\n",
      "                                  'prognoses in NSCLC [74], which indicated '\n",
      "                                  'that THBS1+ EndMT-like cells may be related '\n",
      "                                  'to the prognosis of NSCLC, and SMI '\n",
      "                                  'assisting PD-1 inhibitor may improve the '\n",
      "                                  'prognosis of NSCLC by increasing the '\n",
      "                                  'proportion of THBS1+ EndMT-like cells.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Combination therapies such as PD-1/PD-L1 '\n",
      "                                  'inhibitors combined with chemotherapy, '\n",
      "                                  'targeted therapy, or other immunotherapies '\n",
      "                                  'may be effective NSCLC treatments [10].'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38952673'],\n",
      " 'resourceScore': 98,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 386,\n",
      "                          'dStart': 381,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 372,\n",
      "                          'tStart': 368,\n",
      "                          'text': 'CD161 is expressed in many immune cells, '\n",
      "                                  'such as NK cells, CD4+/CD8+ T cells, and '\n",
      "                                  'some unconventional T cells such as '\n",
      "                                  'mucosal-associated invariant T cells, γδT '\n",
      "                                  'cells, and NKT cells.56–58 Harms et al. '\n",
      "                                  'reported that CD161+CD8+ T cells enhance '\n",
      "                                  'differentiation in patients with type 1 '\n",
      "                                  'DM.59 CD127 expression may be a key '\n",
      "                                  'indicator of human inflammatory illness60 '\n",
      "                                  'and anti-PD-1-treated NSCLC.48 In the '\n",
      "                                  'current study, CD161 and CD127 were '\n",
      "                                  'enriched in patients with diabetes, which '\n",
      "                                  'is consistent with the results of previous '\n",
      "                                  'studies.'},\n",
      "                         {'dEnd': 393,\n",
      "                          'dStart': 388,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 255,\n",
      "                          'tStart': 251,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Mass cytometry by time-of-flight (CyTOF) '\n",
      "                                  'showed a higher percentage of '\n",
      "                                  'CD161+CD127+CD8+ T cells among CD8+T cells '\n",
      "                                  'in NSCLC with diabetes before anti-PD-1 '\n",
      "                                  'treatment (p = 0.0071) than that in NSCLC '\n",
      "                                  'without diabetes and this trend continued '\n",
      "                                  'after anti-PD-1 treatment (p = 0.0393).'},\n",
      "                         {'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Moreover, the expression of '\n",
      "                                  'immunosuppressive checkpoints such as PD-1, '\n",
      "                                  'T-cell immunoreceptor with Ig and ITIM '\n",
      "                                  'domains (TIGIT), and lymphocyte activation '\n",
      "                                  'gene-3 (LAG3) were significantly higher in '\n",
      "                                  'NSCLC patients with diabetes (Figure 1g).'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 308,\n",
      "                          'tStart': 304,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 393,\n",
      "                          'dStart': 388,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 63,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Our findings would help in advancing '\n",
      "                                  'anti-PD-1 therapy in NSCLC patients with '\n",
      "                                  'diabetes.'},\n",
      "                         {'dEnd': 393,\n",
      "                          'dStart': 388,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 308,\n",
      "                          'tStart': 304,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 18,\n",
      "                          'dStart': 13,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'We recruited NSCLC patients (n = 436) '\n",
      "                                  'treated with anti-PD-1 immunotherapy as '\n",
      "                                  'first-line treatment.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 130,\n",
      "                          'tStart': 126,\n",
      "                          'text': 'These findings demonstrate the distinctive '\n",
      "                                  'molecular features and potential functions '\n",
      "                                  'of CD161+CD127+CD8+ T cells during '\n",
      "                                  'anti-PD-1 treatment of NSCLC patients with '\n",
      "                                  'diabetes, which may facilitate future '\n",
      "                                  'investigations.'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 255,\n",
      "                          'tStart': 251,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 393,\n",
      "                          'dStart': 388,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 365,\n",
      "                          'tStart': 361,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 426,\n",
      "                          'dStart': 421,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 316,\n",
      "                          'tStart': 312,\n",
      "                          'text': 'Some effector CD8+ T cells increase the '\n",
      "                                  'levels of the IL-7 receptor (CD127) and can '\n",
      "                                  'differentiate into memory T cells.64 The '\n",
      "                                  'activated CD127 can induce precursor B '\n",
      "                                  'cells during acute lymphoblastic '\n",
      "                                  'leukemia.65 Recently, Hui et al. reported '\n",
      "                                  'that compared to neoadjuvant chemotherapy '\n",
      "                                  'alone, the combination of anti-PD-1 and '\n",
      "                                  'neoadjuvant chemotherapy changed the '\n",
      "                                  'infiltration of immune cells and '\n",
      "                                  'interactions in patients with NSCLC, '\n",
      "                                  'reestablishing the tumor immune '\n",
      "                                  'microenvironment.'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Overall, 436 patients with advanced or '\n",
      "                                  'metastatic NSCLC who received anti-PD-1 '\n",
      "                                  'immunotherapy as a first-line treatment '\n",
      "                                  'between November 2018 and December 2021 '\n",
      "                                  'were enrolled in the study.'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 160,\n",
      "                          'tStart': 156,\n",
      "                          'text': 'This identified DEGs provide novel insights '\n",
      "                                  'into the molecular characteristics and '\n",
      "                                  'potential functional roles of '\n",
      "                                  'CD161+CD127+CD8+ T cells in the context of '\n",
      "                                  'PD-1 inhibitor treatment of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'CD161+CD127+CD8+ T cell subsets can predict '\n",
      "                                  'the efficacy of anti-PD-1 immunotherapy in '\n",
      "                                  'non-small cell lung cancer with diabetes '\n",
      "                                  'mellitus'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 255,\n",
      "                          'tStart': 251,\n",
      "                          'text': 'We also compared the proportion of immune '\n",
      "                                  'clusters in patients with or without '\n",
      "                                  'diabetes before and after anti-PD-1 '\n",
      "                                  'treatment, and the results showed that the '\n",
      "                                  'proportion of immune clusters highly '\n",
      "                                  'differed among NSCLC patients with diabetes '\n",
      "                                  'before anti-PD-1 treatment (DMB), NSCLC '\n",
      "                                  'with diabetes after anti-PD-1 treatment '\n",
      "                                  '(DMA), NSCLC without diabetes before '\n",
      "                                  'anti-PD-1 treatment (NDMB), and NSCLC '\n",
      "                                  'without diabetes after anti-PD-1 treatment '\n",
      "                                  '(NDMA) (Supplementary Figure S1C).'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'These findings indicate that diabetes is a '\n",
      "                                  'risk factor for NSCLC patients who undergo '\n",
      "                                  'anti-PD-1 immunotherapy.CD161+CD127+CD8+ T '\n",
      "                                  'cells could be a key indicator of a poor '\n",
      "                                  'prognosis in NSCLC with diabetes.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37384302'],\n",
      " 'resourceScore': 98,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 17,\n",
      "                          'tStart': 13,\n",
      "                          'text': 'Furthermore, PD-1+ IFN-γ+ cell percentages '\n",
      "                                  'of CD8+ T cells at baseline correlate with '\n",
      "                                  'PFS in patients with NSCLC and may be an '\n",
      "                                  'independent prognostic factor for anti–PD-1 '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'These data demonstrate that circulating '\n",
      "                                  'PD-1+ IFN-γ+ cell percentages of CD8+ T '\n",
      "                                  'cells may serve as markers of NSCLC treated '\n",
      "                                  'with chemotherapy combined with anti–PD-1 '\n",
      "                                  'therapy to predict progression.'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Notably, we observed that the percentages '\n",
      "                                  'of IFN-γ–producing CD8+ PD-1+ T cells in '\n",
      "                                  'circulation were significantly higher than '\n",
      "                                  'those in CD8+ PD-1− T cells in healthy '\n",
      "                                  'controls (P < 0.001; Figure 1A) and in '\n",
      "                                  'patients with NSCLC (P < 0.001; Figure '\n",
      "                                  '1B).'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'PD-1+ IFN-γ+ cell percentages in CD8+ T '\n",
      "                                  'cells in circulation predict therapeutic '\n",
      "                                  'response to anti–PD-1 in patients with '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 145,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'Notably, we observed that the percentages '\n",
      "                                  'of IFN-γ–producing CD8+ PD-1+ T cells in '\n",
      "                                  'circulation were significantly higher than '\n",
      "                                  'those in CD8+ PD-1− T cells in healthy '\n",
      "                                  'controls (P < 0.001; Figure 1A) and in '\n",
      "                                  'patients with NSCLC (P < 0.001; Figure '\n",
      "                                  '1B).'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'In conclusion, we have found that a new '\n",
      "                                  'PD-1+ IFN-γ+ subset of CD8+ T cells can '\n",
      "                                  'predict responses in patients with NSCLC '\n",
      "                                  'during treatment with nivolumab or '\n",
      "                                  'atezolizumab plus platinum.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1+ IFN-γ+ subset of CD8+ T cell in '\n",
      "                                  'circulation predicts response to anti–PD-1 '\n",
      "                                  'therapy in NSCLC'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Logistic regression analysis between serum '\n",
      "                                  'biomarkers and PFS in patients with NSCLC '\n",
      "                                  'with anti–PD-1 therapy and chemotherapy.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Therefore, we use cutoff point value of '\n",
      "                                  'PD-1+ IFN-γ+ cell percentages of CD8+ T '\n",
      "                                  'cells in 30 patients with NSCLC to '\n",
      "                                  'calculate PFS (time from the time starting '\n",
      "                                  'anti–PD-1 therapy until disease progression '\n",
      "                                  'or death from any cause, follow-up for 12 '\n",
      "                                  'months).'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'In daily practice, only a few patients with '\n",
      "                                  'NSCLC treated with anti–PD-1 therapy alone '\n",
      "                                  'and most patients were treated with '\n",
      "                                  'chemotherapy combined with anti–PD-1 '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 148,\n",
      "                          'tStart': 144,\n",
      "                          'text': 'In this study, we demonstrate that PD-1+ '\n",
      "                                  'IFN-γ+ subset of CD8+ T cells in the '\n",
      "                                  'peripheral blood at baseline can predict '\n",
      "                                  'response and PFS to anti–PD-1 therapy '\n",
      "                                  'combined with chemotherapy in patients with '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Immune checkpoint molecules such as '\n",
      "                                  'programmed cell death protein-1/programmed '\n",
      "                                  'death-ligand 1 (PD-1/PD-L1) blockade '\n",
      "                                  'therapy offer a new model for NSCLC '\n",
      "                                  'treatment, but only about 30% of patients '\n",
      "                                  'with NSCLC benefit from PD-1/PD-L1 blockade '\n",
      "                                  'therapy (3).'},\n",
      "                         {'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'In this study, we demonstrate that PD-1+ '\n",
      "                                  'IFN-γ+ subset of CD8+ T cells in the '\n",
      "                                  'peripheral blood at baseline can predict '\n",
      "                                  'response and PFS to anti–PD-1 therapy '\n",
      "                                  'combined with chemotherapy in patients with '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 154,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Meanwhile, Gene Expression Profiling '\n",
      "                                  'Interactive Analysis, version 2 (GEPIA2) '\n",
      "                                  'calculations based on TCGA database show '\n",
      "                                  'that programmed cell death 1 (PDCD1) '\n",
      "                                  'expressions are associated with interferon '\n",
      "                                  'gamma (IFNG) expression in NSCLC (Figure '\n",
      "                                  '2C).'},\n",
      "                         {'dEnd': 314,\n",
      "                          'dStart': 309,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'All these data suggest that, following '\n",
      "                                  'confirmation and extension of our results '\n",
      "                                  'in future, peripheral blood immune cell '\n",
      "                                  'biomarkers may provide a precious and '\n",
      "                                  'practical strategy to predict early '\n",
      "                                  'responses to anti–PD-1 therapy in '\n",
      "                                  'combination with chemotherapy that may '\n",
      "                                  'assist in the treatment of patients with '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1+ IFN-γ+ cell percentages in CD8+ T '\n",
      "                                  'cells in circulation are associated with '\n",
      "                                  'progression-free survival in patients with '\n",
      "                                  'NSCLC treated with anti–PD-1 therapy'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'PD-1+ IFN-γ+ subset of CD8+ T cell in '\n",
      "                                  'circulation predicts response to anti–PD-1 '\n",
      "                                  'therapy in NSCLC'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1+ IFN-γ+ cell percentages in CD8+ T '\n",
      "                                  'cells in circulation predict therapeutic '\n",
      "                                  'response to anti–PD-1 in patients with '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Moreover, high percentage of PD-1+ IFN-γ+ '\n",
      "                                  'subset in CD8+ T cells was relevant to long '\n",
      "                                  'progression-free survival in patients with '\n",
      "                                  'NSCLC treated with chemotherapy combined '\n",
      "                                  'with anti–PD-1 therapy.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Immune checkpoint molecules such as '\n",
      "                                  'programmed cell death protein-1/programmed '\n",
      "                                  'death-ligand 1 (PD-1/PD-L1) blockade '\n",
      "                                  'therapy offer a new model for NSCLC '\n",
      "                                  'treatment, but only about 30% of patients '\n",
      "                                  'with NSCLC benefit from PD-1/PD-L1 blockade '\n",
      "                                  'therapy (3).'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Immune checkpoint molecules such as '\n",
      "                                  'programmed cell death protein-1/programmed '\n",
      "                                  'death-ligand 1 (PD-1/PD-L1) blockade '\n",
      "                                  'therapy offer a new model for NSCLC '\n",
      "                                  'treatment, but only about 30% of patients '\n",
      "                                  'with NSCLC benefit from PD-1/PD-L1 blockade '\n",
      "                                  'therapy (3).'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'Meanwhile, Gene Expression Profiling '\n",
      "                                  'Interactive Analysis, version 2 (GEPIA2) '\n",
      "                                  'calculations based on TCGA database show '\n",
      "                                  'that programmed cell death 1 (PDCD1) '\n",
      "                                  'expressions are associated with interferon '\n",
      "                                  'gamma (IFNG) expression in NSCLC (Figure '\n",
      "                                  '2C).'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Immune checkpoint molecules such as '\n",
      "                                  'programmed cell death protein-1/programmed '\n",
      "                                  'death-ligand 1 (PD-1/PD-L1) blockade '\n",
      "                                  'therapy offer a new model for NSCLC '\n",
      "                                  'treatment, but only about 30% of patients '\n",
      "                                  'with NSCLC benefit from PD-1/PD-L1 blockade '\n",
      "                                  'therapy (3).'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Treatment with programmed cell death '\n",
      "                                  'protein-1 (PD-1) antibodies has minimal '\n",
      "                                  'response rates in patients with non–small '\n",
      "                                  'cell lung cancer (NSCLC), and, actually, '\n",
      "                                  'they are treated with chemotherapy combined '\n",
      "                                  'with anti–PD-1 therapy clinically.'},\n",
      "                         {'dEnd': 197,\n",
      "                          'dStart': 192,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'In this study, we investigated whether the '\n",
      "                                  'percentage of circulating PD-1+ IFN-γ+ CD8+ '\n",
      "                                  'T cell at baseline could be a potential '\n",
      "                                  'marker to predict early response or '\n",
      "                                  'progression in patients with NSCLC '\n",
      "                                  'receiving chemotherapy combined with '\n",
      "                                  'anti–PD-1 therapy.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'The percentage of circulating PD-1+ IFN-γ+ '\n",
      "                                  'subset of CD8+ T cell could be a potential '\n",
      "                                  'marker at baseline to predict early '\n",
      "                                  'response or progression in patients with '\n",
      "                                  'NSCLC receiving chemotherapy combined with '\n",
      "                                  'anti–PD-1 therapy.'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Treatment with programmed cell death '\n",
      "                                  'protein-1 (PD-1) antibodies has minimal '\n",
      "                                  'response rates in patients with non–small '\n",
      "                                  'cell lung cancer (NSCLC), and, actually, '\n",
      "                                  'they are treated with chemotherapy combined '\n",
      "                                  'with anti–PD-1 therapy clinically.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38231411'],\n",
      " 'resourceScore': 91,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 129,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'The introduction of the anti-PD-1 antibody '\n",
      "                                  'has greatly improved the clinical outcomes '\n",
      "                                  'of patients with non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'In this study, we retrospectively analyzed '\n",
      "                                  'the efficacy of PD-1 antibody-based therapy '\n",
      "                                  'in patients with locally advanced '\n",
      "                                  'inoperable or metastatic NSCLC and reported '\n",
      "                                  'an association between peripheral blood '\n",
      "                                  'biomarkers and clinical response in these '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'Research suggests that pretreatment levels '\n",
      "                                  'of AEC, AMC, ALB, NLR, and PLR were '\n",
      "                                  'independent positive predictors of PD-1 '\n",
      "                                  'inhibitors in patients with advanced NSCLC '\n",
      "                                  '[9].'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'To identify the correlation between '\n",
      "                                  'existing T cell phenotypes in the '\n",
      "                                  'peripheral blood of patients with NSCLC and '\n",
      "                                  'their clinical response during cancer '\n",
      "                                  'immunotherapy with PD-1/PD-L1 blockade, we '\n",
      "                                  'conducted flow cytometry analyses of CD4+ '\n",
      "                                  'and CD8+ T cells derived from the PBMCs of '\n",
      "                                  'patients with NSCLC at baseline.'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'In patients with NSCLC who undergo '\n",
      "                                  'anti-PD-1 treatment, the dynamic '\n",
      "                                  'alterations of cytokine levels could not be '\n",
      "                                  'used to predict clinical responses, even '\n",
      "                                  'among those showing a stable or clinical '\n",
      "                                  'response.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': 'In this retrospective study, 88 patients '\n",
      "                                  'with stage IIIA–IV NSCLC who had undergone '\n",
      "                                  'at least two cycles of PD-1 inhibitors '\n",
      "                                  'between 2020 and 2022 were enrolled.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Here, we retrospectively analyzed the '\n",
      "                                  'efficacy of PD-1 antibody therapy in '\n",
      "                                  'locally advanced or metastatic NSCLC '\n",
      "                                  'patients, and preliminarily explored the '\n",
      "                                  'correlation between peripheral blood '\n",
      "                                  'biomarkers and clinical efficacy thus '\n",
      "                                  'enabling us to identify the population that '\n",
      "                                  'would benefit most from PD-1-based therapy '\n",
      "                                  'through a simple blood draw.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'The introduction of the anti-PD-1 antibody '\n",
      "                                  'has greatly improved the clinical outcomes '\n",
      "                                  'of patients with non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': 'Immunotherapy has caused a transformation '\n",
      "                                  'in the TCR repertoire, with early changes '\n",
      "                                  'in TCR clonality correlating with the '\n",
      "                                  'immune response, thus influencing the '\n",
      "                                  'clinical outcomes of anti-PD-1/PD-L1 '\n",
      "                                  'treatment in NSCLC [33, 37–40].'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'Dynamic changes of cytokine levels were not '\n",
      "                                  'associated with disease control related '\n",
      "                                  'with anti-PD-1 blockade in patients with '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Serum cytokine levels may predict the '\n",
      "                                  'effectiveness and survival rates of '\n",
      "                                  'anti-PD-1 blockade therapy in patients with '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Nevertheless, recent clinical trials '\n",
      "                                  'involving anti-PD-1 therapy have revealed '\n",
      "                                  'that only 15–25% of patients with NSCLC '\n",
      "                                  'responded to immune checkpoint blockade '\n",
      "                                  'therapy alone, regardless of their PD-L1 '\n",
      "                                  'expression [3–5].'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Blood serum samples were collected from 86 '\n",
      "                                  'patients with late-stage NSCLC who received '\n",
      "                                  'PD-1 or PD-L1 inhibitors.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Even with an increased sample size in our '\n",
      "                                  'recent study, these markers did not yield '\n",
      "                                  'significant insights in predicting the PD-1 '\n",
      "                                  'blockade outcomes in patients with NSCLC.'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 160,\n",
      "                          'tStart': 156,\n",
      "                          'text': 'The lack of significant results in other '\n",
      "                                  'aspects indicates the challenges of using T '\n",
      "                                  'cell phenotypes to identify patients who '\n",
      "                                  'would clinically benefit from PD-1/PD-L1 '\n",
      "                                  'inhibitors in the context of NSCLC.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'To address this concern, research has been '\n",
      "                                  'conducted to identify peripheral blood '\n",
      "                                  'biomarkers that can signal a response to '\n",
      "                                  'PD-1 blockade in patients with NSCLC.'},\n",
      "                         {'dEnd': 299,\n",
      "                          'dStart': 294,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'To identify the correlation between '\n",
      "                                  'existing T cell phenotypes in the '\n",
      "                                  'peripheral blood of patients with NSCLC and '\n",
      "                                  'their clinical response during cancer '\n",
      "                                  'immunotherapy with PD-1/PD-L1 blockade, we '\n",
      "                                  'conducted flow cytometry analyses of CD4+ '\n",
      "                                  'and CD8+ T cells derived from the PBMCs of '\n",
      "                                  'patients with NSCLC at baseline.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'This single-center study included medical '\n",
      "                                  'record data of patients with NSCLC treated '\n",
      "                                  'with the PD-1 antibody as a first-line or '\n",
      "                                  'subsequent line of treatment, either as '\n",
      "                                  'monotherapy or in combination with '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'As shown in Fig. 4, the progression-free '\n",
      "                                  'survival (PFS) of patients with late-stage '\n",
      "                                  'NSCLC who received PD-1 inhibitors was '\n",
      "                                  'analyzed based on multiple serum cytokine '\n",
      "                                  'levels collected before immunotherapy.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Predictive value of serum cytokine levels '\n",
      "                                  'for clinical response with anti-PD-1 '\n",
      "                                  'blockade therapy in patients with NSCLC'},\n",
      "                         {'dEnd': 243,\n",
      "                          'dStart': 238,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'To investigate the effects of PD-1 blockade '\n",
      "                                  'on immune responses during cancer '\n",
      "                                  'immunotherapy and to identify the '\n",
      "                                  'population that could benefit from '\n",
      "                                  'immunotherapy, we analyzed Th1/Th2 '\n",
      "                                  'cytokines from the peripheral blood of 53 '\n",
      "                                  'patients with NSCLC at baseline and at the '\n",
      "                                  'first treatment evaluation, usually after '\n",
      "                                  'two cycles of treatment.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Our findings highlight the potential of '\n",
      "                                  'peripheral blood biomarkers to predict the '\n",
      "                                  'effectiveness of PD-1-targeted treatments '\n",
      "                                  'in patients with NSCLC.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 115,\n",
      "                          'tStart': 111,\n",
      "                          'text': 'Predictive value of peripheral blood '\n",
      "                                  'biomarkers in patients with non-small-cell '\n",
      "                                  'lung cancer responding to anti-PD-1-based '\n",
      "                                  'treatment'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Our analysis also uncovered that baseline '\n",
      "                                  'blood serum cytokine levels could predict '\n",
      "                                  'the effectiveness of anti-PD-1 blockade '\n",
      "                                  'therapy in patients with NSCLC.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Predictive value of serum cytokine levels '\n",
      "                                  'for progression-free survival after '\n",
      "                                  'anti-PD-1 blockade therapy in patients with '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Clinical trials have demonstrated that the '\n",
      "                                  'administration of anti-PD-1 or PD-L1 '\n",
      "                                  'antibodies to patients with advanced NSCLC '\n",
      "                                  'has shown beneficial clinical outcomes, '\n",
      "                                  'such as improved clinical response and '\n",
      "                                  'survival rates.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35479081'],\n",
      " 'resourceScore': 90,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Thus, we need to be cautious about using '\n",
      "                                  'PD-1 inhibitors and there is a need for '\n",
      "                                  'more explorations of PD-1 inhibitors in '\n",
      "                                  'NSCLC individuals aged ≥75 years.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'On EGFR mutant NSCLC, it is possible that '\n",
      "                                  'PD-1 inhibitors are ineffective due to the '\n",
      "                                  'fact that: NSCLC individuals with EGFR '\n",
      "                                  'wild-type and high levels of PD-L1 '\n",
      "                                  'expression may benefit better from immune '\n",
      "                                  'checkpoint blockade therapy than standard '\n",
      "                                  'chemotherapy (71–73).'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 inhibitors have become an '\n",
      "                                  'indispensable treatment in Non-Small Cell '\n",
      "                                  'Lung Cancer (NSCLC), but the potential '\n",
      "                                  'predictive value of clinical and molecular '\n",
      "                                  'features need to be clarified.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 inhibitors have become an '\n",
      "                                  'indispensable treatment in Non-Small Cell '\n",
      "                                  'Lung Cancer (NSCLC), but the potential '\n",
      "                                  'predictive value of clinical and molecular '\n",
      "                                  'features need to be clarified.'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'Age group, smoking history, metastasis '\n",
      "                                  'status/site, EGFR mutation status, and '\n",
      "                                  'region can be used to predict the potency '\n",
      "                                  'of PD-1 inhibitors, and to be '\n",
      "                                  'individualized to choose different types of '\n",
      "                                  'PD-1 inhibitors, and treatment regimen for '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 48,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Inhibitors of PD-1 in Non-Small Cell Lung '\n",
      "                                  'Cancer: A Meta-Analysis of Clinical and '\n",
      "                                  'Molecular Features'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'The objective of the study was to study the '\n",
      "                                  'potency of PD-1 inhibitors in patients with '\n",
      "                                  'NSCLC in contexts of both clinical and '\n",
      "                                  'molecular features, and to aid '\n",
      "                                  'identification of patients for choice of '\n",
      "                                  'type of PD-1 inhibitor therapy in order to '\n",
      "                                  'acquire more accurate NSCLC treatment in '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'RCTs that had PD-1 inhibitor alone or in '\n",
      "                                  'combination with chemotherapy with non-PD-1 '\n",
      "                                  'inhibitor for the treatment of NSCLC '\n",
      "                                  'patients were selected.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 204,\n",
      "                          'tStart': 200,\n",
      "                          'text': 'As a result, we performed this '\n",
      "                                  'meta-analysis to determine the predictive '\n",
      "                                  'value of various clinical and molecular '\n",
      "                                  'attributes for guiding the selection of '\n",
      "                                  'individuals with NSCLC who should benefit '\n",
      "                                  'from PD-1 inhibitors.'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Actively, PD-1 inhibitors are widely used '\n",
      "                                  'in clinical practice, and this region '\n",
      "                                  'information will be essential to bring '\n",
      "                                  'maximum benefit to individuals with NSCLC.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'The potency of PD-1 inhibitors on squamous '\n",
      "                                  'and non-squamous NSCLC was studied in seven '\n",
      "                                  'and eight studies, respectively.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'The integrated findings revealed that PD-1 '\n",
      "                                  'inhibitors obviously enhanced OS in both '\n",
      "                                  'squamous (HR 0.70; 95% CI, 0.62–0.79; P '\n",
      "                                  '<0.00001) and non-squamous NSCLC (HR 0.74; '\n",
      "                                  '95% CI, 0.63–0.87; P = 0.0003) (Figure '\n",
      "                                  '3C).'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'RCTs that had PD-1 inhibitor alone or in '\n",
      "                                  'combination with chemotherapy with non-PD-1 '\n",
      "                                  'inhibitor for the treatment of NSCLC '\n",
      "                                  'patients were selected.'},\n",
      "                         {'dEnd': 37,\n",
      "                          'dStart': 32,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Some studies have shown that in NSCLC, '\n",
      "                                  'smokers have a favorable trend of PD-1 '\n",
      "                                  'inhibitor treatment compared with '\n",
      "                                  'non-smokers (65–67) and support the result '\n",
      "                                  'of our meta-analysis.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The effect of the gender of individuals on '\n",
      "                                  'the potency of PD-1 inhibitors as treatment '\n",
      "                                  'in NSCLC still remains controversial '\n",
      "                                  '(51–55).'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'The comprehensive results showed that PD-1 '\n",
      "                                  'inhibitors substantially enhanced OS in '\n",
      "                                  'both gender NSCLC individuals compared with '\n",
      "                                  'non-PD-1 inhibitor therapy (HR 0.73; 95% '\n",
      "                                  'CI, 0.67–0.80; P <0.00001 for male; HR '\n",
      "                                  '0.69; 95% CI, 0.53–0.90; P = 0.0005 for '\n",
      "                                  'female) (Figure 3B).'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Age group, smoking history, metastasis '\n",
      "                                  'status/site, EGFR mutation status, and '\n",
      "                                  'region can be used to predict the potency '\n",
      "                                  'of PD-1 inhibitors, and to be '\n",
      "                                  'individualized to choose different types of '\n",
      "                                  'PD-1 inhibitors, and treatment regimen for '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Based on previous clinical trials, it '\n",
      "                                  'remains controversial whether PD-1 '\n",
      "                                  'inhibitors benefit elderly patients with '\n",
      "                                  'NSCLC (39–43).'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'OS was improved in patients with NSCLC who '\n",
      "                                  'received PD-1 inhibitors regardless of '\n",
      "                                  'their gender (male or female), '\n",
      "                                  'histomorphological subtypes (squamous or '\n",
      "                                  'non-squamous NSCLC), performance status (0 '\n",
      "                                  'or 1), and PD-L1 tumor proportion score '\n",
      "                                  '(TPS) (<1%, ≥1%, 1–49%, or ≥50%).'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'Consequently, metastatic status/site may be '\n",
      "                                  'independent predictors of survival outcome '\n",
      "                                  'in NSCLC individuals given with PD-1 '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'They are useful in the practical '\n",
      "                                  'application of PD-1 inhibitors to better '\n",
      "                                  'guide the treatment of NSCLC patients and '\n",
      "                                  'to acquire more accurate NSCLC treatment in '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 208,\n",
      "                          'tStart': 204,\n",
      "                          'text': 'However, only a minority of individuals '\n",
      "                                  'have benefited from PD-1 inhibitors (9), '\n",
      "                                  'and it becomes even more urgent to '\n",
      "                                  'investigate suitable biomarkers in order to '\n",
      "                                  'identify individuals who are candidates for '\n",
      "                                  'PD-1 inhibitor therapy and to achieve '\n",
      "                                  'accurate treatment of NSCLC—both to protect '\n",
      "                                  'individuals from ineffective treatments and '\n",
      "                                  'to limit the number of individuals exposed '\n",
      "                                  'to potential autoimmune side effects from '\n",
      "                                  'drugs targeting the axis (10, 11).'},\n",
      "                         {'dEnd': 93,\n",
      "                          'dStart': 88,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'The objective of the study was to study the '\n",
      "                                  'potency of PD-1 inhibitors in patients with '\n",
      "                                  'NSCLC in contexts of both clinical and '\n",
      "                                  'molecular features, and to aid '\n",
      "                                  'identification of patients for choice of '\n",
      "                                  'type of PD-1 inhibitor therapy in order to '\n",
      "                                  'acquire more accurate NSCLC treatment in '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'However, only a minority of individuals '\n",
      "                                  'have benefited from PD-1 inhibitors (9), '\n",
      "                                  'and it becomes even more urgent to '\n",
      "                                  'investigate suitable biomarkers in order to '\n",
      "                                  'identify individuals who are candidates for '\n",
      "                                  'PD-1 inhibitor therapy and to achieve '\n",
      "                                  'accurate treatment of NSCLC—both to protect '\n",
      "                                  'individuals from ineffective treatments and '\n",
      "                                  'to limit the number of individuals exposed '\n",
      "                                  'to potential autoimmune side effects from '\n",
      "                                  'drugs targeting the axis (10, 11).'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 211,\n",
      "                          'tStart': 207,\n",
      "                          'text': 'The objective of the study was to study the '\n",
      "                                  'potency of PD-1 inhibitors in patients with '\n",
      "                                  'NSCLC in contexts of both clinical and '\n",
      "                                  'molecular features, and to aid '\n",
      "                                  'identification of patients for choice of '\n",
      "                                  'type of PD-1 inhibitor therapy in order to '\n",
      "                                  'acquire more accurate NSCLC treatment in '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Our meta-analysis of a longer PFS but not '\n",
      "                                  'OS for PD-1 inhibitors in patients with '\n",
      "                                  'asymptomatic brain metastases does not '\n",
      "                                  'support previous studies that patients with '\n",
      "                                  'advanced brain metastasis of NSCLC given '\n",
      "                                  'with PD-1/PD-L1 inhibitors obtained longer '\n",
      "                                  'OS (69).'},\n",
      "                         {'dEnd': 67,\n",
      "                          'dStart': 62,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'In earlier meta-analyses of the effects of '\n",
      "                                  'PD-1 inhibitors on NSCLC clinical and '\n",
      "                                  'molecular characteristics, a smaller number '\n",
      "                                  'of individuals were included than in the '\n",
      "                                  'active study.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'They are useful in the practical '\n",
      "                                  'application of PD-1 inhibitors to better '\n",
      "                                  'guide the treatment of NSCLC patients and '\n",
      "                                  'to acquire more accurate NSCLC treatment in '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Thus, we need to be cautious about using '\n",
      "                                  'PD-1 inhibitors and there is a need for '\n",
      "                                  'more explorations of PD-1 inhibitors in '\n",
      "                                  'NSCLC individuals aged ≥75 years.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'OS was improved in patients with NSCLC who '\n",
      "                                  'received PD-1 inhibitors regardless of '\n",
      "                                  'their gender (male or female), '\n",
      "                                  'histomorphological subtypes (squamous or '\n",
      "                                  'non-squamous NSCLC), performance status (0 '\n",
      "                                  'or 1), and PD-L1 tumor proportion score '\n",
      "                                  '(TPS) (<1%, ≥1%, 1–49%, or ≥50%).'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'Individuals with advanced NSCLC of '\n",
      "                                  'different regions have different clinical, '\n",
      "                                  'genetic characteristics, and '\n",
      "                                  'socioenvironmental make-up that may '\n",
      "                                  'influence their response to PD-1 inhibitors '\n",
      "                                  '(88).'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'So far, the outcome of many large-scale '\n",
      "                                  'randomized controlled trials (RCTs) of PD-1 '\n",
      "                                  'inhibitors against NSCLC individuals have '\n",
      "                                  'verified the concept of lasting anti-tumor '\n",
      "                                  'response and improved progression free '\n",
      "                                  'survival (PFS) and overall survival (OS) '\n",
      "                                  '(8).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36281084'],\n",
      " 'resourceScore': 88,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'The proportion of CD4+ T helper cells and '\n",
      "                                  'PD-1 expression was higher and the '\n",
      "                                  'proportion of CD8+ T cytotoxic cells was '\n",
      "                                  'lower in NSCLC group than in healthy group '\n",
      "                                  '(P < .05).'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'In conclusion, we analyzed T lymphocyte '\n",
      "                                  'subsets and PD-1 expression in peripheral '\n",
      "                                  'blood of NSCLC patients and healthy '\n",
      "                                  'controls.'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'However, there are difficulties in their '\n",
      "                                  'application as not all NSCLC patients are '\n",
      "                                  'sensitive to PD-1/PD-L1 inhibitors, or '\n",
      "                                  'patients may eventually develop drug '\n",
      "                                  'resistance.'},\n",
      "                         {'dEnd': 394,\n",
      "                          'dStart': 389,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'Factors affecting the efficacy of '\n",
      "                                  'PD-1/PD-L1 inhibitors include accumulation '\n",
      "                                  'of CD4+foxp3-PD-1hi tumor cells that '\n",
      "                                  'inhibit T cell function.[13] Additionally, '\n",
      "                                  'myeloid-derived immune cells, such as '\n",
      "                                  'monocytes and DC cells, can be used as '\n",
      "                                  'biomarkers to monitor the efficacy of PD-1 '\n",
      "                                  'inhibitor.[14,15] In this study, we found a '\n",
      "                                  'population of lymphocytes with larger '\n",
      "                                  'volumes and more particles in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'T lymphocyte subsets and PD-1 expression '\n",
      "                                  'were compared between NSCLC and healthy '\n",
      "                                  'groups by gating Lym1.'},\n",
      "                         {'dEnd': 62,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': '3.3. T lymphocyte subsets and PD-1 '\n",
      "                                  'expression on Lym1 in NSCLC and healthy '\n",
      "                                  'groups'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 167,\n",
      "                          'tStart': 163,\n",
      "                          'text': 'In addition, we did not compare and analyze '\n",
      "                                  'whether there were differences among the '\n",
      "                                  'patients with different pathological '\n",
      "                                  'stages, and the T lymphocyte subsets and '\n",
      "                                  'PD-1 expression on Lym2 in peripheral blood '\n",
      "                                  'of NSCLC patients may change with the '\n",
      "                                  'disease progression.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 expression on lymphocytes may be used '\n",
      "                                  'as a recurrence indicator for NSCLC '\n",
      "                                  'patients treated with PD-1 inhibitors.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'T lymphocyte subsets and PD-1 expression '\n",
      "                                  'were compared between Lym1 and Lym2 in '\n",
      "                                  'NSCLC group.'},\n",
      "                         {'dEnd': 248,\n",
      "                          'dStart': 243,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'This study aimed to analyze the T '\n",
      "                                  'lymphocyte subsets and programmed death-1 '\n",
      "                                  '(PD-1) expression on lymphocytes in the '\n",
      "                                  'peripheral blood of non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients and explore whether '\n",
      "                                  'there were changes in cellular immunity in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': '3.1. T lymphocyte subsets and PD-1 '\n",
      "                                  'expression in NSCLC and healthy groups'},\n",
      "                         {'dEnd': 394,\n",
      "                          'dStart': 389,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 276,\n",
      "                          'tStart': 272,\n",
      "                          'text': 'Factors affecting the efficacy of '\n",
      "                                  'PD-1/PD-L1 inhibitors include accumulation '\n",
      "                                  'of CD4+foxp3-PD-1hi tumor cells that '\n",
      "                                  'inhibit T cell function.[13] Additionally, '\n",
      "                                  'myeloid-derived immune cells, such as '\n",
      "                                  'monocytes and DC cells, can be used as '\n",
      "                                  'biomarkers to monitor the efficacy of PD-1 '\n",
      "                                  'inhibitor.[14,15] In this study, we found a '\n",
      "                                  'population of lymphocytes with larger '\n",
      "                                  'volumes and more particles in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 28,\n",
      "                          'dStart': 23,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Additionally, when the NSCLC patient '\n",
      "                                  'treated with PD-1 inhibitor relapsed, the '\n",
      "                                  'PD-1 expression on lymphocytes increased.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Lym2 may be tumor-infiltrating lymphocytes '\n",
      "                                  '(TILs) which upregulated PD-1 expression in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'This study aimed to analyze the T '\n",
      "                                  'lymphocyte subsets and programmed death-1 '\n",
      "                                  '(PD-1) expression on lymphocytes in the '\n",
      "                                  'peripheral blood of non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients and explore whether '\n",
      "                                  'there were changes in cellular immunity in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Its high expression of PD-1 and the '\n",
      "                                  'presence of DPT cells further proved that '\n",
      "                                  'Lym2 was closely related to NSCLC.'},\n",
      "                         {'dEnd': 131,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'Since Lym2 was almost absent in healthy '\n",
      "                                  'individuals, we compared the T lymphocyte '\n",
      "                                  'subsets and PD-1 expression on Lym1 between '\n",
      "                                  'NSCLC and healthy groups.'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Compared with the healthy group, the '\n",
      "                                  'proportion of CD4+ T cells and PD-1 '\n",
      "                                  'expression on Lym1 was higher, and that of '\n",
      "                                  'CD8+ T cells was lower in the NSCLC group.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'T lymphocyte subsets and PD-1 expression on '\n",
      "                                  'lymphocytes in peripheral blood of patients '\n",
      "                                  'with non-small cell lung cancer'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'This study aimed to analyze the T '\n",
      "                                  'lymphocyte subsets and programmed death-1 '\n",
      "                                  '(PD-1) expression on lymphocytes in the '\n",
      "                                  'peripheral blood of non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients and explore whether '\n",
      "                                  'there were changes in cellular immunity in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 51,\n",
      "                          'dStart': 46,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'It may also provide monitoring biomarkers '\n",
      "                                  'for NSCLC patients treated with PD-1 '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 21,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 expression in a NSCLC patient who '\n",
      "                                  'treated with PD-1 inhibitor was detected.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Moreover, decreased proportion of CD8+ '\n",
      "                                  'cytotoxic T cells, while increased PD-1 '\n",
      "                                  'expression in the NSCLC group, suggested T '\n",
      "                                  'cell depletion in TME.'},\n",
      "                         {'dEnd': 51,\n",
      "                          'dStart': 46,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1 overexpression on lymphocytes in '\n",
      "                                  'the NSCLC group, especially on Lym2 subset, '\n",
      "                                  'indicated that Lym2 subset may participate '\n",
      "                                  'in tumor immune escape via upregulating the '\n",
      "                                  'expression of immune checkpoint.'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'The appearance of CD4+CD8+ DPT cells and '\n",
      "                                  'increased expression of PD-1 on lymphocytes '\n",
      "                                  'with larger volume and more particles '\n",
      "                                  'suggested that these cells may be involved '\n",
      "                                  'in immune regulation of NSCLC.'},\n",
      "                         {'dEnd': 77,\n",
      "                          'dStart': 72,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': '3.4. T lymphocyte subsets and PD-1 '\n",
      "                                  'expression on Lym1 and Lym2 cells in NSCLC '\n",
      "                                  'group'},\n",
      "                         {'dEnd': 47,\n",
      "                          'dStart': 42,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'In addition, with the recurrence in those '\n",
      "                                  'NSCLC patients treated with PD-1 inhibitor, '\n",
      "                                  'the PD-1 expression on lymphocytes '\n",
      "                                  'increased.'},\n",
      "                         {'dEnd': 56,\n",
      "                          'dStart': 51,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'However, PD-1 inhibitors are not effective '\n",
      "                                  'for all NSCLC patients, as the patients may '\n",
      "                                  'be either be insensitive to these '\n",
      "                                  'inhibitors or develop resistance during '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'T lymphocyte subsets and PD-1 expression in '\n",
      "                                  'peripheral blood of the NSCLC patients and '\n",
      "                                  'healthy individuals were analyzed using '\n",
      "                                  'flow cytometry.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38915783'],\n",
      " 'resourceScore': 87,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Our recent findings indicate that while the '\n",
      "                                  'co-expression of PD-1 and CD28 is '\n",
      "                                  'associated with impaired functionality of '\n",
      "                                  'CD8+ T cells in peripheral blood, it '\n",
      "                                  'significantly enhances the fitness of these '\n",
      "                                  'cells in the tumor site of non-small cell '\n",
      "                                  'lung cancer (NSCLC) patients.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'We then assessed how diverse CD39, ADA, and '\n",
      "                                  'CD26 co-expression patterns are distributed '\n",
      "                                  'within PD-1+CD28− and PD-1+CD28+ T-cell '\n",
      "                                  'subsets across the three sites in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 280,\n",
      "                          'dStart': 275,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'We recently reported the CD28 pivotal role '\n",
      "                                  'in improving the functional state of PD-1+ '\n",
      "                                  'CD8+ T cells in the tumor site of NSCLC '\n",
      "                                  'patients.1 To explore the potential '\n",
      "                                  'mechanisms underlying the functional '\n",
      "                                  'advantage of PD-1+ CD8+ T cells within the '\n",
      "                                  'immunosuppressive, CD39-enriched NSCLC '\n",
      "                                  'tumor site, we investigated whether the '\n",
      "                                  'ADA/CD26 axis might counteract this '\n",
      "                                  'immunosuppressive phenotype.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'To explore the mechanism driving the '\n",
      "                                  'beneficial influence of CD28 expression on '\n",
      "                                  'CD8+ PD-1+ T cells in the transition from '\n",
      "                                  'the periphery to the NSCLC tumor site, as '\n",
      "                                  'we have recently reported,1 we focused on '\n",
      "                                  'the ADA/CD26 axis within a microenvironment '\n",
      "                                  'enriched in CD39-expressing T cells.'},\n",
      "                         {'dEnd': 280,\n",
      "                          'dStart': 275,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 216,\n",
      "                          'tStart': 212,\n",
      "                          'text': 'We recently reported the CD28 pivotal role '\n",
      "                                  'in improving the functional state of PD-1+ '\n",
      "                                  'CD8+ T cells in the tumor site of NSCLC '\n",
      "                                  'patients.1 To explore the potential '\n",
      "                                  'mechanisms underlying the functional '\n",
      "                                  'advantage of PD-1+ CD8+ T cells within the '\n",
      "                                  'immunosuppressive, CD39-enriched NSCLC '\n",
      "                                  'tumor site, we investigated whether the '\n",
      "                                  'ADA/CD26 axis might counteract this '\n",
      "                                  'immunosuppressive phenotype.'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'We have recently reported that while the '\n",
      "                                  'co-expression of PD-1 and CD28 is '\n",
      "                                  'associated with impaired functionality in '\n",
      "                                  'peripheral blood, it significantly enhances '\n",
      "                                  'T-cell fitness in the tumor site of '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 187,\n",
      "                          'tStart': 183,\n",
      "                          'text': 'These findings suggest that although '\n",
      "                                  'differently distributed within the two '\n",
      "                                  'subsets across the different districts, the '\n",
      "                                  'individual CD26, CD39, CD73, or ADA '\n",
      "                                  'expression does not impact PD-1+CD8+ T-cell '\n",
      "                                  'functionality in the tumor site of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 230,\n",
      "                          'dStart': 225,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'We have recently reported that while the '\n",
      "                                  'co-expression of PD-1 and CD28 is '\n",
      "                                  'associated with impaired functionality in '\n",
      "                                  'peripheral blood, it significantly enhances '\n",
      "                                  'T-cell fitness in the tumor site of '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'Our results unveil the effects of the '\n",
      "                                  'ADA/CD26 axis in maintaining the functional '\n",
      "                                  'fitness of CD8+PD-1+CD28+ T cells as they '\n",
      "                                  'transition to the immunosuppressive NSCLC '\n",
      "                                  'tumor site.16 Based on these results, we '\n",
      "                                  'focused on lung adenocarcinoma (LUAD) and '\n",
      "                                  'identified a signature associated with '\n",
      "                                  'enhanced OS in LUAD TCGA patients and '\n",
      "                                  'improved OS and responsiveness in '\n",
      "                                  'ICB-treated advanced patients.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'We aimed to establish the direct influence '\n",
      "                                  'of ADA on the functional capability of CD8+ '\n",
      "                                  'PD-1/CD28 subsets within the NSCLC tumor '\n",
      "                                  'site using the specific ADA inhibitor '\n",
      "                                  'EHNA,19 focusing on the production of '\n",
      "                                  'IFN-γ, a primary functional target affected '\n",
      "                                  'by ADA deficiency.20'},\n",
      "                         {'dEnd': 262,\n",
      "                          'dStart': 257,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 171,\n",
      "                          'tStart': 167,\n",
      "                          'text': 'First, we assessed the impact of the '\n",
      "                                  'individual CD26, CD39, CD73, and ADA '\n",
      "                                  'expression on the distribution and '\n",
      "                                  'functional state of the two CD8+ subsets '\n",
      "                                  'characterized by PD-1 with or without CD28 '\n",
      "                                  'in peripheral blood, non-tumor lung tissue '\n",
      "                                  'and tumor site of 18 NSCLC patients.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'We then assessed how diverse CD39, ADA, and '\n",
      "                                  'CD26 co-expression patterns are distributed '\n",
      "                                  'within PD-1+CD28− and PD-1+CD28+ T-cell '\n",
      "                                  'subsets across the three sites in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 131,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'The ADA/CD26 axis in CD8+PD-1+CD28+ T cells '\n",
      "                                  'provides a signature predicting outcomes in '\n",
      "                                  'lung ADC and ICB Response in advanced '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'ADA/CD26 axis increases intra-tumor '\n",
      "                                  'PD-1+CD28+CD8+ T-cell fitness and affects '\n",
      "                                  'NSCLC prognosis and response to ICB'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 177,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Deciphering the role of CD26, CD39, CD73, '\n",
      "                                  'and ADA in shaping PD-1+CD28− and '\n",
      "                                  'PD-1+CD28+ CD8+ T-cell subset distribution '\n",
      "                                  'across peripheral blood, normal tissue, and '\n",
      "                                  'tumor site in NSCLC patients'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Herein, we explored the potential '\n",
      "                                  'involvement of the ADA/CD26 axis in the '\n",
      "                                  'enhanced functionality of '\n",
      "                                  'CD8+PD-1+CD28+cells from the NSCLC tumor '\n",
      "                                  'site in a context enriched with '\n",
      "                                  'immunosuppressive CD39 and CD73 '\n",
      "                                  'molecules.16'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'ADA/CD26 axis impacts the functional '\n",
      "                                  'fitness of CD8+ PD-1+CD28+ CD39+T cells in '\n",
      "                                  'NSCLC tumor site'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 177,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'Deciphering the role of CD26, CD39, CD73, '\n",
      "                                  'and ADA in shaping PD-1+CD28− and '\n",
      "                                  'PD-1+CD28+ CD8+ T-cell subset distribution '\n",
      "                                  'across peripheral blood, normal tissue, and '\n",
      "                                  'tumor site in NSCLC patients'},\n",
      "                         {'dEnd': 270,\n",
      "                          'dStart': 265,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 231,\n",
      "                          'tStart': 227,\n",
      "                          'text': 'Since ADA can be released into the '\n",
      "                                  'extracellular milieu and engage with CD26 '\n",
      "                                  'on neighboring T cells,7 our findings '\n",
      "                                  'suggest a pivotal role for exogenous ADA in '\n",
      "                                  'delivering a co-stimulatory signal via '\n",
      "                                  'interaction with CD26 on CD8+PD-1+ T cells '\n",
      "                                  'lacking CD28 within the NSCLC tumor site.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'We recently reported the CD28 pivotal role '\n",
      "                                  'in improving the functional state of PD-1+ '\n",
      "                                  'CD8+ T cells in the tumor site of NSCLC '\n",
      "                                  'patients.1 To explore the potential '\n",
      "                                  'mechanisms underlying the functional '\n",
      "                                  'advantage of PD-1+ CD8+ T cells within the '\n",
      "                                  'immunosuppressive, CD39-enriched NSCLC '\n",
      "                                  'tumor site, we investigated whether the '\n",
      "                                  'ADA/CD26 axis might counteract this '\n",
      "                                  'immunosuppressive phenotype.'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 228,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Our recent findings indicate that while the '\n",
      "                                  'co-expression of PD-1 and CD28 is '\n",
      "                                  'associated with impaired functionality of '\n",
      "                                  'CD8+ T cells in peripheral blood, it '\n",
      "                                  'significantly enhances the fitness of these '\n",
      "                                  'cells in the tumor site of non-small cell '\n",
      "                                  'lung cancer (NSCLC) patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37180581'],\n",
      " 'resourceScore': 86,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'In this system, we co-cultured the human '\n",
      "                                  'NSCLC cell line HCC827 cells and PBMCs from '\n",
      "                                  'NSCLC patients with different '\n",
      "                                  'concentrations of PD-1 mAb (Fig. 1A), and '\n",
      "                                  'analyzed the death rates and exhaustion of '\n",
      "                                  'T cells and NK cells in the co-culture '\n",
      "                                  'system by gating CD45+CD3+ cells and '\n",
      "                                  'CD45+CD3−CD19− cells, respectively (Fig. '\n",
      "                                  '1B).'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Although the exact mechanisms remain '\n",
      "                                  'unclear, we speculate that blockade of '\n",
      "                                  'NSCLC-intrinsic PD-1 can release PD-L1 and '\n",
      "                                  'stimulate the expression of co-inhibitory '\n",
      "                                  'molecules such as Fas ligand, which jointly '\n",
      "                                  'mediate the apoptotic pathway of activated '\n",
      "                                  'lymphocytes after application of PD-1 mAb '\n",
      "                                  '(Zhao et al., 2018).'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'It seems that the accumulated PD-1 mAb '\n",
      "                                  'might be responsible for the recurrence of '\n",
      "                                  'NSCLC in some responders by inducing the '\n",
      "                                  'death and exhaustion of T cells and NK '\n",
      "                                  'cells in TME.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'To further determine whether the activated '\n",
      "                                  '(CD69high) T cells and NK cells were prone '\n",
      "                                  'to death and exhaustion after using PD-1 '\n",
      "                                  'mAb, we used PHA to activate PBMCs from '\n",
      "                                  'either healthy volunteers (n = 3) or NSCLC '\n",
      "                                  'patients (n = 3) (Fig. 3A) and analyzed the '\n",
      "                                  'activation status of T cells and NK cells '\n",
      "                                  'by gating CD45+CD3+CD69+ cells and '\n",
      "                                  'CD45+CD3−CD20−CD69+ cells, respectively '\n",
      "                                  '(Fig. 3B).'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 mAb induced the death and exhaustion '\n",
      "                                  'of T cells and NK cells from CD69high NSCLC '\n",
      "                                  'patients'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'To determine the effect of PD-1 mAb on '\n",
      "                                  'activated T cells and NK cells, PBMCs from '\n",
      "                                  'NSCLC patients (n = 11) and healthy '\n",
      "                                  'volunteers (n = 19) were cultured in four '\n",
      "                                  'different types of in vitro co-culture '\n",
      "                                  'system (Fig. 4A), respectively.'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'We focused attention on whether PD-1 mAb '\n",
      "                                  'promoted the death and exhaustion of '\n",
      "                                  'lymphocytes in TME of NSCLC and tried to '\n",
      "                                  'identify the influence of activated '\n",
      "                                  'lymphocytes (CD69high expression) in the '\n",
      "                                  'process.'},\n",
      "                         {'dEnd': 39,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Since most patients with advanced NSCLC '\n",
      "                                  'lose the opportunity for surgical '\n",
      "                                  'resection, they often require anti-tumor '\n",
      "                                  'immunotherapy, such as anti-programmed cell '\n",
      "                                  'death-1 (PD-1) immunotherapy (Shepherd, '\n",
      "                                  'Douillard & Blumenschein, 2011).'},\n",
      "                         {'dEnd': 62,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'To study the effect of PD-1 mAb on '\n",
      "                                  'lymphocytes in TME of NSCLC, we established '\n",
      "                                  'an in vitro model system of anti-tumor '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 11,\n",
      "                          'dStart': 6,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'In an NSCLC patient expressing '\n",
      "                                  'tumor-intrinsic PD-1, the tumor rapidly '\n",
      "                                  'progressed upon anti-PD-1 therapy for 2 '\n",
      "                                  'months (Du et al., 2018).'},\n",
      "                         {'dEnd': 281,\n",
      "                          'dStart': 276,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In order to determine the effect of the '\n",
      "                                  'activation state in peripheral blood '\n",
      "                                  'lymphocytes on anti-PD-1 tumor '\n",
      "                                  'immunotherapy, we randomly selected five '\n",
      "                                  'NSCLC patients whose the percentages of '\n",
      "                                  'CD69+ cells in peripheral blood T cells '\n",
      "                                  'were greater than 5% (CD69high group) and '\n",
      "                                  'five NSCLC patients whose the percentages '\n",
      "                                  'of CD69+ cells in peripheral blood T cells '\n",
      "                                  'were less than 5% (CD69low group).'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In order to determine the effect of the '\n",
      "                                  'activation state in peripheral blood '\n",
      "                                  'lymphocytes on anti-PD-1 tumor '\n",
      "                                  'immunotherapy, we randomly selected five '\n",
      "                                  'NSCLC patients whose the percentages of '\n",
      "                                  'CD69+ cells in peripheral blood T cells '\n",
      "                                  'were greater than 5% (CD69high group) and '\n",
      "                                  'five NSCLC patients whose the percentages '\n",
      "                                  'of CD69+ cells in peripheral blood T cells '\n",
      "                                  'were less than 5% (CD69low group).'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'The result showed that PD-1 mAb increased '\n",
      "                                  'the death rates of T cells (CD45+CD3+ '\n",
      "                                  'Annexin V+) and NK cells (CD45+CD3−CD19− '\n",
      "                                  'Annexin V+) of several NSCLC patients '\n",
      "                                  '(patient No. 1, and No. 6-8) in a '\n",
      "                                  'dose-dependent way (Fig. 1C and Fig. S2).'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'These data may provide ideas to guide '\n",
      "                                  'individualized medication of PD-1 mAb in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'However, no study investigated the '\n",
      "                                  'relationship between expression level of '\n",
      "                                  'CD69 on lymphocytes and the acquired '\n",
      "                                  'resistance of anti-PD-1 immunotherapy in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'The application of PD-1 monoclonal antibody '\n",
      "                                  '(mAb) helps to treat non-small cell lung '\n",
      "                                  'cancer, but acquired resistance has emerged '\n",
      "                                  'in clinical practice.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'We found that PD-1 mAb increase the death '\n",
      "                                  'and exhaustion of T cells and NK cells in a '\n",
      "                                  'dose-dependent way when PBMCs from NSCLC '\n",
      "                                  'patients whose the percentages of CD69+ '\n",
      "                                  'cells in peripheral blood T cells were '\n",
      "                                  'greater than 5% (CD69high NSCLC patients).'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'By analyzing PBMCs from healthy volunteers '\n",
      "                                  'and CD69low NSCLC patients, we found that T '\n",
      "                                  'cells and NK cells can be induced to die by '\n",
      "                                  'PD-1 mAb after PHA activation, and had a '\n",
      "                                  'tendency to raise the rate of cell '\n",
      "                                  'exhaustion.'},\n",
      "                         {'dEnd': 237,\n",
      "                          'dStart': 232,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'We found that PD-1 mAb increase the death '\n",
      "                                  'and exhaustion of T cells and NK cells in a '\n",
      "                                  'dose-dependent way when PBMCs from NSCLC '\n",
      "                                  'patients whose the percentages of CD69+ '\n",
      "                                  'cells in peripheral blood T cells were '\n",
      "                                  'greater than 5% (CD69high NSCLC patients).'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 mAb induced the death of PHA-activated '\n",
      "                                  'T cells and NK cells from PBMCs of CD69low '\n",
      "                                  'NSCLC patients'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 mAb promoted the death and exhaustion '\n",
      "                                  'of T cells and NK cells in the in vitro '\n",
      "                                  'co-culture system of HCC827 cells and PBMCs '\n",
      "                                  'from NSCLC patients'},\n",
      "                         {'dEnd': 28,\n",
      "                          'dStart': 23,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'From this perspective, NSCLC patients who '\n",
      "                                  'possibly represent acquired resistance to '\n",
      "                                  'PD-1 mAb immunotherapy should be screened '\n",
      "                                  'in early stage and the clincians are '\n",
      "                                  'necessary to reconsider the application '\n",
      "                                  'strategy of PD-1 mAbs for these patients.'},\n",
      "                         {'dEnd': 57,\n",
      "                          'dStart': 52,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 93,\n",
      "                          'text': 'Similarly, T cells and NK cells in PBMCs of '\n",
      "                                  'CD69low NSCLC patients could be induce to '\n",
      "                                  'die by PD-1 mAb after PHA activation, and '\n",
      "                                  'had a tendency to raise the rate of cell '\n",
      "                                  'exhaustion, as shown in Figs. 4C, 4E and '\n",
      "                                  '4F.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 214,\n",
      "                          'tStart': 210,\n",
      "                          'text': 'And phytohemagglutinin (PHA) was then used '\n",
      "                                  'to activate PBMCs from CD69low NSCLC '\n",
      "                                  'patients and healthy volunteers to verify '\n",
      "                                  'the predisposing role of CD69high '\n",
      "                                  'expression for death and exhaustion of '\n",
      "                                  'lymphocytes in PD-1 mAb immunotherapy.'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'In this study, we found that PD-1 mAb '\n",
      "                                  'promoted the death and exhaustion of T '\n",
      "                                  'cells and NK cells with a dose-dependent '\n",
      "                                  'way in the in vitro co-culture system of '\n",
      "                                  'HCC827 cells and PBMCs from NSCLC patients, '\n",
      "                                  'as shown in Figs. 1C and 1D.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32920330'],\n",
      " 'resourceScore': 85,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': '•Anti-PD-1 therapy upregulates Tregs levels '\n",
      "                                  'in NSCLC patients and mouse model.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'However, the impact of anti-PD-1 treatment '\n",
      "                                  'on these immunosuppressive cells has not '\n",
      "                                  'been clearly defined in non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'The distinct response of M-MDSCs to '\n",
      "                                  'anti-PD-1 therapy may predict different '\n",
      "                                  'anti-tumor efficacy in NSCLC patients.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'However, the impact of anti-PD-1 treatment '\n",
      "                                  'on these immunosuppressive cells has not '\n",
      "                                  'been clearly defined in non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'Here, we demonstrated that anti-PD-1 '\n",
      "                                  'upregulated Tregs levels, and a low M-MDSCs '\n",
      "                                  'levels was associated with the better '\n",
      "                                  'anti-tumor efficacy of anti-PD-1 therapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Neutralization of M-MDSCs may be a '\n",
      "                                  'promising option to augment anti-PD-1 '\n",
      "                                  'therapy efficacy in NSCLC.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Next, we investigated whether the expansion '\n",
      "                                  'of CD8+ effector T cells after anti-PD-1 '\n",
      "                                  'therapy was conserved in NSCLC patients.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'The results showed that anti-PD-1 treatment '\n",
      "                                  'did not change the levels iNOS+ G-MDSCs and '\n",
      "                                  'iNOS+ M-MDSCs in peripheral blood of NSCLC '\n",
      "                                  'patients (Figs. S4E and 4F).'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'The baseline characteristics and clinical '\n",
      "                                  'outcomes after anti-PD-1 therapy of NSCLC '\n",
      "                                  'patients'},\n",
      "                         {'dEnd': 131,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'The association between monocytic '\n",
      "                                  'myeloid-derived suppressor cells levels and '\n",
      "                                  'the anti-tumor efficacy of anti-PD-1 '\n",
      "                                  'therapy in NSCLC patients'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 171,\n",
      "                          'tStart': 167,\n",
      "                          'text': 'As for the biological significance, we '\n",
      "                                  'supposed that the upregulated Tregs on one '\n",
      "                                  'hand might just constructively balance the '\n",
      "                                  'excessive immune hyperfunction after '\n",
      "                                  'anti-PD-1 therapy in NSCLC patients, which '\n",
      "                                  'perhaps also explained the upregulating '\n",
      "                                  'Tregs even in the PR group.'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Here, we longitudinally analyzed the impact '\n",
      "                                  'of anti-PD-1 therapy on Tregs, G-MDSCs and '\n",
      "                                  'M-MDSCs levels in peripheral blood and '\n",
      "                                  'primarily investigated the association of '\n",
      "                                  'M-MDSCs with the anti-tumor efficacy of '\n",
      "                                  'anti-PD-1 therapy in NSCLC patients and the '\n",
      "                                  'syngeneic tumor model.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'The decreasing M-MDSCs levels are '\n",
      "                                  'associated with the better anti-tumor '\n",
      "                                  'efficacy of anti-PD-1 therapy in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'However, the regulation of anti-PD-1 '\n",
      "                                  'therapy on the Tregs is not very clear in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 therapy overall boosted the Tregs '\n",
      "                                  'levels while showed no obvious impact on '\n",
      "                                  'G-MDSCs and M-MDSCs levels in NSCLC '\n",
      "                                  'patients'},\n",
      "                         {'dEnd': 66,\n",
      "                          'dStart': 61,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'In conclusion, anti-PD-1 therapy '\n",
      "                                  'upregulates Tregs levels in NSCLC patients, '\n",
      "                                  'and the M-MDSC levels are associated with '\n",
      "                                  'the anti-tumor efficacy of anti-PD-1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 211,\n",
      "                          'dStart': 206,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'Although it has been known that G-MDSCs and '\n",
      "                                  'M-MDSCs undermined the efficacy of '\n",
      "                                  'anti-PD-1 therapy, few associated studies '\n",
      "                                  'investigated the impact of consecutive '\n",
      "                                  'anti-PD-1 treatment on G-MDSCs and M-MDSCs '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 72,\n",
      "                          'dStart': 67,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Pembrolizumab (anti-PD-1 antibody) also '\n",
      "                                  'have been used in advanced NSCLC patients '\n",
      "                                  'meeting the PD-L1 cutoff point and '\n",
      "                                  'successfully improved the overall survival '\n",
      "                                  'up to 22.1 months [5].'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Therefore, the distinct response of '\n",
      "                                  'M-MDSCs, not G-MDSCs, to anti-PD-1 therapy '\n",
      "                                  'is associated with the anti-tumor efficacy '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 211,\n",
      "                          'dStart': 206,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Although it has been known that G-MDSCs and '\n",
      "                                  'M-MDSCs undermined the efficacy of '\n",
      "                                  'anti-PD-1 therapy, few associated studies '\n",
      "                                  'investigated the impact of consecutive '\n",
      "                                  'anti-PD-1 treatment on G-MDSCs and M-MDSCs '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'Clinical trials have verified the effect of '\n",
      "                                  'PD-1/L1 checkpoint inhibitors in refractory '\n",
      "                                  'and advanced NSCLC [[4], [5], [6], [7], '\n",
      "                                  '[8]].'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Therefore, the impact of anti-PD-1 therapy '\n",
      "                                  'on Tregs is remained to be studied, '\n",
      "                                  'especially in NSCLC patients.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'A previous study showed that anti-PD-1 '\n",
      "                                  'therapy decreased the frequency of M-MDSCs '\n",
      "                                  'in NSCLC patients [28].'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Here, we demonstrated that anti-PD-1 '\n",
      "                                  'upregulated Tregs levels, and a low M-MDSCs '\n",
      "                                  'levels was associated with the better '\n",
      "                                  'anti-tumor efficacy of anti-PD-1 therapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Compared to M-MDSCs, we did not observe an '\n",
      "                                  'obvious effect of anti-PD-1 on circulating '\n",
      "                                  'G-MDSCs in NSCLC patients.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Neutralization of M-MDSCs may be a '\n",
      "                                  'promising option to augment anti-PD-1 '\n",
      "                                  'efficacy in NSCLC.'},\n",
      "                         {'dEnd': 58,\n",
      "                          'dStart': 53,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 therapy upregulated Tregs in all '\n",
      "                                  'groups of NSCLC patients while decreased '\n",
      "                                  'M-MDSCs levels only in the PR group'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'Here, we longitudinally analyzed the impact '\n",
      "                                  'of anti-PD-1 therapy on Tregs, G-MDSCs and '\n",
      "                                  'M-MDSCs levels in peripheral blood and '\n",
      "                                  'primarily investigated the association of '\n",
      "                                  'M-MDSCs with the anti-tumor efficacy of '\n",
      "                                  'anti-PD-1 therapy in NSCLC patients and the '\n",
      "                                  'syngeneic tumor model.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': \"Therefore, it's urgent to explore the \"\n",
      "                                  'pathway to resist the low efficacy and '\n",
      "                                  'unresponsiveness to anti-PD-1 therapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Here, we found that anti-PD-1 treatment '\n",
      "                                  'boosted circulating Tregs levels, which '\n",
      "                                  'presented the most remarkable augment '\n",
      "                                  'during the first two therapeutic cycles, in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Collectively, anti-PD-1 therapy robustly '\n",
      "                                  'promotes Tregs proliferation in NSCLC '\n",
      "                                  'patients and the syngeneic tumor model.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34455737'],\n",
      " 'resourceScore': 83,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 5,\n",
      "                          'dStart': 0,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'NSCLC患者的临床病理特征、PD-1、PD-L1的蛋白表达、EFGR突变与预后的相关因素分析'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'PD-L1与PD-1相结合,传递免疫抑制信号,抑制T细胞的活化与增殖,参与肿瘤免疫逃逸[12]。目前经美国食品药品监督管理局(Food '\n",
      "                                  'and Drug Administration, '\n",
      "                                  'FDA)批准可作为晚期NSCLC二线治疗的免疫检查点抑制剂主要有PD-1抗体Nivolumab、Pembrolizumab和PD-L1抗体Atezolizumab,其中Pembrolizumab '\n",
      "                                  '2016年获批成为NSCLC的一线治疗用药,用药效果与PD-L1的表达水平相关。研究Keynote-024表明驱动基因阴性的PD-L1≥50% '\n",
      "                                  'NSCLC一线使用帕博利珠单抗单药治疗显著优于化疗,可使患者获益显著,中位无进展生存时间和总生存期与化疗组相应延长,且不良反应较化疗少[13],而在PD-L1表达在1%-49%的患者则获益有限,随着PD-L1表达的增高,患者使用帕博利珠单抗治疗的OS逐步延长[14]。'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 324,\n",
      "                          'tStart': 320,\n",
      "                          'text': '肺癌的治疗模式以表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth '\n",
      "                                  'factor receptor-tyrosine kinase inhibitors, '\n",
      "                                  'EGFR-TKIs)作为EGFR突变的非小细胞肺癌(non-small cell '\n",
      "                                  'lung cancer, '\n",
      "                                  'NSCLC)患者一线治疗;同时以程序性死亡受体1(programmed death '\n",
      "                                  'receptor 1, PD-1)及其配体(programmed death '\n",
      "                                  'receptor ligand 1, '\n",
      "                                  'PD-L1)抑制剂为代表的免疫检查点抑制剂(immune checkpoint '\n",
      "                                  'inhibitors, '\n",
      "                                  'ICIs)的免疫治疗在肺癌治疗中疗效显著。本研究旨在探讨PD-1和PD-L1在NSCLC中的表达及其与临床病理特征、EGFR突变之间的关系。'},\n",
      "                         {'dEnd': 37,\n",
      "                          'dStart': 32,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1 positive expression in NSCLC tumor '\n",
      "                                  'cells and tumor infiltrating immune cells '\n",
      "                                  'is 53.5% (68/127), PD-L1 is 57.5% '\n",
      "                                  '(73/127).'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'The protein expression of PD-L1 and PD-1 '\n",
      "                                  'had the consistency in NSCLC patients '\n",
      "                                  '(kappa=0.107, 5, P=0.487).'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'PD-1与PD-L1表达的相关性分析(kappa=0.107, 5, '\n",
      "                                  'P=0.487)说明PD-1与PD-L1表达存在一致性,同时PD-1与PD-L1表达一致性还表现在临床病理特征的关系中,PD-1与PD-L1的表达与性别、年龄、吸烟史、组织类型、淋巴结转移均无统计学意义;在分化程度和临床分期中,PD-1与PD-L1在低分化癌中的表达65.9%(29/44)、70.5%(31/44)高于高、中分化癌47.0%(39/83)、50.6%(42/83),在临床分期I期和II期的阳性表达率60%(57/95)、63.2%(60/95)高于III期和IV期的阳性表达率34.4%(11/32)、40.6%(13/32)(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);高锋等[14]研究PD-L1在NSCLC中的表达与淋巴结转移、肿瘤细胞分化程度、TNM分期及生存期有关(P '\n",
      "                                  '< '\n",
      "                                  '0.05),其中该作者PD-L1在低分化癌中的表达83.3%(15/18)高于高、中分化癌52.4%(22/42),但在临床分期中III期(75.0%, '\n",
      "                                  '9/12)和II期(70.9%, 22/31)表达高于I期(35.3%, '\n",
      "                                  '6/17),PD-L1在临床分期中的表达差异,可能存在样本量少、各组样本不均衡,导致统计结果不一致。'},\n",
      "                         {'dEnd': 271,\n",
      "                          'dStart': 266,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': '研究[13]显示NSCLC中PD-1为29.2%-75.0%,PD-L1的阳性表达率为39.9%-53.1%。本研究中PD-1的表达采用CPS评分,为53.5%(68/127),肿瘤细胞和免疫细胞都表达为46.5%(59/127);依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》[10]对样本进行PD-L1检测,包括推荐试剂、仪器、检测结果判读等都参照专家共识,PD-L1表达率为57.5%(73/127),其中PD-L1高表达占11%(14/127),低表达占46.5%(59/127),高锋等[14]PD-L1在NSCLC中阳性表达率为61.67%,在不同研究中PD-L1在NSCLC中的表达存在的异质性,在手术标本与活检标本间存在一定异质性[15],国内相关研究同样显示类似结果[16],本研究样本也存在手术标本57.5%,穿刺与支气管镜标本30.7%,肺癌转移标本11.8%,了解标本间PD-L1表达的异质性对临床检测有着重要的指导作用。'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 93,\n",
      "                          'text': '参照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》检测非小细胞肺癌PD-L1表达,筛选出抗PD-1/PD-L1治疗的优势人群;同时检测出EGFR突变的患者,并且EGFR突变与PD-1、PD-L1表达存在负相关关系,依据PD-L1表达和EGFR突变状态,可能使NSCLC患者在的个体化治疗中获益,同时65岁以下、腺癌、高中分化、PD-L1低表达的患者有相对好的预后,为NSCLC预后评估提供参考。'},\n",
      "                         {'dEnd': 302,\n",
      "                          'dStart': 297,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': '研究[13]显示NSCLC中PD-1为29.2%-75.0%,PD-L1的阳性表达率为39.9%-53.1%。本研究中PD-1的表达采用CPS评分,为53.5%(68/127),肿瘤细胞和免疫细胞都表达为46.5%(59/127);依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》[10]对样本进行PD-L1检测,包括推荐试剂、仪器、检测结果判读等都参照专家共识,PD-L1表达率为57.5%(73/127),其中PD-L1高表达占11%(14/127),低表达占46.5%(59/127),高锋等[14]PD-L1在NSCLC中阳性表达率为61.67%,在不同研究中PD-L1在NSCLC中的表达存在的异质性,在手术标本与活检标本间存在一定异质性[15],国内相关研究同样显示类似结果[16],本研究样本也存在手术标本57.5%,穿刺与支气管镜标本30.7%,肺癌转移标本11.8%,了解标本间PD-L1表达的异质性对临床检测有着重要的指导作用。'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 313,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': '采用免疫组化方法检测127例NSCLC '\n",
      "                                  'PD-1和PD-L1蛋白表达,同时用定量聚合酶链反应(quantitative '\n",
      "                                  'polymerase chain reaction, '\n",
      "                                  'qPCR)检测EGFR基因突变,分析其与临床病理特征之间的关系,研究PD-1、PD-L1表达之间以及其与EGFR突变的关系。'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': '应用SPSS '\n",
      "                                  '20.0软件对数据进行统计分析。NSCLC组织中PD-L1和PD-1表达、EGFR基因突变状态与临床病理特征等分类资料指标采用频数和百分比进行描述,组间的差异比较采用卡方(或秩和)检验,组间的相关性采用McNemar和列联系数进行相关性分析,用Kaplan-Meier曲线分析各因子与NSCLC患者生存情况的关系,所有检验均为双侧检验,以P '\n",
      "                                  '< 0.05为差异有统计学意义。'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 313,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 221,\n",
      "                          'tStart': 217,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'The aim of this study was to investigate '\n",
      "                                  'the correlation between the expression of '\n",
      "                                  'PD-1 and PD-L1 in NSCLC and '\n",
      "                                  'clinicopathologic feature, EGFR gene '\n",
      "                                  'mutation.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': '参照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》检测非小细胞肺癌PD-L1表达,筛选出抗PD-1/PD-L1治疗的优势人群;同时检测出EGFR突变的患者,并且EGFR突变与PD-1、PD-L1表达存在负相关关系,依据PD-L1表达和EGFR突变状态,可能使NSCLC患者在的个体化治疗中获益,同时65岁以下、腺癌、高中分化、PD-L1低表达的患者有相对好的预后,为NSCLC预后评估提供参考。'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'PD-L1与PD-1相结合,传递免疫抑制信号,抑制T细胞的活化与增殖,参与肿瘤免疫逃逸[12]。目前经美国食品药品监督管理局(Food '\n",
      "                                  'and Drug Administration, '\n",
      "                                  'FDA)批准可作为晚期NSCLC二线治疗的免疫检查点抑制剂主要有PD-1抗体Nivolumab、Pembrolizumab和PD-L1抗体Atezolizumab,其中Pembrolizumab '\n",
      "                                  '2016年获批成为NSCLC的一线治疗用药,用药效果与PD-L1的表达水平相关。研究Keynote-024表明驱动基因阴性的PD-L1≥50% '\n",
      "                                  'NSCLC一线使用帕博利珠单抗单药治疗显著优于化疗,可使患者获益显著,中位无进展生存时间和总生存期与化疗组相应延长,且不良反应较化疗少[13],而在PD-L1表达在1%-49%的患者则获益有限,随着PD-L1表达的增高,患者使用帕博利珠单抗治疗的OS逐步延长[14]。'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': '参照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》检测非小细胞肺癌PD-L1表达,筛选出抗PD-1/PD-L1治疗的优势人群;同时检测出EGFR突变的患者,并且EGFR突变与PD-1、PD-L1表达存在负相关关系,依据PD-L1表达和EGFR突变状态,可能使NSCLC患者在的个体化治疗中获益,同时65岁以下、腺癌、高中分化、PD-L1低表达的患者有相对好的预后,为NSCLC预后评估提供参考。'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': '肺癌的治疗模式以表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth '\n",
      "                                  'factor receptor-tyrosine kinase inhibitors, '\n",
      "                                  'EGFR-TKIs)作为EGFR突变的非小细胞肺癌(non-small cell '\n",
      "                                  'lung cancer, '\n",
      "                                  'NSCLC)患者一线治疗;同时以程序性死亡受体1(programmed death '\n",
      "                                  'receptor 1, PD-1)及其配体(programmed death '\n",
      "                                  'receptor ligand 1, '\n",
      "                                  'PD-L1)抑制剂为代表的免疫检查点抑制剂(immune checkpoint '\n",
      "                                  'inhibitors, '\n",
      "                                  'ICIs)的免疫治疗在肺癌治疗中疗效显著。本研究旨在探讨PD-1和PD-L1在NSCLC中的表达及其与临床病理特征、EGFR突变之间的关系。'},\n",
      "                         {'dEnd': 302,\n",
      "                          'dStart': 297,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': '研究[13]显示NSCLC中PD-1为29.2%-75.0%,PD-L1的阳性表达率为39.9%-53.1%。本研究中PD-1的表达采用CPS评分,为53.5%(68/127),肿瘤细胞和免疫细胞都表达为46.5%(59/127);依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》[10]对样本进行PD-L1检测,包括推荐试剂、仪器、检测结果判读等都参照专家共识,PD-L1表达率为57.5%(73/127),其中PD-L1高表达占11%(14/127),低表达占46.5%(59/127),高锋等[14]PD-L1在NSCLC中阳性表达率为61.67%,在不同研究中PD-L1在NSCLC中的表达存在的异质性,在手术标本与活检标本间存在一定异质性[15],国内相关研究同样显示类似结果[16],本研究样本也存在手术标本57.5%,穿刺与支气管镜标本30.7%,肺癌转移标本11.8%,了解标本间PD-L1表达的异质性对临床检测有着重要的指导作用。'},\n",
      "                         {'dEnd': 5,\n",
      "                          'dStart': 0,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': '肺癌是全球癌症相关死亡的主要原因,肺癌的治疗已经全面进入精准医学时代,在NSCLC治疗中,EGFR-TKI已成为EGFR敏感突变晚期NSCLC的一线治疗。尽管如此,靶向治疗出现获得性耐药不可避免,并最终导致治疗失败。随着对肿瘤免疫逃逸机制的认识不断深入,对PD-1/PD-L1通路的免疫靶向药物在NSCLC治疗中已经表现出令人惊喜的效果。'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'PD-L1与PD-1相结合,传递免疫抑制信号,抑制T细胞的活化与增殖,参与肿瘤免疫逃逸[12]。目前经美国食品药品监督管理局(Food '\n",
      "                                  'and Drug Administration, '\n",
      "                                  'FDA)批准可作为晚期NSCLC二线治疗的免疫检查点抑制剂主要有PD-1抗体Nivolumab、Pembrolizumab和PD-L1抗体Atezolizumab,其中Pembrolizumab '\n",
      "                                  '2016年获批成为NSCLC的一线治疗用药,用药效果与PD-L1的表达水平相关。研究Keynote-024表明驱动基因阴性的PD-L1≥50% '\n",
      "                                  'NSCLC一线使用帕博利珠单抗单药治疗显著优于化疗,可使患者获益显著,中位无进展生存时间和总生存期与化疗组相应延长,且不良反应较化疗少[13],而在PD-L1表达在1%-49%的患者则获益有限,随着PD-L1表达的增高,患者使用帕博利珠单抗治疗的OS逐步延长[14]。'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'PD-1与PD-L1表达的相关性分析(kappa=0.107, 5, '\n",
      "                                  'P=0.487)说明PD-1与PD-L1表达存在一致性,同时PD-1与PD-L1表达一致性还表现在临床病理特征的关系中,PD-1与PD-L1的表达与性别、年龄、吸烟史、组织类型、淋巴结转移均无统计学意义;在分化程度和临床分期中,PD-1与PD-L1在低分化癌中的表达65.9%(29/44)、70.5%(31/44)高于高、中分化癌47.0%(39/83)、50.6%(42/83),在临床分期I期和II期的阳性表达率60%(57/95)、63.2%(60/95)高于III期和IV期的阳性表达率34.4%(11/32)、40.6%(13/32)(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);高锋等[14]研究PD-L1在NSCLC中的表达与淋巴结转移、肿瘤细胞分化程度、TNM分期及生存期有关(P '\n",
      "                                  '< '\n",
      "                                  '0.05),其中该作者PD-L1在低分化癌中的表达83.3%(15/18)高于高、中分化癌52.4%(22/42),但在临床分期中III期(75.0%, '\n",
      "                                  '9/12)和II期(70.9%, 22/31)表达高于I期(35.3%, '\n",
      "                                  '6/17),PD-L1在临床分期中的表达差异,可能存在样本量少、各组样本不均衡,导致统计结果不一致。'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'The protein expression of PD-1 and PD-L1 '\n",
      "                                  'was detected by immunohistochemistry from '\n",
      "                                  '127 patients with NSCLC and EGFR gene '\n",
      "                                  'mutation was detected by quantitative '\n",
      "                                  'polymerase chain reaction (qPCR) to analyze '\n",
      "                                  'its relation with clinicopathologic '\n",
      "                                  'feature.'},\n",
      "                         {'dEnd': 13,\n",
      "                          'dStart': 8,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': '研究[13]显示NSCLC中PD-1为29.2%-75.0%,PD-L1的阳性表达率为39.9%-53.1%。本研究中PD-1的表达采用CPS评分,为53.5%(68/127),肿瘤细胞和免疫细胞都表达为46.5%(59/127);依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》[10]对样本进行PD-L1检测,包括推荐试剂、仪器、检测结果判读等都参照专家共识,PD-L1表达率为57.5%(73/127),其中PD-L1高表达占11%(14/127),低表达占46.5%(59/127),高锋等[14]PD-L1在NSCLC中阳性表达率为61.67%,在不同研究中PD-L1在NSCLC中的表达存在的异质性,在手术标本与活检标本间存在一定异质性[15],国内相关研究同样显示类似结果[16],本研究样本也存在手术标本57.5%,穿刺与支气管镜标本30.7%,肺癌转移标本11.8%,了解标本间PD-L1表达的异质性对临床检测有着重要的指导作用。'},\n",
      "                         {'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': '本研究依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》对127例NSCLC组织进行PD-L1检测、判读,筛选出PD-L1高表达和低表达的患者,能够使这些患者在抗PD-1/PD-L1免疫治疗中获益,从而提高生存率;PD-1、PD-L1的表达都与肿瘤分化程度、临床分期有关,EGFR突变与PD-1、PD-L1存在负相关的关系,临床医生依据EGFR基因状态和免疫检测点PD-L1表达情况选择合适的治疗方案。同时本研究中65岁以下、腺癌、高、中分化、PD-L1表达的患者有较好的预后,为NSCLC预后评估提供依据。'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'PD-1与PD-L1表达的相关性分析(kappa=0.107, 5, '\n",
      "                                  'P=0.487)说明PD-1与PD-L1表达存在一致性,同时PD-1与PD-L1表达一致性还表现在临床病理特征的关系中,PD-1与PD-L1的表达与性别、年龄、吸烟史、组织类型、淋巴结转移均无统计学意义;在分化程度和临床分期中,PD-1与PD-L1在低分化癌中的表达65.9%(29/44)、70.5%(31/44)高于高、中分化癌47.0%(39/83)、50.6%(42/83),在临床分期I期和II期的阳性表达率60%(57/95)、63.2%(60/95)高于III期和IV期的阳性表达率34.4%(11/32)、40.6%(13/32)(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);高锋等[14]研究PD-L1在NSCLC中的表达与淋巴结转移、肿瘤细胞分化程度、TNM分期及生存期有关(P '\n",
      "                                  '< '\n",
      "                                  '0.05),其中该作者PD-L1在低分化癌中的表达83.3%(15/18)高于高、中分化癌52.4%(22/42),但在临床分期中III期(75.0%, '\n",
      "                                  '9/12)和II期(70.9%, 22/31)表达高于I期(35.3%, '\n",
      "                                  '6/17),PD-L1在临床分期中的表达差异,可能存在样本量少、各组样本不均衡,导致统计结果不一致。'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'PD-L1与PD-1相结合,传递免疫抑制信号,抑制T细胞的活化与增殖,参与肿瘤免疫逃逸[12]。目前经美国食品药品监督管理局(Food '\n",
      "                                  'and Drug Administration, '\n",
      "                                  'FDA)批准可作为晚期NSCLC二线治疗的免疫检查点抑制剂主要有PD-1抗体Nivolumab、Pembrolizumab和PD-L1抗体Atezolizumab,其中Pembrolizumab '\n",
      "                                  '2016年获批成为NSCLC的一线治疗用药,用药效果与PD-L1的表达水平相关。研究Keynote-024表明驱动基因阴性的PD-L1≥50% '\n",
      "                                  'NSCLC一线使用帕博利珠单抗单药治疗显著优于化疗,可使患者获益显著,中位无进展生存时间和总生存期与化疗组相应延长,且不良反应较化疗少[13],而在PD-L1表达在1%-49%的患者则获益有限,随着PD-L1表达的增高,患者使用帕博利珠单抗治疗的OS逐步延长[14]。'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Correlation of expression of PD-1 and PD-L1 '\n",
      "                                  'with clinical features in NSCLC (n=127) '\n",
      "                                  '[n(%)]'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 313,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'},\n",
      "                         {'dEnd': 271,\n",
      "                          'dStart': 266,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': '研究[13]显示NSCLC中PD-1为29.2%-75.0%,PD-L1的阳性表达率为39.9%-53.1%。本研究中PD-1的表达采用CPS评分,为53.5%(68/127),肿瘤细胞和免疫细胞都表达为46.5%(59/127);依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》[10]对样本进行PD-L1检测,包括推荐试剂、仪器、检测结果判读等都参照专家共识,PD-L1表达率为57.5%(73/127),其中PD-L1高表达占11%(14/127),低表达占46.5%(59/127),高锋等[14]PD-L1在NSCLC中阳性表达率为61.67%,在不同研究中PD-L1在NSCLC中的表达存在的异质性,在手术标本与活检标本间存在一定异质性[15],国内相关研究同样显示类似结果[16],本研究样本也存在手术标本57.5%,穿刺与支气管镜标本30.7%,肺癌转移标本11.8%,了解标本间PD-L1表达的异质性对临床检测有着重要的指导作用。'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1与PD-L1表达的相关性分析(kappa=0.107, 5, '\n",
      "                                  'P=0.487)说明PD-1与PD-L1表达存在一致性,同时PD-1与PD-L1表达一致性还表现在临床病理特征的关系中,PD-1与PD-L1的表达与性别、年龄、吸烟史、组织类型、淋巴结转移均无统计学意义;在分化程度和临床分期中,PD-1与PD-L1在低分化癌中的表达65.9%(29/44)、70.5%(31/44)高于高、中分化癌47.0%(39/83)、50.6%(42/83),在临床分期I期和II期的阳性表达率60%(57/95)、63.2%(60/95)高于III期和IV期的阳性表达率34.4%(11/32)、40.6%(13/32)(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);高锋等[14]研究PD-L1在NSCLC中的表达与淋巴结转移、肿瘤细胞分化程度、TNM分期及生存期有关(P '\n",
      "                                  '< '\n",
      "                                  '0.05),其中该作者PD-L1在低分化癌中的表达83.3%(15/18)高于高、中分化癌52.4%(22/42),但在临床分期中III期(75.0%, '\n",
      "                                  '9/12)和II期(70.9%, 22/31)表达高于I期(35.3%, '\n",
      "                                  '6/17),PD-L1在临床分期中的表达差异,可能存在样本量少、各组样本不均衡,导致统计结果不一致。'},\n",
      "                         {'dEnd': 16,\n",
      "                          'dStart': 11,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1和PD-L1在NSCLC中的表达与临床特征的关系(n=127)[n(%)]'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 93,\n",
      "                          'text': '参照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》检测非小细胞肺癌PD-L1表达,筛选出抗PD-1/PD-L1治疗的优势人群;同时检测出EGFR突变的患者,并且EGFR突变与PD-1、PD-L1表达存在负相关关系,依据PD-L1表达和EGFR突变状态,可能使NSCLC患者在的个体化治疗中获益,同时65岁以下、腺癌、高中分化、PD-L1低表达的患者有相对好的预后,为NSCLC预后评估提供参考。'},\n",
      "                         {'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': '本研究依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》对127例NSCLC组织进行PD-L1检测、判读,筛选出PD-L1高表达和低表达的患者,能够使这些患者在抗PD-1/PD-L1免疫治疗中获益,从而提高生存率;PD-1、PD-L1的表达都与肿瘤分化程度、临床分期有关,EGFR突变与PD-1、PD-L1存在负相关的关系,临床医生依据EGFR基因状态和免疫检测点PD-L1表达情况选择合适的治疗方案。同时本研究中65岁以下、腺癌、高、中分化、PD-L1表达的患者有较好的预后,为NSCLC预后评估提供依据。'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'PD-1与PD-L1表达的相关性分析(kappa=0.107, 5, '\n",
      "                                  'P=0.487)说明PD-1与PD-L1表达存在一致性,同时PD-1与PD-L1表达一致性还表现在临床病理特征的关系中,PD-1与PD-L1的表达与性别、年龄、吸烟史、组织类型、淋巴结转移均无统计学意义;在分化程度和临床分期中,PD-1与PD-L1在低分化癌中的表达65.9%(29/44)、70.5%(31/44)高于高、中分化癌47.0%(39/83)、50.6%(42/83),在临床分期I期和II期的阳性表达率60%(57/95)、63.2%(60/95)高于III期和IV期的阳性表达率34.4%(11/32)、40.6%(13/32)(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);高锋等[14]研究PD-L1在NSCLC中的表达与淋巴结转移、肿瘤细胞分化程度、TNM分期及生存期有关(P '\n",
      "                                  '< '\n",
      "                                  '0.05),其中该作者PD-L1在低分化癌中的表达83.3%(15/18)高于高、中分化癌52.4%(22/42),但在临床分期中III期(75.0%, '\n",
      "                                  '9/12)和II期(70.9%, 22/31)表达高于I期(35.3%, '\n",
      "                                  '6/17),PD-L1在临床分期中的表达差异,可能存在样本量少、各组样本不均衡,导致统计结果不一致。'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'PD-L1与PD-1相结合,传递免疫抑制信号,抑制T细胞的活化与增殖,参与肿瘤免疫逃逸[12]。目前经美国食品药品监督管理局(Food '\n",
      "                                  'and Drug Administration, '\n",
      "                                  'FDA)批准可作为晚期NSCLC二线治疗的免疫检查点抑制剂主要有PD-1抗体Nivolumab、Pembrolizumab和PD-L1抗体Atezolizumab,其中Pembrolizumab '\n",
      "                                  '2016年获批成为NSCLC的一线治疗用药,用药效果与PD-L1的表达水平相关。研究Keynote-024表明驱动基因阴性的PD-L1≥50% '\n",
      "                                  'NSCLC一线使用帕博利珠单抗单药治疗显著优于化疗,可使患者获益显著,中位无进展生存时间和总生存期与化疗组相应延长,且不良反应较化疗少[13],而在PD-L1表达在1%-49%的患者则获益有限,随着PD-L1表达的增高,患者使用帕博利珠单抗治疗的OS逐步延长[14]。'},\n",
      "                         {'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': '本研究依照《非小细胞肺癌PD-L1免疫组织化学检测规范中国专家共识》对127例NSCLC组织进行PD-L1检测、判读,筛选出PD-L1高表达和低表达的患者,能够使这些患者在抗PD-1/PD-L1免疫治疗中获益,从而提高生存率;PD-1、PD-L1的表达都与肿瘤分化程度、临床分期有关,EGFR突变与PD-1、PD-L1存在负相关的关系,临床医生依据EGFR基因状态和免疫检测点PD-L1表达情况选择合适的治疗方案。同时本研究中65岁以下、腺癌、高、中分化、PD-L1表达的患者有较好的预后,为NSCLC预后评估提供依据。'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 313,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 267,\n",
      "                          'tStart': 263,\n",
      "                          'text': 'NSCLC肿瘤细胞及肿瘤浸润免疫细胞PD-1阳性表达53.5%(68/127),肿瘤细胞PD-L1表达57.5%(73/127),PD-1和PD-L1的表达在低分化癌、临床分期I期+II期明显高于高中分化癌、III期+IV期(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);EGFR突变率为46.5%(59/127),EGFR突变的患者中女性、无吸烟史、腺癌、高中分化组分别高于男性、吸烟史、鳞癌、低分化组患者(均P '\n",
      "                                  '< '\n",
      "                                  '0.05);NSCLC患者PD-L1与PD-1蛋白表达存在一致性(kappa=0.107, '\n",
      "                                  '5, '\n",
      "                                  'P=0.487),EGFR突变与PD-1、PD-L1表达存在负相关关系(Φ=-0.209,Φ=-0.221,均P '\n",
      "                                  '< 0.05);对NSCLC患者随访,在 < '\n",
      "                                  '65岁、腺癌、高中分化癌、PD-L1表达的患者中位总生存期分别高于≥65岁、鳞癌、低分化癌、PD-L1不表达患者(均P '\n",
      "                                  '< 0.05)。PD-L1低表达患者中位生存期明显高于高表达患者(P=0.04)。'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38560413'],\n",
      " 'resourceScore': 83,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 575,\n",
      "                          'dStart': 570,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 311,\n",
      "                          'tStart': 307,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Collectively, the safety profile of '\n",
      "                                  'anlotinib plus PD-1 blockades in patients '\n",
      "                                  'with previously immunotherapy treated '\n",
      "                                  'advanced NSCLC was tolerable and '\n",
      "                                  'manageable.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'As a result, this study aimed to '\n",
      "                                  'investigate the feasibility and '\n",
      "                                  'tolerability of anlotinib plus PD-1 '\n",
      "                                  'blockades in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC '\n",
      "                                  'retrospectively.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Prognosis of the 67 Patients with '\n",
      "                                  'Previously Immunotherapy Treated Advanced '\n",
      "                                  'NSCLC Who Received Anlotinib Plus PD-1 '\n",
      "                                  'Blockades'},\n",
      "                         {'dEnd': 80,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'Efficacy of the 67 Patients with Previously '\n",
      "                                  'Immunotherapy Treated Advanced NSCLC Who '\n",
      "                                  'Received Anlotinib Plus PD-1 Blockades'},\n",
      "                         {'dEnd': 281,\n",
      "                          'dStart': 276,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 206,\n",
      "                          'tStart': 202,\n",
      "                          'text': 'Second, the heterogeneous PD-1 blockades '\n",
      "                                  'used in our study and the absence of PD-L1 '\n",
      "                                  'expression detection might also confound '\n",
      "                                  'the conclusions regarding the efficacy and '\n",
      "                                  'safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC in '\n",
      "                                  'clinical practice.'},\n",
      "                         {'dEnd': 400,\n",
      "                          'dStart': 395,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 479,\n",
      "                          'dStart': 474,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 274,\n",
      "                          'tStart': 270,\n",
      "                          'text': 'Safety profile in our study showed that the '\n",
      "                                  'incidence of grade ≥3 adverse reactions was '\n",
      "                                  '46.3% of the 67 patients included, which '\n",
      "                                  'was slightly higher than the incidence of '\n",
      "                                  'grade ≥3 adverse reactions among patients '\n",
      "                                  'with advanced NSCLC who were treated with '\n",
      "                                  'anlotinib plus PD-1 blockades as the '\n",
      "                                  'subsequent line therapy (approximately '\n",
      "                                  '40%).18 This result suggested that the '\n",
      "                                  'combination of anlotinib plus PD-1 '\n",
      "                                  'blockades in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC might '\n",
      "                                  'potentiate the incidence of grade ≥3 '\n",
      "                                  'adverse reactions to some extent.'},\n",
      "                         {'dEnd': 575,\n",
      "                          'dStart': 570,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 482,\n",
      "                          'tStart': 478,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 86,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'Safety Profile of the 67 Patients with '\n",
      "                                  'Previously Immunotherapy Treated Advanced '\n",
      "                                  'NSCLC Who Received Anlotinib Plus PD-1 '\n",
      "                                  'Blockades'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'In this retrospective study, the '\n",
      "                                  'feasibility and tolerability of anlotinib '\n",
      "                                  'plus PD-1 blockades among patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'NSCLC were analyzed and presented in '\n",
      "                                  'real-world clinical practice, which '\n",
      "                                  'suggested that this combination regimen '\n",
      "                                  'demonstrated promising efficacy and '\n",
      "                                  'tolerable safety profile in patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Therapeutic regimens with anlotinib plus '\n",
      "                                  'PD-1 blockades provided encouraging '\n",
      "                                  'real-world effectiveness and an acceptable '\n",
      "                                  'safety profile in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC, '\n",
      "                                  'highlighting a potentially feasible '\n",
      "                                  'treatment option.'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Additionally, to identify the therapeutic '\n",
      "                                  'outcomes of anlotinib combined with PD-1 '\n",
      "                                  'blockades among patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC, this '\n",
      "                                  'study performed regular follow-up and '\n",
      "                                  'collected radiological results for each '\n",
      "                                  'patient to evaluate their PFS data.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Effectiveness and Safety of Anlotinib '\n",
      "                                  'Combined with PD-1 Blockades in Patients '\n",
      "                                  'with Previously Immunotherapy Treated '\n",
      "                                  'Advanced Non-Small Cell Lung Cancer: A '\n",
      "                                  'Retrospective Exploratory Study'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 346,\n",
      "                          'dStart': 341,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'Interestingly, this regimen produced a '\n",
      "                                  'longer OS compared to anlotinib monotherapy '\n",
      "                                  'or PD-1 blockades monotherapy (anlotinib: '\n",
      "                                  '9.6 months and PD-1 blockades: 12.5 '\n",
      "                                  'months).37,38 We speculated that one '\n",
      "                                  'possible explanation was that targeted '\n",
      "                                  'drugs and immune checkpoint inhibitors were '\n",
      "                                  'approved in China since 2018, making '\n",
      "                                  'patients with advanced NSCLC in our study '\n",
      "                                  'who progressed on anlotinib combined with '\n",
      "                                  'PD-1 blockades receive subsequent '\n",
      "                                  'treatments with other targeted drugs or '\n",
      "                                  'PD-L1 blockades, providing some patients '\n",
      "                                  'with survival benefits consecutively.39'},\n",
      "                         {'dEnd': 346,\n",
      "                          'dStart': 341,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 144,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'Interestingly, this regimen produced a '\n",
      "                                  'longer OS compared to anlotinib monotherapy '\n",
      "                                  'or PD-1 blockades monotherapy (anlotinib: '\n",
      "                                  '9.6 months and PD-1 blockades: 12.5 '\n",
      "                                  'months).37,38 We speculated that one '\n",
      "                                  'possible explanation was that targeted '\n",
      "                                  'drugs and immune checkpoint inhibitors were '\n",
      "                                  'approved in China since 2018, making '\n",
      "                                  'patients with advanced NSCLC in our study '\n",
      "                                  'who progressed on anlotinib combined with '\n",
      "                                  'PD-1 blockades receive subsequent '\n",
      "                                  'treatments with other targeted drugs or '\n",
      "                                  'PD-L1 blockades, providing some patients '\n",
      "                                  'with survival benefits consecutively.39'},\n",
      "                         {'dEnd': 575,\n",
      "                          'dStart': 570,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'This study aimed to investigate the '\n",
      "                                  'effectiveness and tolerability of anlotinib '\n",
      "                                  'plus PD-1 blockades in patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'The overall tolerability of anlotinib '\n",
      "                                  'combined with PD-1 blockades among patients '\n",
      "                                  'with previously immunotherapy treated '\n",
      "                                  'advanced NSCLC was acceptable and '\n",
      "                                  'manageable.'},\n",
      "                         {'dEnd': 395,\n",
      "                          'dStart': 390,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'In this retrospective study, the '\n",
      "                                  'feasibility and tolerability of anlotinib '\n",
      "                                  'plus PD-1 blockades among patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'NSCLC were analyzed and presented in '\n",
      "                                  'real-world clinical practice, which '\n",
      "                                  'suggested that this combination regimen '\n",
      "                                  'demonstrated promising efficacy and '\n",
      "                                  'tolerable safety profile in patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Anlotinib plus PD-1 blockades demonstrated '\n",
      "                                  'promising effectiveness and tolerable '\n",
      "                                  'safety in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Furthermore, another exploratory study '\n",
      "                                  'initiated by Xu et al included a total of '\n",
      "                                  '40 patients with metastatic NSCLC who were '\n",
      "                                  'rechallenged with mainly PD-1 blockades '\n",
      "                                  'based regimens after they progressed to '\n",
      "                                  'previous immunotherapy-related regimens.32 '\n",
      "                                  'These PD-1 blockades based regimens '\n",
      "                                  'achieved an ORR of 22.5%, a DCR of 85%, a '\n",
      "                                  'median PFS of 6.8 months and the OS data '\n",
      "                                  'were immature, which was consistent with '\n",
      "                                  'the therapeutic outcomes in our study.'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'This study aimed to investigate the '\n",
      "                                  'effectiveness and tolerability of anlotinib '\n",
      "                                  'plus PD-1 blockades in patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Recent years have witnessed that '\n",
      "                                  'immunotherapy represented by PD-1 blockades '\n",
      "                                  'had made great breakthrough in the '\n",
      "                                  'treatment of advanced NSCLC.'},\n",
      "                         {'dEnd': 400,\n",
      "                          'dStart': 395,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 311,\n",
      "                          'tStart': 307,\n",
      "                          'text': 'Additionally, results of our study were '\n",
      "                                  'consistent with those of two recently '\n",
      "                                  'reported single-arm clinical studies '\n",
      "                                  'regarding anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with advanced '\n",
      "                                  'NSCLC.18,33 Interestingly, another '\n",
      "                                  'exploratory study investigated the efficacy '\n",
      "                                  'and safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades compared to anlotinib alone in '\n",
      "                                  'patients with previously treated advanced '\n",
      "                                  'NSCLC.34 They recruited a total of 139 '\n",
      "                                  'patients who received either anlotinib plus '\n",
      "                                  'PD-1 blockades combination therapy or '\n",
      "                                  'anlotinib monotherapy for previously '\n",
      "                                  'treated advanced NSCLC.'},\n",
      "                         {'dEnd': 281,\n",
      "                          'dStart': 276,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'Second, the heterogeneous PD-1 blockades '\n",
      "                                  'used in our study and the absence of PD-L1 '\n",
      "                                  'expression detection might also confound '\n",
      "                                  'the conclusions regarding the efficacy and '\n",
      "                                  'safety of anlotinib combined with PD-1 '\n",
      "                                  'blockades in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC in '\n",
      "                                  'clinical practice.'},\n",
      "                         {'dEnd': 230,\n",
      "                          'dStart': 225,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 140,\n",
      "                          'tStart': 136,\n",
      "                          'text': 'Hypertension and hand-foot syndrome might '\n",
      "                                  'be caused by anlotinib, whereas liver '\n",
      "                                  'toxicity, skin toxicity and pneumonia might '\n",
      "                                  'result from PD-1 blockades.41 Therefore, '\n",
      "                                  'for patients with previously immunotherapy '\n",
      "                                  'treated advanced NSCLC, the combination of '\n",
      "                                  'anlotinib and PD-1 blockades might increase '\n",
      "                                  'the incidence of liver toxicity.'},\n",
      "                         {'dEnd': 170,\n",
      "                          'dStart': 165,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Therefore, it was necessary to identify the '\n",
      "                                  'feasibility and tolerability of anlotinib '\n",
      "                                  'plus PD-1 blockades in patients with '\n",
      "                                  'previously immunotherapy treated advanced '\n",
      "                                  'NSCLC.28'},\n",
      "                         {'dEnd': 479,\n",
      "                          'dStart': 474,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 404,\n",
      "                          'tStart': 400,\n",
      "                          'text': 'Safety profile in our study showed that the '\n",
      "                                  'incidence of grade ≥3 adverse reactions was '\n",
      "                                  '46.3% of the 67 patients included, which '\n",
      "                                  'was slightly higher than the incidence of '\n",
      "                                  'grade ≥3 adverse reactions among patients '\n",
      "                                  'with advanced NSCLC who were treated with '\n",
      "                                  'anlotinib plus PD-1 blockades as the '\n",
      "                                  'subsequent line therapy (approximately '\n",
      "                                  '40%).18 This result suggested that the '\n",
      "                                  'combination of anlotinib plus PD-1 '\n",
      "                                  'blockades in patients with previously '\n",
      "                                  'immunotherapy treated advanced NSCLC might '\n",
      "                                  'potentiate the incidence of grade ≥3 '\n",
      "                                  'adverse reactions to some extent.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['31303759'],\n",
      " 'resourceScore': 82,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'In summary, the four combination regimens '\n",
      "                                  'involving PD-1/L1 inhibitors with CTLA-4 '\n",
      "                                  'inhibitors, chemotherapy, EGFR-TKIs and IDO '\n",
      "                                  'inhibitors were potential treatment '\n",
      "                                  'strategies and well tolerated for NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'We then performed a subgroup analysis of '\n",
      "                                  'the combination regimens, dividing into '\n",
      "                                  'four groups: anti-PD-1/L1 antibody '\n",
      "                                  'combination therapy with anti-CTLA-4 '\n",
      "                                  'antibody/chemotherapy/EGFR-TKIs/IDO '\n",
      "                                  'inhibitors for NSCLC patients.'},\n",
      "                         {'dEnd': 186,\n",
      "                          'dStart': 181,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'A total of 11 eligible trials21,22,30–37,39 '\n",
      "                                  'involving 990 patients were included to '\n",
      "                                  'evaluate the efficacy of anti-PD-1/L1 '\n",
      "                                  'antibody combination therapy in the '\n",
      "                                  'first-line setting for NSCLC patients, and '\n",
      "                                  'the ORRs ranged from 16% to 70%.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'The pooled ORR of combination therapy '\n",
      "                                  'involving PD-1/L1 inhibitors was similar in '\n",
      "                                  'PD-L1 positive and negative NSCLC patients '\n",
      "                                  '(OR=0.67, 95% CI: 0.38–1.20, Figure 6).'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Objective: Immune checkpoint inhibitors, '\n",
      "                                  'especially the programmed cell death '\n",
      "                                  'receptor-1/ligand 1 (PD-1/L1) inhibitors, '\n",
      "                                  'displayed promising efficacy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Our result showed that the pooled ORR of '\n",
      "                                  'combination therapy of PD-1/L1 inhibitors '\n",
      "                                  'for PD-L1 positive or negative NSCLC '\n",
      "                                  'patients had no significant difference.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'The pooled ORR of anti-PD-1/L1 antibody '\n",
      "                                  'combination therapy with anti-CTLA-4 '\n",
      "                                  'antibody/chemotherapy/EGFR-TKIs in the '\n",
      "                                  'first-line setting for NSCLC patients was '\n",
      "                                  '35% (95% CI: 17–53%), 51% (95% CI: 46–56%) '\n",
      "                                  'and 43% (−7–93%) respectively (Figure 4A).'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Therefore, in the current meta-analysis, we '\n",
      "                                  'also pooled the available data for '\n",
      "                                  'combination therapy of PD-1/L1 inhibitors '\n",
      "                                  'with IDO inhibitors for NSCLC patients.'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 213,\n",
      "                          'tStart': 209,\n",
      "                          'text': 'Considering the small samples of these '\n",
      "                                  'studies, therefore, we made a timely '\n",
      "                                  'summarization by quantitative '\n",
      "                                  'meta-analysis, in which all available '\n",
      "                                  'evidence was incorporated to evaluate the '\n",
      "                                  'efficacy and safety of PD-1/L1 inhibitors '\n",
      "                                  'combination therapy including anti-CTLA-4 '\n",
      "                                  'antibody, chemotherapy, EGFR-TKIs and IDO '\n",
      "                                  'inhibitors on NSCLC patients.'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 178,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'We then performed a subgroup analysis of '\n",
      "                                  'the combination regimens, dividing into two '\n",
      "                                  'groups: anti-PD-1/L1 antibody combination '\n",
      "                                  'therapy with anti-CTLA-4 '\n",
      "                                  'antibody/chemotherapy for NSCLC patients.'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'To enhance clinical benefits of '\n",
      "                                  'immunotherapy for NSCLC patients, '\n",
      "                                  'anti-PD-1/L1 antibodies are being evaluated '\n",
      "                                  'in combination with CTLA-4 inhibitors, '\n",
      "                                  'chemotherapeutic agents, epidermal growth '\n",
      "                                  'factor receptor-tyrosine kinase inhibitors '\n",
      "                                  '(EGFR-TKIs), indoleamine-2,3-dioxygenase '\n",
      "                                  '(IDO) inhibitors, etc. A series of phase '\n",
      "                                  'I/II studies on NSCLC have confirmed the '\n",
      "                                  'efficacy of combination therapy.21–24 '\n",
      "                                  'However, most of those trials were '\n",
      "                                  'performed without comparable forms, and '\n",
      "                                  'usually as a single arm.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'This might be partly associated with the '\n",
      "                                  'reason that monotherapy of PD-1/L1 '\n",
      "                                  'inhibitors achieved lower efficacy in the '\n",
      "                                  'second or more line setting for NSCLC '\n",
      "                                  'patients.46'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Objective: Immune checkpoint inhibitors, '\n",
      "                                  'especially the programmed cell death '\n",
      "                                  'receptor-1/ligand 1 (PD-1/L1) inhibitors, '\n",
      "                                  'displayed promising efficacy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'A total of 5 eligible trials24,27,28,34,39 '\n",
      "                                  'involving 125 patients were included to '\n",
      "                                  'evaluate the efficacy of anti-PD-1/L1 '\n",
      "                                  'antibody combination therapy in the second '\n",
      "                                  'or more line setting for NSCLC patients, '\n",
      "                                  'and the ORR ranged from 17% to 55%.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'The pooled ORR of the combination regimens '\n",
      "                                  'of PD-1/L1 inhibitors for NSCLC patients '\n",
      "                                  'was 44% in our meta-analysis.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'The pooled ORR of anti-PD-1/L1 antibody '\n",
      "                                  'combination therapy with anti-CTLA-4 '\n",
      "                                  'antibody/chemotherapy/EGFR-TKIs/IDO '\n",
      "                                  'inhibitors in the second or more line '\n",
      "                                  'setting for NSCLC patients was 36% (95% CI: '\n",
      "                                  '8–65%), 17% (95% CI: −13–46%), 39% (95% '\n",
      "                                  'CI:19–59%) and 35% (95% CI:20–50%), '\n",
      "                                  'respectively (Figure 4B).'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 477,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 443,\n",
      "                          'tStart': 439,\n",
      "                          'text': 'Oncogenic alteration in the EGFR pathway is '\n",
      "                                  'related to the induction of PD-L1 '\n",
      "                                  'expression and makes lung tumors '\n",
      "                                  'susceptible to PD-1 blockade in a '\n",
      "                                  'preclinical model,42 which demonstrated '\n",
      "                                  'that a combination of EGFR TKIs with '\n",
      "                                  'PD-1/L1 inhibitors might be a promising '\n",
      "                                  'therapeutic regimen to prolong the duration '\n",
      "                                  'of response and prevent or delay '\n",
      "                                  'resistance.43 In the current meta-analysis, '\n",
      "                                  'we pooled the available data for '\n",
      "                                  'combination therapy of PD-1/L1 inhibitors '\n",
      "                                  'with EGFR TKIs for NSCLC patients.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 121,\n",
      "                          'text': 'Methods: We searched PubMed, the Cochrane '\n",
      "                                  'Library and the Embase database up to July '\n",
      "                                  '2018, on the combination therapy of PD-1/L1 '\n",
      "                                  'inhibitors in NSCLC patients.'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 477,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 226,\n",
      "                          'tStart': 222,\n",
      "                          'text': 'Oncogenic alteration in the EGFR pathway is '\n",
      "                                  'related to the induction of PD-L1 '\n",
      "                                  'expression and makes lung tumors '\n",
      "                                  'susceptible to PD-1 blockade in a '\n",
      "                                  'preclinical model,42 which demonstrated '\n",
      "                                  'that a combination of EGFR TKIs with '\n",
      "                                  'PD-1/L1 inhibitors might be a promising '\n",
      "                                  'therapeutic regimen to prolong the duration '\n",
      "                                  'of response and prevent or delay '\n",
      "                                  'resistance.43 In the current meta-analysis, '\n",
      "                                  'we pooled the available data for '\n",
      "                                  'combination therapy of PD-1/L1 inhibitors '\n",
      "                                  'with EGFR TKIs for NSCLC patients.'},\n",
      "                         {'dEnd': 337,\n",
      "                          'dStart': 332,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'To enhance clinical benefits of '\n",
      "                                  'immunotherapy for NSCLC patients, '\n",
      "                                  'anti-PD-1/L1 antibodies are being evaluated '\n",
      "                                  'in combination with CTLA-4 inhibitors, '\n",
      "                                  'chemotherapeutic agents, epidermal growth '\n",
      "                                  'factor receptor-tyrosine kinase inhibitors '\n",
      "                                  '(EGFR-TKIs), indoleamine-2,3-dioxygenase '\n",
      "                                  '(IDO) inhibitors, etc. A series of phase '\n",
      "                                  'I/II studies on NSCLC have confirmed the '\n",
      "                                  'efficacy of combination therapy.21–24 '\n",
      "                                  'However, most of those trials were '\n",
      "                                  'performed without comparable forms, and '\n",
      "                                  'usually as a single arm.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'In our meta-analysis, we focused on the '\n",
      "                                  'combination regimens of PD-1/L1 inhibitors '\n",
      "                                  'for NSCLC patients.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'A pooled meta-analysis of PD-1/L1 '\n",
      "                                  'inhibitors incorporation therapy for '\n",
      "                                  'advanced non-small cell lung cancer'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Among these 17 studies, 6 studies21,27–31 '\n",
      "                                  'reported the efficacy and toxicities of '\n",
      "                                  'anti-PD-1/L1 antibody in combination with '\n",
      "                                  'anti-CTLA-4 antibody therapy for the '\n",
      "                                  'treatment of advanced NSCLC, and 384 '\n",
      "                                  'patients were enrolled.'},\n",
      "                         {'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'A summary of ongoing clinical trials '\n",
      "                                  'enrolling NSCLC patients for the '\n",
      "                                  'combination therapy of anti-PD1/L1 antibody '\n",
      "                                  'with other treatments, including '\n",
      "                                  'anti-CTLA-4 antibody, chemotherapy, '\n",
      "                                  'targeted therapy or IDO inhibitors other '\n",
      "                                  'immunotherapies, and chemotherapy, is '\n",
      "                                  'presented in Table 4.'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 477,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 130,\n",
      "                          'tStart': 126,\n",
      "                          'text': 'Oncogenic alteration in the EGFR pathway is '\n",
      "                                  'related to the induction of PD-L1 '\n",
      "                                  'expression and makes lung tumors '\n",
      "                                  'susceptible to PD-1 blockade in a '\n",
      "                                  'preclinical model,42 which demonstrated '\n",
      "                                  'that a combination of EGFR TKIs with '\n",
      "                                  'PD-1/L1 inhibitors might be a promising '\n",
      "                                  'therapeutic regimen to prolong the duration '\n",
      "                                  'of response and prevent or delay '\n",
      "                                  'resistance.43 In the current meta-analysis, '\n",
      "                                  'we pooled the available data for '\n",
      "                                  'combination therapy of PD-1/L1 inhibitors '\n",
      "                                  'with EGFR TKIs for NSCLC patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34113560'],\n",
      " 'resourceScore': 79,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'The activation of the PD-1 pathway is thus '\n",
      "                                  'believed to contribute to immune escape in '\n",
      "                                  'EGFR-driven NSCLC.'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'To date, four anti-PD-1/PD-L1 monoclonal '\n",
      "                                  'antibodies (nivolumab, pembrolizumab '\n",
      "                                  '(anti-PD-1); atezolimumab and durvalumab '\n",
      "                                  '(anti-PD-L1)) have been approved as 1st or '\n",
      "                                  '2nd line therapy for NSCLC patients with '\n",
      "                                  'metastatic and locally advanced NSCLC '\n",
      "                                  'respectively (12, 13).'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Further investigation is needed to verify '\n",
      "                                  'the beneficial effect of combining YAP '\n",
      "                                  'inhibitors with anti-PD-1/PD-L1 ICIs for '\n",
      "                                  'treating EGFR TKI resistant NSCLC.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'The underlying mechanisms leading to the '\n",
      "                                  'inferior clinical efficacy of PD-1/PD-L1 '\n",
      "                                  'inhibitors in EGFR-mutated NSCLC and new '\n",
      "                                  'strategies for its potentiation are '\n",
      "                                  'discussed.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'PD-L1 expression on tumor cells is '\n",
      "                                  'considered not only a predictive biomarker '\n",
      "                                  'for response to PD-1/PD-L1 ICIs but also a '\n",
      "                                  'prognostic factor in NSCLC patients (17).'},\n",
      "                         {'dEnd': 70,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Furthermore, emerging evidence shows that '\n",
      "                                  'PD-1/PD-L1 blockade in NSCLC patients can '\n",
      "                                  'lead to hyperprogressive disease associated '\n",
      "                                  'with dismal prognosis.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Representative clinical trials evaluating '\n",
      "                                  'the combination of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy and targeted therapy in '\n",
      "                                  'EGFR-mutant NSCLC patients.'},\n",
      "                         {'dEnd': 5,\n",
      "                          'dStart': 0,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'NSCLC patients with high TMB and the '\n",
      "                                  'smokers were found to respond better to '\n",
      "                                  'anti-PD-1/PD-L1 ICIs (33).'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'A few clinical studies have been conducted '\n",
      "                                  'to evaluate the combination of PD-1-based '\n",
      "                                  'immunotherapy and EGFR targeted therapy in '\n",
      "                                  'EGFR TKI-naïve and/or pretreated '\n",
      "                                  'EGFR-mutant NSCLC patients (Table 3).'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Novel strategies to potentiate the use of '\n",
      "                                  'PD-1 blockade therapy in EGFR mutant NSCLC '\n",
      "                                  'are discussed.'},\n",
      "                         {'dEnd': 72,\n",
      "                          'dStart': 67,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Key Clinical Trials Evaluating '\n",
      "                                  'Anti-PD-1/PD-L1 ICIs in EGFR-Mutant NSCLC'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Since these clinical trials were not '\n",
      "                                  'designed solely to investigate the role of '\n",
      "                                  'PD-1/PD-L1 blockade immunotherapy in EGFR '\n",
      "                                  'mutant NSCLC patients, the efficacy in EGFR '\n",
      "                                  'mutant patients was revealed by patient '\n",
      "                                  'subgroup analysis.'},\n",
      "                         {'dEnd': 41,\n",
      "                          'dStart': 36,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Efficacy of Anti-PD-1/PD-L1 ICIs in NSCLC '\n",
      "                                  'Bearing the Two Most Common EGFR '\n",
      "                                  'Sensitizing Mutation Subtypes'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'In a retrospective efficacy analysis of '\n",
      "                                  'PD-1 inhibitors conducted by a Japanese '\n",
      "                                  'group, NSCLC patients harboring uncommon '\n",
      "                                  'EGFR mutations and without T790M mutations '\n",
      "                                  'were associated with significantly longer '\n",
      "                                  'PFS than those with common EGFR mutations '\n",
      "                                  'or with T790M mutation (97).'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Emerging evidence from a few recent studies '\n",
      "                                  'suggest that the efficacy of PD-1 blockade '\n",
      "                                  'therapy is relatively more favorable in '\n",
      "                                  'NSCLC patients bearing uncommon EGFR '\n",
      "                                  'mutations compared to those with the '\n",
      "                                  'classical mutations (46, 69, 90).'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Representative clinical trials '\n",
      "                                  'investigating the combination of PD-1/PD-L1 '\n",
      "                                  'and CTLA-4 blockade immunotherapies in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'The contribution of PD-L1 expression to '\n",
      "                                  'poor efficacy of anti-PD-1/PD-L1 therapy in '\n",
      "                                  'EGFR mutant NSCLC is controversial.'},\n",
      "                         {'dEnd': 40,\n",
      "                          'dStart': 35,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'However, patients with EGFR-mutant NSCLC '\n",
      "                                  'show poor response to anti-PD-1/PD-L1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Representative studies (clinical trials and '\n",
      "                                  'animal studies) evaluating the combination '\n",
      "                                  'of PD-1/PD-L1 blockade immunotherapy and '\n",
      "                                  'other miscellaneous therapies in '\n",
      "                                  'EGFR-mutant NSCLC.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'has revealed that EGFR mutations were '\n",
      "                                  'associated with low clinical response to '\n",
      "                                  'PD-1 blockade in NSCLC patients (48).'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Immune checkpoint inhibitors, including '\n",
      "                                  'monoclonal antibodies against programmed '\n",
      "                                  'death-1 (PD-1) and programmed death '\n",
      "                                  'ligand-1 (PD-L1), have dramatically '\n",
      "                                  'improved the survival and quality of life '\n",
      "                                  'of a subset of non-small cell lung cancer '\n",
      "                                  '(NSCLC) patients.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'A pooled analysis evaluating data from 3 '\n",
      "                                  'clinical trials (CheckMate-057, KEYNOTE-010 '\n",
      "                                  'and POPLAR) confirmed that PD-1/PD-L1 ICIs '\n",
      "                                  'did not enhance OS versus docetaxel in '\n",
      "                                  'advanced NSCLC patients bearing EGFR '\n",
      "                                  'mutation (n = 186, HR = 1.05, 95% CI: '\n",
      "                                  '0.70-1.55, P < 0.81) (47).'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Representative clinical trials evaluating '\n",
      "                                  'the combination of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy and conventional chemotherapy '\n",
      "                                  'in EGFR-mutant NSCLC patients.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'To date, four anti-PD-1/PD-L1 monoclonal '\n",
      "                                  'antibodies (nivolumab, pembrolizumab '\n",
      "                                  '(anti-PD-1); atezolimumab and durvalumab '\n",
      "                                  '(anti-PD-L1)) have been approved as 1st or '\n",
      "                                  '2nd line therapy for NSCLC patients with '\n",
      "                                  'metastatic and locally advanced NSCLC '\n",
      "                                  'respectively (12, 13).'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Initial Enthusiasm About Using PD-1 ICIs in '\n",
      "                                  'EGFR-Driven NSCLC According to Preclinical '\n",
      "                                  'Studies'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'On the other hand, the combination of EGFR '\n",
      "                                  'TKIs with PD-1/PD-L1 inhibitors did not '\n",
      "                                  'demonstrate favorable clinical efficacy in '\n",
      "                                  'EGFR-mutated NSCLC patients in a few other '\n",
      "                                  'trials.'},\n",
      "                         {'dEnd': 180,\n",
      "                          'dStart': 175,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'A Phase II clinical trial (NCT0287994) was '\n",
      "                                  'conducted to specifically evaluate the '\n",
      "                                  'efficacy of pembrolizumab (anti-PD-1 '\n",
      "                                  'monoclonal antibody) in TKI-naïve '\n",
      "                                  'EGFR-mutant advanced NSCLC patients whose '\n",
      "                                  'tumors have high PD-L1 expression (49).'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'CheckMate-057 is the first Phase III trial '\n",
      "                                  'to report the clinical efficacy of '\n",
      "                                  'PD-1/PD-L1 inhibitors in NSCLC patients '\n",
      "                                  'bearing EGFR mutant tumors.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'Hyperprogressive Disease (HPD) Associated '\n",
      "                                  'With PD-1/PD-L1 Blockade in NSCLC Patients'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Key clinical trials reporting efficacy and '\n",
      "                                  'toxicity of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy in EGFR-mutant NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'New biomarkers are urgently needed to '\n",
      "                                  'predict response and toxicity associated '\n",
      "                                  'with the use of PD-1/PD-L1 immunotherapy in '\n",
      "                                  'EGFR-mutated NSCLC.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': 'This review recapitulates the underlying '\n",
      "                                  'mechanisms contributing to the inferior '\n",
      "                                  'clinical outcomes of anti-PD-1/PD-L1 '\n",
      "                                  'immune-checkpoint inhibitors (ICIs) in '\n",
      "                                  'NSCLC patients bearing EGFR mutations.'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'However, overall survival (OS) in anti-PD-1 '\n",
      "                                  'ICI-treated NSCLC patients was not affected '\n",
      "                                  'by TMB alone.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'In this review, we summarize the recent '\n",
      "                                  'investigations about the use of PD-1/PD-L1 '\n",
      "                                  'blockade therapy in EGFR-mutated NSCLC.'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 blockade immunotherapy did not '\n",
      "                                  'enhance OS versus docetaxel in advanced '\n",
      "                                  'NSCLC patients bearing EGFR mutation '\n",
      "                                  '(n=186, HR=1.05, 95% CI: 0.70-1.55, '\n",
      "                                  'P<0.81)'},\n",
      "                         {'dEnd': 243,\n",
      "                          'dStart': 238,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Immune checkpoint inhibitors, including '\n",
      "                                  'monoclonal antibodies against programmed '\n",
      "                                  'death-1 (PD-1) and programmed death '\n",
      "                                  'ligand-1 (PD-L1), have dramatically '\n",
      "                                  'improved the survival and quality of life '\n",
      "                                  'of a subset of non-small cell lung cancer '\n",
      "                                  '(NSCLC) patients.'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Multiple studies have investigated the '\n",
      "                                  'combination of PD-1/PD-L1 plus CTLA-4 '\n",
      "                                  'antibodies in treating NSCLC (Table 4).'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Mechanisms Contributing to the Poor '\n",
      "                                  'Efficacy of Anti-PD-1/PD-L1 Therapy in EGFR '\n",
      "                                  'Mutant NSCLC'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'Patient subgroup analysis in another Phase '\n",
      "                                  'III trial (KEYNOTE-010) evaluating '\n",
      "                                  'pembrolizumab (another PD-1 inhibitor) also '\n",
      "                                  'indicated that EGFR mutant NSCLC did not '\n",
      "                                  'achieve statistically significant OS '\n",
      "                                  'benefit from immunotherapy over salvage '\n",
      "                                  'chemotherapy (46).'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Recently, the combination of MEK inhibitor '\n",
      "                                  'and anti-PD-1/PD-L1 antibodies have been '\n",
      "                                  'shown to produce synergistic anticancer '\n",
      "                                  'effect and prolong survival of NSCLC '\n",
      "                                  'tumor-bearing mice (147).'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Novel Strategies to Potentiate PD-1/PD-L1 '\n",
      "                                  'Blockade Immunotherapy in EGFR Mutant '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'To date, four anti-PD-1/PD-L1 monoclonal '\n",
      "                                  'antibodies (nivolumab, pembrolizumab '\n",
      "                                  '(anti-PD-1); atezolimumab and durvalumab '\n",
      "                                  '(anti-PD-L1)) have been approved as 1st or '\n",
      "                                  '2nd line therapy for NSCLC patients with '\n",
      "                                  'metastatic and locally advanced NSCLC '\n",
      "                                  'respectively (12, 13).'},\n",
      "                         {'dEnd': 248,\n",
      "                          'dStart': 243,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'On the other hand, monoclonal antibodies '\n",
      "                                  'targeting programmed death-1 (PD-1) and '\n",
      "                                  'programmed death ligand-1 (PD-L1) have '\n",
      "                                  'demonstrated survival benefits, long '\n",
      "                                  'lasting responses and good safety profile '\n",
      "                                  'over chemotherapy in patients with advanced '\n",
      "                                  'NSCLC in several recent Phase III trials '\n",
      "                                  '(8–11).'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'Therefore, screening for EGFR mutation '\n",
      "                                  'subtypes could be useful for personalized '\n",
      "                                  'use of PD-1/PD-L1 ICIs in EGFR-mutant NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Therefore, it is also speculated that '\n",
      "                                  'addition of PD-1/PD-L1 immunotherapy to '\n",
      "                                  'chemotherapy in NSCLC patients with EGFR '\n",
      "                                  'mutation could also achieve desirable '\n",
      "                                  'clinical outcomes.'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'To date, four anti-PD-1/PD-L1 monoclonal '\n",
      "                                  'antibodies (nivolumab, pembrolizumab '\n",
      "                                  '(anti-PD-1); atezolimumab and durvalumab '\n",
      "                                  '(anti-PD-L1)) have been approved as 1st or '\n",
      "                                  '2nd line therapy for NSCLC patients with '\n",
      "                                  'metastatic and locally advanced NSCLC '\n",
      "                                  'respectively (12, 13).'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Identification of predictive biomarkers to '\n",
      "                                  'select NSCLC patients most likely '\n",
      "                                  'responding to anti-PD-1/PD-L1 ICIs is '\n",
      "                                  'currently an area of intensive research.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'It follows that therapies targeting YAP may '\n",
      "                                  'potentially enhance the efficacy of '\n",
      "                                  'anti-PD-1/PD-L1 ICIs in EGFR-mutant '\n",
      "                                  'NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['37655051'],\n",
      " 'resourceScore': 78,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 66,\n",
      "                          'dStart': 62,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'Thymol treatment dramatically sensitizes '\n",
      "                                  'the PD‐1 blockade in LUAD by targeting '\n",
      "                                  'IL4I1‐mediated AHR activation, which '\n",
      "                                  'provides a novel strategy for the '\n",
      "                                  'combination immunotherapy in LUAD.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 187,\n",
      "                          'tStart': 183,\n",
      "                          'text': 'Here, we show that silencing IL4I1 '\n",
      "                                  'significantly remodels the immune '\n",
      "                                  'microenvironment via inhibiting aryl '\n",
      "                                  'hydrocarbon receptor (AHR) signaling, '\n",
      "                                  'thereby enhancing the efficacy of anti‐PD‐1 '\n",
      "                                  'antibody in LUAD, which suggests that IL4I1 '\n",
      "                                  'is a potential drug target for the '\n",
      "                                  'combination immunotherapy.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 149,\n",
      "                          'tStart': 145,\n",
      "                          'text': 'Taken together, these data suggest that '\n",
      "                                  'silencing IL4I1 significantly reactivates '\n",
      "                                  'the immune microenvironment, thereby '\n",
      "                                  'improving the efficacy of PD‐1 blockade in '\n",
      "                                  'LUAD.'},\n",
      "                         {'dEnd': 77,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'To further detect the role of thymol in '\n",
      "                                  'sensitizing the PD‐1 blockade in LUAD, we '\n",
      "                                  'test the efficacy of thymol single (75 '\n",
      "                                  'mg/kg) or in combination with anti‐PD‐1 '\n",
      "                                  'antibody in the treatment of C57BL/6 mice '\n",
      "                                  'orthotopically transplanted with '\n",
      "                                  'LLC‐luciferase cells (Figure 5A).'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Thus, we demonstrate that thymol is an '\n",
      "                                  'effective small molecule to sensitize the '\n",
      "                                  'PD‐1 blockade in LUAD via targeting IL4I1, '\n",
      "                                  'which provides a novel strategy for the '\n",
      "                                  'immunotherapy of LUAD.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Strikingly, the combination treatment of '\n",
      "                                  'thymol with anti‐PD‐1 antibody shows '\n",
      "                                  'significant tumor regression in LUAD mice.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 165,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'The tumors are almost repressed upon the '\n",
      "                                  'combination treatment of thymol and '\n",
      "                                  'anti‐PD‐1 antibody, meaning that thymol is '\n",
      "                                  'a strong sensitizer for the PD‐1 blockade '\n",
      "                                  'in LUAD.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'In summary, we show that thymol targeting '\n",
      "                                  'IL4I1 expression remodels the immune '\n",
      "                                  'microenvironment to sensitize the PD‐1 '\n",
      "                                  'blockade in LUAD.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'Thymol treatment dramatically sensitizes '\n",
      "                                  'the PD‐1 blockade in LUAD by targeting '\n",
      "                                  'IL4I1‐mediated AHR activation, which '\n",
      "                                  'provides a novel strategy for the '\n",
      "                                  'combination immunotherapy in LUAD.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 165,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 152,\n",
      "                          'tStart': 148,\n",
      "                          'text': 'The tumors are almost repressed upon the '\n",
      "                                  'combination treatment of thymol and '\n",
      "                                  'anti‐PD‐1 antibody, meaning that thymol is '\n",
      "                                  'a strong sensitizer for the PD‐1 blockade '\n",
      "                                  'in LUAD.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'Thymol treatment dramatically restores the '\n",
      "                                  'antitumor immune response to sensitize the '\n",
      "                                  'PD‐1 blockade in LUAD via targeting '\n",
      "                                  'IL4I1‐mediated aryl hydrocarbon receptor '\n",
      "                                  '(AHR) activation, which provides a novel '\n",
      "                                  'strategy for the combination immunotherapy '\n",
      "                                  'for LUAD.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 131,\n",
      "                          'tStart': 127,\n",
      "                          'text': 'Therefore, these data demonstrate that '\n",
      "                                  'thymol targeting IL4I1 expression remodels '\n",
      "                                  'the immune microenvironment to sensitize '\n",
      "                                  'the PD‐1 blockade in LUAD.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 72,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Thymol dramatically sensitizes the PD‐1 '\n",
      "                                  'blockade in an orthotopic mouse LUAD model'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Thymol significantly reactivates the immune '\n",
      "                                  'microenvironment to sensitize the PD‐1 '\n",
      "                                  'blockade in LUAD via targeting '\n",
      "                                  'IL4I1‐mediated AHR activation, which '\n",
      "                                  'provides a novel strategy for the '\n",
      "                                  'combination immunotherapy for LUAD (Figure '\n",
      "                                  '7).'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Therefore, these data suggest that thymol '\n",
      "                                  'is an effective small molecule to sensitize '\n",
      "                                  'the anti‐PD‐1 antibody treatment in LUAD.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 181,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'The IL4I1‐silenced tumors are nearly '\n",
      "                                  'undetected upon the treatment of anti‐PD‐1 '\n",
      "                                  'antibody meaning that targeting IL4I1 '\n",
      "                                  'provides a hopeful avenue for the '\n",
      "                                  'combination immunotherapy of LUAD.'},\n",
      "                         {'dEnd': 219,\n",
      "                          'dStart': 215,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Thymol significantly reactivates the immune '\n",
      "                                  'microenvironment to sensitize the PD‐1 '\n",
      "                                  'blockade in LUAD via targeting '\n",
      "                                  'IL4I1‐mediated AHR activation, which '\n",
      "                                  'provides a novel strategy for the '\n",
      "                                  'combination immunotherapy for LUAD (Figure '\n",
      "                                  '7).'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Strikingly, compared with a single '\n",
      "                                  'treatment with thymol or anti‐PD‐1 '\n",
      "                                  'antibody, combination treatment '\n",
      "                                  'dramatically suppresses the progression of '\n",
      "                                  'LUAD and greatly enhances the survival of '\n",
      "                                  'mice (Figure 5B–D).'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Taken together, we reveal that IL4I1 is a '\n",
      "                                  'key gene modulating the efficacy of PD‐1 '\n",
      "                                  'blockade in LUAD through blocking the AHR '\n",
      "                                  'pathway.'},\n",
      "                         {'dEnd': 255,\n",
      "                          'dStart': 251,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'Thymol treatment dramatically restores the '\n",
      "                                  'antitumor immune response to sensitize the '\n",
      "                                  'PD‐1 blockade in LUAD via targeting '\n",
      "                                  'IL4I1‐mediated aryl hydrocarbon receptor '\n",
      "                                  '(AHR) activation, which provides a novel '\n",
      "                                  'strategy for the combination immunotherapy '\n",
      "                                  'for LUAD.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 181,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Thus, we demonstrate that thymol is an '\n",
      "                                  'effective small molecule to sensitize the '\n",
      "                                  'PD‐1 blockade in LUAD via targeting IL4I1, '\n",
      "                                  'which provides a novel strategy for the '\n",
      "                                  'immunotherapy of LUAD.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'We further knock down IL4I1 in Lewis lung '\n",
      "                                  'cancer (LLC) cells to investigate the role '\n",
      "                                  'of IL4I1 in sensitizing the PD‐1 blockade '\n",
      "                                  'in an orthotopic LUAD murine model (Figure '\n",
      "                                  'S2A,B).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['33643442'],\n",
      " 'resourceScore': 77,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Multiple KEYNOTE trials (either alone or as '\n",
      "                                  'part of a combined study) are being '\n",
      "                                  'investigated using PD-1/PD-L1 inhibitors in '\n",
      "                                  'various tumour types, with a focus on '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Currently, the level of PD-L1 is commonly '\n",
      "                                  'used as a tumour biomarker to evaluate the '\n",
      "                                  'efficacy of anti-PD-1/PD-L1 therapy in '\n",
      "                                  'patients with NSCLC.34,118 The KEYNOTE-024 '\n",
      "                                  'and KEYNOTE-042 trials49, –51 suggested '\n",
      "                                  'that pembrolizumab could significantly '\n",
      "                                  'improve the survival rate in patients with '\n",
      "                                  'high expression levels of PD-L1.'},\n",
      "                         {'dEnd': 211,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'The use of programmed cell-death protein 1 '\n",
      "                                  '(PD-1)/programmed cell-death ligand 1 '\n",
      "                                  '(PD-L1) inhibitors is the standard therapy '\n",
      "                                  'for the first-line or second-line treatment '\n",
      "                                  'of patients with non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 404,\n",
      "                          'dStart': 399,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 171,\n",
      "                          'tStart': 167,\n",
      "                          'text': 'Their results revealed that EGFR mutations '\n",
      "                                  'and ALK rearrangements in patients with '\n",
      "                                  'advanced NSCLC were associated with '\n",
      "                                  'beneficial outcomes and prolonged mOS from '\n",
      "                                  'anti-PD-1/PD-L1 treatment compared with '\n",
      "                                  'chemotherapy when administered as '\n",
      "                                  'second-line treatment.71,72,77,78,81, –83 '\n",
      "                                  'In a study assessing the effects of '\n",
      "                                  'nivolumab, the ORR was significantly lower '\n",
      "                                  'in patients with EGFR-mutant non-squamous '\n",
      "                                  'NSCLC than in patients without the mutation '\n",
      "                                  '(8.8% versus 19.6%, p = 0.007).98 It is '\n",
      "                                  'well known that the acquired EGFR-T790M '\n",
      "                                  'mutation is a major reason for patients '\n",
      "                                  'developing resistance to EGFR-TKIs.'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Other potential biomarkers being '\n",
      "                                  'investigated in anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapy on NSCLC include the '\n",
      "                                  'pretreatment haemoglobin level,158 serum '\n",
      "                                  'vascular endothelial growth factor (VEGF) '\n",
      "                                  'concentration,159 serum lactate '\n",
      "                                  'dehydrogenase level,160 gut microbiome '\n",
      "                                  'composition116 and neo-antigen load.161'},\n",
      "                         {'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'To date, four anti-PD-1/PD-L1 drugs, '\n",
      "                                  'including pembrolizumab, nivolumab, '\n",
      "                                  'atezolizumab and durvalumab, have been '\n",
      "                                  'registered and approved for the '\n",
      "                                  'neoadjuvant, first-line and second-line '\n",
      "                                  'treatment of NSCLC.'},\n",
      "                         {'dEnd': 330,\n",
      "                          'dStart': 325,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'Camrelizumab, a PD-1 inhibitor, developed '\n",
      "                                  'by Jiangsu Hengrui Pharmaceutical Co., '\n",
      "                                  'Ltd., has recently been approved for the '\n",
      "                                  'treatment of relapsed or refractory '\n",
      "                                  'classical Hodgkin’s lymphoma in China.109 A '\n",
      "                                  'study evaluated the efficacy and safety of '\n",
      "                                  'camrelizumab combined with microwave '\n",
      "                                  'ablation (MWA) in patients with metastatic '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 48,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors in cases of advanced '\n",
      "                                  'NSCLC with driver-gene mutations'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'In addition, compared with traditional '\n",
      "                                  'therapy, PD-1/PD-L1 inhibitor monotherapy '\n",
      "                                  'can significantly prolong survival without '\n",
      "                                  'obvious side effects in the treatment of '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'Furthermore, patients with ERBB-family '\n",
      "                                  'mutations failed to respond to treatment '\n",
      "                                  'with PD-1 antibodies.104 The efficacy data '\n",
      "                                  'of anti-PD-1/PD-L1 for advanced NSCLC with '\n",
      "                                  'driver gene mutations is shown in Table 4.'},\n",
      "                         {'dEnd': 44,\n",
      "                          'dStart': 39,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors licensed for '\n",
      "                                  'NSCLC treatment.'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Application of PD-1/PD-L1 inhibitors in '\n",
      "                                  'advanced NSCLC cases in China'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'These analyses help to understand the '\n",
      "                                  'dynamic changes of T-cell clones in the '\n",
      "                                  'peripheral blood during PD-1 blockade of '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 63,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors as first-line '\n",
      "                                  'treatment of advanced NSCLC'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'In this review, we aimed to summarise the '\n",
      "                                  'latest progress in anti-PD-1/anti-PD-L1 '\n",
      "                                  'treatment of advanced NSCLC, worldwide, '\n",
      "                                  'including in China.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'In this review, we aimed to outline the '\n",
      "                                  'recent development of PD-1/PD-L1 inhibitors '\n",
      "                                  'as first-, second-, and third-line '\n",
      "                                  'treatments, and to discuss driver-gene '\n",
      "                                  'mutation in NSCLC patients.'},\n",
      "                         {'dEnd': 44,\n",
      "                          'dStart': 39,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Regulatory mechanisms of PD-1/PD-L1 in '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 53,\n",
      "                          'dStart': 48,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Efficacy of anti-PD-1/PD-L1 agents for '\n",
      "                                  'advanced NSCLC in second line and third '\n",
      "                                  'line.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'The human anti-PD-1 mAb nivolumab was the '\n",
      "                                  'first to be approved as second-line therapy '\n",
      "                                  'for stage IV NSCLC.69 CheckMate 017, a '\n",
      "                                  'randomised, open-label, phase III study '\n",
      "                                  'assessed the efficacy and safety of '\n",
      "                                  'nivolumab for advanced squamous NSCLC; '\n",
      "                                  'greater efficacy was obtained during or '\n",
      "                                  'after first-line chemotherapy.'},\n",
      "                         {'dEnd': 64,\n",
      "                          'dStart': 59,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors as second-line '\n",
      "                                  'treatment in advanced NSCLC'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 72,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'The progress and challenge of '\n",
      "                                  'anti-PD-1/PD-L1 immunotherapy in treating '\n",
      "                                  'non-small cell lung cancer'},\n",
      "                         {'dEnd': 218,\n",
      "                          'dStart': 213,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'The use of programmed cell-death protein 1 '\n",
      "                                  '(PD-1)/programmed cell-death ligand 1 '\n",
      "                                  '(PD-L1) inhibitors is the standard therapy '\n",
      "                                  'for the first-line or second-line treatment '\n",
      "                                  'of patients with non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 323,\n",
      "                          'dStart': 318,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1 antibody, tislelizumab, has '\n",
      "                                  'demonstrated clinical tolerability and '\n",
      "                                  'safety in treating solid tumours, including '\n",
      "                                  'NSCLC in Chinese patients.112 Toripalimab, '\n",
      "                                  'sintilimab, camrelizumab and tislelizumab '\n",
      "                                  'are all currently undergoing clinical '\n",
      "                                  'trials for the treatment of various solid '\n",
      "                                  'tumours, including advanced NSCLC; these '\n",
      "                                  'are summarised in Table 5.'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 270,\n",
      "                          'tStart': 266,\n",
      "                          'text': 'Therefore, with the continuous development '\n",
      "                                  'of clinical trials, more retrospective and '\n",
      "                                  'prospective clinical studies need to '\n",
      "                                  'comprehensively evaluate more underlying '\n",
      "                                  'biomarkers to improve treatment efficacy '\n",
      "                                  'and enable more NSCLC patients to benefit '\n",
      "                                  'from ICIs for anti-PD-1/PD-L1 therapy.'},\n",
      "                         {'dEnd': 53,\n",
      "                          'dStart': 48,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Efficacy of anti-PD-1/PD-L1 agents for '\n",
      "                                  'advanced NSCLC in first line.'},\n",
      "                         {'dEnd': 53,\n",
      "                          'dStart': 48,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Efficacy of anti-PD-1/PD-L1 agents for '\n",
      "                                  'advanced NSCLC with driver gene mutations.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'With the approval of ICIs, '\n",
      "                                  'immune-checkpoint therapy based on '\n",
      "                                  'modulating PD-1/PD-L1 signalling provides '\n",
      "                                  'more choices for treating advanced NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1 antibody, tislelizumab, has '\n",
      "                                  'demonstrated clinical tolerability and '\n",
      "                                  'safety in treating solid tumours, including '\n",
      "                                  'NSCLC in Chinese patients.112 Toripalimab, '\n",
      "                                  'sintilimab, camrelizumab and tislelizumab '\n",
      "                                  'are all currently undergoing clinical '\n",
      "                                  'trials for the treatment of various solid '\n",
      "                                  'tumours, including advanced NSCLC; these '\n",
      "                                  'are summarised in Table 5.'},\n",
      "                         {'dEnd': 501,\n",
      "                          'dStart': 496,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 164,\n",
      "                          'tStart': 160,\n",
      "                          'text': 'Toripalimab (also known as JS001 or TAB001) '\n",
      "                                  'is a recombinant human anti-PD-1 mAb '\n",
      "                                  'developed by Shanghai Junshi Biotechnology '\n",
      "                                  'Co., Ltd. that selectively inhibits PD-1 '\n",
      "                                  'and PD-L1/PD-L2 interactions to facilitate '\n",
      "                                  'T-cell activation.105 Yang et al. conducted '\n",
      "                                  'a phase I dose escalation and expansion '\n",
      "                                  'clinical study to evaluate the safety and '\n",
      "                                  'tolerability of toripalimab in patients '\n",
      "                                  'with advanced or recurrent malignancies in '\n",
      "                                  'China.106 Thirty-three patients '\n",
      "                                  'participated in this study, seven of which '\n",
      "                                  'had NSCLC.'},\n",
      "                         {'dEnd': 211,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'The use of programmed cell-death protein 1 '\n",
      "                                  '(PD-1)/programmed cell-death ligand 1 '\n",
      "                                  '(PD-L1) inhibitors is the standard therapy '\n",
      "                                  'for the first-line or second-line treatment '\n",
      "                                  'of patients with non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 218,\n",
      "                          'dStart': 213,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'The use of programmed cell-death protein 1 '\n",
      "                                  '(PD-1)/programmed cell-death ligand 1 '\n",
      "                                  '(PD-L1) inhibitors is the standard therapy '\n",
      "                                  'for the first-line or second-line treatment '\n",
      "                                  'of patients with non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Furthermore, patients with ERBB-family '\n",
      "                                  'mutations failed to respond to treatment '\n",
      "                                  'with PD-1 antibodies.104 The efficacy data '\n",
      "                                  'of anti-PD-1/PD-L1 for advanced NSCLC with '\n",
      "                                  'driver gene mutations is shown in Table 4.'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'A previous study evaluated the predictive '\n",
      "                                  'role of the TMB in 76 NSCLC patients '\n",
      "                                  'treated with anti-PD-1/PD-L1 therapy.'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitor therapy in advanced '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 58,\n",
      "                          'dStart': 53,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Application of PD-1/PD-L1 inhibitors in the '\n",
      "                                  'advanced NSCLC in China.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'At present, some anti-PD-1/PD-L1 antibodies '\n",
      "                                  'have been approved by the FDA for clinical '\n",
      "                                  'treatment of advanced NSCLC;39 these '\n",
      "                                  'clinical studies will have a very important '\n",
      "                                  'role in guiding long-term clinical '\n",
      "                                  'practice.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors as third-line or '\n",
      "                                  'greater treatment in advanced NSCLC'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'Therefore, identification of predictive '\n",
      "                                  'biomarkers is crucial for selecting '\n",
      "                                  'patients with NSCLC who would most benefit '\n",
      "                                  'from anti-PD-1/PD-L1 therapy.'},\n",
      "                         {'dEnd': 208,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Patients with KRAS mutations experienced a '\n",
      "                                  'longer mPFS and mOS than patients without a '\n",
      "                                  'KRAS mutation using anti-PD-1/PD-L1 '\n",
      "                                  'treatment, thus immunotherapy may be a '\n",
      "                                  'promising strategy with KRAS mutation of '\n",
      "                                  'NSCLC owing to regulating immune response.'},\n",
      "                         {'dEnd': 501,\n",
      "                          'dStart': 496,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'Toripalimab (also known as JS001 or TAB001) '\n",
      "                                  'is a recombinant human anti-PD-1 mAb '\n",
      "                                  'developed by Shanghai Junshi Biotechnology '\n",
      "                                  'Co., Ltd. that selectively inhibits PD-1 '\n",
      "                                  'and PD-L1/PD-L2 interactions to facilitate '\n",
      "                                  'T-cell activation.105 Yang et al. conducted '\n",
      "                                  'a phase I dose escalation and expansion '\n",
      "                                  'clinical study to evaluate the safety and '\n",
      "                                  'tolerability of toripalimab in patients '\n",
      "                                  'with advanced or recurrent malignancies in '\n",
      "                                  'China.106 Thirty-three patients '\n",
      "                                  'participated in this study, seven of which '\n",
      "                                  'had NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39134346'],\n",
      " 'resourceScore': 76,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 370,\n",
      "                          'dStart': 365,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 339,\n",
      "                          'tStart': 335,\n",
      "                          'text': 'Recently, neoantigen-specific '\n",
      "                                  'tumor-infiltrating T cells with the '\n",
      "                                  'transcriptional feature of tissue residency '\n",
      "                                  'were shown to correlate with the '\n",
      "                                  'neoadjuvant anti-PD-1 response in breast '\n",
      "                                  'cancer and NSCLC.18 26 Consistently, we '\n",
      "                                  'demonstrated that the quantity of '\n",
      "                                  'tumor-infiltrating CD8+ TRMs was positively '\n",
      "                                  'correlated with neoadjuvant anti-PD-1 '\n",
      "                                  'response of non-advanced NSCLC.'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Galectin-9 expressing tumor cells sustained '\n",
      "                                  'the primary resistance of neoadjuvant '\n",
      "                                  'anti-PD-1 therapy in NSCLC through '\n",
      "                                  'galectin-9/TIM-3-mediated suppression of '\n",
      "                                  'imcDC2 and CD8+ TRMs.'},\n",
      "                         {'dEnd': 216,\n",
      "                          'dStart': 211,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 193,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'Mechanistically, we demonstrated that a '\n",
      "                                  'cancer cell-derived galectin-9/TIM-3/imcDC2 '\n",
      "                                  'loop, which inhibits the activation of CD8+ '\n",
      "                                  'TRMs in the TME, is essential for primary '\n",
      "                                  'resistance of anti-PD-1 therapy in human '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 237,\n",
      "                          'dStart': 232,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 150,\n",
      "                          'tStart': 146,\n",
      "                          'text': 'In addition, we found that a higher '\n",
      "                                  'proportion of effector cells (CD38+ CD39+ '\n",
      "                                  'CD103+ CD69+ CD8+ T cells) in CD8+ TRMs '\n",
      "                                  'correlated with better anti-PD-1 response, '\n",
      "                                  'which is consistent with the finding of '\n",
      "                                  'CD39+ CD8+ T cells in advanced NSCLC.40'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Collectively, these results demonstrate '\n",
      "                                  'that neoadjuvant anti-PD-1 immunotherapy '\n",
      "                                  'modulates NSCLC TME immune landscape such '\n",
      "                                  'as alterations of the quantity, '\n",
      "                                  'constitution, and gene signatures of '\n",
      "                                  'tumor-infiltrating immune cells, especially '\n",
      "                                  'CD8+ T cells.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Epithelium/imcDC2 axis facilitates the '\n",
      "                                  'resistance of neoadjuvant anti-PD-1 in '\n",
      "                                  'human NSCLC'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'These results suggest that the '\n",
      "                                  'differentiation of CD8+ TRM effector cells '\n",
      "                                  'from precursor cells holds the key for '\n",
      "                                  'neoadjuvant anti-PD-1 response in NSCLC.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 170,\n",
      "                          'tStart': 166,\n",
      "                          'text': 'Based on these findings, we propose a '\n",
      "                                  'working model outlining the key factors in '\n",
      "                                  'the TME of human NSCLC that determine '\n",
      "                                  'response versus resistance to neoadjuvant '\n",
      "                                  'anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 326,\n",
      "                          'dStart': 321,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 309,\n",
      "                          'tStart': 305,\n",
      "                          'text': 'Collectedly, our results suggest that '\n",
      "                                  'galectin-9+ tumor cells, such as AGER+ '\n",
      "                                  'alveolar epithelial type 1-like cells, '\n",
      "                                  'AREG+ alveolar epithelial type 2-like '\n",
      "                                  'cells, and MUC5B+ goblet like cells, '\n",
      "                                  'establish epithelium/imcDC2/CD8+ TRMs '\n",
      "                                  'suppressive loop that is responsible for '\n",
      "                                  'the resistance of neoadjuvant anti-PD-1 '\n",
      "                                  'therapy in NSCLC and can be reversed by '\n",
      "                                  'anti-TIM-3.'},\n",
      "                         {'dEnd': 44,\n",
      "                          'dStart': 39,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'To explore the changes of TME in human '\n",
      "                                  'NSCLC during neoadjuvant anti-PD-1 therapy, '\n",
      "                                  'a cohort of 30 NSCLC patients were '\n",
      "                                  'recruited and 27 patients (90%) had '\n",
      "                                  'completed all cycles of planned treatment '\n",
      "                                  '(online supplemental figure 1A).'},\n",
      "                         {'dEnd': 250,\n",
      "                          'dStart': 245,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 179,\n",
      "                          'tStart': 175,\n",
      "                          'text': 'Collectively, our findings uncover the '\n",
      "                                  'crucial role of the tumor-intrinsic '\n",
      "                                  'suppressive loop in anti-PD-1 resistance '\n",
      "                                  'and suggest that combined treatment of '\n",
      "                                  'anti-TIM-3 and anti-PD-1 is a promising '\n",
      "                                  'approach in the neoadjuvant ICIs therapy of '\n",
      "                                  'human NSCLC.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Here, we used a cohort of non-advanced '\n",
      "                                  'human NSCLC receiving short-term '\n",
      "                                  'neoadjuvant anti-PD-1 therapy, we '\n",
      "                                  'discovered that this therapy induced a '\n",
      "                                  'dramatic change in the TME of patients.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 186,\n",
      "                          'tStart': 182,\n",
      "                          'text': 'The quantity, differentiation status, and '\n",
      "                                  'clonal expansion of tissue-resident memory '\n",
      "                                  'CD8+ T cells (CD8+ TRMs) are positively '\n",
      "                                  'correlated with therapeutic efficacy of '\n",
      "                                  'neoadjuvant anti-PD-1 therapy in human '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Our results demonstrate that CD8+ TRM is '\n",
      "                                  'the key subset of tumor-infiltrating CD8+ T '\n",
      "                                  'cells which specifically correlates with a '\n",
      "                                  'favorable anti-PD-1 response in NSCLC.'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 195,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 164,\n",
      "                          'tStart': 160,\n",
      "                          'text': 'Recently, neoantigen-specific '\n",
      "                                  'tumor-infiltrating T cells with the '\n",
      "                                  'transcriptional feature of tissue residency '\n",
      "                                  'were shown to correlate with the '\n",
      "                                  'neoadjuvant anti-PD-1 response in breast '\n",
      "                                  'cancer and NSCLC.18 26 Consistently, we '\n",
      "                                  'demonstrated that the quantity of '\n",
      "                                  'tumor-infiltrating CD8+ TRMs was positively '\n",
      "                                  'correlated with neoadjuvant anti-PD-1 '\n",
      "                                  'response of non-advanced NSCLC.'},\n",
      "                         {'dEnd': 250,\n",
      "                          'dStart': 245,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Collectively, our findings uncover the '\n",
      "                                  'crucial role of the tumor-intrinsic '\n",
      "                                  'suppressive loop in anti-PD-1 resistance '\n",
      "                                  'and suggest that combined treatment of '\n",
      "                                  'anti-TIM-3 and anti-PD-1 is a promising '\n",
      "                                  'approach in the neoadjuvant ICIs therapy of '\n",
      "                                  'human NSCLC.'},\n",
      "                         {'dEnd': 289,\n",
      "                          'dStart': 284,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 266,\n",
      "                          'tStart': 262,\n",
      "                          'text': 'Growing evidence suggests that '\n",
      "                                  'tissue-resident memory CD8+ T cells (CD8+ '\n",
      "                                  'TRMs) play a crucial role in cancer '\n",
      "                                  'immunosurveillance and correlate with the '\n",
      "                                  'survival of multiple advanced cancers.16 27 '\n",
      "                                  '28 However, the correlation between CD8+ '\n",
      "                                  'TRMs and neoadjuvant anti-PD-1 therapy of '\n",
      "                                  'human NSCLC remains largely unclear.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'To explore the changes of TME in human '\n",
      "                                  'NSCLC during neoadjuvant anti-PD-1 therapy, '\n",
      "                                  'a cohort of 30 NSCLC patients were '\n",
      "                                  'recruited and 27 patients (90%) had '\n",
      "                                  'completed all cycles of planned treatment '\n",
      "                                  '(online supplemental figure 1A).'},\n",
      "                         {'dEnd': 370,\n",
      "                          'dStart': 365,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 164,\n",
      "                          'tStart': 160,\n",
      "                          'text': 'Recently, neoantigen-specific '\n",
      "                                  'tumor-infiltrating T cells with the '\n",
      "                                  'transcriptional feature of tissue residency '\n",
      "                                  'were shown to correlate with the '\n",
      "                                  'neoadjuvant anti-PD-1 response in breast '\n",
      "                                  'cancer and NSCLC.18 26 Consistently, we '\n",
      "                                  'demonstrated that the quantity of '\n",
      "                                  'tumor-infiltrating CD8+ TRMs was positively '\n",
      "                                  'correlated with neoadjuvant anti-PD-1 '\n",
      "                                  'response of non-advanced NSCLC.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'The expression level of CD8+ TRMs and '\n",
      "                                  'galectin-9+ cancer cell-related genes '\n",
      "                                  'predict the clinical outcome of anti-PD-1 '\n",
      "                                  'neoadjuvant therapy in human NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Neoadjuvant anti-PD-1 therapy remodels the '\n",
      "                                  'TME of human NSCLC'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35493454'],\n",
      " 'resourceScore': 75,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Herein, we used CyTOF mass cytometry to '\n",
      "                                  'link monocyte heterogeneity with '\n",
      "                                  'responsiveness to PD-1 blockade in patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'To assess monocyte heterogeneity in '\n",
      "                                  'response to anti-PD-1 therapy, we performed '\n",
      "                                  'mass cytometry on peripheral blood '\n",
      "                                  'mononuclear cell (PBMC) samples collected '\n",
      "                                  'from non-small cell lung cancer (NSCLC) '\n",
      "                                  'patients prior to treatment with anti-PD-1 '\n",
      "                                  'therapy (n=26 patients), as well as 10 '\n",
      "                                  'matched patient samples collected after '\n",
      "                                  'treatment (Figures 1A, B).'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapy '\n",
      "                                  'targeted at inhibiting the PD-L1:PD-1 '\n",
      "                                  'signaling axis is beneficial for patients '\n",
      "                                  'with a variety of cancers including NSCLC '\n",
      "                                  '(2, 3).'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'As CD33 was by far the most significant '\n",
      "                                  'marker identified in terms of predicting '\n",
      "                                  'anti-PD-1 responses, we next examined '\n",
      "                                  'correlations between CD33 overall survival '\n",
      "                                  '(OS) in our NSCLC cohorts.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'CD33 Expression on Peripheral Blood '\n",
      "                                  'Monocytes Predicts Efficacy of Anti-PD-1 '\n",
      "                                  'Immunotherapy Against Non-Small Cell Lung '\n",
      "                                  'Cancer'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) has '\n",
      "                                  'transformed cancer medicine, with '\n",
      "                                  'anti-programmed cell death protein 1 '\n",
      "                                  '(anti-PD-1) therapy now well-utilized for '\n",
      "                                  'treating NSCLC.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'As a second independent analysis method, we '\n",
      "                                  'utilized machine learning to examine '\n",
      "                                  'monocyte markers that were most associated '\n",
      "                                  'with responses to anti-PD-1 in our NSCLC '\n",
      "                                  'cohorts.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'However, we found that PD-L1, together with '\n",
      "                                  'PD-L2 and their receptor PD-1, were '\n",
      "                                  'expressed across different monocyte '\n",
      "                                  'subsets, including cMo and iMo in NSCLC '\n",
      "                                  'patients (Figures 2C–E).'},\n",
      "                         {'dEnd': 212,\n",
      "                          'dStart': 207,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In order to identify novel relationships '\n",
      "                                  'between monocyte markers and positive '\n",
      "                                  'responses to anti-PD-1 therapy, we used '\n",
      "                                  'cytometry by time-of-flight (CyTOF) to '\n",
      "                                  'explore monocyte heterogeneity in two '\n",
      "                                  'cohorts of NSCLC patients receiving '\n",
      "                                  'anti-PD-1 ICB treatment.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) has '\n",
      "                                  'transformed cancer medicine, with '\n",
      "                                  'anti-programmed cell death protein 1 '\n",
      "                                  '(anti-PD-1) therapy now well-utilized for '\n",
      "                                  'treating NSCLC.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Thus, CD33 enriched on monocytes is '\n",
      "                                  'predictive of positive anti-PD1 responses '\n",
      "                                  'in both NSCLC and melanoma.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Total CD14+ cMo frequencies are predictive '\n",
      "                                  'of anti-PD-1 responses in melanoma patients '\n",
      "                                  '(14), but we did not observe this in our '\n",
      "                                  'cohorts of NSCLC patients (Figure 1F).'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'Our work provides a high-dimensional '\n",
      "                                  'profile of monocytes in NSCLC and links '\n",
      "                                  'CD33 expression on monocytes with anti-PD-1 '\n",
      "                                  'effectiveness in patients with NSCLC.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'To assess monocyte heterogeneity in '\n",
      "                                  'response to anti-PD-1 therapy, we performed '\n",
      "                                  'mass cytometry on peripheral blood '\n",
      "                                  'mononuclear cell (PBMC) samples collected '\n",
      "                                  'from non-small cell lung cancer (NSCLC) '\n",
      "                                  'patients prior to treatment with anti-PD-1 '\n",
      "                                  'therapy (n=26 patients), as well as 10 '\n",
      "                                  'matched patient samples collected after '\n",
      "                                  'treatment (Figures 1A, B).'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'Thus, CD9 may serve as an indicator of '\n",
      "                                  'anti-PD-1 responsiveness in an NSCLC '\n",
      "                                  'subtype-dependent manner.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 124,\n",
      "                          'tStart': 120,\n",
      "                          'text': 'Our results link specific monocyte subsets, '\n",
      "                                  'and particularly CD33hi classical '\n",
      "                                  'monocytes, with the effectiveness of '\n",
      "                                  'anti-PD-1 treatment for NSCLC.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'We found that a subset of circulating '\n",
      "                                  'CD14+CD33+ monocytes were significantly '\n",
      "                                  'associated with anti-PD-1 therapy '\n",
      "                                  'responsiveness in NSCLC patients.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'To this end, we performed mass cytometry on '\n",
      "                                  'peripheral blood mononuclear cells from 26 '\n",
      "                                  'patients with NSCLC during anti-PD-1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Still, many patients with NSCLC are either '\n",
      "                                  'non-responsive (2, 4) or eventually become '\n",
      "                                  'resistant to anti-PD-1 treatment (5).'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': 'To determine if specific monocyte subsets '\n",
      "                                  'distinguished non-responders from '\n",
      "                                  'responders amongst NSCLC patients treated '\n",
      "                                  'with anti-PD-1, we split our monocyte UMAP '\n",
      "                                  'between non-responders and responders '\n",
      "                                  '(Figure 3A).'},\n",
      "                         {'dEnd': 34,\n",
      "                          'dStart': 29,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Still, not all patients with NSCLC respond '\n",
      "                                  'positively to anti-PD-1 therapy, and some '\n",
      "                                  'patients acquire resistance to treatment.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36104103'],\n",
      " 'resourceScore': 75,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'To distinguish the expression pattern of '\n",
      "                                  'FBW7 and its association with the clinical '\n",
      "                                  'response to immunotherapy, we '\n",
      "                                  'retrospectively examined FBW7 status in 48 '\n",
      "                                  'cases of patients with advanced NSCLC who '\n",
      "                                  'received anti-PD-1 immunotherapy.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 131,\n",
      "                          'tStart': 127,\n",
      "                          'text': 'Our findings are not reminiscent of the '\n",
      "                                  'FBXO38 experiments, in contrast, we report '\n",
      "                                  'that FBW7 is a key determinant in directing '\n",
      "                                  'PD-1 protein abundance and stability in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'FBW7-mediated ubiquitination and '\n",
      "                                  'destruction of PD-1 protein primes '\n",
      "                                  'sensitivity to anti-PD-1 immunotherapy in '\n",
      "                                  'non-small cell lung cancer'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'Although there is a pioneering preclinical '\n",
      "                                  'report in colon cancer indicating FBXO38 as '\n",
      "                                  'a E3 ligase for PD-1 protein,27 it is yet '\n",
      "                                  'not clear which E3 ligases are responsible '\n",
      "                                  'for PD-1 ubiquitination in NSCLC.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Our findings thus indicate that the '\n",
      "                                  'FBW7-PD-1 signaling plays a pivotal role in '\n",
      "                                  'regulating the efficacy of anti-PD-1 '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Screening FBW7 status may help to predict '\n",
      "                                  'the responsiveness to anti-PD-1 '\n",
      "                                  'immunotherapy and cotargeting FBW7 would '\n",
      "                                  'provide more clinical benefits for patients '\n",
      "                                  'with advanced NSCLC.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'FBW7-mediated ubiquitination and '\n",
      "                                  'destruction of PD-1 protein primes '\n",
      "                                  'sensitivity to anti-PD-1 immunotherapy in '\n",
      "                                  'non-small cell lung cancer'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'It was noted that higher expression of PD-1 '\n",
      "                                  'protein tended to be detected in NSCLC '\n",
      "                                  'patients with relatively lower level of '\n",
      "                                  'endogenous FBW7 protein, whereas higher '\n",
      "                                  'level of FBW7 expression elicited an '\n",
      "                                  'opposite outcome (figure 7A).'},\n",
      "                         {'dEnd': 93,\n",
      "                          'dStart': 88,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'The correlation between FBW7 and PD-1 was '\n",
      "                                  'verified in surgical resected samples from '\n",
      "                                  '23 NSCLC patients (stages I–IIIA) by IHC '\n",
      "                                  'staining.'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 247,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 227,\n",
      "                          'tStart': 223,\n",
      "                          'text': 'Our study highlighted a novel regulatory '\n",
      "                                  'machinery of PD-1 protein stability, in '\n",
      "                                  'which we identified the FBW7 E3 ligase '\n",
      "                                  'promotes its ubiquitination and proteasomal '\n",
      "                                  'degradation, thereby facilitates the '\n",
      "                                  'antitumor response of PD-1 blockade agents '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Our findings thus indicate that the '\n",
      "                                  'FBW7-PD-1 signaling plays a pivotal role in '\n",
      "                                  'regulating the efficacy of anti-PD-1 '\n",
      "                                  'immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'Although there is a pioneering preclinical '\n",
      "                                  'report in colon cancer indicating FBXO38 as '\n",
      "                                  'a E3 ligase for PD-1 protein,27 it is yet '\n",
      "                                  'not clear which E3 ligases are responsible '\n",
      "                                  'for PD-1 ubiquitination in NSCLC.'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 247,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Our study highlighted a novel regulatory '\n",
      "                                  'machinery of PD-1 protein stability, in '\n",
      "                                  'which we identified the FBW7 E3 ligase '\n",
      "                                  'promotes its ubiquitination and proteasomal '\n",
      "                                  'degradation, thereby facilitates the '\n",
      "                                  'antitumor response of PD-1 blockade agents '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'The linear regression analysis of IHC score '\n",
      "                                  'in the 23 cases of NSCLC also confirmed a '\n",
      "                                  'negative correlation between FBW7 and PD-1 '\n",
      "                                  '(figure 7B).'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Screening FBW7 status would serve as a '\n",
      "                                  'biomarker predicting patient’s response to '\n",
      "                                  'anti-PD-1 immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'FBW7 status predicts clinical response to '\n",
      "                                  'anti-PD-1 therapy in patients with NSCLC'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'By using biochemistry-based approaches, we '\n",
      "                                  'identify the FBW7 E3 ligase whose '\n",
      "                                  'activation potentiates response to '\n",
      "                                  'anti-PD-1 immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Screening FBW7 status would predict '\n",
      "                                  'clinical response to anti-PD-1 '\n",
      "                                  'immunotherapy in patients with NSCLC, and '\n",
      "                                  'targeting FBW7 is a promising strategy to '\n",
      "                                  'enhance antitumor immunity.'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 163,\n",
      "                          'tStart': 159,\n",
      "                          'text': 'By characterizing FBW7 status in NSCLC '\n",
      "                                  'patients, we present a clinically relevant '\n",
      "                                  'finding that higher expression of FBW7 '\n",
      "                                  'confers increased sensitivity to anti-PD-1 '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'To extend these results and determine their '\n",
      "                                  'applications in patients treated with '\n",
      "                                  'anti-PD-1 immunotherapy, we validated FBW7 '\n",
      "                                  'as a biomarker predicting response to '\n",
      "                                  'immunotherapy in patients with NSCLC.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 131,\n",
      "                          'tStart': 127,\n",
      "                          'text': 'Therefore, the FBW7 status could mirror the '\n",
      "                                  'tumor microenvironment and screening its '\n",
      "                                  'expression would predict response to '\n",
      "                                  'anti-PD-1 immunotherapy in NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34430609'],\n",
      " 'resourceScore': 74,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 16,\n",
      "                          'tStart': 12,\n",
      "                          'text': 'The role of PD-1 targets in the progression '\n",
      "                                  'of NSCLC has not been fully revealed.'},\n",
      "                         {'dEnd': 276,\n",
      "                          'dStart': 271,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'In our current research, 48 PD-1 target '\n",
      "                                  'molecules were involved in the cell '\n",
      "                                  'division, cell proliferation, DNA '\n",
      "                                  'replication, cell cycle, Lung Cancer, etc. '\n",
      "                                  'studies indicated that cell proliferation, '\n",
      "                                  'DNA replication, cell cycle played an '\n",
      "                                  'important role in the development of NSCLC '\n",
      "                                  '(16-18).'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Targeted programmed cell death protein 1 '\n",
      "                                  '(PD-1) therapy could effectively improve '\n",
      "                                  'the long-term prognosis of patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 72,\n",
      "                          'dStart': 67,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'The differentially expressed genes (DEGs) '\n",
      "                                  'in patients’ blood after NSCLC treatment '\n",
      "                                  'with PD-1 blocker nivolumab in the '\n",
      "                                  'GSE141479 dataset were analyzed by GEO2R '\n",
      "                                  'and identified in the TCGA database.'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'The high-risk group was enriched in '\n",
      "                                  'signaling mechanisms such as cell cycle, '\n",
      "                                  'DNA replication, homologous recombination, '\n",
      "                                  'etc. The risk model based on PD-1 target '\n",
      "                                  'molecules was helpful to assess the '\n",
      "                                  'prognosis of NSCLC patients, and '\n",
      "                                  'independent factors such as HIST1H2BH and '\n",
      "                                  'PLK1 might become important prognostic '\n",
      "                                  'biomarkers of NSCLC patients.'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'The expression levels of PD-1 target '\n",
      "                                  'molecules in NSCLC tissues'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Compared with 41 NSCLC patients, there were '\n",
      "                                  '64 DEGs in the blood of 33 NSCLC patients '\n",
      "                                  'who received PD-1 inhibitor treatment '\n",
      "                                  '(P<0.05).'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'PD-1 inhibitor nivolumab could block the '\n",
      "                                  'binding of PD-1 and PD-L1, promote T cells '\n",
      "                                  'to participate in the recognition and '\n",
      "                                  'killing of tumor cells, and prolong the '\n",
      "                                  'survival of NSCLC patients (15).'},\n",
      "                         {'dEnd': 197,\n",
      "                          'dStart': 192,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Therefore, this study explored the '\n",
      "                                  'signaling mechanisms of PD-1 in the '\n",
      "                                  'treatment of NSCLC and screen potential new '\n",
      "                                  'target molecules for NSCLC progression to '\n",
      "                                  'improve the long-term prognosis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Targeted programmed cell death protein 1 '\n",
      "                                  '(PD-1) therapy could effectively improve '\n",
      "                                  'the long-term prognosis of patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'The risk model based on PD-1 target '\n",
      "                                  'molecules was helpful to assess the '\n",
      "                                  'prognosis of NSCLC patients.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'This study analyzed the gene expression '\n",
      "                                  'levels in the blood of PD-1 inhibitor in '\n",
      "                                  'the treatment of NSCLC, and verified it in '\n",
      "                                  'the TCGA database to construct the risk '\n",
      "                                  'model and nomogram for assessing the '\n",
      "                                  'prognosis of NSCLC.'},\n",
      "                         {'dEnd': 219,\n",
      "                          'dStart': 214,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'This study analyzed the gene expression '\n",
      "                                  'levels in the blood of PD-1 inhibitor in '\n",
      "                                  'the treatment of NSCLC, and verified it in '\n",
      "                                  'the TCGA database to construct the risk '\n",
      "                                  'model and nomogram for assessing the '\n",
      "                                  'prognosis of NSCLC.'},\n",
      "                         {'dEnd': 64,\n",
      "                          'dStart': 59,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'The expression level of PD-1 target '\n",
      "                                  'molecules in GSE141479 NSCLC blood samples'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'Therefore, differentially expressed genes '\n",
      "                                  '(DEGs) in the blood of patients from the '\n",
      "                                  'GSE141479 dataset were analyzed after '\n",
      "                                  'nivolumab treatment (12), the mechanisms of '\n",
      "                                  'PD-1 target molecules in the progression of '\n",
      "                                  'NSCLC were explored, and hub target '\n",
      "                                  'molecules were screened in order to '\n",
      "                                  'construct a risk model and nomogram to '\n",
      "                                  'assess the prognosis of NSCLC patients.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Targeted programmed cell death protein 1 '\n",
      "                                  '(PD-1) therapy could effectively improve '\n",
      "                                  'the long-term prognosis of patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'The expression levels of PD-1 target '\n",
      "                                  'molecules in NSCLC'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Therefore, this study explored the '\n",
      "                                  'signaling mechanisms of PD-1 in the '\n",
      "                                  'treatment of NSCLC and screen potential new '\n",
      "                                  'target molecules for NSCLC progression to '\n",
      "                                  'improve the long-term prognosis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Evaluation of the roles and regulatory '\n",
      "                                  'mechanisms of PD-1 target molecules in '\n",
      "                                  'NSCLC progression'},\n",
      "                         {'dEnd': 330,\n",
      "                          'dStart': 325,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'The high-risk group was enriched in '\n",
      "                                  'signaling mechanisms such as cell cycle, '\n",
      "                                  'DNA replication, homologous recombination, '\n",
      "                                  'etc. The risk model based on PD-1 target '\n",
      "                                  'molecules was helpful to assess the '\n",
      "                                  'prognosis of NSCLC patients, and '\n",
      "                                  'independent factors such as HIST1H2BH and '\n",
      "                                  'PLK1 might become important prognostic '\n",
      "                                  'biomarkers of NSCLC patients.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Therefore, this study explored the '\n",
      "                                  'signaling mechanisms of PD-1 in the '\n",
      "                                  'treatment of NSCLC and screen potential new '\n",
      "                                  'target molecules for NSCLC progression to '\n",
      "                                  'improve the long-term prognosis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 inhibitor nivolumab could block the '\n",
      "                                  'binding of PD-1 and PD-L1, promote T cells '\n",
      "                                  'to participate in the recognition and '\n",
      "                                  'killing of tumor cells, and prolong the '\n",
      "                                  'survival of NSCLC patients (15).'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'In the TCGA database, compared with normal '\n",
      "                                  'lung tissues, the expression levels of 48 '\n",
      "                                  'PD-1 target molecules in NSCLC tissues were '\n",
      "                                  'significantly increased (Figure 2 and Table '\n",
      "                                  '2).'},\n",
      "                         {'dEnd': 349,\n",
      "                          'dStart': 344,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'Therefore, differentially expressed genes '\n",
      "                                  '(DEGs) in the blood of patients from the '\n",
      "                                  'GSE141479 dataset were analyzed after '\n",
      "                                  'nivolumab treatment (12), the mechanisms of '\n",
      "                                  'PD-1 target molecules in the progression of '\n",
      "                                  'NSCLC were explored, and hub target '\n",
      "                                  'molecules were screened in order to '\n",
      "                                  'construct a risk model and nomogram to '\n",
      "                                  'assess the prognosis of NSCLC patients.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Targeted programmed cell death protein 1 '\n",
      "                                  '(PD-1) therapy could effectively improve '\n",
      "                                  'the long-term prognosis of patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['28938671'],\n",
      " 'resourceScore': 73,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'The forest plot analysis of overall '\n",
      "                                  'survival with PD-1/PD-L1 antibodies '\n",
      "                                  'indicated better prognosis than docetaxel, '\n",
      "                                  'in advanced NSCLC patients, as shown in '\n",
      "                                  'Figure 3.'},\n",
      "                         {'dEnd': 351,\n",
      "                          'dStart': 346,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'To address this issue, we conducted a '\n",
      "                                  'meta-analysis of randomized clinical trials '\n",
      "                                  '(RCTs) to determine the efficacy and safety '\n",
      "                                  'of PD-1 or PD-L1 antibodies compared with '\n",
      "                                  'standard second-line therapy docetaxel '\n",
      "                                  'alone and to assess the possible '\n",
      "                                  'association between the level of PD-L1 and '\n",
      "                                  'the prognosis of PD-1/PD-L1 antibodies in '\n",
      "                                  'patients of advanced NSCLC.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'As can be seen, PD-L1 expression of ≥50% on '\n",
      "                                  'tumor cells has supported the application '\n",
      "                                  'of PD1/PDL1 antibodies therapy in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Similarly, forest plot analysis of PFS '\n",
      "                                  'indicated better results with PD-1/PD-L1 '\n",
      "                                  'antibodies than docetaxel in advanced NSCLC '\n",
      "                                  'patients (Figure 4).'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Meta-analysis was conducted to '\n",
      "                                  'systematically assess the effectiveness and '\n",
      "                                  'safety of programmed cell death protein-1 '\n",
      "                                  'or ligand-1 (PD-1 or PD-L1) antibodies '\n",
      "                                  'versus docetaxel alone in advanced non '\n",
      "                                  'small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'All the 5 included RCTs evaluated and '\n",
      "                                  'compared the effectiveness of PD1/PD-L1 '\n",
      "                                  'antibody therapies in advanced NSCLC over '\n",
      "                                  'docetaxel, representing data from total of '\n",
      "                                  '3579 patients (Table 1 and 2).'},\n",
      "                         {'dEnd': 283,\n",
      "                          'dStart': 278,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 248,\n",
      "                          'tStart': 244,\n",
      "                          'text': 'Brahmer [15] did not suggest PD-L1 '\n",
      "                                  'expression as an effective biomarker of '\n",
      "                                  'selecting patients for PD-1/PD-L antibody '\n",
      "                                  'therapy, especially when those with tumors '\n",
      "                                  'lacking PD-L1 expression (PD-L1 < 1%) has '\n",
      "                                  'also been observed to derive benefit from '\n",
      "                                  'PD-1/PD-L1 antibodies in advanced NSCLC.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Meta-analysis was conducted to '\n",
      "                                  'systematically assess the effectiveness and '\n",
      "                                  'safety of programmed cell death protein-1 '\n",
      "                                  'or ligand-1 (PD-1 or PD-L1) antibodies '\n",
      "                                  'versus docetaxel alone in advanced non '\n",
      "                                  'small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Our meta analysis showed that PD-1/PD-L1 '\n",
      "                                  'antibodies treatment significantly improved '\n",
      "                                  'the OS, PFS and ORR of advanced SQ- and '\n",
      "                                  'NSQ-NSCLC patients as compared to docetaxel '\n",
      "                                  'as second-line therapy.'},\n",
      "                         {'dEnd': 196,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'Recently, the checkpoint '\n",
      "                                  'inhibitors/antibodies, such as PD-1/PD-L1 '\n",
      "                                  'antibodies have been observed to enhance '\n",
      "                                  'the tumor suppressor activity of T immune '\n",
      "                                  'cells in solid tumors including advanced '\n",
      "                                  'NSCLC, and have shown very promising '\n",
      "                                  'results in multiple cancers in many '\n",
      "                                  'clinical trials.'},\n",
      "                         {'dEnd': 239,\n",
      "                          'dStart': 234,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 213,\n",
      "                          'tStart': 209,\n",
      "                          'text': 'The ORR analysis which was done using fixed '\n",
      "                                  'effects model due to very little '\n",
      "                                  'heterogeneity between the different trials, '\n",
      "                                  'except overall RR value of 1.53, (95% CI: '\n",
      "                                  '1.16-2.01, P = 0.003; I2 = 59.2%) in favor '\n",
      "                                  'of PD-1/PD-L1 antibodies in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Consistent with these suggestions, our '\n",
      "                                  'analysis, showed that PD-L1expression '\n",
      "                                  'cutoff of 10% was sufficient to display the '\n",
      "                                  'advantage of choosing PD-1/PD-L1 antibody '\n",
      "                                  'therapy in NSCLC over standard second line '\n",
      "                                  'chemotherapy, docetaxel.'},\n",
      "                         {'dEnd': 283,\n",
      "                          'dStart': 278,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'Brahmer [15] did not suggest PD-L1 '\n",
      "                                  'expression as an effective biomarker of '\n",
      "                                  'selecting patients for PD-1/PD-L antibody '\n",
      "                                  'therapy, especially when those with tumors '\n",
      "                                  'lacking PD-L1 expression (PD-L1 < 1%) has '\n",
      "                                  'also been observed to derive benefit from '\n",
      "                                  'PD-1/PD-L1 antibodies in advanced NSCLC.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Many additional clinical trials of '\n",
      "                                  'PD-1/PD-L1 antibodies are also ongoing such '\n",
      "                                  'as KEYNOTE-042 which intend to compare '\n",
      "                                  'pembrolizumab as first-line therapy against '\n",
      "                                  'platinum doublet chemotherapy for advanced '\n",
      "                                  'NSCLC [22–24].'},\n",
      "                         {'dEnd': 186,\n",
      "                          'dStart': 181,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 150,\n",
      "                          'text': 'Thus, According to our meta analysis, we '\n",
      "                                  'concluded that PD-L1 expression of ≥10% on '\n",
      "                                  'tumor cells, can be a cutoff value for '\n",
      "                                  'guiding the application of PD1/PDL1 '\n",
      "                                  'antibodies therapy in NSCLC patients.'},\n",
      "                         {'dEnd': 47,\n",
      "                          'dStart': 42,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'Herein, we have selected 5 RCTs including '\n",
      "                                  'NSCLC patients to perform the meta-analysis '\n",
      "                                  'to compare the efficacy of PD1/PD-L1 '\n",
      "                                  'antibodies with docetaxel.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Meta-analysis was conducted to '\n",
      "                                  'systematically assess the effectiveness and '\n",
      "                                  'safety of programmed cell death protein-1 '\n",
      "                                  'or ligand-1 (PD-1 or PD-L1) antibodies '\n",
      "                                  'versus docetaxel alone in advanced non '\n",
      "                                  'small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 17,\n",
      "                          'tStart': 13,\n",
      "                          'text': 'In 2015, two PD-1 inhibitors/antibodies '\n",
      "                                  '(nivolumab and pembrolizumab) have received '\n",
      "                                  'US Food and Drug Administration (FDA) '\n",
      "                                  'approval for the use in advanced NSCLC '\n",
      "                                  'after platinum-based chemotherapy.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1/PD-L1 antibodies displayed '\n",
      "                                  'significant improvement in PFS of advanced '\n",
      "                                  'NSCLC patients, with HR value of 0.87 (95% '\n",
      "                                  'CI: 0.80-0.94; p < 0.001).'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'But there is an ambiguity in terms of PD-L1 '\n",
      "                                  'expression being a suitable marker for '\n",
      "                                  'PD-1/PD-L1 antibodies treatment for '\n",
      "                                  'advanced NSCLC compared with docetaxel in '\n",
      "                                  'the second-line treatment.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Thus, in conclusion, our meta-analysis '\n",
      "                                  'study indicated that PD-1/PD-L1 antibodies '\n",
      "                                  'treatment indeed has beneficial effects on '\n",
      "                                  'advanced NSCLC patients in comparison to '\n",
      "                                  'docetaxel monotherapy, along with '\n",
      "                                  'displaying few adverse events.'},\n",
      "                         {'dEnd': 88,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 antibodies efficacy and safety '\n",
      "                                  'versus docetaxel monotherapy in advanced '\n",
      "                                  'NSCLC patients after first-line treatment '\n",
      "                                  'option: systems assessment'},\n",
      "                         {'dEnd': 39,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Our study concluded that advanced NSCLC '\n",
      "                                  'patients benefited more with PD-1/PD-L1 '\n",
      "                                  'antibodies than docetaxel in the second '\n",
      "                                  'line treatment.'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'Latest NCCN 2017 of lung cancer also bring '\n",
      "                                  'forword PD-L1 expression of ≥50% is a '\n",
      "                                  'cutoff value for guiding the application of '\n",
      "                                  'PD1/PDL1 antibodies therapy in NSCLC '\n",
      "                                  'patients in 1st line.'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Meta-analysis was conducted to '\n",
      "                                  'systematically assess the effectiveness and '\n",
      "                                  'safety of programmed cell death protein-1 '\n",
      "                                  'or ligand-1 (PD-1 or PD-L1) antibodies '\n",
      "                                  'versus docetaxel alone in advanced non '\n",
      "                                  'small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 351,\n",
      "                          'dStart': 346,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 304,\n",
      "                          'tStart': 300,\n",
      "                          'text': 'To address this issue, we conducted a '\n",
      "                                  'meta-analysis of randomized clinical trials '\n",
      "                                  '(RCTs) to determine the efficacy and safety '\n",
      "                                  'of PD-1 or PD-L1 antibodies compared with '\n",
      "                                  'standard second-line therapy docetaxel '\n",
      "                                  'alone and to assess the possible '\n",
      "                                  'association between the level of PD-L1 and '\n",
      "                                  'the prognosis of PD-1/PD-L1 antibodies in '\n",
      "                                  'patients of advanced NSCLC.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'There have been some studies indicating '\n",
      "                                  'that PD-L1 expression level can serve as a '\n",
      "                                  'biomarker for PD-1/PD-L1 antibodies based '\n",
      "                                  'immunotherapy in NSCLC [15–20].'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35116644'],\n",
      " 'resourceScore': 71,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 101,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'The incidence of gastrointestinal adverse '\n",
      "                                  'events in patients with advanced non-small '\n",
      "                                  'cell lung cancer (NSCLC) treated with PD-1 '\n",
      "                                  'inhibitors: a meta-analysis'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 249,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'Google Scholar, PubMed, Science Direct and '\n",
      "                                  'proceedings of major oncology conferences '\n",
      "                                  'were systematically searched from their '\n",
      "                                  'inception to December 2020, to identify '\n",
      "                                  'studies which reported the GI adverse '\n",
      "                                  'events of PD-1 inhibitors among patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Thirteen studies (9-13,15-22) evaluated the '\n",
      "                                  'incidence of nausea associated with the use '\n",
      "                                  'of PD-1 inhibitor in 3,361 patients with '\n",
      "                                  'advanced/metastatic NSCLC (Table 4).'},\n",
      "                         {'dEnd': 77,\n",
      "                          'dStart': 72,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Treatment-related GI adverse events '\n",
      "                                  'occurring in patients with advanced NSCLC '\n",
      "                                  'treated with anti-PD-1 therapy are '\n",
      "                                  'presented in Table 2.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'Eleven studies (1,9-13,15,17-19,21,22) '\n",
      "                                  'evaluated the incidence of constipation '\n",
      "                                  'associated with the use of PD-1 inhibitor '\n",
      "                                  'in 2,641 patients with advanced/metastatic '\n",
      "                                  'NSCLC (Table 6).'},\n",
      "                         {'dEnd': 180,\n",
      "                          'dStart': 175,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'To the best of our knowledge, the current '\n",
      "                                  'meta-analysis involves the largest number '\n",
      "                                  'of patients in assessing the rates of PD-1 '\n",
      "                                  'inhibitor-related GI adverse events in '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Six studies reported the incidence of '\n",
      "                                  'colitis between PD-1 inhibitors monotherapy '\n",
      "                                  'and chemotherapy in patients with '\n",
      "                                  'advanced/metastatic NSCLC.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In summary, our meta-analysis recruited 15 '\n",
      "                                  'studies and has demonstrated the GI adverse '\n",
      "                                  'events of PD-1 monotherapy in patients with '\n",
      "                                  'advanced/metastatic NSCLC.'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'We conducted a meta-analysis to evaluates '\n",
      "                                  'the incidence of the gastrointestinal (GI) '\n",
      "                                  'adverse events with the use of PD-1 '\n",
      "                                  'inhibitors among patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'We conducted a meta-analysis to evaluates '\n",
      "                                  'the incidence of the gastrointestinal (GI) '\n",
      "                                  'adverse events with the use of PD-1 '\n",
      "                                  'inhibitors among patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Eleven studies (9-13,15,18,19,21-23) '\n",
      "                                  'evaluated the incidence of vomiting '\n",
      "                                  'associated with the use of PD-1 inhibitor '\n",
      "                                  'in 2,943 patients with advanced/metastatic '\n",
      "                                  'NSCLC (Table 5).'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'Fourteen studies (9-12,14-23) evaluated the '\n",
      "                                  'incidence of decreased appetite associated '\n",
      "                                  'with the use of PD-1 inhibitor in 3,664 '\n",
      "                                  'patients with advanced/metastatic NSCLC '\n",
      "                                  '(Table 9).'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'All the 15 studies evaluated the incidence '\n",
      "                                  'of diarrhea associated with the use of PD-1 '\n",
      "                                  'inhibitor in 3,716 patients with '\n",
      "                                  'advanced/metastatic NSCLC (Table 3).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Six studies (9,11,16,18,19,21) evaluated '\n",
      "                                  'the incidence of stomatitis associated with '\n",
      "                                  'the use of PD-1 inhibitor in 2,102 patients '\n",
      "                                  'with advanced/metastatic NSCLC (Table 8).'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Treatment-related gastrointestinal adverse '\n",
      "                                  'events occurring in patients with advanced '\n",
      "                                  'NSCLC treated with anti-PD-1 therapy'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'Nine studies (9,10,14,16,18-21,23) '\n",
      "                                  'evaluated the incidence of colitis '\n",
      "                                  'associated with the use of PD-1 inhibitor '\n",
      "                                  'in 2,359 patients with advanced/metastatic '\n",
      "                                  'NSCLC (Table 7).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36077868'],\n",
      " 'resourceScore': 70,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 41,\n",
      "                          'dStart': 36,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Among 648 patients who had advanced NSCLC '\n",
      "                                  'and received PD-1/PD-L1 inhibitors, 61 had '\n",
      "                                  'liver metastases and 587 did not have.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Accordingly, this study intended to explore '\n",
      "                                  'the efficacy of PD-1/PD-L1 inhibitors in '\n",
      "                                  'liver metastasis–NSCLC patients and '\n",
      "                                  'preliminarily investigate the specific '\n",
      "                                  'immune microenvironment of these patients.'},\n",
      "                         {'dEnd': 58,\n",
      "                          'dStart': 53,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'One possible explanation for the limited '\n",
      "                                  'efficacy in NSCLC patients with liver '\n",
      "                                  'metastasis treated with PD-1/PD-L1 '\n",
      "                                  'inhibitors is the immune microenvironment, '\n",
      "                                  'which is specific to liver metastasis as '\n",
      "                                  'mentioned above, and the suppression of '\n",
      "                                  'systemic immunity by liver metastasis.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Furthermore, PD-L1 expression and CD8+ T '\n",
      "                                  'cell infiltration might act as biomarkers '\n",
      "                                  'to predict the efficacy of PD-1/PD-L1 '\n",
      "                                  'inhibitors in patients with NSCLC and liver '\n",
      "                                  'metastasis.'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'To our knowledge, this is the first largest '\n",
      "                                  'scale retrospective study to evaluate the '\n",
      "                                  'efficacy of PD-1/PD-L1 inhibitors in NSCLC '\n",
      "                                  'patients with liver metastasis in the '\n",
      "                                  'real-world.'},\n",
      "                         {'dEnd': 62,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'Meanwhile, the control group consisted of '\n",
      "                                  '587 metastatic NSCLC patients who were free '\n",
      "                                  'of liver metastasis treated with '\n",
      "                                  'PD-1/PD-L1inhibitors.'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 177,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Background: A controversy exists regarding '\n",
      "                                  'the efficacy of programmed death-1 (PD-1)/ '\n",
      "                                  'programmed death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors for patients with non-small cell '\n",
      "                                  'lung cancer (NSCLC) and liver metastases.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Our study demonstrated the advantages of '\n",
      "                                  'PD-1/PD-L1 inhibitors for liver '\n",
      "                                  'metastasis–NSCLC patients in the real-world '\n",
      "                                  'situation.'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Our study retrospectively evaluated the '\n",
      "                                  'efficacy of PD-1/PD-L1 inhibitors in NSCLC '\n",
      "                                  'patients with liver metastases.'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'In addition, PD-L1 expression and CD8+ T '\n",
      "                                  'cell infiltration may be potential '\n",
      "                                  'biomarkers for PD-1/PD-L1 inhibitor therapy '\n",
      "                                  'in NSCLC patients with liver metastases.'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), '\n",
      "                                  'represented by programmed death-1 (PD-1)/ '\n",
      "                                  'programmed death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors, have significantly improved '\n",
      "                                  'efficacy in patients with advanced NSCLC, '\n",
      "                                  'but the efficacy in patients with NSCLC and '\n",
      "                                  'liver metastases remains controversial.'},\n",
      "                         {'dEnd': 77,\n",
      "                          'dStart': 72,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Our findings imply that PD-1/PD-L1 '\n",
      "                                  'inhibitors enhances effectiveness in NSCLC '\n",
      "                                  'patients who have liver metastases, but the '\n",
      "                                  'benefit is inferior to those in patients '\n",
      "                                  'without liver metastasis.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 17,\n",
      "                          'tStart': 13,\n",
      "                          'text': 'Conclusions: PD-1/PD-L1 inhibitors are '\n",
      "                                  'effective in liver metastasis–NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 18,\n",
      "                          'dStart': 13,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'For advanced NSCLC patients, immune '\n",
      "                                  'checkpoint inhibitors (ICI) such as '\n",
      "                                  'programmed cell death-1 (PD-1)/programmed '\n",
      "                                  'cell death ligand-1 (PD-L1) inhibitors have '\n",
      "                                  'been established as first-line therapy '\n",
      "                                  'regimen [8,9].'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'The Efficacy of PD-1/PD-L1 Inhibitors in '\n",
      "                                  'Patients with Liver Metastasis of Non-Small '\n",
      "                                  'Cell Lung Cancer: A Real-World Study'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Background: A controversy exists regarding '\n",
      "                                  'the efficacy of programmed death-1 (PD-1)/ '\n",
      "                                  'programmed death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors for patients with non-small cell '\n",
      "                                  'lung cancer (NSCLC) and liver metastases.'},\n",
      "                         {'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), '\n",
      "                                  'represented by programmed death-1 (PD-1)/ '\n",
      "                                  'programmed death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors, have significantly improved '\n",
      "                                  'efficacy in patients with advanced NSCLC, '\n",
      "                                  'but the efficacy in patients with NSCLC and '\n",
      "                                  'liver metastases remains controversial.'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'The results of several recent large phase '\n",
      "                                  'III clinical studies have shown that '\n",
      "                                  'PD-1/PD-L1 inhibitors are effective in '\n",
      "                                  'liver-metastatic NSCLC patients [3,4,5].'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'PD-L1 expression is related to an excellent '\n",
      "                                  'response to anti-PD-1 therapy in NSCLC '\n",
      "                                  'patients [29,31].'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Therefore, we conducted this retrospective '\n",
      "                                  'study in order to evaluate the '\n",
      "                                  'effectiveness for PD-1/PD-L1 inhibitors on '\n",
      "                                  'liver metastasis-NSCLC patients.'},\n",
      "                         {'dEnd': 63,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors have revealed '\n",
      "                                  'promising activity in NSCLC patients with '\n",
      "                                  'liver metastases.'},\n",
      "                         {'dEnd': 44,\n",
      "                          'dStart': 39,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 168,\n",
      "                          'tStart': 164,\n",
      "                          'text': 'The above performance implies that for '\n",
      "                                  'NSCLC patients with liver metastases, '\n",
      "                                  'anti-angiogenesis treatment may serve as a '\n",
      "                                  'promising scheme when they have failed with '\n",
      "                                  'PD-1/PD-L1 inhibitors; however, further '\n",
      "                                  'confirmation of this finding in larger '\n",
      "                                  'scale studies is required.'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'On the basis of the available evidence from '\n",
      "                                  'subgroup analyses of clinical studies and '\n",
      "                                  'retrospective studies, the efficacy of '\n",
      "                                  'anti-PD-1/PD-L1 therapy in patients with '\n",
      "                                  'NSCLC and liver metastases remains '\n",
      "                                  'controversial.'},\n",
      "                         {'dEnd': 41,\n",
      "                          'dStart': 36,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'Therefore, the inferior survival of NSCLC '\n",
      "                                  'patients with liver metastasis treated with '\n",
      "                                  'PD-1/PD-L1 inhibitors may be related to the '\n",
      "                                  'characteristic of poor prognosis in liver '\n",
      "                                  'metastasis.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'We aimed to evaluate the efficacy of '\n",
      "                                  'PD-1/PD-L1 inhibitors in patients with '\n",
      "                                  'NSCLC and liver metastases in the '\n",
      "                                  'real-world.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'In comparison to the effectiveness of '\n",
      "                                  'chemotherapy, we discovered that '\n",
      "                                  'anti-PD-1/PD-L1 therapy improves outcomes '\n",
      "                                  'among liver metastasis–NSCLC patients.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'In this study, we illustrated that '\n",
      "                                  'PD-1/PD-L1 inhibitors are effective in '\n",
      "                                  'NSCLC patients with liver metastases but '\n",
      "                                  'were inferiorly effective in patients '\n",
      "                                  'without liver metastases.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36093740'],\n",
      " 'resourceScore': 69,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'We engineered a highly sensitive '\n",
      "                                  'immunogold‐based biochip to co‐quantify '\n",
      "                                  'PD‐1/PD‐L1 proteins and mRNAs in single EVs '\n",
      "                                  'sorted from NSCLC patient serum.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Until now, the FDA has approved three ICIs '\n",
      "                                  'targeting PD‐L1 (atezolizumab, durvalumab, '\n",
      "                                  'and avelumab) and two ICIs targeting PD‐1 '\n",
      "                                  '(nivolumab and pembrolizumab) for NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Dual single‐EV PD‐1/PD‐L1 mRNA detection '\n",
      "                                  'differentiated responders from '\n",
      "                                  'non‐responders with an accuracy of 72.2% '\n",
      "                                  'and achieved an NSCLC diagnosis accuracy of '\n",
      "                                  '93.2%, suggesting the potential for AuSERP '\n",
      "                                  'to provide enhanced immunotherapy '\n",
      "                                  'predictions and cancer diagnoses within the '\n",
      "                                  'clinical setting.'},\n",
      "                         {'dEnd': 351,\n",
      "                          'dStart': 346,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Despite the minute levels of PD‐1/PD‐L1 '\n",
      "                                  'protein and mRNA present in healthy donor '\n",
      "                                  'EVs, indicative of inflammatory events '\n",
      "                                  'outside the NSCLC microenvironment '\n",
      "                                  'consistent with previous investigations '\n",
      "                                  '(Chen et al., 2018; Ricklefs et al., 2018; '\n",
      "                                  'Wang et al., 2020), the differences in '\n",
      "                                  'expression measured by AuSERP demonstrate '\n",
      "                                  'its potential to diagnose NSCLC.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'To evaluate the performance of AuSERP in '\n",
      "                                  \"predicting a patient's response to \"\n",
      "                                  'immunotherapy, we compared single‐EV '\n",
      "                                  'PD‐1/PD‐L1 protein and mRNA signals from 54 '\n",
      "                                  'NSCLC patients with their PD‐L1 IHC assay '\n",
      "                                  'results (Figure 4b).'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Thus, our technology allows for the '\n",
      "                                  'co‐quantification of PD‐1/PD‐L1 molecular '\n",
      "                                  'contents inside and on the surface of '\n",
      "                                  'single EVs, thereby providing more '\n",
      "                                  'comprehensive information on single EVs '\n",
      "                                  'from NSCLC patient serum.'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'We asked whether any single‐EV single '\n",
      "                                  'biomarkers (PD‐1/PD‐L1 proteins and mRNAs) '\n",
      "                                  'could be good predictors for NSCLC '\n",
      "                                  'diagnosis with AuSERP.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Using 20 μl of purified serum, all four '\n",
      "                                  'biomarkers in the single EVs of the NSCLC '\n",
      "                                  'patients were successfully detected with '\n",
      "                                  'PD‐1/PD‐L1 antibodies and CLN‐MBs.'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'The simultaneous detection of PD‐1 and '\n",
      "                                  'PD‐L1 on single EVs from NSCLC patient '\n",
      "                                  'serum indicates the presence of EV PD‐L1 '\n",
      "                                  'derived from non‐tumour cells (Figure '\n",
      "                                  'S14c).'},\n",
      "                         {'dEnd': 116,\n",
      "                          'dStart': 111,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'Our study, therefore, showed that '\n",
      "                                  'pre‐treatment single‐EV dual PD‐1/PD‐L1 '\n",
      "                                  'mRNA are good predictors to identify NSCLC '\n",
      "                                  'patients that will benefit from '\n",
      "                                  'anti‐PD‐1/PD‐L1 immunotherapy.'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'By combining single‐EV PD‐1/PD‐L1 mRNA '\n",
      "                                  'biomarkers, AuSERP diagnosed NSCLC patients '\n",
      "                                  'and predicted patient responses to '\n",
      "                                  'anti‐PD‐1/PD‐L1 immunotherapy with '\n",
      "                                  'accuracies of 93.2% and 72.2%, '\n",
      "                                  'respectively, suggesting the potential '\n",
      "                                  'applications of AuSERP as a non‐invasive '\n",
      "                                  'and competitive alternative to diagnose '\n",
      "                                  'cancer patients and predict immunotherapy '\n",
      "                                  'responses.'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'AuSERP enables single‐EV PD‐1/PD‐L1 protein '\n",
      "                                  'and mRNA detection from NSCLC patient '\n",
      "                                  'serum'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Serum samples from 27 NSCLC non‐responders '\n",
      "                                  'and 27 NSCLC responders collected before '\n",
      "                                  'immunotherapy were analysed for four '\n",
      "                                  'single‐EV biomarkers (PD‐1/PD‐L1 proteins '\n",
      "                                  'and mRNAs).'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 240,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 179,\n",
      "                          'tStart': 175,\n",
      "                          'text': 'Given the robustness of AuSERP and its '\n",
      "                                  'potential to co‐quantify various single‐EV '\n",
      "                                  'protein and mRNA biomarkers, we '\n",
      "                                  'hypothesized that a combination of the '\n",
      "                                  'single‐EV biomarkers (PD‐1/PD‐L1 proteins '\n",
      "                                  'and mRNAs) would provide higher accuracy '\n",
      "                                  'for NSCLC diagnosis.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Despite the minute levels of PD‐1/PD‐L1 '\n",
      "                                  'protein and mRNA present in healthy donor '\n",
      "                                  'EVs, indicative of inflammatory events '\n",
      "                                  'outside the NSCLC microenvironment '\n",
      "                                  'consistent with previous investigations '\n",
      "                                  '(Chen et al., 2018; Ricklefs et al., 2018; '\n",
      "                                  'Wang et al., 2020), the differences in '\n",
      "                                  'expression measured by AuSERP demonstrate '\n",
      "                                  'its potential to diagnose NSCLC.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Single‐EV PD‐1/PD‐L1 protein and mRNA '\n",
      "                                  'expression levels of the NSCLC patients, in '\n",
      "                                  'comparison with those of healthy donors, '\n",
      "                                  'were quantified using the custom‐built '\n",
      "                                  'MATLAB algorithm (Figure 4d).'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'Circulating microRNAs (miRNAs) have been '\n",
      "                                  'utilized as potential predictive biomarkers '\n",
      "                                  'for anti‐PD‐1/PD‐L1 immunotherapy for '\n",
      "                                  'non‐small cell lung cancer (NSCLC) (Fan et '\n",
      "                                  'al., 2020; Shukuya et al., 2020).'},\n",
      "                         {'dEnd': 198,\n",
      "                          'dStart': 193,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'With AuSERP, we successfully demonstrated a '\n",
      "                                  'comprehensive profile of four immunotherapy '\n",
      "                                  'biomarkers (PD‐1/PD‐L1 proteins and mRNAs) '\n",
      "                                  'at a single‐EV resolution from EVs isolated '\n",
      "                                  'from the serum of NSCLC patients.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'Circumventing the artefact of dilution '\n",
      "                                  'observed in the bulk characterization of '\n",
      "                                  'EVs, AuSERP emphasized PD‐L1/PD‐1 events '\n",
      "                                  'from single EVs derived from the NSCLC '\n",
      "                                  'immunological landscape as bright spots, '\n",
      "                                  'while minimizing signals from peripheral '\n",
      "                                  'molecules or other inflammatory events.'},\n",
      "                         {'dEnd': 59,\n",
      "                          'dStart': 54,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'A previous study showed that compared to '\n",
      "                                  'treating all NSCLC patients with '\n",
      "                                  'anti‐PD‐1/PD‐L1 immunotherapy, the '\n",
      "                                  'selection of patients based on positive '\n",
      "                                  'PD‐L1 IHC scores improved incremental '\n",
      "                                  'quality‐adjusted life years by up to 183% '\n",
      "                                  'and decreased the incremental '\n",
      "                                  'cost‐effectiveness ratio by up to 65% '\n",
      "                                  '(Aguiar et al., 2017).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34095230'],\n",
      " 'resourceScore': 69,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 12,\n",
      "                          'tStart': 8,\n",
      "                          'text': 'Current PD-1/PD-L1 blockade therapies have '\n",
      "                                  'shown durable disease control and improved '\n",
      "                                  'survival in patients with advanced NSCLC '\n",
      "                                  '(Rangachari and Costa, 2019).'},\n",
      "                         {'dEnd': 116,\n",
      "                          'dStart': 111,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 131,\n",
      "                          'tStart': 127,\n",
      "                          'text': 'High levels of the serum metabolite '\n",
      "                                  'biomarkers were found to correlate with '\n",
      "                                  'improved survival of patients with NSCLC '\n",
      "                                  'receiving PD-1 blockade therapy.'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Methods: We recruited 74 Chinese patients '\n",
      "                                  'who had stage IIIB/IV NSCLC-proven tumor '\n",
      "                                  'progression and were treated with PD-1 '\n",
      "                                  'inhibitor.'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 210,\n",
      "                          'tStart': 206,\n",
      "                          'text': 'In conclusion, we report that the '\n",
      "                                  'identification of metabolite biomarkers in '\n",
      "                                  'early on-treatment serum constitutes a '\n",
      "                                  'predictive tool for selecting NSCLC '\n",
      "                                  'patients who stand to gain clinical benefit '\n",
      "                                  'from anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'ICIs targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1) or its ligand PD-L1 have '\n",
      "                                  'demonstrated improved clinical efficacy in '\n",
      "                                  'both second-line and first-line treatment '\n",
      "                                  'of advanced NSCLC when compared to '\n",
      "                                  'conventional chemotherapy (Sui et al., '\n",
      "                                  '2018).'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'ICIs targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1) or its ligand PD-L1 have '\n",
      "                                  'demonstrated improved clinical efficacy in '\n",
      "                                  'both second-line and first-line treatment '\n",
      "                                  'of advanced NSCLC when compared to '\n",
      "                                  'conventional chemotherapy (Sui et al., '\n",
      "                                  '2018).'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'Background: Despite remarkable success of '\n",
      "                                  'immunotherapies with checkpoint blockade '\n",
      "                                  'antibodies targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1), the majority of patients '\n",
      "                                  'with non-small-cell lung cancer (NSCLC) '\n",
      "                                  'have yet to receive durable benefits.'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Background: Despite remarkable success of '\n",
      "                                  'immunotherapies with checkpoint blockade '\n",
      "                                  'antibodies targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1), the majority of patients '\n",
      "                                  'with non-small-cell lung cancer (NSCLC) '\n",
      "                                  'have yet to receive durable benefits.'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 142,\n",
      "                          'text': 'Thus, the results from the two independent '\n",
      "                                  'validation sets confirmed the serum '\n",
      "                                  'metabolite panel as predictive biomarkers '\n",
      "                                  'of NSCLC response to PD-1 blockade '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Results: A serum metabolite panel '\n",
      "                                  'consisting of hypoxanthine and histidine '\n",
      "                                  'was identified and validated as a predictor '\n",
      "                                  'of response to PD-1 blockade treatment in '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In this equation, (p = Responder) is the '\n",
      "                                  'predicted probability of NSCLC patients '\n",
      "                                  'benefiting from PD-1 blockade therapy, '\n",
      "                                  '(Hyp) and (His) are the serum '\n",
      "                                  'concentrations of hypoxanthine and '\n",
      "                                  'histidine, respectively, at early '\n",
      "                                  'on-treatment.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'In the present study, we identified the '\n",
      "                                  'serum metabolite biomarkers predictive of '\n",
      "                                  'response to anti-PD-1 treatment in patients '\n",
      "                                  'with advanced NSCLC based on metabolomic '\n",
      "                                  'profiling using UHPLC-MS.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'We used the metabolomic profiling of early '\n",
      "                                  'on-treatment serum to explore predictors of '\n",
      "                                  'clinical outcomes of anti-PD-1 treatment in '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'To identify potential serum biomarkers of '\n",
      "                                  'clinical response to PD-1 blockade, we '\n",
      "                                  'collected serum samples from a discovery '\n",
      "                                  'cohort of 43 patients with advanced NSCLC '\n",
      "                                  'treated with the anti-PD-1 antibody '\n",
      "                                  'nivolumab.'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Conclusion: Our results revealed that '\n",
      "                                  'hypoxanthine and histidine in early '\n",
      "                                  'on-treatment serum are predictive '\n",
      "                                  'biomarkers of response to PD-1 blockade '\n",
      "                                  'therapy in patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 202,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'Background: Despite remarkable success of '\n",
      "                                  'immunotherapies with checkpoint blockade '\n",
      "                                  'antibodies targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1), the majority of patients '\n",
      "                                  'with non-small-cell lung cancer (NSCLC) '\n",
      "                                  'have yet to receive durable benefits.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 115,\n",
      "                          'tStart': 111,\n",
      "                          'text': 'Several clinical trials have been initiated '\n",
      "                                  'to test the efficacy of combined adenosine '\n",
      "                                  'pathway inhibitors with PD-1/PD-L1 blockade '\n",
      "                                  'in several cancers including NSCLC (Boison '\n",
      "                                  'and Yegutkin, 2019).'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Immunotherapies with checkpoint blockade '\n",
      "                                  'antibodies targeting PD-1, PD-L1, and '\n",
      "                                  'cytotoxic T-lymphocyte antigen 4 (CTLA-4) '\n",
      "                                  'have remarkably improved the outcome of '\n",
      "                                  'patients with advanced NSCLC and other '\n",
      "                                  'cancers (Ribas and Wolchok, 2018).'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Although the validation set one was '\n",
      "                                  'comprised of patients receiving PD-1 '\n",
      "                                  'inhibitor in combination with chemotherapy, '\n",
      "                                  'the metabolite biomarkers need to be '\n",
      "                                  'validated in more patient cohorts treated '\n",
      "                                  'with combination therapy that is becoming a '\n",
      "                                  'promising treatment strategy for NSCLC '\n",
      "                                  '(Dong et al., 2019).'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'The serum biomarker panel would enable '\n",
      "                                  'early identification of NSCLC patients who '\n",
      "                                  'may benefit from PD-1 blockade therapy.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'A validation cohort was comprised of 21 '\n",
      "                                  'patients with advanced NSCLC treated with '\n",
      "                                  'another PD-1 inhibitor, tislelizumab.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Recently, an anti-PD-1 antibody '\n",
      "                                  'tislelizumab has been approved in China for '\n",
      "                                  'treatment of NSCLC and other cancers (Liu '\n",
      "                                  'and Wu, 2020).'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Serum Metabolite Biomarkers Predictive of '\n",
      "                                  'Response to PD-1 Blockade Therapy in '\n",
      "                                  'Non-Small Cell Lung Cancer'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 202,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Background: Despite remarkable success of '\n",
      "                                  'immunotherapies with checkpoint blockade '\n",
      "                                  'antibodies targeting programmed cell death '\n",
      "                                  'protein 1 (PD-1), the majority of patients '\n",
      "                                  'with non-small-cell lung cancer (NSCLC) '\n",
      "                                  'have yet to receive durable benefits.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['31315783'],\n",
      " 'resourceScore': 68,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 319,\n",
      "                          'dStart': 314,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immunological checkpoint inhibitors '\n",
      "                                  'targeting PD-1/PD-L1 are benefcial to '\n",
      "                                  'patients, both in the frst-line and '\n",
      "                                  'second-line treatment of advanced NSCLC, in '\n",
      "                                  'the adjuvant treatment of locally-advanced '\n",
      "                                  'NSCLC, and in the neoadjuvant therapy of '\n",
      "                                  'early NSCLC, which show an important role '\n",
      "                                  'in the comprehensive treatment of NSCLC.'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂在NSCLC一线、二线及辅助治疗中的临床研究'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Immune checkpoint inhibitors, especially '\n",
      "                                  'programmed death-1 (PD-1)/programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitors have made '\n",
      "                                  'a breakthrough in the treatment of NSCLC '\n",
      "                                  'and changed the treatment patern for '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Tis article reviews the clinical research '\n",
      "                                  'progress of immunological checkpoint '\n",
      "                                  'inhibitors targeting PD-1/PD-L1 in NSCLC.'},\n",
      "                         {'dEnd': 23,\n",
      "                          'dStart': 18,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂已成为晚期NSCLC二线治疗的标准治疗。在各项研究中,患者PFS获益不一致,OS基本均有获益,其中少部分患者(约20%)可持续获益,无论组织学类型均有获益,PD-L1表达对免疫治疗疗效预测有一定的指导意义。其中多项研究的亚组分析显示,免疫治疗并不能给驱动基因阳性患者带来更大的获益。'},\n",
      "                         {'dEnd': 86,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Ongoing clinical researches of PD-1/PD-L1 '\n",
      "                                  'inhibitors in neoadjuvant therapy with '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immunological checkpoint inhibitors '\n",
      "                                  'targeting PD-1/PD-L1 are benefcial to '\n",
      "                                  'patients, both in the frst-line and '\n",
      "                                  'second-line treatment of advanced NSCLC, in '\n",
      "                                  'the adjuvant treatment of locally-advanced '\n",
      "                                  'NSCLC, and in the neoadjuvant therapy of '\n",
      "                                  'early NSCLC, which show an important role '\n",
      "                                  'in the comprehensive treatment of NSCLC.'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 240,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂用于早期NSCLC的新辅助治疗'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂在NSCLC新辅助治疗中的临床研究(已有五项研究结果汇总)'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Clinical researches of PD-1/PD-L1 '\n",
      "                                  'inhibitors in neoadjuvant therapy with '\n",
      "                                  'NSCLC (summary of five research results)'},\n",
      "                         {'dEnd': 260,\n",
      "                          'dStart': 255,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 195,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 329,\n",
      "                          'dStart': 324,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 305,\n",
      "                          'tStart': 301,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Clinical researches of PD-1/PD-L1 '\n",
      "                                  'inhibitors in first-line, second-line and '\n",
      "                                  'adjuvant therapy with NSCLC'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 24,\n",
      "                          'dStart': 19,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂用于局部晚期NSCLC的辅助治疗'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 329,\n",
      "                          'dStart': 324,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂用于晚期NSCLC的二线治疗'},\n",
      "                         {'dEnd': 329,\n",
      "                          'dStart': 324,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 195,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 282,\n",
      "                          'dStart': 277,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 195,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 195,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Immune checkpoint inhibitors, especially '\n",
      "                                  'programmed death-1 (PD-1)/programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitors have made '\n",
      "                                  'a breakthrough in the treatment of NSCLC '\n",
      "                                  'and changed the treatment patern for '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 260,\n",
      "                          'dStart': 255,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 240,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 199,\n",
      "                          'tStart': 195,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂在NSCLC新辅助治中的临床研究(正在进行)'},\n",
      "                         {'dEnd': 249,\n",
      "                          'dStart': 244,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immunological checkpoint inhibitors '\n",
      "                                  'targeting PD-1/PD-L1 are benefcial to '\n",
      "                                  'patients, both in the frst-line and '\n",
      "                                  'second-line treatment of advanced NSCLC, in '\n",
      "                                  'the adjuvant treatment of locally-advanced '\n",
      "                                  'NSCLC, and in the neoadjuvant therapy of '\n",
      "                                  'early NSCLC, which show an important role '\n",
      "                                  'in the comprehensive treatment of NSCLC.'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂用于晚期NSCLC的一线治疗'},\n",
      "                         {'dEnd': 282,\n",
      "                          'dStart': 277,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': '非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)是肺癌最常见的病理类型。近年来,免疫治疗迅速发展,免疫检查点抑制剂尤其是程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed '\n",
      "                                  'death-ligand 1, '\n",
      "                                  'PD-L1)抑制剂已在NSCLC的治疗中取得突破性进展,改变了NSCLC治疗的格局。以PD-1/PD-L1为靶点的免疫检查点抑制剂无论在晚期NSCLC的一线和二线治疗,局部晚期NSCLC的辅助治疗,还是早期NSCLC的新辅助治疗中均为患者带来获益,在NSCLC的综合治疗中显示出重要地位。本文针对以PD-1/PD-L1为靶点的免疫检查点抑制剂在NSCLC中的临床研究进展展开综述。'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immunological checkpoint inhibitors '\n",
      "                                  'targeting PD-1/PD-L1 are benefcial to '\n",
      "                                  'patients, both in the frst-line and '\n",
      "                                  'second-line treatment of advanced NSCLC, in '\n",
      "                                  'the adjuvant treatment of locally-advanced '\n",
      "                                  'NSCLC, and in the neoadjuvant therapy of '\n",
      "                                  'early NSCLC, which show an important role '\n",
      "                                  'in the comprehensive treatment of NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35673884'],\n",
      " 'resourceScore': 67,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Compared with chemotherapy alone,PD-1/L1 or '\n",
      "                                  'CTLA-4 inhibitors alone or in combination '\n",
      "                                  '(PD-1/L1 + CTLA-4) had beenproved to be '\n",
      "                                  'capable to prolong OS in patients with '\n",
      "                                  'advanced or metastatic NSCLC[HR = .75, 95% '\n",
      "                                  'CI (.70-.80), P < .001], as being '\n",
      "                                  'detaillyshowed in Figure 2.PD-1/L1 or '\n",
      "                                  'CTLA-4 inhibitors alone or in combination '\n",
      "                                  'compared with chemotherapyalone could '\n",
      "                                  'improve OS of patients both in the first '\n",
      "                                  '[HR = .77, 95% CI(.70-.84)] and non-first '\n",
      "                                  'line treatment [HR = .74, 95% CI (.67-.81)] '\n",
      "                                  '(Table 2).'},\n",
      "                         {'dEnd': 284,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Among PD-1 [HR = .75, 95% CI(.61-.91)], '\n",
      "                                  'PD-L1 [HR = .94, 95% CI (.81-1.09)] and '\n",
      "                                  'PD-1/L1+CTLA-4 [HR = 1.05,95% CI '\n",
      "                                  '(.72-1.53)] inhibitors, only PD-1 has '\n",
      "                                  'showed a statistically '\n",
      "                                  'significantimprovement, comparing with '\n",
      "                                  'chemotherapy alone, in PFS in patients with '\n",
      "                                  'advancedor metastatic NSCLC (Table3).'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 208,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Herein, weinvestigated the efficacy and '\n",
      "                                  'safety of adding PD-1/L1 or CTLA-4 '\n",
      "                                  'inhibitors aloneand the combination '\n",
      "                                  '(PD-1/L1 + CTLA-4) compared with only '\n",
      "                                  'giving chemotherapy inpatients with '\n",
      "                                  'advanced or metastatic NSCLC.'},\n",
      "                         {'dEnd': 219,\n",
      "                          'dStart': 214,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'The resultssuggested that PD-1/L1 or CTLA-4 '\n",
      "                                  'inhibitors alone or in combination can '\n",
      "                                  'improve OSas well as PFS and these '\n",
      "                                  'advantageous outcomes are in relationship '\n",
      "                                  'with fewer AEs inpatients with advanced or '\n",
      "                                  'metastatic NSCLC compared to conventional '\n",
      "                                  'chemotherapy.The results also elucidated '\n",
      "                                  'that patients can benefit differently from '\n",
      "                                  'ICIsdepending on their disease subgroups.'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'However, in this research, PD-1/L1 orCTLA-4 '\n",
      "                                  'inhibitors alone or in combination seemed '\n",
      "                                  'to merit over chemotherapy alonenot only in '\n",
      "                                  'promoting survival time but also in '\n",
      "                                  'reducing drug AEs in NSCLC patients.To '\n",
      "                                  'conclude, patients with advanced or '\n",
      "                                  'metastatic NSCLC seem to benefit more '\n",
      "                                  'fromICIs compared to conventional '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 284,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Among PD-1 [HR = .75, 95% CI(.61-.91)], '\n",
      "                                  'PD-L1 [HR = .94, 95% CI (.81-1.09)] and '\n",
      "                                  'PD-1/L1+CTLA-4 [HR = 1.05,95% CI '\n",
      "                                  '(.72-1.53)] inhibitors, only PD-1 has '\n",
      "                                  'showed a statistically '\n",
      "                                  'significantimprovement, comparing with '\n",
      "                                  'chemotherapy alone, in PFS in patients with '\n",
      "                                  'advancedor metastatic NSCLC (Table3).'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'To sum up, PD-1/L1 or CTLA-4 inhibitors '\n",
      "                                  'alone or in combination have a '\n",
      "                                  'bettertherapeutic effect and fewer AEs than '\n",
      "                                  'conventional chemotherapy in patients '\n",
      "                                  'withadvanced or metastatic NSCLC.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'The benefit of PD-1/L1 or CTLA-4 '\n",
      "                                  'inhibitorsalone or in combination compared '\n",
      "                                  'with chemotherapy for advanced ormetastatic '\n",
      "                                  'NSCLC was elucidated in both OS [HR = .75, '\n",
      "                                  '95% CI (.70-.80),P < .001] and PFS [HR = '\n",
      "                                  '.83, 95% CI (.73-.95),P < .001].'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 208,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Herein, weinvestigated the efficacy and '\n",
      "                                  'safety of adding PD-1/L1 or CTLA-4 '\n",
      "                                  'inhibitors aloneand the combination '\n",
      "                                  '(PD-1/L1 + CTLA-4) compared with only '\n",
      "                                  'giving chemotherapy inpatients with '\n",
      "                                  'advanced or metastatic NSCLC.'},\n",
      "                         {'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'Compared with chemotherapy alone,PD-1/L1 or '\n",
      "                                  'CTLA-4 inhibitors alone or in combination '\n",
      "                                  '(PD-1/L1 + CTLA-4) had beenproved to be '\n",
      "                                  'capable to prolong OS in patients with '\n",
      "                                  'advanced or metastatic NSCLC[HR = .75, 95% '\n",
      "                                  'CI (.70-.80), P < .001], as being '\n",
      "                                  'detaillyshowed in Figure 2.PD-1/L1 or '\n",
      "                                  'CTLA-4 inhibitors alone or in combination '\n",
      "                                  'compared with chemotherapyalone could '\n",
      "                                  'improve OS of patients both in the first '\n",
      "                                  '[HR = .77, 95% CI(.70-.84)] and non-first '\n",
      "                                  'line treatment [HR = .74, 95% CI (.67-.81)] '\n",
      "                                  '(Table 2).'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/L1 With or Without CTLA-4 Inhibitors '\n",
      "                                  'Versus Chemotherapy in\\n'\n",
      "                                  'Advanced Non-Small Cell Lung Cancer'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/L1 or CTLA-4 inhibitors alone or in '\n",
      "                                  'combination, with fewer AEs, wasassociated '\n",
      "                                  'with significant improvements in terms of '\n",
      "                                  'OS and PFS thanchemotherapy in advanced or '\n",
      "                                  'metastatic NSCLC.'},\n",
      "                         {'dEnd': 212,\n",
      "                          'dStart': 207,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 121,\n",
      "                          'text': 'Herein, the meta-analysis was conducted to '\n",
      "                                  'evaluate the efficacy ofPD-1/L1 or CTLA-4 '\n",
      "                                  'inhibitors alone or in combination (PD-1/L1 '\n",
      "                                  '+ CTLA-4) vsconventional chemotherapy in '\n",
      "                                  'patients with advanced or metastatic NSCLC, '\n",
      "                                  'setting upPFS as and OS as primary '\n",
      "                                  'endpoints and AEs as secondary endpoints.'},\n",
      "                         {'dEnd': 257,\n",
      "                          'dStart': 252,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'However, in this research, PD-1/L1 orCTLA-4 '\n",
      "                                  'inhibitors alone or in combination seemed '\n",
      "                                  'to merit over chemotherapy alonenot only in '\n",
      "                                  'promoting survival time but also in '\n",
      "                                  'reducing drug AEs in NSCLC patients.To '\n",
      "                                  'conclude, patients with advanced or '\n",
      "                                  'metastatic NSCLC seem to benefit more '\n",
      "                                  'fromICIs compared to conventional '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 174,\n",
      "                          'dStart': 169,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'Similar to OS, giving PD-1/L1 or '\n",
      "                                  'CTLA-4inhibitors alone or in combination '\n",
      "                                  'resulted better in PFS than '\n",
      "                                  'applyingchemotherapy alone in patients with '\n",
      "                                  'advanced or metastatic NSCLC [HR = .83, '\n",
      "                                  '95%CI (.73-.95), P < .001] (detailed data '\n",
      "                                  'are shown in Figure 3).'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Previousstudies have shown that the effect '\n",
      "                                  'of PD-1 inhibitors and PD-L1 inhibitors '\n",
      "                                  'inimproving OS, in patients with NSCLC, are '\n",
      "                                  'similar.22 However, in this study, the '\n",
      "                                  'effects of the different inhibitors seemed '\n",
      "                                  'toresult differently in prognosis.'},\n",
      "                         {'dEnd': 284,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 142,\n",
      "                          'text': 'Among PD-1 [HR = .75, 95% CI(.61-.91)], '\n",
      "                                  'PD-L1 [HR = .94, 95% CI (.81-1.09)] and '\n",
      "                                  'PD-1/L1+CTLA-4 [HR = 1.05,95% CI '\n",
      "                                  '(.72-1.53)] inhibitors, only PD-1 has '\n",
      "                                  'showed a statistically '\n",
      "                                  'significantimprovement, comparing with '\n",
      "                                  'chemotherapy alone, in PFS in patients with '\n",
      "                                  'advancedor metastatic NSCLC (Table3).'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'Furthermore, in the study of Yixin Zhou,3 '\n",
      "                                  'PD-1/PD-L1 inhibitor plus chemotherapy, '\n",
      "                                  'compared with chemotherapy, hascontributed '\n",
      "                                  'to improved PFS and OS in first-line '\n",
      "                                  'therapy in NSCLC, but at theexpense of '\n",
      "                                  'increase in treatment-related AEs.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'We seemed to havereached the same '\n",
      "                                  'conclusion that PD-1 inhibitors are more '\n",
      "                                  'promising in treatingpatients with advanced '\n",
      "                                  'or metastatic NSCLC.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'No matter first-line or second-line '\n",
      "                                  'treatment for advanced or metastatic NSCLC, '\n",
      "                                  'thereare promising PD-1 inhibitors and '\n",
      "                                  'PD-L1 inhibitors in clinical treatment.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['33102221'],\n",
      " 'resourceScore': 67,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'The most common anti-PD-1/PD-L1-related '\n",
      "                                  'fatalities were from pneumonitis in a '\n",
      "                                  'meta-analysis predominantly consisting of '\n",
      "                                  'NSCLC and melanoma (40).'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Notably, in the IMMUNOTARGET study that '\n",
      "                                  'evaluated the efficacy of PD-1/L1 '\n",
      "                                  'inhibitors alone in patients with NSCLC '\n",
      "                                  'with driver gene mutations, none of the '\n",
      "                                  'twenty-three patients with ALK fusions had '\n",
      "                                  'a disease response (29).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'The clinical outcomes of PD-1 inhibitor '\n",
      "                                  'plus chemotherapy as second-line or later '\n",
      "                                  'therapy were similar to those of PD-1/PD-L1 '\n",
      "                                  'inhibitor alone in advanced NSCLC.'},\n",
      "                         {'dEnd': 248,\n",
      "                          'dStart': 243,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'In conclusion, our study suggested that the '\n",
      "                                  'addition of chemotherapy to PD-1 inhibitors '\n",
      "                                  'did not improve clinical outcomes compared '\n",
      "                                  'to monotherapy with PD-1/PD-L1 inhibitors '\n",
      "                                  'in second-line or later treatment settings '\n",
      "                                  'for patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Programmed death-1 (PD-1)/programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitor '\n",
      "                                  'monotherapy has been approved as '\n",
      "                                  'second-line or later therapy in advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Our study revealed that addition of '\n",
      "                                  'chemotherapy to PD-1 inhibitors did not '\n",
      "                                  'improve OS or PFS compared with PD-1/PD-L1 '\n",
      "                                  'inhibitor alone for NSCLC patients as '\n",
      "                                  'second-line and later therapy.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'The clinical data of patients with advanced '\n",
      "                                  'NSCLC who received PD-1/PD-L1 inhibitors as '\n",
      "                                  'second-line or later line therapy was '\n",
      "                                  'retrospectively collected.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'The clinical outcomes of PD-1 inhibitor '\n",
      "                                  'plus chemotherapy as second-line or later '\n",
      "                                  'therapy were similar to those of PD-1/PD-L1 '\n",
      "                                  'inhibitor alone in advanced NSCLC.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'Our study revealed that addition of '\n",
      "                                  'chemotherapy to PD-1 inhibitors did not '\n",
      "                                  'improve OS or PFS compared with PD-1/PD-L1 '\n",
      "                                  'inhibitor alone for NSCLC patients as '\n",
      "                                  'second-line and later therapy.'},\n",
      "                         {'dEnd': 62,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'However, in a retrospective analysis of 58 '\n",
      "                                  'patients with NSCLC treated with PD-1/PD-L1 '\n",
      "                                  'inhibitors, the response rate was 3.6% in '\n",
      "                                  'the EGFR mutation or ALK fusion subgroups '\n",
      "                                  'and 23.3% in the wild-type subgroups (27).'},\n",
      "                         {'dEnd': 170,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Programmed death-1 (PD-1)/programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitor '\n",
      "                                  'monotherapy has been approved as '\n",
      "                                  'second-line or later therapy in advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Therefore, we performed this retrospective '\n",
      "                                  'study to explore the clinical efficacy and '\n",
      "                                  'safety of second-line or later therapy with '\n",
      "                                  'PD-1/PD-L1 inhibitors plus chemotherapy in '\n",
      "                                  'advanced NSCLC patients and to compare the '\n",
      "                                  'clinical outcomes of PD-1/PD-L1 inhibitors '\n",
      "                                  'plus chemotherapy with PD-1/PD-L1 inhibitor '\n",
      "                                  'monotherapy as second-line or later therapy '\n",
      "                                  'further.'},\n",
      "                         {'dEnd': 248,\n",
      "                          'dStart': 243,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 155,\n",
      "                          'tStart': 151,\n",
      "                          'text': 'In conclusion, our study suggested that the '\n",
      "                                  'addition of chemotherapy to PD-1 inhibitors '\n",
      "                                  'did not improve clinical outcomes compared '\n",
      "                                  'to monotherapy with PD-1/PD-L1 inhibitors '\n",
      "                                  'in second-line or later treatment settings '\n",
      "                                  'for patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'In the study of pretreated patients with '\n",
      "                                  'NSCLC, the rates of hyperprogressive '\n",
      "                                  'disease (HPD) of patients receiving '\n",
      "                                  'PD-1/PD-L1 inhibitors and single-agent '\n",
      "                                  'chemotherapy were 13.8 and 5.1%, '\n",
      "                                  'respectively (23).'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'The study aimed to compare the clinical '\n",
      "                                  'outcomes of PD-1 inhibitor plus '\n",
      "                                  'chemotherapy with PD-1/PD-L1 inhibitor '\n",
      "                                  'monotherapy as second-line or later therapy '\n",
      "                                  'in advanced NSCLC.'},\n",
      "                         {'dEnd': 313,\n",
      "                          'dStart': 308,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 264,\n",
      "                          'tStart': 260,\n",
      "                          'text': 'In our study, the PFS of the monotherapy '\n",
      "                                  'group was longer than that of the '\n",
      "                                  'combination therapy group, which was '\n",
      "                                  'different from the result of a prior '\n",
      "                                  'retrospective analysis that compared the '\n",
      "                                  'efficacy of a PD-1 inhibitor plus '\n",
      "                                  'chemotherapy and/or bevacizumab and PD-1 '\n",
      "                                  'inhibitor alone for patients with advanced '\n",
      "                                  'NSCLC in second-line or later therapy '\n",
      "                                  '(25).'},\n",
      "                         {'dEnd': 313,\n",
      "                          'dStart': 308,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 208,\n",
      "                          'tStart': 204,\n",
      "                          'text': 'In our study, the PFS of the monotherapy '\n",
      "                                  'group was longer than that of the '\n",
      "                                  'combination therapy group, which was '\n",
      "                                  'different from the result of a prior '\n",
      "                                  'retrospective analysis that compared the '\n",
      "                                  'efficacy of a PD-1 inhibitor plus '\n",
      "                                  'chemotherapy and/or bevacizumab and PD-1 '\n",
      "                                  'inhibitor alone for patients with advanced '\n",
      "                                  'NSCLC in second-line or later therapy '\n",
      "                                  '(25).'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'Clinical Outcomes for PD-1 Inhibitor Plus '\n",
      "                                  'Chemotherapy as Second-Line or Later '\n",
      "                                  'Therapy Compared to PD-1/PD-L1 Inhibitor '\n",
      "                                  'Alone in Advanced Non-small-cell Lung '\n",
      "                                  'Cancer'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'The study aimed to compare the clinical '\n",
      "                                  'outcomes of PD-1 inhibitor plus '\n",
      "                                  'chemotherapy with PD-1/PD-L1 inhibitor '\n",
      "                                  'monotherapy as second-line or later therapy '\n",
      "                                  'in advanced NSCLC.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Clinical Outcomes for PD-1 Inhibitor Plus '\n",
      "                                  'Chemotherapy as Second-Line or Later '\n",
      "                                  'Therapy Compared to PD-1/PD-L1 Inhibitor '\n",
      "                                  'Alone in Advanced Non-small-cell Lung '\n",
      "                                  'Cancer'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'The total number of patients with stage '\n",
      "                                  'IIIB or IV or recurrent NSCLC who received '\n",
      "                                  'PD-1/PD-L1 inhibitor treatment was 121.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39164816'],\n",
      " 'resourceScore': 65,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 202,\n",
      "                          'tStart': 198,\n",
      "                          'text': 'Future clinical and translational research '\n",
      "                                  'will provide mechanistic insights into how '\n",
      "                                  'one or more variations in the 15-gene panel '\n",
      "                                  'can predict survival benefit of NSCLC '\n",
      "                                  'patients receiving first-line PD-1 blockade '\n",
      "                                  'plus chemotherapy.'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'Accordingly, we integrated clinical, '\n",
      "                                  'genomic, and survival data of 287 patients '\n",
      "                                  'with advanced NSCLC who received first-line '\n",
      "                                  'PD-1 blockade plus chemotherapy or '\n",
      "                                  'chemotherapy alone from five registered '\n",
      "                                  'trials and found that the 15-gene panel '\n",
      "                                  'could negatively predict the response to '\n",
      "                                  'PD-1 blockade plus chemotherapy in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'This study aimed to investigate the '\n",
      "                                  'predictors of PD-1 blockade plus '\n",
      "                                  'chemotherapy in untreated advanced NSCLC.'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'Taken together, these data highlight the '\n",
      "                                  'utility of the 15-gene panel and indicate '\n",
      "                                  'it to be a potential negative biomarker to '\n",
      "                                  'first-line PD-1 blockade plus chemotherapy, '\n",
      "                                  'but not chemotherapy alone, in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 130,\n",
      "                          'tStart': 126,\n",
      "                          'text': 'In this study, we integrated clinical, '\n",
      "                                  'genomic, and survival data of 287 patients '\n",
      "                                  'with advanced NSCLC who received first-line '\n",
      "                                  'PD-1 blockade plus chemotherapy or '\n",
      "                                  'chemotherapy alone as part of several '\n",
      "                                  'registered clinical trials in our center, '\n",
      "                                  'and investigated the negatively predictive '\n",
      "                                  'value of variations in certain genes to '\n",
      "                                  'PD-1 blockade plus chemotherapy.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'These findings indicate that a 15-gene '\n",
      "                                  'panel can serve as a negative prediction '\n",
      "                                  'biomarker for first-line PD-1 blockade plus '\n",
      "                                  'chemotherapy in patients with advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'Additionally, variation in at least two of '\n",
      "                                  '52 candidate genes was superior to TMB in '\n",
      "                                  'predicting the clinical benefits for PD-1 '\n",
      "                                  'blockade in patients with advanced '\n",
      "                                  'NSCLC.[35] Bai et al[36] developed a '\n",
      "                                  'genomic variation signature consisting of '\n",
      "                                  'eight genes that could predict the response '\n",
      "                                  'to anti-PD-(L)1 therapy in non-squamous '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Genomic correlates of the response to '\n",
      "                                  'first-line PD-1 blockade plus chemotherapy '\n",
      "                                  'in patients with advanced non-small-cell '\n",
      "                                  'lung cancer'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Programmed death 1 (PD-1) blockade plus '\n",
      "                                  'chemotherapy has become the new first-line '\n",
      "                                  'standard of care for patients with advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 225,\n",
      "                          'tStart': 221,\n",
      "                          'text': 'In summary, we suggest that one or more '\n",
      "                                  'variations in the 15-gene panel represents '\n",
      "                                  'a potential negative biomarker to predict '\n",
      "                                  'the treatment response and survival outcome '\n",
      "                                  'of patients with untreated advanced NSCLC '\n",
      "                                  'receiving PD-1 blockade plus chemotherapy.'},\n",
      "                         {'dEnd': 39,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'First, although a large cohort of NSCLC '\n",
      "                                  'patients treated with first-line PD-1 '\n",
      "                                  'blockade plus chemotherapy from clinical '\n",
      "                                  'trials was analyzed, this study was a '\n",
      "                                  'retrospective analysis and lacked an '\n",
      "                                  'independent validation cohort.'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'Baseline characteristics of all included '\n",
      "                                  'patients with advanced NSCLC who received '\n",
      "                                  'first-line PD-1 blockade plus chemotherapy '\n",
      "                                  'or chemotherapy alone from five registered '\n",
      "                                  'phase 3, randomized clinical trials.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Despite the obvious survival benefit of '\n",
      "                                  'PD-1 blockade plus chemotherapy in some '\n",
      "                                  'patients with untreated advanced NSCLC, '\n",
      "                                  'nearly half showed no response.'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Programmed death 1 (PD-1) blockade plus '\n",
      "                                  'chemotherapy has become the new first-line '\n",
      "                                  'standard of care for patients with advanced '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Hence, there is an urgent need to identify '\n",
      "                                  'reliable biomarkers to predict the response '\n",
      "                                  'to PD-1 blockade plus chemotherapy in '\n",
      "                                  'untreated advanced NSCLC.'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 140,\n",
      "                          'tStart': 136,\n",
      "                          'text': 'These findings indicate that combining the '\n",
      "                                  '15-gene panel and the PD-L1 expression '\n",
      "                                  'level could improve survival prediction of '\n",
      "                                  'first-line PD-1 blockade plus '\n",
      "                                  'chemotherapy-treated advanced NSCLC '\n",
      "                                  'patients [Figure 4C–F].'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'These results support the use of immune '\n",
      "                                  'infiltrates as a potential predictor for '\n",
      "                                  'PD-1 blockade plus chemotherapy in NSCLC.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Previous studies have investigated positive '\n",
      "                                  'predictive biomarkers for first-line PD-1 '\n",
      "                                  'blockade plus chemotherapy in NSCLC; '\n",
      "                                  'however, it is also important to identify '\n",
      "                                  'patients who cannot benefit from this '\n",
      "                                  'combination regimen.'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Patients with low-risk and positive PD-L1 '\n",
      "                                  'expression are most likely to benefit from '\n",
      "                                  'PD-1 blockade plus chemotherapy, '\n",
      "                                  'underscoring the rationale of using the '\n",
      "                                  '15-gene panel combined with PD-L1 '\n",
      "                                  'expression level in advanced NSCLC patients '\n",
      "                                  'treated with first-line PD-1 blockade plus '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'We integrated clinical, genomic, and '\n",
      "                                  'survival data from 287 patients with '\n",
      "                                  'untreated advanced NSCLC who were enrolled '\n",
      "                                  'in one of five registered phase 3 trials '\n",
      "                                  'and received PD-1 blockade plus '\n",
      "                                  'chemotherapy or chemotherapy alone.'},\n",
      "                         {'dEnd': 329,\n",
      "                          'dStart': 324,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 284,\n",
      "                          'tStart': 280,\n",
      "                          'text': 'Accordingly, we integrated clinical, '\n",
      "                                  'genomic, and survival data of 287 patients '\n",
      "                                  'with advanced NSCLC who received first-line '\n",
      "                                  'PD-1 blockade plus chemotherapy or '\n",
      "                                  'chemotherapy alone from five registered '\n",
      "                                  'trials and found that the 15-gene panel '\n",
      "                                  'could negatively predict the response to '\n",
      "                                  'PD-1 blockade plus chemotherapy in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 329,\n",
      "                          'dStart': 324,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'Accordingly, we integrated clinical, '\n",
      "                                  'genomic, and survival data of 287 patients '\n",
      "                                  'with advanced NSCLC who received first-line '\n",
      "                                  'PD-1 blockade plus chemotherapy or '\n",
      "                                  'chemotherapy alone from five registered '\n",
      "                                  'trials and found that the 15-gene panel '\n",
      "                                  'could negatively predict the response to '\n",
      "                                  'PD-1 blockade plus chemotherapy in advanced '\n",
      "                                  'NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38410222'],\n",
      " 'resourceScore': 65,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'The IMMUNOTARGET retrospective study '\n",
      "                                  'evaluating the efficacy of anti-PD-1 '\n",
      "                                  'monotherapy in NSCLC patients harboring '\n",
      "                                  'oncogenic alterations showed ORRs ranging '\n",
      "                                  'from 0% to 26%, with a median PFS of 2.8 '\n",
      "                                  'months (16).'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Despite the limitations above, our study '\n",
      "                                  'highlights the clinical benefits of '\n",
      "                                  'anti-PD-1 inhibitor-based combinational '\n",
      "                                  'therapy in NSCLC patients with oncogenic '\n",
      "                                  'mutations, in particular for those who '\n",
      "                                  'failed on standard or salvage therapy.'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1 inhibitor-based combinational '\n",
      "                                  'therapy elicited exciting anti-tumor '\n",
      "                                  'efficacy and prolonged patient survival '\n",
      "                                  'with manageable adverse effects in NSCLC '\n",
      "                                  'patients harboring oncogenic alterations.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'These lines of evidence prompted potential '\n",
      "                                  'application of PD-1/PD-L1 blockade therapy '\n",
      "                                  'in NSCLC patients harboring mutant '\n",
      "                                  'oncogenic genes, unfortunately, such data '\n",
      "                                  'in real world is lacking and increasing '\n",
      "                                  'cautions regarding the incidence of irAEs '\n",
      "                                  'in these patients have been raised.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'Accumulating evidence from clinical '\n",
      "                                  'practice indicates a favorable response in '\n",
      "                                  'NSCLC patients whose tumor possesses a high '\n",
      "                                  'level of PD-1/PD-L1 (6).'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Given that randomized controlled trials of '\n",
      "                                  'chemotherapy combined with PD-1 blockade '\n",
      "                                  'therapy for EGFR mutant NSCLC are still '\n",
      "                                  'ongoing (NCT02864251 and NCT03515837), the '\n",
      "                                  'screening of mutant subtypes of EGFR '\n",
      "                                  'alterations before the initiation of '\n",
      "                                  'immunotherapy would be essential.'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'In consistent with these notions, the '\n",
      "                                  'Orient-31 trail indicated that anti-PD-1 '\n",
      "                                  'treatment in combination with anti-VEGF '\n",
      "                                  'blockade therapy and chemotherapy yielded '\n",
      "                                  'an ORR of 43.9% and a mPFS of 6.9 months in '\n",
      "                                  'EGFR-mutated NSCLC patients after targeted '\n",
      "                                  'therapy, which was significantly higher '\n",
      "                                  'than that in the chemotherapy cohort (ORR: '\n",
      "                                  '25.2%, mPFS: 4.3 months) (14).'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'The IMMUNOTARGET study also elicited a '\n",
      "                                  'minimal clinical benefit of PD-1 inhibitors '\n",
      "                                  'monotherapy in NSCLC patients with RET '\n",
      "                                  'rearrangement, with an ORR of 6% (16).'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Interestingly, these oncogene-driven NSCLC '\n",
      "                                  'tends to be mutually exclusive for a '\n",
      "                                  'positive status of PD-1/PD-L1, and the '\n",
      "                                  'application of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy in NSCLC patients harboring '\n",
      "                                  'mutant driven genes remains controversial.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'The anti-programmed cell death 1 '\n",
      "                                  '(PD-1)/programmed cell death ligand 1 '\n",
      "                                  '(PD-L1) immunotherapy has been extensively '\n",
      "                                  'used in patients with non-small cell lung '\n",
      "                                  'cancer (NSCLC) in which the tumors are '\n",
      "                                  'negative for oncogenic alterations.'},\n",
      "                         {'dEnd': 48,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'In comparison to the pooled dataset of 431 '\n",
      "                                  'NSCLC patients treated with PD-1 /PD-L1 '\n",
      "                                  'inhibitor alone, which revealed mOS data '\n",
      "                                  'for the good (18.4 months), intermediate '\n",
      "                                  '(11.3 months), and poor LIPI (4.5 months) '\n",
      "                                  '(15), we reported here the mOS for LIPI =0 '\n",
      "                                  'and LIPI >0 groups extended to not reached '\n",
      "                                  'and 12 months, respectively.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'However, not all the patients benefit from '\n",
      "                                  'the PD-1/PD-L1 blockade immunotherapy, in '\n",
      "                                  'non-small cell lung cancer (NSCLC), the '\n",
      "                                  'objective response rate (ORR) of '\n",
      "                                  'anti-PD-1/PD-L1 monotherapy is '\n",
      "                                  'approximately 20% (4,5).'},\n",
      "                         {'dEnd': 42,\n",
      "                          'dStart': 37,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Interestingly, these oncogene-driven NSCLC '\n",
      "                                  'tends to be mutually exclusive for a '\n",
      "                                  'positive status of PD-1/PD-L1, and the '\n",
      "                                  'application of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy in NSCLC patients harboring '\n",
      "                                  'mutant driven genes remains controversial.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'In this retrospective study, we analyzed '\n",
      "                                  'the safety and efficacy of anti-PD-1 '\n",
      "                                  'inhibitor-based combinational therapy in a '\n",
      "                                  'NSCLC cohort of 84 patients who harbored '\n",
      "                                  'oncogenic alterations in epidermal growth '\n",
      "                                  'factor receptor (EGFR), anaplastic lymphoma '\n",
      "                                  'kinase (ALK), k-Ras, RET, HER2 and BRAF.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-programmed cell death 1 '\n",
      "                                  '(PD-1)/programmed cell death ligand 1 '\n",
      "                                  '(PD-L1) immunotherapy has been extensively '\n",
      "                                  'used in patients with non-small cell lung '\n",
      "                                  'cancer (NSCLC) in which the tumors are '\n",
      "                                  'negative for oncogenic alterations.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-programmed cell death 1 '\n",
      "                                  '(PD-1)/programmed cell death ligand 1 '\n",
      "                                  '(PD-L1) immunotherapy has been extensively '\n",
      "                                  'used in patients with non-small cell lung '\n",
      "                                  'cancer (NSCLC) in which the tumors are '\n",
      "                                  'negative for oncogenic alterations.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Interestingly, these oncogene-driven NSCLC '\n",
      "                                  'tends to be mutually exclusive for a '\n",
      "                                  'positive status of PD-1/PD-L1, and the '\n",
      "                                  'application of PD-1/PD-L1 blockade '\n",
      "                                  'immunotherapy in NSCLC patients harboring '\n",
      "                                  'mutant driven genes remains controversial.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'However, not all the patients benefit from '\n",
      "                                  'the PD-1/PD-L1 blockade immunotherapy, in '\n",
      "                                  'non-small cell lung cancer (NSCLC), the '\n",
      "                                  'objective response rate (ORR) of '\n",
      "                                  'anti-PD-1/PD-L1 monotherapy is '\n",
      "                                  'approximately 20% (4,5).'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'In this study, we evaluated therapeutic '\n",
      "                                  'outcomes of anti-PD-1-based combinational '\n",
      "                                  'therapy in NSCLC patients with oncogenic '\n",
      "                                  'mutations.'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'These findings raised concerns that LIPI '\n",
      "                                  'score may inversely confer therapeutic '\n",
      "                                  'response of PD-1 blockade-based '\n",
      "                                  'combinational therapy in NSCLC.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Our study also highlighted the predictive '\n",
      "                                  'value of PD-L1 expression for '\n",
      "                                  'anti-PD-1-based combinational therapy in '\n",
      "                                  'NSCLC harboring distinct genetic '\n",
      "                                  'alterations, as a high value of this '\n",
      "                                  'parameter is correlated with more '\n",
      "                                  'beneficial outcomes.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Our study also provides inspiring data '\n",
      "                                  'showing the safety and efficacy of '\n",
      "                                  'combining PD-1 blockade immunotherapy with '\n",
      "                                  'chemotherapy in NSCLC patients with '\n",
      "                                  'distinct genetic alterations.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'In this study, we evaluated the safety and '\n",
      "                                  'efficacy of anti-PD-1-based combinational '\n",
      "                                  'therapy in NSCLC patients with oncogenic '\n",
      "                                  'alterations and got inspiriting results.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'For example, pre-clinical evidence from '\n",
      "                                  'transgenetic engineered mouse model '\n",
      "                                  'indicates a higher response rate of '\n",
      "                                  'anti-PD-1 therapy in EGFR mutant NSCLC '\n",
      "                                  '(11).'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'Bodor and colleagues recently reported the '\n",
      "                                  'real world PFS data of anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy from a NSCLC cohort of 1,746 '\n",
      "                                  'patients with EGFR, ALK, BRAF, and k-Ras '\n",
      "                                  'mutations.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 156,\n",
      "                          'tStart': 152,\n",
      "                          'text': 'To our knowledge, our study is the first to '\n",
      "                                  'explore the significance of LIPI in NSCLC '\n",
      "                                  'patients harboring a panel of oncogenic '\n",
      "                                  'alterations and receiving PD-1 '\n",
      "                                  'blockade-based combinational therapy.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'The anti-programmed cell death 1 '\n",
      "                                  '(PD-1)/programmed cell death ligand 1 '\n",
      "                                  '(PD-L1) immunotherapy has been extensively '\n",
      "                                  'used in patients with non-small cell lung '\n",
      "                                  'cancer (NSCLC) in which the tumors are '\n",
      "                                  'negative for oncogenic alterations.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'The safety and efficacy of anti-PD-1 '\n",
      "                                  'inhibitor-based combinational therapy in '\n",
      "                                  'non-small cell lung cancer patients with '\n",
      "                                  'oncogenic alterations'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'However, whether LIPI could be used to '\n",
      "                                  'predict the response to PD-1 blockade-based '\n",
      "                                  'combinational therapy in NSCLC patients '\n",
      "                                  'with oncogenic mutations remains elusive.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'As such, it would be reasonable to believe '\n",
      "                                  'the front-line combinational treatment '\n",
      "                                  'might be more suitable than posterior-line '\n",
      "                                  'PD-1/PD-L1 blockade monotherapy for NSCLC '\n",
      "                                  'patients with RET alterations, or with '\n",
      "                                  'other oncogenic mutations.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35800365'],\n",
      " 'resourceScore': 65,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 243,\n",
      "                          'dStart': 238,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 220,\n",
      "                          'tStart': 216,\n",
      "                          'text': 'We determined that hsa_circ_0020714 was '\n",
      "                                  'upregulated in NSCLC tissues compared with '\n",
      "                                  'paired adjacent nontumor tissues, and '\n",
      "                                  'forced hsa_circ_0020714 expression was '\n",
      "                                  'associated with a poor prognosis and '\n",
      "                                  'resistance to anti-PD-1 immunotherapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Recent evidence suggests a critical role '\n",
      "                                  'for anti-programmed death-1 (anti-PD-1) '\n",
      "                                  'immunotherapy in driver gene negative '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 220,\n",
      "                          'tStart': 216,\n",
      "                          'text': 'We determined that hsa_circ_0020714 was '\n",
      "                                  'upregulated in NSCLC tissues compared with '\n",
      "                                  'paired adjacent nontumor tissues, and '\n",
      "                                  'forced hsa_circ_0020714 expression was '\n",
      "                                  'associated with a poor prognosis and '\n",
      "                                  'resistance to anti-PD-1 immunotherapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Conclusion: Hsa_circ_0020714 induces the '\n",
      "                                  'immune evasion and resistance to anti-PD-1 '\n",
      "                                  'immunotherapy of NSCLC via the '\n",
      "                                  'miR-30a-5p/SOX4 axis, and may be an '\n",
      "                                  'promising immunotherapeutic target in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Functionally, knockdown and overexpression '\n",
      "                                  'experiments indicated that hsa_circ_0020714 '\n",
      "                                  'regulates the sensitivity of NSCLC to '\n",
      "                                  'anti-PD-1 immunotherapy.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 152,\n",
      "                          'tStart': 148,\n",
      "                          'text': 'Mechanistically, hsa_circ_0020714 functions '\n",
      "                                  'as an endogenous miR-30a-5p sponge to '\n",
      "                                  'enhance SOX4 expression, subsequently '\n",
      "                                  'inducing resistance to anti-PD-1 '\n",
      "                                  'immunotherapy in NSCLC patients.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 144,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'Increasingly studies have verified that '\n",
      "                                  'dysregulated circRNAs expression play '\n",
      "                                  'critical roles in NSCLC immune evasion and '\n",
      "                                  'resistance to anti-PD-1 immunotherapy.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'For example, our previous study '\n",
      "                                  'demonstrated that forced circFGFR1 promotes '\n",
      "                                  'resistance to anti-PD-1 treatment in NSCLC '\n",
      "                                  'immunotherapy via sponging miR-381-3p to '\n",
      "                                  'upregulate the expression of C-X-C motif '\n",
      "                                  'chemokine receptor 4[8].'},\n",
      "                         {'dEnd': 173,\n",
      "                          'dStart': 168,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'Mechanistically, hsa_circ_0020714 functions '\n",
      "                                  'as an endogenous miR-30a-5p sponge to '\n",
      "                                  'enhance SOX4 expression, thereby promoting '\n",
      "                                  'immune evasion and anti-PD-1 resistance in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'These results showed that hsa_circ_0020714 '\n",
      "                                  'likely participates in the immune evasion '\n",
      "                                  'and resistance to anti-PD-1 immunotherapy '\n",
      "                                  'of NSCLC.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Conclusion: Hsa_circ_0020714 induces the '\n",
      "                                  'immune evasion and resistance to anti-PD-1 '\n",
      "                                  'immunotherapy of NSCLC via the '\n",
      "                                  'miR-30a-5p/SOX4 axis, and may be an '\n",
      "                                  'promising immunotherapeutic target in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Although anti-PD-1 immunotherapy has '\n",
      "                                  'improved the prognosis of patients with '\n",
      "                                  'advanced NSCLC, a larger proportion of '\n",
      "                                  'patients still did not respond to anti-PD-1 '\n",
      "                                  'therapy due to primary or secondary '\n",
      "                                  'resistance and failed to demonstrate '\n",
      "                                  'clinically effective responses[3,4].'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Higher levels of hsa_circ_0020714 '\n",
      "                                  'expression is correlated with resistance to '\n",
      "                                  'anti-PD-1 therapy in NSCLC patients'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'In vivo experiments were executed to '\n",
      "                                  'investigate the biological function of '\n",
      "                                  'hsa_circ_0020714 in the sensitivity of '\n",
      "                                  'NSCLC to anti-PD-1 immunotherapy.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'Therefore, blocking the '\n",
      "                                  'hsa_circ_0020714/miR-30a-5p/SOX4-related '\n",
      "                                  'pathway may effectively reverse resistance '\n",
      "                                  'to anti-PD-1-based immunotherapy in NSCLC.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Circular RNA drives resistance to anti-PD-1 '\n",
      "                                  'immunotherapy by regulating the '\n",
      "                                  'miR-30a-5p/SOX4 axis in non-small cell lung '\n",
      "                                  'cancer'},\n",
      "                         {'dEnd': 290,\n",
      "                          'dStart': 285,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 253,\n",
      "                          'tStart': 249,\n",
      "                          'text': 'Results: The expression of hsa_circ_0020714 '\n",
      "                                  'was upregulated in NSCLC tissues compared '\n",
      "                                  'to the paired adjacent non-tumor tissues, '\n",
      "                                  'and an increased expression of '\n",
      "                                  'hsa_circ_0020714 was significantly '\n",
      "                                  'associated with a bad prognosis and '\n",
      "                                  'resistance to anti-PD-1 immunotherapy in '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 253,\n",
      "                          'tStart': 249,\n",
      "                          'text': 'Results: The expression of hsa_circ_0020714 '\n",
      "                                  'was upregulated in NSCLC tissues compared '\n",
      "                                  'to the paired adjacent non-tumor tissues, '\n",
      "                                  'and an increased expression of '\n",
      "                                  'hsa_circ_0020714 was significantly '\n",
      "                                  'associated with a bad prognosis and '\n",
      "                                  'resistance to anti-PD-1 immunotherapy in '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'Here, we elucidated the function and '\n",
      "                                  'molecular mechanism of hsa_circ_0020714 in '\n",
      "                                  'promoting the resistance to anti-PD-1 '\n",
      "                                  'immunotherapy of NSCLC.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 193,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'Then, we analyzed retrospective data from '\n",
      "                                  '42 NSCLC patients (29 cases of lung '\n",
      "                                  'adenocarcinoma and 13 cases of lung '\n",
      "                                  'squamous cell carcinoma) with relapse or '\n",
      "                                  'distant metastasis receiving anti-PD-1 '\n",
      "                                  'immunotherapy.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37353805'],\n",
      " 'resourceScore': 65,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 169,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Without the clear immunophenotyping of '\n",
      "                                  'brain metastases (BrMs), the optimal '\n",
      "                                  'treatment strategy based on PD-1/PD-L1 '\n",
      "                                  'inhibitor for patients with non-small-cell '\n",
      "                                  'lung cancer (NSCLC) and BrMs remains '\n",
      "                                  'unknown.'},\n",
      "                         {'dEnd': 173,\n",
      "                          'dStart': 168,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Several clinical trials suggested that '\n",
      "                                  'PD-1/PD-L1 inhibitor plus chemotherapy '\n",
      "                                  'and/or antiangiogenic therapy could '\n",
      "                                  'dramatically prolong both PFS and OS in '\n",
      "                                  'patients with NSCLC [13–15].'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'PD-1/PD-L1 inhibitor plus antiangiogenic '\n",
      "                                  'therapy may be one of the promising '\n",
      "                                  'therapeutic options for patients with NSCLC '\n",
      "                                  'and BrMs.'},\n",
      "                         {'dEnd': 375,\n",
      "                          'dStart': 370,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 258,\n",
      "                          'tStart': 254,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'BrMs of NSCLC possessed an '\n",
      "                                  'immunosuppressive TIME; anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy showed limited antitumor '\n",
      "                                  'efficacy in patients with NSCLC and BrMs; '\n",
      "                                  'the anti-PD-1/PD-L1 based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could be an '\n",
      "                                  'alternative and effective treatment option '\n",
      "                                  'for patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 5,\n",
      "                          'dStart': 0,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'NSCLC with BrMs obtained barely '\n",
      "                                  'satisfactory overall benefit from '\n",
      "                                  'anti-PD-1/PD-L1 monotherapy, partly due to '\n",
      "                                  'its immunosuppressive TIME.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'Even some studies indicated that the '\n",
      "                                  'presence of BrMs was correlated with '\n",
      "                                  'inferior survival in patients with NSCLC '\n",
      "                                  'received anti-PD-1/PD-L1 monotherapy [11, '\n",
      "                                  '12], suggesting an unmet treatment need for '\n",
      "                                  'these populations.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'BrMs of NSCLC possessed an '\n",
      "                                  'immunosuppressive TIME; anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy showed limited antitumor '\n",
      "                                  'efficacy in patients with NSCLC and BrMs; '\n",
      "                                  'the anti-PD-1/PD-L1 based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could be an '\n",
      "                                  'alternative and effective treatment option '\n",
      "                                  'for patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 56,\n",
      "                          'dStart': 51,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'BrMs of NSCLC possessed an '\n",
      "                                  'immunosuppressive TIME; anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy showed limited antitumor '\n",
      "                                  'efficacy in patients with NSCLC and BrMs; '\n",
      "                                  'the anti-PD-1/PD-L1 based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could be an '\n",
      "                                  'alternative and effective treatment option '\n",
      "                                  'for patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 121,\n",
      "                          'text': 'In summary, the current study suggests that '\n",
      "                                  'NSCLC with BrMs could obtain barely '\n",
      "                                  'satisfactory treatment benefit from '\n",
      "                                  'anti-PD-1/PD-L1 monotherapy, partly due to '\n",
      "                                  'the specific immunosuppressive TIME of '\n",
      "                                  'BrMs.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'To date, PD-1/PD-L1 inhibitors monotherapy '\n",
      "                                  'or plus chemotherapy have become the new '\n",
      "                                  'standard of care for patients with NSCLC '\n",
      "                                  'without driver gene alterations in '\n",
      "                                  'first-line setting.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Thus, whether anti-PD-1/PD-L1 based '\n",
      "                                  'combination treatments could show better '\n",
      "                                  'efficacy than anti-PD-1/PD-L1 monotherapy '\n",
      "                                  'in NSCLC patients with less-selected BrMs '\n",
      "                                  'remains unknown.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitor-based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could '\n",
      "                                  'significantly improve the clinical outcomes '\n",
      "                                  'of patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': '719 patients with metastatic or advanced '\n",
      "                                  'NSCLC treated with PD-1/PD-L1 '\n",
      "                                  'inhibitor-based treatments were initially '\n",
      "                                  'identified.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Thus, whether anti-PD-1/PD-L1 based '\n",
      "                                  'combination treatments could show better '\n",
      "                                  'efficacy than anti-PD-1/PD-L1 monotherapy '\n",
      "                                  'in NSCLC patients with less-selected BrMs '\n",
      "                                  'remains unknown.'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': 'Collectively, BrMs presence showed limited '\n",
      "                                  'impact on the efficacy of '\n",
      "                                  'anti-PD-1/PD-L1based combination therapy '\n",
      "                                  'but the impact of BrMs presence on efficacy '\n",
      "                                  'of anti-PD-1/PD-L1monotherapy in NSCLC '\n",
      "                                  'still remains undetermined.'},\n",
      "                         {'dEnd': 263,\n",
      "                          'dStart': 258,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'Here, we performed this multicenter '\n",
      "                                  'retrospective study to investigate the '\n",
      "                                  'impact of BrMs on the efficacy of ICI based '\n",
      "                                  'treatments in NSCLC, and the outcome '\n",
      "                                  'differences between PD-1/PD-L1 '\n",
      "                                  'inhibitor-based monotherapy and combination '\n",
      "                                  'therapies in patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 23,\n",
      "                          'dStart': 18,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': '308 patients with NSCLC received PD-1/PD-L1 '\n",
      "                                  'inhibitor-based monotherapy or combination '\n",
      "                                  'therapy were retrospectively identified.'},\n",
      "                         {'dEnd': 375,\n",
      "                          'dStart': 370,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'BrMs of NSCLC possessed an '\n",
      "                                  'immunosuppressive TIME; anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy showed limited antitumor '\n",
      "                                  'efficacy in patients with NSCLC and BrMs; '\n",
      "                                  'the anti-PD-1/PD-L1 based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could be an '\n",
      "                                  'alternative and effective treatment option '\n",
      "                                  'for patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Outcome differences between PD-1/PD-L1 '\n",
      "                                  'inhibitors-based monotherapy and '\n",
      "                                  'combination treatments in NSCLC with brain '\n",
      "                                  'metastases'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Without the clear immunophenotyping of '\n",
      "                                  'brain metastases (BrMs), the optimal '\n",
      "                                  'treatment strategy based on PD-1/PD-L1 '\n",
      "                                  'inhibitor for patients with non-small-cell '\n",
      "                                  'lung cancer (NSCLC) and BrMs remains '\n",
      "                                  'unknown.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'Here, we performed this multicenter '\n",
      "                                  'retrospective study to investigate the '\n",
      "                                  'impact of BrMs on the efficacy of ICI based '\n",
      "                                  'treatments in NSCLC, and the outcome '\n",
      "                                  'differences between PD-1/PD-L1 '\n",
      "                                  'inhibitor-based monotherapy and combination '\n",
      "                                  'therapies in patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Collectively, BrMs presence showed limited '\n",
      "                                  'impact on the efficacy of '\n",
      "                                  'anti-PD-1/PD-L1based combination therapy '\n",
      "                                  'but the impact of BrMs presence on efficacy '\n",
      "                                  'of anti-PD-1/PD-L1monotherapy in NSCLC '\n",
      "                                  'still remains undetermined.'},\n",
      "                         {'dEnd': 375,\n",
      "                          'dStart': 370,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 202,\n",
      "                          'tStart': 198,\n",
      "                          'text': 'Collectively, these findings indicate that '\n",
      "                                  'BrMs of NSCLC possessed an '\n",
      "                                  'immunosuppressive TIME; anti-PD-1/PD-L1 '\n",
      "                                  'monotherapy showed limited antitumor '\n",
      "                                  'efficacy in patients with NSCLC and BrMs; '\n",
      "                                  'the anti-PD-1/PD-L1 based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could be an '\n",
      "                                  'alternative and effective treatment option '\n",
      "                                  'for patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'In this study, 308 patients with '\n",
      "                                  'anti-PD-1/PD-L1 treated metastatic or '\n",
      "                                  'advanced NSCLC were included and 83 (26.9%) '\n",
      "                                  'of them had BrMs.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1/PD-L1 based combination therapy '\n",
      "                                  'could significantly improve the clinical '\n",
      "                                  'outcomes of patients with NSCLC and BrMs.'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'including programmed cell death 1 (PD-1) '\n",
      "                                  'and its ligand (PD-L1) inhibitors have '\n",
      "                                  'significantly improved the prognosis and '\n",
      "                                  'shifted the treatment paradigm in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'More recently, several clinical trials '\n",
      "                                  'demonstrated that PD-1/PD-L1 inhibitors '\n",
      "                                  'plus chemotherapy and/or antiangiogenic '\n",
      "                                  'therapy could significantly prolong '\n",
      "                                  'progression-free and overall survival (PFS '\n",
      "                                  'and OS) in patients with advanced or '\n",
      "                                  'metastatic NSCLC [13–15].'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'including programmed cell death 1 (PD-1) '\n",
      "                                  'and its ligand (PD-L1) inhibitors have '\n",
      "                                  'significantly improved the prognosis and '\n",
      "                                  'shifted the treatment paradigm in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'PD-1/PD-L1 inhibitor-based combination '\n",
      "                                  'treatment, especially anti-PD-1/PD-L1 plus '\n",
      "                                  'anti-angiogenic treatment, could '\n",
      "                                  'significantly improve the clinical outcomes '\n",
      "                                  'of patients with NSCLC and BrMs.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39891730'],\n",
      " 'resourceScore': 64,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Herein, the current study had two moderate '\n",
      "                                  'novelties: (i) PD-1 blockade plus '\n",
      "                                  'chemotherapy was superior PD-1 blockade '\n",
      "                                  'monotherapy in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC; (ii) NSCLC '\n",
      "                                  'patients with rare driver gene alterations '\n",
      "                                  'including HER2, RET and BRAF could also '\n",
      "                                  'benefit from PD-1 blockade plus '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'In summary, the present study reported that '\n",
      "                                  'PD-1 blockade plus chemotherapy showed '\n",
      "                                  'superior efficacy than PD-1 blockade '\n",
      "                                  'monotherapy or chemotherapy alone in '\n",
      "                                  'several patients with oncogenic-driven '\n",
      "                                  'advanced NSCLC, particularly in KRAS, EGFR '\n",
      "                                  'and BRAF subgroups.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'To date, PD-1 blockade in combination with '\n",
      "                                  'platinum-based chemotherapy has become the '\n",
      "                                  'new first-line standard of care for '\n",
      "                                  'patients with advanced NSCLC without '\n",
      "                                  'actionable oncogenic drivers [15].'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Herein, the current study had two moderate '\n",
      "                                  'novelties: (i) PD-1 blockade plus '\n",
      "                                  'chemotherapy was superior PD-1 blockade '\n",
      "                                  'monotherapy in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC; (ii) NSCLC '\n",
      "                                  'patients with rare driver gene alterations '\n",
      "                                  'including HER2, RET and BRAF could also '\n",
      "                                  'benefit from PD-1 blockade plus '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Our main findings showed that PD-1 blockade '\n",
      "                                  'plus chemotherapy showed superior efficacy '\n",
      "                                  'than PD-1 blockade monotherapy or '\n",
      "                                  'chemotherapy alone in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC, '\n",
      "                                  'particularly in KRAS, EGFR and BRAF '\n",
      "                                  'subgroup.'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 21,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Three hundred twelve NSCLC patients with at '\n",
      "                                  'least one oncogenic driver alteration '\n",
      "                                  'received PD-1 plus chemotherapy or each '\n",
      "                                  'monotherapy were retrospectively '\n",
      "                                  'identified.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Our main findings showed that PD-1 blockade '\n",
      "                                  'plus chemotherapy showed superior efficacy '\n",
      "                                  'than PD-1 blockade monotherapy or '\n",
      "                                  'chemotherapy alone in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC, '\n",
      "                                  'particularly in KRAS, EGFR and BRAF '\n",
      "                                  'subgroup.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'PD-1 blockade plus chemotherapy '\n",
      "                                  'demonstrated superior efficacy than PD-1 '\n",
      "                                  'blockade monotherapy or chemotherapy alone '\n",
      "                                  'in patients with oncogenic-driven advanced '\n",
      "                                  'NSCLC, particularly in KRAS, EGFR and BRAF '\n",
      "                                  'subgroups.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'Here, we conducted this retrospective '\n",
      "                                  'analysis and aimed to investigate the '\n",
      "                                  'efficacy of PD-1 blockade plus chemotherapy '\n",
      "                                  'in patients with oncogenic-driven NSCLC.'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'Herein, the current study had two moderate '\n",
      "                                  'novelties: (i) PD-1 blockade plus '\n",
      "                                  'chemotherapy was superior PD-1 blockade '\n",
      "                                  'monotherapy in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC; (ii) NSCLC '\n",
      "                                  'patients with rare driver gene alterations '\n",
      "                                  'including HER2, RET and BRAF could also '\n",
      "                                  'benefit from PD-1 blockade plus '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting the programmed death-1 (PD-1) and '\n",
      "                                  'its ligand (PD-L1) axis have emerged as a '\n",
      "                                  'significant advance in NSCLC, yielding '\n",
      "                                  'durable responses in approximately 10–15% '\n",
      "                                  'of patients with advanced-stage disease [8, '\n",
      "                                  '9].'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 210,\n",
      "                          'tStart': 206,\n",
      "                          'text': 'The largest retrospective study on this '\n",
      "                                  'field, named IMMUNOTARGET, identified 551 '\n",
      "                                  'patients with advanced NSCLC and molecular '\n",
      "                                  'alterations across 24 centers in 10 '\n",
      "                                  'countries and observed limited efficacy '\n",
      "                                  'with PD-1 blockade monotherapy in patients '\n",
      "                                  'with oncogene-driven NSCLC [14].'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'In this real-world study, we identified 312 '\n",
      "                                  'patients with at least one oncogenic driver '\n",
      "                                  'alteration NSCLC receiving PD-1 plus '\n",
      "                                  'chemotherapy or each monotherapy.'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 202,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Several elegant clinical trials such as '\n",
      "                                  'CheckMate-057 and KEYNOTE-010 reported that '\n",
      "                                  'PD-1 blockade showed similar efficacy to '\n",
      "                                  'chemotherapy as second or above-line '\n",
      "                                  'treatment for patients with EGFR-mutant '\n",
      "                                  'NSCLC [10–12].'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'We firstly identified a total of 382 '\n",
      "                                  'patients with advanced NSCLC and oncogenic '\n",
      "                                  'drivers who received PD-1 blockade '\n",
      "                                  'monotherapy, chemotherapy alone or PD-1 '\n",
      "                                  'blockade plus chemotherapy (Fig. 1A).'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Oncogenic-driven advanced NSCLC showed '\n",
      "                                  'limited response to PD-1 blockade '\n",
      "                                  'monotherapy or chemotherapy alone.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 blockade plus chemotherapy has become '\n",
      "                                  'the first-line standard of care for '\n",
      "                                  'patients with advanced non-small-cell lung '\n",
      "                                  'cancer (NSCLC) without oncogenic drivers.'},\n",
      "                         {'dEnd': 164,\n",
      "                          'dStart': 159,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 blockade plus chemotherapy '\n",
      "                                  'demonstrated superior efficacy than PD-1 '\n",
      "                                  'blockade monotherapy or chemotherapy alone '\n",
      "                                  'in patients with oncogenic-driven advanced '\n",
      "                                  'NSCLC, particularly in KRAS, EGFR and BRAF '\n",
      "                                  'subgroups.'},\n",
      "                         {'dEnd': 86,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'Nevertheless, most of these trials did not '\n",
      "                                  'include patients with oncogene-driven NSCLC '\n",
      "                                  'and whether these patients could benefit '\n",
      "                                  'from PD-1 blockade plus chemotherapy '\n",
      "                                  'remains undetermined.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'The incorporation of platinum-based '\n",
      "                                  'chemotherapy into PD-1 blockade has been '\n",
      "                                  'demonstrated to broaden the potential for '\n",
      "                                  'immunotherapy benefits to a wider '\n",
      "                                  'population of NSCLC patients without '\n",
      "                                  'oncogenic driver alterations [31].'},\n",
      "                         {'dEnd': 289,\n",
      "                          'dStart': 284,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'A series of phase 3 randomized clinical '\n",
      "                                  'trials have demonstrated that first-line '\n",
      "                                  'PD-1 blockade plus chemotherapy could '\n",
      "                                  'markedly improve the objective response '\n",
      "                                  'rate (ORR), progression-free survival '\n",
      "                                  '(PFS), and/or overall survival (OS) '\n",
      "                                  'compared with traditional chemotherapy in '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'Herein, the current study had two moderate '\n",
      "                                  'novelties: (i) PD-1 blockade plus '\n",
      "                                  'chemotherapy was superior PD-1 blockade '\n",
      "                                  'monotherapy in patients with '\n",
      "                                  'oncogenic-driven advanced NSCLC; (ii) NSCLC '\n",
      "                                  'patients with rare driver gene alterations '\n",
      "                                  'including HER2, RET and BRAF could also '\n",
      "                                  'benefit from PD-1 blockade plus '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 13,\n",
      "                          'dStart': 8,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Whether NSCLC patients with oncogenic '\n",
      "                                  'drivers could benefit from PD-1 blockade '\n",
      "                                  'plus chemotherapy remains undetermined.'},\n",
      "                         {'dEnd': 270,\n",
      "                          'dStart': 265,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 210,\n",
      "                          'tStart': 206,\n",
      "                          'text': 'The largest retrospective study on this '\n",
      "                                  'field, named IMMUNOTARGET, identified 551 '\n",
      "                                  'patients with advanced NSCLC and molecular '\n",
      "                                  'alterations across 24 centers in 10 '\n",
      "                                  'countries and observed limited efficacy '\n",
      "                                  'with PD-1 blockade monotherapy in patients '\n",
      "                                  'with oncogene-driven NSCLC [14].'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Several elegant clinical trials and '\n",
      "                                  'retrospective studies reported limited '\n",
      "                                  'efficacy of PD-1 blockade monotherapy in '\n",
      "                                  'patients with oncogene-driven NSCLC '\n",
      "                                  '[10–12].'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 blockade plus chemotherapy has become '\n",
      "                                  'the first-line standard of care for '\n",
      "                                  'patients with advanced non-small-cell lung '\n",
      "                                  'cancer (NSCLC) without oncogenic drivers.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'In summary, the present study reported that '\n",
      "                                  'PD-1 blockade plus chemotherapy showed '\n",
      "                                  'superior efficacy than PD-1 blockade '\n",
      "                                  'monotherapy or chemotherapy alone in '\n",
      "                                  'several patients with oncogenic-driven '\n",
      "                                  'advanced NSCLC, particularly in KRAS, EGFR '\n",
      "                                  'and BRAF subgroups.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 16,\n",
      "                          'tStart': 12,\n",
      "                          'text': 'Efficacy of PD-1 blockade plus chemotherapy '\n",
      "                                  'in patients with oncogenic-driven '\n",
      "                                  'non-small-cell lung cancer'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32581056'],\n",
      " 'resourceScore': 64,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 354,\n",
      "                          'dStart': 349,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 268,\n",
      "                          'tStart': 264,\n",
      "                          'text': 'Many reviews indicated that XRT could '\n",
      "                                  'increase the treatment efficacy of '\n",
      "                                  'immunotherapy by reprogramming tumor '\n",
      "                                  'microenvironment.19 20 Our previous study '\n",
      "                                  'showed that XRT could induce type I IFN '\n",
      "                                  'production, upregulated MHC-I expression, '\n",
      "                                  'and restored response to anti-PD-1 in our '\n",
      "                                  'anti-PD-1-resistant model.9 Although XRT '\n",
      "                                  'can overcome PD-1 resistance in NSCLC,21–24 '\n",
      "                                  'XRT seems to be a double-edged sword to the '\n",
      "                                  'immune system.'},\n",
      "                         {'dEnd': 354,\n",
      "                          'dStart': 349,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 285,\n",
      "                          'tStart': 281,\n",
      "                          'text': 'Many reviews indicated that XRT could '\n",
      "                                  'increase the treatment efficacy of '\n",
      "                                  'immunotherapy by reprogramming tumor '\n",
      "                                  'microenvironment.19 20 Our previous study '\n",
      "                                  'showed that XRT could induce type I IFN '\n",
      "                                  'production, upregulated MHC-I expression, '\n",
      "                                  'and restored response to anti-PD-1 in our '\n",
      "                                  'anti-PD-1-resistant model.9 Although XRT '\n",
      "                                  'can overcome PD-1 resistance in NSCLC,21–24 '\n",
      "                                  'XRT seems to be a double-edged sword to the '\n",
      "                                  'immune system.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Moreover, the combination of XRT, '\n",
      "                                  'anti-PD-1, and OXPHOS inhibition represents '\n",
      "                                  'a promising approach to promote abscopal '\n",
      "                                  'responses in PD-1-resistant NSCLC.'},\n",
      "                         {'dEnd': 440,\n",
      "                          'dStart': 435,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 409,\n",
      "                          'tStart': 405,\n",
      "                          'text': 'However, recent studies indicate that '\n",
      "                                  'mitochondrial OXPHOS is not impaired, but '\n",
      "                                  'also more activated.1 Others have '\n",
      "                                  'demonstrated that mitochondrial OXPHOS '\n",
      "                                  'could be a target for cancer treatment and '\n",
      "                                  'enhancement of immunotherapy outcomes, '\n",
      "                                  'which currently remain low in metastatic '\n",
      "                                  'non-small cell lung cancer (NSCLC).2 3 '\n",
      "                                  'Therefore, it is valuable to explore if '\n",
      "                                  'inhibition of mitochondrial OXPHOS could '\n",
      "                                  'overcome PD-1 resistance in metastatic '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'Moreover, the combination of XRT, '\n",
      "                                  'anti-PD-1, and OXPHOS inhibition represents '\n",
      "                                  'a promising approach to promote abscopal '\n",
      "                                  'responses in PD-1-resistant NSCLC.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Thus, we explored the effect of the novel '\n",
      "                                  'OXPHOS inhibitor IACS-010759 on '\n",
      "                                  'PD-1-resistant NSCLC in an effort to '\n",
      "                                  'overcome XRT-induced immunosuppression and '\n",
      "                                  'maximize response to PD-1.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'In the current study, our goals are to '\n",
      "                                  'assess differential metabolic parameters in '\n",
      "                                  'PD-1-sensitive and PD-1-resistant NSCLC '\n",
      "                                  'models, evaluate the combined effect of XRT '\n",
      "                                  'and IACS-010759 in both models, explore the '\n",
      "                                  'effect of combination therapy on abscopal '\n",
      "                                  'responses, and provide mechanistic insight '\n",
      "                                  'into these observations.'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'For in vivo experiments, we treated '\n",
      "                                  '129Sv/Ev mice with anti-PD1-sensitive and '\n",
      "                                  'anti-PD1-resistant 344SQ NSCLC '\n",
      "                                  'adenocarcinoma xenografts with oral '\n",
      "                                  'IACS-010759 combined with radiotherapy '\n",
      "                                  '(XRT).'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'Taken together, in addition to having '\n",
      "                                  'higher OXPHOS at baseline, the '\n",
      "                                  'PD1-resistant cells showed a differential '\n",
      "                                  'induction of OXPHOS following radiation '\n",
      "                                  'compared with the PD-1-sensitive NSCLC '\n",
      "                                  'cells in vitro.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'Despite outstanding responses to anti-PD-1 '\n",
      "                                  'agents in a subset of non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients, approximately 80% '\n",
      "                                  'of patients fail to have prolonged '\n",
      "                                  'favorable response.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 176,\n",
      "                          'tStart': 172,\n",
      "                          'text': 'We performed the Seahorse Mito Stress Test '\n",
      "                                  'to acquire baseline, oligomycin-inhibited, '\n",
      "                                  'FCCP-activated, and '\n",
      "                                  'rotenone/antimycin-inhibited OCR values in '\n",
      "                                  'the PD-1-sensitive and PD-1-resistant '\n",
      "                                  '344-SQ NSCLC cell lines growing in vitro '\n",
      "                                  '(figure 1A).'},\n",
      "                         {'dEnd': 354,\n",
      "                          'dStart': 349,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 334,\n",
      "                          'tStart': 330,\n",
      "                          'text': 'Many reviews indicated that XRT could '\n",
      "                                  'increase the treatment efficacy of '\n",
      "                                  'immunotherapy by reprogramming tumor '\n",
      "                                  'microenvironment.19 20 Our previous study '\n",
      "                                  'showed that XRT could induce type I IFN '\n",
      "                                  'production, upregulated MHC-I expression, '\n",
      "                                  'and restored response to anti-PD-1 in our '\n",
      "                                  'anti-PD-1-resistant model.9 Although XRT '\n",
      "                                  'can overcome PD-1 resistance in NSCLC,21–24 '\n",
      "                                  'XRT seems to be a double-edged sword to the '\n",
      "                                  'immune system.'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Taken together, in addition to having '\n",
      "                                  'higher OXPHOS at baseline, the '\n",
      "                                  'PD1-resistant cells showed a differential '\n",
      "                                  'induction of OXPHOS following radiation '\n",
      "                                  'compared with the PD-1-sensitive NSCLC '\n",
      "                                  'cells in vitro.'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 112,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'OXPHOS inhibition as part of a '\n",
      "                                  'combinatorial regimen with XRT is a '\n",
      "                                  'promising strategy to address '\n",
      "                                  'PD-1-resistant NSCLC, and this combination '\n",
      "                                  'is being tested clinically.'},\n",
      "                         {'dEnd': 341,\n",
      "                          'dStart': 336,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Recent studies show that tumor cell '\n",
      "                                  'oxidative metabolism is a barrier to PD-1 '\n",
      "                                  'immunotherapy and radiotherapy could '\n",
      "                                  'overcome PD-1 resistance, so it is urgent '\n",
      "                                  'to determine if combination treatment with '\n",
      "                                  'radiotherapy and a novel oxidative '\n",
      "                                  'phosphorylation (OXPHOS) inhibitor '\n",
      "                                  '(IACS-010759) is an effective strategy '\n",
      "                                  'against PD-1 resistance in NSCLC.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 106,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'In the current study, our goals are to '\n",
      "                                  'assess differential metabolic parameters in '\n",
      "                                  'PD-1-sensitive and PD-1-resistant NSCLC '\n",
      "                                  'models, evaluate the combined effect of XRT '\n",
      "                                  'and IACS-010759 in both models, explore the '\n",
      "                                  'effect of combination therapy on abscopal '\n",
      "                                  'responses, and provide mechanistic insight '\n",
      "                                  'into these observations.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 157,\n",
      "                          'tStart': 153,\n",
      "                          'text': 'We performed the Seahorse Mito Stress Test '\n",
      "                                  'to acquire baseline, oligomycin-inhibited, '\n",
      "                                  'FCCP-activated, and '\n",
      "                                  'rotenone/antimycin-inhibited OCR values in '\n",
      "                                  'the PD-1-sensitive and PD-1-resistant '\n",
      "                                  '344-SQ NSCLC cell lines growing in vitro '\n",
      "                                  '(figure 1A).'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'The OXPHOS inhibitor IACS-010759 may be '\n",
      "                                  'preferentially beneficial to PD-1-resistant '\n",
      "                                  'NSCLC, especially in combination with XRT, '\n",
      "                                  'and can alleviate radiation-induced '\n",
      "                                  'immunosuppression and increase antitumor '\n",
      "                                  'immunity.'},\n",
      "                         {'dEnd': 341,\n",
      "                          'dStart': 336,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 321,\n",
      "                          'tStart': 317,\n",
      "                          'text': 'Recent studies show that tumor cell '\n",
      "                                  'oxidative metabolism is a barrier to PD-1 '\n",
      "                                  'immunotherapy and radiotherapy could '\n",
      "                                  'overcome PD-1 resistance, so it is urgent '\n",
      "                                  'to determine if combination treatment with '\n",
      "                                  'radiotherapy and a novel oxidative '\n",
      "                                  'phosphorylation (OXPHOS) inhibitor '\n",
      "                                  '(IACS-010759) is an effective strategy '\n",
      "                                  'against PD-1 resistance in NSCLC.'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'For in vivo experiments, we treated '\n",
      "                                  '129Sv/Ev mice with anti-PD1-sensitive and '\n",
      "                                  'anti-PD1-resistant 344SQ NSCLC '\n",
      "                                  'adenocarcinoma xenografts with oral '\n",
      "                                  'IACS-010759 combined with radiotherapy '\n",
      "                                  '(XRT).'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'Despite outstanding responses to anti-PD-1 '\n",
      "                                  'agents in a subset of non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients, approximately 80% '\n",
      "                                  'of patients fail to have prolonged '\n",
      "                                  'favorable response.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'We further found that IACS-010759, a novel '\n",
      "                                  'OXPHOS inhibitor, might be preferentially '\n",
      "                                  'beneficial to PD-1-resistant NSCLC, '\n",
      "                                  'especially in combination with XRT.'},\n",
      "                         {'dEnd': 341,\n",
      "                          'dStart': 336,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'Recent studies show that tumor cell '\n",
      "                                  'oxidative metabolism is a barrier to PD-1 '\n",
      "                                  'immunotherapy and radiotherapy could '\n",
      "                                  'overcome PD-1 resistance, so it is urgent '\n",
      "                                  'to determine if combination treatment with '\n",
      "                                  'radiotherapy and a novel oxidative '\n",
      "                                  'phosphorylation (OXPHOS) inhibitor '\n",
      "                                  '(IACS-010759) is an effective strategy '\n",
      "                                  'against PD-1 resistance in NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['31358938'],\n",
      " 'resourceScore': 64,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Anti-TERT Th1 response and exhausted '\n",
      "                                  'PD-1+/TIM-3+ CD4+ T cells have distinct '\n",
      "                                  'prognostic value in NSCLC'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Firstly, we showed that the rate of both '\n",
      "                                  'CD4+ and CD8+ T cells expressing PD-1 or '\n",
      "                                  'TIM-3 was higher in NSCLC patients than '\n",
      "                                  'HD.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Notably, the circulating T cells '\n",
      "                                  'co-expressing both PD-1 and TIM-3 '\n",
      "                                  '(PD-1+TIM-3+T cells) were preferentially '\n",
      "                                  'detected at high level in NSCLC patients '\n",
      "                                  '(Fig. 2d, e).'},\n",
      "                         {'dEnd': 317,\n",
      "                          'dStart': 312,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'Accordingly, recent studies in NSCLC and '\n",
      "                                  'melanoma reported pharmacodynamic changes '\n",
      "                                  'of circulating Ki-67+PD-1+CD8+ T cells '\n",
      "                                  'following anti-PD-1 therapies.46,51,52 '\n",
      "                                  'Another report also demonstrated that high '\n",
      "                                  'circulating central memory T cell to '\n",
      "                                  'effector T-cell ratios were associated with '\n",
      "                                  'better clinical outcome in NSCLC receiving '\n",
      "                                  'anti-PD-1 therapy.53 Our previous findings '\n",
      "                                  'also support the critical role of treatment '\n",
      "                                  'induced anti-TERT CD4+ Th1 immunity.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Collectively, ours results indicated that '\n",
      "                                  'the level of anti-TERT Th1 response and '\n",
      "                                  'exhausted PD-1+TIM3+CD4+ T cells have '\n",
      "                                  'distinct prognostic value in NSCLC, so that '\n",
      "                                  'the decrease of functional anti-TERT Th1 '\n",
      "                                  'cells and increase of exhausted '\n",
      "                                  'PD-1+TIM-3+CD4+ T cells were associated '\n",
      "                                  'with disease progression (Fig. 5g).'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'The presence of anti-TERT Th1 response is '\n",
      "                                  'inversely correlated with the level of '\n",
      "                                  'exhausted PD-1+/TIM-3+ T cells in NSCLC '\n",
      "                                  'patients'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Notably, the circulating T cells '\n",
      "                                  'co-expressing both PD-1 and TIM-3 '\n",
      "                                  '(PD-1+TIM-3+T cells) were preferentially '\n",
      "                                  'detected at high level in NSCLC patients '\n",
      "                                  '(Fig. 2d, e).'},\n",
      "                         {'dEnd': 411,\n",
      "                          'dStart': 406,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 253,\n",
      "                          'tStart': 249,\n",
      "                          'text': 'PD-1 and TIM-3 are inhibitory receptors '\n",
      "                                  'involved in T cells exhaustion.28,29 These '\n",
      "                                  'receptors are commonly expressed on '\n",
      "                                  'antigen-experienced T cells in the context '\n",
      "                                  'of a chronic antigen stimulation (virus '\n",
      "                                  'infection or cancer), and T-cell '\n",
      "                                  'co-expressing PD-1 and TIM-3 were '\n",
      "                                  'characterised by a loss of most T-cell '\n",
      "                                  'functions.28,29 So, we investigated the '\n",
      "                                  'functions of circulating PD-1+/TIM-3+ T '\n",
      "                                  'cells detected in NSCLC patients.'},\n",
      "                         {'dEnd': 14,\n",
      "                          'dStart': 9,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Thus, in NSCLC, tumour growth was '\n",
      "                                  'associated with a decrease of circulating '\n",
      "                                  'antitumor Th1 responses, but an '\n",
      "                                  'accumulation of exhausted PD-1+/TIM-3+ CD4+ '\n",
      "                                  'T cells.'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'As shown in Fig. 3a, patients with an '\n",
      "                                  'anti-TERT Th1 response had significantly '\n",
      "                                  'lower rates of circulating PD-1+/TIM-3+ '\n",
      "                                  'CD4+ T cells than non-responders NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 411,\n",
      "                          'dStart': 406,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 377,\n",
      "                          'tStart': 373,\n",
      "                          'text': 'PD-1 and TIM-3 are inhibitory receptors '\n",
      "                                  'involved in T cells exhaustion.28,29 These '\n",
      "                                  'receptors are commonly expressed on '\n",
      "                                  'antigen-experienced T cells in the context '\n",
      "                                  'of a chronic antigen stimulation (virus '\n",
      "                                  'infection or cancer), and T-cell '\n",
      "                                  'co-expressing PD-1 and TIM-3 were '\n",
      "                                  'characterised by a loss of most T-cell '\n",
      "                                  'functions.28,29 So, we investigated the '\n",
      "                                  'functions of circulating PD-1+/TIM-3+ T '\n",
      "                                  'cells detected in NSCLC patients.'},\n",
      "                         {'dEnd': 317,\n",
      "                          'dStart': 312,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Accordingly, recent studies in NSCLC and '\n",
      "                                  'melanoma reported pharmacodynamic changes '\n",
      "                                  'of circulating Ki-67+PD-1+CD8+ T cells '\n",
      "                                  'following anti-PD-1 therapies.46,51,52 '\n",
      "                                  'Another report also demonstrated that high '\n",
      "                                  'circulating central memory T cell to '\n",
      "                                  'effector T-cell ratios were associated with '\n",
      "                                  'better clinical outcome in NSCLC receiving '\n",
      "                                  'anti-PD-1 therapy.53 Our previous findings '\n",
      "                                  'also support the critical role of treatment '\n",
      "                                  'induced anti-TERT CD4+ Th1 immunity.'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'To assess the prognostic value of '\n",
      "                                  'circulating anti-TERT Th1 immunity and '\n",
      "                                  'exhausted PD-1+/TIM-3+ T cells in this '\n",
      "                                  'cohort of treatment-naive NSCLC, we '\n",
      "                                  'considered two groups of patients with low '\n",
      "                                  'versus high circulating rates of these two '\n",
      "                                  'immune parameters (see details in the '\n",
      "                                  'Methods section and Supplementary Table '\n",
      "                                  '3).'},\n",
      "                         {'dEnd': 411,\n",
      "                          'dStart': 406,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and TIM-3 are inhibitory receptors '\n",
      "                                  'involved in T cells exhaustion.28,29 These '\n",
      "                                  'receptors are commonly expressed on '\n",
      "                                  'antigen-experienced T cells in the context '\n",
      "                                  'of a chronic antigen stimulation (virus '\n",
      "                                  'infection or cancer), and T-cell '\n",
      "                                  'co-expressing PD-1 and TIM-3 were '\n",
      "                                  'characterised by a loss of most T-cell '\n",
      "                                  'functions.28,29 So, we investigated the '\n",
      "                                  'functions of circulating PD-1+/TIM-3+ T '\n",
      "                                  'cells detected in NSCLC patients.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['34081628'],\n",
      " 'resourceScore': 64,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 315,\n",
      "                          'dStart': 296,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'We conclude that IL-15/IL-15RαFc + PD-1 '\n",
      "                                  'blockade activates/disinhibits both CTLs '\n",
      "                                  'and NK cells, that CTLs and NK cells are '\n",
      "                                  'the main targets of this therapy, and that '\n",
      "                                  'CTLs and NK cells are equally required for '\n",
      "                                  'maximal antitumor response in human solid '\n",
      "                                  'tumor as demonstrated in our TIL-PDX model '\n",
      "                                  'of lung adenocarcinoma.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'Taken together, these data demonstrate '\n",
      "                                  'findings consistent with IL-15 stimulation '\n",
      "                                  'and PD-1 blockade activating/disinhibiting '\n",
      "                                  'NK cells and CTLs in our TIL-PDX-LUAD '\n",
      "                                  'model.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'Notably, transpresented IL-15 alone, but '\n",
      "                                  'not PD-1 blockade, significantly reduced '\n",
      "                                  'tumor burden in all treated TIL-PDX-LUAD '\n",
      "                                  'animals.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'We found that the combination of PD-1 '\n",
      "                                  'blockade and IL-15 signaling resulted in '\n",
      "                                  'the profound regression of transplanted '\n",
      "                                  'LUAD in about one-half of treated '\n",
      "                                  'TIL-PDX-LUAD mice.'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 162,\n",
      "                          'tStart': 158,\n",
      "                          'text': 'These data suggest that PD-1, PD-L1, and '\n",
      "                                  'PD-L2 are expressed on lung tissue, and '\n",
      "                                  'LUAD-resident NK cells and a significantly '\n",
      "                                  'higher number of NK cells express PD-1, '\n",
      "                                  'PD-L1, and/or PD-L2 in LUAD compared with '\n",
      "                                  'nontumor lung tissue.'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Notably, the combination of IL-15 '\n",
      "                                  'stimulation and PD-1 blockade resulted in '\n",
      "                                  'the most pronounced tumor regression in all '\n",
      "                                  'treated TIL-PDX-LUAD mice, demonstrating '\n",
      "                                  'that IL-15 stimulation prevents tumor '\n",
      "                                  'escape from ICI and augments antitumor '\n",
      "                                  'immunity.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'We found that the combination of PD-1 '\n",
      "                                  'blockade and IL-15 signaling resulted in '\n",
      "                                  'the profound regression of transplanted '\n",
      "                                  'LUAD in about one-half of treated '\n",
      "                                  'TIL-PDX-LUAD mice.'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 314,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 178,\n",
      "                          'tStart': 174,\n",
      "                          'text': 'As our freshly excised and TIL-PDX–derived '\n",
      "                                  'tumor tissues were not always from the same '\n",
      "                                  'donor, it is not possible to determine '\n",
      "                                  'whether this reduction in PD-L1 and '\n",
      "                                  'increase in PD-1 expression are due to '\n",
      "                                  'patient-to-patient variation or whether '\n",
      "                                  'factors that drive PD-L1/PD-1 expression on '\n",
      "                                  'human NK cells, T cells, and LUAD in humans '\n",
      "                                  'are reduced in TIL-PDX mice.'},\n",
      "                         {'dEnd': 318,\n",
      "                          'dStart': 314,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 270,\n",
      "                          'tStart': 266,\n",
      "                          'text': 'As our freshly excised and TIL-PDX–derived '\n",
      "                                  'tumor tissues were not always from the same '\n",
      "                                  'donor, it is not possible to determine '\n",
      "                                  'whether this reduction in PD-L1 and '\n",
      "                                  'increase in PD-1 expression are due to '\n",
      "                                  'patient-to-patient variation or whether '\n",
      "                                  'factors that drive PD-L1/PD-1 expression on '\n",
      "                                  'human NK cells, T cells, and LUAD in humans '\n",
      "                                  'are reduced in TIL-PDX mice.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'These data suggest that PD-1, PD-L1, and '\n",
      "                                  'PD-L2 are expressed on lung tissue, and '\n",
      "                                  'LUAD-resident NK cells and a significantly '\n",
      "                                  'higher number of NK cells express PD-1, '\n",
      "                                  'PD-L1, and/or PD-L2 in LUAD compared with '\n",
      "                                  'nontumor lung tissue.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'We hypothesized that CTLs and NK cells are '\n",
      "                                  'key players behind the combined IL-15 and '\n",
      "                                  'PD-1 blockade immunotherapy response in our '\n",
      "                                  'TIL-PDX-LUAD model.'},\n",
      "                         {'dEnd': 264,\n",
      "                          'dStart': 260,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 166,\n",
      "                          'tStart': 162,\n",
      "                          'text': 'In line with our long-term goal to use '\n",
      "                                  'TIL-PDX mice to develop effective primary '\n",
      "                                  'combination immunotherapies, we examined if '\n",
      "                                  'the addition of IL-15 stimulation to PD-1 '\n",
      "                                  'blockade augments the antitumor response of '\n",
      "                                  'tumor-exhausted CTLs and NK cells in our '\n",
      "                                  'TIL-PDX-LUAD model.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'The proportion of CD16-, NKG2D-, and '\n",
      "                                  'PD-1–expressing NK cells or T cells was '\n",
      "                                  'largely preserved between the input human '\n",
      "                                  'LUAD and TIL-PDX-LUAD 2 to 3 months '\n",
      "                                  'postimplant (Supplemental Figure 5).'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'These data suggest that PD-1, PD-L1, and '\n",
      "                                  'PD-L2 are expressed on lung tissue, and '\n",
      "                                  'LUAD-resident NK cells and a significantly '\n",
      "                                  'higher number of NK cells express PD-1, '\n",
      "                                  'PD-L1, and/or PD-L2 in LUAD compared with '\n",
      "                                  'nontumor lung tissue.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38297019'],\n",
      " 'resourceScore': 63,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'CD57+CD8+ T cells were predictive for '\n",
      "                                  'response to anti-PD-1 treatment in patients '\n",
      "                                  'with NSCLC'},\n",
      "                         {'dEnd': 88,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 121,\n",
      "                          'text': 'Major peripheral immune compositions were '\n",
      "                                  'essentially the same among patients with '\n",
      "                                  'NSCLC with distinct responses to anti-PD-1 '\n",
      "                                  'immunotherapy'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'We examined immune cell subpopulations in '\n",
      "                                  'the peripheral blood of patients with '\n",
      "                                  'advanced NSCLC before and during PD-1 '\n",
      "                                  'inhibitor monotherapy using '\n",
      "                                  'high-dimensional single-cell analysis via '\n",
      "                                  'CyTOF.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'CyTOF analysis was performed on 34 '\n",
      "                                  'peripheral blood mononuclear cells (PBMCs) '\n",
      "                                  'samples from a prospective discovery cohort '\n",
      "                                  'comprising 20 patients with NSCLC treated '\n",
      "                                  'with PD-1 inhibitor monotherapy to perform '\n",
      "                                  'an in-depth evaluation of the immunological '\n",
      "                                  'profiles of PBMCs in NSCLC (Fig. 1a).'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'We enrolled six patients with NSCLC who '\n",
      "                                  'received single-agent PD-1 inhibitors from '\n",
      "                                  'the flow cytometry cohort.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'These data suggested that upregulated CD57 '\n",
      "                                  'expression in both CD8+ T and T cells can '\n",
      "                                  'predict the response to anti-PD-1 '\n",
      "                                  'immunotherapy in patients with NSCLC.'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Cohort 1 comprised 27 NSCLC patients (16 in '\n",
      "                                  'the DCB group and 11 in the NDB group) '\n",
      "                                  'treated with PD-1 inhibitor monotherapy '\n",
      "                                  'between May 2021 and April 2022.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'CD57+CD8+T cells, as determined using '\n",
      "                                  'mIHC/IF, predicted response to anti-PD-1 '\n",
      "                                  'treatment in patients with NSCLC'},\n",
      "                         {'dEnd': 277,\n",
      "                          'dStart': 272,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'CyTOF analysis was performed on 34 '\n",
      "                                  'peripheral blood mononuclear cells (PBMCs) '\n",
      "                                  'samples from a prospective discovery cohort '\n",
      "                                  'comprising 20 patients with NSCLC treated '\n",
      "                                  'with PD-1 inhibitor monotherapy to perform '\n",
      "                                  'an in-depth evaluation of the immunological '\n",
      "                                  'profiles of PBMCs in NSCLC (Fig. 1a).'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'CD57-positive CD8 + T cells define the '\n",
      "                                  'response to anti-programmed cell death '\n",
      "                                  'protein-1 immunotherapy in patients with '\n",
      "                                  'advanced non-small cell lung cancer'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 172,\n",
      "                          'tStart': 168,\n",
      "                          'text': 'The identified DEGs provided valuable '\n",
      "                                  'information for understanding the molecular '\n",
      "                                  'characteristics and potential functional '\n",
      "                                  'roles of CD57+CD8+ T cells in the context '\n",
      "                                  'of PD-1 inhibitor treatment in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 174,\n",
      "                          'dStart': 169,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 154,\n",
      "                          'tStart': 150,\n",
      "                          'text': 'This supported the notion that CD57+CD8+ T '\n",
      "                                  'cells played a crucial role in immune '\n",
      "                                  'responses and potentially contributed to '\n",
      "                                  'the therapeutic response to PD-1 inhibitors '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'In conclusion, our study demonstrates that '\n",
      "                                  'both blood- and tissue-based measurements '\n",
      "                                  'of CD57+CD8+ T cells may serve as promising '\n",
      "                                  'biomarkers for predicting the response to '\n",
      "                                  'anti-PD-1 treatment in NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34268872'],\n",
      " 'resourceScore': 61,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'A combination of PD‐1 inhibitors and '\n",
      "                                  'antiangiogenic targeting agents may be '\n",
      "                                  'beneficial for patients with advanced or '\n",
      "                                  'metastatic NSCLC as subsequent treatment, '\n",
      "                                  'especially for patients with PD‐L1 protein '\n",
      "                                  'expression positive, and treatment is well '\n",
      "                                  'tolerated.'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Efficacy and safety profile of combining '\n",
      "                                  'programmed cell death‐1 (PD‐1) inhibitors '\n",
      "                                  'and antiangiogenic targeting agents as '\n",
      "                                  'subsequent therapy for advanced or '\n",
      "                                  'metastatic non‐small cell lung cancer '\n",
      "                                  '(NSCLC)'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'Treatment‐related adverse events (AEs) in '\n",
      "                                  'all advanced NSCLC patients who received '\n",
      "                                  'combination therapy of PD‐1 inhibitors and '\n",
      "                                  'antiangiogenic agents'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'The combination therapy of PD‐1 inhibitors '\n",
      "                                  'and antiangiogenic agents has been reported '\n",
      "                                  'to be favorable in clinical use with the '\n",
      "                                  'support of some preclinical data on their '\n",
      "                                  'effect and safety,8, 9 and has been shown '\n",
      "                                  'to be effective as first‐line therapy for '\n",
      "                                  'advanced NSCLC in clinical use.11'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'A recent phase Ib clinical trial from China '\n",
      "                                  'has released the initial outcome of '\n",
      "                                  'combining PD‐1 and anlotinib as first‐line '\n",
      "                                  'therapy for advanced NSCLC, with ORR of '\n",
      "                                  '72.7% (16/22 PR, 6/22 SD), and DCR of '\n",
      "                                  '100%.15'},\n",
      "                         {'dEnd': 244,\n",
      "                          'dStart': 239,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 162,\n",
      "                          'tStart': 158,\n",
      "                          'text': 'Further studies should be conducted with a '\n",
      "                                  'greater number of samples to explore '\n",
      "                                  'whether the expression level of PD‐L1 '\n",
      "                                  'protein would influence the efficacy of '\n",
      "                                  'PD‐1 inhibitors and antiangiogenic '\n",
      "                                  'combination in subsequent therapy of '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'A total of 30 evaluable advanced NSCLC '\n",
      "                                  'patients who were undergoing, or had '\n",
      "                                  'received combination therapy of PD‐1 '\n",
      "                                  'inhibitors and antiangiogenic agents as '\n",
      "                                  'subsequent treatment, were enrolled in the '\n",
      "                                  'study.'},\n",
      "                         {'dEnd': 272,\n",
      "                          'dStart': 267,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 202,\n",
      "                          'tStart': 198,\n",
      "                          'text': 'Our multicenter prospective interventional '\n",
      "                                  'study is now recruiting patients, based on '\n",
      "                                  'the results of this retrospective study, '\n",
      "                                  'with the aim of providing more evidence for '\n",
      "                                  'the efficacy and safety of PD‐1 inhibitors '\n",
      "                                  'and antiangiogenic treatment in advanced '\n",
      "                                  'nonsquamous NSCLC patients (NCT04670913).'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Treatment outcome of 29 advanced NSCLC '\n",
      "                                  'patients with targetable lesions who '\n",
      "                                  'received PD‐1 inhibitors and antiangiogenic '\n",
      "                                  'combined therapy'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'However, whether the combination of PD‐1 '\n",
      "                                  'inhibitors and antiangiogenic agents '\n",
      "                                  'benefit advanced NSCLC patients as '\n",
      "                                  'subsequent therapy remains unknown.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'This study provides further evidence for '\n",
      "                                  'combining PD‐1 inhibitor and antiangiogenic '\n",
      "                                  'targeting agents as an effective and safe '\n",
      "                                  'subsequent therapy for advanced or '\n",
      "                                  'metastatic NSCLC, by reviewing the records '\n",
      "                                  'of 30 patients.'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'The study indicated that the combination of '\n",
      "                                  'PD‐1 inhibitors and antiangiogenic '\n",
      "                                  'targeting agents might be beneficial and '\n",
      "                                  'safe for patients with advanced or '\n",
      "                                  'metastatic NSCLC as subsequent treatment, '\n",
      "                                  'especially for those patients that were '\n",
      "                                  'PD‐L1 protein expression positive.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Clinicopathological features of all '\n",
      "                                  'advanced NSCLC patients who received '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and antiangiogenic '\n",
      "                                  'combined therapy'},\n",
      "                         {'dEnd': 42,\n",
      "                          'dStart': 37,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 193,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'A total of 30 patients with advanced NSCLC, '\n",
      "                                  'who progressed after at least two cycles of '\n",
      "                                  'platinum‐based chemotherapy or targeted '\n",
      "                                  'therapy and subsequently received '\n",
      "                                  'combination therapy with a PD‐1 inhibitor '\n",
      "                                  'and antiangiogenic agent, were included in '\n",
      "                                  'this study.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Previous studies have demonstrated that '\n",
      "                                  'PD‐1 inhibitors are effective in the '\n",
      "                                  'treatment of advanced or metastatic '\n",
      "                                  'non‐small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'In this retrospective study, we therefore '\n",
      "                                  'mainly focus on the effect of PD‐1 '\n",
      "                                  'inhibitors combining antiangiogenic '\n",
      "                                  'targeting agents as second‐line or later '\n",
      "                                  'therapy for advanced or metastatic NSCLC, '\n",
      "                                  'and explore the potential optimal therapy '\n",
      "                                  'for this group of patients who have '\n",
      "                                  'progressed after prior treatments.'},\n",
      "                         {'dEnd': 260,\n",
      "                          'dStart': 255,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'Also, no novel adverse events have been '\n",
      "                                  'observed in this combination therapy as '\n",
      "                                  'first‐line treatment, which has provided '\n",
      "                                  'evidence for the efficacy and safety in '\n",
      "                                  'combining PD‐1 inhibitors and '\n",
      "                                  'antiangiogenic targeting agents treating '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'The level of PD‐L1 expression may affect '\n",
      "                                  'the immune effects in first‐line therapy, '\n",
      "                                  'with PD‐1 inhibiting treatment of PD‐L1 '\n",
      "                                  'positive (tumor proportion score ≥50%) '\n",
      "                                  'advanced NSCLC achieving longer PFS than '\n",
      "                                  'platinum‐based chemotherapy.19'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'In conclusion, our study indicates that '\n",
      "                                  'combination therapy of PD‐1 inhibitors and '\n",
      "                                  'antiangiogenic targeting agents may be '\n",
      "                                  'beneficial for patients with advanced or '\n",
      "                                  'metastatic NSCLC as second‐line or later '\n",
      "                                  'treatment, especially for patients with '\n",
      "                                  'PD‐L1 protein expression positive, and is '\n",
      "                                  'well tolerated.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39262495'],\n",
      " 'resourceScore': 61,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 86,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Logistic analysis for independent '\n",
      "                                  'predictors for anti-PD-1 treatment efficacy '\n",
      "                                  'in NSCLC patients'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'After anti-PD-1 treatment, 78 NSCLC '\n",
      "                                  'patients and 40 NSCLC patients were '\n",
      "                                  'classified as the effective and ineffective '\n",
      "                                  'groups, respectively.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'Programmed cell death protein 1/programmed '\n",
      "                                  'cell death ligand 1 (PD-1/PD-L1) inhibitors '\n",
      "                                  'show promising efficiency in some solid '\n",
      "                                  'tumors, such as NSCLC (2,4).'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'Programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitor therapy has become a routine '\n",
      "                                  'treatment for advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'Programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitor therapy has become a routine '\n",
      "                                  'treatment for advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 57,\n",
      "                          'dStart': 52,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'After anti-PD-1 treatment, 78 NSCLC '\n",
      "                                  'patients and 40 NSCLC patients were '\n",
      "                                  'classified as the effective and ineffective '\n",
      "                                  'groups, respectively.'},\n",
      "                         {'dEnd': 24,\n",
      "                          'dStart': 19,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'However, only some NSCLC patients would '\n",
      "                                  'benefit from anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'The percentage of CD4+ T cells at baseline '\n",
      "                                  'could predict anti-PD-1 efficacy in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'Although this study demonstrated that the '\n",
      "                                  'percentage of CD4+ T cells at baseline '\n",
      "                                  'could predict the efficacy of anti-PD-1 '\n",
      "                                  'treatment in NSCLC patients, we just '\n",
      "                                  'focused on the percentages of CD4+ T cells '\n",
      "                                  'before and after anti-PD-1 treatment.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 142,\n",
      "                          'tStart': 138,\n",
      "                          'text': 'Additionally, PD-L1 single nucleotide '\n",
      "                                  'polymorphisms rs822336 could induce of '\n",
      "                                  'PD-L1 expression and act as a novel '\n",
      "                                  'biomarker for predicting PD-1 inhibitors '\n",
      "                                  'immunotherapy in advanced NSCLC patients '\n",
      "                                  '(7).'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'ROC curves revealed that the AUC area of '\n",
      "                                  'the percentage of peripheral CD4+ T cells '\n",
      "                                  'at baseline for predicting the efficacy of '\n",
      "                                  'anti-PD-1 treatment in NSCLC patients was '\n",
      "                                  '0.7834 (Figure 5).'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Several studies have revealed lymphocyte '\n",
      "                                  'subsets in PB that could predict anti-PD-1 '\n",
      "                                  'treatment efficacy in NSCLC patients '\n",
      "                                  '(17,18).'},\n",
      "                         {'dEnd': 24,\n",
      "                          'dStart': 19,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'In this study, 118 NSCLC patients who '\n",
      "                                  'received anti-PD-1 therapy were enrolled.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'In this study, we sought to determine '\n",
      "                                  'whether peripheral CD4+ T cells and CD8+ T '\n",
      "                                  'cells could be potential biomarkers for '\n",
      "                                  'predicting anti-PD-1 treatment efficacy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Programmed cell death protein 1/programmed '\n",
      "                                  'cell death ligand 1 (PD-1/PD-L1) inhibitors '\n",
      "                                  'show promising efficiency in some solid '\n",
      "                                  'tumors, such as NSCLC (2,4).'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'Programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitor therapy has become a routine '\n",
      "                                  'treatment for advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Furthermore, considering that the primary '\n",
      "                                  'goal of anti-PD-1 treatment for NSCLC '\n",
      "                                  'patients is to prolong overall survival, '\n",
      "                                  'the following research should extend the '\n",
      "                                  'duration of follow-up and monitor the '\n",
      "                                  'changes in CD4+ T cells and CD8+ T cells '\n",
      "                                  'longitudinally to explore their correlation '\n",
      "                                  'with overall survival.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'There is still an urgent need to explore '\n",
      "                                  'novel and reliable predictors for anti-PD-1 '\n",
      "                                  'efficacy despite some researchers having '\n",
      "                                  'identified some biomarkers for predicting '\n",
      "                                  'the effectiveness of anti-PD-1 treatment in '\n",
      "                                  'NSCLC patients (19).'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'The percentage of peripheral CD4+ T cells '\n",
      "                                  'could predict anti-PD-1 efficacy in NSCLC '\n",
      "                                  'patients'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'There is still an urgent need to explore '\n",
      "                                  'novel and reliable predictors for anti-PD-1 '\n",
      "                                  'efficacy despite some researchers having '\n",
      "                                  'identified some biomarkers for predicting '\n",
      "                                  'the effectiveness of anti-PD-1 treatment in '\n",
      "                                  'NSCLC patients (19).'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'Programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitor therapy has become a routine '\n",
      "                                  'treatment for advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35784705'],\n",
      " 'resourceScore': 61,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'A summary of global PD-1/PD-L1 clinical '\n",
      "                                  'trials and five PD-1/PD-L1 inhibitors '\n",
      "                                  'approved by FDA, EMA and NMPA for advanced '\n",
      "                                  'NSCLC were analyzed.'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'FDA/EMA/NMPA-approved NSCLC treatments of '\n",
      "                                  'PD-1/PD-L1 blocking antibodies.'},\n",
      "                         {'dEnd': 24,\n",
      "                          'dStart': 19,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Previously treated NSCLC with PD-1/PD-L1 '\n",
      "                                  'expression >50%'},\n",
      "                         {'dEnd': 433,\n",
      "                          'dStart': 428,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 340,\n",
      "                          'tStart': 336,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors, approved by the '\n",
      "                                  'European Medicines Agency (EMA) and the '\n",
      "                                  'United States Food and Drug Administration '\n",
      "                                  '(FDA) and the China National Medical '\n",
      "                                  'Products Administration (NMPA) for the '\n",
      "                                  'treatment of advanced NSCLC (Xu et al., '\n",
      "                                  '2018) (Table 2) domestic preparations '\n",
      "                                  'include Sintilimab (PD-1, February 2021), '\n",
      "                                  'Camrelizumab (PD-1, December 2021), '\n",
      "                                  'Tislelizumab (PD-1, June 2021; approved in '\n",
      "                                  'China for the treatment of NSCLC).'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 197,\n",
      "                          'tStart': 193,\n",
      "                          'text': 'The PD-1 inhibitor includes Nivolumab, '\n",
      "                                  'Pembrolizumab, Cemiplimab, Sintilimab, '\n",
      "                                  'Toripalimab, Camrelizumab, Tislelizumab, '\n",
      "                                  'etc. PD-L1 inhibitor includes Durvalumab, '\n",
      "                                  'Atezolizumab, etc. There are 15 PD-1/PD-L1 '\n",
      "                                  'inhibitors for NSCLC in clinical trials '\n",
      "                                  'registered in clinicaltrials.gov until 15 '\n",
      "                                  'January 2022 (Table 1).'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Clinical trials show that the treatment of '\n",
      "                                  'non-small cell lung cancer (NSCLC) with '\n",
      "                                  'PD-1/PD-L1 inhibitors has significant '\n",
      "                                  'advantages.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors have produced '\n",
      "                                  'significant survival benefits in the '\n",
      "                                  'treatment of some advanced NSCLC, bringing '\n",
      "                                  'hope to the treatment of all NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'The review briefly describes these basic '\n",
      "                                  'principles of the PD-1/PD-L1 pathway and '\n",
      "                                  'action mechanism in the treatment of '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'The mechanism of action of PD-1 and PD-L1 '\n",
      "                                  'immunosuppressants is to block the PD-1 and '\n",
      "                                  'PD-L1 signaling pathways of NSCLC cells '\n",
      "                                  '(Figure 1), activate the immune activity of '\n",
      "                                  'T cells, leading to the inhibition on the '\n",
      "                                  'growth and proliferation of tumor cells, '\n",
      "                                  'then achieving its final apoptosis (Li et '\n",
      "                                  'al., 2018b).'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'Programmed Cell Death Protein 1/Programmed '\n",
      "                                  'Cell Death Protein Ligand 1 '\n",
      "                                  'Immunosuppressants in Advanced Non-Small '\n",
      "                                  'Cell Lung Cancer Research Progress in '\n",
      "                                  'Treatment'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'It is found that the PD-1 inhibitors (e.g., '\n",
      "                                  'Nivolumab, Cimipritimab and Bolizumab) and '\n",
      "                                  'the PD-L1 inhibitors (e.g., Durvalumab and '\n",
      "                                  'Atezolizumab) have benefited OS in clinical '\n",
      "                                  'trials of NSCLC treatments.'},\n",
      "                         {'dEnd': 433,\n",
      "                          'dStart': 428,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors, approved by the '\n",
      "                                  'European Medicines Agency (EMA) and the '\n",
      "                                  'United States Food and Drug Administration '\n",
      "                                  '(FDA) and the China National Medical '\n",
      "                                  'Products Administration (NMPA) for the '\n",
      "                                  'treatment of advanced NSCLC (Xu et al., '\n",
      "                                  '2018) (Table 2) domestic preparations '\n",
      "                                  'include Sintilimab (PD-1, February 2021), '\n",
      "                                  'Camrelizumab (PD-1, December 2021), '\n",
      "                                  'Tislelizumab (PD-1, June 2021; approved in '\n",
      "                                  'China for the treatment of NSCLC).'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 13,\n",
      "                          'text': 'Mechanism of Programmed Cell Death Protein '\n",
      "                                  '1/Programmed Cell Death Protein Ligand 1 in '\n",
      "                                  'Non-Small Cell Lung Cancer'},\n",
      "                         {'dEnd': 433,\n",
      "                          'dStart': 428,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 304,\n",
      "                          'tStart': 300,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors, approved by the '\n",
      "                                  'European Medicines Agency (EMA) and the '\n",
      "                                  'United States Food and Drug Administration '\n",
      "                                  '(FDA) and the China National Medical '\n",
      "                                  'Products Administration (NMPA) for the '\n",
      "                                  'treatment of advanced NSCLC (Xu et al., '\n",
      "                                  '2018) (Table 2) domestic preparations '\n",
      "                                  'include Sintilimab (PD-1, February 2021), '\n",
      "                                  'Camrelizumab (PD-1, December 2021), '\n",
      "                                  'Tislelizumab (PD-1, June 2021; approved in '\n",
      "                                  'China for the treatment of NSCLC).'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1 inhibitor includes Nivolumab, '\n",
      "                                  'Pembrolizumab, Cemiplimab, Sintilimab, '\n",
      "                                  'Toripalimab, Camrelizumab, Tislelizumab, '\n",
      "                                  'etc. PD-L1 inhibitor includes Durvalumab, '\n",
      "                                  'Atezolizumab, etc. There are 15 PD-1/PD-L1 '\n",
      "                                  'inhibitors for NSCLC in clinical trials '\n",
      "                                  'registered in clinicaltrials.gov until 15 '\n",
      "                                  'January 2022 (Table 1).'},\n",
      "                         {'dEnd': 433,\n",
      "                          'dStart': 428,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 376,\n",
      "                          'tStart': 372,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors, approved by the '\n",
      "                                  'European Medicines Agency (EMA) and the '\n",
      "                                  'United States Food and Drug Administration '\n",
      "                                  '(FDA) and the China National Medical '\n",
      "                                  'Products Administration (NMPA) for the '\n",
      "                                  'treatment of advanced NSCLC (Xu et al., '\n",
      "                                  '2018) (Table 2) domestic preparations '\n",
      "                                  'include Sintilimab (PD-1, February 2021), '\n",
      "                                  'Camrelizumab (PD-1, December 2021), '\n",
      "                                  'Tislelizumab (PD-1, June 2021; approved in '\n",
      "                                  'China for the treatment of NSCLC).'},\n",
      "                         {'dEnd': 173,\n",
      "                          'dStart': 168,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'The review summarizes and analyzes the '\n",
      "                                  'clinical studies of five currently used '\n",
      "                                  'drugs targeting PD-1/PD-L1 immune '\n",
      "                                  'checkpoints approved by FDA, EMA, and NMPA '\n",
      "                                  'in advanced NSCLC.'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors have produced '\n",
      "                                  'significant survival benefits in the '\n",
      "                                  'treatment of some advanced NSCLC, bringing '\n",
      "                                  'hope to the treatment of all NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'A summary of global PD-1/PD-L1 clinical '\n",
      "                                  'trials and five PD-1/PD-L1 inhibitors '\n",
      "                                  'approved by FDA, EMA and NMPA for advanced '\n",
      "                                  'NSCLC were analyzed.'},\n",
      "                         {'dEnd': 229,\n",
      "                          'dStart': 224,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'The PD-1/PD-L1 inhibitors, approved by the '\n",
      "                                  'European Medicines Agency (EMA) and the '\n",
      "                                  'United States Food and Drug Administration '\n",
      "                                  '(FDA) and the China National Medical '\n",
      "                                  'Products Administration (NMPA) for the '\n",
      "                                  'treatment of advanced NSCLC (Xu et al., '\n",
      "                                  '2018) (Table 2) domestic preparations '\n",
      "                                  'include Sintilimab (PD-1, February 2021), '\n",
      "                                  'Camrelizumab (PD-1, December 2021), '\n",
      "                                  'Tislelizumab (PD-1, June 2021; approved in '\n",
      "                                  'China for the treatment of NSCLC).'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 46,\n",
      "                          'tStart': 42,\n",
      "                          'text': 'FDA/EMA/NMPA-approved NSCLC treatments of '\n",
      "                                  'PD-1/PD-L1 blocking antibodies clinical '\n",
      "                                  'trials.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'The mechanism of action of PD-1 and PD-L1 '\n",
      "                                  'immunosuppressants is to block the PD-1 and '\n",
      "                                  'PD-L1 signaling pathways of NSCLC cells '\n",
      "                                  '(Figure 1), activate the immune activity of '\n",
      "                                  'T cells, leading to the inhibition on the '\n",
      "                                  'growth and proliferation of tumor cells, '\n",
      "                                  'then achieving its final apoptosis (Li et '\n",
      "                                  'al., 2018b).'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Summary of clinical trials of PD-1/PD-L1 '\n",
      "                                  'immunosuppressants for NSCLC registered in '\n",
      "                                  'clinicaltrials.gov.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['28275222'],\n",
      " 'resourceScore': 60,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and PD-L1 have been described in '\n",
      "                                  'several malignancies, including ovarian '\n",
      "                                  'cancer [35], lung cancer [33,36], breast '\n",
      "                                  'cancer [34], etc. In our study, PD-L1 was '\n",
      "                                  'expressed on 36.4% of NSCLC cell lines.'},\n",
      "                         {'dEnd': 23,\n",
      "                          'dStart': 18,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and PD-L1 on NSCLC cell lines'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 178,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 (NAT105, Cell Marque) and PD-L1 (22C3, '\n",
      "                                  'Dako) protein expression was evaluated by '\n",
      "                                  'IHC, and TIL percentage was scored, in 139 '\n",
      "                                  'surgically resected specimens from patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 was not expressed on NSCLC cell '\n",
      "                                  'lines.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Our results showed that PD-1 expression, '\n",
      "                                  'not PD-L1, was correlated with TILs in '\n",
      "                                  'NSCLC, which was consistent with the other '\n",
      "                                  'results of the past.'},\n",
      "                         {'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 was expressed on TILs in tumor tissues '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Characterization of PD-1, PD-L1, and TILs '\n",
      "                                  'in NSCLC and their association with '\n",
      "                                  'clinicopathological factors'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'In this study, we analyzed PD-1 and PD-L1 '\n",
      "                                  'in NSCLC cell lines and patient tumor '\n",
      "                                  'tissues as well as described the '\n",
      "                                  'correlations between TILs and survival.'},\n",
      "                         {'dEnd': 58,\n",
      "                          'dStart': 53,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Association between PD-1 and PD-L1 and RFS '\n",
      "                                  'and OS in NSCLC patients'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'In this study, we investigated PD-1 and '\n",
      "                                  'PD-L1 protein expression in NSCLC cell '\n",
      "                                  'lines and NSCLC patient tumor tissues by '\n",
      "                                  'immunohistochemistry (IHC); analyzed the '\n",
      "                                  'correlation between PD-1 and PD-L1, '\n",
      "                                  'clinicopathological characteristics, and '\n",
      "                                  'tumor-infiltrating lymphocytes (TILs); and '\n",
      "                                  'conducted survival analysis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Immunotherapy targeting the programmed '\n",
      "                                  'death-1 (PD-1)/programmed death ligand-1 '\n",
      "                                  '(PD-L1) checkpoint has shown the good '\n",
      "                                  'outcomes in non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 317,\n",
      "                          'dStart': 312,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'In this study, we investigated PD-1 and '\n",
      "                                  'PD-L1 protein expression in NSCLC cell '\n",
      "                                  'lines and NSCLC patient tumor tissues by '\n",
      "                                  'immunohistochemistry (IHC); analyzed the '\n",
      "                                  'correlation between PD-1 and PD-L1, '\n",
      "                                  'clinicopathological characteristics, and '\n",
      "                                  'tumor-infiltrating lymphocytes (TILs); and '\n",
      "                                  'conducted survival analysis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1, PD-L1 Protein Expression in Non-Small '\n",
      "                                  'Cell Lung Cancer and Their Relationship '\n",
      "                                  'with Tumor-Infiltrating Lymphocytes'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'We investigated PD-1 and PD-L1 protein '\n",
      "                                  'expression and their correlation with '\n",
      "                                  'tumor-infiltrating lymphocytes (TILs), and '\n",
      "                                  'association with survival in NSCLC.'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Immunotherapy targeting the programmed '\n",
      "                                  'death-1 (PD-1)/programmed death ligand-1 '\n",
      "                                  '(PD-L1) checkpoint has shown the good '\n",
      "                                  'outcomes in non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'In this study, we investigated PD-1 and '\n",
      "                                  'PD-L1 protein expression in NSCLC cell '\n",
      "                                  'lines and NSCLC patient tumor tissues by '\n",
      "                                  'immunohistochemistry (IHC); analyzed the '\n",
      "                                  'correlation between PD-1 and PD-L1, '\n",
      "                                  'clinicopathological characteristics, and '\n",
      "                                  'tumor-infiltrating lymphocytes (TILs); and '\n",
      "                                  'conducted survival analysis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'We have demonstrated the expression of PD-1 '\n",
      "                                  'and PD-L1 in surgically resected specimens '\n",
      "                                  'of NSCLC.'},\n",
      "                         {'dEnd': 45,\n",
      "                          'dStart': 40,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 was not expressed on any of the 55 '\n",
      "                                  'NSCLC cell lines.'},\n",
      "                         {'dEnd': 317,\n",
      "                          'dStart': 312,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 185,\n",
      "                          'tStart': 181,\n",
      "                          'text': 'In this study, we investigated PD-1 and '\n",
      "                                  'PD-L1 protein expression in NSCLC cell '\n",
      "                                  'lines and NSCLC patient tumor tissues by '\n",
      "                                  'immunohistochemistry (IHC); analyzed the '\n",
      "                                  'correlation between PD-1 and PD-L1, '\n",
      "                                  'clinicopathological characteristics, and '\n",
      "                                  'tumor-infiltrating lymphocytes (TILs); and '\n",
      "                                  'conducted survival analysis of NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'The expression of PD-1 (NAT105, Cell '\n",
      "                                  'Marque) and PD-L1 (28-8, Dako) protein was '\n",
      "                                  'assessed in 55 NSCLC cell lines by '\n",
      "                                  'immunohistochemistry (IHC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36205311'],\n",
      " 'resourceScore': 60,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'The clinical efficacy of anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy in Chinese '\n",
      "                                  'advanced NSCLC patients is closely related '\n",
      "                                  'to the gut microbiota, and Bifidobacterium '\n",
      "                                  'breve may be a potential biomarker to '\n",
      "                                  'predict the efficacy of immune‐combined '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'To explore the effect of anti‐PD‐1 '\n",
      "                                  'immunotherapy combined with chemotherapy on '\n",
      "                                  'the gut microbiota of NSCLC patients, this '\n",
      "                                  'study analyzed paired stool samples from 15 '\n",
      "                                  'NSCLC patients before treatment (before '\n",
      "                                  'group) and after treatment (after group).'},\n",
      "                         {'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting anti‐programmed cell death '\n",
      "                                  'protein 1 (PD‐1) or its ligand (PD‐L1) have '\n",
      "                                  'significantly changed the treatment and '\n",
      "                                  'management of locally advanced and advanced '\n",
      "                                  'NSCLC.2, 3, 4'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 140,\n",
      "                          'tStart': 136,\n",
      "                          'text': 'The important thing is that this study '\n",
      "                                  'analyzed that B.breve in the gut '\n",
      "                                  'significantly affects the mPFS of NSCLC '\n",
      "                                  'patients receiving anti‐PD‐1 immunotherapy '\n",
      "                                  'combined with chemotherapy, and B.breve may '\n",
      "                                  'be an effective biomarker to predict its '\n",
      "                                  'clinical benefit.'},\n",
      "                         {'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting anti‐programmed cell death '\n",
      "                                  'protein 1 (PD‐1) or its ligand (PD‐L1) have '\n",
      "                                  'significantly changed the treatment and '\n",
      "                                  'management of locally advanced and advanced '\n",
      "                                  'NSCLC.2, 3, 4'},\n",
      "                         {'dEnd': 225,\n",
      "                          'dStart': 220,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'In this study, we mainly performed 16S '\n",
      "                                  'sequencing on fecal samples of NSCLC '\n",
      "                                  'patients who received anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy to explore '\n",
      "                                  'whether there were significant changes in '\n",
      "                                  'the intestinal flora of NSCLC patients '\n",
      "                                  'after the combination therapy.'},\n",
      "                         {'dEnd': 36,\n",
      "                          'dStart': 31,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'Changes of intestinal flora in NSCLC '\n",
      "                                  'patients before and after anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy'},\n",
      "                         {'dEnd': 47,\n",
      "                          'dStart': 42,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Metabolic difference analysis showed that '\n",
      "                                  'NSCLC patients received PD‐1 immunotherapy '\n",
      "                                  'combined with chemotherapy accompanied by '\n",
      "                                  'significant metabolic changes.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Bifidobacterium breve predicts the efficacy '\n",
      "                                  'of anti‐PD‐1 immunotherapy combined with '\n",
      "                                  'chemotherapy in Chinese NSCLC patients'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'The clinical efficacy of anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy in NSCLC '\n",
      "                                  'patients is closely related to the '\n",
      "                                  'intestinal flora'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 112,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'Predictive effect of bifidobacteria on the '\n",
      "                                  'clinical efficacy of anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy in NSCLC'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'The combination of radiotherapy and '\n",
      "                                  'oxidative phosphorylation inhibitors has '\n",
      "                                  'been proved to be an effective strategy '\n",
      "                                  'against PD‐1 resistance in NSCLC.36'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'The effect of intestinal microbiota on PD‐1 '\n",
      "                                  'immunotherapy combined with chemotherapy in '\n",
      "                                  'Chinese NSCLC patients remains unclear.'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'To explore the effect of anti‐PD‐1 '\n",
      "                                  'immunotherapy combined with chemotherapy on '\n",
      "                                  'the gut microbiota of NSCLC patients, this '\n",
      "                                  'study analyzed paired stool samples from 15 '\n",
      "                                  'NSCLC patients before treatment (before '\n",
      "                                  'group) and after treatment (after group).'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'In this study, we mainly performed 16S '\n",
      "                                  'sequencing on fecal samples of NSCLC '\n",
      "                                  'patients who received anti‐PD‐1 therapy '\n",
      "                                  'combined with chemotherapy to explore '\n",
      "                                  'whether there were significant changes in '\n",
      "                                  'the intestinal flora of NSCLC patients '\n",
      "                                  'after the combination therapy.'},\n",
      "                         {'dEnd': 12,\n",
      "                          'dStart': 7,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'In the NSCLC group, 12 patients received '\n",
      "                                  'anti‐PD‐1 therapy combined with '\n",
      "                                  'chemotherapy as first‐line therapy, and the '\n",
      "                                  'remaining 9 patients started therapy after '\n",
      "                                  'failure of previous therapy.'},\n",
      "                         {'dEnd': 67,\n",
      "                          'dStart': 62,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'The study analyzed the characteristics of '\n",
      "                                  'intestinal flora in NSCLC patients '\n",
      "                                  'receiving anti‐PD‐1 immunotherapy combined '\n",
      "                                  'with chemotherapy.'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 263,\n",
      "                          'tStart': 259,\n",
      "                          'text': 'Compared with patients who did not benefit '\n",
      "                                  'from clinical practice, there was a '\n",
      "                                  'significant enrichment of Bifidobacterium, '\n",
      "                                  'Escherichia, and Sarterella in the '\n",
      "                                  'intestinal flora of patients with clinical '\n",
      "                                  'benefit, which could predict NSCLC patients '\n",
      "                                  'receiving anti‐PD‐1 Efficacy of treatment '\n",
      "                                  'combined with chemotherapy.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39670021'],\n",
      " 'resourceScore': 59,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 antibody plus chemotherapy may '\n",
      "                                  'offer greater clinical benefits for NSCLC '\n",
      "                                  'patients compared to chemotherapy alone.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), such '\n",
      "                                  'as programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitors, have significantly transformed '\n",
      "                                  'the treatment strategy for NSCLC, '\n",
      "                                  'particularly in patients without epidermal '\n",
      "                                  'growth factor receptor (EGFR) or anaplastic '\n",
      "                                  'lymphoma kinase (ALK) gene mutations.'},\n",
      "                         {'dEnd': 88,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 118,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'However, data on baseline peripheral blood '\n",
      "                                  'D-dimer and platelet levels in stage IV '\n",
      "                                  'NSCLC patients undergoing anti-PD-1 '\n",
      "                                  'antibody are scarce.'},\n",
      "                         {'dEnd': 88,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'The predictive value of baseline plasma '\n",
      "                                  'D-dimer for anti-PD-1 antibody in stage IV '\n",
      "                                  'NSCLC patients without driver gene '\n",
      "                                  'mutations remains unclear.'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 183,\n",
      "                          'tStart': 179,\n",
      "                          'text': 'Nevertheless, in our research, we found '\n",
      "                                  'that high baseline D-dimer and platelet '\n",
      "                                  'levels are significantly associated with '\n",
      "                                  'poor prognosis in stage IV NSCLC patients '\n",
      "                                  'undergoing anti-PD-1 antibody.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 286,\n",
      "                          'tStart': 282,\n",
      "                          'text': 'This study collected demographic '\n",
      "                                  'information and clinical-pathological '\n",
      "                                  'characteristics of stage IV NSCLC patients '\n",
      "                                  'without driver gene mutations to explore '\n",
      "                                  'the predictive value of baseline peripheral '\n",
      "                                  'blood D-dimer and platelet levels as '\n",
      "                                  'biomarkers for prognosis and efficacy of '\n",
      "                                  'anti-PD-1 antibody.'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': 'Additionally, statistical analysis of '\n",
      "                                  'distant metastasis sites (lung, pleura, '\n",
      "                                  'abdomen, and brain) did not confirm their '\n",
      "                                  'association with PFS in stage IV NSCLC '\n",
      "                                  'patients treated with anti-PD-1 '\n",
      "                                  'antibodies.'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 155,\n",
      "                          'tStart': 151,\n",
      "                          'text': 'Baseline plasma D-dimer and platelet levels '\n",
      "                                  'are negatively correlated with PFS in stage '\n",
      "                                  'IV NSCLC patients without driver gene '\n",
      "                                  'mutations receiving anti-PD-1 antibody, '\n",
      "                                  'making them important predictive biomarkers '\n",
      "                                  'for prognosis.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'Pretreatment plasma D-dimer and platelet '\n",
      "                                  'levels could serve as convenient prognostic '\n",
      "                                  'biomarkers for stage IV NSCLC patients '\n",
      "                                  'without driver gene mutations receiving '\n",
      "                                  'anti-PD-1 antibody.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'Therefore, identifying simpler and more '\n",
      "                                  'precise predictive biomarkers for NSCLC '\n",
      "                                  'patients undergoing anti-PD-1 antibody is '\n",
      "                                  'urgent.'},\n",
      "                         {'dEnd': 377,\n",
      "                          'dStart': 372,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'Given that stage IV NSCLC patients are '\n",
      "                                  'often treated with anti-PD-1 antibody '\n",
      "                                  'combined chemotherapy, this study includes '\n",
      "                                  'a control group of patients treated with '\n",
      "                                  'chemotherapy alone to compare with the '\n",
      "                                  'anti-PD-1 plus chemotherapy group, aiming '\n",
      "                                  'to validate the relationship between '\n",
      "                                  'baseline plasma D-dimer and platelet levels '\n",
      "                                  'and prognosis and treatment efficacy in '\n",
      "                                  'stage IV NSCLC patients receiving anti-PD-1 '\n",
      "                                  'antibody.'},\n",
      "                         {'dEnd': 262,\n",
      "                          'dStart': 257,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Patients receiving first-line anti-PD-1 '\n",
      "                                  'antibody plus chemotherapy have better '\n",
      "                                  'prognosis, while those with high baseline '\n",
      "                                  'D-dimer and platelet levels have worse '\n",
      "                                  'prognosis; (II) differences in first-line '\n",
      "                                  'treatment regimens are associated with ORR '\n",
      "                                  'in stage IV NSCLC patients (P<0.001).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), such '\n",
      "                                  'as programmed cell death protein 1 (PD-1) '\n",
      "                                  'inhibitors, have significantly transformed '\n",
      "                                  'the treatment strategy for NSCLC, '\n",
      "                                  'particularly in patients without epidermal '\n",
      "                                  'growth factor receptor (EGFR) or anaplastic '\n",
      "                                  'lymphoma kinase (ALK) gene mutations.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 286,\n",
      "                          'tStart': 282,\n",
      "                          'text': 'Although some research has explored '\n",
      "                                  'platelet count’s impact on prognosis in '\n",
      "                                  'initially treated, unresectable stage '\n",
      "                                  'III/IV NSCLC patients (40), studies on '\n",
      "                                  'platelet count’s correlation with efficacy '\n",
      "                                  'and prognosis in stage IV NSCLC patients '\n",
      "                                  'without driver gene mutations receiving '\n",
      "                                  'anti-PD-1 antibody are scarce.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 159,\n",
      "                          'tStart': 155,\n",
      "                          'text': 'Association of baseline plasma D-dimer and '\n",
      "                                  'platelets with progression-free survival in '\n",
      "                                  'patients with stage IV non-small cell lung '\n",
      "                                  'cancer treated with anti-PD-1 antibody'},\n",
      "                         {'dEnd': 25,\n",
      "                          'dStart': 20,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'Given that stage IV NSCLC patients are '\n",
      "                                  'often treated with anti-PD-1 antibody '\n",
      "                                  'combined chemotherapy, this study includes '\n",
      "                                  'a control group of patients treated with '\n",
      "                                  'chemotherapy alone to compare with the '\n",
      "                                  'anti-PD-1 plus chemotherapy group, aiming '\n",
      "                                  'to validate the relationship between '\n",
      "                                  'baseline plasma D-dimer and platelet levels '\n",
      "                                  'and prognosis and treatment efficacy in '\n",
      "                                  'stage IV NSCLC patients receiving anti-PD-1 '\n",
      "                                  'antibody.'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'We first generated survival curves for the '\n",
      "                                  '150 stage IV NSCLC patients using the '\n",
      "                                  'Kaplan-Meier method to compare PFS between '\n",
      "                                  'the anti-PD-1 plus chemotherapy group and '\n",
      "                                  'the chemotherapy group, with validation '\n",
      "                                  'using the log-rank test.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Therefore, identifying biomarkers that '\n",
      "                                  'predict the efficacy and prognosis of '\n",
      "                                  'anti-PD-1 antibody in NSCLC patients is '\n",
      "                                  'crucial for advancing more effective, '\n",
      "                                  'precise, and individualized treatment '\n",
      "                                  'plans.'},\n",
      "                         {'dEnd': 377,\n",
      "                          'dStart': 372,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 209,\n",
      "                          'tStart': 205,\n",
      "                          'text': 'Given that stage IV NSCLC patients are '\n",
      "                                  'often treated with anti-PD-1 antibody '\n",
      "                                  'combined chemotherapy, this study includes '\n",
      "                                  'a control group of patients treated with '\n",
      "                                  'chemotherapy alone to compare with the '\n",
      "                                  'anti-PD-1 plus chemotherapy group, aiming '\n",
      "                                  'to validate the relationship between '\n",
      "                                  'baseline plasma D-dimer and platelet levels '\n",
      "                                  'and prognosis and treatment efficacy in '\n",
      "                                  'stage IV NSCLC patients receiving anti-PD-1 '\n",
      "                                  'antibody.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'Considering the current state of anti-PD-1 '\n",
      "                                  'antibody combined chemotherapy for stage IV '\n",
      "                                  'NSCLC, we established a chemotherapy group '\n",
      "                                  'as a control to more clearly define the '\n",
      "                                  'advantages of anti-PD-1 antibody therapy.'},\n",
      "                         {'dEnd': 56,\n",
      "                          'dStart': 51,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Soyano et al.’s retrospective analysis of '\n",
      "                                  'advanced NSCLC patients did not find a '\n",
      "                                  'correlation between platelet count prior to '\n",
      "                                  'anti-PD-1 antibody and PFS or OS (52).'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 231,\n",
      "                          'tStart': 200,\n",
      "                          'text': 'However, it remains unclear whether '\n",
      "                                  'pretreatment D-dimer and platelets can '\n",
      "                                  'serve as biomarkers for predicting efficacy '\n",
      "                                  'and prognosis in stage IV NSCLC patients '\n",
      "                                  'without driver gene mutations receiving '\n",
      "                                  'programmed cell death protein 1 (PD-1) '\n",
      "                                  'antibody.'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 184,\n",
      "                          'tStart': 180,\n",
      "                          'text': 'In this study, we compared the impact of '\n",
      "                                  'different first-line treatment regimens on '\n",
      "                                  'the prognosis of patients with stage IV '\n",
      "                                  'NSCLC and found that patients receiving '\n",
      "                                  'first-line anti-PD-1 antibody plus '\n",
      "                                  'chemotherapy had better survival outcomes.'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'However, these biomarkers have not '\n",
      "                                  'accurately predicted responses to anti-PD-1 '\n",
      "                                  'antibody in NSCLC patients, and their '\n",
      "                                  'associated testing methods face significant '\n",
      "                                  'challenges in clinical practice.'},\n",
      "                         {'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Li et al.’s retrospective analysis of '\n",
      "                                  'advanced NSCLC patients (stage IIIB–IV) '\n",
      "                                  'planned for anti-PD-1 or anti-PD-L1 therapy '\n",
      "                                  'observed that high D-dimer levels prior to '\n",
      "                                  'immunotherapy are an independent risk '\n",
      "                                  'factor for poor prognosis (17).'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 272,\n",
      "                          'tStart': 268,\n",
      "                          'text': 'Univariate Cox regression analysis revealed '\n",
      "                                  'that high baseline plasma D-dimer (HR: '\n",
      "                                  '2.114, 95% CI: 1.231–3.631, P=0.007) and '\n",
      "                                  'high platelet levels (HR: 2.136, 95% CI: '\n",
      "                                  '1.233–3.700, P=0.007) are significant '\n",
      "                                  'factors affecting PFS in stage IV NSCLC '\n",
      "                                  'patients undergoing anti-PD-1 antibody plus '\n",
      "                                  'chemotherapy.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38528526'],\n",
      " 'resourceScore': 59,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 47,\n",
      "                          'dStart': 42,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'Currently, advanced non-oncogene addicted '\n",
      "                                  'NSCLC patients are treated in first line '\n",
      "                                  'either with the combination of '\n",
      "                                  'anti-PD-1/PD-L1 mAbs and chemotherapy or '\n",
      "                                  'with anti-PD-1/PD-L1 mAbs alone, based on '\n",
      "                                  'PD-L1 tumor expression < 50% or ≥ 50% [26, '\n",
      "                                  '27].'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'rs822336 efficiently predicted response to '\n",
      "                                  'anti-PD-1/PD-L1 immunotherapy in advanced '\n",
      "                                  'non-oncogene addicted NSCLC patients as '\n",
      "                                  'compared to rs2282055 and rs4143815.'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'As a result, whether rs822336 genotype can '\n",
      "                                  'also influence the susceptibility to '\n",
      "                                  'anti-PD-1/PD-L1 therapy in EGFRmut NSCLC '\n",
      "                                  'should be further investigated.'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 240,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 203,\n",
      "                          'tStart': 199,\n",
      "                          'text': 'To assess the functional significance of '\n",
      "                                  'the changes induced by rs822336 on the '\n",
      "                                  'clinical activity of anti-PD-1 based '\n",
      "                                  'immunotherapy and/or PD-L1 induction by '\n",
      "                                  'IFN-ɣ, we investigated the effect of '\n",
      "                                  'anti-PD-1 mAb nivolumab on the recognition '\n",
      "                                  'of NSCLC cells carrying different rs822336 '\n",
      "                                  'genotypes by activated HLA class I antigen '\n",
      "                                  'matched peripheral blood mononuclear cells '\n",
      "                                  '(HLA-matched PBMCs).'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 240,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'To assess the functional significance of '\n",
      "                                  'the changes induced by rs822336 on the '\n",
      "                                  'clinical activity of anti-PD-1 based '\n",
      "                                  'immunotherapy and/or PD-L1 induction by '\n",
      "                                  'IFN-ɣ, we investigated the effect of '\n",
      "                                  'anti-PD-1 mAb nivolumab on the recognition '\n",
      "                                  'of NSCLC cells carrying different rs822336 '\n",
      "                                  'genotypes by activated HLA class I antigen '\n",
      "                                  'matched peripheral blood mononuclear cells '\n",
      "                                  '(HLA-matched PBMCs).'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 200,\n",
      "                          'tStart': 196,\n",
      "                          'text': 'Overall, we believe that our findings have '\n",
      "                                  'high clinical relevance since identify '\n",
      "                                  'rs822336 and induction of PD-L1 expression '\n",
      "                                  'as novel and efficient predictive '\n",
      "                                  'biomarkers of tumor response to '\n",
      "                                  'anti-PD-1/PD-L1 therapy in patients with '\n",
      "                                  'advanced non-oncogene addicted NSCLC.'},\n",
      "                         {'dEnd': 253,\n",
      "                          'dStart': 248,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 185,\n",
      "                          'tStart': 181,\n",
      "                          'text': 'rs822336 mapped to the promoter/enhancer '\n",
      "                                  'region of PD-L1. In order to study the '\n",
      "                                  'mechanisms underlying the modulation by '\n",
      "                                  'rs822336 allele-specificity of the in vitro '\n",
      "                                  'activity of anti-PD-1 associated to a '\n",
      "                                  'differential induction of PD-L1 expression '\n",
      "                                  'on NSCLC cells we investigated whether '\n",
      "                                  'differential TFs binding to rs822336 '\n",
      "                                  'allele-specificity might affect PD-L1 '\n",
      "                                  'expression.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 73,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'In addition, rs822336 efficiently predicted '\n",
      "                                  'clinical benefit to anti-PD-1/PD-L1 mAbs in '\n",
      "                                  'advanced non-oncogene addicted NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'Modulation by rs822336 of the in vitro '\n",
      "                                  'activity of anti-PD-1 nivolumab on NSCLC '\n",
      "                                  'cells co-cultured with HLA class I antigen '\n",
      "                                  'matched PBMCs'},\n",
      "                         {'dEnd': 257,\n",
      "                          'dStart': 252,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'Recently, immunotherapy with immune '\n",
      "                                  'checkpoint inhibitors (ICIs) such as '\n",
      "                                  'programmed cell death-1 (PD-1)- and '\n",
      "                                  'programmed death-ligand 1 (PD-L1) '\n",
      "                                  'monoclonal antibodies (mAbs) has '\n",
      "                                  'revolutionized the treatment algorithm of '\n",
      "                                  'several types of cancer including NSCLC '\n",
      "                                  '[16–23].'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'Indeed, oncogene addicted NSCLC patients '\n",
      "                                  'such as those carrying EGFR alterations are '\n",
      "                                  'shown to be resistant to anti-PD-1/PD-L1 '\n",
      "                                  'mAbs [76] although there is also data '\n",
      "                                  'suggesting that activating EGFR mutations '\n",
      "                                  'led to PD-L1 upregulation in NSCLC as well '\n",
      "                                  'as animal models showing increase survival '\n",
      "                                  'after PD-1 therapy in EGFR driven '\n",
      "                                  'adenocarcinoma [77–80].'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'This data validated the role of rs822336 on '\n",
      "                                  'in vitro sensitivity of NSCLC cells to '\n",
      "                                  'anti-PD-1.'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 142,\n",
      "                          'text': 'These findings have high clinical relevance '\n",
      "                                  'since identify rs822336 and induction of '\n",
      "                                  'PD-L1 expression as novel biomarkers for '\n",
      "                                  'predicting anti-PD-1/PD-L1-based '\n",
      "                                  'immunotherapy in advanced NSCLC patients.'},\n",
      "                         {'dEnd': 257,\n",
      "                          'dStart': 252,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Recently, immunotherapy with immune '\n",
      "                                  'checkpoint inhibitors (ICIs) such as '\n",
      "                                  'programmed cell death-1 (PD-1)- and '\n",
      "                                  'programmed death-ligand 1 (PD-L1) '\n",
      "                                  'monoclonal antibodies (mAbs) has '\n",
      "                                  'revolutionized the treatment algorithm of '\n",
      "                                  'several types of cancer including NSCLC '\n",
      "                                  '[16–23].'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'rs822336 binding to C/EBPβ and NFIC '\n",
      "                                  'modulates induction of PD-L1 expression and '\n",
      "                                  'predicts anti-PD-1/PD-L1 therapy in '\n",
      "                                  'advanced NSCLC'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1/PD-L1 therapy has revolutionized '\n",
      "                                  'the therapeutic management of several types '\n",
      "                                  'of cancer including NSCLC [16–22, 65].'},\n",
      "                         {'dEnd': 275,\n",
      "                          'dStart': 270,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 183,\n",
      "                          'tStart': 179,\n",
      "                          'text': 'Lastly, the functional significance of the '\n",
      "                                  'changes induced by rs822336 on the '\n",
      "                                  'induction of PD-L1 expression as well as '\n",
      "                                  'the predictive value of rs822336 on the '\n",
      "                                  'sensitivity to anti-PD-1/PD-L1-based '\n",
      "                                  'immunotherapy is demonstrated by the in '\n",
      "                                  'vitro differential recognition of NSCLC '\n",
      "                                  'cells carrying different rs822336 genotypes '\n",
      "                                  'utilizing HLA-matched PBMCs, and incubation '\n",
      "                                  'with anti-PD-1 nivolumab.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['29892065'],\n",
      " 'resourceScore': 58,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 181,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'To address these issues, we analyzed the '\n",
      "                                  'properties of three populations of '\n",
      "                                  'intratumoral CD8+ TILs with defined levels '\n",
      "                                  'of PD-1 expression in patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC): CD8+ '\n",
      "                                  'TILs without detectable PD-1 expression '\n",
      "                                  '(PD-1-), CD8+ TILs with a PD-1 expression '\n",
      "                                  'level similar to that on healthy donor '\n",
      "                                  'PBMCs (PD-1N), and CD8+ TILs with levels of '\n",
      "                                  'PD-1 that exceed those commonly observed on '\n",
      "                                  'healthy donor PBMCs (PD-1T).'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 122,\n",
      "                          'text': 'To address these issues, we analyzed the '\n",
      "                                  'properties of three populations of '\n",
      "                                  'intratumoral CD8+ TILs with defined levels '\n",
      "                                  'of PD-1 expression in patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC): CD8+ '\n",
      "                                  'TILs without detectable PD-1 expression '\n",
      "                                  '(PD-1-), CD8+ TILs with a PD-1 expression '\n",
      "                                  'level similar to that on healthy donor '\n",
      "                                  'PBMCs (PD-1N), and CD8+ TILs with levels of '\n",
      "                                  'PD-1 that exceed those commonly observed on '\n",
      "                                  'healthy donor PBMCs (PD-1T).'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 255,\n",
      "                          'tStart': 251,\n",
      "                          'text': 'As effector functions are gradually lost '\n",
      "                                  'during progressive T cell exhaustion8, with '\n",
      "                                  'a recent study reporting an inverse '\n",
      "                                  'correlation between T cell function and '\n",
      "                                  'PD-1 expression levels21, we first assessed '\n",
      "                                  'cytokine secretion by sorted PD-1T, PD-1N '\n",
      "                                  'and PD-1- TILs from three NSCLC samples '\n",
      "                                  '(Supplementary Fig. 1f,g).'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'We compared transcriptional, metabolic, and '\n",
      "                                  'functional signatures of intratumoral CD8+ '\n",
      "                                  'T lymphocyte populations with high (PD-1T), '\n",
      "                                  'intermediate (PD-1N) and no PD-1 expression '\n",
      "                                  '(PD-1-) from non-small cell lung cancer '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 296,\n",
      "                          'dStart': 291,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'To first understand whether the expression '\n",
      "                                  'level of PD-1 can be used to identify '\n",
      "                                  'tumor-infiltrating CD8+ T cells that differ '\n",
      "                                  'in the expression of other inhibitory '\n",
      "                                  'receptors18–20, we determined the '\n",
      "                                  'expression of Tim-3, Lag-3, TIGIT, 2B4 '\n",
      "                                  '(CD244), and BTLA in nine subsets of CD8+ '\n",
      "                                  'TILs from 24 NSCLC specimens that were '\n",
      "                                  'subdivided according to their PD-1 mean '\n",
      "                                  'fluorescence intensity (MFI) (Fig. 1a and '\n",
      "                                  'Supplementary Fig. 1a).'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'To establish a more objective subdivision '\n",
      "                                  'of PD-1+ populations that can be applied '\n",
      "                                  'across studies, we compared the PD-1 '\n",
      "                                  'expression levels on NSCLC TILs with those '\n",
      "                                  'of peripheral blood T cells from healthy '\n",
      "                                  'donors.'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 165,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'As effector functions are gradually lost '\n",
      "                                  'during progressive T cell exhaustion8, with '\n",
      "                                  'a recent study reporting an inverse '\n",
      "                                  'correlation between T cell function and '\n",
      "                                  'PD-1 expression levels21, we first assessed '\n",
      "                                  'cytokine secretion by sorted PD-1T, PD-1N '\n",
      "                                  'and PD-1- TILs from three NSCLC samples '\n",
      "                                  '(Supplementary Fig. 1f,g).'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'A transcriptionally and functionally '\n",
      "                                  'distinct PD-1+ CD8+ T cell pool with '\n",
      "                                  'predictive potential in non-small cell lung '\n",
      "                                  'cancer treated with PD-1 blockade'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'Furthermore, the presence of PD-1T TILs was '\n",
      "                                  'highly predictive for response and survival '\n",
      "                                  'upon anti-PD-1 treatment in NSCLC.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'To establish a more objective subdivision '\n",
      "                                  'of PD-1+ populations that can be applied '\n",
      "                                  'across studies, we compared the PD-1 '\n",
      "                                  'expression levels on NSCLC TILs with those '\n",
      "                                  'of peripheral blood T cells from healthy '\n",
      "                                  'donors.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': 'In support of this, retrospective analysis '\n",
      "                                  'of PD-1T TIL infiltration in pretreatment '\n",
      "                                  'biopsies of NSCLC patients undergoing '\n",
      "                                  'anti-PD-1 therapy revealed a clear '\n",
      "                                  'correlation between the frequency of these '\n",
      "                                  'cells and both treatment response and '\n",
      "                                  'patient survival.'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'Having validated this strategy for '\n",
      "                                  'quantitative analysis of PD-1T cell levels, '\n",
      "                                  'we applied this method to evaluate the '\n",
      "                                  'presence of PD-1T cells in pretreatment '\n",
      "                                  'biopsies of 21 stage IV NSCLC patients '\n",
      "                                  'undergoing anti-PD-1 therapy (Supplementary '\n",
      "                                  'Fig. 6d).'},\n",
      "                         {'dEnd': 38,\n",
      "                          'dStart': 33,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'Our data show that PD-1T TILs in NSCLC are '\n",
      "                                  'a highly exhausted T cell subset that '\n",
      "                                  'displays profound molecular, metabolic and '\n",
      "                                  'functional differences relative to PD-1N '\n",
      "                                  'and PD-1- TILs, and that also contains the '\n",
      "                                  'bulk of the tumor recognition potential of '\n",
      "                                  'intratumoral CD8+ lymphocytes.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 163,\n",
      "                          'tStart': 159,\n",
      "                          'text': 'We compared transcriptional, metabolic, and '\n",
      "                                  'functional signatures of intratumoral CD8+ '\n",
      "                                  'T lymphocyte populations with high (PD-1T), '\n",
      "                                  'intermediate (PD-1N) and no PD-1 expression '\n",
      "                                  '(PD-1-) from non-small cell lung cancer '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Here we describe the properties of T cells '\n",
      "                                  'with different PD-1 expression levels in '\n",
      "                                  'NSCLC and their potential relationship with '\n",
      "                                  'immune-mediated tumor control.'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'Strikingly, the presence of PD-1T cells was '\n",
      "                                  'strongly predictive for both response and '\n",
      "                                  'survival in a small cohort of non-small '\n",
      "                                  'cell lung cancer patients treated with PD-1 '\n",
      "                                  'blockade.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39027153'],\n",
      " 'resourceScore': 57,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 48,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1/PD-L1 immunotherapy in stage III '\n",
      "                                  'NSCLC has not yet been established, and '\n",
      "                                  'until the completion of this review, the '\n",
      "                                  'only anti-PD-1/PD-L1 agents approved for '\n",
      "                                  'stage III NSCLC were durvalumab as '\n",
      "                                  'consolidation therapy in patients with '\n",
      "                                  'unresectable tumors and without disease '\n",
      "                                  'progression after first-line concurrent '\n",
      "                                  'chemoradiation therapy7 and adjuvant '\n",
      "                                  'atezolizumab in patients with surgically '\n",
      "                                  'removed tumors after adjuvant chemotherapy '\n",
      "                                  'and with tumor PD-L1 expression of at least '\n",
      "                                  '1%.5'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Eight studies17,18,20,22, 23, 24,26,27 on '\n",
      "                                  'first-line PD-1 inhibitors administered for '\n",
      "                                  'advanced NSCLC that included 680 '\n",
      "                                  'participants were grouped together; '\n",
      "                                  'however, the OS and PFS benefits could not '\n",
      "                                  'be estimated.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Programmed death 1 (PD-1) and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitors are '\n",
      "                                  'widely used to treat stage IV NSCLC.'},\n",
      "                         {'dEnd': 180,\n",
      "                          'dStart': 175,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1/PD-L1 immunotherapy in stage III '\n",
      "                                  'NSCLC has not yet been established, and '\n",
      "                                  'until the completion of this review, the '\n",
      "                                  'only anti-PD-1/PD-L1 agents approved for '\n",
      "                                  'stage III NSCLC were durvalumab as '\n",
      "                                  'consolidation therapy in patients with '\n",
      "                                  'unresectable tumors and without disease '\n",
      "                                  'progression after first-line concurrent '\n",
      "                                  'chemoradiation therapy7 and adjuvant '\n",
      "                                  'atezolizumab in patients with surgically '\n",
      "                                  'removed tumors after adjuvant chemotherapy '\n",
      "                                  'and with tumor PD-L1 expression of at least '\n",
      "                                  '1%.5'},\n",
      "                         {'dEnd': 286,\n",
      "                          'dStart': 281,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 235,\n",
      "                          'tStart': 231,\n",
      "                          'text': 'OS and PFS were improved (risk ratio [RR]: '\n",
      "                                  '0.85; 95% confidence interval [CI]: '\n",
      "                                  '0.75–0.96 and RR: 0.75; 95% CI: 0.70–0.86, '\n",
      "                                  'respectively) based on the use of PD-L1 '\n",
      "                                  'inhibitors after chemoradiation and OS was '\n",
      "                                  'improved using first-line PD-1 inhibitors '\n",
      "                                  'plus chemotherapy in non-squamous NSCLC '\n",
      "                                  '(RR: 0.40; 95% CI: 0.17–0.95), with the '\n",
      "                                  'GRADE results indicating moderate quality '\n",
      "                                  'of evidence.'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'In this systematic review, we aimed to '\n",
      "                                  'provide an overall picture of the efficacy '\n",
      "                                  'of all PD-1/PD-L1 inhibitors administered '\n",
      "                                  'for all patients with stage III NSCLC and '\n",
      "                                  'perform appropriate subanalyses according '\n",
      "                                  \"to the patient's histology, tumor PD-L1 \"\n",
      "                                  'expression levels, and timeline of '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'This study systematically reviewed the '\n",
      "                                  'literature to clarify the effects of '\n",
      "                                  'PD-1/PD-L1 inhibitor treatment on the '\n",
      "                                  'survival of patients diagnosed with stage '\n",
      "                                  'III NSCLC.'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Impact of PD-1/PD-L1 inhibitors on survival '\n",
      "                                  'in stage III non-small-cell lung cancer: A '\n",
      "                                  'systematic review'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Randomized phase III clinical trials of '\n",
      "                                  'PD-1/PD-L1 inhibitors administered to '\n",
      "                                  'patients with stage III NSCLC that were '\n",
      "                                  'written in English and published between '\n",
      "                                  'November 2012 and November 2022 were '\n",
      "                                  'eligible for review.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Two studies5,21 on adjuvant PD-1/PD-L1 '\n",
      "                                  'inhibitors administered for resected NSCLC '\n",
      "                                  'that included 752 participants were grouped '\n",
      "                                  'together; however, the DFS benefit could '\n",
      "                                  'not be estimated.'},\n",
      "                         {'dEnd': 286,\n",
      "                          'dStart': 281,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'The evidence presented in this review '\n",
      "                                  'points to the expansion of '\n",
      "                                  'anti-PD-1/anti-PD-L1 immunotherapy in stage '\n",
      "                                  'III NSCLC, and such therapeutic strategy '\n",
      "                                  'could become more robust if future clinical '\n",
      "                                  'trials of PD-1/PD-L1 inhibitors are '\n",
      "                                  'designed to mainly include patients with '\n",
      "                                  'stage III NSCLC according to the '\n",
      "                                  'appropriate characteristics, such as '\n",
      "                                  'histological subtype or PD-L1 expression '\n",
      "                                  'levels.'},\n",
      "                         {'dEnd': 180,\n",
      "                          'dStart': 175,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Anti-PD-1/PD-L1 immunotherapy in stage III '\n",
      "                                  'NSCLC has not yet been established, and '\n",
      "                                  'until the completion of this review, the '\n",
      "                                  'only anti-PD-1/PD-L1 agents approved for '\n",
      "                                  'stage III NSCLC were durvalumab as '\n",
      "                                  'consolidation therapy in patients with '\n",
      "                                  'unresectable tumors and without disease '\n",
      "                                  'progression after first-line concurrent '\n",
      "                                  'chemoradiation therapy7 and adjuvant '\n",
      "                                  'atezolizumab in patients with surgically '\n",
      "                                  'removed tumors after adjuvant chemotherapy '\n",
      "                                  'and with tumor PD-L1 expression of at least '\n",
      "                                  '1%.5'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Two studies17,23 on first-line PD-1 '\n",
      "                                  'inhibitors as combination therapy '\n",
      "                                  'administered for non-squamous NSCLC that '\n",
      "                                  'included 97 participants were grouped '\n",
      "                                  'together and showed statistically '\n",
      "                                  'significant improvements in OS (RR: 0.40; '\n",
      "                                  '95% CI: 0.17–0.95), with moderate quality '\n",
      "                                  'of evidence.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 20,\n",
      "                          'text': 'Two studies26,27 on PD-1 inhibitors '\n",
      "                                  'administered for PD-L1-expressing NSCLC '\n",
      "                                  'that included 247 participants were grouped '\n",
      "                                  'together and showed statistically '\n",
      "                                  'insignificant improvements in PFS (RR: '\n",
      "                                  '0.90; 95% CI: 0.65–1.24), with low quality '\n",
      "                                  'of evidence.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'This study systematically reviewed the '\n",
      "                                  'literature to clarify the impact of '\n",
      "                                  'PD-1/PD-L1 inhibitor treatment on the '\n",
      "                                  'survival of patients with stage III NSCLC.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 16,\n",
      "                          'tStart': 12,\n",
      "                          'text': '•First-line PD-1 inhibitors plus '\n",
      "                                  'chemotherapy improved overall survival in '\n",
      "                                  'unresected non-squamous stage III NSCLC.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'The evidence presented in this review '\n",
      "                                  'points to the expansion of '\n",
      "                                  'anti-PD-1/anti-PD-L1 immunotherapy in stage '\n",
      "                                  'III NSCLC, and such therapeutic strategy '\n",
      "                                  'could become more robust if future clinical '\n",
      "                                  'trials of PD-1/PD-L1 inhibitors are '\n",
      "                                  'designed to mainly include patients with '\n",
      "                                  'stage III NSCLC according to the '\n",
      "                                  'appropriate characteristics, such as '\n",
      "                                  'histological subtype or PD-L1 expression '\n",
      "                                  'levels.'},\n",
      "                         {'dEnd': 286,\n",
      "                          'dStart': 281,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 208,\n",
      "                          'tStart': 204,\n",
      "                          'text': 'The evidence presented in this review '\n",
      "                                  'points to the expansion of '\n",
      "                                  'anti-PD-1/anti-PD-L1 immunotherapy in stage '\n",
      "                                  'III NSCLC, and such therapeutic strategy '\n",
      "                                  'could become more robust if future clinical '\n",
      "                                  'trials of PD-1/PD-L1 inhibitors are '\n",
      "                                  'designed to mainly include patients with '\n",
      "                                  'stage III NSCLC according to the '\n",
      "                                  'appropriate characteristics, such as '\n",
      "                                  'histological subtype or PD-L1 expression '\n",
      "                                  'levels.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': ',34 In the neoadjuvant setting of stage III '\n",
      "                                  'NSCLC, two phase III studies will assess '\n",
      "                                  'the efficacy of adding a PD-1 inhibitor to '\n",
      "                                  'chemotherapy35,36 and one study will assess '\n",
      "                                  'the efficacy of adding the PD-L1 inhibitor '\n",
      "                                  'atezolizumab to chemotherapy.37'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['26313362'],\n",
      " 'resourceScore': 57,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 154,\n",
      "                          'tStart': 150,\n",
      "                          'text': 'The p-values of the Log rank test are '\n",
      "                                  'displayed for both, PD-1 (in TILs) and PDL1 '\n",
      "                                  '(in NSCLC tumor cells) in Table 3 and in '\n",
      "                                  'Fig 2 (Fig 2A: p-value for PD-1 in TILs = '\n",
      "                                  '0.421; Fig 2B: p-value for PD-L1 in NSCLC '\n",
      "                                  'tumor cells = 0.265).'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'With respect to therapeutic interventions, '\n",
      "                                  'inhibition of PD-1/PD-L1 is expected to '\n",
      "                                  'become a powerful therapeutic alternative '\n",
      "                                  'for NSCLC [31].'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Associations of clinicopathological '\n",
      "                                  'variables with PD-1 (in TILs) or PD-L1 (in '\n",
      "                                  'NSCLC cells).'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Overall, for advanced NSCLC patients, the '\n",
      "                                  'overall response rate (ORR) for PD-1 '\n",
      "                                  'inhibitory drugs was 24%, whereas for NSCLC '\n",
      "                                  'patients with PD-L1 expression the ORR was '\n",
      "                                  '100% compared to 15% for PD-L1 negative '\n",
      "                                  'tumors [32].'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'The present study aims at the evaluation of '\n",
      "                                  'the prognostic significance of PD-1 '\n",
      "                                  'expression in TILs and PD-L1 expression in '\n",
      "                                  'NSCLC tumor cells in a large study '\n",
      "                                  'collective of NSCLC using '\n",
      "                                  'immunohistochemistry, with a particular '\n",
      "                                  'emphasis on clinicopathological '\n",
      "                                  'parameters.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'In order to evaluate the prognostic impact '\n",
      "                                  'of tumor infiltration by PD-1 positive '\n",
      "                                  'lymphocytes and PD-L1 expression by tumor '\n",
      "                                  'cells, we performed a systematic study in a '\n",
      "                                  'well-defined collective of 321 NSCLC '\n",
      "                                  'patients undergoing primary tumor resection '\n",
      "                                  'without preceding neoadjuvant therapy.'},\n",
      "                         {'dEnd': 37,\n",
      "                          'dStart': 32,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Expression of PD-1 and PD-L1 in NSCLC'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'The present study aims at the evaluation of '\n",
      "                                  'the prognostic significance of PD-1 '\n",
      "                                  'expression in TILs and PD-L1 expression in '\n",
      "                                  'NSCLC tumor cells in a large study '\n",
      "                                  'collective of NSCLC using '\n",
      "                                  'immunohistochemistry, with a particular '\n",
      "                                  'emphasis on clinicopathological '\n",
      "                                  'parameters.'},\n",
      "                         {'dEnd': 27,\n",
      "                          'dStart': 22,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Overall, for advanced NSCLC patients, the '\n",
      "                                  'overall response rate (ORR) for PD-1 '\n",
      "                                  'inhibitory drugs was 24%, whereas for NSCLC '\n",
      "                                  'patients with PD-L1 expression the ORR was '\n",
      "                                  '100% compared to 15% for PD-L1 negative '\n",
      "                                  'tumors [32].'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'In first clinical studies, anti-PD-1 '\n",
      "                                  'antibodies have shown activity in some '\n",
      "                                  'NSCLC patients [13].'},\n",
      "                         {'dEnd': 34,\n",
      "                          'dStart': 29,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and PD-L1 Expression in NSCLC Indicate '\n",
      "                                  'a Favorable Prognosis in Defined Subgroups'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'Further studies are necessary both to '\n",
      "                                  'confirm this observation and to evaluate '\n",
      "                                  'the predictive value of PD-1 and PD-L1 in '\n",
      "                                  'NSCLC in the context of PD-1 inhibition.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 expression by tumor infiltrating '\n",
      "                                  'lymphocytes (TILs) was found in 22%, '\n",
      "                                  'whereas tumor cell associated PD-L1 '\n",
      "                                  'expression was observed in 24% of the NSCLC '\n",
      "                                  'tumors.'},\n",
      "                         {'dEnd': 206,\n",
      "                          'dStart': 201,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The p-values of the Log rank test are '\n",
      "                                  'displayed for both, PD-1 (in TILs) and PDL1 '\n",
      "                                  '(in NSCLC tumor cells) in Table 3 and in '\n",
      "                                  'Fig 2 (Fig 2A: p-value for PD-1 in TILs = '\n",
      "                                  '0.421; Fig 2B: p-value for PD-L1 in NSCLC '\n",
      "                                  'tumor cells = 0.265).'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 150,\n",
      "                          'tStart': 146,\n",
      "                          'text': 'The prognostic analysis of the full study '\n",
      "                                  'cohort, including all NSCLC histologies, '\n",
      "                                  'did not reveal any significant effect of '\n",
      "                                  'tumor infiltration by PD-1 positive '\n",
      "                                  'lymphocytes and/or PD-L1 expression of the '\n",
      "                                  'tumor cells on overall survival (Fig 2A and '\n",
      "                                  '2B).'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The p-values of the Log rank test are '\n",
      "                                  'displayed for both, PD-1 (in TILs) and PDL1 '\n",
      "                                  '(in NSCLC tumor cells) in Table 3 and in '\n",
      "                                  'Fig 2 (Fig 2A: p-value for PD-1 in TILs = '\n",
      "                                  '0.421; Fig 2B: p-value for PD-L1 in NSCLC '\n",
      "                                  'tumor cells = 0.265).'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'Univariate Log-rank test results for the '\n",
      "                                  'association of PD-1 (in TILs) or PD-L1 (in '\n",
      "                                  'NSCLC cells) with overall survival for '\n",
      "                                  'defined subgroups.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34503105'],\n",
      " 'resourceScore': 56,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 140,\n",
      "                          'dStart': 135,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'The identified CD27, PD1, and PDL1 network '\n",
      "                                  '(Figure 4A) was used to discover '\n",
      "                                  'repurposing drugs with potential '\n",
      "                                  'implications in improving NSCLC treatment '\n",
      "                                  'in combination with immunotherapy.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 48,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Immune-Omics Networks of CD27, PD1, and '\n",
      "                                  'PDL1 in Non-Small Cell Lung Cancer'},\n",
      "                         {'dEnd': 228,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'The following mechanisms of action were '\n",
      "                                  'considered in the selection of small '\n",
      "                                  'molecules: (1) to downregulate CD27, PD1, '\n",
      "                                  'and PDL1 expression; (2) to inhibit '\n",
      "                                  'proliferation genes that had a significant '\n",
      "                                  'impact in 100% of tested NSCLC cell lines '\n",
      "                                  'in CRISPR-Cas9 and RNAi assays; (3) to '\n",
      "                                  'maintain a high expression of survival '\n",
      "                                  'protection genes that expressed higher in '\n",
      "                                  'the long survival patient group; (4) to '\n",
      "                                  'downregulate the expression of survival '\n",
      "                                  'hazard genes that expressed higher in the '\n",
      "                                  'short survival patient group.'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'Like CD27, PD1, and PDL1, the identified '\n",
      "                                  'NSCLC prognostic genes and proliferation '\n",
      "                                  'genes in the immune-omics network had a '\n",
      "                                  'higher occurrence of CNVs than mutations in '\n",
      "                                  'TCGA-LUAD and LUSC tumors (Table A1 and '\n",
      "                                  'Table A2).'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'Based on the identified multi-omics network '\n",
      "                                  'of CD27, PD1, and PDL1, proliferation genes '\n",
      "                                  'were identified from CRISPR-Cas9 (n = 78) '\n",
      "                                  'and RNAi (n = 92) screening data; '\n",
      "                                  'prognostic genes were selected and '\n",
      "                                  'validated in NSCLC tumors (n = 1163).'},\n",
      "                         {'dEnd': 232,\n",
      "                          'dStart': 227,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'It was recently reported that the '\n",
      "                                  'combination of pembrolizumab (anti-PD1 '\n",
      "                                  'immunotherapy) plus docetaxel was well '\n",
      "                                  'tolerated and substantially improved '\n",
      "                                  'progression-free survival and overall '\n",
      "                                  'response rate in patients with advanced '\n",
      "                                  'NSCLC after platinum-based chemotherapy, '\n",
      "                                  'including patients with EGFR variations '\n",
      "                                  '[95].'},\n",
      "                         {'dEnd': 225,\n",
      "                          'dStart': 220,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'The results from this study showed that '\n",
      "                                  'doxorubicin, mitoxantrone, irinotecan may '\n",
      "                                  'have inhibitory effects on CD27 and PD1 '\n",
      "                                  'based on the CMap pharmacogenomic profiles '\n",
      "                                  '[54], with potential implications in '\n",
      "                                  'combined use with NSCLC immunotherapy.'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'This study identified a CNV-mediated '\n",
      "                                  'transcriptional regulatory network of CD27, '\n",
      "                                  'PD1, and PDL1 with substantiation in '\n",
      "                                  'multiple NSCLC cohorts using Boolean '\n",
      "                                  'implication networks.'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'This study provided the first evidence that '\n",
      "                                  'these agents had inhibitory effects on CD27 '\n",
      "                                  'and PD1, based on the CMap pharmacological '\n",
      "                                  'database and the CCLE NSCLC panel.'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 247,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'The final immune-omics network (Figure 4A) '\n",
      "                                  'contained genes having a direct or indirect '\n",
      "                                  'association with CD27, PD1, and PDL1, with '\n",
      "                                  'each network edge indicating a '\n",
      "                                  'co-occurrence of CNV, co-expression, or '\n",
      "                                  'CNV-mediated gene expression dysregulation '\n",
      "                                  'in NSCLC tumors observed in multiple '\n",
      "                                  'patient cohorts.'},\n",
      "                         {'dEnd': 259,\n",
      "                          'dStart': 254,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'In the identified CD27, PD1, and PDL1 '\n",
      "                                  'network (Figure 4A), multiple genes were '\n",
      "                                  'associated with chemosensitivity or '\n",
      "                                  'chemoresistance to cisplatin, docetaxel, '\n",
      "                                  'erlotinib, etoposide, gefitinib, '\n",
      "                                  'gemcitabine, paclitaxel, pemetrexed, and '\n",
      "                                  'vinorelbine in the CCLE NSCLC cell lines (n '\n",
      "                                  '= 117, Table 1).'},\n",
      "                         {'dEnd': 358,\n",
      "                          'dStart': 353,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 336,\n",
      "                          'tStart': 333,\n",
      "                          'text': 'These compounds were further selected by '\n",
      "                                  'using the following criteria in the CCLE '\n",
      "                                  'NSCLC panel (n = 117): (1) choosing the '\n",
      "                                  'small molecules with strong inhibitory '\n",
      "                                  'effects of NSCLC cells, i.e., with low IC50 '\n",
      "                                  'and EC50 values, and (2) filtering the '\n",
      "                                  'compounds with a negative correlation of '\n",
      "                                  'drug concentration and mRNA expression of '\n",
      "                                  'CD27, PD1, or PDL1 in the NSCLC cell '\n",
      "                                  'lines.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'These identified genes are '\n",
      "                                  'gnomically/transcriptomically associated '\n",
      "                                  'with ICIs, including CD27, PD1, and PDL1, '\n",
      "                                  'and are linked to chemotherapy and '\n",
      "                                  'radiotherapy response in NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34084219'],\n",
      " 'resourceScore': 56,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Among them, anti-programmed death-1 (PD-1) '\n",
      "                                  'monoclonal antibodies have been widely used '\n",
      "                                  'for treating advanced NSCLC (7–10).'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'DEG set-based prediction of the efficacy of '\n",
      "                                  'anti-PD-1 treatment in patients with '\n",
      "                                  'metastatic NSCLC'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'At present, identification of patients with '\n",
      "                                  'NSCLC for anti-PD-1 therapy is mainly based '\n",
      "                                  'on the visual assessment of PD-1 expression '\n",
      "                                  'levels in tumor tissue specimens by '\n",
      "                                  'immunohistochemistry (IHC) (16).'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 170,\n",
      "                          'tStart': 166,\n",
      "                          'text': 'The present study aimed to investigate the '\n",
      "                                  'roles of robust biomarkers in determining '\n",
      "                                  'whether patients with primary or metastatic '\n",
      "                                  'advanced NSCLC may benefit from anti-PD-1 '\n",
      "                                  'antibody treatment.'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 208,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 172,\n",
      "                          'tStart': 168,\n",
      "                          'text': 'Although DMBT1 is lowly expressed in '\n",
      "                                  'patients with NSCLC, its relatively high '\n",
      "                                  'expression levels may potentially be used '\n",
      "                                  'as an index for predicting the efficacy of '\n",
      "                                  'anti-PD-1 treatment in patients with '\n",
      "                                  'primary NSCLC.'},\n",
      "                         {'dEnd': 273,\n",
      "                          'dStart': 268,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 231,\n",
      "                          'tStart': 227,\n",
      "                          'text': 'Therefore, patients with metastatic NSCLC '\n",
      "                                  'with high expression levels of HLA-A and '\n",
      "                                  'TNFSF18 may benefit from anti-PD-1 '\n",
      "                                  'treatment, suggesting that HLA-A and '\n",
      "                                  'TNFSF18 may be potential biomarkers for '\n",
      "                                  'predicting the efficacy of anti-PD-1 '\n",
      "                                  'therapy in patients with metastatic NSCLC.'},\n",
      "                         {'dEnd': 273,\n",
      "                          'dStart': 268,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'Therefore, patients with metastatic NSCLC '\n",
      "                                  'with high expression levels of HLA-A and '\n",
      "                                  'TNFSF18 may benefit from anti-PD-1 '\n",
      "                                  'treatment, suggesting that HLA-A and '\n",
      "                                  'TNFSF18 may be potential biomarkers for '\n",
      "                                  'predicting the efficacy of anti-PD-1 '\n",
      "                                  'therapy in patients with metastatic NSCLC.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'In addition, the effects of anti-PD-1 '\n",
      "                                  'antibodies differ between patients with '\n",
      "                                  'primary and metastatic NSCLC (8).'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'In summary, the present study conducted RNA '\n",
      "                                  'IO panel sequencing to identify potential '\n",
      "                                  'biomarkers for predicting the response to '\n",
      "                                  'anti-PD-1 therapy in patients with primary '\n",
      "                                  'or metastatic NSCLC.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'The present study performed the RNA IO '\n",
      "                                  'panel sequencing on samples form 24 '\n",
      "                                  'patients with NSCLC prior to anti-PD-1 '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'The role of anti-PD-1 antibodies in the '\n",
      "                                  'first- and second-line treatment of NSCLC '\n",
      "                                  'or in the local adjuvant therapy of NSCLC '\n",
      "                                  'has been established in previous studies '\n",
      "                                  '(36–38).'},\n",
      "                         {'dEnd': 220,\n",
      "                          'dStart': 215,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 164,\n",
      "                          'tStart': 160,\n",
      "                          'text': 'Literature review and data analysis '\n",
      "                                  'revealed that five immune-related genes and '\n",
      "                                  'two gene sets may potentially be used for '\n",
      "                                  'predicting the therapeutic effects of PD-1 '\n",
      "                                  'inhibitors in patients with primary or '\n",
      "                                  'metastatic NSCLC.'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 209,\n",
      "                          'tStart': 205,\n",
      "                          'text': 'In the present study, RNA IO panel '\n",
      "                                  'sequencing was used to examine the '\n",
      "                                  'expression levels of 395 genes associated '\n",
      "                                  'with immune pathways in patients with '\n",
      "                                  'primary or metastatic NSCLC prior to the '\n",
      "                                  'standard anti-PD-1 antibody therapy (41).'},\n",
      "                         {'dEnd': 281,\n",
      "                          'dStart': 276,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 158,\n",
      "                          'tStart': 154,\n",
      "                          'text': 'Previous clinical trials, including '\n",
      "                                  'CheckMate 017 (13) and 057 (14), '\n",
      "                                  'KEYNOTE-010(9) and KN-024 (10), have '\n",
      "                                  'demonstrated that compared with docetaxel, '\n",
      "                                  'anti-PD-1 antibodies significantly '\n",
      "                                  'prolonged the overall survival and had a '\n",
      "                                  'favorable safety profile in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 138,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Thus, there is an urgent need to identify '\n",
      "                                  'efficient and precise biomarkers for '\n",
      "                                  'screening patients with NSCLC that may '\n",
      "                                  'respond to anti-PD-1 antibody therapy.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'Therefore, developing reliable methods to '\n",
      "                                  'predict the efficacy of anti-PD-1 '\n",
      "                                  'monoclonal antibody in treating patients '\n",
      "                                  'with advanced NSCLC may provide economic '\n",
      "                                  'relief for non-responding patients and save '\n",
      "                                  'time to start other types of therapy.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'The role of anti-PD-1 antibodies in the '\n",
      "                                  'first- and second-line treatment of NSCLC '\n",
      "                                  'or in the local adjuvant therapy of NSCLC '\n",
      "                                  'has been established in previous studies '\n",
      "                                  '(36–38).'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Although antibodies targeting the immune '\n",
      "                                  'checkpoint protein programmed death-1 '\n",
      "                                  '(PD-1) exert therapeutic effects in '\n",
      "                                  'patients with primary or metastatic '\n",
      "                                  'non-small cell lung cancer (NSCLC), the '\n",
      "                                  'majority of patients exhibit partial or '\n",
      "                                  'complete resistance to anti-PD1 treatment.'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Although antibodies targeting the immune '\n",
      "                                  'checkpoint protein programmed death-1 '\n",
      "                                  '(PD-1) exert therapeutic effects in '\n",
      "                                  'patients with primary or metastatic '\n",
      "                                  'non-small cell lung cancer (NSCLC), the '\n",
      "                                  'majority of patients exhibit partial or '\n",
      "                                  'complete resistance to anti-PD1 treatment.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'DEG set-based prediction of the efficacy of '\n",
      "                                  'anti-PD-1 therapy in patients with primary '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 monoclonal antibody, an immune '\n",
      "                                  'checkpoint inhibitor, has provided a '\n",
      "                                  'breakthrough in the treatment of patients '\n",
      "                                  'with advanced NSCLC (35).'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 176,\n",
      "                          'tStart': 172,\n",
      "                          'text': 'The results of the present study '\n",
      "                                  'demonstrated a gene set comprising six DEGs '\n",
      "                                  '(HLA-F-AS1, NCF1, RORC, DMBT1, KLRF and '\n",
      "                                  'IL-18) may be used for predicting the '\n",
      "                                  'efficacy of anti-PD-1 therapy in patients '\n",
      "                                  'with primary NSCLC; specifically, patients '\n",
      "                                  'with a calculated expression level of the '\n",
      "                                  'DEG set >6.501 may benefit from anti-PD-1 '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Despite the prominent therapeutic effects '\n",
      "                                  'of anti-PD-1 monoclonal antibodies on '\n",
      "                                  'patients with advanced NSCLC, only a '\n",
      "                                  'limited fraction of patients benefit from '\n",
      "                                  'this immunotherapeutic agent (15).'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 142,\n",
      "                          'tStart': 138,\n",
      "                          'text': 'Patients with a calculated expression level '\n",
      "                                  'of the DEG sets >6.501 (primary NSCLC) or '\n",
      "                                  '>6.741 (metastatic NSCLC) may benefit from '\n",
      "                                  'the anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'In addition, a DEG set comprising two DEGs '\n",
      "                                  '(HLA-A and TNFSF18) may be applied to '\n",
      "                                  'predict the efficacy of anti-PD-1 therapy '\n",
      "                                  'in patients with metastatic NSCLC.'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 203,\n",
      "                          'tStart': 199,\n",
      "                          'text': 'In addition, two DEG sets comprising either '\n",
      "                                  'six (HLA-F-AS1, NCF1, RORC, DMBT1, KLRF and '\n",
      "                                  'IL-18) or two (HLA-A and TNFSF18) DEGs as '\n",
      "                                  'potential combination biomarkers for '\n",
      "                                  'predicting the efficacy of anti-PD-1 '\n",
      "                                  'therapy in patients with NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['30968711'],\n",
      " 'resourceScore': 56,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 228,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 206,\n",
      "                          'tStart': 202,\n",
      "                          'text': 'Results also demonstrated that the high '\n",
      "                                  'expression level of PD-1 on CD4+ T, but not '\n",
      "                                  'CD8+, cells is correlated with poor '\n",
      "                                  'clinical outcomes, suggesting that '\n",
      "                                  'PD-1+CD4+ T cells play more decisive role '\n",
      "                                  'than PD-1+CD8+ T cells in NSCLC.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'More importantly, high expression of PD-1 '\n",
      "                                  'molecule on CD4+ T cells could be '\n",
      "                                  'responsible for the inhibition of antitumor '\n",
      "                                  'immune activity in NSCLC; and the '\n",
      "                                  'chemotherapy has no impact on the frequency '\n",
      "                                  'of PD-1+CD8+ and PD-1+CD4+ T cells.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'The frequency of PD-1+ expression on CD8+ T '\n",
      "                                  'cells had no statistically significant '\n",
      "                                  'difference between patients with NSCLC and '\n",
      "                                  'healthy controls (3.867 ± 0.214% versus '\n",
      "                                  '3.212 ± 0.179%) (Figure 1(d)), but it is '\n",
      "                                  'important to mention that subgroup analysis '\n",
      "                                  'showed that 41% of patients with NSCLC had '\n",
      "                                  'high levels of PD-1 expression on their '\n",
      "                                  'CD8+ T cells.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The absolute number and frequency of '\n",
      "                                  'CD3+CD8+ T cells and PD-1 expression on '\n",
      "                                  'CD8+ and CD4+ T cells were assessed in '\n",
      "                                  'peripheral blood from healthy donors and '\n",
      "                                  'patients with NSCLC before and after '\n",
      "                                  'chemotherapy.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Results showed that the frequency of '\n",
      "                                  'PD-1+CD8+ T cells had no remarkable '\n",
      "                                  'correlation with PFS in NSCLC.'},\n",
      "                         {'dEnd': 228,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 159,\n",
      "                          'tStart': 155,\n",
      "                          'text': 'Results also demonstrated that the high '\n",
      "                                  'expression level of PD-1 on CD4+ T, but not '\n",
      "                                  'CD8+, cells is correlated with poor '\n",
      "                                  'clinical outcomes, suggesting that '\n",
      "                                  'PD-1+CD4+ T cells play more decisive role '\n",
      "                                  'than PD-1+CD8+ T cells in NSCLC.'},\n",
      "                         {'dEnd': 289,\n",
      "                          'dStart': 284,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'The frequency of PD-1+ expression on CD8+ T '\n",
      "                                  'cells had no statistically significant '\n",
      "                                  'difference between patients with NSCLC and '\n",
      "                                  'healthy controls (3.867 ± 0.214% versus '\n",
      "                                  '3.212 ± 0.179%) (Figure 1(d)), but it is '\n",
      "                                  'important to mention that subgroup analysis '\n",
      "                                  'showed that 41% of patients with NSCLC had '\n",
      "                                  'high levels of PD-1 expression on their '\n",
      "                                  'CD8+ T cells.'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'CD3+CD8+ T cells, but not PD-1 expressing '\n",
      "                                  'CD4+ and CD8+ T cells, were markedly '\n",
      "                                  'decreased in the peripheral blood from '\n",
      "                                  'patients with NSCLC after chemotherapy'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 90,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 35,\n",
      "                          'tStart': 31,\n",
      "                          'text': 'Furthermore, the high level of PD-1+CD4+ '\n",
      "                                  'cells plays a crucial role in the '\n",
      "                                  'progression of NSCLC and could be used as a '\n",
      "                                  'prognostic marker; and the high level of '\n",
      "                                  'Th1 could predict better clinical outcomes '\n",
      "                                  'of chemotherapy.'},\n",
      "                         {'dEnd': 119,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'The frequency of PD-1+ expression on CD4+ T '\n",
      "                                  'cells was significantly higher in '\n",
      "                                  'peripheral blood from patients with NSCLC '\n",
      "                                  'than healthy donors (7.785 ± 0.542% versus '\n",
      "                                  '3.968 ± 0.244%) (Figure 1(f)), without a '\n",
      "                                  'significant alteration after chemotherapy '\n",
      "                                  '(6.968 ± 0.480) (Figure 1(f) and (g)).'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'These results indicate that the high level '\n",
      "                                  'of CD8+ and PD-1+CD4+ T cells could be used '\n",
      "                                  'as prognostic markers for NSCLC.'},\n",
      "                         {'dEnd': 228,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Results also demonstrated that the high '\n",
      "                                  'expression level of PD-1 on CD4+ T, but not '\n",
      "                                  'CD8+, cells is correlated with poor '\n",
      "                                  'clinical outcomes, suggesting that '\n",
      "                                  'PD-1+CD4+ T cells play more decisive role '\n",
      "                                  'than PD-1+CD8+ T cells in NSCLC.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'In conclusion, these results indicate that '\n",
      "                                  'the expression of PD-1 on CD4+ T cells '\n",
      "                                  'might play the main role in the progression '\n",
      "                                  'of NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['29423118'],\n",
      " 'resourceScore': 56,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'We found that PD-L1 expression might be an '\n",
      "                                  'important prognostic factor for the '\n",
      "                                  'efficacy of PD-1/PD-L1 inhibitors in '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Moreover, we compared the severe adverse '\n",
      "                                  'events (grade 3,4, or 5) of anti-PD-1/PD-L1 '\n",
      "                                  'antibody therapy with chemotherapy for '\n",
      "                                  'advanced NSCLC patients.'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 249,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Several previously published meta-analyses '\n",
      "                                  'have analyzed the efficacy and toxicity of '\n",
      "                                  'anti-PD-1/PD-L1 antibodies [6, 10, 11], but '\n",
      "                                  'none of them compared anti-PD-1/PD-L1 '\n",
      "                                  'antibodies with the second-line '\n",
      "                                  'chemotherapy, docetaxel, for pretreated '\n",
      "                                  'advanced NSCLC patients.'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': 'In our meta-analysis, we included 5 '\n",
      "                                  'randomized clinical trials to evaluate the '\n",
      "                                  'efficacy and safety of anti-PD-1/PD-L1 '\n",
      "                                  'antibody therapy compared with docetaxel in '\n",
      "                                  'previously treated advanced NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'In conclusion, our study indicates that '\n",
      "                                  'anti-PD-1/PD-L1 antibody therapy improves '\n",
      "                                  'PFS, OS and ORR and shows less toxicity in '\n",
      "                                  'patients with advanced or metastatic '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'In contrast, many clinical trials involving '\n",
      "                                  'anti-PD-1/PD-L1 antibodies achieved '\n",
      "                                  'breakthroughs for previously treated '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'In conclusion, our study revealed that, '\n",
      "                                  'compared with docetaxel, anti-PD-1/PD-L1 '\n",
      "                                  'antibody therapy improved clinical efficacy '\n",
      "                                  'and safety in previously treated advanced '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Antibodies against the immune checkpoint '\n",
      "                                  'proteins PD-1 and PD-L1 are novel '\n",
      "                                  'therapeutic drugs for the treatment of '\n",
      "                                  'advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'These PD-1/PD-L1 inhibitors are '\n",
      "                                  'breakthroughs in the treatment of NSCLC '\n",
      "                                  '[23].'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'The efficacy and safety of anti-PD-1/PD-L1 '\n",
      "                                  'antibody therapy versus docetaxel for '\n",
      "                                  'pretreated advanced NSCLC: a meta-analysis'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'In this report, we performed a '\n",
      "                                  'meta-analysis to assess the efficacy and '\n",
      "                                  'safety of anti-PD-1/PD-L1 antibodies '\n",
      "                                  'compared with docetaxel treatment for '\n",
      "                                  'advanced NSCLC patients from 5 randomized '\n",
      "                                  'clinical trials.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'We compared the overall response rate of '\n",
      "                                  'anti-PD-1/PD-L1 antibodies (nivolumab, '\n",
      "                                  'pembrolizumab and atezolizumab) with '\n",
      "                                  'docetaxel for advanced NSCLC patients.'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 249,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 161,\n",
      "                          'tStart': 157,\n",
      "                          'text': 'Several previously published meta-analyses '\n",
      "                                  'have analyzed the efficacy and toxicity of '\n",
      "                                  'anti-PD-1/PD-L1 antibodies [6, 10, 11], but '\n",
      "                                  'none of them compared anti-PD-1/PD-L1 '\n",
      "                                  'antibodies with the second-line '\n",
      "                                  'chemotherapy, docetaxel, for pretreated '\n",
      "                                  'advanced NSCLC patients.'},\n",
      "                         {'dEnd': 222,\n",
      "                          'dStart': 217,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Therefore, we performed this meta-analysis '\n",
      "                                  'systematically utilizing data from the '\n",
      "                                  'published literature to evaluate the '\n",
      "                                  'efficacy and safety of anti-PD-1/PD-L1 '\n",
      "                                  'antibodies versus docetaxel in previously '\n",
      "                                  'treated advanced NSCLC patients.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 125,\n",
      "                          'tStart': 121,\n",
      "                          'text': 'Although several phase II/III randomized '\n",
      "                                  'clinical trials have been conducted to '\n",
      "                                  'assess the efficacy and toxicity of '\n",
      "                                  'anti-PD-1/PD-L1 antibodies for previously '\n",
      "                                  'treated patients with advanced NSCLC, '\n",
      "                                  'outcomes such as progression-free survival '\n",
      "                                  '(PFS) seem to be controversial.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Guo-Wu Zhou et al. [18] conducted a similar '\n",
      "                                  'meta-analysis comparing anti-PD1/PD-L1 '\n",
      "                                  'antibody therapy with chemotherapy for '\n",
      "                                  'pretreated NSCLC patients, but they only '\n",
      "                                  'included three randomized clinical trials '\n",
      "                                  'enrolling 1141 patients who received '\n",
      "                                  'treatment with nivolumab or atezolizumab.'},\n",
      "                         {'dEnd': 70,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'A few meta-analyses on PD-1/PD-L1 '\n",
      "                                  'inhibitors in the treatment of NSCLC '\n",
      "                                  'patients have been published.'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'The polled odds ratio (OR) for overall '\n",
      "                                  'response rate (ORR) was 1.64 (Figure 4; 95% '\n",
      "                                  'CI 1.19–2.26, P < 0.05), which suggested a '\n",
      "                                  'higher clinical response rate for '\n",
      "                                  'anti-PD-1/PD-L1 antibodies than for '\n",
      "                                  'docetaxel in advanced NSCLC patients.'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 164,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'Because of the above limitations in our '\n",
      "                                  'study, further studies based on the '\n",
      "                                  'information from ongoing trials are needed '\n",
      "                                  'to verify the efficacy and safety of '\n",
      "                                  'anti-PD1/PD-L1 therapy versus docetaxel in '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 93,\n",
      "                          'text': 'For example, Jiaxing Huang et al. [7] wrote '\n",
      "                                  'a meta-analysis about the efficacy and '\n",
      "                                  'safety of PD-1 inhibitors in previously '\n",
      "                                  'treated advanced NSCLC patients.'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Antibodies against the immune checkpoint '\n",
      "                                  'proteins PD-1 and PD-L1 are novel '\n",
      "                                  'therapeutic drugs for the treatment of '\n",
      "                                  'advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38672690'],\n",
      " 'resourceScore': 55,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 177,\n",
      "                          'tStart': 173,\n",
      "                          'text': 'An adjusted Cox proportional hazard '\n",
      "                                  'analysis revealed a 56% reduced adjusted '\n",
      "                                  'hazard of death (aHR 0.44, 95% CI: '\n",
      "                                  '0.26–0.74, p = 0.002) when add-on VA was '\n",
      "                                  'added to first-line PD-1/PD-L1 therapy in '\n",
      "                                  'this subgroup with PD-L1-positive NSCLC; '\n",
      "                                  'see Figure 4.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 165,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'In the present real-world data study, we '\n",
      "                                  'examined patients with advanced or '\n",
      "                                  'metastasised NSCLC and compared overall '\n",
      "                                  'survival between a control group receiving '\n",
      "                                  'a PD-1/PD-L1 inhibitor therapy and the '\n",
      "                                  'combinatorial group receiving PD-1/PD-L1 '\n",
      "                                  'inhibitors plus add-on Viscum album L. Our '\n",
      "                                  'findings revealed that patients in the '\n",
      "                                  'combinatorial group lived seven months '\n",
      "                                  'longer in comparison to the control group '\n",
      "                                  '(p < 0.001).'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'In the present study, we examined the '\n",
      "                                  'efficacy of PD-1/PD-L1 inhibitor therapy in '\n",
      "                                  'combination with add-on VA therapy in '\n",
      "                                  'patients with advanced or metastatic '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': '3.5. Subgroup Analysis of First-Line '\n",
      "                                  'PD-1/PD-L1 Therapy in Advanced or '\n",
      "                                  'Metastasised NSCLC with Low PD-L1 Status'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 103,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Immunotherapy with PD-1/PD-L1 inhibitors '\n",
      "                                  'has been shown to significantly improve the '\n",
      "                                  'survival rates of non-small-cell lung '\n",
      "                                  'cancer (NSCLC) patients in advanced or '\n",
      "                                  'metastasised stages.'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 152,\n",
      "                          'tStart': 148,\n",
      "                          'text': 'It is worth noting that our findings '\n",
      "                                  'suggest a correlation between add-on VA '\n",
      "                                  'application and improved survival in '\n",
      "                                  'advanced NSCLC patients receiving '\n",
      "                                  'PD-1/PD-L1 inhibitors but do not establish '\n",
      "                                  'causation.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Immunotherapy with PD-1/PD-L1 inhibitors '\n",
      "                                  'has been shown to significantly improve the '\n",
      "                                  'survival rates of non-small-cell lung '\n",
      "                                  'cancer (NSCLC) patients in advanced or '\n",
      "                                  'metastasised stages.'},\n",
      "                         {'dEnd': 295,\n",
      "                          'dStart': 290,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 233,\n",
      "                          'tStart': 229,\n",
      "                          'text': 'Further markers such as AXL, HER2, HER3, '\n",
      "                                  'MERTK, VIM, and RAD18 or error-prone '\n",
      "                                  'polymerases could be examined in further '\n",
      "                                  'clinical trials evaluating resistance or '\n",
      "                                  'compensatory pathways and how they are '\n",
      "                                  'affected by the combinational PD-1/PD-L1 '\n",
      "                                  'and add-on VA therapy in advanced or '\n",
      "                                  'metastasised NSCLC patients.'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'However, our data study mirrors the '\n",
      "                                  'real-world application situation of '\n",
      "                                  'PD-1/PD-L1 inhibitor therapy in NSCLC '\n",
      "                                  'patients in standard clinical practice and '\n",
      "                                  'is the first of its kind showing a positive '\n",
      "                                  'survival association between combinatory '\n",
      "                                  'PD-1/PD-L1 inhibitor and VA therapy.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Thus, the synergistic association between '\n",
      "                                  'combinatory PD-1/PD-L1 inhibitors and VA '\n",
      "                                  'therapy in patients with advanced or '\n",
      "                                  'metastasised NSCLC as observed in the '\n",
      "                                  'present study joins the ranks of previous '\n",
      "                                  'achievements.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Immunotherapy with PD-1/PD-L1 inhibitors '\n",
      "                                  'has significantly improved the survival '\n",
      "                                  'rates of patients with metastatic '\n",
      "                                  'non-small-cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'Four hundred and fifteen (n = 415) patients '\n",
      "                                  'with advanced or metastasised NSCLC '\n",
      "                                  'receiving PD-1/PD-L1 inhibitors as the '\n",
      "                                  'standard of care of the Network Oncology '\n",
      "                                  'registry were enrolled.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'We sought to investigate whether the '\n",
      "                                  'addition of VA to PD-1/PD-L1 inhibitors in '\n",
      "                                  'patients with advanced or metastasised '\n",
      "                                  'NSCLC would have an additional survival '\n",
      "                                  'benefit.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'So far, the association of combined '\n",
      "                                  'PD-1/PD-L1 inhibitor plus add-on VA therapy '\n",
      "                                  'with survival outcomes of advanced or '\n",
      "                                  'metastasised NSCLC patients has not been '\n",
      "                                  'studied systematically.'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 112,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 144,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'Our findings suggest that add-on VA '\n",
      "                                  'correlates with improved survival in '\n",
      "                                  'patients with advanced or metastasised '\n",
      "                                  'NSCLC who were treated with PD-1/PD-L1 '\n",
      "                                  'inhibitors irrespective of age, gender, '\n",
      "                                  'tumour stage, or oncological treatment.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Our findings imply that the addition of '\n",
      "                                  'Viscum album L. to PD-1/PD-L1 inhibitors is '\n",
      "                                  'associated with improved survival in '\n",
      "                                  'patients with advanced or metastasised '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 39,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 114,\n",
      "                          'tStart': 110,\n",
      "                          'text': 'Patients with Advanced or Metastasised '\n",
      "                                  'Non-Small-Cell Lung Cancer with Viscum '\n",
      "                                  'album L. Therapy in Addition to PD-1/PD-L1 '\n",
      "                                  'Blockade: A Real-World Data Study'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['30819829'],\n",
      " 'resourceScore': 55,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 225,\n",
      "                          'dStart': 220,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting programmed cell death protein 1 '\n",
      "                                  '(PD‐1) and programmed cell death protein '\n",
      "                                  'ligand 1 (PD‐L1) display apparent benefits '\n",
      "                                  'for the treatment of advanced '\n",
      "                                  'non‐small‐cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 244,\n",
      "                          'dStart': 239,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'Compared with chemotherapy or radiotherapy, '\n",
      "                                  'PD‐1/PD‐L1 blockade therapy significantly '\n",
      "                                  'improves the durable response rate and '\n",
      "                                  'prolongs long‐term survival with limited '\n",
      "                                  'adverse effects in both monotherapy and '\n",
      "                                  'combination therapy for advanced NSCLC.'},\n",
      "                         {'dEnd': 519,\n",
      "                          'dStart': 514,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 240,\n",
      "                          'tStart': 236,\n",
      "                          'text': 'Hence, with the improvement in combination '\n",
      "                                  'therapy, establishing guiding principles to '\n",
      "                                  'identify the optimal combination strategy '\n",
      "                                  'for advanced NSCLC from these combination '\n",
      "                                  'approaches will greatly extend the clinical '\n",
      "                                  'applications of anti‐PD‐1/PD‐L1 antibodies '\n",
      "                                  'in the future.'},\n",
      "                         {'dEnd': 225,\n",
      "                          'dStart': 220,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting programmed cell death protein 1 '\n",
      "                                  '(PD‐1) and programmed cell death protein '\n",
      "                                  'ligand 1 (PD‐L1) display apparent benefits '\n",
      "                                  'for the treatment of advanced '\n",
      "                                  'non‐small‐cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 258,\n",
      "                          'dStart': 253,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': '实践意义:在晚期非小细胞肺癌 (NSCLC) 的治疗中,靶向程序性细胞死亡蛋白 1 '\n",
      "                                  '(PD‐1) 和程序性细胞死亡蛋白配体 1 (PD‐L1) 的免疫检查点抑制剂 '\n",
      "                                  '(ICI) '\n",
      "                                  '呈现出明显益处。然而,这些治疗的临床应用却面临着受益群体有限、额外的高昂经济负担和不良事件等挑战。本篇综述讨论了 '\n",
      "                                  'ICI 疗法在临床实践中的瓶颈,并为预测生物标志物的形成、将 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗与现有治疗相结合的标准确立、以及在单药和联合治疗中观察到的不良事件的管理提供了适当的指导,从而有助于最大化 '\n",
      "                                  'ICI 在晚期 NSCLC 中的应用。'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 153,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'An exploration of the underlying mechanism '\n",
      "                                  'of PD‐1/PD‐L1 blockade therapy and '\n",
      "                                  'biomarker identification will maximize the '\n",
      "                                  'application of ICIs in advanced NSCLC and '\n",
      "                                  'facilitate bedside‐to‐bench studies in '\n",
      "                                  'cancer immunotherapy as well.'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 249,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Up to the end of 2017, five monoclonal '\n",
      "                                  'antibodies targeting PD‐1 or PD‐L1 have '\n",
      "                                  'been approved by the U.S. Food and Drug '\n",
      "                                  'Administration (FDA) for the treatment of '\n",
      "                                  'various advanced cancers (Table 1), '\n",
      "                                  'including melanoma [8], non‐small‐cell lung '\n",
      "                                  'cancer (NSCLC) [9], head and neck squamous '\n",
      "                                  'cell cancer [10], classical Hodgkin '\n",
      "                                  'lymphoma [11], urothelial carcinoma [12], '\n",
      "                                  'hepatocellular carcinoma [8], Merkel cell '\n",
      "                                  'carcinoma [13], renal cell carcinoma [14], '\n",
      "                                  'and colorectal cancer [15].'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'With the approval of ICIs as both '\n",
      "                                  'second‐line and first‐line treatments in '\n",
      "                                  'advanced NSCLC, PD‐1/PD‐L1‐based immune '\n",
      "                                  'checkpoint therapy has provided more '\n",
      "                                  'options for the treatment of advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'Nivolumab thus became the first ICI '\n",
      "                                  'targeting PD‐1/PD‐L1 approved by the FDA '\n",
      "                                  'for metastatic NSCLC therapy in 2015 [9].'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Challenges for PD‐1/PD‐L1 Blockade Therapy '\n",
      "                                  'in Advanced NSCLC'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Nivolumab, a human anti‐PD‐1 monoclonal '\n",
      "                                  'antibody, was the first PD‐1/PD‐L blockade '\n",
      "                                  'agent for second‐line treatment of advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 177,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'An exploration of the underlying mechanism '\n",
      "                                  'of PD‐1/PD‐L1 blockade therapy and '\n",
      "                                  'biomarker identification will maximize the '\n",
      "                                  'application of immune checkpoint inhibitors '\n",
      "                                  'in advanced NSCLC and facilitate '\n",
      "                                  'bedside‐to‐bench studies in cancer '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 439,\n",
      "                          'dStart': 434,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 275,\n",
      "                          'tStart': 271,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 439,\n",
      "                          'dStart': 434,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 439,\n",
      "                          'dStart': 434,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 188,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'ICI therapy using antibodies targeting PD‐1 '\n",
      "                                  'or PD‐L1 has demonstrated profound clinical '\n",
      "                                  'efficacy for advanced NSCLC.'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Nivolumab, a human anti‐PD‐1 monoclonal '\n",
      "                                  'antibody, was the first PD‐1/PD‐L blockade '\n",
      "                                  'agent for second‐line treatment of advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 188,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 45,\n",
      "                          'dStart': 40,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade Therapy in Advanced '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'The incidence of grade 3 or 4 TRAEs ranges '\n",
      "                                  'from 7% to 29.9% in anti‐PD‐1/PD‐L1 '\n",
      "                                  'monotherapy for advanced NSCLC, whereas the '\n",
      "                                  'percentage ranges from 26.1% to 55% in the '\n",
      "                                  'chemotherapy group, displaying the '\n",
      "                                  'promising safety profiles of ICI treatments '\n",
      "                                  '(Table 2).'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 150,\n",
      "                          'tStart': 146,\n",
      "                          'text': 'Likewise, the results of the phase II/III '\n",
      "                                  'clinical trial study KEYNOTE 010 '\n",
      "                                  'demonstrated that compared with docetaxel, '\n",
      "                                  'pembrolizumab, another anti‐PD‐1 antibody, '\n",
      "                                  'significantly improved the OS, PFS, and ORR '\n",
      "                                  'of the patients with advanced NSCLC who had '\n",
      "                                  'PD‐L1 expression on ≥50% of tumor cells '\n",
      "                                  '(Table 2) [54].'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade Therapy for Advanced '\n",
      "                                  'NSCLC in China'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade as First‐Line Treatment '\n",
      "                                  'in Advanced NSCLC'},\n",
      "                         {'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'In addition, anti‐PD‐1/PD‐L1 therapies are '\n",
      "                                  'also under investigation in the neoadjuvant '\n",
      "                                  'and consolidation settings for stage III '\n",
      "                                  'NSCLC, which may provide treatment options '\n",
      "                                  'in the management of stage III NSCLC [77].'},\n",
      "                         {'dEnd': 416,\n",
      "                          'dStart': 411,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 205,\n",
      "                          'tStart': 201,\n",
      "                          'text': 'This review discusses the bottlenecks of '\n",
      "                                  'ICI therapy in clinical practice and '\n",
      "                                  'provides appropriate guidance in the '\n",
      "                                  'development of predictive biomarkers, the '\n",
      "                                  'establishment of the criteria for combining '\n",
      "                                  'PD‐1/PD‐L1 blockade therapy with the '\n",
      "                                  'existing therapies, and the management of '\n",
      "                                  'adverse events observed both in monotherapy '\n",
      "                                  'and combination therapy, which will help '\n",
      "                                  'maximize the applications of ICIs in '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Several ICIs targeting PD‐1 or PD‐L1 have '\n",
      "                                  'been approved by the FDA for the clinical '\n",
      "                                  'treatment of advanced NSCLC, demonstrating '\n",
      "                                  'notable efficacy in clinical practice.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Based on the promising results of '\n",
      "                                  'second‐line treatment, the clinical '\n",
      "                                  'efficacy of PD‐1/PD‐L1 blockade as '\n",
      "                                  'first‐line treatment for advanced NSCLC has '\n",
      "                                  'been investigated.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Therefore, blocking antibodies targeting '\n",
      "                                  'PD‐1 or PD‐L1 have been developed and '\n",
      "                                  'approved for the treatment of various '\n",
      "                                  'advanced cancers, including non‐small‐cell '\n",
      "                                  'lung cancer (NSCLC), making them the most '\n",
      "                                  'successful ICIs.'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 202,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'In addition, anti‐PD‐1/PD‐L1 therapies are '\n",
      "                                  'also under investigation in the neoadjuvant '\n",
      "                                  'and consolidation settings for stage III '\n",
      "                                  'NSCLC, which may provide treatment options '\n",
      "                                  'in the management of stage III NSCLC [77].'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Registered clinical trials of PD‐1/PD‐L1 '\n",
      "                                  'blockade inhibitors against advanced NSCLC '\n",
      "                                  'have been initiated since December 2015.'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 190,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'With the approval of ICIs as both '\n",
      "                                  'second‐line and first‐line treatments in '\n",
      "                                  'advanced NSCLC, PD‐1/PD‐L1‐based immune '\n",
      "                                  'checkpoint therapy has provided more '\n",
      "                                  'options for the treatment of advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade as Third‐Line Treatment '\n",
      "                                  'in Advanced NSCLC'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Collectively, these results demonstrate '\n",
      "                                  'that ICIs targeting PD‐1 and PD‐L1 '\n",
      "                                  'significantly improve clinical efficacy in '\n",
      "                                  'patients with advanced NSCLC with a '\n",
      "                                  'favorable safety profile compared with '\n",
      "                                  'chemotherapy [57], making anti‐PD‐1 and '\n",
      "                                  'PD‐L1 therapeutic antibodies a new option '\n",
      "                                  'as second‐line treatment in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 258,\n",
      "                          'dStart': 253,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': '实践意义:在晚期非小细胞肺癌 (NSCLC) 的治疗中,靶向程序性细胞死亡蛋白 1 '\n",
      "                                  '(PD‐1) 和程序性细胞死亡蛋白配体 1 (PD‐L1) 的免疫检查点抑制剂 '\n",
      "                                  '(ICI) '\n",
      "                                  '呈现出明显益处。然而,这些治疗的临床应用却面临着受益群体有限、额外的高昂经济负担和不良事件等挑战。本篇综述讨论了 '\n",
      "                                  'ICI 疗法在临床实践中的瓶颈,并为预测生物标志物的形成、将 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗与现有治疗相结合的标准确立、以及在单药和联合治疗中观察到的不良事件的管理提供了适当的指导,从而有助于最大化 '\n",
      "                                  'ICI 在晚期 NSCLC 中的应用。'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'In this review, we introduce the '\n",
      "                                  'development of PD‐1/PD‐L1 blockade therapy '\n",
      "                                  'and its clinical applications in advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 135,\n",
      "                          'dStart': 130,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'The expression of PD‐L1 on tumor cells has '\n",
      "                                  'been demonstrated to be associated with the '\n",
      "                                  'efficacy of PD‐1/PD‐L1 blockade therapy in '\n",
      "                                  'NSCLC [54], [80], [81].'},\n",
      "                         {'dEnd': 80,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade as Neoadjuvant and '\n",
      "                                  'Consolidation Treatment in Advanced NSCLC'},\n",
      "                         {'dEnd': 519,\n",
      "                          'dStart': 514,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 474,\n",
      "                          'tStart': 470,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 519,\n",
      "                          'dStart': 514,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 188,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 192,\n",
      "                          'tStart': 188,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'This article summarizes the latest clinical '\n",
      "                                  'applications of PD‐1/PD‐L1 blockade therapy '\n",
      "                                  'in advanced non‐small cell lung cancer '\n",
      "                                  '(NSCLC) worldwide and in China, reporting '\n",
      "                                  'the bottlenecks related to the use of this '\n",
      "                                  'therapy in clinic.'},\n",
      "                         {'dEnd': 519,\n",
      "                          'dStart': 514,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 419,\n",
      "                          'tStart': 415,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 62,\n",
      "                          'dStart': 57,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD‐1/PD‐L1 Blockade as Second‐Line '\n",
      "                                  'Treatment in Advanced NSCLC'},\n",
      "                         {'dEnd': 331,\n",
      "                          'dStart': 326,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 228,\n",
      "                          'tStart': 224,\n",
      "                          'text': 'Collectively, these results demonstrate '\n",
      "                                  'that ICIs targeting PD‐1 and PD‐L1 '\n",
      "                                  'significantly improve clinical efficacy in '\n",
      "                                  'patients with advanced NSCLC with a '\n",
      "                                  'favorable safety profile compared with '\n",
      "                                  'chemotherapy [57], making anti‐PD‐1 and '\n",
      "                                  'PD‐L1 therapeutic antibodies a new option '\n",
      "                                  'as second‐line treatment in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 439,\n",
      "                          'dStart': 434,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 419,\n",
      "                          'tStart': 415,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 519,\n",
      "                          'dStart': 514,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 275,\n",
      "                          'tStart': 271,\n",
      "                          'text': '免疫检查点抑制剂 (ICI) '\n",
      "                                  '的使用已成为癌症治疗领域最具前景的方法之一。与靶向肿瘤细胞的现有疗法(如化疗、放疗或靶向治疗)不同,ICI '\n",
      "                                  '可直接恢复由肿瘤介导的耗竭的宿主抗肿瘤免疫应答。在已确定的多种免疫调节剂中,已经广泛研究了导致慢性感染和肿瘤中 '\n",
      "                                  'T 细胞免疫耗竭的程序性细胞死亡蛋白 1 (PD‐1)/程序性细胞死亡蛋白配体 1 '\n",
      "                                  '(PD‐L1) 轴。因此,已经开发了靶向 PD‐1 或 PD‐L1 '\n",
      "                                  '的阻断抗体,并批准用于治疗各种晚期癌症,包括非小细胞肺癌 '\n",
      "                                  '(NSCLC),这使其成为最成功的 ICI。在晚期 '\n",
      "                                  'NSCLC,与化疗或放疗相比,PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗无论单药和联合治疗均明显提高了持久缓解率并延长了长期生存,而且不良反应很少。然而,对于进一步的临床应用却存在大量挑战,例如,仅有小部分群体受益,存在原发性和获得性耐药,缺乏预测和预后生物标志物,以及存在治疗相关不良反应。在本文中,我们总结了中国及全球范围内 '\n",
      "                                  'PD‐1/PD‐L1 阻断治疗在晚期 NSCLC '\n",
      "                                  '中的最新临床应用,并讨论了在临床实践中使用该疗法的瓶颈。对 PD‐1/PD‐L1 '\n",
      "                                  '阻断治疗和生物标志物鉴定的潜在机制的探索将最大化 ICI 在晚期 NSCLC '\n",
      "                                  '中的应用,同时,也将促进癌症免疫治疗“从临床到实验室”的研究。'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'This is the first Chinese study on '\n",
      "                                  'PD‐1/PD‐L1 inhibitors in NSCLC.'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Although ICIs targeting PD‐1 and PD‐L1 have '\n",
      "                                  'been demonstrated with impressive benefits '\n",
      "                                  'for advanced NSCLC in first‐line treatment '\n",
      "                                  'trials, there still exists a certain '\n",
      "                                  'population of patients who do not respond '\n",
      "                                  'to the therapy.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'In this article, we summarize the latest '\n",
      "                                  'clinical applications of PD‐1/PD‐L1 '\n",
      "                                  'blockade therapy in advanced NSCLC '\n",
      "                                  'worldwide, as well as in China, and discuss '\n",
      "                                  'the bottlenecks related to the use of this '\n",
      "                                  'therapy in clinical practice.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Collectively, these results demonstrate '\n",
      "                                  'that ICIs targeting PD‐1 and PD‐L1 '\n",
      "                                  'significantly improve clinical efficacy in '\n",
      "                                  'patients with advanced NSCLC with a '\n",
      "                                  'favorable safety profile compared with '\n",
      "                                  'chemotherapy [57], making anti‐PD‐1 and '\n",
      "                                  'PD‐L1 therapeutic antibodies a new option '\n",
      "                                  'as second‐line treatment in patients with '\n",
      "                                  'advanced NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36856921'],\n",
      " 'resourceScore': 55,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 102,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'PD-L1/PD-1 blockage enhanced the '\n",
      "                                  'cytotoxicity of natural killer cell on the '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'granzyme B secretion'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'NK cell surface receptor detection revealed '\n",
      "                                  'that the expression levels of PD-1 on NK '\n",
      "                                  'cells from NSCLC patients were '\n",
      "                                  'significantly higher than those on NK cells '\n",
      "                                  'from healthy controls (Fig. 6C and D, p < '\n",
      "                                  '0.01).'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'There were no differences in the NK cell '\n",
      "                                  'percentages between healthy donors and '\n",
      "                                  'NSCLC patients, but the expression levels '\n",
      "                                  'of PD-1 on NK cells from NSCLC patients '\n",
      "                                  'were significantly higher than those on NK '\n",
      "                                  'cells from healthy controls.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'In summary, the present study revealed that '\n",
      "                                  'PD-L1/PD-1 blockade enhanced the '\n",
      "                                  'cytotoxicity of natural killer cells in '\n",
      "                                  'NSCLC via Granzyme B secretion.'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'NK cells from NSCLC patients express high '\n",
      "                                  'levels of PD-1'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'PD-L1/PD-1 blockage enhanced the '\n",
      "                                  'cytotoxicity of natural killer cell on the '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'granzyme B secretion'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'To investigate the pivotal role of the '\n",
      "                                  'PD-L1/PD-1 checkpoint in the cytotoxicity '\n",
      "                                  'of NK cells toward NSCLC cells, an '\n",
      "                                  'anti-PD-L1 antibody was added to the NK '\n",
      "                                  'cell/NSCLC cell coculture system.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'The present study revealed that PD-L1/PD-1 '\n",
      "                                  'blockage enhanced the cytotoxicity of '\n",
      "                                  'natural killer cells in NSCLC via granzyme '\n",
      "                                  'B secretion.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'To investigate the pivotal role of the '\n",
      "                                  'PD-L1/PD-1 checkpoint on the cytotoxicity '\n",
      "                                  'of NK cells in NSCLC cells, an anti-PD-L1 '\n",
      "                                  'antibody was added to the NK cell/NSCLC '\n",
      "                                  'cell coculture system.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'To explore the role of PD-L1/PD-1 blockage '\n",
      "                                  'in the cytotoxicity of natural killer cell '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'To investigate the pivotal role of the '\n",
      "                                  'PD-L1/PD-1 checkpoint in the cytotoxicity '\n",
      "                                  'of NK cells toward NSCLC cells, an '\n",
      "                                  'anti-PD-L1 antibody was added to the NK '\n",
      "                                  'cell/NSCLC cell coculture system.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'There were no differences in the NK cell '\n",
      "                                  'percentages between healthy donors and '\n",
      "                                  'NSCLC patients, but the expression levels '\n",
      "                                  'of PD-1 on NK cells from NSCLC patients '\n",
      "                                  'were significantly higher than those on NK '\n",
      "                                  'cells from healthy controls.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'To investigate the pivotal role of the '\n",
      "                                  'PD-L1/PD-1 checkpoint on the cytotoxicity '\n",
      "                                  'of NK cells in NSCLC cells, an anti-PD-L1 '\n",
      "                                  'antibody was added to the NK cell/NSCLC '\n",
      "                                  'cell coculture system.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37958317'],\n",
      " 'resourceScore': 55,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), '\n",
      "                                  'particularly antibodies to programmed cell '\n",
      "                                  'death protein 1 (anti-PD1) and programmed '\n",
      "                                  'death ligand 1 (anti-PD-L1), are used in '\n",
      "                                  'NSCLC with the rationale that blocking '\n",
      "                                  'programmed cell death protein 1 (PD-1) on '\n",
      "                                  'activated T cells and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) on tumor cells could '\n",
      "                                  'reinvigorate cytotoxic TCD8+ cells by '\n",
      "                                  'activating host adaptive immunity [8,9].'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'Results: A total of seven RCTs comprising '\n",
      "                                  '3915 patients with resectable stage NSCLC '\n",
      "                                  'were randomized to chemotherapy with or '\n",
      "                                  'without PD-1/PD-L1 inhibitors as NAT or '\n",
      "                                  'AT.'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 178,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'Background: The benefit of adding '\n",
      "                                  'programmed cell death protein 1 '\n",
      "                                  '(PD-1)/programmed death-ligand 1 (PD-L1) '\n",
      "                                  'inhibitors to the treatment of early-stage '\n",
      "                                  'non-small cell lung cancer (NSCLC), both '\n",
      "                                  'neoadjuvant therapy (NAT) and adjuvant '\n",
      "                                  'therapy (AT), is not yet fully elucidated.'},\n",
      "                         {'dEnd': 104,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'Currently, PD-1 and PD-L1 inhibitors have '\n",
      "                                  'gained approval as the first-line therapy '\n",
      "                                  'for metastatic NSCLC patients, consistently '\n",
      "                                  'demonstrating better results for OS and PFS '\n",
      "                                  '[5,39].'},\n",
      "                         {'dEnd': 8,\n",
      "                          'dStart': 3,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'In NSCLC, the use of anti-PD-1/PD-L1 agents '\n",
      "                                  'has demonstrated improved overall survival '\n",
      "                                  '(OS) and progression-free survival (PFS) '\n",
      "                                  'following chemoradiotherapy in unresectable '\n",
      "                                  'stage III disease.'},\n",
      "                         {'dEnd': 265,\n",
      "                          'dStart': 260,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'In this comprehensive systematic review and '\n",
      "                                  'meta-analysis of RCTs, the incorporation of '\n",
      "                                  'PD-1/PD-L1 inhibitors alongside '\n",
      "                                  'chemotherapy offers a promising prospect '\n",
      "                                  'for reshaping the established treatment '\n",
      "                                  'paradigms for patients diagnosed with '\n",
      "                                  'resectable stages of NSCLC.'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 178,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'Background: The benefit of adding '\n",
      "                                  'programmed cell death protein 1 '\n",
      "                                  '(PD-1)/programmed death-ligand 1 (PD-L1) '\n",
      "                                  'inhibitors to the treatment of early-stage '\n",
      "                                  'non-small cell lung cancer (NSCLC), both '\n",
      "                                  'neoadjuvant therapy (NAT) and adjuvant '\n",
      "                                  'therapy (AT), is not yet fully elucidated.'},\n",
      "                         {'dEnd': 245,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'Our findings suggest that the incorporation '\n",
      "                                  'of PD-1/PD-L1 inhibitors alongside '\n",
      "                                  'chemotherapy offers a promising prospect '\n",
      "                                  'for reshaping the established treatment '\n",
      "                                  'paradigms for patients diagnosed with '\n",
      "                                  'resectable stages of non-small cell lung '\n",
      "                                  'cancer.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 Inhibitors plus Chemotherapy '\n",
      "                                  'Versus Chemotherapy Alone for Resectable '\n",
      "                                  'Non-Small Cell Lung Cancer: A Systematic '\n",
      "                                  'Review and Meta-Analysis of Randomized '\n",
      "                                  'Controlled Trials'},\n",
      "                         {'dEnd': 278,\n",
      "                          'dStart': 273,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'Conclusions: In this comprehensive '\n",
      "                                  'systematic review and meta-analysis of '\n",
      "                                  'RCTs, the incorporation of PD-1/PD-L1 '\n",
      "                                  'inhibitors alongside chemotherapy offers a '\n",
      "                                  'promising prospect for reshaping the '\n",
      "                                  'established treatment paradigms for '\n",
      "                                  'patients diagnosed with resectable stages '\n",
      "                                  'of NSCLC.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'Background: The benefit of adding '\n",
      "                                  'programmed cell death protein 1 '\n",
      "                                  '(PD-1)/programmed death-ligand 1 (PD-L1) '\n",
      "                                  'inhibitors to the treatment of early-stage '\n",
      "                                  'non-small cell lung cancer (NSCLC), both '\n",
      "                                  'neoadjuvant therapy (NAT) and adjuvant '\n",
      "                                  'therapy (AT), is not yet fully elucidated.'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'A total of 1975 patients with NSCLC were '\n",
      "                                  'randomized to PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy, while 1940 received '\n",
      "                                  'chemotherapy alone.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), '\n",
      "                                  'particularly antibodies to programmed cell '\n",
      "                                  'death protein 1 (anti-PD1) and programmed '\n",
      "                                  'death ligand 1 (anti-PD-L1), are used in '\n",
      "                                  'NSCLC with the rationale that blocking '\n",
      "                                  'programmed cell death protein 1 (PD-1) on '\n",
      "                                  'activated T cells and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) on tumor cells could '\n",
      "                                  'reinvigorate cytotoxic TCD8+ cells by '\n",
      "                                  'activating host adaptive immunity [8,9].'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Immunotherapy, particularly programmed cell '\n",
      "                                  'death protein 1 (PD-1) and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitors, has been '\n",
      "                                  'responsible for changing the natural '\n",
      "                                  'history of advanced or metastatic non-small '\n",
      "                                  'cell lung cancer.'},\n",
      "                         {'dEnd': 211,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Therefore, we aimed to evaluate the '\n",
      "                                  'efficacy and safety of neoadjuvant and '\n",
      "                                  'adjuvant use of PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy versus chemotherapy alone in '\n",
      "                                  'resectable stage (I-III) non-small cell '\n",
      "                                  'lung cancer.'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Immunotherapy, particularly programmed cell '\n",
      "                                  'death protein 1 (PD-1) and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) inhibitors, has been '\n",
      "                                  'responsible for changing the natural '\n",
      "                                  'history of advanced or metastatic non-small '\n",
      "                                  'cell lung cancer.'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 174,\n",
      "                          'tStart': 170,\n",
      "                          'text': 'Therefore, in this systematic review and '\n",
      "                                  'meta-analysis of randomized controlled '\n",
      "                                  'trials (RCTs), we aim to clarify the '\n",
      "                                  'efficacy and safety of using neoadjuvant or '\n",
      "                                  'adjuvant PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy versus chemotherapy alone in '\n",
      "                                  'resectable stage (I-III) NSCLC.'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 178,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Methods: We searched PubMed, Embase, and '\n",
      "                                  'Cochrane databases for randomized '\n",
      "                                  'controlled trials (RCT) that investigated '\n",
      "                                  'PD-1/PD-L1 inhibitors plus chemotherapy for '\n",
      "                                  'resectable stage NSCLC.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'Background: The benefit of adding '\n",
      "                                  'programmed cell death protein 1 '\n",
      "                                  '(PD-1)/programmed death-ligand 1 (PD-L1) '\n",
      "                                  'inhibitors to the treatment of early-stage '\n",
      "                                  'non-small cell lung cancer (NSCLC), both '\n",
      "                                  'neoadjuvant therapy (NAT) and adjuvant '\n",
      "                                  'therapy (AT), is not yet fully elucidated.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'In this systematic review and meta-analysis '\n",
      "                                  'of seven RCTs including 3915 patients, we '\n",
      "                                  'compared PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy as NAT or AT to chemotherapy '\n",
      "                                  'alone in patients with resectable stage '\n",
      "                                  'NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['36209117'],\n",
      " 'resourceScore': 54,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 103,\n",
      "                          'dStart': 99,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'To further verify the impacts of exosomal '\n",
      "                                  'circZNF451 on the TME and immunotherapy, we '\n",
      "                                  'selected ten LUAD patients receiving PD1 '\n",
      "                                  'blockade (Opdivo) treatment, in whom six '\n",
      "                                  'were evaluated as PD and four were '\n",
      "                                  'evaluated as PR (Fig. 7D and Supplementary '\n",
      "                                  'Table 6).'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'The in vivo results identified that '\n",
      "                                  'conditional knockout of ELF4 in macrophages '\n",
      "                                  'enhanced the efficacy of PD1 blockade in '\n",
      "                                  'LUAD with the enhanced infiltration of CD8+ '\n",
      "                                  'T cells and exhausted M2 macrophages.'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 102,\n",
      "                          'text': 'Here, we aimed to uncover a potential role '\n",
      "                                  'of exosomal circular RNAs (circRNAs) in '\n",
      "                                  'LUAD refractory to PD1 blockade.'},\n",
      "                         {'dEnd': 86,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'circZNF451 in the prognosis of LUAD '\n",
      "                                  'patients and the anti-PD1 therapy of '\n",
      "                                  'advanced LUAD patients'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 88,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 187,\n",
      "                          'tStart': 184,\n",
      "                          'text': 'circRNA sequencing and qRT-PCR identified '\n",
      "                                  'the up-regulation of exosomal circZNF451 '\n",
      "                                  'from LUAD patients with progressive disease '\n",
      "                                  '(PD) compared to those with partial '\n",
      "                                  'remission (PR) after PD1 blockade therapy.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Importantly, conditional knockout of ELF4 '\n",
      "                                  'in macrophages was found to enhance the '\n",
      "                                  'efficacy of anti-PD1 in LUAD with high '\n",
      "                                  'expression of circZNF451 by transgenic '\n",
      "                                  'mice.'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 31,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'circZNF451 in the prognosis of LUAD '\n",
      "                                  'patients and the anti-PD1 therapy of '\n",
      "                                  'advanced LUAD patients'},\n",
      "                         {'dEnd': 186,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 214,\n",
      "                          'text': 'To illustrate the potential role of '\n",
      "                                  'exosomal circRNAs in immunotherapy '\n",
      "                                  'resistance, the circRNA sequencing was '\n",
      "                                  'performed to determine the level of '\n",
      "                                  'circRNAs in peripheral blood from 6 LUAD '\n",
      "                                  'patients treated with anti-PD1; of these, '\n",
      "                                  'three patients were classified as '\n",
      "                                  'progression disease (PD), and three '\n",
      "                                  'patients were classified as partial '\n",
      "                                  'response (PR) according to the RECIST1.1 '\n",
      "                                  'evaluation (Supplementary Table 1) [14].'},\n",
      "                         {'dEnd': 208,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 188,\n",
      "                          'text': 'Exosomal circZNF451 reshapes the tumor '\n",
      "                                  'immune microenvironment by inducing '\n",
      "                                  'macrophages polarization via the FXR1- '\n",
      "                                  'ELF4–IRF4 axis and is a novel biomarker for '\n",
      "                                  'predicting the sensitivity of PD1 blockade '\n",
      "                                  'in LUAD.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 168,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 134,\n",
      "                          'text': 'Although success was achieved in the '\n",
      "                                  'therapy for a minority of advanced lung '\n",
      "                                  'adenocarcinoma (LUAD) patients, '\n",
      "                                  'anti-programmed death 1 (PD1) resistance '\n",
      "                                  'was found in most LUAD patients.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'Here, the circRNA sequencing was performed '\n",
      "                                  'on the peripheral blood of six LUAD '\n",
      "                                  'patients receiving PD1 blockade treatment.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 138,\n",
      "                          'text': 'circRNA sequencing and qRT-PCR were '\n",
      "                                  'performed to determine the level of '\n",
      "                                  'exosomal circRNAs in LUAD patients '\n",
      "                                  'subsequently treated with anti-PD1.'},\n",
      "                         {'dEnd': 71,\n",
      "                          'dStart': 52,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Exosomal circZNF451 restrains anti-PD1 '\n",
      "                                  'treatment in lung adenocarcinoma via '\n",
      "                                  'polarizing macrophages by complexing with '\n",
      "                                  'TRIM56 and FXR1'},\n",
      "                         {'dEnd': 218,\n",
      "                          'dStart': 214,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'Thus, our results suggested that the level '\n",
      "                                  'of circZNF451 was elevated in the exosomes '\n",
      "                                  'of advanced LUAD patients resistant to PD1 '\n",
      "                                  'blockade and highlighted the potential '\n",
      "                                  'influence of circZNF451 on the progression '\n",
      "                                  'of LUAD.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['31718573'],\n",
      " 'resourceScore': 54,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 257,\n",
      "                          'dStart': 238,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'In summary, our study examined the PD-1 '\n",
      "                                  'role in the disease process with patients '\n",
      "                                  'collected prior to treatment, indicating '\n",
      "                                  'that the PD-1 gene and the SNPs on it could '\n",
      "                                  'be used as markers for distinguishing '\n",
      "                                  'between early and late stages of lung '\n",
      "                                  'adenocarcinoma in the Northeast Han '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'This further indicated that the four SNPs '\n",
      "                                  'on PD-1 can be used as potential markers '\n",
      "                                  'for lung adenocarcinoma staging.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 49,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and its ligand, PD-L1, were drug '\n",
      "                                  'targets of lung adenocarcinoma [14].'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'For two stages, PD-1 gene polymorphisms at '\n",
      "                                  'three investigated positions and their '\n",
      "                                  'haplotypes were associated with the risk '\n",
      "                                  'and prognosis of lung adenocarcinoma in '\n",
      "                                  'three genetic models (allele model, '\n",
      "                                  'dominant model, and recessive model).'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Association of PD-1 SNPs with lung '\n",
      "                                  'adenocarcinoma in different models'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Our study aimed to examine the effect of '\n",
      "                                  'PD-1 and these four PD-1 polymorphisms on '\n",
      "                                  'disease progression of lung '\n",
      "                                  'adenocarcinoma.'},\n",
      "                         {'dEnd': 257,\n",
      "                          'dStart': 238,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'In summary, our study examined the PD-1 '\n",
      "                                  'role in the disease process with patients '\n",
      "                                  'collected prior to treatment, indicating '\n",
      "                                  'that the PD-1 gene and the SNPs on it could '\n",
      "                                  'be used as markers for distinguishing '\n",
      "                                  'between early and late stages of lung '\n",
      "                                  'adenocarcinoma in the Northeast Han '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Out study indicated that the PD-1 gene and '\n",
      "                                  'the SNPs on it could be used as markers for '\n",
      "                                  'distinguishing lung adenocarcinoma staging '\n",
      "                                  'in the Northeast Han population.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'Our study aimed to examine the effect of '\n",
      "                                  'PD-1 and these four PD-1 polymorphisms on '\n",
      "                                  'disease progression of lung '\n",
      "                                  'adenocarcinoma.'},\n",
      "                         {'dEnd': 246,\n",
      "                          'dStart': 227,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'In view of the high classification '\n",
      "                                  'efficiency of PD-1 and PD-L1 for staging '\n",
      "                                  'and the significant correlation of their '\n",
      "                                  'SNPs and haplotypes on them with staging, '\n",
      "                                  'the polymorphism of PD-1 may be used as a '\n",
      "                                  'marker for the staging of lung '\n",
      "                                  'adenocarcinoma.'},\n",
      "                         {'dEnd': 43,\n",
      "                          'dStart': 24,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'In order to combine the lung adenocarcinoma '\n",
      "                                  'staging information and clinical '\n",
      "                                  'information, four polymorphisms of the PD-1 '\n",
      "                                  'gene, including rs2227981 (PD-1.5), '\n",
      "                                  'rs2227982 (PD-1.9), rs36084323 (PD-1.1) and '\n",
      "                                  'rs7421861, were selected, and the genotypes '\n",
      "                                  'of 287 patients were determined by SNaPshot '\n",
      "                                  'primer extension assays.'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Our investigation into the link between '\n",
      "                                  'PD-1 polymorphisms and lung adenocarcinoma '\n",
      "                                  'would help to provide guidance for the '\n",
      "                                  'treatment and prognosis of lung '\n",
      "                                  'adenocarcinoma.'},\n",
      "                         {'dEnd': 246,\n",
      "                          'dStart': 227,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 183,\n",
      "                          'tStart': 179,\n",
      "                          'text': 'In view of the high classification '\n",
      "                                  'efficiency of PD-1 and PD-L1 for staging '\n",
      "                                  'and the significant correlation of their '\n",
      "                                  'SNPs and haplotypes on them with staging, '\n",
      "                                  'the polymorphism of PD-1 may be used as a '\n",
      "                                  'marker for the staging of lung '\n",
      "                                  'adenocarcinoma.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Association of PD-1 polymorphisms with the '\n",
      "                                  'risk and prognosis of lung adenocarcinoma '\n",
      "                                  'in the northeastern Chinese Han population'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'Our investigation into the link between '\n",
      "                                  'PD-1 polymorphisms and lung adenocarcinoma '\n",
      "                                  'would help to provide guidance for the '\n",
      "                                  'treatment and prognosis of lung '\n",
      "                                  'adenocarcinoma.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38780840'],\n",
      " 'resourceScore': 53,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'Therefore, combining PD-1 with temozolomide '\n",
      "                                  'not only explores new combination therapies '\n",
      "                                  'but also opens up new avenues for the '\n",
      "                                  'treatment of solid tumor with brain '\n",
      "                                  'metastasis, including NSCLC.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'The efficiency and safety of temozolomide '\n",
      "                                  'and PD-1/L1 inhibitors in pretreated NSCLC '\n",
      "                                  'with brain metastasis: a retrospective '\n",
      "                                  'cohort'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Our results exhibited that with tolerated '\n",
      "                                  'toxicity, the combination of TMZ and '\n",
      "                                  'PD-1/L1 shows promising efficiency against '\n",
      "                                  'NSCLC with BM, this would be of great '\n",
      "                                  'significance for the treatment of NSCLC '\n",
      "                                  'with brain metastasis.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'Although the efficiency of PD-1 and CT had '\n",
      "                                  'been widely reported both in the first line '\n",
      "                                  'and the second line treatment toward the '\n",
      "                                  'general population of NSCLC, however, the '\n",
      "                                  'date against special population such as '\n",
      "                                  'brain metastasis is rather scarce (Loiola '\n",
      "                                  'et al. 2021).'},\n",
      "                         {'dEnd': 457,\n",
      "                          'dStart': 452,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 431,\n",
      "                          'tStart': 427,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 457,\n",
      "                          'dStart': 452,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 291,\n",
      "                          'tStart': 287,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'During the past decades, immunotherapy '\n",
      "                                  'exemplified by targeting PD-1/L1 had '\n",
      "                                  'greatly changed the landscape of advanced '\n",
      "                                  'NSCLC (Garassino et al. 2023; Novello et '\n",
      "                                  'al. 2023), however, there still lack of '\n",
      "                                  'high-grade evidence of immunotherapy toward '\n",
      "                                  'the population of brain metastasis (Barlesi '\n",
      "                                  'and Tomasini 2020).'},\n",
      "                         {'dEnd': 326,\n",
      "                          'dStart': 321,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 291,\n",
      "                          'tStart': 287,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Historically, both temozolomide and PD-1/L1 '\n",
      "                                  'inhibitors have exhibited limited efficacy '\n",
      "                                  'in addressing brain metastases from '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 326,\n",
      "                          'dStart': 321,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 218,\n",
      "                          'tStart': 214,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 326,\n",
      "                          'dStart': 321,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'This study marks the first documentation of '\n",
      "                                  'the promising efficacy of combining '\n",
      "                                  'temozolomide and PD-1/L1 inhibitors, '\n",
      "                                  'demonstrating tolerable toxicity levels, in '\n",
      "                                  'treating advanced NSCLC patients with brain '\n",
      "                                  'metastasis.'},\n",
      "                         {'dEnd': 312,\n",
      "                          'dStart': 307,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 457,\n",
      "                          'dStart': 452,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 218,\n",
      "                          'tStart': 214,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'However, the concurrent administration of '\n",
      "                                  'temozolomide and PD-1/L1 inhibitors reveals '\n",
      "                                  'a potential synergistic effect against '\n",
      "                                  'advanced NSCLC patients with brain '\n",
      "                                  'metastasis.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': 'Under such circumstances, with relatively '\n",
      "                                  'higher capacity penetrating blood–brain '\n",
      "                                  'barrier (BBB), TMZ would an ideal partner '\n",
      "                                  'for PD-1/L1 combination, especially for '\n",
      "                                  'NSCLC with brain metastasis (Cortot et al. '\n",
      "                                  '2006; Giorgio et al. 2005; Robins et al. '\n",
      "                                  '2006; Yang et al. 2020).'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Our results exhibited that with tolerated '\n",
      "                                  'toxicity, the combination of TMZ and '\n",
      "                                  'PD-1/L1 shows promising efficiency against '\n",
      "                                  'NSCLC with BM, this would be of great '\n",
      "                                  'significance for the treatment of NSCLC '\n",
      "                                  'with brain metastasis.'},\n",
      "                         {'dEnd': 312,\n",
      "                          'dStart': 307,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 457,\n",
      "                          'dStart': 452,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Actually, latest case report indeed '\n",
      "                                  'exhibited that the drug combination of PD-1 '\n",
      "                                  'and TMZ could bring about long term '\n",
      "                                  'survival benefits for NSCLC with BM (Zhu et '\n",
      "                                  'al. 2022), indicating the potential '\n",
      "                                  'synergism between PD-1 and TMZ, however, up '\n",
      "                                  'to now, no study about the drug combination '\n",
      "                                  'of PD-1 and TMZ had been reported in NSCLC '\n",
      "                                  'with BM, therefore, in this study, we '\n",
      "                                  'retrospectively analyzed the safety and '\n",
      "                                  'efficiency of TMZ and PD-1 against '\n",
      "                                  'pre-treated NSCLC suffering from BM with '\n",
      "                                  'the aim to seek new way to improve the '\n",
      "                                  'therapeutic efficiency of such special '\n",
      "                                  'population.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Previous research has shown that both '\n",
      "                                  'temozolomide (TMZ) and PD-1/L1 inhibitors '\n",
      "                                  '(PD-1/L1) alone exhibit certain potential '\n",
      "                                  'in the treatment of non-small cell lung '\n",
      "                                  'cancer (NSCLC) with brain metastases (BM), '\n",
      "                                  'in this study, we will explore combining '\n",
      "                                  'the two in order to seek new effective '\n",
      "                                  'treatment options for NSCLC with BM.'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'During 2021.1 to 2023.12, we collected the '\n",
      "                                  'date of these pretreated-NSCLC with BM who '\n",
      "                                  'accept the treatment of TMZ and PD-1/L1, '\n",
      "                                  'the objective response ratio (ORR), '\n",
      "                                  'progression-free survival (PFS) and overall '\n",
      "                                  'survival (OS) were set as the primary '\n",
      "                                  'endpoint, meanwhile, the toxicity of such '\n",
      "                                  'regimen was also recorded.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 96,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'To sum up, as far as we know, this is the '\n",
      "                                  'first study to report the promising '\n",
      "                                  'efficiency of PD-1 and TMZ in NSCLC with '\n",
      "                                  'brain metastasis together with lower '\n",
      "                                  'cytotoxicity, further study exhibited that '\n",
      "                                  'the efficiency of such regimen correlate '\n",
      "                                  'with Ds-GPA score, indicating that Ds-GPA '\n",
      "                                  'score can be utilized as a potential '\n",
      "                                  'parameter for efficiency prediction of such '\n",
      "                                  'regime (Sperduto et al. 2010).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36118825'],\n",
      " 'resourceScore': 52,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 370,\n",
      "                          'dStart': 365,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 320,\n",
      "                          'tStart': 316,\n",
      "                          'text': 'This is also in line with our previous '\n",
      "                                  'conclusion that “PD-1 inhibitor combined '\n",
      "                                  'with chemotherapy in the treatment of NSCLC '\n",
      "                                  'could be more effective than chemotherapy '\n",
      "                                  'alone.” This result also showed that PD-1 '\n",
      "                                  'did not markedly increase the related '\n",
      "                                  'adverse reactions in patients receiving '\n",
      "                                  'chemotherapy, suggesting that PD-1 '\n",
      "                                  'inhibitors were generally well tolerated in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 340,\n",
      "                          'dStart': 335,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 243,\n",
      "                          'tStart': 239,\n",
      "                          'text': 'Results of present study suggested that '\n",
      "                                  'CD4+, CD4+/CD8+, and NK cells in both '\n",
      "                                  'groups went markedly higher after '\n",
      "                                  'treatment, and it was notable that OG held '\n",
      "                                  'much vivid improvement on these indicators '\n",
      "                                  'when compared to CG, indicating that the '\n",
      "                                  'PD-1 inhibitor combined with chemotherapy '\n",
      "                                  'could more effectively improve the immune '\n",
      "                                  'function of NSCLC patients than '\n",
      "                                  'chemotherapy alone.'},\n",
      "                         {'dEnd': 36,\n",
      "                          'dStart': 31,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'In this study, we included 150 NSCLC '\n",
      "                                  'patients treated in our hospital from June '\n",
      "                                  '2018 to September 2020 and analyzed the '\n",
      "                                  'efficacy of PD-1 inhibitor combined with '\n",
      "                                  'chemotherapy in treating NSCLC, hopefully '\n",
      "                                  'to provide more clinical treatment options '\n",
      "                                  'for NSCLC patients.'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'In addition, a study [19] showed that in '\n",
      "                                  'the course of NSCLC, the apoptosis of '\n",
      "                                  'tumor-specific T cells was mediated by '\n",
      "                                  'PD-1-dependent and independent mechanisms, '\n",
      "                                  'and the PD-1-dependent mechanism could '\n",
      "                                  'promote the immune escape of tumor cells in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Although the efficacy of PD-1 has been '\n",
      "                                  'affirmed in the past, few studies have '\n",
      "                                  'focused on the comprehensive impact of PD-1 '\n",
      "                                  'combined with chemotherapy on NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Although the efficacy of PD-1 has been '\n",
      "                                  'affirmed in the past, few studies have '\n",
      "                                  'focused on the comprehensive impact of PD-1 '\n",
      "                                  'combined with chemotherapy on NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'To explore the effect of combined treatment '\n",
      "                                  'of PD-1 inhibitor and chemotherapy on the '\n",
      "                                  'level of peripheral blood T lymphocytes in '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'and its relationship with prognosis.'},\n",
      "                         {'dEnd': 20,\n",
      "                          'dStart': 15,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'To sum up, for NSCLC patients, the PD-1 '\n",
      "                                  'inhibitor on the basis of chemotherapy '\n",
      "                                  'could further improve the clinical '\n",
      "                                  'efficacy, as well as the immune function '\n",
      "                                  'and long-term survival rate of patients on '\n",
      "                                  'the premise of ensuring the safety of '\n",
      "                                  'treatment, which is worthy of promotion in '\n",
      "                                  'clinical practice.'},\n",
      "                         {'dEnd': 9,\n",
      "                          'dStart': 4,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'For NSCLC patients, the PD-1 inhibitor '\n",
      "                                  'given on the basis of chemotherapy can '\n",
      "                                  'further improve the clinical efficacy and '\n",
      "                                  'improve immune function and long-term '\n",
      "                                  'survival rate of patients on the premise of '\n",
      "                                  'ensuring the safety of treatment, which is '\n",
      "                                  'worth promoting in clinical practice.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'This is also in line with our previous '\n",
      "                                  'conclusion that “PD-1 inhibitor combined '\n",
      "                                  'with chemotherapy in the treatment of NSCLC '\n",
      "                                  'could be more effective than chemotherapy '\n",
      "                                  'alone.” This result also showed that PD-1 '\n",
      "                                  'did not markedly increase the related '\n",
      "                                  'adverse reactions in patients receiving '\n",
      "                                  'chemotherapy, suggesting that PD-1 '\n",
      "                                  'inhibitors were generally well tolerated in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 129,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'To explore the effect of combined treatment '\n",
      "                                  'of PD-1 inhibitor and chemotherapy on the '\n",
      "                                  'level of peripheral blood T lymphocytes in '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'and its relationship with prognosis.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 168,\n",
      "                          'tStart': 164,\n",
      "                          'text': 'Results of our study showed that CYFRA21-1, '\n",
      "                                  'CEA, and CA125 in both groups all declined '\n",
      "                                  'after treatment, and the decrease in OG was '\n",
      "                                  'even marked, suggesting that the PD-1 '\n",
      "                                  'inhibitor combined with chemotherapy in '\n",
      "                                  'NSCLC treatment could better and '\n",
      "                                  'effectively alleviate the disease than that '\n",
      "                                  'of chemotherapy alone.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': 'And PD-1 prevents autoimmune diseases and '\n",
      "                                  'also hinders the immune system from killing '\n",
      "                                  'cancer cells, making it a novel treatment '\n",
      "                                  'for advanced NSCLC [7].'},\n",
      "                         {'dEnd': 249,\n",
      "                          'dStart': 244,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'In addition, a study [19] showed that in '\n",
      "                                  'the course of NSCLC, the apoptosis of '\n",
      "                                  'tumor-specific T cells was mediated by '\n",
      "                                  'PD-1-dependent and independent mechanisms, '\n",
      "                                  'and the PD-1-dependent mechanism could '\n",
      "                                  'promote the immune escape of tumor cells in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 370,\n",
      "                          'dStart': 365,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 207,\n",
      "                          'tStart': 203,\n",
      "                          'text': 'This is also in line with our previous '\n",
      "                                  'conclusion that “PD-1 inhibitor combined '\n",
      "                                  'with chemotherapy in the treatment of NSCLC '\n",
      "                                  'could be more effective than chemotherapy '\n",
      "                                  'alone.” This result also showed that PD-1 '\n",
      "                                  'did not markedly increase the related '\n",
      "                                  'adverse reactions in patients receiving '\n",
      "                                  'chemotherapy, suggesting that PD-1 '\n",
      "                                  'inhibitors were generally well tolerated in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 247,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 152,\n",
      "                          'tStart': 148,\n",
      "                          'text': 'In this study, we first observed that OG '\n",
      "                                  'patients possessed much higher total '\n",
      "                                  'effective rate than that in CG, indicating '\n",
      "                                  'that combined treatment of PD-1 inhibitor '\n",
      "                                  'and chemotherapy performed better regarding '\n",
      "                                  'short-term efficacy in the treatment of '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 186,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'In this study, we included 150 NSCLC '\n",
      "                                  'patients treated in our hospital from June '\n",
      "                                  '2018 to September 2020 and analyzed the '\n",
      "                                  'efficacy of PD-1 inhibitor combined with '\n",
      "                                  'chemotherapy in treating NSCLC, hopefully '\n",
      "                                  'to provide more clinical treatment options '\n",
      "                                  'for NSCLC patients.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 196,\n",
      "                          'tStart': 192,\n",
      "                          'text': 'Retrospective analysis was conducted on 150 '\n",
      "                                  'NSCLC patients treated in Guangxi Medical '\n",
      "                                  'University Affiliated Tumor Hospital from '\n",
      "                                  'June 2018 to September 2020, including 77 '\n",
      "                                  'patients treated with PD-1 inhibitor '\n",
      "                                  'combined with chemotherapy as the '\n",
      "                                  'observation group (OG) and 73 patients with '\n",
      "                                  'chemotherapy alone as the control group '\n",
      "                                  '(CG).'},\n",
      "                         {'dEnd': 370,\n",
      "                          'dStart': 365,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'This is also in line with our previous '\n",
      "                                  'conclusion that “PD-1 inhibitor combined '\n",
      "                                  'with chemotherapy in the treatment of NSCLC '\n",
      "                                  'could be more effective than chemotherapy '\n",
      "                                  'alone.” This result also showed that PD-1 '\n",
      "                                  'did not markedly increase the related '\n",
      "                                  'adverse reactions in patients receiving '\n",
      "                                  'chemotherapy, suggesting that PD-1 '\n",
      "                                  'inhibitors were generally well tolerated in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 249,\n",
      "                          'dStart': 244,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'In addition, a study [19] showed that in '\n",
      "                                  'the course of NSCLC, the apoptosis of '\n",
      "                                  'tumor-specific T cells was mediated by '\n",
      "                                  'PD-1-dependent and independent mechanisms, '\n",
      "                                  'and the PD-1-dependent mechanism could '\n",
      "                                  'promote the immune escape of tumor cells in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'The Effect of PD-1 Inhibitor Combined with '\n",
      "                                  'Chemotherapy on the Level of Peripheral '\n",
      "                                  'Blood T Lymphocytes among Patients with '\n",
      "                                  'Non-Small-Cell Lung Cancer and Its '\n",
      "                                  'Relationship with Prognosis'},\n",
      "                         {'dEnd': 186,\n",
      "                          'dStart': 181,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'In the 2021 Chinese Society of Clinical '\n",
      "                                  'Oncology (CSCO) guidelines, the PD-1 '\n",
      "                                  'inhibitor combined with chemotherapy is the '\n",
      "                                  'first-line class IA recommended treatment '\n",
      "                                  'for patients with NSCLC; however, there are '\n",
      "                                  'differences in response rates among '\n",
      "                                  'patients treated with immune checkpoint '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 255,\n",
      "                          'dStart': 250,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'In this study, we included 150 NSCLC '\n",
      "                                  'patients treated in our hospital from June '\n",
      "                                  '2018 to September 2020 and analyzed the '\n",
      "                                  'efficacy of PD-1 inhibitor combined with '\n",
      "                                  'chemotherapy in treating NSCLC, hopefully '\n",
      "                                  'to provide more clinical treatment options '\n",
      "                                  'for NSCLC patients.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['37152010'],\n",
      " 'resourceScore': 52,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 45,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 198,\n",
      "                          'tStart': 194,\n",
      "                          'text': 'Here, the bulk-Seq and scRNA-Seq data of '\n",
      "                                  'LUAD were integrated for further analysis '\n",
      "                                  'by comparing the different cell−cell '\n",
      "                                  'interactions in untreated patients, '\n",
      "                                  'responders, and nonresponders to anti-PD-1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 197,\n",
      "                          'tStart': 193,\n",
      "                          'text': 'To explore the cellular diversity and '\n",
      "                                  'transcriptional characteristics in LUAD '\n",
      "                                  'patients who received anti-PD-1 therapy, we '\n",
      "                                  'integrated scRNA-seq and bulk-RNA '\n",
      "                                  'sequencing data associated with anti-PD-1 '\n",
      "                                  'therapy in LUAD patients from our data and '\n",
      "                                  'the GEO database (GSE146100) (19).'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 135,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'In summary, the combination of scRNA-seq '\n",
      "                                  'data reflected the distribution of the cell '\n",
      "                                  'type and transcriptional features in the '\n",
      "                                  'anti-PD-1 treatment cohort of LUAD.'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': 'To further identify the key mediators of '\n",
      "                                  'the important cell types cell-cell '\n",
      "                                  'interactions (CCI) in the anti-PD-1 '\n",
      "                                  'treatment of LUAD patients, we evaluated '\n",
      "                                  'the putative crosstalk with the R package '\n",
      "                                  '“NicheNet” R package based on the '\n",
      "                                  'expression and downstream targets of '\n",
      "                                  'ligand-receptor pairs, the '\n",
      "                                  '“nichenet_seuratobj_aggregate” algorithm '\n",
      "                                  'can be used for downstream differential '\n",
      "                                  'cell communication and receptor-ligand '\n",
      "                                  'regulatory network analysis (25, 26).'},\n",
      "                         {'dEnd': 108,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 180,\n",
      "                          'tStart': 176,\n",
      "                          'text': 'To explore the mechanisms of immunotherapy '\n",
      "                                  'and identify new therapeutic opportunities '\n",
      "                                  'in lung adenocarcinoma (LUAD), data from '\n",
      "                                  'patients who did and did not respond to the '\n",
      "                                  'anti-PD-1 treatment were evaluated using '\n",
      "                                  'single-cell RNA sequencing, and bulk RNA '\n",
      "                                  'sequencing were collected.'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'To explore the cellular diversity and '\n",
      "                                  'transcriptional characteristics in LUAD '\n",
      "                                  'patients who received anti-PD-1 therapy, we '\n",
      "                                  'integrated scRNA-seq and bulk-RNA '\n",
      "                                  'sequencing data associated with anti-PD-1 '\n",
      "                                  'therapy in LUAD patients from our data and '\n",
      "                                  'the GEO database (GSE146100) (19).'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 165,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 248,\n",
      "                          'tStart': 244,\n",
      "                          'text': 'For the DEGs at the tissue and cellular '\n",
      "                                  'level, we performed differential expression '\n",
      "                                  'among the untreated patients, responder, '\n",
      "                                  'and non-responder for each cell type in '\n",
      "                                  'LUAD, providing a comprehensive molecular '\n",
      "                                  'expression change of TME in the anti-PD-1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'All of us provide a comprehensive '\n",
      "                                  'characterization of LR-Pairs of responder '\n",
      "                                  'or no-responder after anti-PD-1 therapy in '\n",
      "                                  'LUAD, Ligand-receptor interactions (LRIs) '\n",
      "                                  'between different cell types in the TME '\n",
      "                                  'play a vital role in the occurrence and '\n",
      "                                  'development of anti-PD-1 treatment '\n",
      "                                  'responses.'},\n",
      "                         {'dEnd': 77,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'To explore the cellular diversity and '\n",
      "                                  'transcriptional characteristics in LUAD '\n",
      "                                  'patients who received anti-PD-1 therapy, we '\n",
      "                                  'integrated scRNA-seq and bulk-RNA '\n",
      "                                  'sequencing data associated with anti-PD-1 '\n",
      "                                  'therapy in LUAD patients from our data and '\n",
      "                                  'the GEO database (GSE146100) (19).'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'Furthermore, to further identify the key '\n",
      "                                  'mediators of the important cell types and '\n",
      "                                  'cell−cell interactions in the anti-PD-1 '\n",
      "                                  'treatment of LUAD patients, we further '\n",
      "                                  'investigated LRIs and the regulation of '\n",
      "                                  'downstream genes.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 214,\n",
      "                          'tStart': 210,\n",
      "                          'text': 'Taken together, our comprehensive analysis '\n",
      "                                  'revealed that the LR-Pairs subgroups were '\n",
      "                                  'significantly correlated with the patient '\n",
      "                                  'prognosis and TME characteristics, which '\n",
      "                                  'might provide new insights into LUAD '\n",
      "                                  'anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 105,\n",
      "                          'text': 'All of us provide a comprehensive '\n",
      "                                  'characterization of LR-Pairs of responders '\n",
      "                                  'or nonresponders after anti-PD-1 therapy in '\n",
      "                                  'LUAD.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['31217824'],\n",
      " 'resourceScore': 52,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 145,\n",
      "                          'tStart': 141,\n",
      "                          'text': 'The results of the current study, for first '\n",
      "                                  'time, provide evidence for a possible '\n",
      "                                  'interaction between ICs and CTCs in NSCLC '\n",
      "                                  'patients via the PD-1/PD-L1 axis and '\n",
      "                                  'strongly support that the levels of PD-1+ '\n",
      "                                  'CD8+ in these patients may be of clinical '\n",
      "                                  'relevance.'},\n",
      "                         {'dEnd': 489,\n",
      "                          'dStart': 484,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 376,\n",
      "                          'tStart': 372,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 365,\n",
      "                          'dStart': 360,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 456,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 321,\n",
      "                          'tStart': 317,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 456,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 60,\n",
      "                          'dStart': 55,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and PD-L1 effector ICs in the '\n",
      "                                  'peripheral blood of NSCLC patients'},\n",
      "                         {'dEnd': 365,\n",
      "                          'dStart': 360,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 237,\n",
      "                          'tStart': 233,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 195,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'The present study evaluated the expression '\n",
      "                                  'of PD-1 and PD-L1 on effector ICs and their '\n",
      "                                  'association with the CTCs isolated from the '\n",
      "                                  'peripheral blood of newly diagnosed and '\n",
      "                                  'untreated patients with NSCLC.'},\n",
      "                         {'dEnd': 330,\n",
      "                          'dStart': 325,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'The present study evaluated the expression '\n",
      "                                  'of PD-1 and PD-L1 on circulating effector '\n",
      "                                  'ICs and CTCs, the association between the '\n",
      "                                  'expression of PD-1+ and PD-L1+ on CTCs, on '\n",
      "                                  'tumor cells and ICs as a possible mechanism '\n",
      "                                  'of CTC escape from immune system '\n",
      "                                  'surveillance and, finally, their possible '\n",
      "                                  'clinical relevance in patients with NSCLC.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'CD8+ PD-1+ T-cells and PD-L1+ circulating '\n",
      "                                  'tumor cells in chemotherapy-naïve '\n",
      "                                  'non-small cell lung cancer: towards their '\n",
      "                                  'clinical relevance?'},\n",
      "                         {'dEnd': 377,\n",
      "                          'dStart': 372,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 115,\n",
      "                          'tStart': 111,\n",
      "                          'text': 'Recently, anti-PD-1/PD-L1 therapies have '\n",
      "                                  'demonstrated a greater benefit in patients '\n",
      "                                  'with PD-L1+ tumors.8,15,35 PD-1 is a major '\n",
      "                                  'negative immune mediator contributing to '\n",
      "                                  'immunosuppression when interacts with its '\n",
      "                                  'ligand, PD-L1, on tumor cells and '\n",
      "                                  'antigen-presenting cells.36 The current '\n",
      "                                  'study demonstrated that several subtypes of '\n",
      "                                  'ICs, from chemotherapy-naïve patients with '\n",
      "                                  'NSCLC, expressed on their surface both PD-1 '\n",
      "                                  'and PD-L1.'},\n",
      "                         {'dEnd': 460,\n",
      "                          'dStart': 455,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 364,\n",
      "                          'tStart': 360,\n",
      "                          'text': 'In addition, the multivariate analysis '\n",
      "                                  'revealed that the high percentages of CD8+ '\n",
      "                                  'PD-1+ before initiation of any systemic '\n",
      "                                  'treatment were associated with a shorter '\n",
      "                                  'PFS; although this finding should be '\n",
      "                                  'interpreted with caution taking into '\n",
      "                                  'account the low number of patients enrolled '\n",
      "                                  'in this study, this observation seems to '\n",
      "                                  'indicate that baseline levels of CD8+ PD-1+ '\n",
      "                                  'cells could represent an independent '\n",
      "                                  'prognostic factor for PFS in patients with '\n",
      "                                  'stage IV NSCLC.'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'In conclusion, the current study indicated '\n",
      "                                  'that high percentages of circulating CD8+ '\n",
      "                                  'PD-1+ are associated with the presence of '\n",
      "                                  'PD-L1+ CTCs, as well as that both could '\n",
      "                                  'emerge as potential prognostic factors for '\n",
      "                                  'patients with un-treated NSCLC.'},\n",
      "                         {'dEnd': 489,\n",
      "                          'dStart': 484,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 321,\n",
      "                          'tStart': 317,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 358,\n",
      "                          'dStart': 332,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 365,\n",
      "                          'dStart': 360,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 489,\n",
      "                          'dStart': 484,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 377,\n",
      "                          'dStart': 372,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 19,\n",
      "                          'tStart': 15,\n",
      "                          'text': 'Recently, anti-PD-1/PD-L1 therapies have '\n",
      "                                  'demonstrated a greater benefit in patients '\n",
      "                                  'with PD-L1+ tumors.8,15,35 PD-1 is a major '\n",
      "                                  'negative immune mediator contributing to '\n",
      "                                  'immunosuppression when interacts with its '\n",
      "                                  'ligand, PD-L1, on tumor cells and '\n",
      "                                  'antigen-presenting cells.36 The current '\n",
      "                                  'study demonstrated that several subtypes of '\n",
      "                                  'ICs, from chemotherapy-naïve patients with '\n",
      "                                  'NSCLC, expressed on their surface both PD-1 '\n",
      "                                  'and PD-L1.'},\n",
      "                         {'dEnd': 482,\n",
      "                          'dStart': 456,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 376,\n",
      "                          'tStart': 372,\n",
      "                          'text': 'One of the mechanisms that cancer cells use '\n",
      "                                  'to escape immune surveillance is the '\n",
      "                                  'activation of the PD-1/PD-L1 pathway.6,7 '\n",
      "                                  'High expression of PD-L1 on tumor cells or '\n",
      "                                  'on tumor-infiltrating immune cells (TILs) '\n",
      "                                  'has been associated with a worse prognosis '\n",
      "                                  'and has been proposed as a potential '\n",
      "                                  'biomarker for the response to PD-1/PD-L1 '\n",
      "                                  'inhibitors.8, –10 Nevertheless, the role of '\n",
      "                                  'PD-1 and PD-L1 expression on peripheral '\n",
      "                                  'blood immune cells (ICs) from patients with '\n",
      "                                  'non-small cell lung cancer (NSCLC) has not '\n",
      "                                  'been sufficiently studied.'},\n",
      "                         {'dEnd': 460,\n",
      "                          'dStart': 455,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'In addition, the multivariate analysis '\n",
      "                                  'revealed that the high percentages of CD8+ '\n",
      "                                  'PD-1+ before initiation of any systemic '\n",
      "                                  'treatment were associated with a shorter '\n",
      "                                  'PFS; although this finding should be '\n",
      "                                  'interpreted with caution taking into '\n",
      "                                  'account the low number of patients enrolled '\n",
      "                                  'in this study, this observation seems to '\n",
      "                                  'indicate that baseline levels of CD8+ PD-1+ '\n",
      "                                  'cells could represent an independent '\n",
      "                                  'prognostic factor for PFS in patients with '\n",
      "                                  'stage IV NSCLC.'},\n",
      "                         {'dEnd': 330,\n",
      "                          'dStart': 325,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 145,\n",
      "                          'tStart': 141,\n",
      "                          'text': 'The present study evaluated the expression '\n",
      "                                  'of PD-1 and PD-L1 on circulating effector '\n",
      "                                  'ICs and CTCs, the association between the '\n",
      "                                  'expression of PD-1+ and PD-L1+ on CTCs, on '\n",
      "                                  'tumor cells and ICs as a possible mechanism '\n",
      "                                  'of CTC escape from immune system '\n",
      "                                  'surveillance and, finally, their possible '\n",
      "                                  'clinical relevance in patients with NSCLC.'},\n",
      "                         {'dEnd': 358,\n",
      "                          'dStart': 332,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 358,\n",
      "                          'dStart': 332,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 237,\n",
      "                          'tStart': 233,\n",
      "                          'text': 'Since tumor cells may escape from immune '\n",
      "                                  'surveillance through the programmed cell '\n",
      "                                  'death 1 (PD-1)/programmed death ligand '\n",
      "                                  '(PD-L)1 axis, this study was designed in '\n",
      "                                  'order to evaluate whether there is a '\n",
      "                                  'correlation between the levels of PD-1+ and '\n",
      "                                  'PD-L1+-expressing immune cells (ICs) and '\n",
      "                                  'circulating tumor cells (CTCs) in patients '\n",
      "                                  'with non-small cell lung cancer (NSCLC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32337213'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Overall, 11 839 patients with NSCLC were '\n",
      "                                  'estimated to be under treatment with '\n",
      "                                  'anti-PD-1 therapy 3 years after routine use '\n",
      "                                  'of these drugs (table 2).'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Overall, 11 839 patients with NSCLC were '\n",
      "                                  'estimated to be eligible for anti-PD-1 '\n",
      "                                  'therapy 3 years after the introduction of '\n",
      "                                  'anti-PD-1 therapies.'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 21,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 agents for NSCLC treatment are '\n",
      "                                  'associated with a substantial economic '\n",
      "                                  'burden.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Overall, the mean annual cost of treatment '\n",
      "                                  'for the four EMA-approved indications of '\n",
      "                                  'anti-PD-1 therapy in NSCLC was estimated to '\n",
      "                                  'be €48.7 million in the control group and '\n",
      "                                  '€421.8 million in the immunotherapy group.'},\n",
      "                         {'dEnd': 263,\n",
      "                          'dStart': 258,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'Our objectives were to estimate the target '\n",
      "                                  'population of immunotherapy in France '\n",
      "                                  '(number of patients eligible for anti-PD-1 '\n",
      "                                  'treatment), and to assess the budget impact '\n",
      "                                  'at the national level for the four '\n",
      "                                  'indications of nivolumab and pembrolizumab '\n",
      "                                  'in advanced NSCLC, which was approved by '\n",
      "                                  'the EMA at the time of analysis (May '\n",
      "                                  '2018).'},\n",
      "                         {'dEnd': 98,\n",
      "                          'dStart': 93,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 17,\n",
      "                          'text': 'Since 2016, anti-PD-1 agents have become '\n",
      "                                  'the new standard of care for patients with '\n",
      "                                  'advanced NSCLC that have progressed during '\n",
      "                                  'or after platinum-based chemotherapy.'},\n",
      "                         {'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'In May 2018, nivolumab and pembrolizumab '\n",
      "                                  'were the first two anti-PD-1 drugs to be '\n",
      "                                  'approved by the European Medicines Agency '\n",
      "                                  '(EMA) for the treatment of advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'We identified only one study that showed '\n",
      "                                  '105 NSCLC patients per year would be '\n",
      "                                  'eligible for anti-PD-1 treatment in Norway, '\n",
      "                                  'with an annual budget impact amounting to '\n",
      "                                  '€5 million [11].'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 127,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'Treatment duration, cost per patient and '\n",
      "                                  'budget impact for the four European '\n",
      "                                  'Medicines Agency-approved indications of '\n",
      "                                  'anti-PD-1 therapy for non-small cell lung '\n",
      "                                  'cancer'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'Patient characteristics selected from the '\n",
      "                                  'ESCAP-2011-CPHG cohort study for each of '\n",
      "                                  'the four EMA-approved indications of '\n",
      "                                  'anti-PD-1 therapy, for advanced NSCLC, are '\n",
      "                                  'shown in table 1.'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Overall, 9939 NSCLC patients were estimated '\n",
      "                                  'to be eligible to receive anti-PD-1 '\n",
      "                                  'treatment according the four indications '\n",
      "                                  'approved by EMA in May 2018.'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'First, we performed a comprehensive '\n",
      "                                  'analysis of the budget impact of the four '\n",
      "                                  'EMA-approved indications for anti-PD-1 '\n",
      "                                  'therapy in NSCLC, a high-volume disease.'},\n",
      "                         {'dEnd': 48,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 agents for treatment of advanced '\n",
      "                                  'NSCLC are associated with a substantial '\n",
      "                                  'economic burden.'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 21,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1 agents for NSCLC treatment are '\n",
      "                                  'associated with a substantial economic '\n",
      "                                  'burdenhttp://bit.ly/2SDXZw0'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'We aimed to quantify the economic impact, '\n",
      "                                  'in France, of anti-PD-1 therapy for NSCLC.'},\n",
      "                         {'dEnd': 186,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'In May 2018, nivolumab and pembrolizumab '\n",
      "                                  'were the first two anti-PD-1 drugs to be '\n",
      "                                  'approved by the European Medicines Agency '\n",
      "                                  '(EMA) for the treatment of advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 195,\n",
      "                          'dStart': 169,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 156,\n",
      "                          'tStart': 152,\n",
      "                          'text': 'Patient characteristics for the populations '\n",
      "                                  'selected from the ESCAP-2011-CPHG study '\n",
      "                                  'that fit the European Medicines '\n",
      "                                  'Agency-approved indications of anti-PD-1 '\n",
      "                                  'therapy for non-small cell lung cancer'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39101140'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Although PD-1 inhibitors have shown many '\n",
      "                                  'potential advantages in the treatment of '\n",
      "                                  'NSCLC, there are also some adverse '\n",
      "                                  'reactions that may occur in patients.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Related studies on the impact of sarcopenia '\n",
      "                                  'on the therapeutic effect of PD-1 '\n",
      "                                  'inhibitors in NSCLC.'},\n",
      "                         {'dEnd': 46,\n",
      "                          'dStart': 41,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 145,\n",
      "                          'tStart': 141,\n",
      "                          'text': 'Current clinical studies have shown that '\n",
      "                                  'NSCLC patients with sarcopenia exhibit '\n",
      "                                  'poorer overall survival and '\n",
      "                                  'progression-free survival during PD-1 '\n",
      "                                  'inhibitor treatment.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 132,\n",
      "                          'tStart': 128,\n",
      "                          'text': 'Ultimately, these endeavors may result in '\n",
      "                                  'enhanced clinical outcomes and improved '\n",
      "                                  'quality of life for NSCLC patients '\n",
      "                                  'undergoing PD-1 inhibitor therapy.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': '3 The mechanism of action of PD-1 '\n",
      "                                  'inhibitors and their clinical applications '\n",
      "                                  'in NSCLC'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In this article, we summarize the reported '\n",
      "                                  'negative impact of sarcopenia on the '\n",
      "                                  'effectiveness of PD-1 inhibitors in the '\n",
      "                                  'treatment of NSCLC in recent years.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 87,\n",
      "                          'tStart': 83,\n",
      "                          'text': 'Among these, immune checkpoint inhibitors '\n",
      "                                  '(ICIs), specifically programmed death-1 '\n",
      "                                  '(PD-1) inhibitors, have demonstrated '\n",
      "                                  'significant success in treating advanced '\n",
      "                                  'NSCLC (Yang et al., 2020; Flores et al., '\n",
      "                                  '2021).'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'However, further research is needed to '\n",
      "                                  'explore the optimal use of PD-1 inhibitors '\n",
      "                                  'in NSCLC treatment and develop personalized '\n",
      "                                  'treatment strategies for patients.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Studies have shown that PD-1 inhibitors '\n",
      "                                  'have demonstrated good efficacy in '\n",
      "                                  'different stages of NSCLC treatment, '\n",
      "                                  'including metastatic NSCLC.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 16,\n",
      "                          'tStart': 12,\n",
      "                          'text': 'In summary, PD-1 inhibitors have become an '\n",
      "                                  'important treatment option in NSCLC as a '\n",
      "                                  'novel immunotherapy drug.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'Serum IL-6 levels may serve as a potential '\n",
      "                                  'biomarker for predicting the efficacy and '\n",
      "                                  'survival benefits of PD-1/PD-L1 inhibitors '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'Wankhede et al. analyzed 12 randomized '\n",
      "                                  'controlled studies and found that compared '\n",
      "                                  'to chemotherapy, PD-1/PD-L1 '\n",
      "                                  'inhibitor-chemotherapy combination regimens '\n",
      "                                  'were more likely to achieve objective '\n",
      "                                  'response in NSCLC patients (Wankhede et '\n",
      "                                  'al., 2023).'},\n",
      "                         {'dEnd': 47,\n",
      "                          'dStart': 42,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'In the study of Park et al. involving 125 '\n",
      "                                  'NSCLC patients receiving PD-1/PD-L1 '\n",
      "                                  'inhibitor treatment, found that the low '\n",
      "                                  'IL-6 group (<13.1 pg/mL) had significantly '\n",
      "                                  'higher ORR and disease control rate (DCR) '\n",
      "                                  'compared to the high IL-6 group (Kang et '\n",
      "                                  'al., 2020).'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'In this review, we aim to comprehensively '\n",
      "                                  'explore the influence of sarcopenia on the '\n",
      "                                  'efficacy of PD-1 inhibitors in NSCLC and '\n",
      "                                  'discuss potential strategies to mitigate '\n",
      "                                  'its deleterious effects.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'A meta-analysis has also demonstrated that '\n",
      "                                  'anti-PD-1/anti-PD-L1 monotherapy is highly '\n",
      "                                  'effective in male patients but not in '\n",
      "                                  'female patients, even in NSCLC with high '\n",
      "                                  'PD-L1 expression levels (Conforti et al., '\n",
      "                                  '2021).'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Sarcopenia may have a negative impact on '\n",
      "                                  'the efficacy of PD-1 inhibitors in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Keegan et al. conducted an observational '\n",
      "                                  'study on NSCLC patients receiving anti-PD-1 '\n",
      "                                  'treatment and measured 11 plasma cytokines '\n",
      "                                  'related to immunotherapy response (Keegan '\n",
      "                                  'et al., 2020).'},\n",
      "                         {'dEnd': 14,\n",
      "                          'dStart': 9,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'However, NSCLC patients may have poorer '\n",
      "                                  'outcomes when receiving PD-1 inhibitor '\n",
      "                                  'treatment, and sarcopenia may affect the '\n",
      "                                  'efficacy of PD-1 inhibitors through immune '\n",
      "                                  'and metabolic mechanisms.'},\n",
      "                         {'dEnd': 63,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 inhibitors have been widely used in '\n",
      "                                  'the treatment of NSCLC, bringing hope to '\n",
      "                                  'patients with this condition.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Recent studies have revealed that '\n",
      "                                  'sarcopenia can adversely affect the '\n",
      "                                  'efficacy of PD-1 inhibitors in the '\n",
      "                                  'treatment of non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 242,\n",
      "                          'dStart': 237,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 222,\n",
      "                          'tStart': 218,\n",
      "                          'text': 'Through the clarification of underlying '\n",
      "                                  'mechanisms and the proposal of effective '\n",
      "                                  'interventions, this review strives to '\n",
      "                                  'contribute to the advancement of '\n",
      "                                  'personalized strategies that optimize the '\n",
      "                                  'therapeutic benefits of PD-1 inhibitors in '\n",
      "                                  'NSCLC patients, irrespective of their '\n",
      "                                  'sarcopenia status.'},\n",
      "                         {'dEnd': 167,\n",
      "                          'dStart': 162,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'However, emerging evidence suggests that '\n",
      "                                  'the presence of sarcopenia, a condition '\n",
      "                                  'characterized by muscle loss, may impact '\n",
      "                                  'the effectiveness of PD-1 inhibitors in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'The impact of sarcopenia on the efficacy of '\n",
      "                                  'PD-1 inhibitors in non-small cell lung '\n",
      "                                  'cancer and potential strategies to overcome '\n",
      "                                  'resistance'},\n",
      "                         {'dEnd': 151,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Recent studies have revealed that '\n",
      "                                  'sarcopenia can adversely affect the '\n",
      "                                  'efficacy of PD-1 inhibitors in the '\n",
      "                                  'treatment of non-small cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 and its ligand (PD-L1) inhibitors are '\n",
      "                                  'a type of ICIs widely used in the treatment '\n",
      "                                  'of various cancers, including melanoma, '\n",
      "                                  'NSCLC, and renal cell carcinoma.'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Studies have shown that PD-1 inhibitors '\n",
      "                                  'have demonstrated good efficacy in '\n",
      "                                  'different stages of NSCLC treatment, '\n",
      "                                  'including metastatic NSCLC.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 150,\n",
      "                          'tStart': 146,\n",
      "                          'text': 'Therefore, close monitoring of patients’ '\n",
      "                                  'adverse reactions and timely implementation '\n",
      "                                  'of corresponding treatment measures are '\n",
      "                                  'necessary when using PD-1 inhibitors to '\n",
      "                                  'treat NSCLC.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Comprehending the influence of sarcopenia '\n",
      "                                  'on the efficacy of PD-1 inhibitors is '\n",
      "                                  'essential for identifying strategies to '\n",
      "                                  'mitigate this impact and enhance treatment '\n",
      "                                  'outcomes in patients with NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36569915'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 355,\n",
      "                          'dStart': 329,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'The aim of this study was to assessment the '\n",
      "                                  'efficacy and safety of Programmed cell '\n",
      "                                  'death protein 1 (PD-1)/Programmed cell '\n",
      "                                  'death-Ligand protein 1 (PD-L1) inhibitors '\n",
      "                                  'plus anti-angiogenic agents with or without '\n",
      "                                  'chemotherapy versus PD-1/PD-L1 inhibitors '\n",
      "                                  'plus chemotherapy as second or later-line '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'conducted a retrospective analysis of the '\n",
      "                                  'efficacy and safety of PD-1 inhibitors plus '\n",
      "                                  'anlotinib in patients with advanced '\n",
      "                                  'non-small cell lung cancer after failure of '\n",
      "                                  'previous systemic therapy (60), which also '\n",
      "                                  'showed anti-tumor activity and tolerable '\n",
      "                                  'adverse effects of immune checkpoint '\n",
      "                                  'inhibitors in combination with '\n",
      "                                  'anti-angiogenic agents.'},\n",
      "                         {'dEnd': 291,\n",
      "                          'dStart': 265,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'KEYNOTE-189 and KEYNOTE-407 are two '\n",
      "                                  'clinical trials that have produced '\n",
      "                                  'promising results (7) (8), have discovered '\n",
      "                                  'that combining PD-1/PD-L1 inhibitors with '\n",
      "                                  'chemotherapy significantly improved '\n",
      "                                  'progression-free survival and overall '\n",
      "                                  'survival in patients with advanced '\n",
      "                                  'non-small cell lung cancer who were '\n",
      "                                  'driver-negative, lowering the risk of '\n",
      "                                  'disease progression and death.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 110,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'The efficacy and safety of PD-1/PD-L1 '\n",
      "                                  'inhibitors plus anti-angiogenic with or '\n",
      "                                  'without chemotherapy versus PD-1/PD-L1 '\n",
      "                                  'inhibitors plus chemotherapy as second or '\n",
      "                                  'later-line therapy for advanced non-small '\n",
      "                                  'cell lung cancer patients were further '\n",
      "                                  'investigated in this study using real-world '\n",
      "                                  'clinical data analysis.'},\n",
      "                         {'dEnd': 220,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy were '\n",
      "                                  'superior to PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy as second or later-line '\n",
      "                                  'therapy in patients with advanced non-small '\n",
      "                                  'cell lung cancer.'},\n",
      "                         {'dEnd': 342,\n",
      "                          'dStart': 316,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Based on the results of the above, '\n",
      "                                  'chemotherapy, PD-1/PD-L1 inhibitors or '\n",
      "                                  'anti-angiogenic agents monotherapy have '\n",
      "                                  'been approved by the Food and Drug '\n",
      "                                  'Administration (FDA) and the National '\n",
      "                                  'Medical Products Administration (NMPA) of '\n",
      "                                  'China for the second or later-line '\n",
      "                                  'treatment of patients with driver-negative '\n",
      "                                  'advanced non-small cell lung cancer.'},\n",
      "                         {'dEnd': 244,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'In this retrospective study, we fully '\n",
      "                                  'evaluated the efficacy and safety of '\n",
      "                                  'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy in the '\n",
      "                                  'second or later-line treatment of patients '\n",
      "                                  'with advanced non-small cell lung cancer.'},\n",
      "                         {'dEnd': 355,\n",
      "                          'dStart': 329,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'The aim of this study was to assessment the '\n",
      "                                  'efficacy and safety of Programmed cell '\n",
      "                                  'death protein 1 (PD-1)/Programmed cell '\n",
      "                                  'death-Ligand protein 1 (PD-L1) inhibitors '\n",
      "                                  'plus anti-angiogenic agents with or without '\n",
      "                                  'chemotherapy versus PD-1/PD-L1 inhibitors '\n",
      "                                  'plus chemotherapy as second or later-line '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer.'},\n",
      "                         {'dEnd': 336,\n",
      "                          'dStart': 331,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'On data related to the use of PD-1/PD-L1 '\n",
      "                                  'inhibitors plus anti-angiogenic agents for '\n",
      "                                  'second or later-line treatment of advanced '\n",
      "                                  'non-small cell lung cancer, a phase I '\n",
      "                                  'clinical study evaluated the use of '\n",
      "                                  'ramucirumab in combination with '\n",
      "                                  'pembrolizumab in the later-line treatment '\n",
      "                                  'of different malignancies and included 27 '\n",
      "                                  'patients with NSCLC, showing an ORR of 30% '\n",
      "                                  '(57).'},\n",
      "                         {'dEnd': 222,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy were '\n",
      "                                  'superior to PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy as second or later-line '\n",
      "                                  'treatment in patients with advanced '\n",
      "                                  'non-small cell lung cancer.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'The efficacy and safety of PD-1/PD-L1 '\n",
      "                                  'inhibitors plus anti-angiogenic with or '\n",
      "                                  'without chemotherapy versus PD-1/PD-L1 '\n",
      "                                  'inhibitors plus chemotherapy as second or '\n",
      "                                  'later-line therapy for advanced non-small '\n",
      "                                  'cell lung cancer patients were further '\n",
      "                                  'investigated in this study using real-world '\n",
      "                                  'clinical data analysis.'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy versus '\n",
      "                                  'PD-1/PD-L1 inhibitors plus chemotherapy as '\n",
      "                                  'second or later-line treatment for patients '\n",
      "                                  'with advanced non-small cell lung cancer: A '\n",
      "                                  'real-world retrospective cohort study'},\n",
      "                         {'dEnd': 222,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 100,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy were '\n",
      "                                  'superior to PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy as second or later-line '\n",
      "                                  'treatment in patients with advanced '\n",
      "                                  'non-small cell lung cancer.'},\n",
      "                         {'dEnd': 355,\n",
      "                          'dStart': 329,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 232,\n",
      "                          'tStart': 228,\n",
      "                          'text': 'The aim of this study was to assessment the '\n",
      "                                  'efficacy and safety of Programmed cell '\n",
      "                                  'death protein 1 (PD-1)/Programmed cell '\n",
      "                                  'death-Ligand protein 1 (PD-L1) inhibitors '\n",
      "                                  'plus anti-angiogenic agents with or without '\n",
      "                                  'chemotherapy versus PD-1/PD-L1 inhibitors '\n",
      "                                  'plus chemotherapy as second or later-line '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer.'},\n",
      "                         {'dEnd': 220,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy were '\n",
      "                                  'superior to PD-1/PD-L1 inhibitors plus '\n",
      "                                  'chemotherapy as second or later-line '\n",
      "                                  'therapy in patients with advanced non-small '\n",
      "                                  'cell lung cancer.'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1 inhibitors plus anti-angiogenic '\n",
      "                                  'agents with or without chemotherapy versus '\n",
      "                                  'PD-1/PD-L1 inhibitors plus chemotherapy as '\n",
      "                                  'second or later-line treatment for patients '\n",
      "                                  'with advanced non-small cell lung cancer: A '\n",
      "                                  'real-world retrospective cohort study'},\n",
      "                         {'dEnd': 153,\n",
      "                          'dStart': 127,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'On data related to the use of PD-1/PD-L1 '\n",
      "                                  'inhibitors plus anti-angiogenic agents for '\n",
      "                                  'second or later-line treatment of advanced '\n",
      "                                  'non-small cell lung cancer, a phase I '\n",
      "                                  'clinical study evaluated the use of '\n",
      "                                  'ramucirumab in combination with '\n",
      "                                  'pembrolizumab in the later-line treatment '\n",
      "                                  'of different malignancies and included 27 '\n",
      "                                  'patients with NSCLC, showing an ORR of 30% '\n",
      "                                  '(57).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34753486'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'We next evaluated whether circUSP7 '\n",
      "                                  'overexpression can further inhibit the '\n",
      "                                  'antitumour effect of anti-PD1 therapy '\n",
      "                                  '(Opdivo) in NSCLC patients.'},\n",
      "                         {'dEnd': 120,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Thus, we conclude that the level of '\n",
      "                                  'exosomal circUSP7 can serve as a newly '\n",
      "                                  'predicted marker of anti-PD1 therapy in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'We have demonstrated that circUSP7 promotes '\n",
      "                                  'NSCLC progression and anti-PD1 '\n",
      "                                  'immunotherapy resistance in vitro and in '\n",
      "                                  'vivo.'},\n",
      "                         {'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 69,\n",
      "                          'text': 'These results indicated that circUSP7 '\n",
      "                                  'promotes NSCLC progression and PD1 '\n",
      "                                  'treatment resistance in an exosome- and '\n",
      "                                  'CD8+ T cell-dependent manner.'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 92,\n",
      "                          'text': 'Thus, we revealed that circUSP7 levels are '\n",
      "                                  'a crucial factor that affects resistance to '\n",
      "                                  'anti-PD1 therapy in NSCLC patients, and '\n",
      "                                  'peripheral blood exosomal circRNAs can be '\n",
      "                                  'used as tumour markers.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'Here, our study emphasized a vital role for '\n",
      "                                  'exosomal circUSP7 in promoting immune '\n",
      "                                  'evasion and resistance to anti-PD1 therapy '\n",
      "                                  'by inducing CD8+ T cell dysfunction in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 107,\n",
      "                          'dStart': 102,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'CircUSP7 induces resistance to anti-PD1 '\n",
      "                                  'immunotherapy, providing a potential '\n",
      "                                  'therapeutic strategy for NSCLC patients.'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'All the results described above indicated '\n",
      "                                  'that exosomal circUSP7 secreted by NSCLC '\n",
      "                                  'cells mediates resistance to anti-PD1 '\n",
      "                                  'therapy by inducing CD8+ T cell exhaustion, '\n",
      "                                  'which may provide a previously undescribed '\n",
      "                                  'therapeutic target for the treatment of '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 253,\n",
      "                          'dStart': 248,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'All the results described above indicated '\n",
      "                                  'that exosomal circUSP7 secreted by NSCLC '\n",
      "                                  'cells mediates resistance to anti-PD1 '\n",
      "                                  'therapy by inducing CD8+ T cell exhaustion, '\n",
      "                                  'which may provide a previously undescribed '\n",
      "                                  'therapeutic target for the treatment of '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 34,\n",
      "                          'dStart': 29,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 97,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'In particular, we found that NSCLC cells '\n",
      "                                  'with high circUSP7 expression were '\n",
      "                                  'resistant to anti-PD1 treatment in HuNSG '\n",
      "                                  'mice with a humanized immune system.'},\n",
      "                         {'dEnd': 88,\n",
      "                          'dStart': 83,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Finally, we show that circUSP7 may promote '\n",
      "                                  'resistance to anti-PD1 immunotherapy in '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Cancer cell-derived exosomal circUSP7 '\n",
      "                                  'induces CD8+ T cell dysfunction and '\n",
      "                                  'anti-PD1 resistance by regulating the '\n",
      "                                  'miR-934/SHP2 axis in NSCLC'},\n",
      "                         {'dEnd': 162,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'Recently, the use of programmed death '\n",
      "                                  'receptor-1 (PD1) antibodies has decreased '\n",
      "                                  'tumour progression and provided long-term '\n",
      "                                  'clinical benefits in patients with NSCLC.'},\n",
      "                         {'dEnd': 109,\n",
      "                          'dStart': 104,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Thus, we revealed that circUSP7 levels are '\n",
      "                                  'a crucial factor affecting resistance to '\n",
      "                                  'anti-PD1 therapy in NSCLC patients, and '\n",
      "                                  'peripheral blood exosomal circRNAs can be '\n",
      "                                  'used as a tumour marker.'},\n",
      "                         {'dEnd': 203,\n",
      "                          'dStart': 198,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 183,\n",
      "                          'tStart': 180,\n",
      "                          'text': 'Unfortunately, the majority of patients '\n",
      "                                  'inevitably acquire resistance after several '\n",
      "                                  'cycles of treatment [2, 3]; therefore, it '\n",
      "                                  'is crucial to actively explore the '\n",
      "                                  'mechanisms of anti-PD1 resistance in '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 21,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Thus, we analysed 20 NSCLC patients who '\n",
      "                                  'received anti-PD1 immunotherapy after six '\n",
      "                                  'treatment cycles, and CT was used to '\n",
      "                                  'evaluate the efficacy based on RECIST1.1 '\n",
      "                                  'analysis.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35945957'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'We performed a retrospective study '\n",
      "                                  'including patients with stage IV NSCLC who '\n",
      "                                  'were treated with anti-PD-1 drugs in first '\n",
      "                                  'or advanced lines of therapy in the '\n",
      "                                  'Affiliated Tumor Hospital of Nantong '\n",
      "                                  'University.'},\n",
      "                         {'dEnd': 80,\n",
      "                          'dStart': 54,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'Clinical Significance of Serum Biomarkers '\n",
      "                                  'in Stage IV Non-Small-Cell Lung Cancer '\n",
      "                                  'Treated with PD-1 Inhibitors: LIPI Score, '\n",
      "                                  'NLR, dNLR, LMR, and PAB'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'To assess the prognostic value of '\n",
      "                                  'pretreatment serum biomarkers in stage IV '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'treated with PD-1 (programmed cell death '\n",
      "                                  'protein 1) inhibitors and their value as a '\n",
      "                                  'predictor of benefit.'},\n",
      "                         {'dEnd': 131,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 158,\n",
      "                          'tStart': 154,\n",
      "                          'text': 'Our retrospective study revealed that '\n",
      "                                  'pretreatment dNLR is an independent '\n",
      "                                  'prognostic indicator of both PFS and OS in '\n",
      "                                  'stage IV NSCLC patients treated with PD-1 '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'The multivariate Cox proportional hazard '\n",
      "                                  'analyses for stage IV NSCLC patients '\n",
      "                                  'treated with PD-1 inhibitors indicated that '\n",
      "                                  'dNLR (P < 0.001) and ALB (P = 0.033) were '\n",
      "                                  'independent prognostic indicators of PFS, '\n",
      "                                  'while liver metastasis (P = 0.01), NLR (P = '\n",
      "                                  '0.01), dNLR (P = 0.001), and LMR (P = '\n",
      "                                  '0.006) were independent prognostic '\n",
      "                                  'indicators of OS.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 124,\n",
      "                          'tStart': 120,\n",
      "                          'text': 'This study investigated the predictive and '\n",
      "                                  'prognostic value of serum biomarkers in '\n",
      "                                  'stage IV NSCLC patients treated with PD-1 '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 42,\n",
      "                          'dStart': 37,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'A total of 85 patients with stage IV NSCLC '\n",
      "                                  'treated with PD-1 inhibitors in the first '\n",
      "                                  'or advanced lines of therapy were included '\n",
      "                                  'in this subject.'},\n",
      "                         {'dEnd': 66,\n",
      "                          'dStart': 40,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'On the other hand, for certain stage IV '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'treated with PD-1 inhibitors, the early '\n",
      "                                  'prediction of prognosis is definitely of '\n",
      "                                  'great significance.'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'As a fully human and monoclonal anti-PD1 '\n",
      "                                  'antibody, nivolumab was the first PD-1 '\n",
      "                                  'inhibitor which demonstrated meaningful '\n",
      "                                  'activity in NSCLC.'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Based on the FDA approvement, nivolumab and '\n",
      "                                  'pembrolizumab (anti-PD-1 antibody) and '\n",
      "                                  'atezolizumab (an anti-PD-L1 antibody) are '\n",
      "                                  'granted as the second-line treatment of '\n",
      "                                  'advanced NSCLC on the basis of improvements '\n",
      "                                  'in OS versus docetaxel [9–11].'},\n",
      "                         {'dEnd': 33,\n",
      "                          'dStart': 28,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': '3.8. PFS and OS in Stage IV NSCLC Patients '\n",
      "                                  'with PD-1 Inhibitor Combination Therapy'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 132,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'As a fully human and monoclonal anti-PD1 '\n",
      "                                  'antibody, nivolumab was the first PD-1 '\n",
      "                                  'inhibitor which demonstrated meaningful '\n",
      "                                  'activity in NSCLC.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 102,\n",
      "                          'tStart': 98,\n",
      "                          'text': '3.9. Multifactor Model of LIPI Score for '\n",
      "                                  'Survival Outcome of Stage IV NSCLC Patients '\n",
      "                                  'Treated with PD-1 Inhibitors'},\n",
      "                         {'dEnd': 33,\n",
      "                          'dStart': 28,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': '3.7. PFS and OS in Stage IV NSCLC Patients '\n",
      "                                  'with PD-1 Inhibitor Monotherapy'},\n",
      "                         {'dEnd': 93,\n",
      "                          'dStart': 88,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 120,\n",
      "                          'tStart': 116,\n",
      "                          'text': 'Pretreatment dNLR is an independent '\n",
      "                                  'prognostic indicator of both PFS and OS in '\n",
      "                                  'stage IV NSCLC patients treated with PD-1 '\n",
      "                                  'inhibitors.'},\n",
      "                         {'dEnd': 208,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 226,\n",
      "                          'tStart': 222,\n",
      "                          'text': 'In view of the drug approval of checkpoint '\n",
      "                                  'inhibitors that were first approved by the '\n",
      "                                  'National Medical Products Administration '\n",
      "                                  '(NMPA) in China since June 2018, we only '\n",
      "                                  'included 85 patients with stage IV NSCLC '\n",
      "                                  'treated with PD-1 inhibitors in detail.'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['33313223'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 158,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'A recent study based on 161 patients also '\n",
      "                                  'showed that PD-1 expression at the protein '\n",
      "                                  'level was associated with better prognosis '\n",
      "                                  'in patients with resected LUAD (35).'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Comparative expression analysis of PD-1, '\n",
      "                                  'PD-L1, and CD8A in lung adenocarcinoma'},\n",
      "                         {'dEnd': 117,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': 'The study defined a group of cutoff values '\n",
      "                                  'for PD-1, PD-L1, and CD8A to identify high '\n",
      "                                  'and low mRNA expression in LUAD.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Based on these cutoff values, we '\n",
      "                                  'demonstrated that PD-1 high expression was '\n",
      "                                  'a favorable prognostic factor in patients '\n",
      "                                  'with LUAD; however, it was not an '\n",
      "                                  'independent factor for OS.'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 171,\n",
      "                          'tStart': 167,\n",
      "                          'text': 'Although PD-1 pathway inhibitors such as '\n",
      "                                  'nivolumab and pembrolizumab are generally '\n",
      "                                  'used in antitumor strategies including the '\n",
      "                                  'treatment of advanced LUAD, the roles of '\n",
      "                                  'PD-1 pathway-related factors in the LUAD '\n",
      "                                  'tumor microenvironment remain unclear '\n",
      "                                  '(13,14).'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 182,\n",
      "                          'tStart': 178,\n",
      "                          'text': 'In the study, we aimed to assess the '\n",
      "                                  'correlation between the mRNA expression of '\n",
      "                                  'these three factors and the clinical '\n",
      "                                  'characteristics of LUAD, and to explore the '\n",
      "                                  'influence of the PD-1/PD-L1/CD8A axis on '\n",
      "                                  'the prognosis of LUAD.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Previous studies have revealed '\n",
      "                                  'microenvironment according to PD-1 pathway '\n",
      "                                  'in LUAD, however exact values for defining '\n",
      "                                  'expression situation were still limited.'},\n",
      "                         {'dEnd': 267,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 226,\n",
      "                          'tStart': 222,\n",
      "                          'text': 'In this study, we first investigated the '\n",
      "                                  'optimal cutoff value for identifying CD8A, '\n",
      "                                  'PD-1, and PD-L1 high or low expression, and '\n",
      "                                  'analyzed the relationship between the mRNA '\n",
      "                                  'expression levels of these three biomarkers '\n",
      "                                  'of the PD-1 pathway and the clinical '\n",
      "                                  'factors of LUAD based on a large data '\n",
      "                                  'derived from TCGA database.'},\n",
      "                         {'dEnd': 111,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Immune checkpoint inhibitors targeting PD-1 '\n",
      "                                  'and PD-L1 have improved the survival of '\n",
      "                                  'patients with advanced LUAD both in the '\n",
      "                                  'second-line and first-line settings '\n",
      "                                  '(28-30).'},\n",
      "                         {'dEnd': 267,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'In this study, we first investigated the '\n",
      "                                  'optimal cutoff value for identifying CD8A, '\n",
      "                                  'PD-1, and PD-L1 high or low expression, and '\n",
      "                                  'analyzed the relationship between the mRNA '\n",
      "                                  'expression levels of these three biomarkers '\n",
      "                                  'of the PD-1 pathway and the clinical '\n",
      "                                  'factors of LUAD based on a large data '\n",
      "                                  'derived from TCGA database.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 31,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'As a new strategy for advanced lung '\n",
      "                                  'adenocarcinoma (LUAD), programmed cell '\n",
      "                                  'death protein 1 (PD-1) pathway inhibitors '\n",
      "                                  'have been used in clinic for several '\n",
      "                                  'years.'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'There is limited data on the prognostic '\n",
      "                                  'and/or predictive value of PD-1 expression, '\n",
      "                                  'and few studies have investigated the '\n",
      "                                  'association of PD-1 protein expression with '\n",
      "                                  'the outcomes of patients with LUAD.'},\n",
      "                         {'dEnd': 140,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 182,\n",
      "                          'tStart': 178,\n",
      "                          'text': 'In the study, we aimed to assess the '\n",
      "                                  'correlation between the mRNA expression of '\n",
      "                                  'these three factors and the clinical '\n",
      "                                  'characteristics of LUAD, and to explore the '\n",
      "                                  'influence of the PD-1/PD-L1/CD8A axis on '\n",
      "                                  'the prognosis of LUAD.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Finally, we did not assess the relationship '\n",
      "                                  'between PD-1, PD-L1, and CD8A expression '\n",
      "                                  'and the therapeutic strategies for patients '\n",
      "                                  'with LUAD, as treatment data are not '\n",
      "                                  'provided by TCGA.'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Although PD-1 pathway inhibitors such as '\n",
      "                                  'nivolumab and pembrolizumab are generally '\n",
      "                                  'used in antitumor strategies including the '\n",
      "                                  'treatment of advanced LUAD, the roles of '\n",
      "                                  'PD-1 pathway-related factors in the LUAD '\n",
      "                                  'tumor microenvironment remain unclear '\n",
      "                                  '(13,14).'},\n",
      "                         {'dEnd': 264,\n",
      "                          'dStart': 260,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 174,\n",
      "                          'tStart': 170,\n",
      "                          'text': 'The results of the Cox regression hazards '\n",
      "                                  'model are shown in Table 4, indicating that '\n",
      "                                  'T stage (P=0.045) and N stage (P<0.001) '\n",
      "                                  'remained statistically significant, whereas '\n",
      "                                  'PD-1 (P=0.266), PD-L1 (P=0.740), and CD8A '\n",
      "                                  '(P=0.193) were not independent risk factors '\n",
      "                                  'for LUAD.'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 148,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Although PD-1 pathway inhibitors such as '\n",
      "                                  'nivolumab and pembrolizumab are generally '\n",
      "                                  'used in antitumor strategies including the '\n",
      "                                  'treatment of advanced LUAD, the roles of '\n",
      "                                  'PD-1 pathway-related factors in the LUAD '\n",
      "                                  'tumor microenvironment remain unclear '\n",
      "                                  '(13,14).'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'However, there are few studies focusing on '\n",
      "                                  'the relationship between PD-1 pathway '\n",
      "                                  'expression at the genetic level and the '\n",
      "                                  'clinicopathological factors of LUAD.'},\n",
      "                         {'dEnd': 84,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'However, the roles of PD-1, programmed cell '\n",
      "                                  'death-ligand 1 (PD-L1), and CD8A in LUAD '\n",
      "                                  'are still unclear.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 88,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 139,\n",
      "                          'tStart': 135,\n",
      "                          'text': 'In conclusion, to differentiate high from '\n",
      "                                  'low mRNA expression, we analyzed TCGA data '\n",
      "                                  'of LUAD patients and defined the cutoff '\n",
      "                                  'values of PD-1, PD-L1, and CD8A expression '\n",
      "                                  'as 27.4, 29.41, and 95.52 respectively.'},\n",
      "                         {'dEnd': 200,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 141,\n",
      "                          'tStart': 137,\n",
      "                          'text': 'There is limited data on the prognostic '\n",
      "                                  'and/or predictive value of PD-1 expression, '\n",
      "                                  'and few studies have investigated the '\n",
      "                                  'association of PD-1 protein expression with '\n",
      "                                  'the outcomes of patients with LUAD.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35755570'],\n",
      " 'resourceScore': 51,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 220,\n",
      "                          'dStart': 215,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': '\\u200bMonoclonal antibodies targeting the '\n",
      "                                  'programmed death-1 receptor (PD-1) '\n",
      "                                  '(nivolumab [Opdivo] and pembrolizumab '\n",
      "                                  '[Keytruda]) and programmed death-ligand 1 '\n",
      "                                  '(PD-L1) (atezolizumab [Tecentriq]) are '\n",
      "                                  'FDA-approved for use in NSCLC [4-7].'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Therefore, this study was designed to study '\n",
      "                                  'the prevalence of PD-1 and PD-L1 in NSCLC '\n",
      "                                  'in a tertiary care center in North India.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'These factors possibly attenuate the risk '\n",
      "                                  'of a markedly different prevalence of PD-1 '\n",
      "                                  'and PD-L1 positivity in NSCLC among primary '\n",
      "                                  'and secondary care patients of NSCLC at the '\n",
      "                                  'geographical location of the study.'},\n",
      "                         {'dEnd': 39,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 148,\n",
      "                          'tStart': 144,\n",
      "                          'text': 'One hundred histologically proven NSCLC '\n",
      "                                  'cases having sufficient tumor material from '\n",
      "                                  'July 2016 to July 2018 were examined, and '\n",
      "                                  'the prevalence of PD-1 and PD-L1 positivity '\n",
      "                                  'in NSCLC was studied.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'The moderately high prevalence may justify '\n",
      "                                  'routine testing for PD-1 or PD-L1 in NSCLC, '\n",
      "                                  'which should preferably be carried out in '\n",
      "                                  'all cases rather than any selected '\n",
      "                                  'subsets.'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'To study the prevalence of programmed '\n",
      "                                  'death-1 receptor (PD-1) and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) positive cases in '\n",
      "                                  'non-small-cell lung carcinoma (NSCLC) and '\n",
      "                                  'their association with other '\n",
      "                                  'clinicopathological parameters in a '\n",
      "                                  'tertiary care setting in North India.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1: Programmed death-1 receptor; PD-L1: '\n",
      "                                  'Programmed death-ligand 1; NSCLC: '\n",
      "                                  'Non-small-cell lung cancer.'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'These factors possibly attenuate the risk '\n",
      "                                  'of a markedly different prevalence of PD-1 '\n",
      "                                  'and PD-L1 positivity in NSCLC among primary '\n",
      "                                  'and secondary care patients of NSCLC at the '\n",
      "                                  'geographical location of the study.'},\n",
      "                         {'dEnd': 57,\n",
      "                          'dStart': 52,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'The moderately high prevalence of PD-L1 and '\n",
      "                                  'PD-1 in NSCLC in the studied population '\n",
      "                                  'suggests that routine testing for PD-1 and '\n",
      "                                  'PD-L1 may be justified, given the '\n",
      "                                  'therapeutic potential of immunotherapy.'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'We believe that such variations would be '\n",
      "                                  'mild and will not change the primary '\n",
      "                                  'conclusion of a moderately high prevalence '\n",
      "                                  'of PD-1 and PD-L1 positivity among NSCLC '\n",
      "                                  'patients in our population.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 60,\n",
      "                          'tStart': 56,\n",
      "                          'text': 'To study the prevalence of programmed '\n",
      "                                  'death-1 receptor (PD-1) and programmed '\n",
      "                                  'death-ligand 1 (PD-L1) positive cases in '\n",
      "                                  'non-small-cell lung carcinoma (NSCLC) and '\n",
      "                                  'their association with other '\n",
      "                                  'clinicopathological parameters in a '\n",
      "                                  'tertiary care setting in North India.'},\n",
      "                         {'dEnd': 203,\n",
      "                          'dStart': 198,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The non-significance of the association '\n",
      "                                  'between PD-L1 and PD-1 positivity with '\n",
      "                                  'known clinicopathological parameters in '\n",
      "                                  'NSCLC suggests that such routine testing '\n",
      "                                  'should be carried out in all cases of NSCLC '\n",
      "                                  'rather than in any selected subsets.'},\n",
      "                         {'dEnd': 52,\n",
      "                          'dStart': 47,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'The prevalence of PD-1 and PD-L1 positivity '\n",
      "                                  'in NSCLC needs to be established in any '\n",
      "                                  'population before generalized guidelines '\n",
      "                                  'are followed.'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The non-significance of the association '\n",
      "                                  'between PD-L1 and PD-1 positivity with '\n",
      "                                  'known clinicopathological parameters in '\n",
      "                                  'NSCLC suggests that such routine testing '\n",
      "                                  'should be carried out in all cases of NSCLC '\n",
      "                                  'rather than in any selected subsets.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Immunoexpression of Programmed Death-1 '\n",
      "                                  'Receptor (PD-1) and Programmed Death-Ligand '\n",
      "                                  '1 (PD-L1) in Non-Small-Cell Lung Carcinoma '\n",
      "                                  'and Its Correlation With Other '\n",
      "                                  'Clinicopathological Parameters: A '\n",
      "                                  'Cross-Sectional Study From North India'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Showing the distribution of PD-1 and PD-L1 '\n",
      "                                  'in tumor cells and PD-L1 in lymphocytes '\n",
      "                                  'among the various pathological and clinical '\n",
      "                                  'groups of non-small-cell lung cancer '\n",
      "                                  'patients in the present study. In addition, '\n",
      "                                  'the p-values for the association by the '\n",
      "                                  \"Fisher's Exact Test of the groups with PD-1 \"\n",
      "                                  'and PD-L1 status are also given.'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'The salient features of our study are that '\n",
      "                                  'the data on the expression of PD-1 and '\n",
      "                                  'PD-L1 in NSCLC, especially from India, is '\n",
      "                                  'very limited.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 148,\n",
      "                          'tStart': 144,\n",
      "                          'text': 'One hundred histologically proven NSCLC '\n",
      "                                  'cases having sufficient tumor material from '\n",
      "                                  'July 2016 to July 2018 were examined, and '\n",
      "                                  'the prevalence of PD-1 and PD-L1 positivity '\n",
      "                                  'in NSCLC was studied.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1: Programmed death-1 receptor; PD-L1: '\n",
      "                                  'Programmed death-ligand 1; NSCLC: '\n",
      "                                  'Non-small-cell lung cancer.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32527929'],\n",
      " 'resourceScore': 50,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 407,\n",
      "                          'dStart': 402,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'Kamphorst and colleagues observed that '\n",
      "                                  'increases in proliferating peripheral PD-1 '\n",
      "                                  '+CD8 T cells after PD-1 blockade predicted '\n",
      "                                  'positive responses.20 We have identified '\n",
      "                                  'prostate cancer immune escape mechanisms '\n",
      "                                  'after prostatic acid phosphatase (PAP) '\n",
      "                                  'vaccination by performing DTH using '\n",
      "                                  'circulating immune cells.16 Here, we '\n",
      "                                  'identified modulation of tvDTH responses of '\n",
      "                                  'tumor antigen-specific immune cells in '\n",
      "                                  'NSCLC PBMCs by PD-1.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'Our results suggest that PD-1-anergy is a '\n",
      "                                  'common feature of NSCLC immune responses, '\n",
      "                                  'whereas PD-1-mediated immune suppression is '\n",
      "                                  'present only in a minority of patients.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Having found that PD-1 interactions '\n",
      "                                  'inhibited immune responses to autologous '\n",
      "                                  'tumor Ag in nearly all of the patients with '\n",
      "                                  'NSCLC prior to treatment, and that therapy '\n",
      "                                  'restored tumor Ag-directed responses in '\n",
      "                                  'those patients who previously showed '\n",
      "                                  'PD1-dependent inhibition, we inquired '\n",
      "                                  'whether these effects were due to ICPI '\n",
      "                                  'impact on effector T cells, regulatory '\n",
      "                                  'cells, or both.'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 21,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Identification of PD1-mediated regulation '\n",
      "                                  'of antitumor antigen response in patients '\n",
      "                                  'with NSCLC using the trans vivo DTH assay'},\n",
      "                         {'dEnd': 198,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'We hypothesized that a functional assay '\n",
      "                                  'could identify the role of PD-1/PD-L1 '\n",
      "                                  'interactions on tumor-specific immune cells '\n",
      "                                  'in the peripheral blood in patients with '\n",
      "                                  'advanced non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 82,\n",
      "                          'tStart': 78,\n",
      "                          'text': 'This suggests that the presence of '\n",
      "                                  'tumor-specific, anergic T cells expressing '\n",
      "                                  'PD-1 may be a common feature of NSCLC.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'To study inhibitory cosignaling molecules '\n",
      "                                  'in regulating the NSCLC antigen-specific '\n",
      "                                  'immune response, 1 μg of antihuman PD-1 '\n",
      "                                  '(pembrolizumab) or antihuman CTLA-4 (AS32) '\n",
      "                                  'was coinjected in a replicate set of '\n",
      "                                  'footpad conditions.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'We were interested in studying the role of '\n",
      "                                  'PD-1/PD-L1 and CTLA-4 as potential '\n",
      "                                  'mediators of this phenomenon due to their '\n",
      "                                  'therapeutic relevance in NSCLC.'},\n",
      "                         {'dEnd': 176,\n",
      "                          'dStart': 171,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'We performed the trans vivo delayed-type '\n",
      "                                  'hypersensitivity assay to identify the role '\n",
      "                                  'of PD-1/PD-L1-mediated tumor-specific '\n",
      "                                  'immune regulation in ten patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'We hypothesized that a functional assay '\n",
      "                                  'could identify the role of PD-1/PD-L1 '\n",
      "                                  'interactions on tumor-specific immune cells '\n",
      "                                  'in the peripheral blood in patients with '\n",
      "                                  'advanced non-small-cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Hence, we detected PD-1-dependent '\n",
      "                                  'suppressive responses towards tumor Ag in '\n",
      "                                  'three out of nine patients with NSCLC in '\n",
      "                                  'our cohort.'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 406,\n",
      "                          'tStart': 403,\n",
      "                          'text': 'This is inherent to the heterogeneity of '\n",
      "                                  'neopitopes in between patients with NSCLC, '\n",
      "                                  'with limited common antigens specific for '\n",
      "                                  'NSCLC.21 However, patient-derived tumor Ag '\n",
      "                                  'preparations could stimulate '\n",
      "                                  'antigen-specific cells unique to each '\n",
      "                                  'patient, and this approach has been used to '\n",
      "                                  'examine memory T-cell function in breast '\n",
      "                                  'and pancreatic cancer.22 23 The lesser '\n",
      "                                  'uncovered response in the presence of '\n",
      "                                  'anti-PD1 antibody in the case of two '\n",
      "                                  'patients tested with self antigen prepared '\n",
      "                                  'from a non-tumor sample (figure 2B) argues '\n",
      "                                  'that the uncovered responses were '\n",
      "                                  '‘tumor-specific’ for each patient.'},\n",
      "                         {'dEnd': 407,\n",
      "                          'dStart': 402,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Kamphorst and colleagues observed that '\n",
      "                                  'increases in proliferating peripheral PD-1 '\n",
      "                                  '+CD8 T cells after PD-1 blockade predicted '\n",
      "                                  'positive responses.20 We have identified '\n",
      "                                  'prostate cancer immune escape mechanisms '\n",
      "                                  'after prostatic acid phosphatase (PAP) '\n",
      "                                  'vaccination by performing DTH using '\n",
      "                                  'circulating immune cells.16 Here, we '\n",
      "                                  'identified modulation of tvDTH responses of '\n",
      "                                  'tumor antigen-specific immune cells in '\n",
      "                                  'NSCLC PBMCs by PD-1.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38040417'],\n",
      " 'resourceScore': 49,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 416,\n",
      "                          'dStart': 411,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'However, a substantial proportion of '\n",
      "                                  'patients fail to respond to PD-1/PD-L1 '\n",
      "                                  'blockade therapy initially and many primary '\n",
      "                                  'responders relapse over time, leading to '\n",
      "                                  'limited clinical application and treatment '\n",
      "                                  'failure.5 6 The expression of PD-L1 has '\n",
      "                                  'been suggested to be one of the critical '\n",
      "                                  'factors for the applicability of PD-1/PD-L1 '\n",
      "                                  'blockade.7 8 Thus, understanding the '\n",
      "                                  'underlying mechanisms of PD-L1 regulation '\n",
      "                                  'in NSCLC is helpful for improving the '\n",
      "                                  'clinical benefit of PD-1/PD-L1 blockade '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 416,\n",
      "                          'dStart': 411,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 322,\n",
      "                          'tStart': 318,\n",
      "                          'text': 'However, a substantial proportion of '\n",
      "                                  'patients fail to respond to PD-1/PD-L1 '\n",
      "                                  'blockade therapy initially and many primary '\n",
      "                                  'responders relapse over time, leading to '\n",
      "                                  'limited clinical application and treatment '\n",
      "                                  'failure.5 6 The expression of PD-L1 has '\n",
      "                                  'been suggested to be one of the critical '\n",
      "                                  'factors for the applicability of PD-1/PD-L1 '\n",
      "                                  'blockade.7 8 Thus, understanding the '\n",
      "                                  'underlying mechanisms of PD-L1 regulation '\n",
      "                                  'in NSCLC is helpful for improving the '\n",
      "                                  'clinical benefit of PD-1/PD-L1 blockade '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 314,\n",
      "                          'dStart': 309,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 144,\n",
      "                          'tStart': 140,\n",
      "                          'text': 'This interaction generates an inhibitory '\n",
      "                                  'signal that suppresses T-cell responses, '\n",
      "                                  'facilitating the evasion of tumor cells.4 '\n",
      "                                  'Blockade of the PD-1/PD-L1 interaction '\n",
      "                                  'enhances the immune recognition and T-cell '\n",
      "                                  'attack to tumor cells, exhibiting '\n",
      "                                  'tremendously improved clinical outcome for '\n",
      "                                  'the treatment of advanced NSCLC.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'With the alteration of PD-L1 and PD-1 '\n",
      "                                  'binding ability, we confirmed the '\n",
      "                                  'sensitivity of NSCLC cells to T '\n",
      "                                  'cell-induced apoptosis by co-culturing '\n",
      "                                  'NSCLC cells with the activated human PBMCs '\n",
      "                                  '(figure 2D).'},\n",
      "                         {'dEnd': 179,\n",
      "                          'dStart': 174,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Limited response to programmed death '\n",
      "                                  'ligand-1 (PD-L1)/programmed death 1 (PD-1) '\n",
      "                                  'immunotherapy is a major hindrance of '\n",
      "                                  'checkpoint immunotherapy in non-small cell '\n",
      "                                  'lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'To test whether LINC02418-mediated '\n",
      "                                  'regulation of PD-L1 affects the binding of '\n",
      "                                  'PD-L1 and PD-1, NSCLC cells with LINC02418 '\n",
      "                                  'overexpression or knockdown were incubated '\n",
      "                                  'with recombinant human PD-1 Fc protein.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 133,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'To the best of our knowledge, lncRNAs that '\n",
      "                                  'negatively regulate PD-L1 expression and '\n",
      "                                  'their biological implications in response '\n",
      "                                  'to PD-1/PD-L1 blockade therapy in NSCLC '\n",
      "                                  'remain unclear.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 146,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'Limited response to programmed death '\n",
      "                                  'ligand-1 (PD-L1)/programmed death 1 (PD-1) '\n",
      "                                  'immunotherapy is a major hindrance of '\n",
      "                                  'checkpoint immunotherapy in non-small cell '\n",
      "                                  'lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Since PD-1/PD-L1 inhibitors are mainly used '\n",
      "                                  'in patients with advanced NSCLC with local '\n",
      "                                  'or distant metastasis, we investigated '\n",
      "                                  'whether mmu-4930573I07Rik could enhance the '\n",
      "                                  'efficacy of PD-L1 mAb to harness the '\n",
      "                                  'metastatic phenotype of NSCLC in vivo '\n",
      "                                  '(figure 5E).'},\n",
      "                         {'dEnd': 8,\n",
      "                          'dStart': 3,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'In NSCLC cells, LINC02418 inhibits PD-1 '\n",
      "                                  'binding ability and enhances T cell-induced '\n",
      "                                  'apoptosis dependent on Trim21 both in vitro '\n",
      "                                  'and in vivo.'},\n",
      "                         {'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'Immunofluorescence, in vitro PD-1 binding '\n",
      "                                  'assay, T cell-induced apoptosis assays and '\n",
      "                                  'in vivo syngeneic mouse models were used to '\n",
      "                                  'investigate the functional roles of '\n",
      "                                  'LINC02418 and mmu-4930573I07Rik in '\n",
      "                                  'regulating anti-PD-L1 therapeutic efficacy '\n",
      "                                  'in NSCLC.'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'LINC02418 dampens PD-1 binding ability and '\n",
      "                                  'enhances T cell-induced apoptosis in NSCLC'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'These findings suggest that LINC02418 '\n",
      "                                  'dampens PD-1 binding ability and enhances T '\n",
      "                                  'cell-induced apoptosis in NSCLC.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 33,\n",
      "                          'text': 'With the alteration of PD-L1 and PD-1 '\n",
      "                                  'binding ability, we confirmed the '\n",
      "                                  'sensitivity of NSCLC cells to T '\n",
      "                                  'cell-induced apoptosis by co-culturing '\n",
      "                                  'NSCLC cells with the activated human PBMCs '\n",
      "                                  '(figure 2D).'},\n",
      "                         {'dEnd': 430,\n",
      "                          'dStart': 425,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 389,\n",
      "                          'tStart': 385,\n",
      "                          'text': 'Non-small cell lung cancer (NSCLC) accounts '\n",
      "                                  'for the majority of lung cancer cases, a '\n",
      "                                  'large number of which are diagnosed at the '\n",
      "                                  'advanced stage, indicating therapeutic '\n",
      "                                  'difficulty and poor prognosis.1 In recent '\n",
      "                                  'years, immune checkpoint inhibitors have '\n",
      "                                  'revolutionized the treatment landscape and '\n",
      "                                  'greatly improved outcomes for numerous '\n",
      "                                  'malignancies including NSCLC.2 3 Programmed '\n",
      "                                  'death 1 (PD-1) is a crucial immune '\n",
      "                                  'checkpoint in NSCLC.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 10,\n",
      "                          'tStart': 6,\n",
      "                          'text': 'Since PD-1/PD-L1 inhibitors are mainly used '\n",
      "                                  'in patients with advanced NSCLC with local '\n",
      "                                  'or distant metastasis, we investigated '\n",
      "                                  'whether mmu-4930573I07Rik could enhance the '\n",
      "                                  'efficacy of PD-L1 mAb to harness the '\n",
      "                                  'metastatic phenotype of NSCLC in vivo '\n",
      "                                  '(figure 5E).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35399232'],\n",
      " 'resourceScore': 49,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 66,\n",
      "                          'dStart': 61,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Kaplan-Meier survival analysis shows that '\n",
      "                                  'the OS of PDCD1 in NSCLC was not '\n",
      "                                  'significant (log rank P=0.76, two tailed '\n",
      "                                  'test); the OS of SH2D3C in NSCLC was not '\n",
      "                                  'significant (log rank P=0.45, two tailed '\n",
      "                                  'test).'},\n",
      "                         {'dEnd': 39,\n",
      "                          'dStart': 34,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'It is generally acknowledged that NSCLC '\n",
      "                                  'patients have high PD-1/PD-L1 expression, '\n",
      "                                  'and thus could have a significant response '\n",
      "                                  'to PD-1/PD-L1 inhibitor treatment.'},\n",
      "                         {'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'SH2D3C expression was moderate relative to '\n",
      "                                  'PDCD1 expression (R=0.49, P<0.001), which '\n",
      "                                  'suggests that SH2D3C is an important gene '\n",
      "                                  'may interact with PD-1 to influence TME and '\n",
      "                                  'ICI treatment in NSCLC (Figure 5G).'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 149,\n",
      "                          'tStart': 145,\n",
      "                          'text': 'This study aimed to identify the '\n",
      "                                  'classification of hot and cold tumors, and '\n",
      "                                  'develop a novel signature to predict the '\n",
      "                                  'ICI treatments response for PD-1/PD-L1 high '\n",
      "                                  'expression NSCLC patients.'},\n",
      "                         {'dEnd': 86,\n",
      "                          'dStart': 81,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'It suggested that the OS of PDCD1 and '\n",
      "                                  'SH2D3C was not associated with that of the '\n",
      "                                  'NSCLC patients (Figure 5A,5B) or the cold '\n",
      "                                  'tumor subtype (Figure 5C,5D).'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Kaplan-Meier survival analysis shows that '\n",
      "                                  'the OS of PDCD1 in NSCLC was not '\n",
      "                                  'significant (log rank P=0.76, two tailed '\n",
      "                                  'test); the OS of SH2D3C in NSCLC was not '\n",
      "                                  'significant (log rank P=0.45, two tailed '\n",
      "                                  'test).'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'We identified novel signatures [STMN3, '\n",
      "                                  'KIRREL1, SH2D3C, VCL, PDCD1, CD274, PTGS2, '\n",
      "                                  'combined diagnostic (AUC) =0.838], in order '\n",
      "                                  'to diagnose the hot and cold tumor subtype '\n",
      "                                  'to indicate the treatment response of '\n",
      "                                  'PD-1/PD-L1 inhibitor in NSCLC.'},\n",
      "                         {'dEnd': 49,\n",
      "                          'dStart': 44,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 29,\n",
      "                          'tStart': 25,\n",
      "                          'text': 'SH2D3C was correlated to PD-1 expression in '\n",
      "                                  'NSCLC samples (R=0.49, P<0.001).'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'We speculated that SH2D3C likely plays a '\n",
      "                                  'crucial role in PD-1-related immunotherapy '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 193,\n",
      "                          'dStart': 188,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 149,\n",
      "                          'tStart': 145,\n",
      "                          'text': 'SH2D3C expression was moderate relative to '\n",
      "                                  'PDCD1 expression (R=0.49, P<0.001), which '\n",
      "                                  'suggests that SH2D3C is an important gene '\n",
      "                                  'may interact with PD-1 to influence TME and '\n",
      "                                  'ICI treatment in NSCLC (Figure 5G).'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 211,\n",
      "                          'tStart': 207,\n",
      "                          'text': 'We identified novel signatures [STMN3, '\n",
      "                                  'KIRREL1, SH2D3C, VCL, PDCD1, CD274, PTGS2, '\n",
      "                                  'combined diagnostic (AUC) =0.838], in order '\n",
      "                                  'to diagnose the hot and cold tumor subtype '\n",
      "                                  'to indicate the treatment response of '\n",
      "                                  'PD-1/PD-L1 inhibitor in NSCLC.'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'According to the infiltration of cluster of '\n",
      "                                  'differentiation 8 positive (CD8+) T cells '\n",
      "                                  'and the expression of PD-1/PD-L1 in these '\n",
      "                                  'six clusters, three ICI-related subtypes of '\n",
      "                                  'NSCLC were identified (Figure 2A-2C).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36117837'],\n",
      " 'resourceScore': 49,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 159,\n",
      "                          'dStart': 154,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': 'In detail, PD-1 inhibitor plus chemotherapy '\n",
      "                                  'realized median PFS and OS of 10.1 and 17.4 '\n",
      "                                  'months, respectively in advanced '\n",
      "                                  'driver-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Typically, some trials disclose that PD-1 '\n",
      "                                  'inhibitor has been applied to treat '\n",
      "                                  'advanced driver-gene-negative nonsquamous '\n",
      "                                  'NSCLC: one trial discloses that '\n",
      "                                  'camrelizumab plus carboplatin and '\n",
      "                                  'pemetrexed prolonged the progression-free '\n",
      "                                  'survival (PFS) of advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients (12).'},\n",
      "                         {'dEnd': 163,\n",
      "                          'dStart': 158,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 inhibitor plus chemotherapy exhibits a '\n",
      "                                  'better efficacy and equal tolerance '\n",
      "                                  'compared with chemotherapy alone in '\n",
      "                                  'advanced driver-gene-negative nonsquamous '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 68,\n",
      "                          'dStart': 63,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': 'Adverse events of PD-1 inhibitor plus '\n",
      "                                  'chemotherapy in advanced NSCLC patients are '\n",
      "                                  'also critical concerns to its application.'},\n",
      "                         {'dEnd': 306,\n",
      "                          'dStart': 301,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'It has been also illustrated that PD-1 '\n",
      "                                  'inhibitor plus chemotherapy could prolong '\n",
      "                                  'the survival for advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients: a previous study discloses that '\n",
      "                                  'sintilimab plus chemotherapy could realize '\n",
      "                                  'a median PFS of 8.9 months in advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients (16).'},\n",
      "                         {'dEnd': 292,\n",
      "                          'dStart': 287,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Typically, some trials disclose that PD-1 '\n",
      "                                  'inhibitor has been applied to treat '\n",
      "                                  'advanced driver-gene-negative nonsquamous '\n",
      "                                  'NSCLC: one trial discloses that '\n",
      "                                  'camrelizumab plus carboplatin and '\n",
      "                                  'pemetrexed prolonged the progression-free '\n",
      "                                  'survival (PFS) of advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients (12).'},\n",
      "                         {'dEnd': 177,\n",
      "                          'dStart': 172,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Conclusively, PD-1 inhibitor plus '\n",
      "                                  'chemotherapy exhibits a better efficacy and '\n",
      "                                  'equal tolerance compared with chemotherapy '\n",
      "                                  'alone in advanced driver-gene-negative '\n",
      "                                  'nonsquamous NSCLC patients.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'Programmed cell death 1 inhibitor plus '\n",
      "                                  'chemotherapy vs. chemotherapy in advanced '\n",
      "                                  'drive-gene-negative non-small-cell lung '\n",
      "                                  'cancer patients: A real-world study'},\n",
      "                         {'dEnd': 196,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 104,\n",
      "                          'tStart': 100,\n",
      "                          'text': 'Hence, the current real-world study aimed '\n",
      "                                  'to further explore the treatment outcome '\n",
      "                                  'and tolerance of PD-1 inhibitor plus '\n",
      "                                  'chemotherapy in patients with advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC.'},\n",
      "                         {'dEnd': 144,\n",
      "                          'dStart': 139,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'It has been also illustrated that PD-1 '\n",
      "                                  'inhibitor plus chemotherapy could prolong '\n",
      "                                  'the survival for advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients: a previous study discloses that '\n",
      "                                  'sintilimab plus chemotherapy could realize '\n",
      "                                  'a median PFS of 8.9 months in advanced '\n",
      "                                  'drive-gene-negative nonsquamous NSCLC '\n",
      "                                  'patients (16).'},\n",
      "                         {'dEnd': 124,\n",
      "                          'dStart': 119,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': '(3) This study enrolled nonsquamous NSCLC '\n",
      "                                  'patients, while the efficacy of PD-1 '\n",
      "                                  'inhibitor plus chemotherapy in squamous '\n",
      "                                  'NSCLC patients was not evaluated in the '\n",
      "                                  'present study.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'This retrospective cohort study analyzed 68 '\n",
      "                                  'advanced driver-gene-negative nonsquamous '\n",
      "                                  'NSCLC patients, among which 38 cases '\n",
      "                                  'received PD-1 inhibitor plus chemotherapy '\n",
      "                                  'and 30 cases adopted chemotherapy alone.'},\n",
      "                         {'dEnd': 41,\n",
      "                          'dStart': 36,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': '(3) This study enrolled nonsquamous NSCLC '\n",
      "                                  'patients, while the efficacy of PD-1 '\n",
      "                                  'inhibitor plus chemotherapy in squamous '\n",
      "                                  'NSCLC patients was not evaluated in the '\n",
      "                                  'present study.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'These results above disclose that PD-1 '\n",
      "                                  'inhibitor plus chemotherapy exhibits an '\n",
      "                                  'acceptable treatment efficacy in advanced '\n",
      "                                  'nonsquamous NSCLC patients.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 8,\n",
      "                          'tStart': 4,\n",
      "                          'text': '(2) PD-1 inhibitor synergizes with '\n",
      "                                  'chemotherapy and therefore improves the '\n",
      "                                  'survival profile for advanced NSCLC '\n",
      "                                  'patients (18).'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'These findings disclose that PD-1 inhibitor '\n",
      "                                  'plus chemotherapy exhibits an acceptable '\n",
      "                                  'tolerance in advanced driver-gene-negative '\n",
      "                                  'NSCLC patients.'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Thus, this study intended to assess the '\n",
      "                                  'treatment outcome and tolerance of PD-1 '\n",
      "                                  'inhibitor plus chemotherapy in advanced, '\n",
      "                                  'driver-gene-negative, nonsquamous, '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'in a real clinical setting.'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Thus, this study intended to assess the '\n",
      "                                  'treatment outcome and tolerance of PD-1 '\n",
      "                                  'inhibitor plus chemotherapy in advanced, '\n",
      "                                  'driver-gene-negative, nonsquamous, '\n",
      "                                  'non-small-cell lung cancer (NSCLC) patients '\n",
      "                                  'in a real clinical setting.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'So far, several studies evaluate the '\n",
      "                                  'treatment response of PD-1 inhibitor in '\n",
      "                                  'advanced, driver-gene-negative NSCLC '\n",
      "                                  'patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32953506'],\n",
      " 'resourceScore': 49,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'Thus, it might be an interesting issue for '\n",
      "                                  'researchers to analyze that whether the '\n",
      "                                  'survival of NSCLC patients with various '\n",
      "                                  'histological types differs after treated '\n",
      "                                  'with PD-1/L1 inhibitors.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1 is transcriptionally induced on '\n",
      "                                  'activated T cells, and PD-L1 expression is '\n",
      "                                  'found in multiple tumors including 20–65% '\n",
      "                                  'of NSCLC (46).'},\n",
      "                         {'dEnd': 201,\n",
      "                          'dStart': 196,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'Head-to-head clinical trials comparing '\n",
      "                                  'these emerging PD-1/L1 inhibitors are still '\n",
      "                                  'a necessity to reduce the limitations from '\n",
      "                                  'indirect comparisons, to identify the '\n",
      "                                  'optimal treatments for advanced NSCLC.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Inhibitors of programmed cell death-1 '\n",
      "                                  '(PD-1) and its ligand (PD-L1) have '\n",
      "                                  'represented a novel approach for the '\n",
      "                                  'management of advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Inhibitors of programmed cell death-1 '\n",
      "                                  '(PD-1) and its ligand (PD-L1) have '\n",
      "                                  'represented a novel approach for the '\n",
      "                                  'management of advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Compare the efficacy and safety of '\n",
      "                                  'programmed cell death-1 (PD-1) and '\n",
      "                                  'programmed cell death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors for advanced non-small cell lung '\n",
      "                                  'cancer: a Bayesian analysis'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 44,\n",
      "                          'tStart': 40,\n",
      "                          'text': 'The drug efficacy of regimens including '\n",
      "                                  'PD-1/L1 inhibitors is superior to '\n",
      "                                  'chemotherapy for NSCLC, regardless of the '\n",
      "                                  'therapeutic line used.'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'Inhibitors of programmed cell death-1 '\n",
      "                                  '(PD-1) and its ligand (PD-L1) have '\n",
      "                                  'represented a novel approach for the '\n",
      "                                  'management of advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 159,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Compare the efficacy and safety of '\n",
      "                                  'programmed cell death-1 (PD-1) and '\n",
      "                                  'programmed cell death ligand-1 (PD-L1) '\n",
      "                                  'inhibitors for advanced non-small cell lung '\n",
      "                                  'cancer: a Bayesian analysis'},\n",
      "                         {'dEnd': 228,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'In this study, we aimed to estimate five '\n",
      "                                  'anti-PD-1/L1 agents (nivolumab, '\n",
      "                                  'pembrolizumab, atezolizumab, durvalumab, '\n",
      "                                  'and avelumab) using network meta-analyses '\n",
      "                                  '(NMAs) and the Bayesian method to provide '\n",
      "                                  'suggestions for advanced NSCLC treatments.'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 212,\n",
      "                          'tStart': 189,\n",
      "                          'text': 'Apart from the treatments above, '\n",
      "                                  'immunotherapy has been a novel approach for '\n",
      "                                  'advanced NSCLC over the last decade, where '\n",
      "                                  'the inhibition of immune checkpoints plays '\n",
      "                                  'a pivotal role, including programmed cell '\n",
      "                                  'death-1 (PD-1) and its ligand programmed '\n",
      "                                  'death ligand-1 (PD-L1) (9,10).'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'Three studies associated with NMA had been '\n",
      "                                  'conducted to figure out the best PD-1/L1 '\n",
      "                                  'inhibitor for advanced NSCLC patients in '\n",
      "                                  'the first-line settings (51-53).'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'In the present study, we performed a '\n",
      "                                  'systematic review and meta-analysis of '\n",
      "                                  'several phase II/III RCTs associated with '\n",
      "                                  'PD-1/L1 inhibitors in advanced NSCLC.'},\n",
      "                         {'dEnd': 172,\n",
      "                          'dStart': 167,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'An indirect analysis has shown therapeutic '\n",
      "                                  'advantages of PD-1 inhibitors, nivolumab '\n",
      "                                  'and pembrolizumab, over PD-L1 inhibitor, '\n",
      "                                  'atezolizumab, in pretreated patients with '\n",
      "                                  'NSCLC (26), but the evidence is still '\n",
      "                                  'lacking and there is still a lack of '\n",
      "                                  'head-to-head comparisons to directly '\n",
      "                                  'determine the best agent.'},\n",
      "                         {'dEnd': 149,\n",
      "                          'dStart': 144,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 94,\n",
      "                          'tStart': 90,\n",
      "                          'text': 'The results provided suggestions for '\n",
      "                                  'clinicians to develop individualized '\n",
      "                                  'treatments with PD-1/L1 inhibitors for '\n",
      "                                  'diverse patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 166,\n",
      "                          'dStart': 161,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 37,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Inhibitors of programmed cell death-1 '\n",
      "                                  '(PD-1) and its ligand (PD-L1) have '\n",
      "                                  'represented a novel approach for the '\n",
      "                                  'management of advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Finally, 19 studies involving 11,456 '\n",
      "                                  'participants with advanced NSCLC (eleven '\n",
      "                                  'studies with PD-1/L1 inhibitors in the '\n",
      "                                  'first-line settings involving 6,635 '\n",
      "                                  'patients and eight studies with PD-1/L1 '\n",
      "                                  'inhibitors in the subsequent settings '\n",
      "                                  'involving 4,821 patients) met all the '\n",
      "                                  'inclusion or exclusion criteria and were '\n",
      "                                  'included in the meta-analysis '\n",
      "                                  '(17,19,20,32-44).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['37150133'],\n",
      " 'resourceScore': 49,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 80,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'However, PD-1 blockade monotherapy remains '\n",
      "                                  'inefficient in more than 60% of NSCLC '\n",
      "                                  \"patients, and many patients don't respond \"\n",
      "                                  'or acquire resistance to this modality.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Herein, we will outline the clinical '\n",
      "                                  'benefits of PD-1 blockade therapy alone or '\n",
      "                                  'in combination with other treatments (e.g., '\n",
      "                                  'chemotherapy, radiotherapy, anti-angiogenic '\n",
      "                                  'therapy) in NSCLC patients.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Targeting programmed cell death protein 1 '\n",
      "                                  '(PD-1) for treatment of non-small-cell lung '\n",
      "                                  'carcinoma (NSCLC); the recent advances.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Targeting programmed cell death protein 1 '\n",
      "                                  '(PD-1) for treatment of non-small-cell lung '\n",
      "                                  'carcinoma (NSCLC); the recent advances.'},\n",
      "                         {'dEnd': 95,\n",
      "                          'dStart': 66,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Targeting programmed cell death protein 1 '\n",
      "                                  '(PD-1) for treatment of non-small-cell lung '\n",
      "                                  'carcinoma (NSCLC); the recent advances.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': 'Meanwhile, anti-PD-1 anti-bodies such as '\n",
      "                                  'nivolumab, pembrolizumab, cemiplimab, and '\n",
      "                                  'sintilimab have shown excellent competence '\n",
      "                                  'in successfully inspiring immune responses '\n",
      "                                  'versus NSCLC.'},\n",
      "                         {'dEnd': 102,\n",
      "                          'dStart': 97,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Targeting programmed cell death protein 1 '\n",
      "                                  '(PD-1) for treatment of non-small-cell lung '\n",
      "                                  'carcinoma (NSCLC); the recent advances.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['30159341'],\n",
      " 'resourceScore': 48,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'In addition, these data also showed that '\n",
      "                                  'PD-1 or PD-L1 could serve as a biomarker to '\n",
      "                                  'improve the benefit of anti-PD-1/PD-L1 '\n",
      "                                  'therapy for NSCLC patients.'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 45,\n",
      "                          'tStart': 41,\n",
      "                          'text': 'In addition, these data also showed that '\n",
      "                                  'PD-1 or PD-L1 could serve as a biomarker to '\n",
      "                                  'improve the benefit of anti-PD-1/PD-L1 '\n",
      "                                  'therapy for NSCLC patients.'},\n",
      "                         {'dEnd': 54,\n",
      "                          'dStart': 28,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-PD-1/PD-L1 Therapy for Non-Small-Cell '\n",
      "                                  'Lung Cancer: Toward Personalized Medicine '\n",
      "                                  'and Combination Strategies'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 203,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'These clinical trials clearly demonstrated '\n",
      "                                  'that inhibition of the PD-1/PD-L1 pathway '\n",
      "                                  'could clinically improve the ORR, OS, and '\n",
      "                                  'PFS compared with single-arm chemotherapy '\n",
      "                                  'alone in nonsquamous and squamous NSCLCs.'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 160,\n",
      "                          'tStart': 156,\n",
      "                          'text': 'The encouraging clinical safety and effects '\n",
      "                                  'of anti-PD-1/PD-L1 antibodies in both '\n",
      "                                  'clinical trials and settings have led a '\n",
      "                                  'fast development of inhibitors of PD-1 and '\n",
      "                                  'PD-L1/2 for treatments of solid tumors, '\n",
      "                                  'including the NSCLC.'},\n",
      "                         {'dEnd': 220,\n",
      "                          'dStart': 215,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'Encouragingly, immune checkpoint blockade '\n",
      "                                  'targeting programmed death-1 (PD-1) and '\n",
      "                                  'programmed death-ligand 1 (PD-L1) has '\n",
      "                                  'dramatically changed the landscape for '\n",
      "                                  'treatments in patients with non-small-cell '\n",
      "                                  'lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'The encouraging clinical safety and effects '\n",
      "                                  'of anti-PD-1/PD-L1 antibodies in both '\n",
      "                                  'clinical trials and settings have led a '\n",
      "                                  'fast development of inhibitors of PD-1 and '\n",
      "                                  'PD-L1/2 for treatments of solid tumors, '\n",
      "                                  'including the NSCLC.'},\n",
      "                         {'dEnd': 346,\n",
      "                          'dStart': 341,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Indeed, meta-analysis in randomized '\n",
      "                                  'clinical trials of anti-PD-1/PD-L1 therapy '\n",
      "                                  '(atezolizumab, pembrolizumab, and '\n",
      "                                  'nivolumab) demonstrated the efficacy and '\n",
      "                                  'safety and could dramatically improve the '\n",
      "                                  'PFS and OS compared with docetaxel for '\n",
      "                                  'patients with previously treated NSCLC [56, '\n",
      "                                  '57] and enhance the PFS and OS compared to '\n",
      "                                  'EGFR-TKI alone for NSCLC patients with EGFR '\n",
      "                                  'wild type [56].'},\n",
      "                         {'dEnd': 147,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Equally important, the development of '\n",
      "                                  'resistance to anti-PD-1/PD-L1 immunotherapy '\n",
      "                                  'further leads to the failure and poor '\n",
      "                                  'prognosis in advanced NSCLC patients '\n",
      "                                  'receiving anti-PD-1/PD-L1 treatment.'},\n",
      "                         {'dEnd': 273,\n",
      "                          'dStart': 268,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Indeed, meta-analysis in randomized '\n",
      "                                  'clinical trials of anti-PD-1/PD-L1 therapy '\n",
      "                                  '(atezolizumab, pembrolizumab, and '\n",
      "                                  'nivolumab) demonstrated the efficacy and '\n",
      "                                  'safety and could dramatically improve the '\n",
      "                                  'PFS and OS compared with docetaxel for '\n",
      "                                  'patients with previously treated NSCLC [56, '\n",
      "                                  '57] and enhance the PFS and OS compared to '\n",
      "                                  'EGFR-TKI alone for NSCLC patients with EGFR '\n",
      "                                  'wild type [56].'},\n",
      "                         {'dEnd': 215,\n",
      "                          'dStart': 210,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': 'To date, there are four anti-PD-1/PD-L1 '\n",
      "                                  'agents including pembrolizumab (Keytruda), '\n",
      "                                  'nivolumab (Opdivo), atezolizumab '\n",
      "                                  '(Tecentriq), and durvalumab (Imfinzi) have '\n",
      "                                  'been licensed for serving as first- or '\n",
      "                                  'second-line NSCLC therapy.'},\n",
      "                         {'dEnd': 74,\n",
      "                          'dStart': 69,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 48,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'However, there are grave challenges in '\n",
      "                                  'anti-PD-1/PD-L1 therapies for NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 243,\n",
      "                          'tStart': 239,\n",
      "                          'text': 'The introduction of PD-L1-based companion '\n",
      "                                  'and complementary diagnostic assays has '\n",
      "                                  'greatly increased the efficacy and safety '\n",
      "                                  'of anti-PD-1/PD-L1 therapy in selected '\n",
      "                                  'patients, suggesting that the PD-L1 is one '\n",
      "                                  'of the predictive biomarkers for PD-1/PD-L1 '\n",
      "                                  'inhibitors in NSCLC.'},\n",
      "                         {'dEnd': 123,\n",
      "                          'dStart': 118,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'In addition, with our deeper understanding '\n",
      "                                  'of mechanisms of immune escape and its role '\n",
      "                                  'in the biological behaviors of NSCLC, a '\n",
      "                                  'combinatory approach on the basis of '\n",
      "                                  'anti-PD-1/PD-L1 therapy, such as a '\n",
      "                                  'combination with chemotherapy, targeted '\n",
      "                                  'therapy, radiotherapy, and other '\n",
      "                                  'immunotherapies, may establish landmarks '\n",
      "                                  'for treatment of NSCLC.'},\n",
      "                         {'dEnd': 196,\n",
      "                          'dStart': 191,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'In this review article, we summarized '\n",
      "                                  'several anti-PD-1/PD-L1 agents licensed for '\n",
      "                                  'NSCLC treatment, with a focus on predictive '\n",
      "                                  'biomarkers and companion diagnostic assays '\n",
      "                                  'for identification of NSCLC patients for '\n",
      "                                  'immunotherapy anti-PD-1/PDL1 antibodies.'},\n",
      "                         {'dEnd': 335,\n",
      "                          'dStart': 330,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'In addition, with our deeper understanding '\n",
      "                                  'of mechanisms of immune escape and its role '\n",
      "                                  'in the biological behaviors of NSCLC, a '\n",
      "                                  'combinatory approach on the basis of '\n",
      "                                  'anti-PD-1/PD-L1 therapy, such as a '\n",
      "                                  'combination with chemotherapy, targeted '\n",
      "                                  'therapy, radiotherapy, and other '\n",
      "                                  'immunotherapies, may establish landmarks '\n",
      "                                  'for treatment of NSCLC.'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'For instance, in NSCLC patients with '\n",
      "                                  'acquired resistance to anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapies and EGFR or ALK mutations, '\n",
      "                                  'particularly for patients with high tumor '\n",
      "                                  'burden or rapid disease progression, a '\n",
      "                                  'combination of anti-PD-1/PD-L1 therapy and '\n",
      "                                  'targeted therapy may be an option.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Nowadays, several anti-PD-1/PD-L1 '\n",
      "                                  'antibodies have been licensed for '\n",
      "                                  'treatments of many types of solid tumors in '\n",
      "                                  'clinical settings, including the NSCLC (for '\n",
      "                                  'details see Table 1) and many are in '\n",
      "                                  'developed.'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 60,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 7,\n",
      "                          'tStart': 3,\n",
      "                          'text': '4. PD-1/PD-L1 Signaling Pathway as a '\n",
      "                                  'Therapeutic Target for NSCLC'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 122,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 42,\n",
      "                          'tStart': 38,\n",
      "                          'text': 'Almost at the same time, another anti-PD-1 '\n",
      "                                  'antibody, pembrolizumab, was licensed for '\n",
      "                                  'treatment of PD-L1-positive advanced NSCLC '\n",
      "                                  'by FDA/EMA, based on a mass of clinical '\n",
      "                                  'trials exhibited that pembrolizumab was '\n",
      "                                  'safe and effective for metastatic NSCLC '\n",
      "                                  '(mNSCLC) [14, 15].'},\n",
      "                         {'dEnd': 41,\n",
      "                          'dStart': 36,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 88,\n",
      "                          'tStart': 84,\n",
      "                          'text': 'However, only a small proportion of NSCLC '\n",
      "                                  'patients responded to monotherapy of '\n",
      "                                  'anti-PD-1/PDL1 agents; together, the '\n",
      "                                  'development of resistance to '\n",
      "                                  'anti-PD-1/PD-L1 therapy that leads to '\n",
      "                                  'failure of anti-PD-1/PD-L1 therapy has '\n",
      "                                  'significantly limited a broad applicability '\n",
      "                                  'of the findings in clinical practices.'},\n",
      "                         {'dEnd': 80,\n",
      "                          'dStart': 75,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 25,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'Agents targeting the PD-1/PD-L1 signaling '\n",
      "                                  'have shown promising response in NSCLC '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 303,\n",
      "                          'dStart': 298,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 280,\n",
      "                          'tStart': 276,\n",
      "                          'text': 'Indeed, a recent meta-analysis of five '\n",
      "                                  'trials demonstrated that nivolumab and '\n",
      "                                  'pembrolizumab were correlated with a '\n",
      "                                  'significant increase of ORR as compared to '\n",
      "                                  'atezolizumab, while nivolumab was found to '\n",
      "                                  'associate with a lower incidence of G3-5 '\n",
      "                                  'AEs in comparison with other '\n",
      "                                  'anti-PD-1/PD-L1 agents for NSCLC treatment '\n",
      "                                  '[110].'},\n",
      "                         {'dEnd': 213,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 76,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'Encouragingly, immune checkpoint blockade '\n",
      "                                  'targeting programmed death-1 (PD-1) and '\n",
      "                                  'programmed death-ligand 1 (PD-L1) has '\n",
      "                                  'dramatically changed the landscape for '\n",
      "                                  'treatments in patients with non-small-cell '\n",
      "                                  'lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'In this review article, we summarized '\n",
      "                                  'several anti-PD-1/PD-L1 agents licensed for '\n",
      "                                  'NSCLC treatment, with a focus on predictive '\n",
      "                                  'biomarkers and companion diagnostic assays '\n",
      "                                  'for identification of NSCLC patients for '\n",
      "                                  'immunotherapy anti-PD-1/PDL1 antibodies.'},\n",
      "                         {'dEnd': 129,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'Despite the drug blockading the PD-1/PD-L1 '\n",
      "                                  'pathways has been shown exciting '\n",
      "                                  'therapeutic benefits for patients with '\n",
      "                                  'advanced NSCLC, less than 20% NSCLC '\n",
      "                                  'patients could benefit for these novel '\n",
      "                                  'agents [23–25], suggesting an unmet need '\n",
      "                                  'for identification of patients in this type '\n",
      "                                  'of immunotherapy.'},\n",
      "                         {'dEnd': 335,\n",
      "                          'dStart': 330,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 284,\n",
      "                          'tStart': 280,\n",
      "                          'text': 'Currently, however, the expression of PD-L1 '\n",
      "                                  'is only the tip of the iceberg in the '\n",
      "                                  'predictive index of anti-PD-1/PD-L1 '\n",
      "                                  'therapy; it is necessary to combine the '\n",
      "                                  'multiple indexes to make the best '\n",
      "                                  'predictive ability, indicating an '\n",
      "                                  'importance of personalized biomarkers in '\n",
      "                                  'guiding anti-PD-1/PD-L1 immune checkpoint '\n",
      "                                  'blockade therapy for NSCLC.'},\n",
      "                         {'dEnd': 269,\n",
      "                          'dStart': 264,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 136,\n",
      "                          'tStart': 132,\n",
      "                          'text': 'The introduction of PD-L1-based companion '\n",
      "                                  'and complementary diagnostic assays has '\n",
      "                                  'greatly increased the efficacy and safety '\n",
      "                                  'of anti-PD-1/PD-L1 therapy in selected '\n",
      "                                  'patients, suggesting that the PD-L1 is one '\n",
      "                                  'of the predictive biomarkers for PD-1/PD-L1 '\n",
      "                                  'inhibitors in NSCLC.'},\n",
      "                         {'dEnd': 335,\n",
      "                          'dStart': 330,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 111,\n",
      "                          'tStart': 107,\n",
      "                          'text': 'Currently, however, the expression of PD-L1 '\n",
      "                                  'is only the tip of the iceberg in the '\n",
      "                                  'predictive index of anti-PD-1/PD-L1 '\n",
      "                                  'therapy; it is necessary to combine the '\n",
      "                                  'multiple indexes to make the best '\n",
      "                                  'predictive ability, indicating an '\n",
      "                                  'importance of personalized biomarkers in '\n",
      "                                  'guiding anti-PD-1/PD-L1 immune checkpoint '\n",
      "                                  'blockade therapy for NSCLC.'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 145,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'Despite the drug blockading the PD-1/PD-L1 '\n",
      "                                  'pathways has been shown exciting '\n",
      "                                  'therapeutic benefits for patients with '\n",
      "                                  'advanced NSCLC, less than 20% NSCLC '\n",
      "                                  'patients could benefit for these novel '\n",
      "                                  'agents [23–25], suggesting an unmet need '\n",
      "                                  'for identification of patients in this type '\n",
      "                                  'of immunotherapy.'},\n",
      "                         {'dEnd': 236,\n",
      "                          'dStart': 231,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 52,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'Two antibodies (nivolumab and '\n",
      "                                  'pembrolizumab) to PD-1 and two antibodies '\n",
      "                                  '(atezolizumab and durvalumab) to PD-L1 have '\n",
      "                                  'been approved by the US Food and Drug '\n",
      "                                  'Administration (FDA) and/or European '\n",
      "                                  'Medicines Agency (EMA) for treatment of '\n",
      "                                  'NSCLC (Table 1) [13–16].'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['31527660'],\n",
      " 'resourceScore': 47,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 53,\n",
      "                          'dStart': 48,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Association between SUVmax and response '\n",
      "                                  'rate in NSCLC patients treated with '\n",
      "                                  'anti-PD-1 mAbs'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 107,\n",
      "                          'tStart': 103,\n",
      "                          'text': 'In this study, we evaluated the '\n",
      "                                  'relationship between 18F-FDG uptake on '\n",
      "                                  'PET/CT and the response to anti-PD-1 '\n",
      "                                  'therapy in patients with advanced or '\n",
      "                                  'recurrent NSCLC.'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'In this translational study, we evaluated '\n",
      "                                  'the relationship between 18F-FDG uptake on '\n",
      "                                  'PET/CT and the response to anti-PD-1 mAbs '\n",
      "                                  'in patients with advanced or recurrent '\n",
      "                                  'NSCLC patients by dichotomizing the cohort '\n",
      "                                  'according to the maximum standardized '\n",
      "                                  'uptake value (SUVmax) on imaging.'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'The SUVmax in 18F-FDG PET/CT is a potential '\n",
      "                                  'predictive marker of response to anti-PD-1 '\n",
      "                                  'antibody therapy in NSCLC patients.'},\n",
      "                         {'dEnd': 132,\n",
      "                          'dStart': 106,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 81,\n",
      "                          'text': '18F-FDG uptake in PET/CT is a potential '\n",
      "                                  'predictive biomarker of response to '\n",
      "                                  'anti-PD-1 antibody therapy in non-small '\n",
      "                                  'cell lung cancer'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 219,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 174,\n",
      "                          'tStart': 170,\n",
      "                          'text': 'Nevertheless, the results of this study '\n",
      "                                  'suggest that 18F-FDG PET/CT, which is a '\n",
      "                                  'relatively non-invasive procedure, might be '\n",
      "                                  'a useful tool to predict the efficacy of '\n",
      "                                  'anti-PD-1 mAbs in patients with advanced or '\n",
      "                                  'recurrent NSCLC.'},\n",
      "                         {'dEnd': 231,\n",
      "                          'dStart': 226,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'As such, monoclonal antibodies (mAbs) '\n",
      "                                  'against PD-1 (e.g. nivolumab and '\n",
      "                                  'pembrolizumab) or PD-L1 (e.g. atezolizumab) '\n",
      "                                  'have become one of the standard treatments '\n",
      "                                  'for patients with advanced or recurrent '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 68,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 217,\n",
      "                          'tStart': 213,\n",
      "                          'text': 'However, these studies examined patients '\n",
      "                                  'with surgically resectable NSCLC, not those '\n",
      "                                  'with advanced or recurrent cancer; thus, it '\n",
      "                                  'is unknown whether the relationship between '\n",
      "                                  '18F-FDG uptake and the efficacy of '\n",
      "                                  'anti-PD-1 mAbs is also true in more '\n",
      "                                  'advanced disease.'},\n",
      "                         {'dEnd': 224,\n",
      "                          'dStart': 198,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 50,\n",
      "                          'tStart': 46,\n",
      "                          'text': 'As such, monoclonal antibodies (mAbs) '\n",
      "                                  'against PD-1 (e.g. nivolumab and '\n",
      "                                  'pembrolizumab) or PD-L1 (e.g. atezolizumab) '\n",
      "                                  'have become one of the standard treatments '\n",
      "                                  'for patients with advanced or recurrent '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 312,\n",
      "                          'dStart': 307,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 184,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'},\n",
      "                         {'dEnd': 256,\n",
      "                          'dStart': 251,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'},\n",
      "                         {'dEnd': 256,\n",
      "                          'dStart': 251,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 184,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'},\n",
      "                         {'dEnd': 48,\n",
      "                          'dStart': 43,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'Association between SUVmax and survival of '\n",
      "                                  'NSCLC patients treated with anti-PD-1 mAbs'},\n",
      "                         {'dEnd': 249,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 184,\n",
      "                          'tStart': 161,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'},\n",
      "                         {'dEnd': 160,\n",
      "                          'dStart': 155,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 142,\n",
      "                          'text': 'In conclusion, the SUVmax in 18F-FDG PET/CT '\n",
      "                                  'obtained at the time of treatment '\n",
      "                                  'initiation may be important for predicting '\n",
      "                                  'the efficacy of anti-PD-1 mAbs in NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 249,\n",
      "                          'dStart': 223,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'However, this is the first report to show a '\n",
      "                                  'relationship between 18F-FDG uptake in '\n",
      "                                  'PET/CT and the efficacy of anti-PD-1 mAbs '\n",
      "                                  'in NSCLC patients.'},\n",
      "                         {'dEnd': 312,\n",
      "                          'dStart': 307,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': 'To examine the association between '\n",
      "                                  '18F-fluorodeoxyglucose (18F-FDG) uptake in '\n",
      "                                  'positron emission tomography/computed '\n",
      "                                  'tomography (PET/CT) and the response to '\n",
      "                                  'anti-programmed cell death-1 (PD-1) '\n",
      "                                  'monoclonal antibody therapy in non-small '\n",
      "                                  'cell lung cancer (NSCLC) patients, 89 '\n",
      "                                  'patients with advanced or recurrent NSCLC '\n",
      "                                  'were retrospectively analysed.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['34899709'],\n",
      " 'resourceScore': 47,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 175,\n",
      "                          'tStart': 171,\n",
      "                          'text': 'Our previous study also illustrated that '\n",
      "                                  'high percentages of IFN-γ-producing naïve '\n",
      "                                  'CD4+ T cells and PD-1+CD4+ memory T cells '\n",
      "                                  'were associated with better response to '\n",
      "                                  'anti-PD-1 treatment in NSCLC patients '\n",
      "                                  '(11).'},\n",
      "                         {'dEnd': 161,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'In the present study, we have investigated '\n",
      "                                  'the potential of peripheral B cells in '\n",
      "                                  'predicting the responses to anti-PD-1/PD-L1 '\n",
      "                                  'treatment in Chinese advanced NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 78,\n",
      "                          'tStart': 74,\n",
      "                          'text': 'In summary, our study identified peripheral '\n",
      "                                  'IgM+ memory B cells with high PD-1 and '\n",
      "                                  'PD-L1 expressions as an alternative '\n",
      "                                  'potential indicator to predict the '\n",
      "                                  'responses to anti-PD-1 monotherapy in '\n",
      "                                  'Chinese advanced NSCLC.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 176,\n",
      "                          'tStart': 172,\n",
      "                          'text': 'In summary, our study identified peripheral '\n",
      "                                  'IgM+ memory B cells with high PD-1 and '\n",
      "                                  'PD-L1 expressions as an alternative '\n",
      "                                  'potential indicator to predict the '\n",
      "                                  'responses to anti-PD-1 monotherapy in '\n",
      "                                  'Chinese advanced NSCLC.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'Our previous study also illustrated that '\n",
      "                                  'high percentages of IFN-γ-producing naïve '\n",
      "                                  'CD4+ T cells and PD-1+CD4+ memory T cells '\n",
      "                                  'were associated with better response to '\n",
      "                                  'anti-PD-1 treatment in NSCLC patients '\n",
      "                                  '(11).'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 109,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Herein, we did not define how IgM+ memory B '\n",
      "                                  'cells modulate anti-PD-1 regimen-mediated '\n",
      "                                  'anti-tumor immunity in NSCLC patients.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting programmed cell death1 (PD\\xad1) '\n",
      "                                  'and its ligand (PD-L1) have greatly '\n",
      "                                  'improved therapeutic outcomes in multiple '\n",
      "                                  'carcinomas including advanced non-small '\n",
      "                                  'cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 63,\n",
      "                          'dStart': 58,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': 'In this study, peripheral B cell signatures '\n",
      "                                  'from advanced NSCLC patients receiving '\n",
      "                                  'anti-PD-1/PD-L1 monotherapy were '\n",
      "                                  'systematically assessed by multiplex flow '\n",
      "                                  'cytometry.'},\n",
      "                         {'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 91,\n",
      "                          'text': 'Peripheral IgM+ memory B cells were '\n",
      "                                  'identified to be associated with the '\n",
      "                                  'responses to anti-PD-1 monotherapy in '\n",
      "                                  'advanced NSCLC patients, providing the '\n",
      "                                  'evidence on peripheral B cell signatures as '\n",
      "                                  'a potential biomarker for stratifying the '\n",
      "                                  'patients before the treatment.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs) '\n",
      "                                  'targeting programmed cell death1 (PD\\xad1) '\n",
      "                                  'and its ligand (PD-L1) have greatly '\n",
      "                                  'improved therapeutic outcomes in multiple '\n",
      "                                  'carcinomas including advanced non-small '\n",
      "                                  'cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 29,\n",
      "                          'dStart': 24,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 58,\n",
      "                          'tStart': 54,\n",
      "                          'text': 'A total of 120 advanced NSCLC patients '\n",
      "                                  'receiving anti-PD-1 monotherapy and 30 '\n",
      "                                  'patients receiving anti-PD-L1 monotherapy '\n",
      "                                  'were recruited in this study (Table 1).'},\n",
      "                         {'dEnd': 91,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': 'Herein, we have defined peripheral B cell '\n",
      "                                  'signatures in advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC) patients receiving anti-PD-1 '\n",
      "                                  'monotherapy and investigated their '\n",
      "                                  'associations with clinical efficacy.'},\n",
      "                         {'dEnd': 99,\n",
      "                          'dStart': 94,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 40,\n",
      "                          'tStart': 36,\n",
      "                          'text': 'Firstly, the expression profiles of PD-1 '\n",
      "                                  'positive lymphocytes in the periphery of 50 '\n",
      "                                  'advanced NSCLC patients were measured by '\n",
      "                                  'multiplex flow cytometry.'},\n",
      "                         {'dEnd': 137,\n",
      "                          'dStart': 111,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Predictable Roles of Peripheral IgM Memory '\n",
      "                                  'B Cells for the Responses to Anti-PD-1 '\n",
      "                                  'Monotherapy Against Advanced Non-Small Cell '\n",
      "                                  'Lung Cancer'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 112,\n",
      "                          'tStart': 108,\n",
      "                          'text': 'Therefore, our data suggest the roles of '\n",
      "                                  'peripheral IgM+ memory B cells in '\n",
      "                                  'predicting the responses to anti-PD-1 '\n",
      "                                  'treatment in Chinese advanced NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 188,\n",
      "                          'dStart': 183,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 158,\n",
      "                          'tStart': 154,\n",
      "                          'text': 'Our results thus indicate that the '\n",
      "                                  'percentage of peripheral IgM+ memory B '\n",
      "                                  'cells at the baseline is a novel indicator '\n",
      "                                  'for predicting the responses to anti-PD-1 '\n",
      "                                  'monotherapy in advanced NSCLC patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['28228226'],\n",
      " 'resourceScore': 47,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 272,\n",
      "                          'tStart': 268,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 526,\n",
      "                          'dStart': 521,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 509,\n",
      "                          'tStart': 505,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 490,\n",
      "                          'dStart': 485,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 465,\n",
      "                          'tStart': 461,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 29,\n",
      "                          'dStart': 24,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 12,\n",
      "                          'tStart': 8,\n",
      "                          'text': '多项临床研究证实PD-1/PD-L1抑制剂在晚期NSCLC中有卓越疗效,也发现PD-L1表达水平与疗效密切相关,是直接的疗效预测因子。因此,了解PD-L1在晚期NSCLC中的表达比例及其与组织类型是否相关非常重要。KEYNOTE多项研究均未限定组织类型,但以非鳞癌居多;在KEYNOTE-001研究[10]中接受PD-L1检测的患者824例,其中501例(60.8%)≥1%,191例(23.2%)≥50%;KEYNOTE-010研究[11]纳入2, '\n",
      "                                  '222例患者,其中1, '\n",
      "                                  '475例(66%)≥1%,633例(28%)≥50%;KEYNOTE-024[12]研究检测了1, '\n",
      "                                  '653例患者,其中≥50%的比例是30.2%。而CheckMate-063[13]和CheckMate-017[14]这两项研究入组患者均为鳞癌,前者结果显示PD-L1≥5%的比例为33%(25/76);后者显示PD-L1≥10%的比例为30.7%(69/225),≥1%的比例为52.9%(119/225)。OAK研究[15]同样未限定组织类型,结果显示PD-L1≥50%的比例为16%(137/850),≥1%的比例为54%(463/850)。总结以上数据可以发现,PD-L1在晚期NSCLC中呈高表达状态,其中≥1%的患者比例为52.9%-66%;≥50%的患者比例是16%-30.2%,鳞癌与非鳞癌未见明显差异。'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 223,\n",
      "                          'dStart': 218,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 11,\n",
      "                          'tStart': 7,\n",
      "                          'text': '综上所述,针对PD-1/PD-L1的免疫检查点抑制剂在晚期NSCLC的治疗中显示出了令人瞩目的卓越疗效。对于无驱动基因突变的晚期NSCLC,免疫检查点抑制剂无论在一线、二线还是二线以后的治疗中均显示出了超过化疗的疗效。而且,PD-L1≥1%的患者比例在晚期NSCLC可达60%左右,超过了驱动基因突变的患者人群,意味着多数患者可以接受免疫检查点抑制剂的治疗并从中获益。目前,最重要的是找到最佳的可预测疗效的生物标记生物标记物,来指导晚期NSCLC的临床“精准”治疗。'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 334,\n",
      "                          'dStart': 329,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 34,\n",
      "                          'dStart': 29,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 11,\n",
      "                          'tStart': 7,\n",
      "                          'text': '综上所述,针对PD-1/PD-L1的免疫检查点抑制剂在晚期NSCLC的治疗中显示出了令人瞩目的卓越疗效。对于无驱动基因突变的晚期NSCLC,免疫检查点抑制剂无论在一线、二线还是二线以后的治疗中均显示出了超过化疗的疗效。而且,PD-L1≥1%的患者比例在晚期NSCLC可达60%左右,超过了驱动基因突变的患者人群,意味着多数患者可以接受免疫检查点抑制剂的治疗并从中获益。目前,最重要的是找到最佳的可预测疗效的生物标记生物标记物,来指导晚期NSCLC的临床“精准”治疗。'},\n",
      "                         {'dEnd': 397,\n",
      "                          'dStart': 392,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 479,\n",
      "                          'dStart': 474,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 435,\n",
      "                          'tStart': 431,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 186,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 408,\n",
      "                          'tStart': 404,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 24,\n",
      "                          'tStart': 21,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 526,\n",
      "                          'dStart': 521,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 69,\n",
      "                          'dStart': 64,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 11,\n",
      "                          'tStart': 7,\n",
      "                          'text': '综上所述,针对PD-1/PD-L1的免疫检查点抑制剂在晚期NSCLC的治疗中显示出了令人瞩目的卓越疗效。对于无驱动基因突变的晚期NSCLC,免疫检查点抑制剂无论在一线、二线还是二线以后的治疗中均显示出了超过化疗的疗效。而且,PD-L1≥1%的患者比例在晚期NSCLC可达60%左右,超过了驱动基因突变的患者人群,意味着多数患者可以接受免疫检查点抑制剂的治疗并从中获益。目前,最重要的是找到最佳的可预测疗效的生物标记生物标记物,来指导晚期NSCLC的临床“精准”治疗。'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 162,\n",
      "                          'tStart': 158,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 21,\n",
      "                          'dStart': 16,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂在晚期NSCLC中的临床应用'},\n",
      "                         {'dEnd': 133,\n",
      "                          'dStart': 128,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 11,\n",
      "                          'tStart': 7,\n",
      "                          'text': '综上所述,针对PD-1/PD-L1的免疫检查点抑制剂在晚期NSCLC的治疗中显示出了令人瞩目的卓越疗效。对于无驱动基因突变的晚期NSCLC,免疫检查点抑制剂无论在一线、二线还是二线以后的治疗中均显示出了超过化疗的疗效。而且,PD-L1≥1%的患者比例在晚期NSCLC可达60%左右,超过了驱动基因突变的患者人群,意味着多数患者可以接受免疫检查点抑制剂的治疗并从中获益。目前,最重要的是找到最佳的可预测疗效的生物标记生物标记物,来指导晚期NSCLC的临床“精准”治疗。'},\n",
      "                         {'dEnd': 490,\n",
      "                          'dStart': 485,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 150,\n",
      "                          'dStart': 124,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 191,\n",
      "                          'dStart': 186,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 490,\n",
      "                          'dStart': 485,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 29,\n",
      "                          'text': '程序性死亡受体1(programmed death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab进入一线正式标志着免疫检查点抑制剂在晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)的治疗体系中占据了重要地位。临床试验结果证实PD-1/程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, '\n",
      "                                  'PD-L1)抑制剂在晚期NSCLC的一线、二线和多药耐药后治疗的疗效均要优于传统的化疗。一线使用Pembrolizumab联合化疗的客观有效率(objective '\n",
      "                                  'response rate, '\n",
      "                                  'ORR)最高可达80%;单药Pembrolizumab的无疾病进展时间(progression-free '\n",
      "                                  'survival, '\n",
      "                                  'PFS)接近1年(10.3个月),死亡风险比含铂双药化疗下降40%。单药Pembrolizumab、Nivolumab和Atezolizumab用于二线的疗效同样突出,总生存时间(overall '\n",
      "                                  'survival, '\n",
      "                                  'OS)可至1年左右。PD-L1的表达是PD-1/PD-L1抑制剂疗效的预测因子,在晚期NSCLC中阳性(≥1%)的比例约为60%左右,组织类型间差异不大,但是目前并无检测的金标准。'},\n",
      "                         {'dEnd': 192,\n",
      "                          'dStart': 187,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 162,\n",
      "                          'tStart': 158,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 479,\n",
      "                          'dStart': 474,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 536,\n",
      "                          'dStart': 531,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 12,\n",
      "                          'tStart': 8,\n",
      "                          'text': '多项临床研究证实PD-1/PD-L1抑制剂在晚期NSCLC中有卓越疗效,也发现PD-L1表达水平与疗效密切相关,是直接的疗效预测因子。因此,了解PD-L1在晚期NSCLC中的表达比例及其与组织类型是否相关非常重要。KEYNOTE多项研究均未限定组织类型,但以非鳞癌居多;在KEYNOTE-001研究[10]中接受PD-L1检测的患者824例,其中501例(60.8%)≥1%,191例(23.2%)≥50%;KEYNOTE-010研究[11]纳入2, '\n",
      "                                  '222例患者,其中1, '\n",
      "                                  '475例(66%)≥1%,633例(28%)≥50%;KEYNOTE-024[12]研究检测了1, '\n",
      "                                  '653例患者,其中≥50%的比例是30.2%。而CheckMate-063[13]和CheckMate-017[14]这两项研究入组患者均为鳞癌,前者结果显示PD-L1≥5%的比例为33%(25/76);后者显示PD-L1≥10%的比例为30.7%(69/225),≥1%的比例为52.9%(119/225)。OAK研究[15]同样未限定组织类型,结果显示PD-L1≥50%的比例为16%(137/850),≥1%的比例为54%(463/850)。总结以上数据可以发现,PD-L1在晚期NSCLC中呈高表达状态,其中≥1%的患者比例为52.9%-66%;≥50%的患者比例是16%-30.2%,鳞癌与非鳞癌未见明显差异。'},\n",
      "                         {'dEnd': 20,\n",
      "                          'dStart': 15,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1信号通路与NSCLC'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Pembrolizumab, an inhibitor target '\n",
      "                                  'programmed death 1 (PD-1), was approved '\n",
      "                                  'into the first line therapy in advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 17,\n",
      "                          'dStart': 12,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 22,\n",
      "                          'tStart': 18,\n",
      "                          'text': '目前,已被批准应用于晚期NSCLC的PD-1/PD-L1通路的免疫检查点抑制剂主要有三种:针对PD-1的单克隆抗体:Pembrolizumab(MK-3475)和Nivolumab(BMS-936558);针对PD-L1的单克隆抗体:Atezolizumab(MPDL-3280A)。'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 461,\n",
      "                          'tStart': 457,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 491,\n",
      "                          'dStart': 486,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1和PD-L1是一对免疫抑制性因子,PD1/PD-L1通路的激活可导致免疫抑制性肿瘤微环境形成,使肿瘤细胞逃避机体免疫监视和杀伤[1]。PD-1是免疫球蛋白B7-CD28家族成员之一,主要在免疫细胞(活化的CD4+T细胞、CD8+T细胞、B细胞、自然杀伤T细胞、单核细胞和树突状细胞)中表达[2]。PD-L1是PD-1的主要配体,在很多恶性肿瘤细胞中过表达,其中就包括NSCLC[3-4],乳腺癌[5]和黑色素瘤[6]等。除肿瘤细胞外,PD-L1还在肿瘤浸润性树突状细胞、肿瘤浸润性淋巴细胞、肿瘤浸润性巨噬细胞中表达[7, '\n",
      "                                  '8]。PD-1和PD-L1结合后可抑制CD4+T细胞、CD8+T细胞的增殖和活力,这在正常人表现为减少免疫反应对周围组织的损伤,避免发生自身免疫性疾病[2, '\n",
      "                                  '9],而在肿瘤患者体内则可使肿瘤局部微环境的T细胞免疫杀伤作用降低,从而导致肿瘤免疫逃逸,促进肿瘤生长[1]。因此,阻断PD-1和PD-L1结合在理论上可以恢复肿瘤微环境内T细胞的免疫杀伤作用,从而达到抑制肿瘤的目的。目前针对PD-1/PD-L1的药物已在黑色素瘤、肾癌、头颈部鳞癌和NSCLC等多种恶性肿瘤中被批准应用。'},\n",
      "                         {'dEnd': 85,\n",
      "                          'dStart': 80,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 12,\n",
      "                          'tStart': 8,\n",
      "                          'text': '多项临床研究证实PD-1/PD-L1抑制剂在晚期NSCLC中有卓越疗效,也发现PD-L1表达水平与疗效密切相关,是直接的疗效预测因子。因此,了解PD-L1在晚期NSCLC中的表达比例及其与组织类型是否相关非常重要。KEYNOTE多项研究均未限定组织类型,但以非鳞癌居多;在KEYNOTE-001研究[10]中接受PD-L1检测的患者824例,其中501例(60.8%)≥1%,191例(23.2%)≥50%;KEYNOTE-010研究[11]纳入2, '\n",
      "                                  '222例患者,其中1, '\n",
      "                                  '475例(66%)≥1%,633例(28%)≥50%;KEYNOTE-024[12]研究检测了1, '\n",
      "                                  '653例患者,其中≥50%的比例是30.2%。而CheckMate-063[13]和CheckMate-017[14]这两项研究入组患者均为鳞癌,前者结果显示PD-L1≥5%的比例为33%(25/76);后者显示PD-L1≥10%的比例为30.7%(69/225),≥1%的比例为52.9%(119/225)。OAK研究[15]同样未限定组织类型,结果显示PD-L1≥50%的比例为16%(137/850),≥1%的比例为54%(463/850)。总结以上数据可以发现,PD-L1在晚期NSCLC中呈高表达状态,其中≥1%的患者比例为52.9%-66%;≥50%的患者比例是16%-30.2%,鳞癌与非鳞癌未见明显差异。'},\n",
      "                         {'dEnd': 373,\n",
      "                          'dStart': 368,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 92,\n",
      "                          'tStart': 88,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 115,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 55,\n",
      "                          'text': 'Pembrolizumab, an inhibitor target '\n",
      "                                  'programmed death 1 (PD-1), was approved '\n",
      "                                  'into the first line therapy in advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC).'},\n",
      "                         {'dEnd': 526,\n",
      "                          'dStart': 521,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 435,\n",
      "                          'tStart': 431,\n",
      "                          'text': '2016年10月24日美国食品药品管理局(Food and Drug '\n",
      "                                  'Administration, FDA)正式批准程序性死亡受体1(programmed '\n",
      "                                  'death 1, '\n",
      "                                  'PD-1)抑制剂Pembrolizumab用于一线治疗晚期非小细胞肺癌(non-small '\n",
      "                                  'cell lung cancer, '\n",
      "                                  'NSCLC)。随后,美国国立综合癌症网络(National Comprehensive '\n",
      "                                  'Cancer Network, '\n",
      "                                  'NCCN)指南于10月26日发布的最新版本也对此进行了更新,推荐对于程序性死亡配体1(programmed '\n",
      "                                  'death ligand 1, PD-L1)高表达(Tumor Proportion '\n",
      "                                  'Score, TPS; '\n",
      "                                  '≥50%)的晚期NSCLC患者可一线使用Pembrolizumab。这是免疫检查点抑制剂在晚期NSCLC治疗中的重大突破,标志着免疫治疗在晚期NSCLC的一线治疗中占据了一席之地。除Pembrolizumab外,另外一种PD-1抑制剂Nivolumab和一种PD-L1抑制剂Atezolizumab在最新的NSCLC '\n",
      "                                  'NCCN指南中也被推荐为二线治疗。本文将就以上3种PD-1/PD-L1抑制剂在晚期NSCLC中的治疗进展做一综述。'}]}\n",
      "{'disease': {'id': 'EFO_0000571', 'name': 'lung adenocarcinoma'},\n",
      " 'literature': ['34417435'],\n",
      " 'resourceScore': 47,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 291,\n",
      "                          'dStart': 272,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 230,\n",
      "                          'tStart': 226,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 291,\n",
      "                          'dStart': 272,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 297,\n",
      "                          'dStart': 293,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 230,\n",
      "                          'tStart': 226,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 297,\n",
      "                          'dStart': 293,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 240,\n",
      "                          'tStart': 235,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 65,\n",
      "                          'dStart': 61,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 9,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Both PD-1 and PD-L1 were positively '\n",
      "                                  'correlated with CD226 in LUAD, LUSC, TNBC '\n",
      "                                  'and COAD (Supplementary Fig. 5b–i).'},\n",
      "                         {'dEnd': 291,\n",
      "                          'dStart': 272,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 240,\n",
      "                          'tStart': 235,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 297,\n",
      "                          'dStart': 293,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 297,\n",
      "                          'dStart': 293,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 43,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 49,\n",
      "                          'tStart': 45,\n",
      "                          'text': 'CD226 expression is not only associated '\n",
      "                                  'with PD-1/PD-L1 in CRC, but also in '\n",
      "                                  'triple-negative breast cancer, lung '\n",
      "                                  'adenocarcinoma and lung carcinoma suggested '\n",
      "                                  'by TCGA.'},\n",
      "                         {'dEnd': 291,\n",
      "                          'dStart': 272,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Since expression of the immune checkpoints '\n",
      "                                  'PD-1 and PD-L1 is correlated with '\n",
      "                                  'infiltrating immune cells and Bcl9 '\n",
      "                                  'depletion is synergistic with anti-PD-1 '\n",
      "                                  'treatment in mouse tumor models, we studied '\n",
      "                                  'the relationship among CD226, PD-1 (or '\n",
      "                                  'PDCD1), and PD-L1 (or CD274) in CRC, lung '\n",
      "                                  'adenocarcinoma (LUAD), lung squamous cell '\n",
      "                                  'carcinoma (LUSC) and triple-negative breast '\n",
      "                                  'cancer (TNBC).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39706602'],\n",
      " 'resourceScore': 47,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Anti-programmed cell death 1 (PD-1) '\n",
      "                                  'antibody combined with chemotherapy '\n",
      "                                  'simultaneously is regarded as the standard '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'current clinical guidelines.'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 151,\n",
      "                          'tStart': 147,\n",
      "                          'text': 'Thus, our in vivo study verified the '\n",
      "                                  'results observed in patients with NSCLC and '\n",
      "                                  'demonstrated that D3 was the optimal immune '\n",
      "                                  'status for chemo-anti-PD-1 combination '\n",
      "                                  'therapy.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-programmed cell death 1 (PD-1) '\n",
      "                                  'antibody combined with chemotherapy '\n",
      "                                  'simultaneously is regarded as the standard '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'current clinical guidelines.'},\n",
      "                         {'dEnd': 42,\n",
      "                          'dStart': 37,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'Based on the clinical guidelines for NSCLC, '\n",
      "                                  'chemotherapy combined with anti-PD-1 '\n",
      "                                  'antibodies has been widely applied in '\n",
      "                                  'current clinical practice.3 6 '\n",
      "                                  'Unfortunately, there is still no thorough '\n",
      "                                  'research on diverse combinations of '\n",
      "                                  'chemotherapy and anti-PD-1 antibodies.'},\n",
      "                         {'dEnd': 128,\n",
      "                          'dStart': 123,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 163,\n",
      "                          'tStart': 159,\n",
      "                          'text': 'Overall, these data indicate that D3 after '\n",
      "                                  'chemotherapy is the time frame with the '\n",
      "                                  'optimal immune status for patients with '\n",
      "                                  'NSCLC who benefited from chemo-anti-PD-1 '\n",
      "                                  'combination therapy.'},\n",
      "                         {'dEnd': 101,\n",
      "                          'dStart': 96,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Optimal timing of anti-PD-1 antibody '\n",
      "                                  'combined with chemotherapy administration '\n",
      "                                  'in patients with NSCLC'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'Furthermore, exploring the optimal '\n",
      "                                  'combination timing of '\n",
      "                                  'chemotherapy-anti-PD-1 may be conducive to '\n",
      "                                  'improving the clinical outcomes of patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 53,\n",
      "                          'dStart': 27,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'For patients with advanced non-small cell '\n",
      "                                  'lung cancer (NSCLC) without sensitive gene '\n",
      "                                  'mutations, platinum-based chemotherapy '\n",
      "                                  'combined with anti-PD-1 antibody has been '\n",
      "                                  'recommended as the first-line treatment '\n",
      "                                  'according to the National Comprehensive '\n",
      "                                  'Cancer Network guidelines.3'},\n",
      "                         {'dEnd': 240,\n",
      "                          'dStart': 235,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 26,\n",
      "                          'tStart': 22,\n",
      "                          'text': 'The proportion of CD8+PD-1+ T cells in the '\n",
      "                                  'spleen and tumor tissues peaked on D3 and '\n",
      "                                  'then gradually decreased, whereas the '\n",
      "                                  'expression of PD-L1 on MDSC showed the '\n",
      "                                  'opposite trend (figure 1J,K), which was '\n",
      "                                  'consistent with the patient with NSCLC '\n",
      "                                  'results.'},\n",
      "                         {'dEnd': 96,\n",
      "                          'dStart': 91,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 43,\n",
      "                          'tStart': 39,\n",
      "                          'text': 'To determine the best response to anti-PD-1 '\n",
      "                                  'antibody, we collected PBMC from patients '\n",
      "                                  'with NSCLC before and after chemotherapy '\n",
      "                                  'and treated them with anti-PD-1 antibody at '\n",
      "                                  'different time points (D0, D1, D2, D3, D5, '\n",
      "                                  'and D7).'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 5,\n",
      "                          'text': 'Anti-programmed cell death 1 (PD-1) '\n",
      "                                  'antibody combined with chemotherapy '\n",
      "                                  'simultaneously is regarded as the standard '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'current clinical guidelines.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'In studies of anti-PD-1 antibody treatment '\n",
      "                                  'for patients with melanoma and NSCLC, the '\n",
      "                                  'expansion of T-cell clones consisted of '\n",
      "                                  'novel clonotypes that had not previously '\n",
      "                                  'been observed in the same tumor and further '\n",
      "                                  'confirmed most of the new clonotypes in the '\n",
      "                                  'post-treatment blood.11 45 We speculate '\n",
      "                                  'that this was due to the efficient '\n",
      "                                  'expansion of nascent clones in TCM-like '\n",
      "                                  'cells.46'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 34,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Anti-programmed cell death 1 (PD-1) '\n",
      "                                  'antibody combined with chemotherapy '\n",
      "                                  'simultaneously is regarded as the standard '\n",
      "                                  'treatment for patients with advanced '\n",
      "                                  'non-small cell lung cancer (NSCLC) by '\n",
      "                                  'current clinical guidelines.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32111241'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 197,\n",
      "                          'dStart': 192,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'We retrieved many known factors for '\n",
      "                                  'regulating T cell exhaustion among the '\n",
      "                                  'differentially expressed genes between '\n",
      "                                  'PDCD1-high and PDCD1-low subsets of the TI '\n",
      "                                  'CD8+ T cells in human melanoma and NSCLC.'},\n",
      "                         {'dEnd': 55,\n",
      "                          'dStart': 50,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 98,\n",
      "                          'text': 'The single-cell transcriptome profile '\n",
      "                                  'analysis of NSCLC samples revealed that the '\n",
      "                                  'IC genes in the PDCD1-high subset were '\n",
      "                                  'upregulated.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 76,\n",
      "                          'text': 'We observed that the TFs are differentially '\n",
      "                                  'expressed in the PDCD1-high and PDCD1-low '\n",
      "                                  'subsets among the melanoma or NSCLC samples '\n",
      "                                  '(Fig. 1d).'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 53,\n",
      "                          'tStart': 48,\n",
      "                          'text': 'The distribution patterns of TOX-high cells '\n",
      "                                  'and PDCD1-high cells were similar in the '\n",
      "                                  'latent space of the tSNE plot for both '\n",
      "                                  'melanoma and NSCLC, which were similar to '\n",
      "                                  'the distribution patterns of IC genes (see '\n",
      "                                  'Fig. 1b, c).'},\n",
      "                         {'dEnd': 222,\n",
      "                          'dStart': 217,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'Interestingly, the TOX expression level in '\n",
      "                                  'the TI T cells was inversely correlated '\n",
      "                                  'with the anti-PD-1 immunotherapy response '\n",
      "                                  'in two published cohorts of patients with '\n",
      "                                  'cancer, i.e., melanoma cohorts [19] (Fig. '\n",
      "                                  '5e) and NSCLC cohorts [21] (Fig. 5f).'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 105,\n",
      "                          'tStart': 101,\n",
      "                          'text': 'We also observe that TOX level in the TI T '\n",
      "                                  'cells inversely correlates with overall '\n",
      "                                  'survival and anti-PD-1 response in human '\n",
      "                                  'melanoma and NSCLC, which suggest that TOX '\n",
      "                                  'expression in the TI T cells can be used '\n",
      "                                  'for patient stratification before '\n",
      "                                  'anti-tumor immunotherapy, such as anti-PD-1 '\n",
      "                                  'treatment.'},\n",
      "                         {'dEnd': 197,\n",
      "                          'dStart': 192,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 129,\n",
      "                          'text': 'We retrieved many known factors for '\n",
      "                                  'regulating T cell exhaustion among the '\n",
      "                                  'differentially expressed genes between '\n",
      "                                  'PDCD1-high and PDCD1-low subsets of the TI '\n",
      "                                  'CD8+ T cells in human melanoma and NSCLC.'},\n",
      "                         {'dEnd': 113,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'The expression levels of other TFs did not '\n",
      "                                  'correlate with PD-1 expression in the TI '\n",
      "                                  'CD8+ T cells from human NSCLC tumors '\n",
      "                                  '(Additional file 2: Figure S1C).'},\n",
      "                         {'dEnd': 152,\n",
      "                          'dStart': 147,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 116,\n",
      "                          'tStart': 112,\n",
      "                          'text': 'Finally, the expression levels of TOX in '\n",
      "                                  'the TI T cells could predict the overall '\n",
      "                                  'survival and response to anti-PD-1 therapy '\n",
      "                                  'in human melanoma and NSCLC.'},\n",
      "                         {'dEnd': 121,\n",
      "                          'dStart': 116,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'We observed that the TFs are differentially '\n",
      "                                  'expressed in the PDCD1-high and PDCD1-low '\n",
      "                                  'subsets among the melanoma or NSCLC samples '\n",
      "                                  '(Fig. 1d).'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Finally, the TOX level in the TI T cells '\n",
      "                                  'was found to be highly predictive of '\n",
      "                                  'overall survival and anti-PD-1 efficacy in '\n",
      "                                  'melanoma and NSCLC.'},\n",
      "                         {'dEnd': 181,\n",
      "                          'dStart': 176,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 98,\n",
      "                          'tStart': 94,\n",
      "                          'text': 'TOX expression was positively correlated '\n",
      "                                  'with the expression of various IC '\n",
      "                                  'molecules, such as PD-1, TIM-3, and '\n",
      "                                  'TIGIT—at protein level—in the TI CD8+ T '\n",
      "                                  'cells isolated from both NSCLC and HNSCC '\n",
      "                                  'tumor tissues (Fig. 3a).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32773010'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 125,\n",
      "                          'dStart': 120,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 287,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 184,\n",
      "                          'tStart': 180,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗NSCLC脑转移'},\n",
      "                         {'dEnd': 73,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 158,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 20,\n",
      "                          'dStart': 15,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂治疗NSCLC脑转移的免疫机制与临床研究进展'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 113,\n",
      "                          'tStart': 109,\n",
      "                          'text': 'Nivolumab、Pembrolizumab及Atezolizumab在晚期NSCLC的二线及一线治疗中开展了多项大型、III期随机对照研究,旨在比较免疫单药/联合化疗与标准化疗之间的疗效与不良反应。多项研究结果证明PD-1/PD-L1抑制剂与标准化疗相比具有明显的优效性及良好的耐受性,从而奠定了PD-1/PD-L1抑制剂在晚期NSCLC中的一线/二线标准治疗的地位。这些III期随机对照临床研究中有部分研究允许无症状或经治且稳定的脑转移患者入组,我们将对其中的脑转移亚组进行具体的阐述与分析。'},\n",
      "                         {'dEnd': 51,\n",
      "                          'dStart': 46,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 32,\n",
      "                          'tStart': 28,\n",
      "                          'text': '此外,Hendriks等[33]收集了1, '\n",
      "                                  '025例接受PD-1/PD-L1抑制剂治疗的晚期NSCLC患者,其中脑转移患者255例(39.2%为活动性脑转移患者,27.4%接受皮质类固醇治疗)。伴脑转移患者较不伴脑转移患者的中位OS和PFS较短(8.6个月vs '\n",
      "                                  '11.4个月,P=0.035;1.7个月vs '\n",
      "                                  '2.1个月,P=0.009)。活动性脑转移患者iORR为27.3%,比稳定性脑转移更易发生颅内疾病进展(progressive '\n",
      "                                  'disease, PD)(54.2% vs 30%, P < '\n",
      "                                  '0.001)。在脑转移亚组的多变量分析中,使用皮质类固醇与较差的生存预后有关(HR=2.37),而稳定的脑转移(HR=0.62)和更高的疾病相关性预后分级(diagnosis-specific '\n",
      "                                  'graded prognostic assessment, '\n",
      "                                  'ds-GPA)(HR=0.48-0.52)有较好的生存获益。'},\n",
      "                         {'dEnd': 26,\n",
      "                          'dStart': 18,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': '脑转移是非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)的常见并发症,预后较差。近年来,免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元。程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, '\n",
      "                                  'PD-L1)抑制剂通过激活自身免疫系统,产生抗肿瘤效应。PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒,但其确切疗效及最佳治疗模式仍有待进一步研究。本文针对NSCLC脑转移灶的免疫微环境,PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': '免疫治疗是肿瘤治疗的“变革者”,以程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, PD-L1)抑制剂为代表的免疫检查点抑制剂(immune '\n",
      "                                  'checkpoint inhibitors, '\n",
      "                                  'ICIs)在晚期NSCLC开展了一系列III期随机对照研究,显示出惊人疗效。晚期NSCLC患者的5年生存率由化疗时代的5%提高至16%-23%[6]。一些小样本的回顾性研究和真实世界研究[7, '\n",
      "                                  '8]显示,ICIs对颅内转移灶也能表现出良好的抗肿瘤活性。本文就脑转移灶的免疫微环境、ICIs对颅内转移灶的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 247,\n",
      "                          'dStart': 242,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 190,\n",
      "                          'tStart': 186,\n",
      "                          'text': '脑转移是非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)的常见并发症,预后较差。近年来,免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元。程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, '\n",
      "                                  'PD-L1)抑制剂通过激活自身免疫系统,产生抗肿瘤效应。PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒,但其确切疗效及最佳治疗模式仍有待进一步研究。本文针对NSCLC脑转移灶的免疫微环境,PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 8,\n",
      "                          'dStart': 0,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 205,\n",
      "                          'dStart': 200,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': '脑转移是非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)的常见并发症,预后较差。近年来,免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元。程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, '\n",
      "                                  'PD-L1)抑制剂通过激活自身免疫系统,产生抗肿瘤效应。PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒,但其确切疗效及最佳治疗模式仍有待进一步研究。本文针对NSCLC脑转移灶的免疫微环境,PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 459,\n",
      "                          'dStart': 451,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 440,\n",
      "                          'tStart': 436,\n",
      "                          'text': 'FIR研究[30]是一项旨在评估Atezolizumab治疗晚期NSCLC患者疗效和安全性的II期临床研究,该研究中一个队列纳入了13例经治的无症状NSCLC脑转移患者,应用Atezolizumab治疗的客观缓解率(objective '\n",
      "                                  'response rate, ORR)为23%,中位OS为6.8个月(95%CI: '\n",
      "                                  '3.2-19.5),中位无进展生存期(progression free '\n",
      "                                  'survival, PFS)为4.3个月(95%CI: '\n",
      "                                  '1.1-16.2)。CheckMate-012研究[8]是一项I期多队列研究,其中一个队列纳入了12例初治的无症状NSCLC脑转移患者,接受单药Nivolumab治疗的ORR为16.7%,疾病控制率(disease '\n",
      "                                  'control rate, DCR)为16.7%,中位OS为8.0个月(95%CI: '\n",
      "                                  '1.38-15.50),中位PFS为1.6个月(95%CI: '\n",
      "                                  '0.92-2.50)。从这些小样本、前瞻性研究中可以观察到,PD-1/PD-L1抑制剂治疗NSCLC脑转移患者,颅内病灶的近期疗效与颅外病灶类似,但PFS及OS似乎较短,这种现象是因为小样本研究的偏差还是其他可能,值得进一步研究观察。'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗NSCLC脑转移的疗效一直是大家关心的问题,因为单药能够直观地观察到药物的疗效。在上述大型III期随机对照研究中,脑转移入组病例数相对较多的有OAK研究。OAK研究[7]共纳入850例经治晚期NSCLC患者,其中Atezolizumab组和多西他赛组分别纳入61例和62例无症状小脑幕上转移的NSCLC脑转移患者。研究结果显示,Atezolizumab组和多西他赛组脑转移患者的中位OS分别为16.0个月和11.9个月(HR=0.74, '\n",
      "                                  '95%CI: 0.49-1.13, P=0.163, '\n",
      "                                  '3);脑转移患者出现脑部新发转移灶的中位时间,Atezolizumab组未达到,多西他赛组为9.5个月(HR=0.38, '\n",
      "                                  '95%CI: 0.16-0.91, P=0.023, '\n",
      "                                  '9)。在安全性方面,使用Atezolizumab治疗的脑转移患者仅2例(3%)出现3级神经相关的不良事件(adverse '\n",
      "                                  'event, '\n",
      "                                  'AE),未观察到4级/5级神经相关AE。尽管在脑转移亚组,Atezolizumab组相比多西他赛组的中位OS未达到统计学差异,但对颅内新发病灶有一定的预防作用; '\n",
      "                                  'Atezolizumab在脑转移患者的治疗中安全性可控。'},\n",
      "                         {'dEnd': 22,\n",
      "                          'dStart': 17,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗NSCLC脑转移的疗效一直是大家关心的问题,因为单药能够直观地观察到药物的疗效。在上述大型III期随机对照研究中,脑转移入组病例数相对较多的有OAK研究。OAK研究[7]共纳入850例经治晚期NSCLC患者,其中Atezolizumab组和多西他赛组分别纳入61例和62例无症状小脑幕上转移的NSCLC脑转移患者。研究结果显示,Atezolizumab组和多西他赛组脑转移患者的中位OS分别为16.0个月和11.9个月(HR=0.74, '\n",
      "                                  '95%CI: 0.49-1.13, P=0.163, '\n",
      "                                  '3);脑转移患者出现脑部新发转移灶的中位时间,Atezolizumab组未达到,多西他赛组为9.5个月(HR=0.38, '\n",
      "                                  '95%CI: 0.16-0.91, P=0.023, '\n",
      "                                  '9)。在安全性方面,使用Atezolizumab治疗的脑转移患者仅2例(3%)出现3级神经相关的不良事件(adverse '\n",
      "                                  'event, '\n",
      "                                  'AE),未观察到4级/5级神经相关AE。尽管在脑转移亚组,Atezolizumab组相比多西他赛组的中位OS未达到统计学差异,但对颅内新发病灶有一定的预防作用; '\n",
      "                                  'Atezolizumab在脑转移患者的治疗中安全性可控。'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 166,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 154,\n",
      "                          'tStart': 150,\n",
      "                          'text': 'Nivolumab、Pembrolizumab及Atezolizumab在晚期NSCLC的二线及一线治疗中开展了多项大型、III期随机对照研究,旨在比较免疫单药/联合化疗与标准化疗之间的疗效与不良反应。多项研究结果证明PD-1/PD-L1抑制剂与标准化疗相比具有明显的优效性及良好的耐受性,从而奠定了PD-1/PD-L1抑制剂在晚期NSCLC中的一线/二线标准治疗的地位。这些III期随机对照临床研究中有部分研究允许无症状或经治且稳定的脑转移患者入组,我们将对其中的脑转移亚组进行具体的阐述与分析。'},\n",
      "                         {'dEnd': 287,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 263,\n",
      "                          'tStart': 259,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 19,\n",
      "                          'dStart': 14,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 128,\n",
      "                          'tStart': 124,\n",
      "                          'text': '这两项数据基本说明了目前晚期NSCLC大型临床研究中有关脑转移亚组的情况,由于这些研究对脑转移的入组有非常严格的限制,入组的脑转移患者数量十分有限,且都是颅内肿瘤负荷较小的稳定脑转移患者,并不能很好地代表NSCLC脑转移的整体人群,所以无法完整反映PD-1/PD-L1抑制剂治疗脑转移人群的疗效,但基本可以观察到PD-1/PD-L1抑制剂对脑转移的疗效。'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': '综上所述不难发现,有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的临床数据仍然非常粗糙和有限。尽管我们引用了不少PD-1/PD-L1抑制剂治疗NSCLC的大型随机对照研究的脑转移亚组数据,但是,这些研究对脑转移患者的入组有着非常严格的限制; '\n",
      "                                  '均排除了活动性或有症状的脑转移患者及所有的脑膜转移患者; '\n",
      "                                  '有的研究要求脑部病灶必须经过脑部放疗且病灶稳定。显而易见,这些入组的脑转移患者与真实世界的脑转移人群存在较大的差距。其次,在这些临床研究中最终能够成功入组的脑转移患者数量非常少,这在很大程度上影响了统计的效能,导致尽管可以观察到研究组有较好的OS延长,但两组最终并没有差异。再者,到目前为止,最有指导价值的前瞻性的临床研究仍然非常缺乏,哪怕是样本量稍大一点的单臂II期研究。'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 114,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 247,\n",
      "                          'dStart': 242,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': '脑转移是非小细胞肺癌(non-small cell lung cancer, '\n",
      "                                  'NSCLC)的常见并发症,预后较差。近年来,免疫检查点抑制剂将恶性肿瘤的治疗带入新纪元。程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, '\n",
      "                                  'PD-L1)抑制剂通过激活自身免疫系统,产生抗肿瘤效应。PD-1/PD-L1抑制剂在NSCLC脑转移治疗中初露锋芒,但其确切疗效及最佳治疗模式仍有待进一步研究。本文针对NSCLC脑转移灶的免疫微环境,PD-1/PD-L1抑制剂在颅内的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': '综上所述不难发现,有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的临床数据仍然非常粗糙和有限。尽管我们引用了不少PD-1/PD-L1抑制剂治疗NSCLC的大型随机对照研究的脑转移亚组数据,但是,这些研究对脑转移患者的入组有着非常严格的限制; '\n",
      "                                  '均排除了活动性或有症状的脑转移患者及所有的脑膜转移患者; '\n",
      "                                  '有的研究要求脑部病灶必须经过脑部放疗且病灶稳定。显而易见,这些入组的脑转移患者与真实世界的脑转移人群存在较大的差距。其次,在这些临床研究中最终能够成功入组的脑转移患者数量非常少,这在很大程度上影响了统计的效能,导致尽管可以观察到研究组有较好的OS延长,但两组最终并没有差异。再者,到目前为止,最有指导价值的前瞻性的临床研究仍然非常缺乏,哪怕是样本量稍大一点的单臂II期研究。'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'NSCLC脑转移在临床症状、影像表现、疾病进程及治疗方案的选择上均存在明显的异质性。到目前为止,尚无PD-1/PD-L1抑制剂针对NSCLC脑转移患者开展的前瞻性III期随机对照研究。目前报道的有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效数据主要来自3个方面:1针对晚期NSCLC的大型III期随机对照研究中的脑转移亚组分析; '\n",
      "                                  '2针对脑转移开展的前瞻性、小样本的单臂研究; 3真实世界的临床研究数据。'},\n",
      "                         {'dEnd': 287,\n",
      "                          'dStart': 279,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗在NSCLC脑转移患者中已经初步观察到疗效,但这种治疗手段是否适合所有的脑转移人群,需要进一步研究; '\n",
      "                                  '因为,已经有研究提示似乎活动性脑转移患者并不能从单纯的免疫治疗中获益。免疫联合化疗及抗血管生成治疗是晚期NSCLC的标准治疗,在脑转移人群亦有较好的疗效数据。放疗在NSCLC脑转移的治疗中占据有非常重要的地位; '\n",
      "                                  '因此,如何将PD-1/PD-L1抑制剂与放疗、化疗及抗血管生成治疗进行有机结合,是未来的研究关键。进一步探索脑转移病灶的免疫微环境,研究预测疗效的相关生物标记物,将有助于PD-1/PD-L1抑制剂更加有效地用于NSCLC脑转移患者的治疗。'},\n",
      "                         {'dEnd': 31,\n",
      "                          'dStart': 26,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 15,\n",
      "                          'tStart': 11,\n",
      "                          'text': '综上所述不难发现,有关PD-1/PD-L1抑制剂治疗NSCLC脑转移的临床数据仍然非常粗糙和有限。尽管我们引用了不少PD-1/PD-L1抑制剂治疗NSCLC的大型随机对照研究的脑转移亚组数据,但是,这些研究对脑转移患者的入组有着非常严格的限制; '\n",
      "                                  '均排除了活动性或有症状的脑转移患者及所有的脑膜转移患者; '\n",
      "                                  '有的研究要求脑部病灶必须经过脑部放疗且病灶稳定。显而易见,这些入组的脑转移患者与真实世界的脑转移人群存在较大的差距。其次,在这些临床研究中最终能够成功入组的脑转移患者数量非常少,这在很大程度上影响了统计的效能,导致尽管可以观察到研究组有较好的OS延长,但两组最终并没有差异。再者,到目前为止,最有指导价值的前瞻性的临床研究仍然非常缺乏,哪怕是样本量稍大一点的单臂II期研究。'},\n",
      "                         {'dEnd': 171,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂单药治疗NSCLC脑转移的疗效一直是大家关心的问题,因为单药能够直观地观察到药物的疗效。在上述大型III期随机对照研究中,脑转移入组病例数相对较多的有OAK研究。OAK研究[7]共纳入850例经治晚期NSCLC患者,其中Atezolizumab组和多西他赛组分别纳入61例和62例无症状小脑幕上转移的NSCLC脑转移患者。研究结果显示,Atezolizumab组和多西他赛组脑转移患者的中位OS分别为16.0个月和11.9个月(HR=0.74, '\n",
      "                                  '95%CI: 0.49-1.13, P=0.163, '\n",
      "                                  '3);脑转移患者出现脑部新发转移灶的中位时间,Atezolizumab组未达到,多西他赛组为9.5个月(HR=0.38, '\n",
      "                                  '95%CI: 0.16-0.91, P=0.023, '\n",
      "                                  '9)。在安全性方面,使用Atezolizumab治疗的脑转移患者仅2例(3%)出现3级神经相关的不良事件(adverse '\n",
      "                                  'event, '\n",
      "                                  'AE),未观察到4级/5级神经相关AE。尽管在脑转移亚组,Atezolizumab组相比多西他赛组的中位OS未达到统计学差异,但对颅内新发病灶有一定的预防作用; '\n",
      "                                  'Atezolizumab在脑转移患者的治疗中安全性可控。'},\n",
      "                         {'dEnd': 35,\n",
      "                          'dStart': 30,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 20,\n",
      "                          'tStart': 16,\n",
      "                          'text': '这些回顾性研究在很大程度上肯定了PD-1/PD-L1抑制剂在NSCLC脑转移患者中的治疗作用,但由于回顾性研究本身的局限性,并不能全面回答PD-1/PD-L1抑制剂在脑转移治疗中的一些关键问题,例如确切的疗效、真正获益的人群、最佳的治疗时机及治疗方案等。'},\n",
      "                         {'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 51,\n",
      "                          'tStart': 47,\n",
      "                          'text': '免疫治疗是肿瘤治疗的“变革者”,以程序性死亡因子-1(programmed '\n",
      "                                  'death-1, PD-1)/程序性死亡因子配体-1(programmed death '\n",
      "                                  'ligand 1, PD-L1)抑制剂为代表的免疫检查点抑制剂(immune '\n",
      "                                  'checkpoint inhibitors, '\n",
      "                                  'ICIs)在晚期NSCLC开展了一系列III期随机对照研究,显示出惊人疗效。晚期NSCLC患者的5年生存率由化疗时代的5%提高至16%-23%[6]。一些小样本的回顾性研究和真实世界研究[7, '\n",
      "                                  '8]显示,ICIs对颅内转移灶也能表现出良好的抗肿瘤活性。本文就脑转移灶的免疫微环境、ICIs对颅内转移灶的作用机制及其临床研究现状进行综述。'},\n",
      "                         {'dEnd': 20,\n",
      "                          'dStart': 15,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 4,\n",
      "                          'tStart': 0,\n",
      "                          'text': 'PD-1/PD-L1抑制剂治疗NSCLC脑转移的疗效'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38514660'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Moreover, the density of TCF1+PD1+CD8+ T '\n",
      "                                  'cells, but not TIM3+PD1+CD8+ T cells, '\n",
      "                                  'significantly correlated with the number of '\n",
      "                                  'mTLSs in both NSCLC and HGSOC samples (Fig. '\n",
      "                                  '3J).'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'Furthermore, although the frequency of '\n",
      "                                  'TIM3+PD1+CD8+ T cells was comparable in '\n",
      "                                  'HGSOC and NSCLC samples (Fig. 3G), PD1+CD8+ '\n",
      "                                  'T cells in NSCLC samples were '\n",
      "                                  'preferentially polarized toward a TCF1+PD1+ '\n",
      "                                  'T cell phenotype with effector functions '\n",
      "                                  '(in both the TME as a whole and TLS areas) '\n",
      "                                  'as compared to HGSOC samples (Fig. 3G–I).'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 120,\n",
      "                          'text': 'On the other hand, our data linking the '\n",
      "                                  'HGSOC (but not the NSCLC) environment to a '\n",
      "                                  'predominance of ICI-insensitive '\n",
      "                                  'TIM3+PD1+CD8+ T cells phenotype over '\n",
      "                                  '(ICI-sensitive) TCF1+PD1+CD8+ T '\n",
      "                                  'cells52,53,65–67 suggest that – at odds '\n",
      "                                  'with NSCLC – the sparcity and limited '\n",
      "                                  'maturation of TLSs in HGSOC fail to '\n",
      "                                  'preserve an ICI-sensitive TCF1+PD1+CD8+ T '\n",
      "                                  'cell compartment, rather allowing for the '\n",
      "                                  'acquisition of a TIM3+PD1+ phenotype that '\n",
      "                                  'has been associated with ICI resistance '\n",
      "                                  '(Fig. 3).'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'In this setting, B-cell depletion decreased '\n",
      "                                  'the percentage of TIM3-PD1+CD8+ T cells '\n",
      "                                  'while increasing the abundance of '\n",
      "                                  'TIM3+PD1+CD8+ T cells from both HGSOC and '\n",
      "                                  'NSCLC samples (Fig. 4H, I).'},\n",
      "                         {'dEnd': 94,\n",
      "                          'dStart': 89,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 47,\n",
      "                          'tStart': 44,\n",
      "                          'text': 'Furthermore, although the frequency of '\n",
      "                                  'TIM3+PD1+CD8+ T cells was comparable in '\n",
      "                                  'HGSOC and NSCLC samples (Fig. 3G), PD1+CD8+ '\n",
      "                                  'T cells in NSCLC samples were '\n",
      "                                  'preferentially polarized toward a TCF1+PD1+ '\n",
      "                                  'T cell phenotype with effector functions '\n",
      "                                  '(in both the TME as a whole and TLS areas) '\n",
      "                                  'as compared to HGSOC samples (Fig. 3G–I).'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Moreover, the density of TCF1+PD1+CD8+ T '\n",
      "                                  'cells, but not TIM3+PD1+CD8+ T cells, '\n",
      "                                  'significantly correlated with the number of '\n",
      "                                  'mTLSs in both NSCLC and HGSOC samples (Fig. '\n",
      "                                  '3J).'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 188,\n",
      "                          'text': 'As enhanced TFH cell differentiation in a '\n",
      "                                  'TMBHigh mouse cancer model has been shown '\n",
      "                                  'to induce larger TLSs and superior B-cell '\n",
      "                                  'recruitment37,56, we next determined the '\n",
      "                                  'density of CD4+CXCR5+PD1+FoxP3− TFH cells '\n",
      "                                  'in HGSOC and NSCLC samples using multiplex '\n",
      "                                  'immunofluorescence (panel 3) (Fig. 4A).'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 109,\n",
      "                          'tStart': 106,\n",
      "                          'text': 'We also demonstrated that TLS-associated B '\n",
      "                                  'cells are important for the preservation of '\n",
      "                                  'ICI-sensitive TCF1+PD1+CD8+ T cells in '\n",
      "                                  'HGSOC and NSCLC, and that their '\n",
      "                                  'interactions with CD8+ T cells favorably '\n",
      "                                  'influence disease outcome.'},\n",
      "                         {'dEnd': 165,\n",
      "                          'dStart': 160,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 126,\n",
      "                          'tStart': 123,\n",
      "                          'text': 'In this setting, B-cell depletion decreased '\n",
      "                                  'the percentage of TIM3-PD1+CD8+ T cells '\n",
      "                                  'while increasing the abundance of '\n",
      "                                  'TIM3+PD1+CD8+ T cells from both HGSOC and '\n",
      "                                  'NSCLC samples (Fig. 4H, I).'},\n",
      "                         {'dEnd': 139,\n",
      "                          'dStart': 134,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 114,\n",
      "                          'text': 'Furthermore, although the frequency of '\n",
      "                                  'TIM3+PD1+CD8+ T cells was comparable in '\n",
      "                                  'HGSOC and NSCLC samples (Fig. 3G), PD1+CD8+ '\n",
      "                                  'T cells in NSCLC samples were '\n",
      "                                  'preferentially polarized toward a TCF1+PD1+ '\n",
      "                                  'T cell phenotype with effector functions '\n",
      "                                  '(in both the TME as a whole and TLS areas) '\n",
      "                                  'as compared to HGSOC samples (Fig. 3G–I).'},\n",
      "                         {'dEnd': 234,\n",
      "                          'dStart': 229,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 176,\n",
      "                          'tStart': 173,\n",
      "                          'text': 'On the other hand, our data linking the '\n",
      "                                  'HGSOC (but not the NSCLC) environment to a '\n",
      "                                  'predominance of ICI-insensitive '\n",
      "                                  'TIM3+PD1+CD8+ T cells phenotype over '\n",
      "                                  '(ICI-sensitive) TCF1+PD1+CD8+ T '\n",
      "                                  'cells52,53,65–67 suggest that – at odds '\n",
      "                                  'with NSCLC – the sparcity and limited '\n",
      "                                  'maturation of TLSs in HGSOC fail to '\n",
      "                                  'preserve an ICI-sensitive TCF1+PD1+CD8+ T '\n",
      "                                  'cell compartment, rather allowing for the '\n",
      "                                  'acquisition of a TIM3+PD1+ phenotype that '\n",
      "                                  'has been associated with ICI resistance '\n",
      "                                  '(Fig. 3).'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['29254184'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 87,\n",
      "                          'dStart': 82,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1/PD-L1 therapy has been '\n",
      "                                  'demonstrated effective and safe for '\n",
      "                                  'advanced NSCLC patients, especially for '\n",
      "                                  'EGFR-TKIs (epidermal growth factor receptor '\n",
      "                                  '- tyrosine kinase inhibitors) resistant '\n",
      "                                  'NSCLC (non-small cell lung cancer) patients '\n",
      "                                  'with EGFR mutations.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 148,\n",
      "                          'tStart': 145,\n",
      "                          'text': 'To further confirm that the NSCLC cells '\n",
      "                                  'with T790M EGFR mutation would have '\n",
      "                                  'increased level of PD-L1 promoter '\n",
      "                                  'methylation when subjected to anti-PD1 '\n",
      "                                  'treatment, the NSCLC cell line SK-MES-1 '\n",
      "                                  'with wild type of EGFR was used for '\n",
      "                                  'establishing cell lines with EGFR mutations '\n",
      "                                  '(L858R and T790M) via target genome editing '\n",
      "                                  'technology.'},\n",
      "                         {'dEnd': 89,\n",
      "                          'dStart': 84,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 72,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'PD-L1 promoter methylation mediates the '\n",
      "                                  'resistance response to anti-PD-1 therapy in '\n",
      "                                  'NSCLC patients with EGFR-TKI resistance'},\n",
      "                         {'dEnd': 61,\n",
      "                          'dStart': 56,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 96,\n",
      "                          'text': 'Promoter methylation analysis showed that '\n",
      "                                  'the secondary NSCLC after cancer recurrence '\n",
      "                                  'with anti-PD1 therapy had much higher '\n",
      "                                  'promoter methylation level than the primary '\n",
      "                                  'cancer tissue or normal tissues.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Thus anti-PD-1/PD-L1 antibodies could be an '\n",
      "                                  'optional therapy for advanced NSCLC '\n",
      "                                  'patients, especially for EGFR-TKIs '\n",
      "                                  'resistant NSCLC patients with EGFR mutation '\n",
      "                                  '[9, 13–15].'},\n",
      "                         {'dEnd': 155,\n",
      "                          'dStart': 150,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 130,\n",
      "                          'text': 'Thus, we conducted the present study to '\n",
      "                                  'investigate the expression dynamics of '\n",
      "                                  'PD-L1 after chemotherapy, EGFR-TKI therapy '\n",
      "                                  'or anti–PD-1 therapy in the NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 154,\n",
      "                          'dStart': 149,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'Antibodies blocking the PD-1 pathway, such '\n",
      "                                  'as Nivolumab, have recently been approved '\n",
      "                                  'by the FDA for treating several solid '\n",
      "                                  'tumors including advanced NSCLC [9].'},\n",
      "                         {'dEnd': 202,\n",
      "                          'dStart': 197,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1/PD-L1 therapy has been '\n",
      "                                  'demonstrated effective and safe for '\n",
      "                                  'advanced NSCLC patients, especially for '\n",
      "                                  'EGFR-TKIs (epidermal growth factor receptor '\n",
      "                                  '- tyrosine kinase inhibitors) resistant '\n",
      "                                  'NSCLC (non-small cell lung cancer) patients '\n",
      "                                  'with EGFR mutations.'},\n",
      "                         {'dEnd': 28,\n",
      "                          'dStart': 23,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 41,\n",
      "                          'tStart': 37,\n",
      "                          'text': 'Azacytidine sensitizes NSCLC to anti-PD-1 '\n",
      "                                  'therapy'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 139,\n",
      "                          'tStart': 135,\n",
      "                          'text': 'Taken together, these results suggest that '\n",
      "                                  'DNA hypomethylating agent AZA could '\n",
      "                                  'eliminate the PD-L1 promoter methylation '\n",
      "                                  'effect of anti-PD-1 therapy and sensitizes '\n",
      "                                  'NSCLC to the anti-PD-1 therapy.'},\n",
      "                         {'dEnd': 230,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'The anti-PD-1/PD-L1 therapy has been '\n",
      "                                  'demonstrated effective and safe for '\n",
      "                                  'advanced NSCLC patients, especially for '\n",
      "                                  'EGFR-TKIs (epidermal growth factor receptor '\n",
      "                                  '- tyrosine kinase inhibitors) resistant '\n",
      "                                  'NSCLC (non-small cell lung cancer) patients '\n",
      "                                  'with EGFR mutations.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 14,\n",
      "                          'tStart': 10,\n",
      "                          'text': 'Thus anti-PD-1/PD-L1 antibodies could be an '\n",
      "                                  'optional therapy for advanced NSCLC '\n",
      "                                  'patients, especially for EGFR-TKIs '\n",
      "                                  'resistant NSCLC patients with EGFR mutation '\n",
      "                                  '[9, 13–15].'},\n",
      "                         {'dEnd': 33,\n",
      "                          'dStart': 28,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 65,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'Reduction of PD-L1 level in NSCLC patients '\n",
      "                                  'resistant to anti-PD-1 therapy'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36439419'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 237,\n",
      "                          'dStart': 232,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Although PD-1 is mainly expressed on the '\n",
      "                                  'activated T cells, B cells, and monocytes, '\n",
      "                                  'recent studies have shown that PD-1 is '\n",
      "                                  'expressed in a subpopulation of various '\n",
      "                                  'cancer cells, including melanoma, '\n",
      "                                  'hepatocellular carcinoma (HCC) and NSCLC '\n",
      "                                  '(42).'},\n",
      "                         {'dEnd': 301,\n",
      "                          'dStart': 296,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Of note, anti-PD-1 therapy (pembrolizumab) '\n",
      "                                  'has recently replaced chemotherapy in the '\n",
      "                                  'first line treatment for NSCLC with high '\n",
      "                                  'PD-L1 expression, and the addition of '\n",
      "                                  'pembrolizumab to platinum chemotherapy '\n",
      "                                  'resulted in a significant improvement in '\n",
      "                                  'overall survival (OS) in patients with '\n",
      "                                  'non-squamous NSCLC, regardless of PD-L1 '\n",
      "                                  'expression.'},\n",
      "                         {'dEnd': 175,\n",
      "                          'dStart': 170,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'The introduction of the monoclonal '\n",
      "                                  'antibodies anti-PD-1 and anti-PD-L1 has '\n",
      "                                  'significantly changed the landscape of the '\n",
      "                                  'treatments for advanced non-small-cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 237,\n",
      "                          'dStart': 232,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 119,\n",
      "                          'tStart': 115,\n",
      "                          'text': 'Although PD-1 is mainly expressed on the '\n",
      "                                  'activated T cells, B cells, and monocytes, '\n",
      "                                  'recent studies have shown that PD-1 is '\n",
      "                                  'expressed in a subpopulation of various '\n",
      "                                  'cancer cells, including melanoma, '\n",
      "                                  'hepatocellular carcinoma (HCC) and NSCLC '\n",
      "                                  '(42).'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 142,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'The introduction of the monoclonal '\n",
      "                                  'antibodies anti-PD-1 and anti-PD-L1 has '\n",
      "                                  'significantly changed the landscape of the '\n",
      "                                  'treatments for advanced non-small-cell lung '\n",
      "                                  'cancer (NSCLC).'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'As pembrolizumab interacts with PD-1, we '\n",
      "                                  'hypothesised that blocking the '\n",
      "                                  'intracellular signalling could also affect '\n",
      "                                  'the cell proliferation of NSCLC cells, as '\n",
      "                                  'described by mean of the inhibition of the '\n",
      "                                  'canonical signalling pathways, i.e. the AKT '\n",
      "                                  'and ERK1/2 pathways (43).'},\n",
      "                         {'dEnd': 115,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 18,\n",
      "                          'tStart': 14,\n",
      "                          'text': 'Of note, anti-PD-1 therapy (pembrolizumab) '\n",
      "                                  'has recently replaced chemotherapy in the '\n",
      "                                  'first line treatment for NSCLC with high '\n",
      "                                  'PD-L1 expression, and the addition of '\n",
      "                                  'pembrolizumab to platinum chemotherapy '\n",
      "                                  'resulted in a significant improvement in '\n",
      "                                  'overall survival (OS) in patients with '\n",
      "                                  'non-squamous NSCLC, regardless of PD-L1 '\n",
      "                                  'expression.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['32944405'],\n",
      " 'resourceScore': 46,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 145,\n",
      "                          'dStart': 140,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Based on the above analysis and current '\n",
      "                                  'literature, anti-PD-1/PD-L1 blockade is '\n",
      "                                  'probably not applicable for EGFR-mutated '\n",
      "                                  'and ALK-rearranged NSCLC patients.'},\n",
      "                         {'dEnd': 199,\n",
      "                          'dStart': 194,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Recent clinical trials7–11 and real-world '\n",
      "                                  'data12–14 have shown that anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapy results in robust disease '\n",
      "                                  'control, long-term survival, and improved '\n",
      "                                  'quality of life in advanced NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 34,\n",
      "                          'dStart': 29,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Results: Based on East Asian NSCLC '\n",
      "                                  'patients, TIDE analyses revealed that for '\n",
      "                                  'anti-PD-1/PD-L1 immunotherapy, epidermal '\n",
      "                                  'growth factor receptor (EGFR)-mutant and '\n",
      "                                  'anaplastic lymphoma kinase (ALK)-rearranged '\n",
      "                                  'tumors yielded inferior responses; however, '\n",
      "                                  'although Kirsten rat sarcoma viral oncogene '\n",
      "                                  'homolog (KRAS)-mutant tumors responded '\n",
      "                                  'better, the difference was not '\n",
      "                                  'statistically significant (EGFR: P = 0.037; '\n",
      "                                  'ALK: P < 0.001; KRAS: P = 0.701).'},\n",
      "                         {'dEnd': 43,\n",
      "                          'dStart': 38,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'A total of 207 patients with advanced NSCLC '\n",
      "                                  'treated with anti-PD-1/PD-L1 monotherapy '\n",
      "                                  'were included in this analysis.'},\n",
      "                         {'dEnd': 106,\n",
      "                          'dStart': 101,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 147,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Additionally, at the time of survival '\n",
      "                                  'analysis, we investigated the DCB of '\n",
      "                                  'patients according to the NSCLC molecular '\n",
      "                                  'genotype after initiating PD-1/PD-L1 '\n",
      "                                  'blockade treatment.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 164,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 23,\n",
      "                          'tStart': 19,\n",
      "                          'text': 'Furthermore, using PD-1/PD-L1 inhibitors as '\n",
      "                                  'second- or third-line therapy improved the '\n",
      "                                  'overall survival (OS), when compared to '\n",
      "                                  'standard chemotherapy in KRAS-mutant NSCLC '\n",
      "                                  'patients5,8,9,17.'},\n",
      "                         {'dEnd': 169,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'Molecular heterogeneity of anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapy efficacy is correlated with '\n",
      "                                  'tumor immune microenvironment in East Asian '\n",
      "                                  'patients with non-small cell lung cancer'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 249,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 137,\n",
      "                          'tStart': 133,\n",
      "                          'text': 'Methods: We performed an integrated '\n",
      "                                  'analysis using publicly available data to '\n",
      "                                  'identify associations between '\n",
      "                                  'anti-programmed death 1 (PD-1)/ programmed '\n",
      "                                  'death-ligand 1 (PD-L1) immunotherapy '\n",
      "                                  'efficacy and classic driver oncogene '\n",
      "                                  'mutations in East Asian NSCLC patients.'},\n",
      "                         {'dEnd': 116,\n",
      "                          'dStart': 111,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 155,\n",
      "                          'tStart': 151,\n",
      "                          'text': 'In the present study, we characterized the '\n",
      "                                  'association between classic driver oncogene '\n",
      "                                  'mutations in East Asian NSCLC patients and '\n",
      "                                  'the efficacy of anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapy, in addition to tumor '\n",
      "                                  'immunity-associated features such as PD-L1 '\n",
      "                                  'expression, the presence of CD8+ TIL, and '\n",
      "                                  'the intratumoral immune cell composition.'},\n",
      "                         {'dEnd': 92,\n",
      "                          'dStart': 87,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'To assess the activity of PD-1/PD-L1 '\n",
      "                                  'inhibitors according to the molecular '\n",
      "                                  'genotype of NSCLC, we reanalyzed the '\n",
      "                                  'publicly available trial data (2018 MSKCC), '\n",
      "                                  'focusing on patients with EGFR, KRAS, and '\n",
      "                                  'ALK fusion mutations30.'},\n",
      "                         {'dEnd': 105,\n",
      "                          'dStart': 100,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 67,\n",
      "                          'tStart': 63,\n",
      "                          'text': 'Correlation between classic driver oncogene '\n",
      "                                  'mutations and anti-PD-1/PD-L1 immunotherapy '\n",
      "                                  'efficacy in NSCLC patients'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Thus, it is critical to investigate the '\n",
      "                                  'correlation between anti-PD-1/PD-L1 '\n",
      "                                  'immunotherapy efficacy and classic driver '\n",
      "                                  'oncogene mutations in East Asian NSCLC '\n",
      "                                  'patients.'},\n",
      "                         {'dEnd': 148,\n",
      "                          'dStart': 143,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'In this study, we evaluated the correlation '\n",
      "                                  'between anti-PD-1/PD-L1 immunotherapy '\n",
      "                                  'efficacy and classic driver oncogene '\n",
      "                                  'mutations in East Asian NSCLC patients.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['33465302'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 303,\n",
      "                          'dStart': 298,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Compared with non‐combination therapy, '\n",
      "                                  'combination radio‐immunotherapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT was '\n",
      "                                  'significantly associated with longer 1‐year '\n",
      "                                  'OS (I2 = 0.0%, OR 1.77, 95% CI 1.35–2.33, p '\n",
      "                                  '= 0.000) and 2‐year OS (I2 = 56.3%, OR '\n",
      "                                  '1.77, 95% CI 1.35–2.33, p = 0.000) in '\n",
      "                                  'patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 168,\n",
      "                          'dStart': 163,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': '(c) To our knowledge, this is the first '\n",
      "                                  'study to assess the efficacy and safety '\n",
      "                                  'profile of combination therapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT in patients '\n",
      "                                  'with NSCLC.'},\n",
      "                         {'dEnd': 126,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 79,\n",
      "                          'tStart': 75,\n",
      "                          'text': 'As mentioned earlier, the efficacy and '\n",
      "                                  'safety of combination therapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT in patients '\n",
      "                                  'with NSCLC remains controversial.'},\n",
      "                         {'dEnd': 178,\n",
      "                          'dStart': 173,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'Combination therapy using PD‐1/PD‐L1 '\n",
      "                                  'inhibitors and RT may improve OS, PFS, and '\n",
      "                                  'tumor response rates without an increase in '\n",
      "                                  'serious adverse events in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 83,\n",
      "                          'dStart': 78,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 31,\n",
      "                          'tStart': 27,\n",
      "                          'text': 'Radiotherapy combined with PD‐1/PD‐L1 '\n",
      "                                  'inhibitors in the treatment of advanced '\n",
      "                                  'NSCLC showed clinical long‐term survival '\n",
      "                                  'benefit and short‐term efficacy benefit, '\n",
      "                                  'and might not increase the serious adverse '\n",
      "                                  'events.'},\n",
      "                         {'dEnd': 187,\n",
      "                          'dStart': 182,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 129,\n",
      "                          'tStart': 125,\n",
      "                          'text': 'Therefore, we performed a systematic review '\n",
      "                                  'and meta‐analysis of the safety and '\n",
      "                                  'efficacy of combination therapy using RT '\n",
      "                                  'and PD‐1/PD‐L1 inhibitors for the treatment '\n",
      "                                  'of patients with NSCLC.'},\n",
      "                         {'dEnd': 50,\n",
      "                          'dStart': 45,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Two meta‐analyses performed in patients '\n",
      "                                  'with NSCLC showed a higher incidence of '\n",
      "                                  'pneumonitis in patients treated with PD‐1 '\n",
      "                                  'inhibitors than in those treated with PD‐L1 '\n",
      "                                  'inhibitors.59, 60'},\n",
      "                         {'dEnd': 156,\n",
      "                          'dStart': 151,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 122,\n",
      "                          'tStart': 118,\n",
      "                          'text': 'Clinical trials are increasingly being '\n",
      "                                  'performed in recent times to investigate '\n",
      "                                  'the role of combination therapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT for NSCLC.4'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 83,\n",
      "                          'tStart': 79,\n",
      "                          'text': 'Subgroup analyses also revealed that '\n",
      "                                  'combination therapy using SBRT or SRS and '\n",
      "                                  'PD‐1/PD‐L1 inhibitors may be more effective '\n",
      "                                  'than combination therapy using conventional '\n",
      "                                  'RT and PD‐1/PD‐L1 inhibitors in patients '\n",
      "                                  'with advanced NSCLC.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 74,\n",
      "                          'tStart': 70,\n",
      "                          'text': 'Combination of stereotactic body RT or '\n",
      "                                  'stereotactic radiosurgery with PD‐1/PD‐L1 '\n",
      "                                  'inhibitors may be more effective than a '\n",
      "                                  'combination of conventional RT with '\n",
      "                                  'PD‐1/PD‐L1 inhibitors in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 373,\n",
      "                          'dStart': 368,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 81,\n",
      "                          'tStart': 77,\n",
      "                          'text': 'Compared with non‐combination therapy, '\n",
      "                                  'combination radio‐immunotherapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT was '\n",
      "                                  'significantly associated with a longer '\n",
      "                                  '0.5‐year PFS (I2 = 43.1%, OR 1.83, 95% CI '\n",
      "                                  '1.13–2.98, p = 0.014), 1‐year PFS (I2 = '\n",
      "                                  '45.9%, OR 2.09, 95% CI 1.29–3.38, p = '\n",
      "                                  '0.003), and 2‐year PFS (I2 = 0.0%, OR 2.47, '\n",
      "                                  '95% CI 1.13–5.37, p = 0.023) in patients '\n",
      "                                  'with advanced NSCLC.'},\n",
      "                         {'dEnd': 157,\n",
      "                          'dStart': 152,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 55,\n",
      "                          'tStart': 51,\n",
      "                          'text': 'Our results suggest that combination '\n",
      "                                  'therapy using PD‐1/PD‐L1 inhibitors and RT '\n",
      "                                  'may improve OS, PFS, and tumor response '\n",
      "                                  'rates in patients with advanced NSCLC.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 93,\n",
      "                          'tStart': 89,\n",
      "                          'text': 'Two retrospective studies have shown that '\n",
      "                                  'combination treatment with RT and nivolumab '\n",
      "                                  '(a PD‐1 inhibitor) in patients with '\n",
      "                                  'advanced NSCLC may improve OS and PFS '\n",
      "                                  'without an increase in acute toxicity '\n",
      "                                  'rates.7, 8'},\n",
      "                         {'dEnd': 227,\n",
      "                          'dStart': 222,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 178,\n",
      "                          'tStart': 174,\n",
      "                          'text': 'Subgroup analyses also revealed that '\n",
      "                                  'combination therapy using SBRT or SRS and '\n",
      "                                  'PD‐1/PD‐L1 inhibitors may be more effective '\n",
      "                                  'than combination therapy using conventional '\n",
      "                                  'RT and PD‐1/PD‐L1 inhibitors in patients '\n",
      "                                  'with advanced NSCLC.'},\n",
      "                         {'dEnd': 197,\n",
      "                          'dStart': 192,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 54,\n",
      "                          'tStart': 50,\n",
      "                          'text': 'A combination of programmed cell death '\n",
      "                                  'protein‐1 (PD‐1)/programmed cell death '\n",
      "                                  'ligand‐1 (PD‐L1) inhibitors and '\n",
      "                                  'radiotherapy (RT) is increasingly being '\n",
      "                                  'used to treat non‐small‐cell lung cancer '\n",
      "                                  '(NSCLC).'},\n",
      "                         {'dEnd': 265,\n",
      "                          'dStart': 260,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Notably, combination therapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT did not '\n",
      "                                  'significantly increase the incidence of '\n",
      "                                  'cerebral radiation‐induced necrosis One '\n",
      "                                  'study showed no significant differences in '\n",
      "                                  'the progression of brain peritumoral edema '\n",
      "                                  'between patients with NSCLC treated with '\n",
      "                                  'and without combination therapy.26'},\n",
      "                         {'dEnd': 173,\n",
      "                          'dStart': 168,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 117,\n",
      "                          'tStart': 113,\n",
      "                          'text': 'The aforementioned mechanisms could '\n",
      "                                  'contribute to the short‐ and long‐term '\n",
      "                                  'benefits of combination therapy using '\n",
      "                                  'PD‐1/PD‐L1 inhibitors and RT in patients '\n",
      "                                  'with advanced NSCLC.'},\n",
      "                         {'dEnd': 90,\n",
      "                          'dStart': 85,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 30,\n",
      "                          'tStart': 26,\n",
      "                          'text': 'Combination therapy using PD‐1/PD‐L1 '\n",
      "                                  'inhibitors and RT for the treatment of '\n",
      "                                  'advanced NSCLC may improve OS, PFS, and '\n",
      "                                  'tumor response rates without an increase in '\n",
      "                                  '≥grade 3 AEs.'},\n",
      "                         {'dEnd': 210,\n",
      "                          'dStart': 205,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 161,\n",
      "                          'tStart': 157,\n",
      "                          'text': 'Combination of stereotactic body RT or '\n",
      "                                  'stereotactic radiosurgery with PD‐1/PD‐L1 '\n",
      "                                  'inhibitors may be more effective than a '\n",
      "                                  'combination of conventional RT with '\n",
      "                                  'PD‐1/PD‐L1 inhibitors in patients with '\n",
      "                                  'advanced NSCLC.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['35492873'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 84,\n",
      "                          'dStart': 79,\n",
      "                          'section': 'other',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 58,\n",
      "                          'text': '•Preliminary clinical data supports '\n",
      "                                  'inhibition of Axl and PD-1 in STK11 mutant '\n",
      "                                  'NSCLC'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapy, '\n",
      "                                  'especially anti-programmed cell death '\n",
      "                                  'protein 1/programmed death-ligand 1 '\n",
      "                                  '(PD-1/PD-L1) therapy, has revolutionized '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'treatment, with clinical trials showing '\n",
      "                                  'significantly prolonged survival for '\n",
      "                                  'responding subjects.1'},\n",
      "                         {'dEnd': 142,\n",
      "                          'dStart': 137,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 90,\n",
      "                          'tStart': 86,\n",
      "                          'text': 'As a part of a multi-arm, ongoing phase II '\n",
      "                                  'clinical trial of bemcentinib and the '\n",
      "                                  'anti-PD-1 inhibitor pembrolizumab in '\n",
      "                                  'previously treated NSCLC (BerGenBio ASA and '\n",
      "                                  'Merck, Kenilworth NJ, USA, NCT03184571), '\n",
      "                                  'all individuals with sufficiently large '\n",
      "                                  'tumor biopsies were subjected to '\n",
      "                                  'whole-exome sequencing and IHC staining for '\n",
      "                                  'AXL and PD-L1 expression.46'},\n",
      "                         {'dEnd': 207,\n",
      "                          'dStart': 202,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 169,\n",
      "                          'tStart': 165,\n",
      "                          'text': 'All three of these individuals experienced '\n",
      "                                  'clinical benefit from the combination '\n",
      "                                  'therapy and are presented here as case '\n",
      "                                  'studies for the efficacy of combined AXL '\n",
      "                                  'and PD-1 inhibition in STK11/LKB1 mutant '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 75,\n",
      "                          'dStart': 70,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'AXL targeting restores PD-1 blockade '\n",
      "                                  'sensitivity of STK11/LKB1 mutant NSCLC '\n",
      "                                  'through expansion of TCF1+ CD8 T cells'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 174,\n",
      "                          'tStart': 170,\n",
      "                          'text': 'In conclusion, we have shown in murine- and '\n",
      "                                  'human-derived preclinical models that '\n",
      "                                  'systemic treatment with an Axl inhibitor, '\n",
      "                                  'bemcentinib, in clinical trials combined '\n",
      "                                  'with PD-1 checkpoint blockade leads to '\n",
      "                                  'anti-tumor responses in STK11/LKB1 mutant '\n",
      "                                  'NSCLCs.'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapy, '\n",
      "                                  'especially anti-programmed cell death '\n",
      "                                  'protein 1/programmed death-ligand 1 '\n",
      "                                  '(PD-1/PD-L1) therapy, has revolutionized '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'treatment, with clinical trials showing '\n",
      "                                  'significantly prolonged survival for '\n",
      "                                  'responding subjects.1'},\n",
      "                         {'dEnd': 244,\n",
      "                          'dStart': 239,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 167,\n",
      "                          'tStart': 163,\n",
      "                          'text': 'Although Axl is expressed widely on tumor '\n",
      "                                  'cells, vasculature and myeloid '\n",
      "                                  'cells,23,48,49 inhibition of Axl on DCs '\n",
      "                                  'appears to be the main executor in '\n",
      "                                  'expanding TCF1+PD-1+CD8 T cells to achieve '\n",
      "                                  'anti-PD-1-mediated control of STK11/LKB1 '\n",
      "                                  'mutant NSCLC growth control.'},\n",
      "                         {'dEnd': 190,\n",
      "                          'dStart': 185,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 121,\n",
      "                          'tStart': 117,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapy, '\n",
      "                                  'especially anti-programmed cell death '\n",
      "                                  'protein 1/programmed death-ligand 1 '\n",
      "                                  '(PD-1/PD-L1) therapy, has revolutionized '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'treatment, with clinical trials showing '\n",
      "                                  'significantly prolonged survival for '\n",
      "                                  'responding subjects.1'},\n",
      "                         {'dEnd': 183,\n",
      "                          'dStart': 157,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Immune checkpoint blockade (ICB) therapy, '\n",
      "                                  'especially anti-programmed cell death '\n",
      "                                  'protein 1/programmed death-ligand 1 '\n",
      "                                  '(PD-1/PD-L1) therapy, has revolutionized '\n",
      "                                  'non-small cell lung cancer (NSCLC) '\n",
      "                                  'treatment, with clinical trials showing '\n",
      "                                  'significantly prolonged survival for '\n",
      "                                  'responding subjects.1'},\n",
      "                         {'dEnd': 76,\n",
      "                          'dStart': 71,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 36,\n",
      "                          'tStart': 32,\n",
      "                          'text': 'Furthermore, the status of TCF1+PD-1+CD8 T '\n",
      "                                  'cells in STK11/LKB1 mutated NSCLC tumors '\n",
      "                                  'has not been investigated.'},\n",
      "                         {'dEnd': 185,\n",
      "                          'dStart': 180,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 153,\n",
      "                          'tStart': 149,\n",
      "                          'text': 'These preclinical observations are being '\n",
      "                                  'evaluated in a clinical trial testing the '\n",
      "                                  'benefit of combining bemcentinib, an Axl '\n",
      "                                  'inhibitor, with the anti-PD-1 antibody '\n",
      "                                  'pembrolizumab in NSCLC-affected '\n",
      "                                  'individuals, some of which harbor mutations '\n",
      "                                  'in STK11/LKB1.'},\n",
      "                         {'dEnd': 127,\n",
      "                          'dStart': 121,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Mutant KRAS-driven NSCLCs tend to have a '\n",
      "                                  'higher response rate to PD-1/PD-L1 '\n",
      "                                  'inhibition compared with KRAS wild-type '\n",
      "                                  '(WT) NSCLCs.5'},\n",
      "                         {'dEnd': 114,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'To investigate whether the therapeutic '\n",
      "                                  'effects of combined AXL and PD-1 inhibition '\n",
      "                                  'apply to human KL mutant NSCLCs, we studied '\n",
      "                                  'two human LUAD KL-mutated cell lines, A549 '\n",
      "                                  'and H2122, in a humanized NSG-SGM3 mouse '\n",
      "                                  'model.'},\n",
      "                         {'dEnd': 244,\n",
      "                          'dStart': 239,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 200,\n",
      "                          'tStart': 196,\n",
      "                          'text': 'Although Axl is expressed widely on tumor '\n",
      "                                  'cells, vasculature and myeloid '\n",
      "                                  'cells,23,48,49 inhibition of Axl on DCs '\n",
      "                                  'appears to be the main executor in '\n",
      "                                  'expanding TCF1+PD-1+CD8 T cells to achieve '\n",
      "                                  'anti-PD-1-mediated control of STK11/LKB1 '\n",
      "                                  'mutant NSCLC growth control.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Thus, our data strongly support clinical '\n",
      "                                  'testing of AXL inhibition in combination '\n",
      "                                  'with PD-1 checkpoint blockade in STK11/LKB1 '\n",
      "                                  'mutant NSCLC individuals and potentially in '\n",
      "                                  'other tumor settings that are refractory to '\n",
      "                                  'PD-1 blockade and that also exhibit '\n",
      "                                  'deficits in TCF1+CD8 T cells.'},\n",
      "                         {'dEnd': 226,\n",
      "                          'dStart': 221,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'In this study, we identified that '\n",
      "                                  'combination of bemcentinib with anti-PD-1 '\n",
      "                                  'effectively sensitizes STK11/LKB1 mutant '\n",
      "                                  'NSCLC tumors in syngeneic models, '\n",
      "                                  'human-derived xenografts implanted into '\n",
      "                                  'humanized mice, and anecdotal '\n",
      "                                  'NSCLC-affected individuals.'},\n",
      "                         {'dEnd': 122,\n",
      "                          'dStart': 117,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 75,\n",
      "                          'tStart': 71,\n",
      "                          'text': 'In this study, we identified that '\n",
      "                                  'combination of bemcentinib with anti-PD-1 '\n",
      "                                  'effectively sensitizes STK11/LKB1 mutant '\n",
      "                                  'NSCLC tumors in syngeneic models, '\n",
      "                                  'human-derived xenografts implanted into '\n",
      "                                  'humanized mice, and anecdotal '\n",
      "                                  'NSCLC-affected individuals.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['29016555'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 91,\n",
      "                          'dStart': 86,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 62,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'Anyway, we could not detect a positive '\n",
      "                                  'correlation between PD1 and tumour diameter '\n",
      "                                  'in NSCLC TU.'},\n",
      "                         {'dEnd': 214,\n",
      "                          'dStart': 209,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 81,\n",
      "                          'text': 'Concerning immunotherapeutic intentions, we '\n",
      "                                  'think a combination of PEG-IL-10 and '\n",
      "                                  'PD1-antagonists could have a synergistic '\n",
      "                                  'effect and might be a potent weapon against '\n",
      "                                  'the devastating effect of tumoural PDL1 in '\n",
      "                                  'NSCLC (Naing et al, 2016b), whereas '\n",
      "                                  'PEG-IL-10 might be less useful in SCC, but '\n",
      "                                  'especially useful in ADC.'},\n",
      "                         {'dEnd': 33,\n",
      "                          'dStart': 28,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 61,\n",
      "                          'text': 'On the subtended TU side of NSCLC, we see '\n",
      "                                  'elevated levels of PD1 and CD3, typical for '\n",
      "                                  'lung cancer stroma (Banat et al, 2015), '\n",
      "                                  'being predominant especially in the lung '\n",
      "                                  'tumoural region of patients with ADC.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 146,\n",
      "                          'tStart': 143,\n",
      "                          'text': 'Finally, IL-10 terminates the PD1/PDL1 '\n",
      "                                  'signalling induced by IFN-γ, by inhibiting '\n",
      "                                  'PD1 and PDL1 in tumour, thus resulting in '\n",
      "                                  'resistance to anti-PD1/PDL1 treatment in '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 131,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 68,\n",
      "                          'text': 'In conclusion, here we discovered that the '\n",
      "                                  'distribution of CD3+ and PD1+ stained cells '\n",
      "                                  'is strongly correlated in lung tissues from '\n",
      "                                  'NSCLC, showing a rise of them in the tumour '\n",
      "                                  'region, especially in the tumour region of '\n",
      "                                  'patients with ADC, compared to the control '\n",
      "                                  'regions of each cancer type.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Finally, IL-10 terminates the PD1/PDL1 '\n",
      "                                  'signalling induced by IFN-γ, by inhibiting '\n",
      "                                  'PD1 and PDL1 in tumour, thus resulting in '\n",
      "                                  'resistance to anti-PD1/PDL1 treatment in '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 33,\n",
      "                          'tStart': 30,\n",
      "                          'text': 'Finally, IL-10 terminates the PD1/PDL1 '\n",
      "                                  'signalling induced by IFN-γ, by inhibiting '\n",
      "                                  'PD1 and PDL1 in tumour, thus resulting in '\n",
      "                                  'resistance to anti-PD1/PDL1 treatment in '\n",
      "                                  'patients with NSCLC.'},\n",
      "                         {'dEnd': 103,\n",
      "                          'dStart': 98,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 58,\n",
      "                          'text': 'Moreover, a direct positive correlation was '\n",
      "                                  'found between PD1 and PDL1 in SCC '\n",
      "                                  'specifically and in NSCLC, in general '\n",
      "                                  '(Figure 2D and E, respectively) and between '\n",
      "                                  'CD3 and PD1 in the tumoural region of '\n",
      "                                  'patients with ADC (Figure 2F).'},\n",
      "                         {'dEnd': 301,\n",
      "                          'dStart': 296,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 142,\n",
      "                          'tStart': 139,\n",
      "                          'text': 'PDL1 promotes the accumulation and function '\n",
      "                                  'of Tregs (Francisco et al, 2009; Chen et '\n",
      "                                  'al, 2016b), as well as the accumulation of '\n",
      "                                  'exhausted, PD1 expressing Th cells '\n",
      "                                  '(Zun-Qiang Zhou et al, 2016), which is '\n",
      "                                  'underlined by our transcription analysis '\n",
      "                                  'showing positive correlation between PDL1 '\n",
      "                                  'and PD1 in NSCLC TU, as well as the '\n",
      "                                  'upregulation of the IL-10R in Foxp-3+ '\n",
      "                                  'TU-infiltrating T-cells, shown in our flow '\n",
      "                                  'cytometric analysis of human ADC biopsies.'},\n",
      "                         {'dEnd': 301,\n",
      "                          'dStart': 296,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 292,\n",
      "                          'tStart': 289,\n",
      "                          'text': 'PDL1 promotes the accumulation and function '\n",
      "                                  'of Tregs (Francisco et al, 2009; Chen et '\n",
      "                                  'al, 2016b), as well as the accumulation of '\n",
      "                                  'exhausted, PD1 expressing Th cells '\n",
      "                                  '(Zun-Qiang Zhou et al, 2016), which is '\n",
      "                                  'underlined by our transcription analysis '\n",
      "                                  'showing positive correlation between PDL1 '\n",
      "                                  'and PD1 in NSCLC TU, as well as the '\n",
      "                                  'upregulation of the IL-10R in Foxp-3+ '\n",
      "                                  'TU-infiltrating T-cells, shown in our flow '\n",
      "                                  'cytometric analysis of human ADC biopsies.'},\n",
      "                         {'dEnd': 217,\n",
      "                          'dStart': 212,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 134,\n",
      "                          'tStart': 131,\n",
      "                          'text': 'Moreover, in confirmation of this finding, '\n",
      "                                  'we discovered a strong statistically '\n",
      "                                  'significant inverse correlation between '\n",
      "                                  'IL-10R and PD1 in the tumoural area of '\n",
      "                                  'patients with ADC in particular and in '\n",
      "                                  'patients with NSCLC in general (Figure '\n",
      "                                  '5B).'},\n",
      "                         {'dEnd': 82,\n",
      "                          'dStart': 77,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 12,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Enhanced PD1 expression in the tumoural '\n",
      "                                  'region of patients who suffered from NSCLC '\n",
      "                                  'is directly correlated with CD3 and PDL1 '\n",
      "                                  'levels'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['39004699'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 189,\n",
      "                          'dStart': 184,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 84,\n",
      "                          'tStart': 80,\n",
      "                          'text': 'Blocking TGF-β can reshape the TME and '\n",
      "                                  'enhance the therapeutic efficacy of '\n",
      "                                  'anti-PD-1 in EGFR-mutated tumors, which '\n",
      "                                  'provides a potential combination '\n",
      "                                  'immunotherapy strategy for advanced NSCLC '\n",
      "                                  'patients with EGFR mutations.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 80,\n",
      "                          'tStart': 49,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICI) '\n",
      "                                  'targeting the programmed cell death '\n",
      "                                  'protein-1 (PD-1)/programmed cell death '\n",
      "                                  'ligand-1 (PD-L1) axis have significantly '\n",
      "                                  'improved the survival of patients with '\n",
      "                                  'advanced NSCLC [5, 6].'},\n",
      "                         {'dEnd': 141,\n",
      "                          'dStart': 136,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Altogether, these results indicate that '\n",
      "                                  'TGF-β inhibition could enhance the '\n",
      "                                  'therapeutic efficacy of anti-PD-1 against '\n",
      "                                  'EGFR-TKI resistant NSCLC, highlighting the '\n",
      "                                  'potential of a new combined immunotherapy '\n",
      "                                  'strategy for EGFR-mutated NSCLC patients '\n",
      "                                  'after EGFR-TKI failure.'},\n",
      "                         {'dEnd': 97,\n",
      "                          'dStart': 92,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 39,\n",
      "                          'tStart': 35,\n",
      "                          'text': 'Combination of anti-TGF-β and anti-PD-1 '\n",
      "                                  'promotes CD8+ T cell responses against '\n",
      "                                  'EGFR-mutated NSCLC'},\n",
      "                         {'dEnd': 131,\n",
      "                          'dStart': 126,\n",
      "                          'section': 'concl',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Importantly, treatment with a combination '\n",
      "                                  'of anti-TGF-β and anti-PD-1 enhanced the '\n",
      "                                  'CD8+ T cells response against EGFR-mutated '\n",
      "                                  'NSCLC tumors when compared with treatment '\n",
      "                                  'with anti-PD-1 alone.'},\n",
      "                         {'dEnd': 138,\n",
      "                          'dStart': 133,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 101,\n",
      "                          'tStart': 97,\n",
      "                          'text': 'The underlying mechanism of immunologically '\n",
      "                                  '\"cold\" phenotype formation and primary '\n",
      "                                  'resistance to PD-1/PD-L1 blockade in '\n",
      "                                  'EGFR-mutated NSCLC is still unclear.'},\n",
      "                         {'dEnd': 233,\n",
      "                          'dStart': 228,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 108,\n",
      "                          'tStart': 104,\n",
      "                          'text': 'Altogether, these results indicate that '\n",
      "                                  'TGF-β inhibition could enhance the '\n",
      "                                  'therapeutic efficacy of anti-PD-1 against '\n",
      "                                  'EGFR-TKI resistant NSCLC, highlighting the '\n",
      "                                  'potential of a new combined immunotherapy '\n",
      "                                  'strategy for EGFR-mutated NSCLC patients '\n",
      "                                  'after EGFR-TKI failure.'},\n",
      "                         {'dEnd': 204,\n",
      "                          'dStart': 199,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 86,\n",
      "                          'tStart': 82,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICI) '\n",
      "                                  'targeting the programmed cell death '\n",
      "                                  'protein-1 (PD-1)/programmed cell death '\n",
      "                                  'ligand-1 (PD-L1) axis have significantly '\n",
      "                                  'improved the survival of patients with '\n",
      "                                  'advanced NSCLC [5, 6].'},\n",
      "                         {'dEnd': 112,\n",
      "                          'dStart': 107,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 68,\n",
      "                          'tStart': 64,\n",
      "                          'text': 'Therefore, we investigated the potential of '\n",
      "                                  'anti-TGF-β and anti-PD-1 combination '\n",
      "                                  'treatment in EGFR-mutated NSCLC after '\n",
      "                                  'EGFR-TKI treatment failure, for which the '\n",
      "                                  'treatment options are limited.'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'Importantly, the combination of anti-TGF-β '\n",
      "                                  'and anti-PD-1 suppressed the growth of '\n",
      "                                  'EGFR-mutated NSCLC in vivo by enhancing the '\n",
      "                                  'T cell response.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 69,\n",
      "                          'tStart': 65,\n",
      "                          'text': 'Importantly, treatment with a combination '\n",
      "                                  'of anti-TGF-β and anti-PD-1 enhanced the '\n",
      "                                  'CD8+ T cells response against EGFR-mutant '\n",
      "                                  'NSCLC tumors when compared with treatment '\n",
      "                                  'with anti-PD-1 alone.'},\n",
      "                         {'dEnd': 146,\n",
      "                          'dStart': 141,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'Finally, we explored the therapeutic effect '\n",
      "                                  'of anti-TGF-β and anti-PD-1 combination '\n",
      "                                  'therapy in malignant pleural effusions from '\n",
      "                                  'EGFR-mutated NSCLC patients after EGFR-TKI '\n",
      "                                  'failure.'},\n",
      "                         {'dEnd': 136,\n",
      "                          'dStart': 110,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 66,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'EGFR mutations induce the suppression of '\n",
      "                                  'CD8+ T cell and anti-PD-1 resistance via '\n",
      "                                  'ERK1/2-p90RSK-TGF-β axis in non-small cell '\n",
      "                                  'lung cancer'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['36472770'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 251,\n",
      "                          'dStart': 246,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 103,\n",
      "                          'tStart': 99,\n",
      "                          'text': 'To our knowledge, this is the first study '\n",
      "                                  'to demonstrate whether GDF15 can predict '\n",
      "                                  'the efficacy of PD-1/PD-L1 inhibitors and '\n",
      "                                  'identify the association between '\n",
      "                                  'circulating GDF15 levels and immune cell '\n",
      "                                  'populations of PBMCs in patients with '\n",
      "                                  'advanced NSCLC.'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 214,\n",
      "                          'tStart': 210,\n",
      "                          'text': 'Since PD-L1 expression in tumor tissues, '\n",
      "                                  'such as soluble PD-1 and PD-L1, was also '\n",
      "                                  'not significantly related to plasma GDF15 '\n",
      "                                  'levels, these results suggest an important '\n",
      "                                  'association between PD-1+ CD8+ T cells and '\n",
      "                                  'PD-1+ Treg cells and plasma GDF15 levels in '\n",
      "                                  'advanced NSCLC patients treated with '\n",
      "                                  'PD-1/PD-L1 inhibitors.'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 61,\n",
      "                          'tStart': 57,\n",
      "                          'text': 'Since PD-L1 expression in tumor tissues, '\n",
      "                                  'such as soluble PD-1 and PD-L1, was also '\n",
      "                                  'not significantly related to plasma GDF15 '\n",
      "                                  'levels, these results suggest an important '\n",
      "                                  'association between PD-1+ CD8+ T cells and '\n",
      "                                  'PD-1+ Treg cells and plasma GDF15 levels in '\n",
      "                                  'advanced NSCLC patients treated with '\n",
      "                                  'PD-1/PD-L1 inhibitors.'},\n",
      "                         {'dEnd': 184,\n",
      "                          'dStart': 179,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 280,\n",
      "                          'tStart': 276,\n",
      "                          'text': 'Since we previously reported that '\n",
      "                                  'circulating regulatory T (Treg) cells '\n",
      "                                  'represent a promising potential dynamic '\n",
      "                                  'biomarker to predict efficacy after '\n",
      "                                  'immunotherapy in patients with NSCLC (Kang '\n",
      "                                  'et al. 2022), we analyzed the immune cell '\n",
      "                                  'populations, including Treg cells, soluble '\n",
      "                                  'PD-1, and soluble PD-L1 levels between the '\n",
      "                                  'low GDF15 group and high GDF15 group in '\n",
      "                                  'patients with lung cancer (Table 2).'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'Collectively, plasma GDF15 levels were '\n",
      "                                  'associated with the proportion of PD-1+CD8+ '\n",
      "                                  'T cells and PD-1+ Treg cells in patients '\n",
      "                                  'with advanced NSCLC who underwent '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 182,\n",
      "                          'dStart': 156,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 89,\n",
      "                          'tStart': 85,\n",
      "                          'text': 'Plasma GDF15 levels associated with '\n",
      "                                  'circulating immune cells predict the '\n",
      "                                  'efficacy of PD-1/PD-L1 inhibitor treatment '\n",
      "                                  'and prognosis in patients with advanced '\n",
      "                                  'non-small cell lung cancer'},\n",
      "                         {'dEnd': 143,\n",
      "                          'dStart': 138,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 77,\n",
      "                          'tStart': 73,\n",
      "                          'text': 'Collectively, plasma GDF15 levels were '\n",
      "                                  'associated with the proportion of PD-1+CD8+ '\n",
      "                                  'T cells and PD-1+ Treg cells in patients '\n",
      "                                  'with advanced NSCLC who underwent '\n",
      "                                  'immunotherapy.'},\n",
      "                         {'dEnd': 51,\n",
      "                          'dStart': 46,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 71,\n",
      "                          'tStart': 67,\n",
      "                          'text': 'This study included 87 patients with '\n",
      "                                  'advanced NSCLC receiving anti-PD-1/PD-L1 '\n",
      "                                  'inhibitors between March 2018 and May '\n",
      "                                  '2020.'},\n",
      "                         {'dEnd': 268,\n",
      "                          'dStart': 263,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 191,\n",
      "                          'tStart': 187,\n",
      "                          'text': 'Since PD-L1 expression in tumor tissues, '\n",
      "                                  'such as soluble PD-1 and PD-L1, was also '\n",
      "                                  'not significantly related to plasma GDF15 '\n",
      "                                  'levels, these results suggest an important '\n",
      "                                  'association between PD-1+ CD8+ T cells and '\n",
      "                                  'PD-1+ Treg cells and plasma GDF15 levels in '\n",
      "                                  'advanced NSCLC patients treated with '\n",
      "                                  'PD-1/PD-L1 inhibitors.'}]}\n",
      "{'disease': {'id': 'EFO_0003060', 'name': 'non-small cell lung carcinoma'},\n",
      " 'literature': ['38835662'],\n",
      " 'resourceScore': 45,\n",
      " 'target': {'approvedSymbol': 'PDCD1', 'id': 'ENSG00000188389'},\n",
      " 'textMiningSentences': [{'dEnd': 70,\n",
      "                          'dStart': 65,\n",
      "                          'section': 'results',\n",
      "                          'tEnd': 99,\n",
      "                          'tStart': 95,\n",
      "                          'text': 'We retrospectively collected data for 913 '\n",
      "                                  'patients with advanced NSCLC who received '\n",
      "                                  'first-line PD-1 inhibitor treatment '\n",
      "                                  '(monotherapy or combined with '\n",
      "                                  'chemotherapy).'},\n",
      "                         {'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), which '\n",
      "                                  'primarily comprise programmed cell death-1 '\n",
      "                                  '(PD-1) inhibitors and programmed cell death '\n",
      "                                  'ligand 1 (PD-L1) inhibitors, have become '\n",
      "                                  'the standard treatment option for patients '\n",
      "                                  'with advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC) without driver gene mutations.'},\n",
      "                         {'dEnd': 209,\n",
      "                          'dStart': 204,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 123,\n",
      "                          'tStart': 119,\n",
      "                          'text': 'To date, only one phase II randomized '\n",
      "                                  'controlled clinical trial (CTONG 1901) has '\n",
      "                                  'directly compared the efficacy of two PD-1 '\n",
      "                                  'inhibitors (sintilimab and pembrolizumab) '\n",
      "                                  'as first-line treatments for advanced NSCLC '\n",
      "                                  '(Liu et al., 2022).'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 228,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 91,\n",
      "                          'tStart': 87,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), which '\n",
      "                                  'primarily comprise programmed cell death-1 '\n",
      "                                  '(PD-1) inhibitors and programmed cell death '\n",
      "                                  'ligand 1 (PD-L1) inhibitors, have become '\n",
      "                                  'the standard treatment option for patients '\n",
      "                                  'with advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC) without driver gene mutations.'},\n",
      "                         {'dEnd': 79,\n",
      "                          'dStart': 74,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 38,\n",
      "                          'tStart': 34,\n",
      "                          'text': 'Furthermore, choosing the optimal PD-1 '\n",
      "                                  'therapy for patients with advanced NSCLC is '\n",
      "                                  'crucial.'},\n",
      "                         {'dEnd': 261,\n",
      "                          'dStart': 256,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), which '\n",
      "                                  'primarily comprise programmed cell death-1 '\n",
      "                                  '(PD-1) inhibitors and programmed cell death '\n",
      "                                  'ligand 1 (PD-L1) inhibitors, have become '\n",
      "                                  'the standard treatment option for patients '\n",
      "                                  'with advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC) without driver gene mutations.'},\n",
      "                         {'dEnd': 239,\n",
      "                          'dStart': 234,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 63,\n",
      "                          'tStart': 59,\n",
      "                          'text': 'In real-world clinical practice in China, '\n",
      "                                  'for example, six PD-1 inhibitors, including '\n",
      "                                  'pembrolizumab, nivolumab, sintilimab, '\n",
      "                                  'tislelizumab, toripalimab, and '\n",
      "                                  'camrelizumab, are used to varying degrees '\n",
      "                                  'as first-line treatment for advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 118,\n",
      "                          'dStart': 113,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 64,\n",
      "                          'tStart': 60,\n",
      "                          'text': 'Our study directly compared the efficacies '\n",
      "                                  'of the six major PD-1 inhibitors as '\n",
      "                                  'first-line treatment for advanced NSCLC for '\n",
      "                                  'the first time.'},\n",
      "                         {'dEnd': 130,\n",
      "                          'dStart': 125,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 70,\n",
      "                          'tStart': 66,\n",
      "                          'text': 'Further, authoritative guidelines are yet '\n",
      "                                  'to recommend a specific PD-1 inhibitor as '\n",
      "                                  'more suitable for patients with advanced '\n",
      "                                  'NSCLC.'},\n",
      "                         {'dEnd': 134,\n",
      "                          'dStart': 108,\n",
      "                          'section': 'title',\n",
      "                          'tEnd': 59,\n",
      "                          'tStart': 28,\n",
      "                          'text': 'Comparative efficacy of six programmed cell '\n",
      "                                  'death Protein-1 inhibitors as first-line '\n",
      "                                  'treatment for advanced non-small cell lung '\n",
      "                                  'cancer: a multicenter retrospective cohort '\n",
      "                                  'study'},\n",
      "                         {'dEnd': 252,\n",
      "                          'dStart': 247,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 173,\n",
      "                          'tStart': 169,\n",
      "                          'text': 'Therefore, building upon previous research, '\n",
      "                                  'we conducted a multicenter, head-to-head '\n",
      "                                  'real-world retrospective study to '\n",
      "                                  'investigate differences in efficacy among '\n",
      "                                  'the six PD-1 inhibitors that are frequently '\n",
      "                                  'used as first-line treatment for advanced '\n",
      "                                  'NSCLC in clinical practice.'},\n",
      "                         {'dEnd': 110,\n",
      "                          'dStart': 105,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 56,\n",
      "                          'tStart': 52,\n",
      "                          'text': 'In several retrospective studies, the '\n",
      "                                  'efficacies of PD-1 inhibitors as first-line '\n",
      "                                  'treatment for advanced NSCLC have been '\n",
      "                                  'compared.'},\n",
      "                         {'dEnd': 194,\n",
      "                          'dStart': 189,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 13,\n",
      "                          'tStart': 9,\n",
      "                          'text': 'Multiple PD-1 inhibitors have been approved '\n",
      "                                  'by the United States Food and Drug '\n",
      "                                  'Administration and the National Medical '\n",
      "                                  'Products Administration of China as '\n",
      "                                  'first-line treatment for advanced NSCLC.'},\n",
      "                         {'dEnd': 301,\n",
      "                          'dStart': 296,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'The purpose of this study was to assess the '\n",
      "                                  'comparative efficacy of six programmed cell '\n",
      "                                  'death-1 inhibitors (nivolumab, '\n",
      "                                  'pembrolizumab, sintilimab, tislelizumab, '\n",
      "                                  'toripalimab, and camrelizumab) that have '\n",
      "                                  'been used as first-line therapy for Chinese '\n",
      "                                  'patients with advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC), which remains unclear.'},\n",
      "                         {'dEnd': 81,\n",
      "                          'dStart': 76,\n",
      "                          'section': 'table',\n",
      "                          'tEnd': 27,\n",
      "                          'tStart': 23,\n",
      "                          'text': 'Short-term efficacy of PD-1 inhibitors as '\n",
      "                                  'first-line treatment for advanced NSCLC.'},\n",
      "                         {'dEnd': 78,\n",
      "                          'dStart': 73,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 57,\n",
      "                          'tStart': 53,\n",
      "                          'text': 'The findings suggest comparable efficacy '\n",
      "                                  'among these PD-1 inhibitors for NSCLC '\n",
      "                                  'treatment, underscoring their collective '\n",
      "                                  'suitability and aiding treatment '\n",
      "                                  'decisions.'},\n",
      "                         {'dEnd': 100,\n",
      "                          'dStart': 95,\n",
      "                          'section': 'discuss',\n",
      "                          'tEnd': 28,\n",
      "                          'tStart': 24,\n",
      "                          'text': 'An increasing number of PD-1 inhibitors '\n",
      "                                  'have been approved as first-line treatment '\n",
      "                                  'of advanced NSCLC, and in clinical trials, '\n",
      "                                  'these drugs have demonstrated superior '\n",
      "                                  'efficacy relative to standard chemotherapy, '\n",
      "                                  'providing clinicians with more treatment '\n",
      "                                  'options.'},\n",
      "                         {'dEnd': 254,\n",
      "                          'dStart': 228,\n",
      "                          'section': 'intro',\n",
      "                          'tEnd': 85,\n",
      "                          'tStart': 62,\n",
      "                          'text': 'Immune checkpoint inhibitors (ICIs), which '\n",
      "                                  'primarily comprise programmed cell death-1 '\n",
      "                                  '(PD-1) inhibitors and programmed cell death '\n",
      "                                  'ligand 1 (PD-L1) inhibitors, have become '\n",
      "                                  'the standard treatment option for patients '\n",
      "                                  'with advanced non-small cell lung cancer '\n",
      "                                  '(NSCLC) without driver gene mutations.'},\n",
      "                         {'dEnd': 294,\n",
      "                          'dStart': 268,\n",
      "                          'section': 'abstract',\n",
      "                          'tEnd': 95,\n",
      "                          'tStart': 72,\n",
      "                          'text': 'The purpose of this study was to assess the '\n",
      "                                  'comparative efficacy of six programmed cell '\n",
      "                                  'death-1 inhibitors (nivolumab, '\n",
      "                                  'pembrolizumab, sintilimab, tislelizumab, '\n",
      "                                  'toripalimab, and camrelizumab) that have '\n",
      "                                  'been used as first-line therapy for Chinese '\n",
      "                                  'patients with advanced non-small cell lung '\n",
      "                                  'cancer (NSCLC), which remains unclear.'}]}\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from pprint import pprint\n",
    "\n",
    "data = resp[\"data\"][\"disease\"][\"europePmc\"][\"rows\"]\n",
    "literature_evidence = {}\n",
    "for paper in data:\n",
    "    pprint(paper)\n",
    "    pmcid = paper[\"literature\"][0]\n",
    "    target = paper[\"target\"][\"approvedSymbol\"]\n",
    "    disease = paper[\"disease\"][\"name\"]\n",
    "    text = paper[\"textMiningSentences\"]\n",
    "    text = [t[\"text\"] for t in text]\n",
    "    literature_evidence[pmcid] = [target, disease, text]\n",
    "\n",
    "evidence_df = pd.DataFrame.from_dict(literature_evidence, orient=\"index\", columns=[\"Target\", \"Disease\", \"Text\"])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Target</th>\n",
       "      <th>Disease</th>\n",
       "      <th>Text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>32154170</th>\n",
       "      <td>PDCD1</td>\n",
       "      <td>lung adenocarcinoma</td>\n",
       "      <td>[Given that Science-LUAD cohort was only treat...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>38299030</th>\n",
       "      <td>PDCD1</td>\n",
       "      <td>non-small cell lung carcinoma</td>\n",
       "      <td>[In the current study, we tested the feasibili...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>34194433</th>\n",
       "      <td>PDCD1</td>\n",
       "      <td>non-small cell lung carcinoma</td>\n",
       "      <td>[Thus, PD-1 was highly expressed on ILC2s obta...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>30325558</th>\n",
       "      <td>PDCD1</td>\n",
       "      <td>non-small cell lung carcinoma</td>\n",
       "      <td>[However, we further compared PD‐1 expression ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>27191652</th>\n",
       "      <td>PDCD1</td>\n",
       "      <td>non-small cell lung carcinoma</td>\n",
       "      <td>[We report that surface expression of PD-1 on ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "         Target                        Disease  \\\n",
       "32154170  PDCD1            lung adenocarcinoma   \n",
       "38299030  PDCD1  non-small cell lung carcinoma   \n",
       "34194433  PDCD1  non-small cell lung carcinoma   \n",
       "30325558  PDCD1  non-small cell lung carcinoma   \n",
       "27191652  PDCD1  non-small cell lung carcinoma   \n",
       "\n",
       "                                                       Text  \n",
       "32154170  [Given that Science-LUAD cohort was only treat...  \n",
       "38299030  [In the current study, we tested the feasibili...  \n",
       "34194433  [Thus, PD-1 was highly expressed on ILC2s obta...  \n",
       "30325558  [However, we further compared PD‐1 expression ...  \n",
       "27191652  [We report that surface expression of PD-1 on ...  "
      ]
     },
     "execution_count": 7,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "evidence_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['Given that Science-LUAD cohort was only treated with PD-1 blockade and '\n",
      " 'performed better than Cancer Cell-LUAD cohort on predicting ICB efficacy '\n",
      " '(Figure 2B; AUC = 0.82 and 0.80, respectively), we stratified the '\n",
      " 'Discovery-LUAD cohort into two groups based on the TMB cutoff from '\n",
      " 'Science-LUAD cohort (Figure 2C; TMB = 166.5).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Of particular note, one LUAD patient who derived durable clinical benefit '\n",
      " 'from anti-PD-1 therapy showed the strong staining of both PD-L1 expression '\n",
      " 'and CD8+ T cell infiltration.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'However, in LUAD, the positivity rate of MMRd/MSI assessed by genomic '\n",
      " 'variations is <1% and much lower than the objective response rate to PD-1 '\n",
      " 'blockade in unselected patients (13, 19, 30–33).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'Given that Science-LUAD cohort was only treated with PD-1 blockade and '\n",
      " 'performed better than Cancer Cell-LUAD cohort on predicting ICB efficacy '\n",
      " '(Figure 2B; AUC = 0.82 and 0.80, respectively), we stratified the '\n",
      " 'Discovery-LUAD cohort into two groups based on the TMB cutoff from '\n",
      " 'Science-LUAD cohort (Figure 2C; TMB = 166.5).',\n",
      " 'Given that Science-LUAD cohort was only treated with PD-1 blockade and '\n",
      " 'performed better than Cancer Cell-LUAD cohort on predicting ICB efficacy '\n",
      " '(Figure 2B; AUC = 0.82 and 0.80, respectively), we stratified the '\n",
      " 'Discovery-LUAD cohort into two groups based on the TMB cutoff from '\n",
      " 'Science-LUAD cohort (Figure 2C; TMB = 166.5).',\n",
      " 'Given that Science-LUAD cohort was only treated with PD-1 blockade and '\n",
      " 'performed better than Cancer Cell-LUAD cohort on predicting ICB efficacy '\n",
      " '(Figure 2B; AUC = 0.82 and 0.80, respectively), we stratified the '\n",
      " 'Discovery-LUAD cohort into two groups based on the TMB cutoff from '\n",
      " 'Science-LUAD cohort (Figure 2C; TMB = 166.5).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'Immune checkpoint blockade (ICB) therapies that target programmed cell death '\n",
      " '1 (PD1) and PD1 ligand 1 (PDL1) have demonstrated promising benefits in lung '\n",
      " 'adenocarcinoma (LUAD), and tumor mutational burden (TMB) is the most robust '\n",
      " 'biomarker associated with the efficacy of PD-1-PD-L1 axis blockade in LUAD, '\n",
      " 'but the assessment of TMB by whole-exome sequencing (WES) is rather '\n",
      " 'expensive and time-consuming.',\n",
      " 'We retrieved many previous studies and cancer databases, only collecting '\n",
      " 'four high-quality LUAD datasets that contained both clinical and genomic '\n",
      " 'information: 29 LUAD patients treated with anti-PD-1 therapy (Science-LUAD) '\n",
      " '(1), 59 LUAD patients treated with PD-1 plus CTLA-4 blockade (Cancer '\n",
      " 'Cell-LUAD) (2), 186 LUAD patients treated with anti-PD-1/PD-L1 therapies or '\n",
      " 'in combination with anti-CTLA-4 therapy (JCO-LUAD) (3), and 478 LUAD '\n",
      " 'patients without immunotherapy (TCGA-LUAD) (Figure 1; Table S1).',\n",
      " 'Therefore, this study mainly focused on LUAD for anti-PD-1 therapy.']\n"
     ]
    }
   ],
   "source": [
    "pprint(evidence_df[\"Text\"].iloc[0])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "2.8.0\n",
      "True\n",
      "True\n"
     ]
    }
   ],
   "source": [
    "\"\"\"\n",
    "To install on M3, xcode / metal are required for successful install, execute:\n",
    "\n",
    " xcode-select --install\n",
    " python -m uv pip install --pre torch torchvision torchaudio --extra-index-url https://download.pytorch.org/whl/nightly/cpu\n",
    " python -m uv pip install --upgrade transformers tokenizers accelerate\n",
    "\n",
    " & Restart kernel, checking that install was successful below\n",
    "\"\"\"\n",
    "\n",
    "import torch\n",
    "print(torch.__version__)\n",
    "print(torch.backends.mps.is_available())  # Should print True if MPS is supported\n",
    "print(torch.backends.mps.is_built())      # Should print True"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "torch                   2.8.0\n",
      "torchaudio              2.8.0\n",
      "torchvision             0.23.0\n"
     ]
    }
   ],
   "source": [
    "# Check torch is installed \n",
    "!pip list | grep torch"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### CeLLaTe model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 36,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Device set to use mps:0\n",
      "Asking to truncate to max_length but no maximum length is provided and the model has no predefined maximum length. Default to no truncation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pipeline loaded\n",
      "[{'entity_group': 'CellLine', 'score': np.float32(0.72429657), 'word': 'HeLa cell line', 'start': 4, 'end': 18}]\n"
     ]
    }
   ],
   "source": [
    "from transformers import AutoTokenizer, AutoModelForTokenClassification, pipeline\n",
    "\n",
    "model_name = \"OTAR3088/bioformer-CeLLaTe_V1\"\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "model = AutoModelForTokenClassification.from_pretrained(model_name)\n",
    "\n",
    "nlp_pipeline = pipeline(\"token-classification\", model=model, tokenizer=tokenizer, aggregation_strategy=\"simple\")\n",
    "# Quick check pipeline is behaving\n",
    "print(\"Pipeline loaded\")\n",
    "text = \"The HeLa cell line is widely used in cancer research.\"\n",
    "entities = nlp_pipeline(text)\n",
    "print(entities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Reference for data formatting\n",
    "# from spacy import displacy\n",
    "\n",
    "# # Pre-annotated text and entities\n",
    "# text = \"When Sebastian Thrun started working on self-driving cars at Google in 2007.\"\n",
    "# entities = [\n",
    "#     {\"start\": 5, \"end\": 20, \"label\": \"PERSON\"},\n",
    "#     {\"start\": 45, \"end\": 51, \"label\": \"ORG\"},\n",
    "#     {\"start\": 55, \"end\": 59, \"label\": \"DATE\"}\n",
    "# ]\n",
    "\n",
    "# # Build the data dict\n",
    "# doc_data = {\n",
    "#     \"text\": text,\n",
    "#     \"ents\": entities,\n",
    "#     \"title\": None\n",
    "# }\n",
    "\n",
    "# # Render in Jupyter notebook\n",
    "# displacy.render(doc_data, style=\"ent\", manual=True, jupyter=True)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "04da52297e094b37aecbe5bcb777e0fc",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing in batches:   0%|          | 0/100 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from tqdm.notebook import tqdm\n",
    "hit_column = []\n",
    "\n",
    "texts = evidence_df[\"Text\"].to_list()\n",
    "\n",
    "for text in tqdm(texts, desc=\"Processing in batches\"):\n",
    "    entities = []\n",
    "    res = nlp_pipeline(text)\n",
    "    ent_terms = [[hit[\"word\"] for hit in ent] for ent in res]\n",
    "    # ent_terms = [x for x in ent_terms if x != []] # Remove sentences w.o. hits\n",
    "    entities.extend(ent_terms)\n",
    "    hit_column.append(entities)\n",
    "\n",
    "evidence_df[\"CellateHits\"] = hit_column"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "bf9a07e962f548c9b9fbfafcbcc04d0d",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing in batches:   0%|          | 0/23 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from tqdm.notebook import tqdm\n",
    "\n",
    "def merge_adjacent_ents(ents):\n",
    "    if not ents:\n",
    "        return []\n",
    "    ents = sorted(ents, key=lambda x: x[\"start\"])\n",
    "    merged = [ents[0]]\n",
    "    for next_ent in ents[1:]:\n",
    "        cur = merged[-1]\n",
    "        # Merge if entities are adjacent or overlapping and have the same label\n",
    "        if cur[\"end\"] >= next_ent[\"start\"] and cur[\"label\"] == next_ent[\"label\"]:\n",
    "            cur[\"end\"] = max(cur[\"end\"], next_ent[\"end\"])\n",
    "        else:\n",
    "            merged.append(next_ent)\n",
    "    return merged\n",
    "\n",
    "hit_column = []\n",
    "texts = evidence_df[\"Text\"].to_list()[7]\n",
    "all_ent = []\n",
    "\n",
    "for text in tqdm(texts, desc=\"Processing in batches\"):\n",
    "    entities = []\n",
    "    res = nlp_pipeline(text)\n",
    "    for hit in res:\n",
    "        disp = {\"start\": hit[\"start\"], \"end\": hit[\"end\"], \"label\": hit[\"entity_group\"]}\n",
    "        entities.append(disp)\n",
    "    # Merge adjacent or overlapping entities before appending\n",
    "    merged_entities = merge_adjacent_ents(entities)\n",
    "    all_ent.append(merged_entities)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Conc\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    urrently\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ", within the memory\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -enriched\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " compartment, we observed a higher frequency of the less differentiated PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ phenotype and fewer PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1−CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -small\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lung\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " cancer (\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ") patients when compared to both HD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and other tumor types (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S3\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ").</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To gain a baseline landscape of the composition, functional states, and transcriptomic signatures predictive of prognosis, we analyzed CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets characterized by the presence\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /absence\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and CD28 from periphery, adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site of a cohort of treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients, by integrated multip\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arametric\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " flow cytometry, targeted multi\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -omic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " sc\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA-seq\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " analyses, and computational pipeline\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Considering the critical role of the CXCL\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13/CXCR5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " axis in modulating lymphocyte infiltration [56\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    57\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "], our evidence that intra\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    TR\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " possess highest CXCL\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " chemokine, while memory stem\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -like\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " marker CXCR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " [58] is mostly expressed by CD28+ (CD10\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " low) \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S9), favour\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " a scenario of CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −CXCL13\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " attracting memory reservoir CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "CXCR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    5\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " within the tumor site in our NSCLC setting.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Interestingly, the CD8\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " T\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subset showed the highest poly\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    functionality\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " in each \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    melanoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", and PDAC cancer patients (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " 2E,F).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the present study, we in depth explored the CD8+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets characterized by the presence\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /absence\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and CD28, by integrated multip\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arametric\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " flow cytometry and multi\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -omic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " sc\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RNA-Seq\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " analyses in treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28 impacts the periphery\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " compartmental\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ization\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ", the transcriptional profile and the (dys)functional states of CD8+PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focus\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " on NSCLC, then we evaluated the dynamic distribution and functionality of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets in 68 treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (NT) \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The analysis of the \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " differentiation stage by CCR7 and CD45\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    RA\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " expression in CD8+PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " isolated from \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients, showed a predominant terminal\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -differentiated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " effector\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -memory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (EMR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ", 65\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .4\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "%) and effector\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -memory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (EM, 27\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .3\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "%) phenotype (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " 2C,D).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion our work highlights how the co\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -stimulatory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " molecule CD28 is crucial in dict\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ating\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " different functional states in PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + CD8+ T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site of \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focus\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " on NSCLC, then we evaluated the dynamic distribution and functionality of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets in 68 treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (NT) \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the tumor, a considerable increase of TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " phenotype was observed only in CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T lymphocytes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (percentage of TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " within PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", NT vs \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", P = 0\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .01\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "), strongly indicating that most PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " infiltrating the \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " tumor site possess a TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " phenotype, as previously reported [34\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    36\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "].</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Herein, starting from the analysis of a panel of Ag\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -specific\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " melanoma CD8+PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " clones, we have identified different transcriptomic, phenotypic, and functional patterns dictated by the presence\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /absence\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " of CD28 in peripheral and matched \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /PD1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " co\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -expression\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ": dual impact on CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", and its significance in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients' survival and IC\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    B\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " response</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focus\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " on NSCLC, then we evaluated the dynamic distribution and functionality of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets in 68 treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (NT) \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focus\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " on NSCLC, then we evaluated the dynamic distribution and functionality of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets in 68 treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (NT) \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Conc\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    urrently\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ", within the memory\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -enriched\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " compartment, we observed a higher frequency of the less differentiated PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ phenotype and fewer PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1−CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -small\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lung\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " cancer (\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ") patients when compared to both HD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and other tumor types (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S3\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    A\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ").</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on results obtained on Ag\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -specific\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " CD8+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " clones, we then investigated the frequency and fitness of CD8+ PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+CD28+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in the \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of 68 patients with cancer of different derivation (n = 48 NSCLC, Table S1), n = 10 melanoma, n = 10 pancreas ductal adenocarcinoma cancer (PDAC)) and in 25 healthy donors (HD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "), by multi\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -color\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " flow\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -cytometry\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " analysis (as outlined in the gating strategy, Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S2) (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " 2A,B), defined by the expression of CD28 and\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /or\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " within CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on results obtained on Ag\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -specific\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " CD8+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " clones, we then investigated the frequency and fitness of CD8+ PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+CD28+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in the \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of 68 patients with cancer of different derivation (n = 48 NSCLC, Table S1), n = 10 melanoma, n = 10 pancreas ductal adenocarcinoma cancer (PDAC)) and in 25 healthy donors (HD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "), by multi\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -color\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " flow\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -cytometry\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " analysis (as outlined in the gating strategy, Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S2) (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " 2A,B), defined by the expression of CD28 and\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    /or\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " within CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the tumor, a considerable increase of TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " phenotype was observed only in CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    −\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T lymphocytes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (percentage of TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " within PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", NT vs \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", P = 0\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .01\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "), strongly indicating that most PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " infiltrating the \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " tumor site possess a TR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    M\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " phenotype, as previously reported [34\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ,\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    36\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "].</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focus\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " on NSCLC, then we evaluated the dynamic distribution and functionality of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " and PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " subsets in 68 treatment\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -naïve\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       ", adjacent non\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (NT) \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tissue\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">However, CD28\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T-cell\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " functional fitness was not improved by the absence of the 4 IR\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " evaluated, enfor\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cing\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " the role of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " alone in impairing the functional competence of CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " through a CD28\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -dependent\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " mechanism in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28 expression dict\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ates\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " an opposite functional behavior in CD8+PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " with the transition from the periphery to the tumor site in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " patients</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Next, we focused on the role of co\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -stimulatory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " molecules other than CD28, i\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .e.\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " IC\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    OS\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " [30], CD13\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    7\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " (4\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -1BB\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       ") [31], and integrin CD11\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    a\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " [32] (Fig\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    .\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " S2) as contributors to the functional fitness of PD\n",
       "<mark class=\"entity\" style=\"background: #fde68a; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    1+CD28−\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellLine</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " cancer patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from spacy import displacy\n",
    "# Trying displacy\n",
    "colors = {\n",
    "    \"CellLine\": \"#fde68a\",\n",
    "    \"CellType\": \"#6ee7b7\",\n",
    "    \"Tissue\": \"#a7c7e7\"\n",
    "}\n",
    "options = {\"colors\": colors}\n",
    "\n",
    "for e, t in zip(all_ent, texts):\n",
    "    # Build the data dict\n",
    "    doc_data = {\n",
    "        \"text\": t,\n",
    "        \"ents\": e,\n",
    "        \"title\": None\n",
    "    }\n",
    "\n",
    "    # Render in Jupyter notebook\n",
    "    displacy.render(doc_data, style=\"ent\", manual=True, jupyter=True, options=options)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Cellfinder model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 38,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f0eb323a480c468fba3950b8e2ef26f2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer_config.json: 0.00B [00:00, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d376dbd4a2f24567975845b056b0da4e",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "vocab.txt: 0.00B [00:00, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "8cca3015de734aca8e59ba902a495dd1",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "tokenizer.json: 0.00B [00:00, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "d0e107d2a5f14f8b8cd4230a77d952a8",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "special_tokens_map.json:   0%|          | 0.00/125 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "26a08136e192424682d107f661535d31",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "config.json:   0%|          | 0.00/969 [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "eee7849c0374425d98a42b3b2d28827f",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "model.safetensors:   0%|          | 0.00/166M [00:00<?, ?B/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Device set to use mps:0\n",
      "Asking to truncate to max_length but no maximum length is provided and the model has no predefined maximum length. Default to no truncation.\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Pipeline loaded\n",
      "[{'entity_group': 'CellLine', 'score': np.float32(0.59069914), 'word': 'HeLa', 'start': 4, 'end': 8}]\n"
     ]
    }
   ],
   "source": [
    "from transformers import AutoTokenizer, AutoModelForTokenClassification, pipeline\n",
    "\n",
    "model_name = \"OTAR3088/bioformer-cellfinder_V1\"\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "model = AutoModelForTokenClassification.from_pretrained(model_name)\n",
    "\n",
    "nlp_pipeline = pipeline(\"token-classification\", model=model, tokenizer=tokenizer, aggregation_strategy=\"simple\")\n",
    "# Quick check pipeline is behaving\n",
    "print(\"Pipeline loaded\")\n",
    "text = \"The HeLa cell line is widely used in cancer research.\"\n",
    "entities = nlp_pipeline(text)\n",
    "print(entities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "application/vnd.jupyter.widget-view+json": {
       "model_id": "f2320342243d45069af2301f8440a2d2",
       "version_major": 2,
       "version_minor": 0
      },
      "text/plain": [
       "Processing in batches:   0%|          | 0/23 [00:00<?, ?it/s]"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from tqdm.notebook import tqdm\n",
    "\n",
    "def merge_adjacent_ents(ents):\n",
    "    if not ents:\n",
    "        return []\n",
    "    ents = sorted(ents, key=lambda x: x[\"start\"])\n",
    "    merged = [ents[0]]\n",
    "    for next_ent in ents[1:]:\n",
    "        cur = merged[-1]\n",
    "        # Merge if entities are adjacent or overlapping and have the same label\n",
    "        if cur[\"end\"] >= next_ent[\"start\"] and cur[\"label\"] == next_ent[\"label\"]:\n",
    "            cur[\"end\"] = max(cur[\"end\"], next_ent[\"end\"])\n",
    "        else:\n",
    "            merged.append(next_ent)\n",
    "    return merged\n",
    "\n",
    "hit_column = []\n",
    "texts = evidence_df[\"Text\"].to_list()[7]\n",
    "all_ent = []\n",
    "\n",
    "for text in tqdm(texts, desc=\"Processing in batches\"):\n",
    "    entities = []\n",
    "    res = nlp_pipeline(text)\n",
    "    for hit in res:\n",
    "        disp = {\"start\": hit[\"start\"], \"end\": hit[\"end\"], \"label\": hit[\"entity_group\"]}\n",
    "        entities.append(disp)\n",
    "    # Merge adjacent or overlapping entities before appending\n",
    "    merged_entities = merge_adjacent_ents(entities)\n",
    "    all_ent.append(merged_entities)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Concurrently, within the memory-enriched compartment, we observed a higher frequency of the less differentiated PD1+CD28+ phenotype and fewer PD1−CD28− cells in non-small cell \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lung\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (NSCLC) patients when compared to both \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HDs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " and other tumor types (Fig. S3A).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">To gain a baseline landscape of the composition, functional states, and transcriptomic signatures predictive of prognosis, we analyzed \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+ T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell subsets characterized by the presence/absence of PD1 and CD28 from periphery, adjacent non-tumor tissue and tumor site of a cohort of treatment-naïve NSCLC patients, by integrated multiparametric flow cytometry, targeted multi-omic scRNA-seq analyses, and computational pipelines.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Considering the critical role of the CXCL13/CXCR5 axis in modulating lymphocyte infiltration [56, 57], our evidence that intra-tumor PD1+CD28− TRM possess highest CXCL13 chemokine, while memory stem-like marker CXCR5 [58] is mostly expressed by CD28+ (CD103 low) \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (Fig. S9), favours a scenario of CD28−CXCL13+ T cells attracting memory reservoir CD28+CXCR5+ \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " within the tumor site in our NSCLC setting.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Interestingly, the CD8+PD1+CD28− T\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell subset showed the highest polyfunctionality in each melanoma, \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    NSCLC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", and \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    PDAC\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " cancer patients (Fig. 2E,F).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the present study, we in depth explored the \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+ T\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell subsets characterized by the presence/absence of PD1 and CD28, by integrated multiparametric flow cytometry and multi-omic scRNA-Seq analyses in treatment-naïve NSCLC patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28 impacts the periphery/tissue compartmentalization, the transcriptional profile and the (dys)functional states of CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "PD1\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    + T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in NSCLC patients</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The analysis of the T-cell differentiation stage by CCR7 and CD45RA expression in CD8+PD1+CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " isolated from \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of NSCLC patients, showed a predominant terminal-differentiated \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    effector\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "-memory (EMRA, 65.4%) and \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    effector\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "-memory (EM, 27.3%) phenotype (Fig. 2C,D).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion our work highlights how the co-stimulatory molecule CD28 is crucial in dictating different functional states in PD1\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+ T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " site of NSCLC patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the tumor, a considerable increase of TRM phenotype was observed only in CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T lymphocytes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (percentage of TRM within PD1+CD28\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    − T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", NT vs T, P = 0.01), strongly indicating that most PD1+CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " infiltrating the NSCLC tumor site possess a TRM phenotype, as previously reported [34, 36].</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Herein, starting from the analysis of a panel of Ag-specific melanoma CD8+PD1+ T\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell clones, we have identified different transcriptomic, phenotypic, and functional patterns dictated by the presence/absence of CD28 in peripheral and matched NSCLC tissue.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28/PD1 co-expression: dual impact on \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+ T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tumor\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " tissue, and its significance in NSCLC patients' survival and ICB response</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Concurrently, within the memory-enriched compartment, we observed a higher frequency of the less differentiated PD1+CD28+ phenotype and fewer PD1−CD28− cells in non-small cell \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    lung\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (NSCLC) patients when compared to both \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HDs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " and other tumor types (Fig. S3A).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on results obtained on Ag-specific CD8+ T\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell clones, we then investigated the frequency and fitness of CD8+ PD1+CD28− and PD1+CD28+ T cells in the peripheral blood of 68 patients with cancer of different derivation (n = 48 NSCLC, Table S1), n = 10 melanoma, n = 10 \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pancreas ductal adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " cancer (PDAC)) and in 25 healthy donors (\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HDs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "), by multi-color flow-cytometry analysis (as outlined in the gating strategy, Fig. S2) (Fig. 2A,B), defined by the expression of CD28 and/or PD1 within \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Based on results obtained on Ag-specific CD8+ T\n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    -\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       "cell clones, we then investigated the frequency and fitness of CD8+ PD1+CD28− and PD1+CD28+ T cells in the peripheral blood of 68 patients with cancer of different derivation (n = 48 NSCLC, Table S1), n = 10 melanoma, n = 10 \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pancreas ductal adenocarcinoma\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " cancer (PDAC)) and in 25 healthy donors (\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HDs\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "), by multi-color flow-cytometry analysis (as outlined in the gating strategy, Fig. S2) (Fig. 2A,B), defined by the expression of CD28 and/or PD1 within \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ".</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the tumor, a considerable increase of TRM phenotype was observed only in CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T lymphocytes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " (percentage of TRM within PD1+CD28\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    − T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       ", NT vs T, P = 0.01), strongly indicating that most PD1+CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " infiltrating the NSCLC tumor site possess a TRM phenotype, as previously reported [34, 36].</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Focusing on NSCLC, then we evaluated the dynamic distribution and functionality of PD1+CD28− and PD1+CD28+ T-cell subsets in 68 treatment-naïve NSCLC patients (Table S1), by comparing \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " blood, adjacent non-tumor (NT) tissue and tumor site (T) (n = 32 matched NSCLC patients).</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">However, CD28+ T-cell functional fitness was not improved by the absence of the 4 IRs evaluated, enforcing the role of PD1 alone in impairing the functional competence of \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD8+\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " through a CD28-dependent mechanism in \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of NSCLC patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CD28 expression dictates an opposite functional behavior in CD8\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       "PD1\n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    +\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " with the transition from the periphery to the tumor site in NSCLC patients</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Next, we focused on the role of co-stimulatory molecules other than CD28, i.e. ICOS [30], CD137 (4-1BB) [31], and integrin CD11a [32] (Fig. S2) as contributors to the functional fitness of PD1+CD28− \n",
       "<mark class=\"entity\" style=\"background: #6ee7b7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    T cells\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">CellType</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #a7c7e7; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    peripheral blood\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem\">Tissue</span>\n",
       "</mark>\n",
       " of NSCLC cancer patients.</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "from spacy import displacy\n",
    "# Trying displacy\n",
    "colors = {\n",
    "    \"CellLine\": \"#fde68a\",\n",
    "    \"CellType\": \"#6ee7b7\",\n",
    "    \"Tissue\": \"#a7c7e7\"\n",
    "}\n",
    "options = {\"colors\": colors}\n",
    "\n",
    "for e, t in zip(all_ent, texts):\n",
    "    # Build the data dict\n",
    "    doc_data = {\n",
    "        \"text\": t,\n",
    "        \"ents\": e,\n",
    "        \"title\": None\n",
    "    }\n",
    "\n",
    "    # Render in Jupyter notebook\n",
    "    displacy.render(doc_data, style=\"ent\", manual=True, jupyter=True, options=options)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 37,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from typing import List\n",
    "# def match_hits_text(text: List, hits: List) -> List:\n",
    "#     return [(t, h) for t, h in list(zip(text, hits))]\n",
    "\n",
    "# testing = match_hits_text(evidence_df[\"Text\"].to_list()[4], evidence_df[\"CellateHits\"].to_list()[4])\n",
    "# # testing\n",
    "\n",
    "\n",
    "# df_matched = evidence_df.apply(lambda row: match_hits_text(row[\"Text\"], row[\"CellateHits\"]), axis=1)\n",
    "# df_matched[3]"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### OTAR NER model - to be fixed"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [],
   "source": [
    "# from huggingface_hub import login\n",
    "# login(token=\"my token\")\n",
    "\n",
    "# # Use a pipeline as a high-level helper\n",
    "# from transformers import pipeline\n",
    "\n",
    "# pipe = pipeline(\"token-classification\", model=\"OTAR3088/otar-ner-model\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "BertTokenizerFast(name_or_path='OTAR3088/otar-ner-model', vocab_size=32768, model_max_length=1000000000000000019884624838656, is_fast=True, padding_side='right', truncation_side='right', special_tokens={'unk_token': '[UNK]', 'sep_token': '[SEP]', 'pad_token': '[PAD]', 'cls_token': '[CLS]', 'mask_token': '[MASK]'}, clean_up_tokenization_spaces=False, added_tokens_decoder={\n",
      "\t0: AddedToken(\"[PAD]\", rstrip=False, lstrip=False, single_word=False, normalized=False, special=True),\n",
      "\t100: AddedToken(\"[UNK]\", rstrip=False, lstrip=False, single_word=False, normalized=False, special=True),\n",
      "\t101: AddedToken(\"[CLS]\", rstrip=False, lstrip=False, single_word=False, normalized=False, special=True),\n",
      "\t102: AddedToken(\"[SEP]\", rstrip=False, lstrip=False, single_word=False, normalized=False, special=True),\n",
      "\t103: AddedToken(\"[MASK]\", rstrip=False, lstrip=False, single_word=False, normalized=False, special=True),\n",
      "}\n",
      ")\n"
     ]
    },
    {
     "ename": "OSError",
     "evalue": "OTAR3088/otar-ner-model does not appear to have a file named pytorch_model.bin, model.safetensors, tf_model.h5, model.ckpt or flax_model.msgpack.",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mOSError\u001b[0m                                   Traceback (most recent call last)",
      "Cell \u001b[0;32mIn[13], line 8\u001b[0m\n\u001b[1;32m      6\u001b[0m tokenizer \u001b[38;5;241m=\u001b[39m AutoTokenizer\u001b[38;5;241m.\u001b[39mfrom_pretrained(model_name)\n\u001b[1;32m      7\u001b[0m \u001b[38;5;28mprint\u001b[39m(tokenizer)\n\u001b[0;32m----> 8\u001b[0m model \u001b[38;5;241m=\u001b[39m \u001b[43mAutoModelForTokenClassification\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfrom_pretrained\u001b[49m\u001b[43m(\u001b[49m\u001b[43mmodel_name\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m      9\u001b[0m \u001b[38;5;28mprint\u001b[39m(model)\n\u001b[1;32m     11\u001b[0m nlp_pipeline \u001b[38;5;241m=\u001b[39m pipeline(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtoken-classification\u001b[39m\u001b[38;5;124m\"\u001b[39m, model\u001b[38;5;241m=\u001b[39mmodel, tokenizer\u001b[38;5;241m=\u001b[39mtokenizer, aggregation_strategy\u001b[38;5;241m=\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124msimple\u001b[39m\u001b[38;5;124m\"\u001b[39m)\n",
      "File \u001b[0;32m~/GitProjects/OTAR3088/Data_mining/otarlab/labenv/lib/python3.10/site-packages/transformers/models/auto/auto_factory.py:604\u001b[0m, in \u001b[0;36m_BaseAutoModelClass.from_pretrained\u001b[0;34m(cls, pretrained_model_name_or_path, *model_args, **kwargs)\u001b[0m\n\u001b[1;32m    602\u001b[0m     \u001b[38;5;28;01mif\u001b[39;00m model_class\u001b[38;5;241m.\u001b[39mconfig_class \u001b[38;5;241m==\u001b[39m config\u001b[38;5;241m.\u001b[39msub_configs\u001b[38;5;241m.\u001b[39mget(\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mtext_config\u001b[39m\u001b[38;5;124m\"\u001b[39m, \u001b[38;5;28;01mNone\u001b[39;00m):\n\u001b[1;32m    603\u001b[0m         config \u001b[38;5;241m=\u001b[39m config\u001b[38;5;241m.\u001b[39mget_text_config()\n\u001b[0;32m--> 604\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mmodel_class\u001b[49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43mfrom_pretrained\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m    605\u001b[0m \u001b[43m        \u001b[49m\u001b[43mpretrained_model_name_or_path\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mmodel_args\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[43mconfig\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mconfig\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mhub_kwargs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\n\u001b[1;32m    606\u001b[0m \u001b[43m    \u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    607\u001b[0m \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mValueError\u001b[39;00m(\n\u001b[1;32m    608\u001b[0m     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mUnrecognized configuration class \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mconfig\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__class__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m for this kind of AutoModel: \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;28mcls\u001b[39m\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__name__\u001b[39m\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;130;01m\\n\u001b[39;00m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    609\u001b[0m     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mModel type should be one of \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m\u001b[38;5;124m'\u001b[39m\u001b[38;5;124m, \u001b[39m\u001b[38;5;124m'\u001b[39m\u001b[38;5;241m.\u001b[39mjoin(c\u001b[38;5;241m.\u001b[39m\u001b[38;5;18m__name__\u001b[39m\u001b[38;5;250m \u001b[39m\u001b[38;5;28;01mfor\u001b[39;00m\u001b[38;5;250m \u001b[39mc\u001b[38;5;250m \u001b[39m\u001b[38;5;129;01min\u001b[39;00m\u001b[38;5;250m \u001b[39m\u001b[38;5;28mcls\u001b[39m\u001b[38;5;241m.\u001b[39m_model_mapping)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m    610\u001b[0m )\n",
      "File \u001b[0;32m~/GitProjects/OTAR3088/Data_mining/otarlab/labenv/lib/python3.10/site-packages/transformers/modeling_utils.py:288\u001b[0m, in \u001b[0;36mrestore_default_dtype.<locals>._wrapper\u001b[0;34m(*args, **kwargs)\u001b[0m\n\u001b[1;32m    286\u001b[0m old_dtype \u001b[38;5;241m=\u001b[39m torch\u001b[38;5;241m.\u001b[39mget_default_dtype()\n\u001b[1;32m    287\u001b[0m \u001b[38;5;28;01mtry\u001b[39;00m:\n\u001b[0;32m--> 288\u001b[0m     \u001b[38;5;28;01mreturn\u001b[39;00m \u001b[43mfunc\u001b[49m\u001b[43m(\u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43margs\u001b[49m\u001b[43m,\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[38;5;241;43m*\u001b[39;49m\u001b[43mkwargs\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m    289\u001b[0m \u001b[38;5;28;01mfinally\u001b[39;00m:\n\u001b[1;32m    290\u001b[0m     torch\u001b[38;5;241m.\u001b[39mset_default_dtype(old_dtype)\n",
      "File \u001b[0;32m~/GitProjects/OTAR3088/Data_mining/otarlab/labenv/lib/python3.10/site-packages/transformers/modeling_utils.py:5027\u001b[0m, in \u001b[0;36mPreTrainedModel.from_pretrained\u001b[0;34m(cls, pretrained_model_name_or_path, config, cache_dir, ignore_mismatched_sizes, force_download, local_files_only, token, revision, use_safetensors, weights_only, *model_args, **kwargs)\u001b[0m\n\u001b[1;32m   5017\u001b[0m \u001b[38;5;28;01mif\u001b[39;00m (\n\u001b[1;32m   5018\u001b[0m     gguf_file\n\u001b[1;32m   5019\u001b[0m     \u001b[38;5;129;01mand\u001b[39;00m device_map \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m   5020\u001b[0m     \u001b[38;5;129;01mand\u001b[39;00m ((\u001b[38;5;28misinstance\u001b[39m(device_map, \u001b[38;5;28mdict\u001b[39m) \u001b[38;5;129;01mand\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdisk\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m device_map\u001b[38;5;241m.\u001b[39mvalues()) \u001b[38;5;129;01mor\u001b[39;00m \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mdisk\u001b[39m\u001b[38;5;124m\"\u001b[39m \u001b[38;5;129;01min\u001b[39;00m device_map)\n\u001b[1;32m   5021\u001b[0m ):\n\u001b[1;32m   5022\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mRuntimeError\u001b[39;00m(\n\u001b[1;32m   5023\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mOne or more modules is configured to be mapped to disk. Disk offload is not supported for models \u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   5024\u001b[0m         \u001b[38;5;124m\"\u001b[39m\u001b[38;5;124mloaded from GGUF files.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   5025\u001b[0m     )\n\u001b[0;32m-> 5027\u001b[0m checkpoint_files, sharded_metadata \u001b[38;5;241m=\u001b[39m \u001b[43m_get_resolved_checkpoint_files\u001b[49m\u001b[43m(\u001b[49m\n\u001b[1;32m   5028\u001b[0m \u001b[43m    \u001b[49m\u001b[43mpretrained_model_name_or_path\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mpretrained_model_name_or_path\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5029\u001b[0m \u001b[43m    \u001b[49m\u001b[43msubfolder\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43msubfolder\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5030\u001b[0m \u001b[43m    \u001b[49m\u001b[43mvariant\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mvariant\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5031\u001b[0m \u001b[43m    \u001b[49m\u001b[43mgguf_file\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mgguf_file\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5032\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfrom_tf\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfrom_tf\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5033\u001b[0m \u001b[43m    \u001b[49m\u001b[43mfrom_flax\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mfrom_flax\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5034\u001b[0m \u001b[43m    \u001b[49m\u001b[43muse_safetensors\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43muse_safetensors\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5035\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcache_dir\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcache_dir\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5036\u001b[0m \u001b[43m    \u001b[49m\u001b[43mforce_download\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mforce_download\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5037\u001b[0m \u001b[43m    \u001b[49m\u001b[43mproxies\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mproxies\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5038\u001b[0m \u001b[43m    \u001b[49m\u001b[43mlocal_files_only\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mlocal_files_only\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5039\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtoken\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtoken\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5040\u001b[0m \u001b[43m    \u001b[49m\u001b[43muser_agent\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43muser_agent\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5041\u001b[0m \u001b[43m    \u001b[49m\u001b[43mrevision\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mrevision\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5042\u001b[0m \u001b[43m    \u001b[49m\u001b[43mcommit_hash\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mcommit_hash\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5043\u001b[0m \u001b[43m    \u001b[49m\u001b[43mis_remote_code\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[38;5;28;43mcls\u001b[39;49m\u001b[38;5;241;43m.\u001b[39;49m\u001b[43m_auto_class\u001b[49m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mis\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;129;43;01mnot\u001b[39;49;00m\u001b[43m \u001b[49m\u001b[38;5;28;43;01mNone\u001b[39;49;00m\u001b[43m,\u001b[49m\n\u001b[1;32m   5044\u001b[0m \u001b[43m    \u001b[49m\u001b[43mtransformers_explicit_filename\u001b[49m\u001b[38;5;241;43m=\u001b[39;49m\u001b[43mtransformers_explicit_filename\u001b[49m\u001b[43m,\u001b[49m\n\u001b[1;32m   5045\u001b[0m \u001b[43m\u001b[49m\u001b[43m)\u001b[49m\n\u001b[1;32m   5047\u001b[0m is_sharded \u001b[38;5;241m=\u001b[39m sharded_metadata \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n\u001b[1;32m   5048\u001b[0m is_quantized \u001b[38;5;241m=\u001b[39m hf_quantizer \u001b[38;5;129;01mis\u001b[39;00m \u001b[38;5;129;01mnot\u001b[39;00m \u001b[38;5;28;01mNone\u001b[39;00m\n",
      "File \u001b[0;32m~/GitProjects/OTAR3088/Data_mining/otarlab/labenv/lib/python3.10/site-packages/transformers/modeling_utils.py:1256\u001b[0m, in \u001b[0;36m_get_resolved_checkpoint_files\u001b[0;34m(pretrained_model_name_or_path, subfolder, variant, gguf_file, from_tf, from_flax, use_safetensors, cache_dir, force_download, proxies, local_files_only, token, user_agent, revision, commit_hash, is_remote_code, transformers_explicit_filename)\u001b[0m\n\u001b[1;32m   1250\u001b[0m                 \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mOSError\u001b[39;00m(\n\u001b[1;32m   1251\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mpretrained_model_name_or_path\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m does not appear to have a file named\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1252\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m_add_variant(WEIGHTS_NAME,\u001b[38;5;250m \u001b[39mvariant)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m but there is a file without the variant\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1253\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mvariant\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m. Use `variant=None` to load this model from those weights.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1254\u001b[0m                 )\n\u001b[1;32m   1255\u001b[0m             \u001b[38;5;28;01melse\u001b[39;00m:\n\u001b[0;32m-> 1256\u001b[0m                 \u001b[38;5;28;01mraise\u001b[39;00m \u001b[38;5;167;01mOSError\u001b[39;00m(\n\u001b[1;32m   1257\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;132;01m{\u001b[39;00mpretrained_model_name_or_path\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m does not appear to have a file named\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1258\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m_add_variant(WEIGHTS_NAME,\u001b[38;5;250m \u001b[39mvariant)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m, \u001b[39m\u001b[38;5;132;01m{\u001b[39;00m_add_variant(SAFE_WEIGHTS_NAME,\u001b[38;5;250m \u001b[39mvariant)\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m,\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1259\u001b[0m                     \u001b[38;5;124mf\u001b[39m\u001b[38;5;124m\"\u001b[39m\u001b[38;5;124m \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mTF2_WEIGHTS_NAME\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m, \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mTF_WEIGHTS_NAME\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m or \u001b[39m\u001b[38;5;132;01m{\u001b[39;00mFLAX_WEIGHTS_NAME\u001b[38;5;132;01m}\u001b[39;00m\u001b[38;5;124m.\u001b[39m\u001b[38;5;124m\"\u001b[39m\n\u001b[1;32m   1260\u001b[0m                 )\n\u001b[1;32m   1262\u001b[0m \u001b[38;5;28;01mexcept\u001b[39;00m \u001b[38;5;167;01mOSError\u001b[39;00m:\n\u001b[1;32m   1263\u001b[0m     \u001b[38;5;66;03m# Raise any environment error raise by `cached_file`. It will have a helpful error message adapted\u001b[39;00m\n\u001b[1;32m   1264\u001b[0m     \u001b[38;5;66;03m# to the original exception.\u001b[39;00m\n\u001b[1;32m   1265\u001b[0m     \u001b[38;5;28;01mraise\u001b[39;00m\n",
      "\u001b[0;31mOSError\u001b[0m: OTAR3088/otar-ner-model does not appear to have a file named pytorch_model.bin, model.safetensors, tf_model.h5, model.ckpt or flax_model.msgpack."
     ]
    }
   ],
   "source": [
    "# Highlight annotations in-text\n",
    "# Grab annotations from ePMC - either via graphQL or ePMC API - unsure why they aren't returned as default in graphQL?\n",
    "\n",
    "model_name = \"OTAR3088/otar-ner-model\"\n",
    "\n",
    "tokenizer = AutoTokenizer.from_pretrained(model_name)\n",
    "print(tokenizer)\n",
    "model = AutoModelForTokenClassification.from_pretrained(model_name)\n",
    "print(model)\n",
    "\n",
    "nlp_pipeline = pipeline(\"token-classification\", model=model, tokenizer=tokenizer, aggregation_strategy=\"simple\")\n",
    "# Quick check pipeline is behaving\n",
    "print(\"Pipeline loaded\")\n",
    "text = \"The HeLa cell line is widely used in cancer research.\"\n",
    "entities = nlp_pipeline(text)\n",
    "print(entities)"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python (labenv)",
   "language": "python",
   "name": "labenv"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.16"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
